<SEC-DOCUMENT>0001387131-20-009695.txt : 20201109
<SEC-HEADER>0001387131-20-009695.hdr.sgml : 20201109
<ACCEPTANCE-DATETIME>20201109092242
ACCESSION NUMBER:		0001387131-20-009695
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201109
DATE AS OF CHANGE:		20201109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		201296364

	BUSINESS ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431
		BUSINESS PHONE:		561-961-1900

	MAIL ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>txmd-10q_093020.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:txmd="http://therapeuticsmd.com/20200930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_037_txmd_therapeuticsmd.com_20200930 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20200101_20200930 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_07F_XDX_P%2D%2D\Clients\TherapeuticsMD\2020\q20%2D03831__10%2DQ\txmd%2D10q__093020.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_068_Number_5_Number -->
<!-- Field: Set; Name: xdx; ID: xdx_065_sqft_8_utr%2D%2Dsqft -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_SO_P%2D%2D\Clients\TherapeuticsMD\2020\q20%2D03831__10%2DQ\txmd%2D10q__093020.xdxs -->
<body>
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-09-30" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2019-12-31" id="xdx2ixbrl0125" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-09-30" id="xdx2ixbrl0136" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2019-12-31" id="xdx2ixbrl0137" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-07-012020-09-30" id="xdx2ixbrl0236" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-07-012019-09-30" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-01-01to2020-09-30" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-07-012020-09-30" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2019-07-012019-09-30" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-01to2020-09-30" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2019-01-012019-09-30" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-07-012019-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-07-012019-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-07-012019-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-07-012019-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-07-012019-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-03-31" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" contextRef="From2019-01-012019-09-30" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="From2019-01-012019-09-30" id="xdx2ixbrl0512" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2019-01-012019-09-30" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-01-01to2020-09-30" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2020-01-01to2020-09-30" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="txmd:WarrantGrantedInRelationToFinancingAgreement" contextRef="From2019-01-012019-09-30" id="xdx2ixbrl0596" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="txmd:AmountAccruedForIntellectualPropertyLicense" contextRef="From2020-01-01to2020-09-30" id="xdx2ixbrl0598" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="AsOf2020-09-30" id="xdx2ixbrl0765" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-04-012019-06-30" id="xdx2ixbrl0988" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10057632</ix:nonFraction>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="txmd-20200930.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-01-01to2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-09_custom_FinancingAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment6Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-08_custom_FinancingAgreementAmendment6Period1Member_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment6Period1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-08_custom_FinancingAgreementAmendment6Period2Member_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment6Period2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_TrademarksAndTradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_TrademarksAndTradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_VitaminsAndImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:VitaminsAndImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_BijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_custom_PrescriptionVitaminsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_PrescriptionVitaminsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_PrescriptionVitaminsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_PrescriptionVitaminsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_custom_ImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_ImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_ImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_ImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_custom_BijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_BijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_BijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_BijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_srt_MaximumMember_custom_CouncilLicenseAgreementStep1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_CouncilLicenseAgreementStep1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_srt_MinimumMember_custom_CouncilLicenseAgreementStep2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_srt_MaximumMember_custom_CouncilLicenseAgreementStep2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_CouncilLicenseAgreementStep2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_srt_MinimumMember_custom_CouncilLicenseAgreementStep3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_CouncilLicenseAgreementStep3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_CouncilLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_custom_BijuvaAndAnnoveraMember_custom_KnightLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaAndAnnoveraMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:KnightLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_MultipleTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_MultipleTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_DomesticUSPatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_ForeignPatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_DomesticPatentsBijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsBijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_ForeignPatentsBijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsBijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_DomesticPatentsEstradiolAndProgesteroneCandidatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsEstradiolAndProgesteroneCandidatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_DomesticUSPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_DomesticUSUtilityPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSUtilityPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_DomesticUSDesignPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSDesignPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_ForeignPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_ForeignUtilityPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_ForeignDesignPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignDesignPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_DomesticUtilityPatentTopicalCreamCandidatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTopicalCreamCandidatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_DomesticUtilityPatentTransdermalPatchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_ForeignUtilityPatentTransdermalPatchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_DomesticUtilityPatentTx009HRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTx009HRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_DomesticPatentsProgesteroneFormulationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsProgesteroneFormulationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_ForeignPatentsProgesteroneFormulationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsProgesteroneFormulationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_DomesticUtilityPatentOperaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentOperaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_us-gaap_RevolvingCreditFacilityMember_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_us-gaap_SecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_FinancingAgreementMember_custom_TrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_FinancingAgreementMember_custom_TrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-05-01_us-gaap_SecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-302018-05-01_us-gaap_SecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-30</xbrli:startDate>
        <xbrli:endDate>2018-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-302018-05-01_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-30</xbrli:startDate>
        <xbrli:endDate>2018-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_MidCapAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_MidCapAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-05_custom_LenderWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:LenderWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_TwoTranchesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TwoTranchesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_LenderWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:LenderWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_custom_FinancingAgreementMember226851703">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-27_custom_PaycheckProtectionProgramLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">txmd:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_PerformanceStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:PerformanceStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_WarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_WarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_LenderWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:LenderWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_WarrantMember226853968">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_WarrantsCashlessExerciseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsCashlessExerciseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RestrictedStockMember_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_Plan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_NewSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NewSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_Plan2019Member_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_Plan2019Member_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_srt_MinimumMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_srt_MaximumMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_srt_MinimumMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_srt_MaximumMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-18_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-172020-06-18_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-17</xbrli:startDate>
        <xbrli:endDate>2020-06-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_custom_CatalentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_CatalentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_CatalentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_CatalentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_CatalentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_CatalentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_custom_AmericanInternationalGroupMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:AmericanInternationalGroupMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_AmericanInternationalGroupMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:AmericanInternationalGroupMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_SupplierOneConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierOneConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_SupplierTwoConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_SupplierThreeConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_SupplierOneConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierOneConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_SupplierTwoConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_SupplierThreeConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_ThreeCustomersConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:ThreeCustomersConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_FourCustomersConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:FourCustomersConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_CustomerConcentrationMcKessonCorporationRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_CustomerConcentrationAmerisourceBergenRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_CustomerConcentrationPIServicesMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPIServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-302013-07-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-30</xbrli:startDate>
        <xbrli:endDate>2013-07-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_CatalentMember226859265">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">txmd:CatalentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Number">
      <xbrli:measure>txmd:Number</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <ix:relationship fromRefs="Fact001285" toRefs="Footnote001288"></ix:relationship>
    </ix:resources>
  </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 14pt Times New Roman, Times, Serif"><b>UNITED STATES</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 14pt Times New Roman, Times, Serif"><b>SECURITIES AND EXCHANGE COMMISSION</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 12pt Times New Roman, Times, Serif"><b>WASHINGTON, D.C. 20549</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 16pt Times New Roman, Times, Serif"><b>FORM <span id="xdx_902_edei--DocumentType_c20200101__20200930_zfT2DGjnDknk"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">(Mark One)</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-top: 0; width: 100%">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--DocumentQuarterlyReport_c20200101__20200930_zqrpXvEueJUi"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span></td>
            <td style="text-align: justify">
                <p style="margin-bottom: 0; margin-top: 0"><span style="font: 12pt Times New Roman, Times, Serif"><b>QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b> </span></p>
                <p style="margin-bottom: 0; margin-top: 0">

                </p>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-left: 0.5in; margin-top: 0; text-align: justify; text-indent: 0in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-left: 0.5in; margin-top: 0; text-align: justify; text-indent: 0in">
        <span style="font: 10pt Times New Roman, Times, Serif">For the quarterly period ended <span id="xdx_90B_edei--DocumentPeriodEndDate_c20200101__20200930_zVQKxfdgsLAj"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 30, 2020</ix:nonNumeric></span></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">or</span></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-top: 0; width: 100%">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 0.5in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><span title="Document Transition Report"><span id="xdx_90F_edei--DocumentTransitionReport_c20200101__20200930_zAdI34vqlUf2"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#x2610;</ix:nonNumeric></span></span></span>
            </td>
            <td style="text-align: justify">
                <p style="margin-bottom: 0; margin-top: 0">
                    <span style="font: 12pt Times New Roman, Times, Serif"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span>
                </p>

            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><span title="Entity File Number">For the transition period from________ to ___________</span></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">Commission File No. <b><span style="text-decoration: underline"><span title="Entity File Number"><span id="xdx_90B_edei--EntityFileNumber_c20200101__20200930_zAyWucCSu8oh" title="Entity File Number"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:EntityFileNumber">001-00100</ix:nonNumeric></span></span></span></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 18pt Times New Roman, Times, Serif"><b><span id="xdx_905_edei--EntityRegistrantName_c20200101__20200930_zHHXY1Ih5uO7"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:EntityRegistrantName">THERAPEUTICSMD, INC.</ix:nonNumeric></span></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">(Exact Name of Registrant as Specified in Its Charter)</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
        <tr style="vertical-align: top; text-align: left">
            <td style="width: 22%; text-align: center">&#160;</td>
            <td style="border-bottom: Black 1pt solid; width: 8%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20200101__20200930_zgNnHTWKuPB1" title="Entity Incorporation, State or Country Code"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span>
            </td>
            <td style="width: 22%; text-align: center">&#160;</td>
            <td style="width: 18%; text-align: center">&#160;</td>
            <td style="border-bottom: Black 1pt solid; width: 11%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20200101__20200930_zegeudG7AOH5" title="Entity Tax Identification Number"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:EntityTaxIdentificationNumber">87-0233535</ix:nonNumeric></span></b></span>
            </td>
            <td style="width: 19%; text-align: center">&#160;</td>
        </tr>
        <tr style="vertical-align: top; text-align: left">
            <td colspan="3" style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">(State or Other Jurisdiction of Incorporation or Organization)</span>
            </td>
            <td colspan="3" style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer Identification No.)</span>
            </td>
        </tr>
    </table>
    <p style="margin: 0">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
        <tr style="vertical-align: top; text-align: left">
            <td style="border-bottom: Black 1pt solid; width: 60%; text-align: center"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20200101__20200930_z2XWZSEr7o87" title="Entity Address, Address Line One"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:EntityAddressAddressLine1">951 Yamato Road</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressAddressLine2_c20200101__20200930_zOBMjkeS52I8" title="Entity Address, Address Line Two"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:EntityAddressAddressLine2">Suite 220</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressCityOrTown_c20200101__20200930_zEGe8OF8sMq4" title="Entity Address, City or Town"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:EntityAddressCityOrTown">Boca Raton</ix:nonNumeric></span> <span id="xdx_903_edei--EntityAddressStateOrProvince_c20200101__20200930_zyTewaxQC5ph" title="Entity Address, State or Province"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span></b>
            </td>
            <td style="width: 18%; text-align: center">&#160;</td>
            <td style="border-bottom: Black 1pt solid; width: 4%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--EntityAddressPostalZipCode_c20200101__20200930_zKqqxndAnT34" title="Entity Address, Postal Zip Code"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:EntityAddressPostalZipCode">33431</ix:nonNumeric></span></b></span>
            </td>
            <td style="width: 18%; text-align: center">&#160;</td>
        </tr>
        <tr style="vertical-align: top; text-align: left">
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">(Address of Principal Executive Offices)</span>
            </td>
            <td colspan="3" style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">(Zip Code)</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--CityAreaCode_c20200101__20200930_zGHZ9LyR5ln"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:CityAreaCode">561</ix:nonNumeric></span>
    <span id="xdx_90C_edei--LocalPhoneNumber_c20200101__20200930_za78Z0bOuXa"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:LocalPhoneNumber">961-1900</ix:nonNumeric></span></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">(Registrant&#x2019;s telephone number, including area code)</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Not Applicable</span></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">Securities registered pursuant to Section 12(b) of the Act:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 40%; text-align: center"><b>Title
    of Each Class</b></td>
    <td style="border: Black 1pt solid; width: 15%; text-align: center"><b>Trading Symbol</b></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 45%; text-align: center"><b>Name
    of Each Exchange on Which Registered</b></td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span id="xdx_900_edei--Security12bTitle_c20200101__20200930_zYrV6CoDBzNg"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span id="xdx_906_edei--TradingSymbol_c20200101__20200930_zkB64Xze0yI"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:TradingSymbol">TXMD</ix:nonNumeric></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span id="xdx_90C_edei--SecurityExchangeName_c20200101__20200930_zD9ozn06THw3"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr>
</table>

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <span id="xdx_909_edei--EntityCurrentReportingStatus_c20200101__20200930_z1CfPGrZwkI9"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#x2610;</span>

        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xA7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <span id="xdx_904_edei--EntityInteractiveDataCurrent_c20200101__20200930_zdaoENJt2jIi"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#x2612; No &#x2610;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x201C;large accelerated filer,&#x201D; &#x201C;accelerated filer,&#x201D; &#x201C;smaller reporting company&#x201D; and &#x201C;emerging growth company&#x201D; in Rule 12b-2 of the Exchange Act (Check one):</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 30%"><span id="xdx_900_edei--EntityFilerCategory_c20200101__20200930_zNCDlwhBdhDa"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" name="dei:EntityFilerCategory">Large Accelerated Filer</ix:nonNumeric></span> &#9746;</td>
    <td style="width: 20%">&#160;</td>
    <td style="width: 30%">Accelerated filer &#x2610;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>Non-accelerated filer &#x2610;</td>
    <td>&#160;</td>
    <td>Smaller reporting company <span id="xdx_902_edei--EntitySmallBusiness_c20200101__20200930_zZgXPkNdC9fe"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" format="ixt:booleanfalse" name="dei:EntitySmallBusiness">&#x2610;</ix:nonNumeric></span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Emerging growth company <span id="xdx_904_edei--EntityEmergingGrowthCompany_c20200101__20200930_zevWIp3pmWx9"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#x2610;</ix:nonNumeric></span></td></tr>
</table>

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x2610;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#x2610;<span id="xdx_90B_edei--EntityShellCompany_c20200101__20200930_zuhFutvqJGO"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <span style="font: 10pt Times New Roman, Times, Serif">The
    number of shares outstanding of the registrant&#x2019;s common stock, par value $0.001 per share, as of November 2, 2020 was <span id="xdx_909_edei--EntityCommonStockSharesOutstanding_iI_uShares_c20201102_ztxEGU5Sv8Ek" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2020-11-02" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">272,812,271</ix:nonFraction></span>.</span> </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span>
    </p>
    <!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>
<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Page</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">PART
    I - FINANCIAL INFORMATION</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 10%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 78%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 10%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-top: 2pt; padding-left: 17.3pt; text-indent: -8.65pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Item.
    1</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Financial
    Statements</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#financialsa001">Consolidated Balance Sheets as of September 30, 2020 (Unaudited) and December 31, 2019</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">3</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#financialsa002">Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2020 (Unaudited) and 2019 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">4</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#financialsa003">Consolidated Statements of Stockholders' (Deficit) Equity for the Three and Nine Months Ended September 30, 2020 (Unaudited) and 2019 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">5</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#financialsa004">Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2020 (Unaudited) and 2019 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">6</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#financialsa005">Notes to Unaudited Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">7</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; padding-top: 2pt; padding-left: 17.3pt; text-indent: -8.65pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
    2.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_001">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">25</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-top: 2pt; padding-left: 17.3pt; text-indent: -8.65pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
    3.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_002">Quantitative and Qualitative Disclosures about Market Risks</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">42</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-top: 2pt; padding-left: 17.3pt; text-indent: -8.65pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
    4.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_003">Controls and Procedures</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">42</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_004">Part II - OTHER INFORMATION</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">43</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-top: 2pt; padding-left: 17.3pt; text-indent: -8.65pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
    1.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_005">Legal Proceedings</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">43</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-top: 2pt; padding-left: 17.3pt; text-indent: -8.65pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
    1A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_006">Risk Factors</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">44</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-top: 2pt; padding-left: 17.3pt; text-indent: -8.65pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
    5.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_007">Other Information</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">45</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-top: 2pt; padding-left: 17.3pt; text-indent: -8.65pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
    6.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_008">Exhibits</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">45</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="financialsa001"></span>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_111_pp0p0_zLw8UCwmPnG6" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20200930_z3QH0opNIJHc" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>September 30,</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>2020</b></p></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_494_20191231_zLoyGjcsfVcd" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>December 31,</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>2019</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>(Unaudited)</b></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AssetsAbstract_iB_zXJmNKWe20l7" style="vertical-align: bottom">
    <td colspan="9" style="text-align: center">ASSETS</td></tr>
<tr id="xdx_409_eus-gaap--AssetsCurrentAbstract_i01B_z4ViqXu6lPi8" style="vertical-align: bottom">
    <td style="text-align: left">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--Cash_i02I_maCzCIn_zDQnMEg6nVqf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 73%; text-indent: -8.65pt; padding-left: 17.3pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">79,633,675</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">160,829,713</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzCIn_zl9hKdzGzXIc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span title="Accounts receivable, net of allowance for doubtful accounts of $857,176 and $904,040, respectively">Accounts receivable, net of allowance for doubtful accounts of $<span id="xdx_90A_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20200930_zZfRrrGxeTQd" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">857,176</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20191231_zuD55VG3yci2" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">904,040</ix:nonFraction></span>, respectively</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,059,095</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,395,958</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--InventoryNet_i02I_maCzCIn_z0TRgi9LdhSd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Inventory, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,932,304</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,860,716</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzCIn_ztpxnNiGLzl4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt">Other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,819,239</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,329,793</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AssetsCurrent_i02TI_mtCzCIn_maCzYME_zdH93rPPxUFf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt">&#160;Total current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">122,444,313</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">208,416,180</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzYME_zTSRJ3phMY04" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Fixed assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,969,929</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,507,775</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--OtherAssetsAbstract_i01B_zE4meT0txKl4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 0.125in">Other Assets:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_ecustom--LicenseRights_i02I_uUSD_maCz2j8_zYNh5ed7xIP" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">License rights, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:LicenseRights" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,959,305</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:LicenseRights" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,221,308</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maCz2j8_zmQBc4Ql7WQl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,537,885</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,258,211</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCz2j8_zsst64ST1gs8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Right of use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,975,725</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,109,154</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--OtherAssetsMiscellaneousNoncurrent_i02I_maCz2j8_zf6yKI2WVm2a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt">Other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsMiscellaneousNoncurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">403,643</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsMiscellaneousNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">473,009</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OtherAssetsNoncurrent_i02TI_mtCz2j8_maCzYME_zj5QlUiuY0Pj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt">Total other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,876,558</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,061,682</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--Assets_i01TI_mtCzYME_zXk8VGBZxKC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 0.5in">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">177,290,800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">265,985,637</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_znIoXpZrSCwb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_i01B_z5Wd2mLS0Mqk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_i02I_maCzO2e_zeaebAkGffxk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,109,638</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,181,212</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzO2e_zuov2BK3pyO1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt">Other current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,220,484</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,823,613</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--LiabilitiesCurrent_i02TI_mtCzO2e_maCzNLB_zgJiJBJ5BAeh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 25.9pt">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,330,122</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,004,825</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--LongTermDebtNoncurrentAbstract_i01B_z91sckar8Cj2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-Term Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--LongTermDebtNoncurrent_i02I_maCzMsH_zH0YKnPoYQhl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Long-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">237,051,202</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">194,634,643</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maCzMsH_z0DPTzpzQGh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,907,995</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,145,049</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OtherLiabilitiesNoncurrent_i02I_maCzMsH_z4YdBGWzBRq9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt">Other long-term liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0125">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--LiabilitiesNoncurrent_i02I_mtCzMsH_maCzNLB_zve458ouVDXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt">Total long-term liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">245,994,197</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">203,779,692</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--Liabilities_i01TI_mtCzNLB_maTotalLAndS_z2XlBJmx0se7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 0.5in">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">293,324,319</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">256,784,517</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Commitments and Contingencies - See Note 15</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_i01B_zLsenbW3wFB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders' (Deficit) Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PreferredStockValue_i02I_maCzutK_zEodFx7y7YW4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Preferred stock - par value $<span title="Preferred Stock, Par or Stated Value Per Share"><span title="Preferred Stock, Par or Stated Value Per Share"><span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_uUSDPShares_c20200930_zlZkOFT8ZW5e"><span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_uUSDPShares_c20191231_zjhn3egEV9J"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span></span></span>; <span title="Preferred Stock, Shares Authorized"><span title="Preferred Stock, Shares Authorized"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_uShares_c20200930_zEVEv8HFpQ4h"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_uShares_c20191231_z7VjUF5aNwG1"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span></span></span> shares authorized; &#160;<span title="Preferred Stock, Shares Issued"><span title="Preferred Stock, Shares Issued"><span title="Preferred Stock, Shares Outstanding"><span title="Preferred Stock, Shares Outstanding"><span title="Preferred Stock, Shares Issued"><span title="Preferred Stock, Shares Issued"><span title="Preferred Stock, Shares Outstanding"><span title="Preferred Stock, Shares Outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pip0_do_uShares_c20200930_zo2c7wAR4ZBa"><span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pip0_do_uShares_c20191231_zqsWmtSzlEj9"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_pip0_do_uShares_c20200930_zI0UGSOZwlc8"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pip0_do_uShares_c20191231_zdcrWtiZjWHk"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-09-30" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2019-12-31" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-09-30" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2019-12-31" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span></span></span></span></span></span></span></span></span> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0136">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0137">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--CommonStockValue_i02I_maCzutK_zRXp3cSW3uYc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Common stock - par value $<span title="Common Stock, Par or Stated Value Per Share"><span title="Common Stock, Par or Stated Value Per Share"><span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_uUSDPShares_c20200930_zldtqU1MID0l"><span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_uUSDPShares_c20191231_z0TQh2G12axf"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span></span></span>; <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pip0_uShares_c20200930_zo6Zyg6I8by3"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">600,000,000</ix:nonFraction></span> and <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pip0_uShares_c20191231_zAvgioacBBl3"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">350,000,000</ix:nonFraction></span>&#160;&#160;shares authorized: <span title="Common Stock, Shares, Issued"><span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pip0_uShares_c20200930_zO20iT4wxFQc"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pip0_uShares_c20200930_zXxUj1aEG4r4"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">272,812,271</ix:nonFraction></ix:nonFraction></span></span></span> and <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pip0_uShares_c20191231_zxgi0rvjYXq5"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pip0_uShares_c20191231_zePv5eKczUKl"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">271,177,076</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">272,812</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,177</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maCzutK_zYjlo5kVV2Y6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">720,551,488</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">704,351,222</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzutK_zegLVGOOweK7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">836,857,819</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">695,421,279</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_401_eus-gaap--StockholdersEquity_i02TI_mtCzutK_maTotalLAndS_zKIpwMxduaH7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 34.55pt">Total stockholders' (deficit) equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">116,033,519</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,201,120</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtTotalLAndS_zGdroAXvG1D7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 0.625in">Total liabilities and stockholders' (deficit) equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">177,290,800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">265,985,637</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="financialsa002"></span>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" id="xdx_30F_113_pp0p0_zu7kcXpWp0H6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td id="xdx_498_20200701__20200930_zbZ52q8BjmZ2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="4" id="xdx_492_20190701__20190930_zUyychij2dy3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_49E_20200101__20200930_zNX1wkSjQRpi" style="text-align: center">&#160;</td>
    <td colspan="4" id="xdx_49D_20190101__20190930_zyDkPHh9dXSd" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center"><b>Three Months Ended</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>Nine Months Ended</b></td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: left">Product revenue, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20200701__20200930__srt--ProductOrServiceAxis__us-gaap--ProductMember_zSbOi7wZodDc" title="Total revenue, net" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-07-012020-09-30_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,342,805</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--ProductMember_zQ8QEGNgMzIh" title="Total revenue, net" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,213,341</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--ProductMember_zYJNDpif1xya" title="Total revenue, net" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-09-30_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,294,495</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--ProductMember_zEcI3Rs5d45f" title="Total revenue, net" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-09-30_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,238,857</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">License revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20200701__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z0ASuGJz4GZa" title="Total revenue, net" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-07-012020-09-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zFUlMRBG6bCj" title="Total revenue, net" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,506,400</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zpmCxtuj5Bxl" title="Total revenue, net" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-09-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zA3N5ajkirgh" title="Total revenue, net" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-09-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,506,400</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCzfld_z2FnsMHWt3t5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Total revenue, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,342,805</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,719,741</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,294,495</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,745,257</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--CostOfGoodsAndServicesSold_msCzfld_zhGhJUjBxdi1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Cost of goods sold</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,278,609</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,444,308</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,394,145</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,455,995</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--GrossProfit_iT_mtCzfld_maCzyty_zzCdFLVbFwsj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Gross profit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,064,196</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,275,433</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,900,350</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,289,262</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--OperatingExpensesAbstract_iB_zgEWF7rXYwC2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maCzrT6_zpGpMfnAnp3a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Sales, general, and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,751,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,126,986</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">144,018,899</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">121,378,519</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzrT6_z1RZdbAJRGIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,027,195</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,077,738</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,038,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,359,988</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--DepreciationAndAmortization_i01_maCzrT6_zkOtuwnxmEsl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">258,787</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">141,959</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">777,338</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">363,956</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingExpenses_i01T_mtCzrT6_msCzyty_zqHNzMsk9x3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,037,232</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,346,683</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">152,834,293</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">137,102,463</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_iT_mtCzyty_maCzYA2_z1ZlPqpFrpe1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">24,973,036</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">27,071,250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">120,933,943</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">106,813,201</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zjbP4LfhL9ca" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other (expense) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maNIEzyG4_z79iRd225Ale" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0236">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0237">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,057,632</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--OtherNonoperatingIncome_i01_maNIEzyG4_z4P0nEmosLql" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Miscellaneous income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,405</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">703,662</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">465,745</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,878,980</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--InterestExpense_i01N_di_msNIEzyG4_zF5gzz1HNCqd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt">Interest expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,679,443</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,599,005</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,968,342</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,717,632</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_408_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEzyG4_maCzYA2_zuavGSRVpvAd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt">Total other expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">7,638,038</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,895,343</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">20,502,597</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">19,896,284</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzYA2_maCzwgn_zoauoAomELA5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">32,611,074</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">31,966,593</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">141,436,540</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">126,709,485</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_msCzwgn_zCaTeMwrFMFi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Provision for income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--NetIncomeLoss_iT_mtCzwgn_zvKpuTl9sSvd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">32,611,074</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">31,966,593</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">141,436,540</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">126,709,485</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--EarningsPerShareAbstract_iB_zHHcfeFHE323" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss per share, basic and diluted:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--EarningsPerShareBasicAndDiluted_i01_pip0_zqkm4VX65qD4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.52</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.53</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_zKotoLrrDF2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">Weighted average number of common shares outstanding, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">272,564,635</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">241,261,299</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">271,968,981</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">241,163,994</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="financialsa003"></span>CONSOLIDATED
STATEMENTS OF STOCKHOLDERS&#8217; (DEFICIT) EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_114_zezGB4f0Lqw1" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (DEFICIT) (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zJmv5UpZHSLc">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z0Z6HPwMzr7i" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zHw3VyU72cCf">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B9_zZLUr3CvQOpa">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Additional</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2"><b>&#160;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2"><b>&#160;</b></td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Common Stock</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Paid in</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Accumulated</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2"><b>&#160;</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Shares</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Capital</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Deficit</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Total</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_43D_c20190101__20190331_eus-gaap--StockholdersEquity_iS_uUSD_zsi5Ve9a5brh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-weight: bold">Balance, December 31, 2018</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--CommonStockSharesOutstanding_iS_d0_uShares_c20190101__20190331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCZ6CKbk8Xi" title="Beginning balance, shares" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">240,462,439</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td title="Beginning balance, value" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,463</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td title="Beginning balance, value" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">616,559,938</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td title="Beginning balance, value" style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">519,276,280</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td title="Beginning balance, value" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,524,121</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_uUSD_zOWjne1mQm3g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued for exercise of options and warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_uShares_c20190101__20190331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQVgwupKL5Ee" title="Shares issued for exercise of options and warrants, net (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">759,401</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Shares issued for exercise of options and warrants, net" style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">759</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,348</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,107</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_uUSD_zmV5raHSW9mi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Share-based compensation" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,575,369</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,575,369</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--NetIncomeLoss_uUSD_z9N6u18Yi8mi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Net loss" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,506,375</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,506,375</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_435_c20190101__20190331_eus-gaap--StockholdersEquity_iE_uUSD_zTFK9Q2jBvz6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance, March 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--CommonStockSharesOutstanding_iE_d0_uShares_c20190101__20190331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7KhC2A8stE4" title="Ending balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">241,221,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">241,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">619,234,655</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">558,782,655</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,693,222</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, shares" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43D_c20190401__20190630_eus-gaap--StockholdersEquity_iS_uUSD_zOAlgJQRGVrg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance, March 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--CommonStockSharesOutstanding_iS_d0_uShares_c20190401__20190630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxYM2UxrriN" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">241,221,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">241,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">619,234,655</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">558,782,655</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,693,222</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_uUSD_zIY2aDXrXzh9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Share-based compensation" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,637,264</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,637,264</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--NetIncomeLoss_uUSD_z854SeX8AS0b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Net loss" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">55,236,517</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">55,236,517</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_433_c20190401__20190630_eus-gaap--StockholdersEquity_iE_uUSD_zgv0QEmMhsak" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance, June 30, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--CommonStockSharesOutstanding_iE_d0_uShares_c20190401__20190630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvJjylF0NNPh" title="Ending balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">241,221,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">241,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">621,871,919</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">614,019,172</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,093,969</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, shares" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_437_c20190701__20190930_eus-gaap--StockholdersEquity_iS_uUSD_zIfWbAwvjMAf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance, June 30, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--CommonStockSharesOutstanding_iS_d0_uShares_c20190701__20190930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zundfNdOiIzc" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">241,221,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">241,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">621,871,919</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">614,019,172</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,093,969</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_uUSD_zxMHy2Gn1X32" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued for exercise of options and warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_uShares_c20190701__20190930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjrKpIqPjhTc" title="Shares issued for exercise of options and warrants, net (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2019-07-012019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,236</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Shares issued for exercise of options and warrants, net" style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-07-012019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-07-012019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,494</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,549</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_uUSD_zCvoH8Itpjrc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Share-based compensation" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-07-012019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,635,146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,635,146</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--NetIncomeLoss_uUSD_z6Jzr1TSvjj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Net loss" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-07-012019-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">31,966,593</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">31,966,593</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_431_c20190701__20190930_eus-gaap--StockholdersEquity_iE_zQhdCIjhCwxg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance, September 30, 2019</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--CommonStockSharesOutstanding_iE_d0_uShares_c20190701__20190930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoY6VQXOnNve" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">241,277,076</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">241,277</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">624,515,559</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">645,985,765</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,228,929</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_431_c20200101__20200331_eus-gaap--StockholdersEquity_iS_uUSD_zAhpq1PuQ7w6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance, December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--CommonStockSharesOutstanding_iS_uShares_c20200101__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdCxCr5uwPw7" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,177,076</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td title="Beginning balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,177</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td title="Beginning balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">704,351,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td title="Beginning balance, value" style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">695,421,279</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td title="Beginning balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,201,120</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_uUSD_zZowDo9QrAz2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued for exercise of options and warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_uShares_c20200101__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9FzuUIhN5ye" title="Shares issued for exercise of options and warrants, net (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,666</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Shares issued for exercise of options, net" style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">351</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Shares issued for exercise of options, net" style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,758</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Shares issued for exercise of options, net" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Shares issued for exercise of options, net" style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2020-01-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_uUSD_zrz5UaiacEa4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of shares from release of restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_uShares_c20200101__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDj8kKsjDOtk" title="Issuance of shares from release of restricted stock (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Issuance of shares from release of restricted stock" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Issuance of shares from release of restricted stock" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">150</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Issuance of shares from release of restricted stock" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Issuance of shares from release of restricted stock" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_uUSD_z3bKI9uXW6Kf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Share-based compensation" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Share-based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,366,453</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Share-based compensation" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Share-based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,366,453</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NetIncomeLoss_uUSD_z9s1YBEigxdb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Net loss" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Net loss" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Net loss" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">56,848,802</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Net loss" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">56,848,802</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_433_c20200101__20200331_eus-gaap--StockholdersEquity_iE_uUSD_zNC7mhxXdhU7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance, March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--CommonStockSharesOutstanding_iE_uShares_c20200101__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdPoFhb8fgTa" title="Ending balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,677,742</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,678</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">706,789,283</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, value" style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">752,270,081</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, value" style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">45,209,120</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, shares" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, value" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, value" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, value" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, value" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_438_c20200401__20200630_eus-gaap--StockholdersEquity_iS_uUSD_z5uBYqvbwa31" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance, March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--CommonStockSharesOutstanding_iS_uShares_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbLP6nDtrMdd" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,677,742</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,678</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">706,789,283</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, value" style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">752,270,081</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, value" style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">45,209,120</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_uUSD_zorSO25Lrdmf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued for exercise of options and warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_uShares_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHIabpaN9Oji" title="Shares issued for exercise of options and warrants, net (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">313,638</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Shares issued for exercise of options, net" style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">313</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Shares issued for exercise of options, net" style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,762</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Shares issued for exercise of options, net" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Shares issued for exercise of options, net" style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,075</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_uUSD_zzk16dqjZZml" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of shares from release of restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_uShares_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjiFbOYdzM" title="Issuance of shares from release of restricted stock (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">303,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Issuance of shares from release of restricted stock" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">303</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Issuance of shares from release of restricted stock" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">303</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0426">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Issuance of shares from release of restricted stock" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_uUSD_zTCt1KOcHkCd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Share-based compensation" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Share-based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,002,826</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Share-based compensation" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Share-based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,002,826</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--NetIncomeLoss_uUSD_zIVrfPbeD7pb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Net loss" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Net loss" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0437">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Net loss" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">51,976,664</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Net loss" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">51,976,664</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_430_c20200401__20200630_eus-gaap--StockholdersEquity_iE_uUSD_z1cCvGgKQ8g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance, June 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--CommonStockSharesOutstanding_iE_uShares_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znS7CSQLatn9" title="Ending balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">272,294,380</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">272,294</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">709,885,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">804,246,745</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,088,883</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, shares" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43A_c20200701__20200930_eus-gaap--StockholdersEquity_iS_uUSD_zbgEo7xhMTI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance, June 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--CommonStockSharesOutstanding_iS_uShares_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQKyBRrm3L57" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">272,294,380</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">272,294</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">709,885,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">804,246,745</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Ending balance, value" style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,088,883</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_uUSD_zqr7waiC2nG4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued for exercise of options and warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_uShares_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMdyBxronoda" title="Shares issued for exercise of options and warrants, net (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">517,891</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Shares issued for exercise of options, net" style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">518</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Shares issued for exercise of options, net" style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,976</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Shares issued for exercise of options, net" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Shares issued for exercise of options, net" style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,494</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_uUSD_zgd8TfpU4IB6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Share-based compensation" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Share-based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,132,765</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Share-based compensation" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Share-based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,132,765</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_uUSD_zlNPWsuoBOQk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrant granted in relation to Financing Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Warrant granted in relation to Financing Agreement" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Warrant granted in relation to Financing Agreement" style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,428,179</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Warrant granted in relation to Financing Agreement" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Warrant granted in relation to Financing Agreement" style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,428,179</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--NetIncomeLoss_uUSD_z5TwnQvogVok" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Net loss" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0472">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Net loss" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0473">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Net loss" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,611,074</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Net loss" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,611,074</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_432_c20200701__20200930_eus-gaap--StockholdersEquity_iE_uUSD_z9ZVKr8MTz8d" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance, September 30, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--CommonStockSharesOutstanding_iE_uShares_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zU61PzW7tjw4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">272,812,271</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">272,812</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">720,551,488</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">836,857,819</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td title="Ending balance, value" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">116,033,519</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="financialsa004"></span>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_112_pp0p0_z3MpuB3J99Wf" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_496_20200101__20200930_z7P65hvNVEAi" style="text-align: center">&#160;</td>
    <td colspan="4" id="xdx_49B_20190101__20190930_z1LgiIQMRrcb" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center"><b>Nine Months Ended</b></td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zxsLO4cZSNYa" style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_uUSD_maCzyMU_zVaHHAIW8Iqk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">141,436,540</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">126,709,485</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zK6VHb5H6vVc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 25.9pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--Depreciation_i02_uUSD_maCzyMU_zZlufYWzxr1i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 34.55pt">Depreciation of fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">576,459</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">223,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--AmortizationOfIntangibleAssets_i02_uUSD_maCzyMU_zyKFqbf2Xcnf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 34.55pt">Amortization of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,879</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">140,206</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_i02_uUSD_maCzyMU_zcpIZY52CEW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 34.55pt">Write off of patent and trademark costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">584,509</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,864</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--WriteOffOfDeferredDebtIssuanceCost_i02_uUSD_maCzyMU_z8VtJg7lxg7f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 34.55pt">Write off of deferred financing fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">275,379</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--NoncashOperatingLeaseExpense_i02_uUSD_maCzyMU_zPoCCw9E4Spj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 34.55pt">Non-cash operating lease expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:NoncashOperatingLeaseExpense" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,050,940</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:NoncashOperatingLeaseExpense" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">711,836</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--ProvisionForDoubtfulAccounts_i02_uUSD_maCzyMU_zpkv2zvCol7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 34.55pt">(Recovery of) provision for doubtful accounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">46,864</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">95,097</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--OperatingLeaseImpairmentLoss_i02_uUSD_maCzyMU_zaQqN3COSVsi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 34.55pt">Lease impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,309</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0512">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--InventoryWriteDown_i02_uUSD_maCzyMU_zMaYG6bLVZzd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 34.55pt">Inventory obsolesence reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,744,464</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_uUSD_msCzyMU_z0K0vBxGfUj7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 34.55pt">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0517">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,057,632</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--ShareBasedCompensation_i02_uUSD_maCzyMU_zwvNqErAyBlj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 34.55pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,502,044</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,859,357</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--AmortizationOfIntellectualPropertyLicenseFee_i02_uUSD_maCzyMU_zFWfOTkDKgYf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 34.55pt">Amortization of intellectual property license fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AmortizationOfIntellectualPropertyLicenseFee" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,262,002</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AmortizationOfIntellectualPropertyLicenseFee" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,998</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AmortizationOfFinancingCosts_i02_uUSD_maCzyMU_zwLJT04k5Vv8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 34.55pt">Amortization of deferred financing fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,370,118</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">582,829</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_uUSD_zNkTx0EYkox8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 0.6in">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_uUSD_msCzyMU_zYStKsPWzIG9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 0.6in">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">383,727</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,354,890</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_401_eus-gaap--IncreaseDecreaseInInventories_i03N_di_uUSD_msCzyMU_zjOuYMGl9qp5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -8.65pt; padding-left: 0.6in">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,816,053</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,265,174</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i03N_di_msCzyMU_zVQVKz3zN6N1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 0.6in">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,003,079</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,128,515</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maCzyMU_zG8q264Puegf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 0.6in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,071,574</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,389,665</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--IncreaseDecreaseInOtherOperatingLiabilities_i03_uUSD_maCzyMU_zY7oN9WQDnaf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 0.6in; padding-bottom: 1pt">Other current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,812,919</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,402,511</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_uUSD_mtCzyMU_maCznNm_zF7rL6hAwI3l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">129,149,041</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">114,900,319</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zzSFvHTHgEK" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_uUSD_msCzVCV_zGw0MDUi4fp" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 25.9pt">Patent costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,065,062</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,068,542</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_uUSD_msCzVCV_zsSMZNGcHNQf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 25.9pt">Purchase of fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,613</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,089,413</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_403_ecustom--IncreaseDecreaseInSecurityDeposit_i01_uUSD_maCzVCV_ztK0D28mSC9k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt">Security deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="txmd:IncreaseDecreaseInSecurityDeposit" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="txmd:IncreaseDecreaseInSecurityDeposit" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">20,420</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_uUSD_mtCzVCV_maCznNm_zVUWEWc7CH39" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,068,675</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,178,375</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zwugACqc1G39" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--ProceedsFromStockOptionsExercised_i01_uUSD_maCzHmj_z31z26mkEyeh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 25.9pt">Proceeds from exercise of options and warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,678</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">108,656</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--RepaymentsOfLinesOfCredit_i01N_di_uUSD_msCzHmj_zQIxwbsAWw08" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 25.9pt">Repayment of the Credit Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,660,719</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--ProceedsFromLinesOfCredit_i01_uUSD_maCzHmj_z49FNtPXELhi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 25.9pt">Proceeds from the Financing Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--PaymentsOfFinancingCosts_i01N_di_uUSD_msCzHmj_zXMoslKzIfYd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt">Payment of deferred financing fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,250,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,652,270</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_uUSD_mtCzHmj_maCznNm_zMPun5l66nQj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,021,678</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">111,795,667</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_uUSD_mtCznNm_zAx0TLUim1M3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Decrease in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">81,196,038</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,283,027</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_uUSD_zi7UuRvQVOg8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt">Cash, beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">160,829,713</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">161,613,077</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_uUSD_zi2kxVD19jZi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 17.3pt">Cash, end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">79,633,675</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">155,330,050</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zUidN4n6JRPc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Supplemental disclosure of noncash investing and financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--WarrantGrantedInRelationToFinancingAgreement_i01_uUSD_zcrf4UEANnp" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 17.3pt">Warrant granted in relation to Financing Agreement</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="txmd:WarrantGrantedInRelationToFinancingAgreement" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,428,179</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0596">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--AmountAccruedForIntellectualPropertyLicense_i01_uUSD_zx07Nq5bL0K6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 17.3pt">Amount accrued for intellectual property license</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0598">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="txmd:AmountAccruedForIntellectualPropertyLicense" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zNoAvsI8Vibl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Supplemental disclosure of cash flow information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--InterestPaidNet_i01_uUSD_z4jr5MIVgPcb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 17.3pt">Interest paid</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,172,847</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,446,792</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="financialsa005"></span>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:NatureOfOperations"><p id="xdx_809_eus-gaap--NatureOfOperations_zQC4O8yz5zy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_826_z8RpcEUJpw05">NOTE
1 &#8211; THE COMPANY</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD,
Inc., a Nevada corporation, or TherapeuticsMD or the Company, has&#160;<span id="xdx_90E_ecustom--NumberOfSubsidiaries_iI_dc_uNumber_c20200930_zxqdmn83mIXb" title="Number of subsidiaries"><ix:nonFraction name="txmd:NumberOfSubsidiaries" contextRef="AsOf2020-09-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Number">three</ix:nonFraction></span>&#160;wholly owned subsidiaries, vitaMedMD, LLC, a
Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and vitaCare Prescription
Services, Inc., a Florida corporation, or vitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen,
and vitaCare collectively are sometimes referred to as &#8220;our company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us.&#8221;
TherapeuticsMD<sup>&#174;</sup>, vitaMedMD<sup>&#174;</sup>, BocaGreenMD<sup>&#174;</sup>, IMVEXXY<sup>&#174;</sup>, BIJUVA<sup>&#174;&#160;</sup>and
ANNOVERA<sup>&#174;</sup>&#160;are registered trademarks of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Nature
of Business</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">We
are a women&#8217;s healthcare company with a mission of creating and commercializing innovative products to support the
lifespan of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical
expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women.
Our solutions range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical
products. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD and
BocaGreenMD brands. Our portfolio of products focused on women&#8217;s health allows us to efficiently leverage our sales and
marketing plan to grow our recently approved products. During 2018, the U.S. Food and Drug Administration, or FDA, approval
of our pharmaceutical products has transitioned our company from predominately focused on conducting research and development
to one focused on commercializing our pharmaceutical products. In July 2018, we launched our FDA-approved product, IMVEXXY
(estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual
activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched our FDA-approved
product BIJUVA (estradiol and progesterone) capsules, our hormone therapy combination of bio-identical 17&#223;-estradiol and
bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or
VMS, due to menopause in women with a uterus. In October 2019, we began a test and learn market introduction for our
FDA-approved product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only annual
patient-controlled, procedure-free, reversible prescription contraceptive option for women. Although we expected to commence
the full commercial launch of ANNOVERA in the first quarter of 2020, as a result of the uncertainty surrounding the COVID-19
pandemic, we paused the commercial launch of ANNOVERA and deferred sales and marketing initiatives into subsequent quarters
as the pandemic began to negatively affect our revenue growth. We resumed the launch of ANNOVERA on July 1, 2020. On July 30,
2018, we entered into an exclusive license agreement, or the Population Council License Agreement, with the Population
Council, Inc., or the Population Council, to commercialize ANNOVERA in the U.S. In addition, on July 30, 2018, we entered
into a license and supply agreement, or the Knight License Agreement, with Knight Therapeutics Inc., or Knight, pursuant to
which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. On June 6, 2019, we
entered into an exclusive license and supply agreement, or the Theramex License Agreement, with Theramex HQ UK Limited, or
Theramex, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel, or the Theramex
Territory.</span></p>

</ix:nonNumeric><p id="xdx_81E_zUGr7BYQH2m9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_801_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z5t4Jc3pzweg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_825_zNY5DSa5H6Hf">NOTE
2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Interim
Financial Statements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries,
should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report
on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission, or the SEC, from which
we derived the accompanying consolidated balance sheet as of December 31, 2019. The accompanying unaudited interim consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America,
or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly,
since they are interim statements, the accompanying unaudited interim consolidated financial statements do not include all of
the information and notes required by GAAP for complete financial statements. The accompanying unaudited interim consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management,
necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative
of results for a full year or any other interim period in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Risks
and Uncertainties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">We
continue to be subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the future impact of the
COVID-19 pandemic on our business continues to be highly uncertain and difficult to predict. We continue to provide an uninterrupted
supply of our portfolio of products for patients. We have sufficient inventory of finished product to meet anticipated demand
in the near future. Additionally, we currently do not foresee any interruption in our ability to continue to manufacture additional
product to be used beyond this period and have sufficient active pharmaceutical ingredients on hand for the continued manufacture
of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_232_z8g8Ap4u3GBc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p id="xdx_231_zIQHJn3zceq5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#160;</p></div>
    <div id="xdx_23D_zMAFb6o2kFyd" style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zSK7XyKeyeA4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">Since
the early phase of the COVID-19 pandemic, we have been using substantial virtual options to ensure business continuity. Our vitaCare
Prescription Services patient model assists patients in obtaining easy and convenient access to their prescriptions for products
at a retail pharmacy of their choice, including via home delivery retail pharmacy options. We have also partnered with independent
community pharmacies and multiple third-party online pharmacies and telemedicine providers that focus on contraception or menopause
to ensure patients have real-time access to both diagnosis and treatment. We continue to support prescribers&#8217; needs with
samples and product materials through our sales force. If access is restricted, we have mailing options in place for these materials.
We also have business continuity plans and infrastructure in place that allows for virtual detailing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">As
part of our response to the COVID-19 pandemic, we implemented measures to reduce marketing expenses for 2020. We also implemented
cost saving measures, which included negotiating lower fees or suspending services from third party vendors; implementing a company-wide
hiring restriction; delaying or cancelling non-critical information technology projects; and eliminating non-essential travel,
entertainment, meeting, and event expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">The
full impact of the&#160;COVID-19 pandemic continues to evolve. However, we remain committed to the execution of our corporate
goals, despite the ongoing COVID-19 pandemic, as demonstrated in part by the increase of our third quarter 2020 product
revenues as compared to our second quarter 2020 product revenues. As of the date of issuance of these consolidated financial
statements, the future extent to which the COVID-19 pandemic may continue to materially impact our financial condition,
liquidity, or results of operations remains uncertain. We are continuing to assess the effect the COVID-19 pandemic on our
operations by monitoring the spread of COVID-19 and the various actions implemented to combat the virus throughout the world.
Even after the&#160;COVID-19 pandemic has subsided, we may continue to experience adverse impacts to our business as a result
of any economic recession or depression that has occurred or may occur in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">While
we currently believe that our COVID-19 contingency plan has the ability to mitigate the effect of the COVID-19 pandemic on our
business, the severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but
not limited to, the duration and severity of the pandemic, the duration of &#8220;social distancing&#8221; orders, the ability
of our sales force to access healthcare providers to promote our products, increases in unemployment, which could reduce access
to commercial health insurance for our patients, thus limiting payer coverage for our products, and the impact of the pandemic
on our global supply chain, all of which are uncertain. Our future results of operations and liquidity could be materially adversely
affected by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions, uncertain
demand, and the impact of any initiatives or programs that we may undertake to address financial and operations challenges that
we may face.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Liquidity
and Going Concern</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">As of the filing date of this Quarterly Report on Form 10-Q, our cash balance was above the $<span id="xdx_90F_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201109__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNRtFj0LMERf" title="Minimum cash balance required under credit agreement"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="AsOf2020-11-09_custom_FinancingAgreementMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">60</ix:nonFraction>
million</span> balance as required by the Financing Agreement (as defined in Note 9 - Debt). On November 8, 2020, we and our subsidiaries entered into
Amendment No. 6 to the Financing Agreement, or Amendment No. 6, with the Administrative Agent (as defined in Note 9 - Debt) and the lenders party thereto,
pursuant to which we temporarily lowered the minimum required cash balance from $<span id="xdx_90E_ecustom--MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6yLSNY2GXQ7" title="Minimum cash balance requirement under credit agreement before adjustment"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">60</ix:nonFraction>
million</span> to $<span id="xdx_906_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Period1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zk6Xsvdsh0w3"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Period1Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">45</ix:nonFraction>
million</span> through December 31, 2020. After December 31, 2020, the minimum cash balance will revert to $<span id="xdx_905_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Period2Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRnQcJzWfiDf"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Period2Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">60</ix:nonFraction>
million</span>. Based on our current projections, we will need to raise additional capital to remain in compliance with this
minimum cash balance covenant for the next twelve months from the issuance of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">In order to address our projected capital needs, we are pursuing various equity financing and other alternatives including the sale of a controlling interest in vitaCare Prescription Services for which we commended a sale process and received initial indications of interest.   The equity financing alternatives may include the private placement of equity, equity-linked, or other similar instruments or obligations with one or more investors, lenders, or other institutional counterparties or an underwritten public equity or equity-linked securities offering. Our ability to sell equity securities may be limited by market conditions. To the extent that we raise additional capital through the sale of such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">Along with considering additional financings, we have reviewed numerous potential scenarios in connection with the impact of COVID-19 on our business including the impact of the recent steps we have taken to reduce our operating expenses in response. Based on our analysis, we believe that our existing cash reserves along with potential proceeds from the sale of certain non-core assets of the Company and proceeds from potential future financings, if available to us, would be sufficient to meet our cash needs arising in the ordinary course of business for the next twelve months from the date of this Quarterly Report on Form 10-Q.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">However,
if we are unsuccessful with future financings and if the successful commercialization of IMVEXXY, BIJUVA, or ANNOVERA is
delayed, or the continued impact of the COVID-19 pandemic on our business is worse than we anticipate, our existing cash
reserves would be insufficient to maintain compliance with the Financing Agreement covenants or satisfy our liquidity
requirements until we are able to successfully commercialize IMVEXXY, BIJUVA, and ANNOVERA. The presence of these projected
factors in conjunction with the uncertainty of the capital markets raises substantial doubt about the Company's ability to
continue as a going concern for the next twelve months from the issuance of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Recently
Issued Accounting Pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2018, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13 which
eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose
certain new information and modifies some disclosure requirements. The FASB developed the amendments to Accounting Standards Codification,
or ASC, 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the
notes to financial statements by focusing on requirements that clearly communicate the most important information to users of
the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and
for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions
that eliminate or modify requirements. We adopted this standard on January 1, 2020, and the adoption did not have a material effect
on our disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div id="xdx_235_z8KSqLI4ugN5" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p id="xdx_23E_zRi5957Z9ACe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#160;</p></div>
    <div id="xdx_23C_z8qWzGCAfFgb" style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_z0Ofu2UnAa36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on
Financial Instruments. The amendments in this update require a financial asset (or a group of financial assets) measured at amortized
cost basis to be presented at the net amount expected to be collected based on historical experience, current conditions, and
reasonable supportable forecasts. The amendments in this update are effective for public business entities for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted no sooner than the
first quarter of 2019. A modified retrospective approach is required for all investments, except debt securities for which an
other-than-temporary impairment had been recognized prior to the effective date, which will require a prospective transition approach
and should be applied either prospectively or retrospectively depending on the nature of the disclosure. The adoption of ASU 2016-13
requires expanded quantitative and qualitative disclosures about the Company&#8217;s expected credit losses. Effective January
1, 2020, we adopted ASU 2016-13 under a modified retrospective approach for all financial assets measured at amortized cost. There
was no adjustment recorded for the cumulative effect of adopting ASU 2016-13. The adoption expanded disclosures about our credit
losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">Other
recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified
Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial
position.</span></p>

</ix:nonNumeric><p id="xdx_81B_zggaMnzRBwKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zMxAWFQxgcpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_829_zWWUZJJcGga7">NOTE
3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"><p id="xdx_84C_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zk6qJabFcbz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_864_zRx3vtNoY2zj">Trade
Accounts Receivable and Allowance for Doubtful Accounts</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">Trade
accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts
and credit card chargebacks and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,
historical collection information, reasonable supportable forecasts and existing economic conditions and we record an allowance
that presents the net amount expected to be collected. We evaluate trade accounts receivable for delinquency. We write off delinquent
receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts,
and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase
in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately reflect bad
debts, adjustments to these reserves may be required. Our exposure to credit losses may increase if our customers are adversely
affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or
global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. Although
we have historically not experienced significant credit losses, it is possible that there could be a material adverse impact from
potential adjustments of the carrying amount of trade receivables in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z3RRKW4uBKpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86F_ztJzml9JFsCf">Fair
Value of Financial Instruments</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">Our
financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The
carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the
short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount
for long-term debt as of September 30, 2020 (as disclosed in Note 9) approximates fair value based on market activity for other
debt instruments with similar characteristics and comparable risk (Level 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by ASC 820, Fair Value Measurements, or ASC 820. The fair value hierarchy gives the highest priority to quoted prices
in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets
and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level 1</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">unadjusted
quoted prices in active markets for identical assets or liabilities;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level 2</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">quoted
prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly
or indirectly through market corroboration, for substantially the full term of the financial instrument; and</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level 3</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">unobservable
inputs for the assets or liabilities.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_234_z42U7rnZvDqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p id="xdx_23A_zfpZxpLje7gg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#160;</p></div>
    <div id="xdx_23D_zqZpGNaEDCTh" style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zGFPLe67kWAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2020 and 2019, we had&#160;<span id="xdx_90A_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_do_c20200930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9mphHV13BCg" title="Assets or liabilities valued at fair value"><span id="xdx_90B_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_do_c20190930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zD0l6Yjdgw3b" title="Assets or liabilities valued at fair value"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2020-09-30_us-gaap_FairValueMeasurementsRecurringMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2019-09-30_us-gaap_FairValueMeasurementsRecurringMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>&#160;assets or liabilities that were valued at fair value on a recurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in
connection with any required impairment test. During the nine months ended September 30, 2020 and 2019, we wrote off $<span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pp0p0_c20200101__20200930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zM1WG9lat7Nk" title="Impairment of intangible assets"><span title="Impairment of intangible assets"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="From2020-01-012020-09-30_us-gaap_TrademarksAndTradeNamesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">584,509</ix:nonFraction></span></span>
and $<span id="xdx_90D_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pp0p0_c20190101__20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zl3Y97le3Ikd" title="Impairment of intangible assets"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="From2019-01-012019-09-30_us-gaap_TrademarksAndTradeNamesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,864</ix:nonFraction></span>, respectively,&#160;in costs related to trademarks and patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z2Q9w6a4qmGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_zVqN6FWuK28k">Share-Based
Compensation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs
in the financial statements over the period during which employees are required to provide services. Share-based compensation
arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and
employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award.
We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718,
Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected
life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield.
The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity
period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price
is expected to fluctuate each year during the term of the award. On January 1, 2017, we began using our own stock price in our
volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our
company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility
is based on historical stock prices over a period equal to the expected term of the awards. On January 1, 2020, we began calculating
the expected term of our stock-based awards, which represents the period that the stock-based awards are expected to be outstanding.
Prior to January 1, 2020, the average expected life of options was based on the contractual terms of the stock option using the
simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current
intention to pay cash dividends. The assumptions used in calculating the fair value of stock-based awards represent our best estimates,
but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change
and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize
the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with
ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#8217;s requisite service
period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which
simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments
to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted
to non-employees in exchange for goods or services used or consumed in an entity&#8217;s own operations and superseded the guidance
in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required
by ASC 505, Equity - Based Payments to Non-Employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
grant performance-based stock units and restricted stock units for shares of common stock, par value $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zOdMlYlKdZH9" title="Common stock, shares, issued (in dollars per share)"><span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0bVDl65G6w1" title="Common stock, shares, issued (in dollars per share)"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-09-30_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share, or Common
Stock, to employees. We value our restricted stock units and our performance-based stock units by reference to our stock price
on the date of grant. We recognize compensation expense for restricted stock units based on a straight-line basis over the requisite
service period of the entire award. We recognize performance-based restricted stock as compensation expense based on the most
likely probability of attaining the prescribed performance and over the requisite service period beginning at its grant date and
through the date the restricted stock vests. The number of target shares that vest are determined based on the level of attainment
of the targets. If a minimum level of performance is attained for the awards, restricted stock is issued based on the level of
attainment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_844_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zcotw2sU4114" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86E_zQp4w9QBwzCi">Revenue
Recognition</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
accordance with ASC 606,&#160;<i>Revenue from Contracts with Customers</i>, or ASC 606, revenue is recognized when a customer
obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect
to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which
we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to
which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1)
identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction
price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as,
we satisfy the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Prescription
Products</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which
we began selling during the third quarter of 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA,
which we began selling in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused
the commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters.
We resumed the launch of ANNOVERA on July 1, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div id="xdx_23A_zn4tnPo17Bvl" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p id="xdx_23B_zXNC8fvTHQW3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#160;</p></div>
    <div id="xdx_235_zhBR4DktY517" style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_z0nvLq4Wnji8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have
one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised
goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer
promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than
as a separate obligation. We recognize prescription product revenue only when we satisfy performance obligations by transferring
a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods
or service or obtains control. Control refers to the customer&#8217;s ability to direct the use of, and obtain substantially all
of the remaining benefits from, an asset. Based on our contracts, we invoice customers once our performance obligations have been
satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement
of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent
to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring
promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined
based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns,
chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed
on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current
liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate
the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method,
depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable
consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount
of cumulative product revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently
resolved. In determining amounts of variable consideration to include in a contract&#8217;s transaction price, we rely on our
historical experience and other evidence that supports our qualitative assessment of whether product revenue would be subject
to a significant reversal. We consider all the facts and circumstances associated with both the risk of a product revenue reversal
arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts
of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates,
we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become
known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
accept returns of unsalable prescription products sold through wholesale distributors within a return period of <span id="xdx_905_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dt_c20200101__20200930__srt--RangeAxis__srt--MinimumMember_zO3SbBGuQ4Lc" title="Return period of unsalable prescription products"><ix:nonNumeric contextRef="From2020-01-012020-09-30_srt_MinimumMember" format="ixt-sec:durwordsen" name="txmd:ReturnPeriodOfUnsalablePrescriptionProducts">six months</ix:nonNumeric></span>
 prior to and up to <span id="xdx_906_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20200930__srt--RangeAxis__srt--MaximumMember_zhsZ9iuNdub8" title="Return period of unsalable prescription products"><ix:nonNumeric contextRef="From2020-01-012020-09-30_srt_MaximumMember" format="ixt-sec:durmonth" name="txmd:ReturnPeriodOfUnsalablePrescriptionProducts">12</ix:nonNumeric></span>
months following product expiration. Our vitamins and IMVEXXY currently have a shelf life of <span id="xdx_909_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200930__srt--ProductOrServiceAxis__custom--VitaminsAndImvexxyMember_z8av3zzitG1l" title="Shelf life of prescription products following product expiration"><ix:nonNumeric contextRef="From2020-01-012020-09-30_custom_VitaminsAndImvexxyMember" format="ixt-sec:durmonth" name="txmd:ShelfLifeOfPrescriptionProducts">24</ix:nonNumeric></span>
months from the date of manufacture and BIJUVA and ANNOVERA currently have a shelf life of <span id="xdx_903_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200930__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zvsYL7Ka94gc"><ix:nonNumeric contextRef="From2020-01-012020-09-30_custom_BijuvaAndAnnoveraMember" format="ixt-sec:durmonth" name="txmd:ShelfLifeOfPrescriptionProducts">18</ix:nonNumeric></span> months from the date of
manufacture. We do not allow product returns for prescription products that have been dispensed to a patient. We estimate the
amount of our product sales that may be returned by our customers and record this estimate as a reduction of product revenue
in the period the related product revenue is recognized. Where historical rates of return exist, we use history as a basis to
establish a returns reserve for products shipped to wholesalers. For our newly launched products, for which the right of
return exists but for which we currently do not have history of product returns, we estimate returns based on available
industry data, our own sales information and our visibility into the inventory remaining in the distribution channel. At the
end of each reporting period, we may decide to constrain product revenue for product returns based on information from
various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products
currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the
amount of expected returns as a refund liability, representing the obligation to return the customer&#8217;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return
asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of
product revenue is deferred due to the anticipated return). Return estimates are recorded in other current liabilities on the
consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales
and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience
and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates
and coupons are deducted from gross product revenues at the time the product revenues are recognized. We record distributor fees
based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in other current liabilities
on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account
prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns
are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts
and chargebacks are deducted from gross product revenues at the time the product revenues are recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
part of commercial launches for our FDA-approved prescription products, we introduced a co-pay assistance program for eligible
enrolled patients whose out of pocket costs are reduced to a more affordable price. This allows patients to access the product
at a reasonable cost and is in line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party
vendors. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize
the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current
level of prescriptions covered by patients&#8217; insurance. Payers may change coverage levels for our prescription products positively
or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction
price of our prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company.
As a result, we constrain variable consideration for our prescription products to an amount that will not result in a significant
product revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription products is
constrained by our estimates of the amount to be paid for the co-pay assistance program which is directly related to the level
of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other
patient assistance based on currently available third-party data and our internal analyses. We re-evaluate variable consideration
each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div id="xdx_23F_z1RPkijnNvX1" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p id="xdx_23E_ztI2zoVZKKv7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#160;</p></div>
    <div id="xdx_236_zcX1uT3qOKzi" style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zyft6Li4BCba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">License
Revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">License
arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending
technology, and various performance or sales milestones and future product royalty payments. Some of these arrangements may
include multiple performance obligations. Non-refundable up-front fees that are not contingent on any future performance by
us, and do not require continuing involvement on our part, are recognized as revenue when the right to use functional IP is
transferred to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Disaggregation
of revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_zwLSIYehkWu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span><span id="xdx_8BF_z1MXKnWRBXE9">The
following table provides information about disaggregated revenue by product mix</span></span> for the three and nine months ended September
30, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Three Months Ended<br /> September 30,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Nine Months Ended<br /> September 30,</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: justify; padding-left: 5.4pt">Prescription vitamins</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zKejnfyswrQ" title="Net revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-07-012020-09-30_custom_PrescriptionVitaminsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,435,903</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z2NEamSswbvb" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30_custom_PrescriptionVitaminsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,550,330</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z3bGmx2GXlVh" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-09-30_custom_PrescriptionVitaminsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,337,976</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z0sVZ7oZ6XXi" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-09-30_custom_PrescriptionVitaminsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,309,174</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">IMVEXXY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zDQQQ4gr8uv3" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-07-012020-09-30_custom_ImvexxyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,841,592</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zmw8LC9wVHT8" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30_custom_ImvexxyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,772,354</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zUy2Zc3HzfH3" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-09-30_custom_ImvexxyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,319,382</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_ztNgP73WaH98" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-09-30_custom_ImvexxyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,904,744</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">BIJUVA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--BijuvaMember_zUGGP1HjNmp4" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-07-012020-09-30_custom_BijuvaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,646,320</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zvySuT2nGia2" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30_custom_BijuvaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">490,705</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--BijuvaMember_zTF6I1TkioOc" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-09-30_custom_BijuvaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,109,925</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_ztMez4EZEkhi" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-09-30_custom_BijuvaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">624,987</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zrOHwGmsEkP1" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-07-012020-09-30_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,418,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zgXrEZCkkDdh" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">399,952</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRYca6rAQPKb" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-09-30_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,527,212</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zgkMsGbGZwxb" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-09-30_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">399,952</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">License revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z3tZZfCwZfq2" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-07-012020-09-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zRHR3xdmecB" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,506,400</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zWr0oyyGelj" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-09-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z2tCEaEiV2j3" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-09-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,506,400</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 0.375in">Net revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930_zkEoA0IraXnd" title="Net revenue" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,342,805</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930_zmbAw1ceQvGc" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,719,741</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930_zK5AEdek3glc" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,294,495</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930_zI1PeJS4ECPk" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,745,257</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A5_zyVKyulKSYwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="txmd:LicenseAgreementWithPopulationCouncilPolicyTextBlock"><p id="xdx_848_ecustom--LicenseAgreementWithPopulationCouncilPolicyTextBlock_zESClL4UWTW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_865_zxUXenFGCps4">License
Agreement with the Population Council</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
July 30, 2018, we entered into the Population Council License Agreement to commercialize ANNOVERA in the U.S. We began selling
ANNOVERA in a &#8220;test and learn&#8221; market introduction in the third quarter of 2019. As a result of the uncertainty surrounding
the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing
initiatives into subsequent quarters. <span style="color: #212529">We resumed the launch of ANNOVERA on July 1, 2020.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $<span id="xdx_90B_ecustom--MilestonePaymentUponFDAApproval_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zbb7Lr3z6SL7" title="Milestone payment upon FDA Approval"><ix:nonFraction name="txmd:MilestonePaymentUponFDAApproval" contextRef="From2020-01-012020-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></span>&#160;within
30 days following the approval by the FDA of the new drug application, or NDA, for ANNOVERA and $<span title="Milestone payments (payment after release of first commercial batch)"><span id="xdx_90D_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_z5iWvTjpO881" title="Milestone payments (payment after release of first commercial batch)"><ix:nonFraction name="txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch" contextRef="From2020-01-012020-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></span></span>&#160;within 30 days
following the first commercial batch release of ANNOVERA. Both milestone payments of $<span id="xdx_909_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zhM9QBi3N3zc" title="License rights acquired"><ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="From2020-01-012020-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></span>&#160;were recorded as license
rights in the consolidated balance sheets. We started amortizing license rights in the third quarter of 2019 once ANNOVERA became
commercially available for use. The cost is amortized over the remaining useful life over which the license rights will contribute
directly or indirectly to our cash flows, which is estimated to be the remaining patent life of the product, which expires in
December 2032. The cost is amortized using the straight-line method as the pattern of economic benefit cannot be reliably determined.
During the three and nine months ended September 30, 2020, we recorded $<span id="xdx_901_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20200701__20200930_z7CLR3V5lPjj" title="Amortization of intellectual property license fee"><ix:nonFraction name="txmd:AmortizationOfIntellectualPropertyLicenseFee" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">762,389</ix:nonFraction></span>&#160;and $<span id="xdx_90C_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20200101__20200930_zuKZh54Yu3g7" title="Amortization of intellectual property license fee"><ix:nonFraction name="txmd:AmortizationOfIntellectualPropertyLicenseFee" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,262,002</ix:nonFraction></span>, respectively, in amortization
expense related to the license fee. During both the three and nine months ended September 30, 2019, we recorded $<span id="xdx_905_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20190701__20190930_zhO37Dwc4Pod" title="Amortization of intellectual property license fee"><span id="xdx_902_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20190101__20190930_zpBN7tHPZXWd" title="Amortization of intellectual property license fee"><ix:nonFraction name="txmd:AmortizationOfIntellectualPropertyLicenseFee" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="txmd:AmortizationOfIntellectualPropertyLicenseFee" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,998</ix:nonFraction></ix:nonFraction></span></span> in amortization
expense related to the license fee which was recorded as a component of cost of sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Population Council is also eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible
for marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council,
on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates
and permitted licensees as follows: (i) if annual net sales are less than or equal to $<span id="xdx_904_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_c20200101__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_z5EMzf4wPEh3" title="Net sales amount per step-based royalty"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2020-01-012020-09-30_srt_MaximumMember_custom_CouncilLicenseAgreementStep1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span>, a royalty of&#160;<span id="xdx_90A_ecustom--RoyaltyPercent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zrOEsMcETNhj" title="Royalty (percent)"><ix:nonFraction name="txmd:RoyaltyPercent" contextRef="From2020-01-012020-09-30_custom_CouncilLicenseAgreementStep1Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% of net
sales; (ii) for annual net sales greater than $<span id="xdx_90F_ecustom--NetSalesAmountPerStepbasedRoyalty_c20200101__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zjIiAQCur1Fk" title="Net sales amount per step-based royalty"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2020-01-012020-09-30_srt_MinimumMember_custom_CouncilLicenseAgreementStep2Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span>&#160;and less than or equal to $<span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_c20200101__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zP1BhwjvVltk"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2020-01-012020-09-30_srt_MaximumMember_custom_CouncilLicenseAgreementStep2Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000,000</ix:nonFraction></span>, a royalty of&#160;<span id="xdx_906_ecustom--RoyaltyPercent_pii_dp_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_ztvmIGBhNfpb" title="Royalty (percent)"><ix:nonFraction name="txmd:RoyaltyPercent" contextRef="From2020-01-012020-09-30_custom_CouncilLicenseAgreementStep2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of
such net sales; and (iii) for net sales greater than $<span id="xdx_906_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_c20200101__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zhW87utZf6c9" title="Net sales amount per step-based royalty"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2020-01-012020-09-30_srt_MinimumMember_custom_CouncilLicenseAgreementStep3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000,000</ix:nonFraction></span>, a royalty of&#160;<span id="xdx_907_ecustom--RoyaltyPercent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zIl6CGAPDBre" title="Royalty (percent)"><ix:nonFraction name="txmd:RoyaltyPercent" contextRef="From2020-01-012020-09-30_custom_CouncilLicenseAgreementStep3Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% of such net sales. The annual royalty
rate will be reduced to&#160;<span id="xdx_901_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zkVZ25eQpoGk" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"><ix:nonFraction name="txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" contextRef="From2020-01-012020-09-30_custom_CouncilLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of the initial rate during the six-month period beginning on the date of the first arms-length
commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the
U.S., and thereafter will be reduced to&#160;<span id="xdx_907_ecustom--AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zrMItUXCRLZg" title="Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent"><ix:nonFraction name="txmd:AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" contextRef="From2020-01-012020-09-30_custom_CouncilLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% of the initial rate. We are required to pay the Population Council milestone
payments of $<span id="xdx_90D_ecustom--MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_pp0p0_dm_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zohSQUs9Uz4d" title="Milestone payments upon specified levels of cumulative net sales"><ix:nonFraction name="txmd:MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" contextRef="From2020-01-012020-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">40</ix:nonFraction> million</span>&#160;upon cumulative net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees
of each of $<span id="xdx_909_ecustom--SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_pn6n6_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zkw86Ij00lI6" title="Specified level one of cumulative net sales for milestone payments"><ix:nonFraction name="txmd:SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" contextRef="From2020-01-012020-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">200</ix:nonFraction></span>&#160;million, $<span id="xdx_901_ecustom--SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_pn6n6_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zGDyxwW763r7" title="Specified level two of cumulative net sales for milestone payments"><ix:nonFraction name="txmd:SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" contextRef="From2020-01-012020-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">400</ix:nonFraction></span>&#160;million&#160;and $<span id="xdx_90F_ecustom--SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_pn9n9_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_z4UimISN9gpk" title="Specified level three of cumulative net sales for milestone payments"><ix:nonFraction name="txmd:SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" contextRef="From2020-01-012020-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-9" scale="9" unitRef="USD">1</ix:nonFraction></span>&#160;billion. The Population Council has agreed to perform and pay
the costs and expenses associated with four post-approval studies required by the FDA for ANNOVERA and we have agreed to perform
and pay the costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism,
provided that if the costs and expenses associated with such post-approval study exceed $<span id="xdx_903_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_pii_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zNOQIfJLTYc6" title="Maximum costs and expenses for post approval"><ix:nonFraction name="txmd:MaximumCostsAndExpensesForPostApprovalStudyToBePaid" contextRef="From2020-01-012020-09-30_custom_CouncilLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span>, half of such excess will
be offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement.
We and the Population Council have agreed to form a joint product committee responsible for overseeing activities under the Population
Council License Agreement. We will be responsible for all aspects of promotion, product positioning, pricing, education programs,
publications, sales messages and any additional desired clinical studies for the one-year vaginal contraceptive system, subject
to oversight and decisions made by the joint product committee. The Population Council License Agreement includes exclusive rights
for us to negotiate co-development of two other investigational vaginal contraceptive systems in development by the Population
Council.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div id="xdx_233_zWUfCffqqIP5" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p id="xdx_233_zg8xuGtT9e1g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#160;</p></div>
    <div id="xdx_233_zjCu4xmqkGA2" style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zNieJCGxf3t" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="txmd:LicenseAgreementWithKnightPolicyTextBlock"><p id="xdx_848_ecustom--LicenseAgreementWithKnightPolicyTextBlock_zNPRMfR2xLZ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86A_z4pk4ByPb04g">License
Agreement with Knight</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we
granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the
Knight License Agreement, Knight paid us $<span id="xdx_905_ecustom--MilestonePaymentReceivedUponRegulatoryApproval_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--KnightLicenseAgreementMember_zUkuasQPehic"><ix:nonFraction name="txmd:MilestonePaymentReceivedUponRegulatoryApproval" contextRef="From2020-07-012020-09-30_custom_BijuvaAndAnnoveraMember_custom_KnightLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></span>
in milestone fees upon the first regulatory approval in Canada for IMVEXXY and BIJUVA in the third quarter of 2020, and is
also required to pay us sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of
IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications,
submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada
within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents.
Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within
certain specified time periods or if the other party files for bankruptcy or other related matters. As part of the Knight
License Agreement, Knight is prohibited from exporting IMVEXXY and BIJUVA to the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock"><p id="xdx_846_eus-gaap--CostOfSalesPolicyTextBlock_zSlKlmze6w85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86E_zEpUISSlKSgk">Cost
of Sales</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of sales includes the cost of inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping and
handling costs. The Population Council License Agreement requires payment of royalties based on the sale of future products. Such
royalties are recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related
to licensed products are classified as components of cost of sales to the extent such payments become due in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zo2CY4CWi0jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_864_zV1WCTQZtMMl">Inventory
Obsolescence Reserve</span> </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
evaluate inventory quarterly and record an allowance for obsolescence primarily associated with materials that are not
currently or likely to be used in production in the near future. As of September 30, 2020 and December 31, 2019, we recorded
an inventory obsolescence reserve of $<span id="xdx_901_eus-gaap--InventoryValuationReserves_iI_pp0p0_c20200930_z3nH5S3tEYUi" title="Inventory valuation reserves"><ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,744,464</ix:nonFraction></span>&#160;and
$<span id="xdx_909_eus-gaap--InventoryValuationReserves_iI_pp0p0_c20191231_zuB0z7VrASU6" title="Inventory valuation reserves"><ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>,
respectively. The reserve recorded as of September 30, 2020 was primarily related to BIJUVA and resulted from the impact of
the COVID-19 pandemic on our business, which decreased demand for our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zCPayzXjlSA2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_865_zVGnNbixIvY8">Segment
Reporting</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single executive leadership team that is chaired by the Chief Executive Officer of our
Company, who oversees all operations. We do not operate separate lines of business with respect to any of our products and we
do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the
United States. Accordingly, we view our business as one reportable operating segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_z1glbuxYfOTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_z0EqH09uYUo6">Research
and Development Expenses</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development, or R&amp;D, expenses include internal R&amp;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal
R&amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO
activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;D expenses include
assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes,
and scientific writing matters, including preparing protocols and FDA submissions. These consulting expenses were direct costs
associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal
R&amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms,
which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services
that will be used in future R&amp;D activities when the activity has been performed or when the goods have been received rather
than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed
and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO
costs are subject to revisions as such studies progress to completion. We charge revisions to expenses in the period in which
the facts that give rise to the revision become known.</span></p>

</ix:nonNumeric><p id="xdx_85A_z0zaxpjxOijb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><p id="xdx_810_zOqisIa0npS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zbNjWte6NqIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_820_zP0RCQHVrPW9">NOTE
4 &#8211; INVENTORY, NET</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z27FoMC11SCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>Inventory,
net consists of the following:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20200930_z5U8PAj7D5U7" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,<br /> &#160;2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_498_20191231_zT02v8DIwNxj" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br />
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--InventoryFinishedGoods_iI_uUSD_maINzGAn_zJhFtjBfcGtb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: justify; padding-left: 5.4pt">Finished products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,794,132</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,976,910</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--InventoryWorkInProcess_iI_uUSD_maINzGAn_zDR0iYpgCtih" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">440,149</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,182,059</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--InventoryRawMaterialsAndSupplies_iI_uUSD_maINzGAn_zZ2qVNfta8N9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Raw materials</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,698,023</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,701,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--InventoryNet_iTI_uUSD_mtINzGAn_zSQLbTIK26f7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">TOTAL INVENTORY, NET</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,932,304</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,860,716</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AA_zRC4R1ao0pC5" style="margin-top: 0; margin-bottom: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_817_zxqMZJQpWSY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_808_eus-gaap--OtherCurrentAssetsTextBlock_z4ddYWwpBCl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_827_zvnOGWl3DmEj">NOTE
5 &#8211; OTHER CURRENT ASSETS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zOYOeTHRUikc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>Other
current assets consist of the following:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20200930_zTNZhfb0cnbf" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,<br /> &#160;2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_498_20191231_zrsIWwqy81jg" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br />
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_406_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAzmtR_z3evkvY2zmXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: left; padding-left: 5.4pt">Prepaid sales and marketing costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="txmd:PrepaidSalesAndMarketingCostsCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">686,346</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="txmd:PrepaidSalesAndMarketingCostsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,583,698</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAzmtR_z8nAdlxrBsHi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Debt financing fees on undrawn tranches (Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0765">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">550,757</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--PrepaidInsurance_iI_maPEAOAzmtR_z2F7mizyJHQg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,599,906</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,812,135</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--PrepaidManufacturing_iI_maPEAOAzmtR_zD3xSwrjhuO9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Prepaid manufacturing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:PrepaidManufacturing" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">543,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:PrepaidManufacturing" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,595,721</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzmtR_zTWiqaYmfWd2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Other prepaid costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,989,937</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,787,482</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzmtR_zJ1DIvpddX25" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.75in; padding-right: 10pt">TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,819,239</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,329,793</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A4_zDj0TaINv2Sj" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_81B_zf6VQ3abwoRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zNKkQipCW9Vd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_82E_zkKdOm48YCQf">NOTE
6 &#8211; FIXED ASSETS, NET</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zD5SrQtIcLT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>Fixed
assets, net consist of the following:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20200930_zshcAQePpHz1" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,<br /> &#160;2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_49F_20191231_zaOonnrrItf4" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br />
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left; padding-left: 5.4pt">Accounting system</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zW0GiXH9G3p4" title="TOTAL FIXED ASSETS" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-09-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">301,096</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z5fEDds8i5i6" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">301,096</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zWlsRjUPWYP1" title="TOTAL FIXED ASSETS" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-09-30_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,658,258</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zlmS80uBzi6j" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,619,646</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z5xX5IOq9fv4" title="TOTAL FIXED ASSETS" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-09-30_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,406,858</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zOsgU67cMY66" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,406,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Computer hardware</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zbLQ8uwDG3mk" title="TOTAL FIXED ASSETS" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-09-30_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,211</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zt274pS2tUT7" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,211</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zAjE9miBz6f2" title="TOTAL FIXED ASSETS" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-09-30_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">68,788</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6FGsklpvoxc" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">68,788</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzuyq_z2OECk4eH9cb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.625in; padding-right: 10pt">TOTAL FIXED ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,515,211</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,476,599</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzuyq_zkoewWMaMsv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,545,282</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">968,824</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzuyq_z6TXxXANuqJb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.375in; padding-right: 10pt">TOTAL FIXED ASSETS, NET</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,969,929</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,507,775</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A3_zUL09iHHnEMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation
expense for the three months ended September 30, 2020 and 2019 was $</span><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20200701__20200930_zOhS4HPggOpe" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">188,810</ix:nonFraction></span><span>&#160;and
$</span><span id="xdx_90D_eus-gaap--Depreciation_pp0p0_c20190701__20190930_zZZvwnwPnUTk" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">90,700</ix:nonFraction></span><span>, respectively, and for the nine months ended September 30, 2020 and 2019
was $</span><span id="xdx_907_eus-gaap--Depreciation_pp0p0_c20200101__20200930_zEQ8zkG3imee" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">576,459</ix:nonFraction></span><span>&#160;and $</span><span id="xdx_907_eus-gaap--Depreciation_pp0p0_c20190101__20190930_zbOAAwYcaOO6" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">223,750</ix:nonFraction></span><span>, respectively.
</span></span></p>

</ix:nonNumeric><p id="xdx_81A_zxc12N6Zffrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><p id="xdx_802_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zowlklt9L3Md" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_826_znn2ph4EEmz">NOTE
7 &#8211; INTANGIBLE ASSETS, NET</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><p id="xdx_896_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zQ7rLu3fyk7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span>The
following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets
as of September 30, 2020 and December 31, 2019:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, 2020</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Net<br /> Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted- Average<br /> Remaining Amortization
    Period (yrs.)</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-left: 0.25in; text-indent: -0.125in">Approved hormone therapy drug candidate patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zcndpuWSOkxd" title="Finite-Lived Intangible Assets, Gross" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,108,745</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zT8YN1FkBoYg" title="Finite-Lived Intangible Assets, Accumulated Amortization" style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">679,959</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zFVvC1C5NdF3" title="Finite-Lived Intangible Assets, Net" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,428,786</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zObdTbfHdJdb" title="Finite-Lived Intangible Assets, Remaining Amortization Period"><ix:nonNumeric contextRef="From2020-01-012020-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">12.25</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Hormone therapy drug candidate patents (pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zBNtQL8fa47g" title="Finite-Lived Intangible Assets, Gross" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-09-30_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,760,923</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zIMkqnkYoGCf" title="Finite-Lived Intangible Assets, Net" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-09-30_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,760,923</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in">Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20200930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zIu7kB4Khspe" title="Indefinite-Lived Trademarks" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedTrademarks" contextRef="AsOf2020-09-30_custom_MultipleTrademarksMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">348,176</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20200930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zsm7MR4r2CXi" title="Indefinite-lived Intangible Assets (Excluding Goodwill)" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2020-09-30_custom_MultipleTrademarksMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">348,176</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.625in; text-indent: -0.125in; padding-right: 10pt">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20200930_zsoTsNWAQLw6" title="Intangible Assets, Gross (Excluding Goodwill)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,217,844</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20200930_zMZWyL4XpNUb" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">679,959</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20200930_zS4NdEtnGoZ9" title="Intangible assets, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,537,885</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Net<br /> Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted- Average<br /> Remaining Amortization
    Period (yrs.)</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-left: 0.25in; text-indent: -0.125in">Approved hormone therapy drug candidate patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zy7FKrAtL3n8" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,463,082</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zfTrTI8UtTE1" style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">478,983</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zcbMKJnrPMgf" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,984,099</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zmi7bd5E8OGk" title="Finite-Lived Intangible Assets, Remaining Amortization Period"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">13</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Hormone therapy drug candidate patents &#160;(pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z9yVdZwy4bVe" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,979,299</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zSaeK4vCLP7d" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,979,299</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zGbPnFHgdsU3" title="Indefinite-Lived Trademarks" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedTrademarks" contextRef="AsOf2019-12-31_custom_MultipleTrademarksMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">294,813</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zSi7S5C0JTwk" title="Indefinite-lived Intangible Assets (Excluding Goodwill)" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2019-12-31_custom_MultipleTrademarksMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">294,813</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-right: 10pt; padding-left: 0.5in">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20191231_zoVg8icnFi7d" title="Intangible Assets, Gross (Excluding Goodwill)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,737,194</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231_zDdsyjH116n7" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">478,983</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20191231_zjzSP5boAYLb" title="Intangible assets, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,258,211</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A4_ziJmNk4pJBsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent
is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated
useful life of approximately&#160;<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zX0WFC8sEiU7" title="Finite-Lived Intangible Asset, Useful Life"><ix:nonNumeric contextRef="From2020-01-012020-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric></span>&#160;years, which is the life of intellectual property patents. If the patent is not granted,
we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During
the nine months ended September 30, 2020 and 2019, we wrote off $<span id="xdx_908_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pp0p0_c20200101__20200930_zEqH37p5BYR7" title="Write off of patent and trademark costs"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">584,509</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pp0p0_c20190101__20190930_z1HQK0NPv6bl" title="Write off of patent and trademark costs"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,864</ix:nonFraction></span>, respectively,&#160;in costs related to trademarks
and patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, we had&#160;<span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsMember_zvhgTOoolh2a" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_DomesticUSPatentsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Number">35</ix:nonFraction></span>&#160;issued domestic patents and&#160;<span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsMember_z4TzhWTmboz2" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_ForeignPatentsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Number">35</ix:nonFraction></span>&#160;issued foreign patents, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsBijuvaMember_zxCrLKZenYMj" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_DomesticPatentsBijuvaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Number">14</ix:nonFraction></span>
                                         domestic patents and <span id="xdx_90F_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsBijuvaMember_zc5vZMnYaZM2" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_ForeignPatentsBijuvaMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Number">seven</ix:nonFraction></span> foreign patents that relate to BIJUVA as well as <span id="xdx_90C_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsEstradiolAndProgesteroneCandidatesMember_zUrHwEOUUII3"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_DomesticPatentsEstradiolAndProgesteroneCandidatesMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Number">three</ix:nonFraction></span> domestic
                                         patents that relate to estradiol and progesterone product candidates. These patents establish
                                         an important intellectual property foundation and are owned by us. The domestic patents
                                         will expire in 2032. The foreign patents will expire no earlier than 2032. In addition,
                                         we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia,
                                         Brazil, Canada, China, Europe, Hong Kong, Israel, Japan, Mexico, New Zealand, Russia,
                                         South Africa, and South Korea.</span></td></tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsImvexxyMember_z3KQgaGeHzlg" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_DomesticUSPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Number">Ten</ix:nonFraction></span>&#160;domestic
                                         patents (<span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSUtilityPatentsImvexxyMember_z6GfXZ1OVPB" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_DomesticUSUtilityPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Number">eight</ix:nonFraction></span>&#160;utility and&#160;<span id="xdx_907_ecustom--NumberOfIssuedPatents_iI_dc_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSDesignPatentsImvexxyMember_zVPCI27LvHV9" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_DomesticUSDesignPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Number">two</ix:nonFraction></span>&#160;design) and&#160;<span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsImvexxyMember_zS4Mx0opSJnf" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_ForeignPatentsImvexxyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Number">16</ix:nonFraction></span>&#160;foreign patents
                                         (<span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentsImvexxyMember_zedi9vQ5MRpc" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_ForeignUtilityPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Number">six</ix:nonFraction></span>&#160;utility and&#160;<span id="xdx_90E_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignDesignPatentsImvexxyMember_zGVIa8cDElx6" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_ForeignDesignPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Number">ten</ix:nonFraction></span>&#160;design) that relate to IMVEXXY. These patents establish
                                         an important intellectual property foundation for IMVEXXY and are owned by us. The domestic
                                         patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier
                                         than 2033. The foreign design patents provide protection expiring no earlier than 2025.
                                         In certain countries, the foreign design patents provide protection through at least
                                         2037. In addition, we have pending patent applications related to IMVEXXY in the U.S.,
                                         Argentina, Australia, Brazil, Canada, Europe, Hong Kong, Israel, Japan, Mexico, New Zealand,
                                         Russia, South Africa, and South Korea.</span></td></tr></table>

<ix:exclude><p id="xdx_237_zX9g5BCiLtwa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div id="xdx_23D_zzzlqH0CY3Q2" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p id="xdx_239_zuz5ArLVSahd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#160;</p></div>
    <div id="xdx_23B_zFmqM4Yn3YG5" style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zG6B2xSMRvq1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTopicalCreamCandidatesMember_z1kW2DLjR936" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_DomesticUtilityPatentTopicalCreamCandidatesMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Number">One</ix:nonFraction></span>&#160;domestic
                                         utility patent that relates to our topical-cream candidates, which is owned by us. The
                                         domestic patent will expire in 2035.</span></td></tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTransdermalPatchMember_zznGE3DMxMXi" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_DomesticUtilityPatentTransdermalPatchMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Number">One</ix:nonFraction></span>&#160;domestic
                                         utility patent and&#160;<span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_dc_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentTransdermalPatchMember_zd9Ko0fHz9yh"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_ForeignUtilityPatentTransdermalPatchMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Number">eight</ix:nonFraction></span>&#160;foreign patents that relate to our transdermal-patch
                                         candidates, which are owned by us. The domestic utility patent will expire in 2032. The
                                         foreign patents will expire no earlier than 2033. We have pending patent applications
                                         with respect to our transdermal-patch candidates in the U.S., Brazil, Canada, Mexico,
                                         and South Africa.</span></td></tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTx009HRMember_zU7wmSGHshla" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_DomesticUtilityPatentTx009HRMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Number">Three</ix:nonFraction></span>&#160;domestic
                                         utility patents that relate to TX-009HR, a progesterone and estradiol product candidate,
                                         which are owned by us and will expire in 2037.</span></td></tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsProgesteroneFormulationsMember_zsSiHwpXiezd" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_DomesticPatentsProgesteroneFormulationsMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Number">Two</ix:nonFraction></span>&#160;domestic
                                         and&#160;<span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsProgesteroneFormulationsMember_zNjMzCkPoRij" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_ForeignPatentsProgesteroneFormulationsMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Number">four</ix:nonFraction></span>&#160;foreign patents that relate to formulations containing progesterone,
                                         which are owned by us. The domestic patents will expire between 2032 and 2036. The foreign
                                         patents will expire no earlier than 2033.</span></td></tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentOperaMember_zb3xrCKblDdb" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-09-30_custom_DomesticUtilityPatentOperaMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Number">One</ix:nonFraction></span>&#160;domestic
                                         utility patent that relates to our OPERA information-technology platform, which is owned
                                         by us and will expire in 2031.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z4V1CUC0hoy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Amortization
expense was $<span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20200701__20200930_zUMstwvHguKh">69,977</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;and
$<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20190701__20190930_zef1mEBbIYZd">51,259</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;for
the three months ended September 30, 2020 and 2019, respectively, and $<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20200101__20200930_zdlMR4nQhdSe">200,879</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;and
$<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20190101__20190930_zKWSvIWlGIwj">140,206</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;for
the nine months ended September 30, 2020 and 2019, respectively. <span id="xdx_8B3_zuQh9i88rL45">Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Year Ending<br /> December 31,</b></td>
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 2px"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Estimated <br />
    Amortization</b></td>
    <td style="text-align: center"><b>&#160;</b></td></tr>
<tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2020 (3 months)</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_uUSD_c20200930_zuJLzRelx1ob" title="2020 (3 months)" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">69,977</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_uUSD_c20200930_zfNvcy4TE9Ka" title="2021" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">279,909</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_uUSD_c20200930_zaomUZJ6Dvb6" title="2022" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">279,909</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_uUSD_c20200930_zUyu8cnU1idj" title="2023" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">279,909</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_uUSD_c20200930_zGx3RJsGkfP4" title="2024" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">279,909</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A3_zeYwC5mhU5Ag" style="margin-top: 0; margin-bottom: 0">&#160;</p>
</ix:nonNumeric><p id="xdx_81C_z4lnbFRwSYy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_809_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z9ztfjXAqfj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_82A_ze3wETkBa5u9">NOTE
8&#8211; OTHER CURRENT LIABILITIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock"><p id="xdx_896_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_z47uqXV0qdcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Other
current liabilities consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20200930_z2UXOuVdXdV" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,<br /> 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_496_20191231_zhaxBHxeebj6" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br />
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--AccruedSalariesCurrent_iI_maOLCz3D1_zfWGmRvrEpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: justify; padding-left: 5.4pt">Accrued payroll, bonuses and commission costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,381,729</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,040,278</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCz3D1_zzK3HTf3QqH" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Allowance for coupons and returns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:SalesDiscountsReturnsAndAllowancesGoods1" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,353,403</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:SalesDiscountsReturnsAndAllowancesGoods1" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,316,298</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCz3D1_z8U82KLNYREj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">Accrued sales and marketing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,578,971</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,285,662</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedVacationCurrent_iI_maOLCz3D1_zy2BO8mJBhZ3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Accrued compensated absences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,558,055</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,463,878</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCz3D1_z9ALBRofLxWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">Allowance for wholesale distributor fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AllowanceForWholesaleDistributorFeesCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,130,230</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AllowanceForWholesaleDistributorFeesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,347,122</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCz3D1_zGf1Vg9E8o1k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Accrued legal and accounting expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,052,935</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">422,336</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--AccruedResearchAndDevelopment_iI_maOLCz3D1_zWPlBP8Uhmxc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">Accrued research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AccruedResearchAndDevelopment" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,059,077</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AccruedResearchAndDevelopment" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,049,603</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCz3D1_zsvnhSKLw4n9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,404,286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,501,539</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--AccruedRebates_iI_maOLCz3D1_zZvhpyeHpvx" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">Accrued rebates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AccruedRebates" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,629,732</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AccruedRebates" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,916,672</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCz3D1_z7PSnGJp0Nhk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Other accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,072,066</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,480,225</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCz3D1_zq0QmxmnADJk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0.125in; padding-left: 0.25in">TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,220,484</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,823,613</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A0_zLLbs11p2yfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><p id="xdx_811_zM6Q8UYPAF4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:LongTermDebtTextBlock"><p id="xdx_804_eus-gaap--LongTermDebtTextBlock_zmxRRFczUK8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_828_zdAjHrceEQB2">NOTE
9 &#8211; DEBT</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
April 24, 2019, we entered into a Financing Agreement, as amended, or the Financing Agreement, with TPG Specialty Lending,
Inc., as administrative agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of
our subsidiaries party thereto from time to time as guarantors, which provides us with up to a $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190424__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z9UqbFedBss2"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-04-24_us-gaap_RevolvingCreditFacilityMember_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000,000</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;first
lien secured term loan credit facility, or the Facility. The Facility provides for availability to us in three tranches: (i)
$<span id="xdx_902_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190424__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zm5jCo6Y72R6"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-04-24_us-gaap_SecuredDebtMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000,000</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;was
drawn upon entering into the Financing Agreement; (ii) $<span id="xdx_902_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_zTLbIe2ZXyfa"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;was
drawn on February 18, 2020 following our achievement of more than $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20191001__20191231__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember__srt--RangeAxis__srt--MinimumMember_z8ooUFyN7eij"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,000,000</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;in
net revenues from IMVEXXY, BIJUVA and ANNOVERA for the fourth quarter of 2019 and (iii) $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20200630__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zI7QIojnIcV8"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2020-06-30_custom_FinancingAgreementMember_custom_TrancheThreeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;was
previously available to us in the Administrative Agent&#8217;s sole and absolute discretion either contemporaneously with the
delivery of our financial statements for the quarter ended June 30, 2020 or at such earlier date as the Administrative Agent
may have consented to. Due to the pause in the successful full launch of ANNOVERA caused by the COVID-19 pandemic, the
undrawn $<span id="xdx_90F_ecustom--LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_iI_pp0p0_c20200930__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zYP9BrtHDmAf"><ix:nonFraction name="txmd:LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" contextRef="AsOf2020-09-30_custom_FinancingAgreementMember_custom_TrancheThreeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span>
tranche under the Financing Agreement is no longer available. Borrowings under the Facility accrue interest at either
(i)&#160;<span id="xdx_902_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zC1sjp4MooC5"><ix:nonNumeric contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">3-month
LIBOR</ix:nonNumeric></span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;plus&#160;<span id="xdx_90D_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zPh3oVNyJcG7"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.75</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%,
subject to a LIBOR floor of<span id="xdx_90A_ecustom--LiborFloorRate_iI_pii_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z3NlJALCpVid">&#160;<ix:nonFraction name="txmd:LiborFloorRate" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.70</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
or (ii) the&#160;<span id="xdx_90D_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zvgF7rfaf3t8"><ix:nonNumeric contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">prime
rate</ix:nonNumeric></span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;plus&#160;<span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zqXwFNjObkha"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.75</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%,
subject to a prime rate floor of&#160;<span id="xdx_90B_ecustom--PrimeRateFloor_iI_pii_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zjuJRIaHBXda"><ix:nonFraction name="txmd:PrimeRateFloor" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.2</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
as selected by us. Interest on amounts borrowed under the Facility is payable quarterly. The outstanding principal amount of
the Facility is payable in&#160;<span id="xdx_906_ecustom--NumberOfInstallmentPayments_iI_dc_uNumber_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zSlmoJGd4Z8d"><ix:nonFraction name="txmd:NumberOfInstallmentPayments" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Number">four</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;equal
quarterly installments beginning on June 30, 2023, with the Facility maturing on March 31, 2024. We have the right to prepay
borrowings under the Facility in whole or in part at any time, subject to a prepayment fee on the principal amount being
prepaid of (i)&#160;<span id="xdx_90E_ecustom--PrepaymentFeeForFirstTwoYearsFundingPercent_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zEzT0ORvbSuh"><ix:nonFraction name="txmd:PrepaymentFeeForFirstTwoYearsFundingPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30.0</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
for the first two years following the initial funding date of the applicable borrowing, (ii)&#160;<span id="xdx_90E_ecustom--PrepaymentFeeThirdYearFundingPercent_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zgTNRvhrkD79"><ix:nonFraction name="txmd:PrepaymentFeeThirdYearFundingPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
for the third year following the initial funding date of the applicable borrowing, (iii)&#160;<span id="xdx_901_ecustom--PrepaymentFeeFourthYearFundingPercent_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zfMK9yTLmEmd"><ix:nonFraction name="txmd:PrepaymentFeeFourthYearFundingPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
for the fourth year following the initial funding date of the applicable borrowing and (iv)&#160;<span id="xdx_90A_ecustom--PrepaymentFeeFifthYearFundingPercent_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zfOdkgedXmVg"><ix:nonFraction name="txmd:PrepaymentFeeFifthYearFundingPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
for the fifth year following the initial funding date of the applicable borrowing but prior to March 31, 2024. In connection
with the initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility fee equal to&#160;<span id="xdx_901_ecustom--FacilityFeePaidPercent_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zQhHBHa4UwL6"><ix:nonFraction name="txmd:FacilityFeePaidPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the initial amount borrowed and will be required to pay such a facility fee in connection with any subsequent borrowings
under the Facility. We are also required to pay the Administrative Agent and the lenders an annual administrative fee in
addition to other fees and expenses. The Financing Agreement contains customary mandatory prepayments, restrictions and
covenants applicable to us that are customary for financings of this type. Among other requirements, we are required to (i)
maintain a minimum unrestricted cash balance of $<span id="xdx_909_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pp0p0_uUSD_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zfmlp8AMvu62" title="Minimum cash balance requirement under credit agreement"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,000,000</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our IMVEXXY, BIJUVA and
ANNOVERA products beginning with the fiscal quarter ending December 31, 2020. Pursuant to Amendment No. 6, the minimum
required cash balance was lowered to $<span id="xdx_90C_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Period1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjQAClj3WUz7" title="Minimum cash balance requirement under credit agreement"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Period1Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">45</ix:nonFraction> million</span> through December 31, 2020. As of September 30, 2020, we were in compliance
with all covenants under the Financing Agreement. The Financing Agreement also includes other representations, warranties,
indemnities and events of default that are customary for financings of this type, including an event of default relating to a
change of control of the Company. Upon or after an event of default, the Administrative Agent and the lenders may declare all
or a portion of our obligations under the Financing Agreement to be immediately due and payable and exercise other rights and
remedies provided for under the Financing Agreement. The obligations of our company and its subsidiaries under the Financing
Agreement are secured, subject to customary permitted liens and other agreed upon exceptions, by a first priority perfected
security interest in all existing and after acquired assets of our company and its subsidiaries. The obligations under the
Financing Agreement will be guaranteed by each of our future direct and indirect subsidiaries, subject to certain
exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
May 1, 2018, we entered into a Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap,
as agent, or Agent, and as lender, and the additional lenders party thereto from time to time (together with MidCap as a lender,
the Lenders), as amended. The Credit Agreement provided a secured term loan facility in an aggregate principal amount of up to
$<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zvPqJDd4qL6i" title="Line of Credit Facility, Maximum Borrowing Capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000,000</ix:nonFraction></span>, or the Term Loan. Under the terms of the Credit Agreement, the Term Loan was available to be made in&#160;<span id="xdx_908_ecustom--NumberOfTranchesUnderTermLoanFacility_iI_pii_dc_uNumber_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zSFKQiBm1SYe" title="Number of tranches under term loan facility"><ix:nonFraction name="txmd:NumberOfTranchesUnderTermLoanFacility" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Number">three</ix:nonFraction></span>&#160;separate
tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. Amounts borrowed
under the Term Loan bore interest at a rate equal to the sum of (i)&#160;<span id="xdx_900_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zgKUMdybmzt3" title="Debt Instrument, Description of Variable Rate Basis"><ix:nonNumeric contextRef="From2018-04-302018-05-01_us-gaap_SecuredDebtMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">one-month LIBOR</ix:nonNumeric></span>&#160;(subject to a LIBOR floor of&#160;<span id="xdx_90A_ecustom--LiborFloorRate_iI_pii_dp_uPure_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zd7EMhguzLnk" title="LIBOR floor rate"><ix:nonFraction name="txmd:LiborFloorRate" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.50</ix:nonFraction></span>%)
plus (ii)&#160;<span id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPure_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zzrmO32ULdl6" title="Debt Instrument, Basis Spread on Variable Rate"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2018-04-302018-05-01_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.75</ix:nonFraction></span>% per annum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
April 24, 2019, we terminated the Credit Agreement. A portion of the initial tranche of borrowing under the Financing Agreement
in the amount of approximately $<span id="xdx_90F_eus-gaap--RepaymentsOfLinesOfCredit_pp0p0_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z7ZkmRM0D9x7" title="Repayments of Lines of Credit"><ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,661,000</ix:nonFraction></span>&#160;was used to repay all amounts outstanding under the Credit Agreement, which included
a prepayment fee of&#160;<span id="xdx_909_ecustom--PrepaymentFeePercentage_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z49XYv8pNpD1" title="Prepayment fee percentage"><ix:nonFraction name="txmd:PrepaymentFeePercentage" contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>%, a repayment fee of&#160;<span id="xdx_907_ecustom--RepaymentFeePercentage_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z3xeFCoh1yXd" title="Repayment fee percentage"><ix:nonFraction name="txmd:RepaymentFeePercentage" contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>%&#160;and other fees and expenses payable to the lenders under the Credit
Agreement. As a result of the termination of the Credit Agreement, we recorded $<span id="xdx_903_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_dxL_c20190401__20190630_zeU3b5K41Le8" title="Loss on extinguishment of debt::XDX::-10057632"><span style="-sec-ix-hidden: xdx2ixbrl0988">10,057,632</span></span>&#160;in loss on extinguishment of debt
in the second quarter of 2019. Interest expense for the nine months ending September 30, 2019 related to the Credit Agreement
was $<span id="xdx_903_eus-gaap--InterestExpenseDebt_pp0p0_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zWHH7uGRDABj" title="Interest Expense, Debt"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2020-01-012020-09-30_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,816,747</ix:nonFraction></span>. During the nine months ended September 30, 2019, and prior to the repayment of the Credit Agreement, we amortized
$<span id="xdx_903_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zYIBtGlnXce8" title="Amortization of deferred financing fees"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2020-01-012020-09-30_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">120,146</ix:nonFraction></span>&#160;of deferred financing fees as interest expense in the accompanying unaudited consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
August 5, 2020, we entered into Amendment No. 5 to the Financing Agreement, or Amendment No. 5. Amendment No. 5 adjusts the covenant
in the Financing Agreement regarding our achievement of minimum consolidated net revenue attributable to commercial sales of our
IMVEXXY, BIJUVA, and ANNOVERA products to reflect the impact of COVID-19 on our business. The covenant is effective beginning
with the fiscal quarter ending December 31, 2020. In connection with Amendment No.5 and in lieu of a cash amendment fee, we issued
to the Administrative Agent and the lenders under the Financing Agreement warrants to purchase an aggregate of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zMmQVXcAMJ05" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-08-05_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,752,116</ix:nonFraction></span> shares
of Common Stock with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zMXmWXl161Fj" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-08-05_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.58</ix:nonFraction></span> per share and a <span title="Warrants term">ten</span>-year term, or the Lender Warrants. The Lender Warrants were
issued pursuant to an exemption from registration under the Securities Act of 1933, as amended, and no registration rights were
issued. The Company concluded that the modification accounting model is applicable to this transaction and recognized the fair value of
the warrants as a debt discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, we </span><span style="font: 10pt Times New Roman, Times, Serif">had $<span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z5CHZGxeM2Rf" title="Long-term Debt, Gross"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2020-09-30_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000,000</ix:nonFraction></span>&#160;in
borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying consolidated
financial statements. We incurred $<span id="xdx_908_eus-gaap--DeferredFinanceCostsGross_iI_pp0p0_c20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zptmA0Ehhcsa" title="Debt Issuance Costs, Gross"><ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="AsOf2020-09-30_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,902,270</ix:nonFraction></span>&#160;in
deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing Agreement
have been allocated pro rata between the funded and unfunded tranches. Allocated deferred financing fees related to the two
tranches of borrowings that we received of $<span id="xdx_90B_eus-gaap--DeferredFinanceCostsGross_iI_pp0p0_c20200930__custom--DebtTrancheAxis__custom--TwoTranchesMember_zzOBP6hxXg82" title="Debt Issuance Costs, Gross"><ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="AsOf2020-09-30_custom_TwoTranchesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,626,891</ix:nonFraction></span>&#160;have
been reflected as a debt discount upon each draw and are amortized to interest expense using the effective interest method.
In addition, during the three months ended September 30, 2020, we recorded the fair value of the Lender Warrants of $<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_c20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zctco8pzxO6c" title="Fair value of warrants"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2020-09-30_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,428,179</ix:nonFraction></span>
as a debt discount, which is being amortized to interest expense using the effective interest method over the term of the
Financing Agreement. During the three months ended September 30, 2020, we concluded that the undrawn $<span id="xdx_90A_ecustom--LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_iI_pp0p0_c20200930__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zCvq8fWLeXUc"><ix:nonFraction name="txmd:LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" contextRef="AsOf2020-09-30_custom_FinancingAgreementMember_custom_TrancheThreeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span>&#160;tranche
under the Financing Agreement is no longer available to us. As such, we wrote off $<span id="xdx_906_eus-gaap--WriteOffOfDeferredDebtIssuanceCost_pp0p0_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zIvf9LbwiAJe" title="Write off of deferred financing fees"><ix:nonFraction name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" contextRef="From2020-07-012020-09-30_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">275,379</ix:nonFraction></span>
of deferred financing fees associated with the unfunded tranche, which were previously deferred as assets until such tranche
had been drawn.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 17; Value: 2 -->
    <div id="xdx_237_zcX6YCoJaR1g" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p id="xdx_234_z9lFcZD5JS77" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#160;</p></div>
    <div id="xdx_234_zOx8iI0CkFPi" style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_z8DbFczlxiuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three and nine months ended September 30, 2020, we amortized $<span id="xdx_900_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20200701__20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zVbN83Wcvq49" title="Amortization of deferred financing fees"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2020-07-012020-09-30_custom_FinancingAgreementMember226851703" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">677,676</ix:nonFraction></span>&#160;and $<span id="xdx_902_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20200101__20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zSTkThpiBscl" title="Amortization of deferred financing fees"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2020-01-012020-09-30_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,370,118</ix:nonFraction></span>, respectively, of deferred financing
fees related to the Financing Agreement&#160;<span>as interest expense in the accompanying consolidated
financial statements.&#160;</span>During the three and nine months ended September 30, 2019, we amortized $<span id="xdx_904_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20190701__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zovtXntihXMe" title="Amortization of deferred financing fees"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2019-07-012019-09-30_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">265,949</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20190101__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_ztv8WYpA6kTd" title="Amortization of deferred financing fees"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2019-01-012019-09-30_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">462,683</ix:nonFraction></span>,
respectively, of deferred financing fees related to the Financing Agreement&#160;<span>as interest
</span>expense in the accompanying consolidated financial statements. Interest on amounts borrowed under the Financing Agreement
is due and payable quarterly in arrears. Interest expense for the three and nine months ended September 30, 2020 was $<span id="xdx_902_eus-gaap--InterestExpenseBorrowings_pp0p0_c20200701__20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zTuX4uHZNUf3" title="Interest Expense, Borrowings"><ix:nonFraction name="us-gaap:InterestExpenseBorrowings" contextRef="From2020-07-012020-09-30_custom_FinancingAgreementMember226851703" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,726,389</ix:nonFraction></span>&#160;and
$<span id="xdx_906_eus-gaap--InterestExpenseBorrowings_pp0p0_c20200101__20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zfu6QG49xqre" title="Interest Expense, Borrowings"><ix:nonFraction name="us-gaap:InterestExpenseBorrowings" contextRef="From2020-01-012020-09-30_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,322,847</ix:nonFraction></span>, respectively. Interest expense for the three and nine months ended September 30, 2019 was $<span id="xdx_90A_eus-gaap--InterestExpenseBorrowings_pp0p0_c20190701__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zBSSPYylhSK6" title="Interest Expense, Borrowings"><ix:nonFraction name="us-gaap:InterestExpenseBorrowings" contextRef="From2019-07-012019-09-30_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,333,056</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--InterestExpenseBorrowings_pp0p0_c20190101__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_ziWKBaLCxBA3" title="Interest Expense, Borrowings"><ix:nonFraction name="us-gaap:InterestExpenseBorrowings" contextRef="From2019-01-012019-09-30_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,318,056</ix:nonFraction></span>,
respectively. The overall effective interest rate under the Financing Agreement was approximately&#160;<span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pii_dp_c20200930_z2DZUgbk066l" title="Debt Instrument, Interest Rate, Effective Percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>%&#160;as of September
30, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfDebtTableTextBlock_zDrNLz8c39v4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><span>As
of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><b>September 30,<br />
2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><b>December 31,<br />
2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: justify; padding-left: 5.4pt">Financing Agreement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zqHJ5q3dEWK1" title="Long-term Debt, Gross"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2020-09-30_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zPrnnkLRHK98" title="Long-term Debt, Gross"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2019-12-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Debt discount and financing fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20200930_zQxR7PVfX23e" title="Debt discount and financing fees" style="border-bottom: Black 1pt solid; text-align: right"><span title="Debt discount and financing fees">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,948,798</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20191231_zFkz36vv9bSd" title="Debt discount and financing fees" style="border-bottom: Black 1pt solid; text-align: right"><span title="Debt discount and financing fees">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,365,357</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.625in">TOTAL LONG-TERM DEBT</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_c20200930_zA5CKNEgBBS9" title="TOTAL LONG-TERM DEBT"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">237,051,202</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_c20191231_z1w0dYI3jfpl" title="TOTAL LONG-TERM DEBT"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">194,634,643</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A1_zhGu5VP4ia09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
April 27, 2020, we received a loan pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic
Security Act (the &#8220;CARES Act&#8221;), as administered by the U.S. Small Business Administration. The loan in the principal
amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20200427__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_z3fr3WEprPCg" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-04-27_custom_PaycheckProtectionProgramLoanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,477,094</ix:nonFraction></span>&#160;(the &#8220;PPP Loan&#8221;) was disbursed by Bank of America, NA, a national banking association, pursuant
to a promissory note issued by the Company. Although we believed, in good faith, we were qualified for the PPP Loan under the
available regulations, as a result of newly-issued guidance, particularly with respect to publicly traded companies receiving
funding under the CARES Act, we voluntarily returned the PPP Loan proceeds on May 14, 2020.</span></p>

</ix:nonNumeric><p id="xdx_81E_zltfTANsEwY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_807_eus-gaap--EarningsPerShareTextBlock_zPJ3QCRowgzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_82C_zo8Jm2YAmdQ5">NOTE
10 &#8211; NET LOSS PER SHARE</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
calculate earnings per share, or EPS, in accordance with ASC 260,&#160;<i>Earnings Per Share</i>, which requires the computation
and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of Common
Stock outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock
outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive
shares of our Common Stock consist of options, warrants and restricted stock units and were excluded from the calculation of diluted
earnings per share because their effect would have been anti-dilutive due to the net loss reported by us. The table below presents
potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders
for the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zdmkJXXDt6df" summary="xdx: Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br />
    2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br />
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: justify; padding-left: 5.4pt">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBYeHEayNYId" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-09-30_custom_StockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,893,180</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUPOt79jOXy1" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-09-30_custom_StockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,849,984</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztJxaI3SeQ96" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,534,687</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zulTC7er37df" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,832,571</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">Performance stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zuLqCM3vNgIj" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-09-30_custom_PerformanceStockUnitsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,422,885</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgMTAgliBORVQgTE9TUyBQRVIgU0hBUkUgKERldGFpbHMpAA__" style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zop3yhrbWp67" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,029,957</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zbzLxz63fPM8" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,240,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930_z0ZrZaIS9hN" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,880,709</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930_zzeYKcOaaIXc" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,922,555</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_816_zivMFNEqdwo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zvSAt3k7HW5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_82C_zN2NPPDvexjl">NOTE
11 &#8211; STOCKHOLDERS&#8217; EQUITY</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Preferred
Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2020, we had&#160;<span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_uShares_c20200930_zhEnoIfCTdz5" title="Preferred Stock, Shares Authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span>&#160;shares of preferred stock, par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20200930_zVGKOst75Pb2" title="Preferred Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>&#160;per share, authorized for issuance,
of which&#160;<span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_dco_uShares_c20200930_zZ8SBcS5OpJi" title="Preferred Stock, Shares Issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_dco_uShares_c20200930_znb2ZKAXONge" title="Preferred Stock, Shares Issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-09-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-09-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span>&#160;shares were issued or outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Common
Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2020, we had&#160;<span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_uShares_c20200930_zucQzDi7MeLc"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600,000,000</ix:nonFraction></span>&#160;shares of Common Stock authorized for issuance, of which&#160;<span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_uShares_c20200930_z2X68C4DTcma"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_uShares_c20200930_zKFP9mrzzDl7"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">272,812,271</ix:nonFraction></ix:nonFraction></span></span>&#160;shares
of Common Stock were issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Issuances
During the Three and Nine Months ended September 30, 2020</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended September 30, 2020, stock options to purchase an aggregate of&#160;<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20200701__20200930_zsT6ui54UaWc" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">517,891</ix:nonFraction></span>&#160;shares of Common Stock
were exercised for $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_uUSD_c20200701__20200930_zf9Y5A4502f3" title="Stock Issued During Period, Value, Stock Options Exercised"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,494</ix:nonFraction></span>&#160;in cash. During the nine months ended September 30, 2020, stock options to purchase an aggregate
of&#160;<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20200101__20200930_zjwY7wiaTv8j"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,182,195</ix:nonFraction></span>&#160;shares of Common Stock were exercised for $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_uUSD_c20200101__20200930_z49LEfFQB0qd"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,678</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;in
cash.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 18; Value: 2 -->
    <div id="xdx_231_zY8lFpuw9c3e" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p id="xdx_237_z2pSS6fuQl5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#160;</p></div>
    <div id="xdx_232_zGe8RfQ6D2d1" style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>


<ix:exclude><p id="xdx_23F_z74lm8V84jZ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Issuances
During the Three and Nine Months ended September 30, 2019</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended September 30, 2019, certain individuals exercised stock options to purchase an aggregate of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20190701__20190930_z9LPOMHhkSNb" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,236</ix:nonFraction></span> shares
of Common Stock for $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_uUSD_c20190701__20190930_z9QCVov1SE89"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,549</ix:nonFraction></span> in cash. During the nine months ended September 30, 2019, certain individuals exercised stock options
to purchase an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20190101__20190930_zCxJ5gHw5N4j"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,619</ix:nonFraction></span> shares of Common Stock for $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_uUSD_c20190101__20190930_z5jDRIbR8pDh"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,656</ix:nonFraction></span> in cash. Also, during the same period, stock options to
purchase an aggregate of <span id="xdx_902_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_uShares_c20190101__20190930_zjH6ZV7s9AS" title="Number of stock options exercised in cashless exercise"><ix:nonFraction name="txmd:NumberOfStockOptionsExercisedInCashlessExercise" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,097</ix:nonFraction></span> shares of Common Stock were exercised pursuant to the options&#8217; cashless exercise provisions,
wherein an aggregate of <span id="xdx_90F_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_uShares_c20190101__20190930_z7dn0Fub2uDd" title="Number of common stock issued during period for stock options exercised in cashless exercise"><ix:nonFraction name="txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,834</ix:nonFraction></span> shares of Common Stock were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Warrants
to Purchase Common Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, we had warrants outstanding to purchase an aggregate of&#160;<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_uUSD_c20200930_z72xqmqA2Hp6" title="Warrants and Rights Outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,534,687</ix:nonFraction></span>&#160;shares of Common Stock with
a weighted-average contractual remaining life of approximately&#160;<span id="xdx_900_ecustom--WarrantsAndRightsWeightedAverageContractualRemainingLife_dtY_c20200101__20200930_zC7h4cfCDxb9" title="Weighted-average contractual remaining life"><ix:nonNumeric contextRef="From2020-01-01to2020-09-30" format="ixt-sec:duryear" name="txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife">7.5</ix:nonNumeric></span>&#160;years, and exercise prices ranging from $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zLnLhGwfXvv" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-09-30_custom_WarrantsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.24</ix:nonFraction></span>&#160;to
$<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_z6mmRC3VLI0k" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-09-30_custom_WarrantsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.20</ix:nonFraction></span> per share, resulting in a weighted average exercise price of $<span id="xdx_900_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iI_uUSDPShares_c20200930_ztOlIeUQARIg" title="Weighted average exercise price of warrants (in dollars per share)"><ix:nonFraction name="txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.83</ix:nonFraction></span>&#160;per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend yield and the
term of the warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with Amendment No. 5 and in lieu of a cash amendment fee, we issued to the Administrative Agent and the lenders
under the Financing Agreement the Lender Warrants. The fair value for the Lender Warrants was determined by using the
Black-Scholes Model on the date of the grant using a term of ten years, volatility of&#160;<span id="xdx_90C_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_uPure_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_z3ZfgKakfKJ4"><ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" contextRef="From2020-01-012020-09-30_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">68.8</ix:nonFraction></span>%,
risk-free interest rate of&#160;<span id="xdx_90C_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_dp_uPure_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zUlV9L9MJ2h8"><ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" contextRef="From2020-01-012020-09-30_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.34</ix:nonFraction></span>%
and dividend yield of&#160;<span id="xdx_909_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_dp_uPure_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zTmONOJzhoN4"><ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" contextRef="From2020-01-012020-09-30_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%.
The grant date fair value of the warrants was $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_z4m7hB62utpe"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-09-30_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.56</ix:nonFraction></span>&#160;per
share. The warrants vested upon issuance. We concluded that the modification accounting model is applicable to this warrant
issuance and recognized the fair value of the warrants as a debt discount. As a result, the fair value of the Lender Warrants
is being amortized to interest expense over the term of the Financing Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
recorded share-based compensation expense related to warrants previously issued of $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_uUSD_c20200701__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zjQO02FbWAdc" title="Share-based Payment Arrangement, Noncash Expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-07-012020-09-30_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>&#160;and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_uUSD_c20190701__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zNQqecM9XJBb" title="Share-based Payment Arrangement, Noncash Expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-07-012019-09-30_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,418</ix:nonFraction></span>&#160;for the three months
ended September 30, 2020 and 2019, respectively, and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_uUSD_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zvZ2BDIWlZs8" title="Share-based Payment Arrangement, Noncash Expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-09-30_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,446</ix:nonFraction></span>&#160;and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_uUSD_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zV3wIx0Q1ZP" title="Share-based Payment Arrangement, Noncash Expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-09-30_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,306</ix:nonFraction></span>&#160;for the nine months ended September 30, 2020
and 2019, respectively, in the accompanying consolidated financial statements. At September 30, 2020, there was no unrecognized
compensation expense remaining related to unvested warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2019, we granted warrants to purchase an aggregate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_uShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zgGhOGKZFna8" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> shares of Common Stock to outside
consultants at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zfQfPKflXv79"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.63</ix:nonFraction></span>. The fair value for these warrants was determined by using the Black-Scholes Model on
the date of the grant using a term of five years, volatility of <span id="xdx_906_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_uPure_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z52Q5tyzUyvg" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate"><ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60.8</ix:nonFraction></span>%, risk-free interest rate of <span id="xdx_90A_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_dp_uPure_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zYQDsy3LXbl8"><ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.52</ix:nonFraction></span>%, and dividend yield of
<span id="xdx_900_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_dp_uPure_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_ztjjmrEpa2eb"><ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%. The grant date fair value of the warrants was $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zo4xKMthRmrc"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span> per share. The warrants are vesting ratably over a <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zwuSwJrx0Reg"><ix:nonNumeric contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">12</ix:nonNumeric></span>-month period and
have an expiration date of February 12, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended </span><span style="font: 10pt Times New Roman, Times, Serif">September 30, 2020, no
warrants were exercised. During the nine months ended September 30, 2019, warrants to purchase an aggregate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_uShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z8oPDnVUiLW9" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2019-01-012019-09-30_us-gaap_WarrantMember226853968" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span> shares
of Common Stock were exercised pursuant to the warrants&#8217; cashless exercise provisions, wherein an aggregate of <span id="xdx_906_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_uShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsCashlessExerciseMember_z3FmxMSSfu1l" title="Number of stock issued in cashless exercise of warrants"><ix:nonFraction name="txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants" contextRef="From2019-01-012019-09-30_custom_WarrantsCashlessExerciseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,184</ix:nonFraction></span> shares
of Common Stock were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Options
to Purchase Common Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees,
directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder
value by providing them stock options and other stock and cash incentives, or the Awards. As of September 30, 2020, there were
non-qualified stock options to purchase an aggregate of&#160;<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zqL8xWBgwgca" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-09-30_custom_LongTermIncentiveCompensationPlan2009Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,346,455</ix:nonFraction></span>&#160;shares of Common Stock outstanding under the 2009
Plan. Effective upon our adoption of the TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no
future awards may be made under the 2009 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012
Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain
consultants and advisors of our company. As of September 30, 2020, there were non-qualified stock options to purchase an aggregate
of&#160;<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zgGVylhXaDN" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-09-30_custom_NonQualified2012StockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,305,974</ix:nonFraction></span>&#160;shares of Common Stock outstanding and an aggregate of&#160;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_uShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zeid45xOe6uk" title="Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-09-30_us-gaap_RestrictedStockMember_custom_NonQualified2012StockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">890,000</ix:nonFraction></span>&#160;restricted stock units under the
2012 Plan. Effective upon our adoption of the 2019 Plan, no future awards may be made under the 2012 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 20, 2019, we adopted the 2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers,
directors, and certain consultants and advisors of our company. The Awards available under the 2019 Plan consist of stock options,
stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or
cash awards as described in the 2019 Plan. Generally, the options vest annually over four years or as determined by our board
of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis
after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any.
The expiration date is generally ten years from the date the option is issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 19; Value: 2 -->
    <div id="xdx_233_zKHPp5BmltIh" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p id="xdx_23D_zngNjJM326e4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#160;</p></div>
    <div id="xdx_237_zqrHFjkOgQv4" style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zoNMc8WR0hx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, there were&#160;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--Plan2019Member_z5WAgZoEAxic" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-09-30_custom_Plan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,465,514</ix:nonFraction></span>&#160;shares of Common Stock available for issuance under the 2019 Plan, consisting
of (i)&#160;<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--NewSharesMember_znUURUMxncIk" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-09-30_custom_NewSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">470,522</ix:nonFraction></span>&#160;new shares, (ii)&#160;<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zT1Ts67wqhz4"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-09-30_custom_NonQualified2012StockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,405,833</ix:nonFraction></span>&#160;unallocated shares previously available for issuance under the 2012
Plan that were not then subject to outstanding &#8220;Awards&#8221; (as defined in the 2012 Plan), and (iii)&#160;<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zocLOgd2rCEd"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-09-30_custom_LongTermIncentiveCompensationPlan2009Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">589,159</ix:nonFraction></span>&#160;unallocated
shares previously available for issuance under the 2009 Plan that were not then subject to outstanding &#8220;Awards&#8221; (as
defined in the 2009 Plan). Any shares subject to outstanding options or other equity &#8220;Awards&#8221; under the 2019 Plan,
the 2012 Plan and the 2009 Plan that are forfeited, expire or otherwise terminate without issuance of the underlying shares, or
if any such Award is settled for cash or otherwise does not result in the issuance of all or a portion of the shares subject to
such Award (other than shares tendered or withheld in connection with the exercise of an Award or the satisfaction of withholding
tax liabilities), the shares to which those Awards were subject, shall, to the extent of such forfeiture, expiration, termination,
cash settlement or non-issuance, again be available for delivery with respect to Awards under the 2019 Plan. As of September 30,
2020, there were non-qualified stock options to purchase an aggregate of&#160;<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--Plan2019Member_zTH1Bc3QKXsk" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-09-30_custom_Plan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,240,751</ix:nonFraction></span>&#160;shares of Common Stock outstanding
under the 2019 Plan and an aggregate of&#160;<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zR7GgdpUsfge" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-09-30_custom_Plan2019Member_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,139,957</ix:nonFraction></span>&#160;restricted stock units and&#160;<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z6XALpbgdNf5" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-09-30_custom_Plan2019Member_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,422,885</ix:nonFraction></span>&#160;performance stock units
outstanding under the 2019 Plan.</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zdD7a759RKPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life
of the stock options. <span id="xdx_8BA_zIVltiQHsPVg">The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020
and 2019 are set forth in the table below.</span></span><span style="font: 10pt Times New Roman, Times, Serif"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, &#160;<br />
    2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, &#160;<br />
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Weighted average grant date fair value</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7nmiUGQaxu6" title="Weighted average grant date fair value" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.95</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXJkhBZg91jc" title="Weighted average grant date fair value" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.84</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6X436sBviji" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.34</ix:nonFraction></span>-<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5ZrKfDKyAY7" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.68</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPWL2pTK1bmc" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.83</ix:nonFraction></span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNVqFbgIC1te" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.54</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zswuhMgxdtgh" title="Volatility, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">63.53</ix:nonFraction></span>-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPEior3MJAf7" title="Volatility, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">67.92</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z928l5oTFKuj" title="Volatility, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">61.25</ix:nonFraction></span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4RPVGscCE95" title="Volatility, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">64.49</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhiXc8Uqg33k" title="Term"><ix:nonNumeric contextRef="From2020-01-012020-09-30_srt_MinimumMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric></span>-<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zP9PJqIzP45f" title="Term"><ix:nonNumeric contextRef="From2020-01-012020-09-30_srt_MaximumMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.8</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrkbCvLBWz71" title="Term"><ix:nonNumeric contextRef="From2019-01-012019-09-30_srt_MinimumMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.5</ix:nonNumeric></span>-<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwEAjWx2Yqx" title="Term"><ix:nonNumeric contextRef="From2019-01-012019-09-30_srt_MaximumMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.5</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjImzCJUI6a6" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zP4UtUna5yp5" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AA_zuk8AaiD2Qv9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zvEVXoBYoxi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span><span id="xdx_8BF_z3HpGB15ZkHi">A
summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September
30, 2020 is as follows</span>:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Number of Shares Under Options</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Exercise Price</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Remaining Contractual Life
    in Years</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Aggregate Intrinsic Value</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; padding-left: 5.4pt">Balance at December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMpi6OqO93mg" title="Number of shares under options, beginning" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,030,234</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsCMYOrb9io6" title="Weighted average exercise price, beginning" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.65</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZlMQ5IEoPQa" title="Weighted average remaining contractual life" style="width: 10%; text-align: right"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.84</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_uUSD_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSLzDKLI7LE1" title="Aggregate intrinsic value, beginning" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,668,171</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;&#160;Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5PqqEG2zYTg" title="Number of shares under options, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">736,500</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znEtZXbedyLb" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.58</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 5.4pt">&#160;&#160;Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFtA2f1Ronkf" title="Number of shares under options, exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,182,195</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv1ExzqMrWJg" title="Weighted average exercise price, exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.23</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zk0L9xOZXdif" title="Aggregate intrinsic value, exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,738,740</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;&#160;Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zc0S5Quq7m5g" title="Number of shares under options, expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">361,109</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z33ShYQHAqF5" title="Weighted average exercise price, expired"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.66</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;Cancelled/Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zO96vznw0Vx" title="Number of shares under options, cancelled forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">330,250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHvNR8QZyfs7" title="Weighted average exercise price, cancelled forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.69</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Balance at September 30, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWs2yolFYyph" title="Number of shares under options, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,893,180</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsrdaKRFvgm1" title="Weighted average exercise price, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwGnABLUKPUb" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.46</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_uUSD_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z48nVCNdzIzd" title="Aggregate intrinsic value, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">379,535</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Vested and Exercisable at September 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_uShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHIfLHq3x253" title="Number of shares under options, vested and exercisable ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,827,306</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpVhxHr3u6j8" title="Weighted average exercise price, vested and exercisable ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.06</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z22ZbK8I6yUb" title="Weighted average remaining contractual life, vested and exercisable" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.83</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_uUSD_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z2ttQgGxMoHh" title="Aggregate intrinsic value, vested and exercisable ending" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,370</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">Unvested at September 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_uShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcCSBP4f1Rv2" title="Number of shares under options, unvested ending" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,065,874</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zx7WEQGpllm3" title="Weighted average exercise price, unvested" style="text-align: right"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7ig9lkWLbx5" title="Weighted average remaining contractual life in years, unvested" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms">8.53</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iI_uUSD_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zI6nICZPvFg2" title="Aggregate intrinsic value, unvested" style="text-align: right"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,165</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AA_zMrOAAnKwmp8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2020, our outstanding options had exercise prices ranging from $<span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_uUSDPShares_c20200930__srt--RangeAxis__srt--MinimumMember_zRvay1vvzg33" title="Range - exercise price of options"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" contextRef="AsOf2020-09-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.38</ix:nonFraction></span>&#160;to $<span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_uUSDPShares_c20200930__srt--RangeAxis__srt--MaximumMember_zIAHwIeOReFk"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" contextRef="AsOf2020-09-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.92</ix:nonFraction></span>&#160;per share. Share-based compensation
expense related to options recognized in our results of operations for the three months ended September 30, 2020 and 2019 was
$<span id="xdx_90F_eus-gaap--ShareBasedCompensation_uUSD_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z2btrWeGGdk" title="Share-based Payment Arrangement, Noncash Expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-07-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,143,920</ix:nonFraction></span>&#160;and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_uUSD_c20190701__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYQ3OG6mXXDa" title="Share-based Payment Arrangement, Noncash Expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-07-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,194,667</ix:nonFraction></span>, respectively, and for the nine months ended September 30, 2020 and 2019 was $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_uUSD_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMPHCE6RaaP5" title="Share-based Payment Arrangement, Noncash Expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,141,061</ix:nonFraction></span>&#160;and
$<span id="xdx_901_eus-gaap--ShareBasedCompensation_uUSD_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDuob47NDCsc" title="Share-based Payment Arrangement, Noncash Expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,568,736</ix:nonFraction></span>, respectively, and it is based on awards vested. At September 30, 2020, total unrecognized estimated compensation expense
related to unvested options was approximately $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_uUSD_c20200930_zNJftiPd1bQb" title="Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,500,000</ix:nonFraction></span>, which may be adjusted for future changes in forfeitures. This cost is
expected to be recognized over a weighted-average period of&#160;<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqXS1YAnaLN6" title="Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"><ix:nonNumeric contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">2.0</ix:nonNumeric></span>&#160;years. No tax benefit was realized due to a continued
pattern of operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Restricted
Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Restricted
stock units granted under our 2009, 2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified
number of shares of our Common Stock. Share-based compensation expense is measured by the market value of our Common Stock on
the day of the grant. The shares vest ratably over the period specified in the grant. There is no partial vesting and any unvested
portion is forfeited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 20; Value: 2 -->
    <div id="xdx_234_zfb0P7ypL3Di" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p id="xdx_231_zFMd29cKvmSb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&#160;</p></div>
    <div id="xdx_233_znWf2ZDjh4T6" style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zIC6WD5Bqidj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Performance
stock units will vest if certain performance targets are achieved. If minimum performance thresholds are achieved, each award
will convert into Common Stock at a defined ratio depending on the degree of achievement of the performance target designated
by each individual award. If minimum performance thresholds are not achieved, then no shares will be issued. We recognize performance-based
restricted stock as compensation expense based on the most likely probability of attaining the prescribed performance and over
the requisite service period beginning at its grant date and through the date the restricted stock vests. The expected levels
of achievement are reassessed over the requisite service periods and, to the extent that the expected levels of achievement change,
stock-based compensation is adjusted and recorded on the consolidated statements of income and the remaining unrecognized stock-based
compensation is recognized over the remaining requisite service period.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three and nine months ended September 30, 2020 we recorded $<span id="xdx_903_eus-gaap--RestrictedStockExpense_uUSD_c20200701__20200930_zFGtSFm0eEyb" title="Restricted Stock or Unit Expense"><ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,988,844</ix:nonFraction></span>&#160;and $<span id="xdx_90B_eus-gaap--RestrictedStockExpense_uUSD_c20200101__20200930_zI5Z354jaZO7" title="Restricted Stock or Unit Expense"><ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,334,537</ix:nonFraction></span>, respectively, and during the three
and nine months ended September 30, 2019 we recorded $<span id="xdx_902_eus-gaap--RestrictedStockExpense_uUSD_c20190701__20190930_zOrihx5Db0gb" title="Restricted Stock or Unit Expense"><ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,061</ix:nonFraction></span>&#160;and $<span id="xdx_90C_eus-gaap--RestrictedStockExpense_uUSD_c20190101__20190930_zQoKGoC8pfEa"><ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,080,738</ix:nonFraction></span>, respectively, in share-based compensation expense
related to restricted stock units and performance stock units. As of September 30, 2020, we recognized performance-based compensation
expense using our assessment of the most likely probability of attaining EBITDA break-even which would result in vesting two times
the base number of performance stock units. At September 30, 2020, total unrecognized estimated compensation expense related to
unvested&#160;restricted stock units and performance stock units&#160;was approximately $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_uUSD_c20200930_zOoYfyAYB9Dh" title="Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,000,000</ix:nonFraction></span>, which may be adjusted if
certain performance targets are achieved or for future changes in forfeitures. <span>This cost is expected to be recognized over a weighted-average
period</span> of&#160;<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zN8WVIO8dfy"><ix:nonNumeric contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.6</ix:nonNumeric></span>&#160;years.</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zRZh1FI0hsz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B5_zPcTQN99nnXa">Schedule of restricted stock units and performance stock units</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b><span>
    <span>Restricted Stock Units</span></span></b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>Performance Stock Units</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>Number of Shares</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>Weighted Average Grant
    Date Fair Value</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>Number of Shares</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>Weighted Average Grant
    Date Fair Value</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2019</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhydhkTMslOk" title="Number of shares, beginning" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2019-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,240,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhpXBRtSmzb5" title="Weighted average grant date fair values, beginning" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2019-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.56</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3ZfVf0avEcj" title="Number of shares, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,102,817</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zGNnDtTLORRg" title="Weighted average grant date fair value, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zJbU32lgehje" title="Number of shares, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2020-01-012020-09-30_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,585,745</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z6vXzH8k03D7" title="Weighted average grant date fair value, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-09-30_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.08</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Vested/Released</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z73pf6G8bBs7" title="Number of shares, vested/released" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">301,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zb0bbIou4Swk" title="Weighted average grant date fair value, vested/released" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.78</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zSDPWOhKe4gh" title="Number of shares, vested/released" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2020-01-012020-09-30_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">151,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zkapLBpAhWa8" title="Weighted average grant date fair value, vested/released" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-09-30_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.14</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1x3WApsvY06" title="Number of shares, forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,360</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0xEKqoWY9S2" title="Weighted average grant date fair value, forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.07</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zk7IQBLSKi84" title="Number of shares, forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2020-01-012020-09-30_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,360</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z3MDo8x2uR8e" title="Weighted average grant date fair value, forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-09-30_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.07</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBv8lGx9ef15" title="Number of shares, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,029,957</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXc5a2LVVRmi" title="Weighted average grant date fair values, ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2020-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.83</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKg_____z4K4eOLt9fu" title="Number of shares, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-09-30_us-gaap_PerformanceSharesMember" id="Fact001285" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,422,885</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"><sup>*</sup></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ztqvxwfpYrTl" title="Weighted average grant date fair value, ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2020-09-30_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.08</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><sup id="xdx_F01_zF3D0gJ2TQ39">*</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F19_z8KYVpaGKtM7" style="font: 10pt Times New Roman, Times, Serif"><ix:footnote id="Footnote001288" xml:lang="en-US">The number
of performance stock units (PSUs) represents the base number of PSUs that may vest. The actual number of PSUs that will vest will
be between zero and two times the base number of PSUs depending on the Company's achievement of break-even quarterly EBITDA.</ix:footnote></span></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8A6_zm1hgrfziUb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Employee
Stock Purchase Plan </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 18, 2020, our stockholders approved the TherapeuticsMD, Inc. 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;),
which reserved <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200618__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_zEKsFf6lcNQ4"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-06-18_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,400,000</ix:nonFraction></span> shares of Common Stock for purchase. The ESPP permits eligible employee participants to purchase Common
Stock at a price per share which is equal to <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dp_c20200617__20200618__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_zUn94t2uT8e2"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="From2020-06-172020-06-18_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85</ix:nonFraction></span>% of the lesser of (a) the fair market value of the shares on the offering date
of the offering period or (b) the fair market value of the shares on the purchase date.</span></p>

</ix:nonNumeric><p id="xdx_817_zXOhbw9MTADh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zl2bkZCExrW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_822_zuyb4w5wDyre">NOTE
12 &#8211; INCOME TAXES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. We do not expect to pay any significant federal or state income tax for 2020 as a result of (i) the losses recorded
during the nine months ended September 30, 2020, (ii) additional losses expected for the remainder of 2020, and/or (iii) net operating
loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax
assets if it is &#8220;more likely than not&#8221; that some component or all of the benefits of deferred tax assets will not
be realized. As of September 30, 2020, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements,
no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the
reporting period.</span></p>

</ix:nonNumeric><p id="xdx_81E_zVgi5wuvKeIg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80D_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zfIGDgj1Beb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_82D_zx6Re9VbXMSf">NOTE
13 &#8211; RELATED PARTIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to
time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements
with Catalent have been reviewed by independent directors of our Company, or a committee consisting of independent directors of
our company, since July 2015. During the three months ended September 30, 2020 and 2019, we were billed by Catalent approximately
$<span id="xdx_904_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200701__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zXGnvS0h23Gc" title="Amount billed"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2020-07-012020-09-30_custom_CatalentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">520,000</ix:nonFraction></span>&#160;and $<span id="xdx_906_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190701__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_z5dt4b7NDic" title="Amount billed"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2019-07-012019-09-30_custom_CatalentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,196,000</ix:nonFraction></span>, respectively, for manufacturing activities related to our clinical trials, scale-up, registration
batches, stability and validation testing. During the nine months ended September 30, 2020 and 2019, we were billed by Catalent
approximately $<span id="xdx_90A_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200101__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zKEazzbXUBFl" title="Amount billed"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2020-01-012020-09-30_custom_CatalentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,563,000</ix:nonFraction></span>&#160;and $<span id="xdx_908_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190101__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zPCO89AEoKYa" title="Amount billed"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2019-01-012019-09-30_custom_CatalentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,118,000</ix:nonFraction></span>, respectively, for manufacturing activities related to our clinical trials, scale-up,
registration batches, stability and validation testing. As of September 30, 2020 and December 31, 2019, there were amounts due
to Catalent of approximately $<span id="xdx_901_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zDm37JWDPs12" title="Amounts due to related party"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2020-09-30_custom_CatalentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,000</ix:nonFraction></span>&#160;and $<span id="xdx_909_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zJlzvape1Zi9" title="Amounts due to related party"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2019-12-31_custom_CatalentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></span>, respectively. In addition, we have minimum purchase requirements in place
with Catalent as disclosed in Note 15, Commitments and Contingencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 21; Value: 2 -->
    <div id="xdx_237_z0MnqXGPAm4d" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p id="xdx_239_zWLhA8Hme8ya" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&#160;</p></div>
    <div id="xdx_23D_zNxdikSUpwbh" style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_z2JUFONh6oAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2020, Karen L. Ling, Executive Vice President and Chief Human Resources Officer of American International Group, Inc., or
AIG, was appointed to our board of directors. From time to time, we have entered into agreements with AIG in the normal course
of business. Agreements with AIG have been reviewed by independent directors of our Company, or a committee consisting of independent
directors of our Company, since April 2020. During the three and nine months ended September 30, 2020, we were billed by AIG approximately
$<span id="xdx_90A_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200701__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AmericanInternationalGroupMember_zkAOYQNVfN6k"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2020-07-012020-09-30_custom_AmericanInternationalGroupMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,000</ix:nonFraction></span>&#160;and $<span id="xdx_906_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200101__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AmericanInternationalGroupMember_zGrjldiNQJ03"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2020-01-012020-09-30_custom_AmericanInternationalGroupMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">195,000</ix:nonFraction></span>, respectively, for various insurance coverage for our Company.</span></p>

</ix:nonNumeric><p id="xdx_81D_z3iLbYqIfsLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_803_eus-gaap--ConcentrationRiskDisclosureTextBlock_zs4dc46xCZS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_825_zzV6I4qmYFii">NOTE
14 - BUSINESS CONCENTRATIONS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
purchase our prescription products from several suppliers with approximately&#160;<span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zwL4LakNGcXd" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-09-30_custom_SupplierOneConcentrationRiskMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">42</ix:nonFraction></span>%,&#160;<span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zFxcoM0f0j6c" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-09-30_custom_SupplierTwoConcentrationRiskMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% and&#160;<span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zspJcPWjz2Jf" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-09-30_custom_SupplierThreeConcentrationRiskMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">24</ix:nonFraction></span>% of our purchases
supplied by three vendors each, respectively, during the nine months ended September 30, 2020, and&#160;<span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zoMLeAEOOue8" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-09-30_custom_SupplierOneConcentrationRiskMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">36</ix:nonFraction></span>%,&#160;<span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zMWXVjNL8BVj" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-09-30_custom_SupplierTwoConcentrationRiskMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">28</ix:nonFraction></span>%,&#160;and
<span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zP9uVKvZQzl7" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-09-30_custom_SupplierThreeConcentrationRiskMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">26</ix:nonFraction></span>% of our purchases supplied by three vendors each, respectively, during the nine months ended September 30, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
sell our prescription products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores
that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the nine months ended
September 30, 2020,&#160;<span id="xdx_908_ecustom--NumberOfCustomers_dc_uNumber_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zqmZxC98tKt4" title="Number of customers - revenue"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2020-01-012020-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Number">three</ix:nonFraction></span>&#160;customers each accounted for more than&#160;<span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zrFlZ5rQJlSe"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of our total product revenues. Product revenue
from the three customers combined accounted for approximately&#160;<span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeCustomersConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zV1ZOrscOwnh"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-09-30_custom_ThreeCustomersConcentrationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">56</ix:nonFraction></span>% of our product revenue for the nine months ended September
30, 2020. During the nine months ended September 30, 2019,&#160;<span id="xdx_90A_ecustom--NumberOfCustomers_dc_uNumber_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zoCRaEdNz5hh"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2019-01-012019-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Number">four</ix:nonFraction></span>&#160;customers each generated more than&#160;<span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zvHJqShCp7oh"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of our product
revenues. Revenue generated from the four customers combined accounted for approximately&#160;<span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z52f3dQl2IBi"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-09-30_custom_FourCustomersConcentrationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">68</ix:nonFraction></span>% of our product revenue for the
nine months ended September 30, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2020, Pillpack, Inc. accounted for approximately $<span id="xdx_90D_eus-gaap--Revenues_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zA69fHNTJ5v3" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-09-30_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,319,000</ix:nonFraction></span>&#160;of our product revenue, Cardinal
Health accounted for approximately $<span id="xdx_90E_eus-gaap--Revenues_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zl8aUhbFhMff" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-09-30_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,415,000</ix:nonFraction></span>&#160;of our product revenue, and McKesson Corporation accounted for approximately
$<span id="xdx_904_eus-gaap--Revenues_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zj31V7kJR2r6" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-09-30_custom_CustomerConcentrationMcKessonCorporationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,009,000</ix:nonFraction></span>&#160;of our product revenue. During the nine months ended September 30, 2019, Pillpack, Inc. accounted for approximately
$<span id="xdx_903_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zBOik5QpNdPb"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-09-30_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,397,000</ix:nonFraction></span> of our product revenue, AmerisourceBergen accounted for approximately $<span id="xdx_902_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zRnvTa6iyHhe"><span id="xdx_905_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z8Fw1vzbTvy1" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-09-30_custom_CustomerConcentrationAmerisourceBergenRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-09-30_custom_CustomerConcentrationAmerisourceBergenRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,226,000</ix:nonFraction></ix:nonFraction></span></span> of our product revenue, PI Services
accounted for approximately $<span id="xdx_907_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPIServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zatreSu1m1aj"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-09-30_custom_CustomerConcentrationPIServicesMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,935,000</ix:nonFraction></span> of our product revenue and Cardinal Health accounted for approximately $<span id="xdx_90D_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_ze1RARlBUZa4" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-09-30_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,863,000</ix:nonFraction></span> of our
product revenue.</span></p>

</ix:nonNumeric><p id="xdx_816_zA08bANlwcld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zfcSSNYMY9g1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_822_z2diCo7MEkrk">NOTE
15 &#8211; COMMITMENTS AND CONTINGENCIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Operating
Leases</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
adopted ASC 842, Leases, effective January 1, 2019. Substantially all our operating lease right-of-use assets and operating
lease liabilities represent leases for office space used to conduct our business. Upon adoption, we recognized a right-of-use
asset and a lease liability for all leases that have commenced as of January 1, 2019. The right-of-use assets represent the
right to use the leased asset for the lease term. The lease liabilities represent the present value of the lease payments
under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the
lease liability, plus any initial direct costs incurred, less any lease incentives received. All right-of-use assets are
reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted
using our secured incremental borrowing rate for the same term as the underlying lease because the rates are not implicit in
the leases. Some of our leases contain variable lease payments, including payments based on an index or rate. Variable lease
payments based on an index or rate are initially measured using the index or rate in effect at lease commencement. Additional
payments based on the change in an index or rate, or payments based on a change in our portion of the operating expenses are
recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease liability. Included in
lease expense are any variable lease payments incurred in the period that were not included in the initial lease
liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1,
2013 and originally provided for a&#160;<span id="xdx_900_ecustom--CapitalLeaseObligationsTerm_dtM_c20130630__20130701_zHc41TLTz5af" title="Non-cancelable operating lease term"><ix:nonNumeric contextRef="From2013-06-302013-07-01" format="ixt-sec:durmonth" name="txmd:CapitalLeaseObligationsTerm">63</ix:nonNumeric></span>-month term. On February 18, 2015, we entered into an agreement with the same lessors
to lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April
26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location.
This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021.
On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the
same location, pursuant to an addendum to such lease. This addendum became effective beginning November 1, 2016.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 22; Value: 2 -->
    <div id="xdx_23D_zd7htHjT4F8l" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p id="xdx_233_z4EvZF8OT306" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&#160;</p></div>
    <div id="xdx_23D_zRV02J0qWsv2" style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>



<ix:exclude><p id="xdx_23B_zOSy2fMYTwdb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes&#160;<span id="xdx_90D_ecustom--NetRentableAreaLease_iI_usqft_c20181002_zWCCrYB91eq7" title="Net rentable area"><ix:nonFraction name="txmd:NetRentableAreaLease" contextRef="AsOf2018-10-02" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">56,212</ix:nonFraction></span>&#160;rentable
square feet, or the full premises, of which the lease on&#160;<span id="xdx_90E_ecustom--RentedAreaLease_iI_usqft_c20181002_zaAa5hIVEEgj" title="Rented area lease"><ix:nonFraction name="txmd:RentedAreaLease" contextRef="AsOf2018-10-02" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">7,561</ix:nonFraction></span>&#160;square
feet commenced in 2018 and the lease on the remaining&#160;<span id="xdx_900_ecustom--AdditionalAreaOfLeaseOccupied_iI_usqft_c20190801_zI04oyrP58zl" title="Additional area of lease occupied"><span id="xdx_904_ecustom--AdditionalAreaOfLeaseOccupied_iI_usqft_c20190801_zau1SkrRoYe4"><ix:nonFraction name="txmd:AdditionalAreaOfLeaseOccupied" contextRef="AsOf2019-08-01" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft"><ix:nonFraction name="txmd:AdditionalAreaOfLeaseOccupied" contextRef="AsOf2019-08-01" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">48,651</ix:nonFraction></ix:nonFraction></span></span>&#160;square
feet commenced in August 2019, or the full premises commencement date. The lease will expire&#160;<span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20190801_z6pzdY8AEFCj" title="Lessee, Operating Lease, Term of Contract"><ix:nonNumeric contextRef="AsOf2019-08-01" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract">11
years</ix:nonNumeric></span>&#160;after the full premises commencement date, unless terminated earlier in accordance with the terms of the
lease. We have the option to extend the term of the lease for&#160;<span id="xdx_90E_ecustom--LesseeOperatingLeaseExistenceOfOptionToExtendNumber_iI_dc_uPure_c20200930_zyQCbBnKO0J1" title="Lessee operating lease existence of option to extend number"><ix:nonFraction name="txmd:LesseeOperatingLeaseExistenceOfOptionToExtendNumber" contextRef="AsOf2020-09-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">two</ix:nonFraction></span>&#160;additional
consecutive periods of&#160;<span id="xdx_903_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dt_c20200930_zsd62cQ0YDWh"><ix:nonNumeric contextRef="AsOf2020-09-30" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm">five years</ix:nonNumeric></span>. The extension option is not included in the determination
of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free
rent periods. We are also responsible for certain other operating costs under the lease, including electricity and utility
expenses. In June 2019, we entered into an <span>agreement with the same lessors</span> to lease additional&#160;<span id="xdx_90A_ecustom--LesseeOperatingLeaseLeaseNotYetCommencedArea_iI_usqft_c20190601_z7HsIlDliUjf" title="Lease not yet commenced (area)"><ix:nonFraction name="txmd:LesseeOperatingLeaseLeaseNotYetCommencedArea" contextRef="AsOf2019-06-01" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">6,536</ix:nonFraction></span>&#160;square
feet of administrative office space in the same location,&#160;<span style="color: #212529">pursuant to an addendum to such
lease, which commenced in May 2020.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="color: #212529">&#160;</span></span></p>


<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_z6BLGFmJmuaj" summary="xdx: Disclosure - Supplemental lease information (Details)" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Supplemental lease information:</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20200930_zKMlsFVVsmd5" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br />
    2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_49F_20191231_z2lUPpRwwXri" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br />
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zLqHZddMxG6g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 5.4pt">Right-of-use asset</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,975,725</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,109,154</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zPtQCwt4f2Y5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Short-term operating lease liability (included in Other current liabilities)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,404,286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,501,539</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zUd5AYS1Trqg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Long-term operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,907,995</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,145,049</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">Weighted average remaining term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Weighted average remaining term::XDX::P8Y9M18D" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20200930_zgBZsKcJU8Xf" title="Weighted average remaining term"><ix:nonNumeric contextRef="AsOf2020-09-30" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">8.8</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Weighted average remaining term::XDX::P9Y" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_zInyTUJoHZUa" title="Weighted average remaining term"><ix:nonNumeric contextRef="AsOf2019-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">9</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_zCdfVlGrIQC4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 5.4pt">Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.3</ix:nonFraction>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.25</ix:nonFraction>%</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20200101__20200930_zuf4wqSlwdgf" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20190101__20190930_zqgrKqMD0BI7" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Supplemental cash flow information</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>for the nine months ended</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, &#160;<br />
    2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, &#160;<br />
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--OperatingLeasePayments_zMuE9QMriFWl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 5.4pt">Cash paid for amounts included in the measurement of lease liabilities for operating lease</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,006,970</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">849,440</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zkcI7REAWafk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Right-of-use assets obtained in exchange for lease obligation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">998,821</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,171,471</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>


<p id="xdx_8A1_zD4Xr3Z61old" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z9tqWaUXtFdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><span>The
following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities
recorded on the balance sheet:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Years Ended December 31,</b></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20200930_z3Yh7MVxkvXi">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz1WK_zFQnea8plN43" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2020 (3 months)</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">610,675</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz1WK_zIu6XN3J8uWf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,334,582</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz1WK_zghllzAwiFZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,413,289</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz1WK_zNxrXusITLdl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,443,143</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz1WK_zizUHmGFOcH3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,476,534</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz1WK_zmejpP5unW48" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,947,869</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz1WK_zlrj5YfaeCM3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Total undiscounted lease payments</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,226,092</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zqGQLbwDaeM6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Less: imputed interest</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,913,811</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_zKTLHCCZFCl1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Present value of lease payments</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,312,281</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8AB_zwrJBIuQV3de" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">During
the three and nine months ended September 30, 2020, operating lease expense related to our real estate leases was
approximately $</span><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20200701__20200930_zKwi3X7g4mxl" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">590,000</ix:nonFraction></span><span>&#160;and
$</span><span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20200101__20200930_zaaXw6dUInt4" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,749,000</ix:nonFraction></span><span>,
respectively, and variable lease expense was approximately $<span id="xdx_90D_eus-gaap--VariableLeaseCost_c20200701__20200930_z1foDxKH1cC7" title="Variable lease expense"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,000</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--VariableLeaseCost_c20200101__20200930_zwNmiPOxUh0j"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2020-01-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,000</ix:nonFraction></span>, respectively, for the same periods. During
the three and nine months ended September 30, 2019, operating lease expense related to our real estate leases was
approximately $</span><span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20190701__20190930_zCoEAZCum7B1" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">458,000</ix:nonFraction></span><span>&#160;and
$</span><span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20190101__20190930_z0LlTjbAU9Ae" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2019-01-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,062,000</ix:nonFraction></span><span>,
respectively, and variable lease expense was insignificant for the same periods.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Intellectual
Property Licenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Population Council License Agreement provides for future milestone payments to be paid by us for access to certain technologies.
In addition, we pay royalties as a percent of product revenue as described in Note 7, Intangible Assets, to these consolidated
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Purchase
Commitments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">We
have manufacturing and supply agreements whereby we are required to purchase from Catalent a minimum number of softgels
during the first contract year and a higher number of softgels after the first contract year. If the minimum order quantities
of specific products are not met, we are required to pay Catalent&#160;<span id="xdx_90E_ecustom--SignificantSupplyCommitmentPercentagePayable_iI_dp_uPure_c20200930_zxpW7tJ3qKae" title="Significant supply commitment percentage payable"><ix:nonFraction name="txmd:SignificantSupplyCommitmentPercentagePayable" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%
of the difference between the total amount we would have paid to Catalent if the minimum requirement had been fulfilled and
the sum of all purchases of our products from Catalent during the contract year. The updated minimum purchase commitments for
Catalent for the next five years are as follows: 2020 - $<span id="xdx_90C_eus-gaap--RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_iI_c20200930__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zevIbu8GnDge" title="Minimum purchase commitment, 2020"><ix:nonFraction name="us-gaap:RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" contextRef="AsOf2020-09-30_custom_CatalentMember226859265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,719,000</ix:nonFraction></span>, 2021 - $<span id="xdx_904_eus-gaap--RecordedUnconditionalPurchaseObligationDueWithinOneYear_iI_c20200930__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zg9l22o0tgmf" title="Minimum purchase commitment, 2021"><ix:nonFraction name="us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear" contextRef="AsOf2020-09-30_custom_CatalentMember226859265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,150,000</ix:nonFraction></span>, 2022 - $<span id="xdx_90E_eus-gaap--RecordedUnconditionalPurchaseObligationDueInSecondYear_iI_c20200930__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zp9BcAymo7p6" title="Minimum purchase commitment, 2022"><ix:nonFraction name="us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear" contextRef="AsOf2020-09-30_custom_CatalentMember226859265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,991,000</ix:nonFraction></span>, 2023 - $<span id="xdx_90E_eus-gaap--RecordedUnconditionalPurchaseObligationDueInThirdYear_iI_c20200930__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zZp5SkgPv99i" title="Minimum purchase commitment, 2023"><ix:nonFraction name="us-gaap:RecordedUnconditionalPurchaseObligationDueInThirdYear" contextRef="AsOf2020-09-30_custom_CatalentMember226859265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,347,000</ix:nonFraction></span>,
and 2024 - $<span id="xdx_90B_eus-gaap--RecordedUnconditionalPurchaseObligationDueInFourthYear_iI_c20200930__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zAZ6gSQXiIg" title="Minimum purchase commitment, 2024"><ix:nonFraction name="us-gaap:RecordedUnconditionalPurchaseObligationDueInFourthYear" contextRef="AsOf2020-09-30_custom_CatalentMember226859265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,786,000</ix:nonFraction></span>. In addition, we have a manufacturing and supply agreement whereby we are required to purchase a minimum
number of units of ANNOVERA during a contract year. As of September 30, 2020, we have met our contract year purchase
commitments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Legal
Proceedings</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">From
time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved
in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations,
or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 23; Value: 2 -->
    <div id="xdx_237_zQCR79ucLtSa" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p id="xdx_233_zSPYrjuocg1f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&#160;</p></div>
    <div id="xdx_234_zSUzaOAVjBI6" style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zzgOMkLnBhfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Off-Balance
Sheet Arrangements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020 and 2019, we had no off-balance sheet arrangements that have had or are reasonably likely to have current
or future effects on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources that are material to investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Employment
Agreements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits.
Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments,
if those circumstances occur during the term of the employment agreement.</span></p>

</ix:nonNumeric><p id="xdx_81F_zncmhBNEK0m2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<ix:nonNumeric contextRef="From2020-01-01to2020-09-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_z5QRTRUrcB9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_82A_zx0pPW90etH6">NOTE
16 &#8211; SUBSEQUENT EVENTS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
November 8, 2020, we entered into Amendment No. 6 which temporarily lowered the minimum required cash balance under the Financing Agreement from $<span id="xdx_90E_ecustom--MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVvdUE19b7mj"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">60</ix:nonFraction>
million</span> to $<span id="xdx_906_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Period1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIP3xT7anoVk"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Period1Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">45</ix:nonFraction>
million</span> through December 31, 2020. After December 31, 2020, the minimum required cash balance will revert to $<span id="xdx_905_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Period2Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfFWG2YmwwC8"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Period2Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">60</ix:nonFraction>
million</span>.&#160;&#160;On November 8, 2020, in connection with entering into Amendment No. 6 to the Financing Agreement, we amended the Lender Warrants to provide for an adjustment to the exercise price if we conduct certain dilutive issuances prior to December 31, 2020, or if the volume-weighted average price of our Common Stock for the fifteen trading days ending December 31, 2020 is lower than the then-current exercise price.</span></p>

</ix:nonNumeric><p id="xdx_812_zr2Wba1Xmufa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: center"><td style="font: 10pt Times New Roman, Times, Serif; width: 25%; white-space: nowrap"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_001"></span>Item
2. Management's Discussion and Analysis of Financial Condition and Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">General</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following discussion and analysis provides information that we believe to be relevant to an assessment and understanding of our
results of operations and financial condition for the periods described. This discussion should be read together with our unaudited
consolidated financial statements and the notes to the financial statements, which are included in this Quarterly Report on Form
10-Q. This information should also be read in conjunction with the information contained in our Annual Report on Form 10-K for
the year ended December 31, 2019 filed with the Securities and Exchange Commission, or the SEC, on February 24, 2020, or our Annual
Report, including the audited financial statements and notes included therein. The reported results will not necessarily reflect
future results of operations or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, this Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties.
Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies as
well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project,
believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as &#8220;believes,&#8221;
&#8220;hopes,&#8221; &#8220;may,&#8221; &#8220;anticipates,&#8221; &#8220;should,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221;
&#8220;will,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;positioned,&#8221; &#8220;strategy&#8221;
and similar expressions and are based on assumptions and assessments made in light of management&#8217;s experience and perception
of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking
statements are made as of the date of this Quarterly Report on Form 10-Q and we undertake no duty to update or revise any such
statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and
regulations of the SEC. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties,
many of which are outside of our control. Important factors that could cause actual results, developments and business decisions
to differ materially from forward-looking statements are described in the sections titled &#8220;Risk Factors&#8221; in our Annual
Report and this Quarterly Report on Form 10-Q, and include the following: the effects of the COVID-19 pandemic; our ability to maintain or increase sales of our approved
products; our ability to successfully commercialize IMVEXXY&#174;, BIJUVA&#174;, and ANNOVERA&#174; and obtain additional financing
necessary therefor; our commercialization, marketing and manufacturing capabilities and strategy for our approved products; the
size of markets and the potential market opportunity for which our products are approved and our ability to penetrate such markets;
the rate and degree of market acceptance of our products; the willingness of healthcare providers to prescribe and patients to
use our products; our ability to obtain additional financing when needed; our competitive position and the success of competing
products that are or become available for the indications that we are pursuing; our intellectual property position; whether we
will be able to comply with the covenants and conditions under our term loan facility; whether we will be able to successfully divest vitaCare Prescription Services and the proceeds that may be generated by such divestiture; the length, cost and uncertain results
of our clinical trials, the potential of adverse side effects or other safety risks that could adversely affect the commercialization
of our current or future approved products or preclude the approval of our future drug candidates; whether the U.S. Food and Drug
Administration (FDA) will approve the efficacy supplement for the lower dose of BIJUVA; our ability to protect our intellectual
property, including with respect to the Paragraph IV notice letters we received regarding IMVEXXY and BIJUVA; the length, cost
and uncertain results of future clinical trials; our reliance on third parties to conduct our manufacturing, research and development
and clinical trials; the ability of our licensees to commercialize and distribute our products; the ability of our marketing contractors
to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for our products;
the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading
price of our common stock; and the concentration of power in our stock ownership.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Throughout
this Quarterly Report on Form 10-Q, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;TherapeuticsMD,&#8221;
or &#8220;our company&#8221; refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our
wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation,
or BocaGreen; and vitaCare Prescription Services, Inc., a Florida corporation, or vitaCare.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">This
Quarterly Report on Form 10-Q includes our trademarks, trade names and service marks, such as vitaMedMD&#174;, BocaGreenMD&#174;,
IMVEXXY&#174;, BIJUVA&#174; and ANNOVERA&#174; which are protected under applicable intellectual property laws and are the property
of, or licensed to, our company. Solely for convenience, trademarks, trade names and service marks referred to in this Quarterly
Report on Form 10-Q may appear without the &#174;, &#8482; or SM symbols, but such references are not intended to indicate, in
any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor
to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#8217; trademarks, trade
names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement
or sponsorship of us by, these other parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Overview</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD
is a women&#8217;s healthcare company with a mission of creating and commercializing innovative products to support the lifespan
of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise,
and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions
range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical products. We also have
a portfolio of branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands that furthers our
women&#8217;s healthcare focus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
portfolio of products focused on women&#8217;s health allows us to efficiently leverage our sales and marketing plans to grow
our recently approved products. During 2018, the U.S. Food and Drug Administration, or FDA, approval of our pharmaceutical products
has transitioned our company from predominately focused on conducting research and development to one focused on commercializing
our pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
                                         July 2018, we launched our FDA-approved product, IMVEXXY (estradiol vaginal inserts)
                                         for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual
                                         activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause, which was
                                         approved by the FDA in May 2018. </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
                                         April 2019, we launched our FDA-approved product, BIJUVA (estradiol and progesterone)
                                         capsules, our hormone therapy combination of bio-identical 17&#223;-estradiol and bio-identical
                                         progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe
                                         vasomotor symptoms, or VMS, due to menopause in women with a uterus, which was approved
                                         by the FDA in October 2018. </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
                                         October 2019, we began a &#8220;test and learn&#8221; market introduction for our FDA-approved
                                         product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first
                                         and only annual patient-controlled, procedure-free, reversible prescription contraceptive option
                                         for women, which was approved by the FDA in August 2018 and which we have licensed for
                                         commercialization in the U.S. pursuant to an exclusive license agreement, or the Population
                                         Council License Agreement, with the Population Council, Inc., or the Population Council.
                                         We paused the planned full commercial launch of ANNOVERA in March 2020 due to the impact
                                         of the COVID-19 pandemic and resumed this initiative on July 1, 2020.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have also entered into license agreements with strategic partners to commercialize IMVEXXY and BIJUVA outside of the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
                                         July 2018, we entered into a license and supply agreement with Knight Therapeutics Inc.,
                                         or Knight, pursuant to which we granted Knight an exclusive license to commercialize
                                         IMVEXXY and BIJUVA in Canada and Israel.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
                                         June 2019, we entered into an exclusive license and supply agreement, or the Theramex
                                         License Agreement, with Theramex HQ UK Limited, or Theramex, a leading, global specialty
                                         pharmaceutical company dedicated to women&#8217;s health, to commercial BIJUVA and IMVEXXY
                                         outside of the U.S., excluding Canada and Israel.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
common stock, par value $0.001 per share, or the Common Stock, is traded on the Nasdaq Global Select Market of The Nasdaq Stock
Market LLC, or the Nasdaq, under the symbol &#8220;TXMD.&#8221; We maintain websites at&#160;<span style="text-decoration: underline">www.therapeuticsmd.com</span>&#160;as
well as various product websites. The information contained on our websites or that can be accessed through our websites does
not constitute part of this Quarterly Report on Form 10-Q.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Impact
of COVID-19 on our Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Our
business has been, and we anticipate that it will continue to be, impacted by the coronavirus (COVID-19) pandemic. Despite the
ongoing COVID-19 pandemic, we remain committed to the execution of our corporate goals, demonstrated in part by the increase of
our third quarter 2020 product revenue as compared to our second quarter of 2020 product revenue. During the third quarter of
2020, our product revenue increased primarily due to our sales force being able to visit more healthcare <span style="background-color: white">providers,
or HCPs,</span> as their offices opened. We resumed the full launch of ANNOVERA on July 1, 2020 and <span style="background-color: white">launched
the new consumer marketing campaign for IMVEXXY in August 2020</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">At
this time, the extent of the impact of the COVID-19 pandemic on our business continues to be highly uncertain and difficult to
predict. We developed a comprehensive COVID-19 contingency plan designed to preserve the value of our investments in our sales
and marketing infrastructure, protect our balance sheet during this period of market disruption, and meet the needs of our patients
and prescribers. This contingency plan was designed to be implemented in stages as we continue to evaluate the length of time
that COVID-19 may impact our business, which is intended to allow us to conserve our financial resources during the COVID-19 pandemic
and re-scale our sales and marketing activity when conditions warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Our
COVID-19 contingency plan is designed to support our strategy of driving product revenue by prioritizing ANNOVERA as the lead
product, IMVEXXY in the second position and BIJUVA in the third position. As part of this plan, we reduced our marketing focus
on BIJUVA so that we can prioritize driving our product revenue growth for ANNOVERA and IMVEXXY. Our COVID-19 contingency plan
includes containing costs and cutting spending, preparing for a potential longer-term impact throughout the year, leveraging vitaCare
to continue to meet the needs of our patients and prescribers, and ensuring continued availability of our products to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Cost
Containment and Spending Cuts</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
reduced our operating expenses during the COVID-19 pandemic and we continue to identify areas in which we can further reduce operating
expenses in the future.&#160;<span style="background-color: white">These cost cuts and reductions included permanent cost savings
that had been identified by management, as well as the interim cessation of certain spending that may be restarted in future quarters.
These cost cuts included:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Negotiating
                                         lower fees or suspending services from third party vendors;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Implementing
                                         certain hiring restrictions;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Delaying
                                         or cancelling non-critical information technology projects;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Eliminating
                                         travel, entertainment, meeting, and event expenses; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Reducing
                                         the size of our sales force and eliminating certain staff positions.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Employees
and Sales Force</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">As
live interactions with HCPs resumed during the third quarter of 2020, when healthcare professional offices opened, </span><span style="font: 10pt Times New Roman, Times, Serif">we
continue to utilize digital engagement tools and tactics and virtual detailing to remain engaged with prescribers and distribution
channels to supplement live interactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
                                         sales force continues to support HCPs remotely, when it is necessary, including the sales
                                         forces&#8217; ability to continue to provide HCPs with access to patient product samples,
                                         product marketing information, and information regarding patient affordability programs
                                         and support services.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
                                         sales force is in regular interaction with HCPs, including conducting live and &#8220;virtual&#8221;
                                         lunch and learn programs with providers.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
                                         sales force also continues product training, including sharing best practices, in advance
                                         of our anticipated future sales and marketing ramp.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Remote
Pharmacy and At-Home Delivery Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">As
of the date of this Quarterly Report on Form 10-Q, we are providing continued access to our products for patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
                                         products have broad distribution at all major retail pharmacy chains across the country.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">vitaCare
                                         patient model assists patients in obtaining easy and convenient access to their prescriptions
                                         for products at a retail pharmacy of their choice, including via home delivery retail
                                         pharmacy options. We anticipate that home delivery pharmacy options will continue to
                                         be attractive to patients during the COVID-19 pandemic.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
                                         anticipate that vitaCare will support continued patient access to our products during
                                         the COVID-19 pandemic and will help sustain refill trends for our products given vitaCare&#8217;s
                                         broad use by our patients.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
                                         have also engaged with independent community pharmacies and multiple third-party online
                                         pharmacies and telemedicine providers that focus on contraception or menopause to help
                                         ensure patients have real-time access to both diagnosis and treatment.</span></td></tr>                                                                                                                                <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We have developed relationships with industry leaders and emerging technology companies in the telehealth sector, a sector that
has seen accelerated growth as a result of COVID-19. Recognizing the importance of telehealth particularly in the contraception category,
we began developing various telehealth partnerships in 2019. Among those partnerships are leading online telemedicine platforms which
focus on directly prescribing and filling birth control directly to patients.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Supply
of Products</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of the date of this Quarterly Report on Form 10-Q, we do not anticipate a shortage of our products due to the COVID-19 pandemic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
                                         currently have sufficient inventory of finished product in our contracted warehouses
                                         to meet anticipated demand through the next six months.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
                                         currently do not foresee any interruption in our contract manufacturers&#8217; abilities
                                         to continue to manufacture additional products to be used. Our contract manufacturers
                                         have sufficient active pharmaceutical ingredients on hand for the continued manufacture
                                         of our products and there is currently no interruption in the supply chain for the active
                                         pharmaceutical ingredients for our products.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
                                         currently have uninterrupted wholesale and retail distribution of our products and are
                                         actively working to ensure that there continues to be an adequate supply of our products
                                         at pharmacies for sales to patients.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">While
we currently believe that our COVID-19 contingency plan has the ability to mitigate the effect of the COVID-19 pandemic on our
business, the severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but
not limited to, the duration and severity of the pandemic, the duration of &#8220;stay at home,&#8221; quarantine or &#8220;social
distancing&#8221; orders, the ability of our sales force to access healthcare providers to promote our products, increases in
unemployment, which could reduce access to commercial health insurance for our patients, thus limiting payer coverage for our
products, and the impact of the pandemic on our global supply chain, all of which are uncertain and cannot be predicted. Our future
results of operations and liquidity could be materially adversely affected by delays in payments of outstanding receivable amounts
beyond normal payment terms, supply chain disruptions, uncertain demand, and the impact of any initiatives or programs that we
may undertake to address financial and operations challenges that we may face.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
business may also be affected by negative impacts of the COVID-19 pandemic on capital markets and economies worldwide, and it
is possible that the pandemic could cause a local and/or global economic recession. While policymakers globally have responded
with fiscal policy actions to support the healthcare industry and economy as a whole, the magnitude and overall effectiveness
of these actions remains uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Our
Products</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>IMVEXXY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
May 2018, the FDA approved the 4-&#956;g and 10-&#956;g doses of IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe
dyspareunia (vaginal pain associated with sexual activity), a symptom of VVA, due to menopause. The 4-&#956;g formulation of IMVEXXY
represents the lowest FDA-approved dose of vaginal estradiol available. IMVEXXY 10-&#956;g became available for commercial distribution
in July 2018 and both doses were commercially available in September 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">IMVEXXY
is a small, digitally inserted, softgel vaginal insert that dissolves completely. It is administered mess-free, without the need
for an applicator, and can be used any time of day. IMVEXXY provides a mechanism of action and dosing that are familiar and comfortable
for patients, with no patient education required for dose application or applicators. IMVEXXY demonstrated efficacy as early as
two weeks (secondary endpoint) and maintained efficacy through week 12 in clinical studies, with no increase in systemic hormone
levels beyond the normal postmenopausal range (the clinical relevance of systemic absorption rates for vaginal estrogen therapies
is not known).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
part of the FDA&#8217;s approval of IMVEXXY, we have committed to conduct a post-approval observational study to evaluate the
risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen.
The FDA has also asked the sponsors of other vaginal estrogen products to participate in the observational study. In connection
with the observational study, we will be required to provide progress reports to the FDA on an annual basis. The development of
this method is underway, and we do not believe that the costs will be material on an annual basis. In addition, the FDA asked
for post-approval information with respect to certain characteristics related to the product&#8217;s specifications, which we
submitted to the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>BIJUVA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2018, the FDA approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bioidentical
hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe VMS
(commonly known as hot flashes or flushes), due to menopause in women with a uterus. The estrogen and progesterone in BIJUVA have
the same molecular structure as the hormones that are naturally produced in a woman&#8217;s body. We launched BIJUVA in April
2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">BIJUVA
offers the convenience of a single-capsule combination of two hormones (estradiol and progesterone), which may improve a user&#8217;s
compliance. The estradiol and progesterone in BIJUVA are plant-based, not animal-sourced, and contain no peanut allergens. BIJUVA
provides a sustained steady state of estradiol which reduced the frequency and severity of hot flashes in clinical studies with
no demonstrated impact on a patient&#8217;s weight or blood pressure. Additionally, through clinical trials BIJUVA has demonstrated
endometrial safety and greater than 90% amenorrhea rates, while providing no clinically meaningful changes in mammograms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In late January 2020, we submitted a New Drug Application, or NDA, efficacy supplement for the 0.5/100 mg dose of BIJUVA to the FDA for review and potential approval. The NDA efficacy supplement used existing data from our Phase 3 REPLENISH trial for BIJUVA, for which we announced results in December 2016, together with additional information and analyses.&#160;&#160;On
November 5, 2020, we withdrew the NDA efficacy supplement. We currently intend to file a Formal Dispute Resolution Request, or FDRR,
with the FDA that disputes the FDA&#8217;s requirement that the efficacy supplement meet approval standards that have not been required
of other approved drugs in BIJUVA&#8217;s therapeutic class. There can be no assurance that we will prevail with respect to
the FDRR, if filed, or that the 0.5/100 mg dose of BIJUVA will be approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">With
the approval of BIJUVA, the FDA required a post-approval commitment to further develop and validate our in-vitro dissolution method
to show how BIJUVA is released from the capsule in an in-vitro setting for quality control assessments. The development of this
method and validation were completed and submitted to the FDA as required in our approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
hormone therapy pharmaceutical products are characterized by safety and efficacy profiles that can be consistently manufactured
to target specifications. This provides an alternative to the non-FDA approved compounded bio-identical market. We believe that
our FDA-approved pharmaceutical products offer advantages in terms of demonstrated safety and efficacy, consistency in the hormone
dose, lower patient cost due to the increased likelihood of insurance coverage and improved access as a result of availability
from major retail pharmacy chains rather than custom order or formulation by individual compounders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANNOVERA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2018, we entered into an exclusive license agreement with the Population Council to commercialize in the U.S. ANNOVERA
(segesterone acetate and ethinyl estradiol vaginal system), the first and only annual patient-controlled, procedure-free,
reversible prescription contraceptive that can prevent pregnancy for up to a total of 13 cycles (one year), which was
approved by the FDA in August 2018. In October 2019, we began a &#8220;test and learn&#8221; market introduction phase of
launch for ANNOVERA. We paused the planned full commercial launch of ANNOVERA in March 2020 due to the impact of the COVID-19
pandemic and resumed this initiative on July 1, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">ANNOVERA
was classified by the FDA as a &#8220;new chemical entity,&#8221; or NCE, and thus has five years of regulatory exclusivity under
the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act. ANNOVERA is a one-year
ring-shaped contraceptive vaginal system, or CVS. ANNOVERA, which is made with a silicone elastomer, contains segesterone acetate,
a 19-nor progesterone derivative also known as Nestorone&#174;, or SA, and ethinyl estradiol, or EE. EE is an approved active ingredient
in many marketed hormonal contraceptive products. Segesterone acetate, an NCE, is a potent progestin that, based on pharmacological
studies in animals and <i>in vitro</i>, does not bind to the androgen or estrogen receptors and has no glucocorticoid activity
at contraceptive doses. SA has been evaluated in 51 clinical studies across these delivery systems with more than 26,794 cycles
of exposure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">ANNOVERA
can be inserted and removed by the woman herself without the aid of a healthcare provider and, unlike oral contraceptives, ANNOVERA
does not require daily administration to obtain the contraceptive effect. After 21 days of use, the woman removes ANNOVERA for
seven days, thereby providing a regular bleeding pattern (i.e., withdrawal/scheduled bleeding). The same CVS is then re-inserted
for additional 21/7-days in/out, for up to a total of 13 cycles (one year). ANNOVERA releases daily vaginal doses of both active
ingredients (SA and EE). The claimed release rate of 150 &#956;g/day SA and 13/day &#956;g EE is supported by the calculated average
release rate from an ex vivo analysis of ANNOVERA used for 13 cycles and is also supported by data from 13 cycles of in vitro
release.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
part of the approval of ANNOVERA, the FDA has required a post-approval observational study be performed to measure the risk of
venous thromboembolism. In accordance with the post-marketing requirements, the full protocol for the study was submitted to the
FDA in August 2019. We have agreed to perform and pay the costs and expenses associated with this post-approval study, provided
that if the costs and expenses associated with such post-approval study exceed $20 million, half of such excess will offset against
royalties or other payments owed by us to the Population Council under the Population Council License Agreement. Given the observational
nature of the study, we do not believe that the costs of the study will be material on an annual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe that ANNOVERA will compete across all the contraception options for women with focus on those women seeking a long-lasting
option without a procedure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
patients, ANNOVERA provides a single long-lasting reversible birth control product that does not require a procedure at the doctor&#8217;s
office for insertion or removal, empowering women to be in complete control of their fertility and menstruation with a 21/7 regimen.
We believe that ANNOVERA is a unique alternative for women who have previously chosen other forms of birth control. These include
nulliparous women (or women who have never given birth), women who are considering an IUD but would rather not have a procedure,
women who are between pregnancies but desire protection without a long-term commitment, and women who are not satisfied with oral
options due to the daily usage or potential side effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe that the strong initial commercial net revenue per unit of ANNOVERA and commercial insurance adoption provide us with
an opportunity to deploy additional financial resources to maximize ANNOVERA&#8217;s consumer-focused commercialization strategy
and leverage the ability of doctor/patient choice of contraceptive to override insurance company formularies when necessary. As
part of this strategy, we are pursuing distribution opportunities for ANNOVERA to provide women with additional access to ANNOVERA,
particularly during the COVID-19 pandemic, with multiple direct-to-consumer contraceptive platforms that extend the reach of our
products. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Commercialization
Model</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are commercializing the products in our portfolio through a common model focused on the belief that providing good experiences
for both HCPs and patients will drive profitability for TherapeuticsMD. Given that our portfolio focus is exclusively in women&#8217;s
health, we believe that each new product launch will allow us to further leverage our existing infrastructure and build out our
reputation as the premier women&#8217;s health organization in the U.S. Below is more detail on our commercialization model:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>HCP
Education</b>&#160;- Initially, we focus on the high writing and high potential HCPs in each territory to gain a full understanding
of their prescribing behavior and practices. Our focus is on driving initial prescriptions of these writers for each new product
launch and utilizing the time to also pull through on our portfolio of existing products. Once regular writing is established
with the initial group of HCPs, we expand our reach to a larger set of HCPs writing in the category. We educate HCPs on our products
primarily with our field sales organization supplemented by non-personal promotion. Our sales force currently targets approximately
130 territories, which includes the most significant part of the addressable markets across our product portfolio. As of September
30, 2020, more than 20,400 HCPs had written at least one prescription for IMVEXXY and more than 6,600 HCPs had written at least
one prescription for BIJUVA, the majority of whom are also IMVEXXY writers demonstrating the value of portfolio and focus. In
addition, as of September 30, 2020, more than 3,500 HCPs had written at least one prescription for ANNOVERA. In addition to our
sales organization, we leverage non-personal promotion (multi-channel advertising) to targets and non-targets designed to drive
awareness, education, and action. These efforts are designed to allow for pull through of the sales organization&#8217;s efforts
and identification of new targets that have interest in writing prescriptions for one or more of our products. We believe this
will drive increased prescribing for our products and lift the overall writing universe and our products to top of mind in the
HCP community.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b>BIO-IGNITE&#160;</b>-
In addition to our sales organization calling on HCPs, we have a Key Account Management, or KAM, team to support our existing
BIO-IGNITE pharmacy partners and additional pharmacies that wish to enroll in the BIO-IGNITE program. Additionally, KAMs
are focusing on supporting current prescribers of BIJUVA as well as high decile prescribers of hormone therapy for menopause<span style="color: red">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Payer
Access&#160;</b>- With the ever-changing payer environment, we believe it is critical to maximize breadth of coverage as quickly
as possible to not inhibit patient access to product. We do this while working to negotiate the best possible contracts for us.
Many commercial payers employ &#8220;new-to-market blocks&#8221; for newly launched products until the payers have the opportunity
to make a coverage decision based upon their internal review of the product. When a product is not covered, the patient is responsible
to pay the full price for the medication, which can significantly limit utilization of the product. As we seek to increase the
number of lives covered by commercial payers, it is our objective to continue to seek unrestricted coverage. As of September 30,
2020, we have obtained coverage for the majority of commercial payers by commercial payer lives for IMVEXXY and BIJUVA and continue
to seek unrestricted coverage from the remaining commercial insurance plans that we have not yet contracted with to provide affordable
access for patients. For IMVEXXY, we achieved unrestricted coverage with the top ten commercial payers of VVA products by commercial
payer lives and we continue to sign new agreements with other payers to cover IMVEXXY. In addition, as of September 30, 2020,
four of the top eight Medicare Part D payers of VVA products, based on covered lives, were adjudicating IMVEXXY, with additional
decisions for other Medicare Part D payers expected during the second half of 2020. For BIJUVA, through September 30, 2020, we
have achieved unrestricted coverage with nine of the top ten commercial payers of VMS products by commercial payer lives and we
continue to sign new agreements with payers to cover BIJUVA. Although Medicare is a small percentage of the VMS market, as of
September 30, 2020, two of the top six Medicare Part D payers of VMS products, based on covered lives, were adjudicating BIJUVA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
ANNOVERA, we believe that its unique characteristics will assist us in pursuing favorable commercial payer coverage, including
only one pharmacy fill fee per year and no office visit or procedure fees. We have made substantial progress in achieving unrestricted
access to ANNOVERA through commercial payers, including having achieved adjudication with six of the top ten commercial payers
by commercial payer lives as of September 30, 2020, and we continue to pursue discussions with several of the country&#8217;s
largest commercial insurers to further expand coverage. As of September 30, 2020, approximately 61% of the commercial payer market
covered ANNOVERA with unrestricted access under pharmacy benefits and approximately 73% covered ANNOVERA with step or prior authorization
access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2020, we entered into an agreement with Afaxys Pharma, LLC, a pharmaceutical company focused on serving women in the
public health system, to market ANNOVERA in the U.S. public health sector. As part of the Population Council License Agreement,
we have agreed to provide significantly reduced pricing to federally designated Title X family planning clinics serving underrepresented
women. We also have agreements to market ANNOVERA to the U.S. Department of Defense, the U.S. Department of Veteran&#8217;s Affairs,
and in Puerto Rico.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Supply
</b>- We want to ensure our products are available in all classes of trade and delivery systems. We offer our products through
traditional chain wholesalers (Cardinal, McKesson and AmerisourceBergen) and independent retail pharmacies, community compounding
pharmacies with our BIO-IGNITE program, and online pharmacies. We continue to develop unique opportunities to sell direct to pharmacies
to streamline distribution and better control costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Patient
Affordability Programs</b>&#160;- We have affordability and adherence programs in place for patients so that we can support appropriate
use of our products by patients. Our co-pay assistance programs allow all patients to access our products at a reasonable cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
                                         continue to support our patient education and affordability program that allows all eligible
                                         patients who enroll to receive IMVEXXY and BIJUVA at a reasonable cost. When a product
                                         is not covered by a patient&#8217;s commercial insurance, the patient is responsible
                                         to pay the full price for the medication, which can significantly limit a patient&#8217;s
                                         ability to pay and subsequent utilization of the product. For IMVEXXY and BIJUVA, enrolled
                                         patients pay as little as $35 for a prescription with commercial insurance coverage and
                                         pay as little as $50 for a prescription without commercial insurance coverage. For ANNOVERA,
                                         for commercially insured patients, we offer patients assistance for as low as $60 for
                                         an annual prescription. Many patients will not need a co-pay assistance program for ANNOVERA
                                         given the requirements of the Affordable Care Act, or ACA, at the federal level and similar
                                         laws at the state level.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
                                         continue to dialogue with the FDA regarding the potential inclusion of ANNOVERA as a
                                         new class of contraception for women in the FDA&#8217;s Birth Control Guide, which would
                                         require private health plans to cover ANNOVERA with no patient out-of-pocket costs as
                                         part of the ACA. There is no assurance that the FDA will make such a determination and
                                         it is possible that other FDA-approved products could also be included in such a new
                                         class. The FDA may also find that ANNOVERA fits into the vaginal contraceptive ring class,
                                         which it would share with NuvaRing and its generic equivalents, and potentially others.
                                         Eight states require insurance coverage of prescription contraception with co-pay regardless
                                         of inclusion in the FDA&#8217;s Birth Control Guide and 11 states, plus Washington D.C.,
                                         require coverage of prescription contraception with no co-pay regardless of inclusion
                                         in the FDA&#8217;s Birth Control Guide.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Patient
Adherence</b>&#160;- Establishing compliance and adherence programs that make getting on a prescription medication and obtaining
prescribed refills easy and convenient for the patient and HCPs is a critical lever in our commercial model. Our focus is on minimizing
complications in patients filling their first prescription and engaging with them throughout the life of their treatment to ensure
patients stay on and use therapy for the appropriate length of time. We have delivered effective patient engagement programs for
all of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Consumer
Communication</b>&#160;- Another critical level in the commercial model is consumer outreach. Our initial focus is on those patients
who are already predisposed to seek treatment, such as those patients new to therapy, and those patients dissatisfied with their
current therapy. Next, we are focused on expanding the market by energizing patients who are experiencing bothersome symptoms
but who have not been motived to seek treatment. Methods of communication include online and offline media and span branded and
unbranded communication to ensure we drive action from awareness of symptoms to desire to speak to an HCP to acquire a prescription.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>License
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>License
Agreement with the Population Council</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $20 million within
30 days following approval by the FDA of the NDA for ANNOVERA. The first commercial batch of ANNOVERA was released during the
third quarter of 2019, and we paid the Population Council a second milestone payment of $20 million as a result of the commercial
batch release. The Population Council is eligible to receive additional milestone payments and royalties from commercial sales
of ANNOVERA, as detailed below. We assumed responsibility for marketing expenses related to the commercialization of ANNOVERA.
We are required to pay the Population Council additional milestone payments of $40 million upon cumulative net sales of ANNOVERA
in the U.S. by us and our affiliates and permitted sublicensees of each of $200 million, $400 million and $1.0 billion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, we are required to pay the Population Council, on a quarterly basis, step-based royalty payments based on annual net
sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Annual
    Net Sales</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Royalty
    <br /> Rate</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 85%; text-align: justify; padding-left: 5.4pt">Less than or equal to $50.0 million</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">5</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 5.4pt">Greater than $50.0 million and less than or equal to $150.0 million</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 5.4pt">Greater than $150.0 million</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
annual royalty rate will be reduced to 50% of the initial rate during the six-month period beginning on the date of the first
arms-length commercial sale of a generic equivalent of ANNOVERA that is launched by a third party in the U.S., and thereafter
will be reduced to 20% of the initial rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Population Council has agreed to perform and pay the costs and expenses associated with two post-approval studies required by
the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post-approval study required
by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such post-approval
study exceed $20 million, half of such excess will be offset against royalties or other payments owed by us to the Population
Council under the Population Council License Agreement. We and the Population Council formed a joint product committee responsible
for overseeing activities under the Population Council License Agreement. We are responsible for all aspects of promotion, product
positioning, pricing, education programs, publications, sales messages and any additional desired clinical studies for the one-year
vaginal contraceptive system, subject to oversight and decisions made by the joint product committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Unless
earlier terminated, the Population Council License Agreement will remain in effect until the later of the expiration of the last-to-expire
of the Population Council&#8217;s U.S. patents that are licensed to us, or the date following such expiration that follows a continuous
period of six months during which we and our affiliates have not made a commercial sale of ANNOVERA in the U.S. The Population
Council License Agreement may also be terminated for certain breach and bankruptcy-related events and by us on 180 days&#8217;
prior notice to the Population Council.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
part of the Population Council License Agreement, we have the exclusive right to negotiate co-development and U.S. marketing rights
for two other investigational vaginal contraceptive systems in development by the Population Council.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>License
Agreement with Knight</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we granted
Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License
Agreement, Knight paid us $2 million in milestone fees upon the first regulatory approval in Canada for IMVEXXY and BIJUVA in
the third quarter of 2020, and is also required to pay us sales milestone fees based upon certain aggregate annual sales in Canada
and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada
and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related to IMVEXXY and
BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or
registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada within certain specified
time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate
the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods
or if the other party files for bankruptcy or other related matters. As part of the Knight License Agreement, Knight is prohibited
from exporting IMVEXXY and BIJUVA to the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>License
Agreement with Theramex</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2019, we entered into a licensing and supply agreement, or the Theramex License Agreement, with Theramex pursuant to which
we granted Theramex an exclusive, perpetual license to commercialize BIJUVA and IMVEXXY for human use outside of the U.S., except
for Canada and Israel, or the Theramex Territory. Pursuant to the terms of the Theramex License Agreement, Theramex paid us an
upfront fee of EUR 14 million in cash. We are also eligible to receive up to an additional EUR 29.5 million in cash milestone
payments, comprised of (i) an aggregate of EUR 2 million in regulatory milestone payments based on regulatory approvals for each
of BIJUVA and IMVEXXY in certain specified markets and (ii) an aggregate of EUR 27.5 million in sales milestone payments to be
paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones in the Theramex Territory
ranging from EUR 25 million to EUR 100 million. We are also entitled to receive quarterly royalty payments based on net sales
of BIJUVA and IMVEXXY in the Theramex Territory. Theramex has agreed to submit all regulatory applications, submissions and/or
registrations required for regulatory approval to use and commercialize BIJUVA and IMVEXXY in certain specified markets within
certain specified time periods and we may terminate the Theramex License Agreement if Theramex does not submit certain of such
regulatory applications, submissions and/or registrations. We may also terminate the Theramex License Agreement if Theramex challenges
our patents. Either party may terminate the Theramex License Agreement for any material breach by the other party that is not
cured within certain specified time periods or if the other party files for bankruptcy or other related matters. Theramex may
sublicense its rights to commercialize BIJUVA and IMVEXXY in the Theramex Territory, except for certain specified markets. Pursuant
to the terms of the Theramex License Agreement, we agreed to supply, or cause to be supplied, BIJUVA and IMVEXXY to Theramex.
We and Theramex have agreed to form a joint product committee responsible for advising and overseeing activities under the Theramex
License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, we had 35 issued foreign patents and 35 issued domestic or, U.S., patents, which included 14 domestic utility
patents that relate to BIJUVA, three domestic patents that relate to estradiol and progesterone product candidates, ten domestic
patents that relate to IMVEXXY, which establish an important intellectual property foundation for IMVEXXY, one domestic utility
patent that relates to a pipeline transdermal patch technology, one domestic utility patent that relates to our topical-cream
candidates, two domestic patents that relate to formulations containing progesterone, one domestic utility patent that relates
to our OPERA&#174; information technology platform, that we wrote off, and three domestic utility patents that relate to TX-009HR,
our progesterone and estradiol drug candidate. During the nine months ended September 30, 2020 and 2019, we wrote off $584,509
and $78,864, respectively,&#160;in costs related to trademarks and patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
significant portion of our historical operating expenses have been incurred in research and development activities. Research and
development expenses relate primarily to the development, support and maintenance of our drug candidates. Our research and development
expenses consist primarily of expenses incurred under agreements with contract research organizations, or CROs, and consultants
that conduct our clinical and preclinical studies; employee related expenses, which include salaries and benefits, and non-cash
share-based compensation; the cost of developing our chemistry, manufacturing, and controls capabilities, and costs associated
with other research activities and regulatory approvals. Other research and development costs listed below consist of costs incurred
with respect to drug candidates that have not received Investigational New Drug Application approval from the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 33; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table indicates our research and development expense by project for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Three Months Ended <br />September 30,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Nine Months Ended <br />September 30,</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>2020</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>2019</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>2020</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>2019</b></td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>(000s)</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>(000s)</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 48%">TX 001-HR(BIJUVA)</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 10%">563</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">454</td><td style="text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 10%">1,680</td><td style="text-align: left; width: 1%">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,869</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">TX 004-HR(IMVEXXY)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">248</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,869</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">439</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,308</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,109</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">777</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,701</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,046</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,513</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,027</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,078</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,038</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,360</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development expenditures have been reduced as we refocused our resources towards the commercialization of our approved pharmaceutical
products. We will continue to deploy limited resources as we develop our drug pipeline, continue stability testing and validation
on our pharmaceutical products, develop and validate secondary manufacturers, prepare regulatory submissions and work with regulatory
authorities on existing submissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
costs of clinical trials may vary significantly over the life of a project owing to a variety of factors. We base our expenses
related to clinical trials on estimates that are based on our experience and estimates from CROs and other third parties. Research
and development expenditures for the drug candidates will continue after the trial completes for on-going stability and laboratory
testing, regulatory submission and response work. For a discussion of the nature of efforts, steps and costs necessary to complete
these projects, see &#8220;Item 1. Business &#8212; Research and Development&#8221; and &#8220;Item 7. Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations &#8212; Research and Development Expenses&#8221; contained in our
Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Results
of Operations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Three
months ended September 30, 2020 compared with three months ended September 30, 2019</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Three Months Ended <br />September 30,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Change</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>(000s)</b></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 61%">Product revenue, net</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 10%">17,343</td><td style="text-align: left; width: 1%">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,213</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,130</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">License revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,506</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,506</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cost of goods sold</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,279</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,444</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,835</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">41,037</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">49,347</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,310</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;&#160;&#160;&#160;&#160;Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24,973</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,072</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,099</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,638</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,895</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,743</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(32,611</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(31,967</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(644</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Revenue
and Cost of Goods Sold</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Product
revenue is recorded net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons and estimated returns. We
launched IMVEXXY in the third quarter of 2018 and BIJUVA in the second quarter of 2019. We started selling ANNOVERA in the third
quarter of 2019. We paused the planned full commercial launch of ANNOVERA in March 2020 due to the impact of the COVID-19 pandemic
and resumed this initiative on July 1, 2020. Product revenue for the three months ended September 30, 2020 increased approximately
$9,130,000, or 111%, to approximately $17,343,000, compared with approximately $8,213,000 for the three months ended September
30, 2019. Product revenue increased primarily due to continued ramping of sales of IMVEXXY, BIJUVA and ANNOVERA during the three
months ended September 30, 2020, as compared to the prior period, partially offset by a decrease in prenatal vitamins sales and
slower than anticipated growth of our product revenue due to the impact of the COVID-19 pandemic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Sales
of IMVEXXY increased approximately $2,069,000 as compared to the prior period, primarily due to increased net product revenue
per unit partially offset by a lower number of units sold. Sales of BIJUVA increased approximately $1,156,000 as compared to the
prior period, primarily due to a higher number of units sold and increased net product revenue per unit. Sales of ANNOVERA increased
approximately $6,019,000 as compared to the prior period, primarily due to a higher number of units sold and increased net product
revenue per unit. In addition, during the three months ended September 30, 2020, our prenatal vitamin sales decreased approximately
$114,000 due to a decreased number of units sold, partially offset by increased net product revenue per unit as compared to the
prior period. In addition to our product revenue, during the three months ended September 30, 2020, we recognized license revenue
of $2,000,000 from two non-refundable milestone payments from Knight under the terms of the Knight License Agreement, which we
recognized at the point in time upon the regulatory approvals in Canada of each of IMVEXXY and BIJUVA. During the three months
ended September 30, 2019, we recognized license revenue of approximately $15,506,000 from the upfront fee, which was a non-refundable
payment, payable to us by Theramex under the terms of the Theramex License Agreement, which we recognized at the point in time
when Theramex was able to use and benefit from the license, which was when the knowledge transfer of regulatory documents occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the launches of IMVEXXY and BIJUVA we introduced co-pay assistance programs which allow eligible enrolled patients to access the
products at a reasonable cost regardless of insurance coverage. We expect that our product revenue will improve in the long term
as commercial and Medicare payer coverage increases, and plans complete the process needed to adjudicate IMVEXXY, BIJUVA, and
ANNOVERA prescriptions at pharmacies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of goods sold increased approximately $1,835,000, or 127%, to approximately $3,279,000 for the three months ended September 30,
2020, as compared with approximately $1,444,000 for the three months ended September 30, 2019. This increase in cost of goods
sold is attributable to the 111% increase in product revenue as compared to the prior period, an increase in the amortization of
our license fee related to ANNOVERA of approximately $746,000, an increase in royalty fees of approximately $301,000, as well
as approximately $152,000 of inventory obsolescence expense recorded during the three months ended September 30, 2020 as compared
to the prior period. Our gross margin related to prescription products was approximately 81% and 82% for the three-month periods
ended September 30, 2020 and 2019, respectively. The change in our gross margin between the two periods is primarily related to
the change in product mix and its related costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Operating
Expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
principal operating costs include the following items as a percentage of total operating expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Three Months Ended &#160; <br />September 30,</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: justify">Sales and marketing costs, excluding human resources costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">39.4</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">45.7</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Human resources related costs, including salaries, benefits and taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27.4</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Product research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.3</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Professional fees and consulting costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.3</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.3</td><td style="text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 35; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
principal operating costs include the following items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Three Months Ended <br />September 30,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Change</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>(000s)</b></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 61%">Sales and marketing costs, excluding human resources costs</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 10%">16,182</td><td style="text-align: left; width: 1%">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22,547</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,365</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Human resources related costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,434</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,507</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">927</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Product research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,027</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,078</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,051</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees and consulting costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,512</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,588</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,882</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,115</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">767</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total operating expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">41,037</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">49,347</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,310</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Sales
and marketing costs, excluding human resources costs, for the three months ended September 30, 2020 decreased by approximately
$6,365,000, or 28%, to approximately $16,182,000, compared with approximately $22,547,000 for the three months ended September
30, 2019. The sales and marketing costs, excluding human resources costs, decreased due to cost cutting initiatives put in place
at the beginning of the COVID-19 pandemic, including&#160;reducing consulting and agency fees, reduced travel and lower physician
education and training expenses caused by restrictions on in-person speaker programs due to the COVID-19 pandemic, which was partially
offset by higher advertising expense and higher incentives during the three months ended September 30, 2020 as compared to the
prior period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Human
resources costs, including salaries, benefits and taxes, for the three months ended September 30, 2020 increased by
approximately $927,000, or 7%, to approximately $14,434,000, compared with approximately $13,507,000 for the three months
ended September 30, 2019, as a result of an increase of approximately $725,000 in non-cash compensation expense included in
this category related to employee stock-based compensation and an increase of approximately $202,000 in personnel costs due
to continued commercialization of our prescription products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Product
research and development costs for the three months ended September 30, 2020 decreased by approximately $2,051,000, or 50%, to
approximately $2,027,000, compared with approximately $4,078,000 for the three months ended September 30, 2019. Product research
and development costs include costs related to manufacturing validation and early development trials, as well as salaries, wages,
non-cash compensation, and benefits of personnel involved in research and development activities. Product research and development
expenditures have been reduced as we refocused our resources towards the commercialization of our approved pharmaceutical products.
We continue to deploy limited resources as we develop our drug pipeline, continue stability testing and validation on our pharmaceutical
products, develop and validate secondary manufacturers, prepare regulatory submissions and work with regulatory authorities on
existing submissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Since
                                         the project&#8217;s inception in February 2013, we have incurred approximately $132,715,000
                                         in research and development costs with respect to BIJUVA.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Since
                                         the project&#8217;s inception in August 2014, we have incurred approximately $49,266,000
                                         in research and development costs with respect to IMVEXXY.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
a discussion of the nature of efforts, steps and costs related to our research and development projects, see &#8220;Item 1. Business
&#8212; Research and Development&#8221; and &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and
Results of Operations &#8212; Research and Development Expenses&#8221; contained in our Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Professional
fees and consulting costs for the three months ended September 30, 2020 decreased by approximately $1,588,000, or 39%, to approximately
$2,512,000, compared with approximately $4,100,000 for the three months ended September 30, 2019, primarily as a result of decreased
recruiting and consulting fees, partially offset by increased legal fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">All
other operating expenses for the three months ended September 30, 2020 increased by approximately $767,000, or 15%, to approximately
$5,882,000, compared with approximately $5,115,000 for the three months ended September 30, 2019, primarily as a result of increased
dues and subscriptions, rent, and insurance, partially offset by decreased information technology, other office and travel expenses
in part due to travel restrictions caused by the COVID-19 pandemic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 36; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Operating
Loss</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
a result of the foregoing, our operating loss decreased approximately $2,099,000, or 8%, to approximately $24,973,000 for the
three months ended September 30, 2020, compared with approximately $27,072,000 for the three months ended September 30, 2019,
primarily as a result of a decrease in total operating expenses due to cost cutting initiatives put in place due to the
COVID-19 pandemic and an increase in product revenue partially offset by increased cost of goods sold and decreased license
revenue as compared to the prior period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
anticipate that we will continue to have operating losses for the near future until we successfully commercialize IMVEXXY, BIJUVA,
and ANNOVERA, although there is no assurance that any commercialization of IMVEXXY, BIJUVA and ANNOVERA will be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Other
expense, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Other
non-operating expenses, net increased by approximately $2,743,000, or 56%, to an expense of approximately $7,638,000 for the three
months ended September 30, 2020, compared with an expense of approximately $4,895,000 for the three months ended September 30,
2019, primarily as a result of increased interest expense related to our Financing Agreement. For more information regarding our
Financing Agreement, see &#8220;Liquidity and Capital Resources&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Net
Loss</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Because
of the net effects of the foregoing, net loss increased approximately $644,000, or 2%, to approximately $32,611,000 for the three
months ended September 30, 2020, compared with approximately $31,967,000 for the three months ended September 30, 2019. Net loss
per share of Common Stock, basic and diluted, was ($0.12) and ($0.13) for the three months ended September 30, 2020 and 2019,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Nine
months ended September 30, 2020 compared with nine months ended September 30, 2019</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Nine Months Ended <br />September 30,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Change</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>(000s)</b></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 61%">Product revenue, net</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 10%">40,294</td><td style="text-align: left; width: 1%">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22,055</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">License revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,506</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,506</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cost of goods sold</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,456</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,938</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">152,834</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">137,102</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,732</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;&#160;&#160;&#160;&#160;Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(120,934</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(106,813</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,121</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(20,503</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(19,896</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(607</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(141,437</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(126,709</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(14,728</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Revenue
and Cost of Goods Sold</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Product
revenue is recorded net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons and estimated returns. We
launched IMVEXXY in the third quarter of 2018 and BIJUVA in the second quarter of 2019. We started selling ANNOVERA in the third
quarter of 2019. We paused the planned full commercial launch of ANNOVERA in March 2020 due to the impact of the COVID-19 pandemic
and resumed this initiative on July 1, 2020. Product revenue for the nine months ended September 30, 2020 increased approximately
$22,055,000, or 121%, to approximately $40,294,000, compared with approximately $18,239,000 for the nine months ended September
30, 2019. Product revenue increased primarily due to continued ramping of sales of IMVEXXY, BIJUVA and ANNOVERA, partially offset
by slower than anticipated growth of our product revenue due to the impact of the COVID-19 pandemic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 37; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Sales
of IMVEXXY increased approximately $8,414,000 as compared to the prior period, sales of BIJUVA increased approximately $3,485,000
as compared to the prior period, and sales of ANNOVERA increased approximately $10,127,000 as compared to the prior period, in
each case primarily due to a higher number of units sold and increased net product revenue per unit. In addition, during the nine
months ended September 30, 2020, our prenatal vitamin sales increased approximately $29,000 due to increased net product revenue
per unit as compared to the prior period, partially offset by a decreased number of units sold. In addition to our product revenue,
during the nine months ended September 30, 2020, we recognized aggregate license revenue of $2,000,000 from two non-refundable
milestone payments from Knight under the terms of the Knight License Agreement, which we recognized at the point in time upon
the regulatory approvals in Canada of each of IMVEXXY and BIJUVA. During the nine months ended September 30, 2019, we recognized
license revenue of approximately $15,506,000 from the upfront fee, which was a non-refundable payment, payable to us by Theramex
under the terms of the Theramex License Agreement, which we recognized at the point in time when Theramex was able to use and
benefit from the license, which was when the knowledge transfer of regulatory documents occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the launches of IMVEXXY and BIJUVA, we introduced co-pay assistance programs which allow eligible enrolled patients to access
the products at a reasonable cost regardless of insurance coverage. We expect that our product revenue will improve in the long
term as commercial and Medicare payer coverage increases, and plans complete the process needed to adjudicate IMVEXXY, BIJUVA,
and ANNOVERA prescriptions at pharmacies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of goods sold increased approximately $6,938,000, or 201%, to approximately $10,394,000 for the nine months ended September
30, 2020, compared with approximately $3,456,000 for the nine months ended September 30, 2019. This increase is attributable
to a 121% increase in product revenue as compared to the prior period, an increase in royalty fees of approximately $506,000,
and an increase in amortization of our license fee related to ANNOVERA of approximately $2,246,000, as well as an increase of
$2,232,000 inventory obsolescence expense, primarily related to BIJUVA, as compared to the prior period. Our gross margin
related to prescription products was approximately 74% and 81% for the nine-month periods ended September 30, 2020 and 2019,
respectively. The change in our gross margin between the two periods is primarily related to the change in product mix and
its related costs, as well as inventory obsolescence expense described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Operating
Expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
principal operating costs include the following items as a percentage of total operating expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Nine Months Ended <br />September 30,</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Sales and marketing costs, excluding human resources costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">46.5</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">44.2</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Human resources related costs, including salaries, benefits and taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27.1</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Product research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.2</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees and consulting costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.3</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.2</td><td style="text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
principal operating costs include the following items:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Nine Months Ended <br />September 30,</b></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Change</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>(000s)</b></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 61%">Sales and marketing costs, excluding human resources costs</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 10%">71,051</td><td style="text-align: left; width: 1%">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">60,537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,514</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Human resources related costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,162</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,617</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Product research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,038</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,360</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,322</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees and consulting costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,734</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,291</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,232</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,018</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,214</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total operating expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">152,834</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">137,102</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,732</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Sales
and marketing costs, excluding human resources costs, for the nine months ended September 30, 2020 increased by approximately
$10,514,000, or 17%, to approximately $71,051,000, compared with approximately $60,537,000 for the nine months ended September
30, 2019. This increase was primarily due to higher expenses associated with sales and marketing efforts to support the significant
initiative related to the launch of ANNOVERA in March 2020, which was subsequently paused as a result of the COVID-19 pandemic
and relaunched on July 1, 2020, as well as continuing to support the commercialization of BIJUVA and IMVEXXY, which was partially
offset by cost cutting initiatives put in place at the beginning of the COVID-19 pandemic, including&#160;reducing consulting
and agency fees. Sales and marketing costs, excluding human resources costs, also increased as compared to the prior period as
a result of higher sales incentives due to the increase in product revenue, which was partially offset by lower physician education,
training and travel expenses caused by restrictions on in-person speaker programs due to the COVID-19 pandemic. In addition, we
recorded the write down of product samples of approximately $5,100,000, during the nine months ended September 30, 2020, primarily
related to BIJUVA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 38; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Human
resources costs, including salaries, benefits and taxes, for the nine months ended September 30, 2020 increased by
approximately $9,617,000, or 26%, to approximately $46,779,000, compared with approximately $37,162,000 for the nine months
ended September 30, 2019, as a result of an increase of approximately $8,180,000 in personnel costs primarily in sales,
marketing and regulatory areas to support commercialization of our prescription products, partially offset by cost cutting
measures implemented due to the COVID-19 pandemic, and an increase of approximately $1,437,000 in non-cash compensation expense
included in this category related to employee stock-based compensation during 2020 as compared to 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Product
research and development costs for the nine months ended September 30, 2020 decreased by approximately $7,322,000, or 48%, to
approximately $8,038,000, compared with approximately $15,360,000 for the nine months ended September 30, 2019. Product research
and development costs include costs related to manufacturing validation and early development trials, as well as salaries, wages,
non-cash compensation, and benefits of personnel involved in research and development activities. Product research and development
expenditures have been reduced as we refocused our resources towards the commercialization of our approved pharmaceutical products.
We continue to deploy limited resources as we develop our drug pipeline, continue stability testing and validation on our pharmaceutical
products, develop and validate secondary manufacturers, prepare regulatory submissions and work with regulatory authorities on
existing submissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Since
                                         the project&#8217;s inception in February 2013, we have incurred approximately $132,715,000
                                         in research and development costs with respect to BIJUVA.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Since
                                         the project&#8217;s inception in August 2014, we have incurred approximately $49,266,000
                                         in research and development costs with respect to IMVEXXY.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
a discussion of the nature of efforts, steps and costs related to our research and development projects, see &#8220;Item 1. Business
&#8212; Research and Development&#8221; and &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and
Results of Operations &#8212; Research and Development Expenses&#8221; contained in our Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Professional
fees and consulting costs for the nine months ended September 30, 2020 decreased by approximately $1,291,000, or 13%, to approximately
$8,734,000, compared with approximately $10,025,000 for the nine months ended September 30, 2019, primarily as a result of reduced
recruiting and consulting fees partially offset by increased legal, accounting and other professional fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">All
other operating expense for the nine months ended September 30, 2020 increased by approximately $4,214,000, or 30%, to approximately
$18,232,000, compared with approximately $14,018,000 for the nine months ended September 30, 2019, primarily as a result of increased
insurance, dues and subscriptions, rent, and information technology expenses, partially offset by lower other office and travel
expenses due to travel restrictions caused by the COVID-19 pandemic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Operating
Loss</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
a result of the foregoing, our operating loss increased approximately $14,121,000, or 13%, to approximately $120,934,000 for the
nine months ended September 30, 2020, compared with approximately $106,813,000 for the nine months ended September 30, 2019, primarily
as a result of an increase in total operating expenses to support commercialization and launch efforts related to our pharmaceutical
products, as well as write off of product samples and inventory due to the COVID-19 pandemic, as described above, partially offset
by increased total net product revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
anticipate that we will continue to have operating losses for the near future until we successfully commercialize IMVEXXY, BIJUVA,
and ANNOVERA, although there is no assurance that any commercialization of IMVEXXY, BIJUVA, and ANNOVERA will be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 39; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Other
expense, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Other
non-operating expense, net increased by approximately $607,000, or 3%, to an expense of approximately $20,503,000 for the nine
months ended September 30, 2020, compared with an expense of approximately $19,896,000 for the nine months ended September 30,
2019,&#160;primarily as a result of increased interest expense related to our Financing Agreement partially offset by the loss
on extinguishment of debt of $10,058,000 incurred during the nine months ended September 30, 2019. For more information regarding
our Financing Agreement, see &#8220;Liquidity and Capital Resources&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Net
Loss</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Because
of the net effects of the foregoing, net loss increased approximately $14,728,000, or 12%, to approximately $141,437,000 for the
nine months ended September 30, 2020, compared with approximately $126,709,000 for the nine months ended September 30, 2019. Net
loss per share of Common Stock, basic and diluted, was ($0.52) and ($0.53) for the nine months ended September 30, 2020 and 2019,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Liquidity
and Capital Resources</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have funded our operations primarily through public offerings of our Common Stock and private placements of equity and debt securities.
For the three-year period ended December 31, 2019, we received approximately $236,000,000 in net proceeds from the issuance of
shares of our Common Stock. As of September 30, 2020, we had cash and cash equivalents totaling approximately $79,634,000. However,
changing circumstances may cause us to consume funds significantly faster than we currently anticipate, and we may need to spend
more money than currently expected because of circumstances beyond our control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
net days sales outstanding, or net DSO, is calculated by dividing gross accounts receivable less the reserve for doubtful accounts,
chargebacks and payment discounts by the average daily net product revenue during the quarter. We also disclose gross DSO, which
includes the calculation of gross accounts receivable divided by the average daily gross product revenue to distributors during
the quarter. For the three months ended September 30, 2020, our gross DSO was 56 days compared to 55 days for the three months
ended December 31, 2019 and our net DSO was 128 days for the three months ended September 30, 2020 compared to 141 days for the
three months ended December 31, 2019. We anticipate that our DSO will fluctuate in the future based upon a variety of factors,
including longer payment terms associated with the launches of IMVEXXY, BIJUVA, and ANNOVERA and changes in the healthcare industry.
Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage, and
reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with
the COVID-19 pandemic, or other customer-specific factors. Although we have historically not experienced significant credit losses,
it is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade receivables
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
April 24, 2019, we entered into a Financing Agreement, as amended, or the Financing Agreement, with TPG Specialty Lending,
Inc., as administrative agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of
our subsidiaries party thereto from time to time as guarantors, which provides us with up to a $300,000,000 first lien
secured term loan credit facility, or the Facility. The Facility provides for fund availability in multiple tranches:
$200,000,000 was drawn upon entering into the Financing Agreement while an additional $50,000,000 was drawn on February 18,
2020. An additional $50,000,000 was previously available to us in the Administrative Agent&#8217;s sole and absolute
discretion either contemporaneously with the delivery of our financial statements for the quarter ended June 30, 2020 or at
such earlier date as the Administrative Agent may have consented to. Due to the pause in the full launch of ANNOVERA
caused by the COVID-19 pandemic, the undrawn $50,000,000 trance under the Financing Agreement is no longer available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
August 5, 2020, we and our subsidiaries entered into Amendment No. 5 to the Financing Agreement, or Amendment No. 5, with the
Administrative Agent and the lenders party thereto, pursuant to which we modified the minimum consolidated net product revenue
requirements attributable to commercial sales of our IMVEXXY, BIJUVA, and ANNOVERA products, which requirements are effective
beginning with the fiscal quarter ending December 31, 2020. In lieu of a cash amendment fee, to induce the lenders to enter into
Amendment No. 5, on August 5, 2020, we issued warrants, or the Warrants, to the lenders under the Financing Agreement to purchase
an aggregate of 4,752,116 shares of Common Stock, pursuant to a subscription agreement among the parties, or the Subscription
Agreement. The Warrants have an exercise price of $1.58 per share of Common Stock and an expiration date of August 5, 2030. The
Warrants may also be exercised via cashless exercise pursuant to the terms thereof. No registration rights were issued pursuant
to the Warrants or Subscription Agreement. On November 8, 2020, in connection with entering into Amendment No. 6 to the Financing Agreement, we amended the Warrants to provide for an adjustment to the exercise price if we conduct certain dilutive issuances prior to December 31, 2020, or if the volume-weighted average price of our Common Stock for the fifteen trading days ending December 31, 2020 is lower than the then-current exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 40; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">
As of the filing date of this Quarterly Report on Form 10-Q, our cash balance was above the $60 million balance as required
by the Financing Agreement. On November 8, 2020, we and our subsidiaries entered into Amendment No. 6 to the Financing
Agreement, or Amendment No. 6, with the Administrative Agent and the lenders party thereto, pursuant to which we temporarily
lowered the minimum required cash balance from $60 million to $45 million through December 31, 2020. After December 31, 2020,
the minimum cash balance will revert to $60 million. Based on our current projections, we will need to raise additional
capital to remain in compliance with this minimum cash balance covenant for the next twelve months from the issuance of these
financial statements. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In order to address our projected capital needs, we are pursuing various equity financing and other alternatives including the sale of a controlling interest in  vitaCare Prescription Services for which we commenced a sale process and received initial indications of interest. The equity financing alternatives may include the private placement of equity, equity-linked, or other similar instruments or obligations with one or more investors, lenders, or other institutional counterparties or an underwritten public equity or equity-linked securities offering. Our ability to sell equity securities may be limited by market conditions. To the extent that we raise additional capital through the sale of such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders.

</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Along with considering additional financings, we have reviewed numerous potential scenarios in connection with the impact of COVID-19 on our business including the impact of the recent steps we have taken to reduce our operating expenses in response. Based on our analysis, we believe that our existing cash reserves along with potential proceeds from the sale of certain non-core assets of the Company and proceeds from potential future financings, if available to us, would be sufficient to meet our cash needs arising in the ordinary course of business for the next twelve months from the date of this Quarterly Report on Form 10-Q.

</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">However, if we are unsuccessful with future financings and if the successful commercialization of IMVEXXY, BIJUVA, or ANNOVERA is delayed, or the continued impact of the COVID-19 pandemic on our business is worse than we anticipate, our existing cash reserves would be insufficient to maintain compliance with the Financing Agreement covenants or satisfy our liquidity requirements until we are able to successfully commercialize IMVEXXY, BIJUVA, and ANNOVERA. The presence of these projected factors in conjunction with the uncertainty of the capital markets raises substantial doubt about the Company's ability to continue as a going concern for the next twelve months from the issuance of these financial statements.

</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
need substantial amounts of cash to complete the launch and commercialization of our hormone therapy and contraceptive drugs.
The following table sets forth the primary sources and uses of cash for each of the periods set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Summary
of (Uses) and Sources of Cash</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Nine Months Ended <br />September 30,</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>(000s)</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 74%">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 10%">(129,149</td><td style="text-align: left; width: 1%">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(114,900</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,069</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,178</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -12.6pt; padding-left: 12.6pt">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">49,022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">111,796</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Operating
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
principal use of cash in operating activities for the nine months ended September 30, 2020 was to fund our current expenses primarily
related to supporting commercialization activities for IMVEXXY, BIJUVA, and ANNOVERA, sales, marketing, scale-up and manufacturing
activities and clinical development, adjusted for non-cash items. The increase of approximately $14,249,000 in cash used in operating
activities for the nine months ended September 30, 2020 compared with the prior year was primarily due to an increase in our net
loss and changes in the components of working capital partially offset by an increase in non-cash items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Investing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Investing
activities include costs related to patents and fixed assets. Net cash used in investing activities for the nine months ended
September 30, 2020 decreased by approximately $2,109,000 primarily due to lower costs related to the purchase of fixed assets
during the nine months ended September 30, 2020 compared with the prior period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Financing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0.5pt; text-align: justify; text-indent: 35.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Financing
activities currently represent the principal source of our cash flow. Our financing activities for the nine months ended September
30, 2020 provided net cash of approximately $49,022,000 which consisted of the funding from our Financing Agreement of $50,000,000
and the exercise of options to purchase Common Stock of approximately $272,000, partially offset by the payment of deferred financing
fees of $1,250,000. Our financing activities for the nine months ended September 30, 2019 provided net cash of approximately $111,796,000,
which consisted of the net funding from our Facility of approximately $193,348,000 and the exercise of options and warrants to
purchase Common Stock of approximately $109,000, partially offset by the repayment of the MidCap Agreement of approximately $81,661,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0.5pt; text-align: justify; text-indent: 35.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 41; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>New
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2018, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13 which
eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose
certain new information and modifies some disclosure requirements. The FASB developed the amendments to Accounting Standards Codification,
or ASC, 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the
notes to financial statements by focusing on requirements that clearly communicate the most important information to users of
the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and
for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions
that eliminate or modify requirements. We adopted this standard on January 1, 2020, and the adoption did not have a material effect
on our disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on
Financial Instruments. The amendments in this update require a financial asset (or a group of financial assets) measured at amortized
cost basis to be presented at the net amount expected to be collected based on historical experience, current conditions, and
reasonable supportable forecasts. The amendments in this update are effective for public business entities for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted no sooner than the
first quarter of 2019. A modified retrospective approach is required for all investments, except debt securities for which an
other-than-temporary impairment had been recognized prior to the effective date, which will require a prospective transition approach
and should be applied either prospectively or retrospectively depending on the nature of the disclosure. The adoption of ASU 2016-13
requires expanded quantitative and qualitative disclosures about the Company&#8217;s expected credit losses. Effective January
1, 2020, we adopted ASU 2016-13 under a modified retrospective approach for all financial assets measured at amortized cost. There
was no adjustment recorded for the cumulative effect of adopting ASU 2016-13. The adoption expanded disclosures about our credit
losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Other
recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified
Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial
position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_002"></span>Item
3. Quantitative and Qualitative Disclosures about Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest
rates. To minimize this risk, we intend to maintain an investment portfolio that may include cash, cash equivalents and investment
securities available-for-sale in a variety of securities which may include money market funds, government and non-government debt
securities and commercial paper, all with various maturity dates. Due to the low risk profile of our investments, an immediate
100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Amounts
borrowed under the Financing Agreement accrue interest at either (i) 3-month LIBOR plus 7.75%, subject to a LIBOR floor of 2.70%
or (ii) the prime rate plus 6.75%, subject to a prime rate floor of 5.20%. Considering the total outstanding principal balance
under the Financing Agreement of $250,000,000 at September 30, 2020, a 1.0% change in interest rates would result in an impact
to loss before income taxes of $2,500,000 per year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_003"></span><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
4. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Disclosure
Controls and Procedures</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Disclosure
controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under
the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported, within
the time period specified in the SEC's rules and forms and is accumulated and communicated to our management, including our principal
executive officer and principal financial officer, as appropriate, in order to allow timely decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 42; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Evaluation
of Disclosure Controls and Procedures</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of
our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the
period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial
Officer concluded that our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on
Form 10-Q were effective in providing reasonable assurance that information required to be disclosed by us in reports that we
file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in
the SEC&#8217;s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer
and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and
procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of
a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative
to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that all control issues, misstatements, errors, and instances of fraud, if any, within our company have been or will be prevented
or detected. Further, internal controls may become inadequate as a result of changes in conditions, or through the deterioration
of the degree of compliance with policies or procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Changes
in Internal Controls</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended September 30, 2020, there were no changes in our internal control over financial reporting that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_004"></span><span style="font: 10pt Times New Roman, Times, Serif"><b>PART
II - OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_005"></span><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
1. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">From
time to time, we are involved in litigation and proceedings in the ordinary course of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
February 20, 2020, we received a Paragraph IV certification notice letter, or the IMVEXXY Notice Letter, regarding an Abbreviated
New Drug Application, or ANDA, submitted to the FDA by Teva Pharmaceuticals USA, Inc., or Teva. The ANDA seeks approval from the
FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY. In the IMVEXXY Notice
Letter, Teva alleges that TherapeuticsMD patents listed in the FDA&#8217;s Orange Book that claim compositions and methods of
IMVEXXY, or the IMVEXXY Patents, are invalid, unenforceable, and/or will not be infringed by Teva&#8217;s commercial manufacture,
use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the IMVEXXY Notice Letter expire in 2032
or 2033. On April 1, 2020, we filed a complaint for patent infringement against Teva in the United States District Court for the
District of New Jersey arising from Teva&#8217;s ANDA filing with the FDA. We are seeking, among other relief, an order that the
effective date of any FDA approval of Teva&#8217;s ANDA would be a date no earlier than the expiration of the IMVEXXY Patents
and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim to the complaint,
alleging that the IMVEXXY Patents are invalid and not infringed. A trial date has not been set.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
March 17, 2020, we received a Paragraph IV certification notice letter, or the BIJUVA Notice Letter, regarding an ANDA submitted
to the FDA by Amneal Pharmaceuticals, or Amneal. The ANDA seeks approval from the FDA to commercially manufacture, use, or sell
a generic version of BIJUVA. In the BIJUVA Notice Letter, Amneal alleges that TherapeuticsMD patents listed in the FDA&#8217;s
Orange Book that claim compositions and methods of BIJUVA, or the BIJUVA Patents, are invalid, unenforceable, and/or will not
be infringed by Amneal&#8217;s commercial manufacture, use, or sale of its proposed generic drug product. The BIJUVA Patents identified
in the BIJUVA Notice Letter expire in 2032. On April 29, 2020, we filed a complaint for patent infringement against Amneal in
the United States District Court for the District of New Jersey arising from Amneal&#8217;s ANDA filing with the FDA. We are seeking,
among other relief, an order that the effective date of any FDA approval of Amneal&#8217;s ANDA would be a date no earlier than
the expiration of the BIJUVA Patents and equitable relief enjoining Amneal from infringing the BIJUVA Patents. Amneal has filed
its answer and counterclaim to the complaint, alleging that the BIJUVA Patents are invalid and not infringed. A trial date has
not been set.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 43; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_006"></span><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Except
as set forth below, there have been no material changes with respect to those risk factors previously disclosed in Item 1A &#8220;Risk
Factors&#8221; in Part I of our Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Our
financial condition and results of operations for fiscal year 2020 and beyond may be materially adversely affected by the ongoing
COVID-19 (coronavirus) pandemic.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
outbreak of the novel COVID-19 has evolved into a global pandemic. COVID-19 has spread to many regions of the world, including
virtually all of the United States. Our business has been, and we anticipate that it will continue to be, impacted by the COVID-19
pandemic. During the third quarter of 2020, all of our products remained affected by the COVID-19 pandemic, primarily due to our
sales force having limited access to healthcare professionals and our patients deferring visits to healthcare professionals in
certain areas. While we have developed a comprehensive COVID-19 contingency plan designed to preserve the value of our investments
in our sales and marketing infrastructure, protect our balance sheet during this period of market disruption and meet the needs
of our patients and prescribers, the severity of the impact of the COVID-19 pandemic on our business and operating results will
depend on future developments that are highly uncertain and cannot be accurately predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Stay
at home, quarantine and social distancing orders and closures and restrictions on travel have negatively affected the ability
of our sales force to access healthcare providers to promote our products and the ability of patients to visit their healthcare
professionals for non-emergent matters. Our sales force is continuing to use a hybrid model of office visits when necessary and
digital engagement tools and tactics and virtual detailing, which may be less effective than our ordinary course sales and marketing
programs. Increases in unemployment could reduce access to commercial health insurance for our patients, thus limiting payer coverage
for our products, which could lead to increased use of our co-pay assistance programs and negatively affect our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
future results of operations and liquidity could be materially adversely affected by, and we may require an increased level of
working capital as a result of, extended billing and collection cycles as a result of displaced employees at our company, payers,
revenue cycle management contractors, or otherwise; delays in payments of outstanding receivable amounts beyond normal payment
terms; supply chain disruptions; uncertain demand; and the impact of any initiatives or programs that we may undertake to address
financial and operations challenges that we may face.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Additionally,
although we currently continue to have uninterrupted wholesale and retail distribution of our products and we do not anticipate
a shortage of our products due to COVID-19 at this time, disruptions may occur for our customers or suppliers that may materially
affect our ability to obtain supplies or other components for our products, manufacture additional products or deliver inventory
in a timely manner. This would result in lost sales, additional costs, or penalties, or damage to our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
business may also be affected by negative impacts of the COVID-19 pandemic on capital markets and economies worldwide, and it
is possible that the pandemic could cause a local and/or global economic recession. While policymakers globally have responded
with fiscal policy actions to support the healthcare industry and economy as a whole, the magnitude and overall effectiveness
of these actions remains uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
may also experience other unknown impacts from COVID-19 that cannot be predicted. Accordingly, disruptions to our business as
a result of COVID-19 could result in a material adverse effect on our business, results of operations, financial condition and
prospects in the near-term and beyond 2020.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Our level of indebtedness
and the terms of the Financing Agreement could adversely affect our operations and limit our ability to plan for or respond to
changes in our business. If we are unable to comply with certain actual net revenue covenants and other restrictions in the Financing
Agreement, the repayment of our existing indebtedness could be accelerated.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the Financing Agreement, we have incurred a substantial amount of debt, which could adversely affect our business. In April 2019,
we drew down the first tranche of $200.0 million under the Financing Agreement and in February 2020 we drew down the second tranche
of $50.0 million under the Financing Agreement. Our high level of indebtedness could affect our business in the following ways,
among other things: make it more difficult for us to satisfy our contractual and commercial commitments; require us to use a substantial
portion of our cash flow from operations to pay interest and principal, which would reduce funds available for working capital,
capital expenditures and other general corporate purposes; limit our ability to obtain additional financing for working capital,
capital expenditures, acquisitions and other investments or general corporate purposes; heighten our vulnerability to downturns
in our business, our industry or in the general economy; place us at a disadvantage compared to those of our competitors that may
have proportionately less debt; limit management&#8217;s discretion in operating our business; and limit our flexibility in planning
for, or reacting to, changes in our business, the industry in which we operate or the general economy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Financing Agreement requires us to make certain payments of principal and interest over time and contains certain minimum quarterly
product revenue requirements and several other restrictive covenants. We are required to achieve total minimum net revenue requirement
for ANNOVERA, IMVEXXY, and BIJUVA equal to (i) $20 million for the fiscal quarter ending December 31, 2020, (ii) $25 million,
$37.5 million, $47.5 million, and $57.5 million for the first, second, third, and fourth quarters of 2021, respectively, (iii)
$65.0 million, $75.0 million, $85.0 million and $95.0 million for the first, second, third, and fourth quarters of 2022, respectively,
and (iv) $95.0 million for each fiscal quarter thereafter. Among other requirements of the Financing Agreement, we and our subsidiaries
party to the Financing Agreement must maintain a minimum unrestricted cash balance of $60.0 million (which, pursuant to Amendment
No. 6, is being temporarily lowered to a minimum required cash balance of $45.0 million through December 31, 2020). The Financing
Agreement also contains covenants that limit, among other things, the ability of us and our subsidiaries party to the Financing
Agreement to (i) incur indebtedness, (ii) incur liens on our property, (iii) pay dividends or make other distributions, (iv) sell
our assets, (v) make certain loans or investments, (vi) merge or consolidate, (vii) voluntarily repay or prepay certain permitted
indebtedness and (viii) enter into transactions with affiliates, in each case subject to certain exceptions. These and other terms
in the Financing Agreement have to be monitored closely for compliance and could restrict our ability to grow our business or
enter into transactions that we believe would be beneficial to our business. In order to maintain compliance with the minimum
unrestricted cash balance requirement of the Financing Agreement, we anticipate that we will need to raise additional capital.&#160;
We cannot guarantee that future financing sufficient to maintain or exceed the minimum unrestricted cash balance will be available
in sufficient amounts, in a timely fashion or on terms acceptable to us, if at all. If we are unable to maintain the minimum unrestricted
cash balance, achieve any of the total minimum net revenue requirements or otherwise comply with any other covenant of the Financing
Agreement, all or a portion of our obligations under the Financing Agreement may be declared immediately due and payable, which
would have a material adverse effect on our business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
business may not generate cash flow from operations in the future sufficient to service our debt and support our growth strategies,
especially in light of the COVID-19 pandemic. If we are unable to generate such cash flow, we may be required to adopt one or
more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous
or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at
such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could
result in a default on our debt obligations, including under our current debt obligations.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in; background-color: white"><b>We
may not recognize any anticipated benefits of the proposed disposition of vitaCare Prescription Services or any other divestitures
we may pursue in the future.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We have commenced a process for the divestiture of vitaCare Prescription Services. Additionally, we may evaluate other potential divestiture opportunities with respect to portions of our business from time to time, and may determine to proceed with a divestiture opportunity if and when we believe such opportunity is consistent with our business strategy and we would be able to realize value for our stockholders in so doing. There can be no assurance that we will be able to sell vitaCare Prescription Services. Any divestiture or disposition, including the planned disposition of vitaCare Prescription Services, could expose us to significant risks, including, without limitation, fees for legal and transaction-related services, diversion of management resources, transaction execution risks (including risks resulting from buyer financing and due diligence contingencies and other closing conditions), loss of key personnel and reduction in revenue. Further, we may be required to retain or indemnify a buyer against certain liabilities and obligations in connection with any such divestiture, and we may also become subject to third-party claims arising out of such divestiture. In addition, we may not achieve the expected price in a divestiture transaction, including the proposed sale of vitaCare Prescription Services, which could result in additional losses being recorded. If we do not realize the expected strategic, economic, or other benefits of any divestiture transaction, it could adversely affect our financial condition and results of operations. A divesture of vitaCare Prescription Services may be subject to various third party consents. There can be no assurances that we will obtain any necessary consents of governmental authorities or other third parties that might be required in order for us to sell vitaCare Prescription Services or effectuate any other divesture. If we are unable to consummate the divestiture of vitaCare Prescription Services for any reason, our business and financial position could be adversely impacted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 44; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="a_007"></span><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
5. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
November 8, 2020, we entered into indemnification agreements with each of our directors and executive officers which may
be, in some cases, broader than the specific indemnification provisions under Nevada law. These agreements, among other
things, require us to indemnify each director and executive officer to the fullest extent permitted by Nevada law, including
indemnification of expenses (including, but not limited to, as attorneys' fees and other litigation-related expenses),
judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or executive officer, or on
the director or executive officer, in connection with such proceeding or any claim, issue, or matter therein, if such
director or executive officer either (i) is not liable under Section 78.138 of the Nevada Revised Statutes, or (ii) acted in
good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of our company, and
with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful in any action or
proceeding, including any action or proceeding by or in right of our company, arising out of the person's services as a
director or executive officer. Pursuant to the indemnification agreements, we have agreed to advance all expenses incurred by
or on behalf of the director or executive officer in connection with defending any proceeding, which amounts shall be repaid
to our company if it is ultimately determined by a court of competent jurisdiction that the director or executive officer is
not entitled to be indemnified by our company. The foregoing summary of the indemnification agreements does not purport to be complete and is subject to, and qualified in its entirety
by, the full text of the form of indemnification agreement, a copy of which is filed as Exhibit 10.3 to this Quarterly Report on Form
10-Q and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On November 8, 2020, we and our subsidiaries entered into Amendment No. 6 to the Financing Agreement with the Administrative Agent and the lenders party
thereto, pursuant to which we temporarily lowered the minimum required cash balance under the Financing Agreement from $60 million to $45 million through December 31, 2020. After December 31, 2020, the minimum cash balance will revert to $60 million. The foregoing summary of Amendment No. 6 does not purport to be complete and is subject to, and qualified in its entirety by, the full text of Amendment No. 6, a copy of which is filed as Exhibit 10.4 to this Quarterly Report on Form 10-Q and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On November 8, 2020, in connection with entering into Amendment No. 6 to the Financing Agreement, we amended the Warrants to provide for an adjustment to the exercise price if we conduct certain dilutive issuances prior to December 31, 2020, or if the volume-weighted average price of our Common Stock for the fifteen trading days ending December 31, 2020 is lower than the then-current exercise price.  The foregoing summary of the Warrant amendments does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Warrant amendments, a copy of which is filed as Exhibit 4.2 to this Quarterly Report on Form 10-Q and is incorporated herein by reference.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_008"></span><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
6. Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 11%; padding-right: 5.4pt"><p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit&#160;</b></span></p></td>
    <td style="width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date&#160;</b></span></p></td>
    <td style="width: 65%; padding-left: 5.4pt"><p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description&#160;</b></span></p></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex4-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">4.1</span></a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">August
    5, 2020</span></td>
    <td style="text-align: justify; padding-left: 5.4pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex4-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Form of Warrant to Purchase Common Stock issued by TherapeuticsMD, Inc. to the Subscribers party to that certain Subscription Agreement, dated as of August 5, 2020.<sup>(1)</sup></span></a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex4-2.htm">4.2</a>*</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">November
    8, 2020</span></td>
    <td style="padding-left: 5.4pt"><a href="ex4-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">Amendment to Form of Warrant to Purchase Common Stock issued by TherapeuticsMD, Inc. to the Subscribers party to that certain Subscription Agreement, dated as of August 5, 2020.</span></a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-4.htm"><span style="font: 10pt Times New Roman, Times, Serif">10.1</span></a></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">August
                                         5, 2020&#160;</span></p></td>
    <td style="padding-left: 5.4pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-4.htm"><span style="font: 10pt Times New Roman, Times, Serif">Amendment No. 5 to Financing Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., VitaCare Prescription Services, Inc., Sixth Street Specialty Lending, Inc., and the lenders thereto.<sup>(1)</sup></span></a></td></tr>

<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-5.htm"><span style="font: 10pt Times New Roman, Times, Serif">10.2</span></a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">August
    5, 2020</span></td>
    <td style="padding-left: 5.4pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-5.htm"><span style="font: 10pt Times New Roman, Times, Serif">Subscription Agreement, by and among TherapeuticsMD, Inc. and the Subscribers identified on the Schedule of Subscribers attached hereto.<sup>(1)</sup></span></a></td></tr>

<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><a href="ex10-3.htm">10.3</a>*</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">n/a</td>
    <td style="text-align: justify; padding-left: 5.4pt"><a href="ex10-3.htm">Form of Indemnification Agreement between TherapeuticsMD, Inc. and each of its executive officers and directors.</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><a href="ex10-4.htm">10.4*</a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">November 8, 2020</td>
    <td style="text-align: justify; padding-left: 5.4pt"><a href="ex10-4.htm">Amendment No. 6 to Financing Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., vitaCare Prescription Services, Inc., Sixth Street Specialty Lending, Inc., and the lenders thereto.</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><a href="ex10-5.htm">10.5</a>*+</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">December 1, 2017</td>
    <td style="text-align: justify; padding-left: 5.4pt"><a href="ex10-5.htm">Amendment No. 1 to the Commercial Supply Agreement, between TherapeuticsMD, Inc. and Catalent Pharma Solutions, LLC.</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><a href="ex10-6.htm">10.6</a>*+</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">September 29, 2020</td>
    <td style="text-align: justify; padding-left: 5.4pt"><a href="ex10-6.htm">Amendment No. 2 to the Commercial Supply Agreement, between TherapeuticsMD, Inc. and Catalent Pharma Solutions, LLC</a>.</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><a href="ex10-7.htm">10.7</a>*+</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">September 29, 2020</td>
    <td style="text-align: justify; padding-left: 5.4pt"><a href="ex10-7.htm">Amendment No. 2 to the Softgel Commercial Supply Agreement, between TherapeuticsMD, Inc. and Catalent Pharma Solutions, LLC.</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; width: 11%"><a href="ex31-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">31.1*</span></a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; width: 24%"><span style="font: 10pt Times New Roman, Times, Serif">November 9, 2020</span></td>
    <td style="text-align: justify; padding-left: 5.4pt; width: 65%"><a href="ex31-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a).</span></a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">
    <a href="ex31-2.htm">31.2*</a></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">November 9, 2020</span></td>
    <td style="text-align: justify; padding-left: 5.4pt"><a href="ex31-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a).</span></a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><a href="ex32-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">32.1**</span></a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">November 9, 2020</span></td>
    <td style="text-align: justify; padding-left: 5.4pt"><a href="ex32-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Section 1350 Certification of Chief Executive Officer.</span></a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><a href="ex32-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">32.2**</span></a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">November 9, 2020</span></td>
    <td style="text-align: justify; padding-left: 5.4pt"><a href="ex32-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">Section 1350 Certification of Chief Financial Officer.</span></a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">101.INS*</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td>
    <td style="text-align: justify; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL Instance Document
    &#8211; the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline
    XBRL document.</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">101.SCH*</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td>
    <td style="text-align: justify; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension
    Schema Document.</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">101.CAL*</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td>
    <td style="text-align: justify; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension
    Calculation Linkbase Document.</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">101.DEF*</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td>
    <td style="text-align: justify; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension
    Definition Linkbase Instance Document.</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">101.LAB*</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td>
    <td style="text-align: justify; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension
    Label Linkbase Instance Document.</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">101.PRE*</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td>
    <td style="text-align: justify; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension
    Presentation Linkbase Instance Document.</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">104*</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td>
    <td style="text-align: justify; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">Cover Page Interactive
    Data File (formatted as Inline XBRL and Contained in Exhibit 101).</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="border-top: Black 1pt solid; margin-right: auto; font-size: 1pt; width: 20%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Filed
herewith.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">**</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Furnished
herewith.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">                                                                                                                                          <tr style="vertical-align: top">
<td>+</td><td style="text-align: justify"><p>Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10). The omitted information is not material
and would likely cause competitive harm to the Company if publicly disclosed.</p>
</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Filed
                                         as an exhibit to Form 10-Q for the quarter ended June 30, 2020 filed with the Commission
                                         on August 7, 2020 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">DATE:
November 9, 2020</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC.</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td style="width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 47%; padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1pt solid; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Robert G. Finizio</i></span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Robert G. Finizio</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1pt solid; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif">/<i>s/
    James C. D&#8217;Arecca</i></span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">James C. D&#8217;Arecca</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(Principal Financial Officer)</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1pt solid; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif">/<i>s/
    Michael Donegan</i></span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Michael Donegan</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Chief Accounting Officer</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(Principal Accounting Officer)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->&#160;</p></div>

    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>ex4-2.htm
<DESCRIPTION>AMENDMENT TO FORM OF WARRANT TO PURCHASE COMMON STOCK
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="txmd-10q_093020.htm">TherapeuticsMD, Inc. 10-Q</A></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibit
4.2</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-align: center"><B>AMENDMENT TO COMPANY WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">This AMENDMENT TO
THE COMPANY WARRANT (this &ldquo;<B>Amendment</B>&rdquo;), dated as of November 8, 2020, is by and among TherapeuticsMD, Inc.,
a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), Tao Finance 1, LLC, a Delaware limited liability company (&ldquo;<B>Tao
Finance</B>&rdquo;), Redwood IV Finance 1, LLC, a Delaware limited liability company (&ldquo;<B>Redwood IV</B>&rdquo;) and Sixth
Street Specialty Lending, Inc., a Delaware corporation (&ldquo;<B>Sixth Street</B>&rdquo; and together with Tao Finance and Redwood
IV, collectively the &ldquo;<B>Holders</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
issued Warrant No. 1 to Sixth Street on August 5, 2020 convertible into 712,817 shares of Company Common Stock (the &ldquo;<B>Sixth
Street Warrant</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
issued Warrant No. 2 to Redwood IV on August 5, 2020 convertible into 1,188,029 shares of Company Common Stock (the &ldquo;<B>Redwood
IV Warrant</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
issued Warrant No. 3 to Tao Finance on August 5, 2020 convertible into 2,851,270 shares of Company Common Stock (the &ldquo;<B>Tao
Finance Warrant</B>&rdquo; and together with the Sixth Street Warrant and Redwood IV Warrant collectively, the &ldquo;<B>Warrants</B>&rdquo;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
and the Holders wish to amend the Warrants on the terms set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">NOW, THEREFORE,
in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Company and the Holders agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Amendment to Warrant: Adjustment to Exercise Price For Subsequent Issuances</U>. Section 3 of each Warrant is
hereby amended and restated in its entirety to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-indent: 0in">3. <U>Adjustment to Exercise Price
For Subsequent Issuances</U>. In order to prevent dilution of the purchase rights granted under this Warrant, the Exercise Price
and the number of Warrant Shares issuable upon exercise of this Warrant shall be subject to adjustment from time to time as provided
in this Section 3 (in each case, after taking into consideration any prior adjustments pursuant to this Section 3 or otherwise),
with any such adjustment automatically becoming effective without further action of any person required; <I>provided</I>, that
there shall be no adjustment to the number of Warrant Shares acquirable upon exercise of the Warrant, as provided in this Section
3 (an &ldquo;<B>Adjustment</B>&rdquo;), unless and until such Adjustment, together with any previous Adjustments to the number
of Warrant Shares so acquirable which would otherwise have resulted in an Adjustment were it not for this proviso, would require
an increase or decrease of at least 5% of the total number of Warrant Shares so acquirable at the time of such Adjustment, in which
event such Adjustment and all such previous Adjustments shall immediately occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For the purposes of this Section 3, the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in">&ldquo;<B>Excluded Issuances</B>&rdquo; means any issuance
or sale (or deemed issuance or sale in accordance with Section 3(d)) by the Company after the Adjustment Date of: (a) shares of
Common Stock issued upon the exercise of the Warrants; (b) shares of Common Stock issued upon the conversion or exercise of options
or convertible securities issued prior to the Adjustment Date, <I>provided</I> that such securities are not amended after the Adjustment
Date to increase the number of shares of Common Stock issuable thereunder or to lower the exercise or conversion price thereof;
or (c) shares of Common Stock under the Company&rsquo;s 2019 Stock Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in">&ldquo;<B>Independent Financial Expert</B>&rdquo; shall
mean a nationally recognized accounting, investment banking or consultant firm, which firm does not have a material financial interest
or other material economic relationship with either the Company or any of its Affiliates or the Holder or any of its Affiliates
that is, in the good faith judgment of the Company&rsquo;s board of directors (the &ldquo;<B>Board</B>&rdquo;), qualified to perform
the task for which it has been engaged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in">&ldquo;<B>Trading Day</B>&rdquo; shall mean a day on
which trading in the shares of Common Stock (or other applicable security) generally occurs on the principal exchange or market
on which the shares of Common Stock (or other applicable security) are then listed or traded; provided that if the shares of Common
Stock (or other applicable security) are not so listed or traded, &ldquo;Trading Day&rdquo; means a Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in">&ldquo;<B>VWAP</B>&rdquo; shall mean, as of any date
of determination, the average per share volume-weighted average price as displayed under the heading &ldquo;Bloomberg VWAP&rdquo;
on Bloomberg page &ldquo;TXMD&lt;equity&gt; AQR&rdquo; (or its equivalent successor if such Bloomberg page is not available) in
respect of the period from the open of trading on the relevant Trading Day until the close of trading on such Trading Day (or if
such volume-weighted average price is unavailable, the market value of one share of Common Stock on such Trading Day reasonably
determined, using a volume-weighted average method, by an Independent Financial Expert appointed (and compensated by the Company)
for such purpose). The VWAP will be determined without regard to after-hours trading or any other trading outside of the regular
trading session trading hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment to Exercise Price</U>. If the Company shall, at any time or from time to time after November 8, 2020 (the
&ldquo;<B>Adjustment Date</B>&rdquo;) and on or prior to December 31, 2020, issue or sell, or in accordance with Section 3(e) is
deemed to have issued or sold, any shares of Common Stock for consideration per share less than the Exercise Price in effect immediately
prior to such issuance or sale (or deemed issuance or sale) (&ldquo;<B>Adjustment Trigger Shares</B>&rdquo;), then immediately
upon such issuance or sale (or deemed issuance or sale), the Exercise Price shall be reduced to the weighted average per share
consideration received by the Company for all Adjustment Trigger Shares so issued or sold (or deemed issued or sold) from and after
the Adjustment Date and on or prior to December 31, 2020, as determined in good faith by the Board. If the Company does not issue
or sell, or in accordance with Section 3(e) is not deemed to have issued or sold, any Adjustment Trigger Shares from and after
the Amendment Date and on or prior to December 31, 2020, then on December 31, 2020 the Exercise Price shall be reduced to the average
of the VWAP for 15 consecutive Trading Days ending on December 31, 2020 (if and only if such average VWAP is lower than the Exercise
Price otherwise in effect on December 31, 2020). Notwithstanding the forgoing, if the Company receives aggregate consideration
equal to or less than $10,000,000 in exchange for all Adjustment Trigger Shares issued or sold (or deemed issued or sold in accordance
with Section 3(e)) after the Adjustment Date and on or prior to December 31, 2020, then the Holder may, at its option delivered
in writing to the Company within five (5) Business Days of December 31, 2020, elect to adjust the Exercise Price based on the VWAP
calculation provided in the second sentence of this Section 3(b) as if no Adjustment Trigger Shares were issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exceptions to Adjustment Upon Issuance of Common Stock</U>. Anything herein to the contrary notwithstanding, there shall
be no adjustment to the Exercise Price or the number of Warrant Shares issuable upon exercise of this Warrant with respect to any
Excluded Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effect of Certain Events on Adjustment to Exercise Price</U>. For purposes of determining the adjusted Exercise Price
under Section 1(a) hereof, the following shall be applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Issuance of Options</I>. If the Company shall, at any time or from time to time after the Adjustment Date, grant or sell
any options, whether or not such options or the right to convert or exchange any convertible securities issuable upon the exercise
of such options are immediately exercisable, and the price per share (determined as provided in this paragraph and in Section 1(d)(iii))
for which Common Stock is issuable upon the exercise of such options or upon the conversion or exchange of convertible securities
issuable upon the exercise of such options is less than the Exercise Price in effect immediately prior to the time of the granting
or sale of such options, then the total maximum number of shares of Common Stock issuable upon the exercise of such options or
upon conversion or exchange of the total maximum amount of convertible securities issuable upon the exercise of such options shall
be deemed to have been issued as of the date of granting or sale of such options at a price per share equal to the quotient obtained
by dividing of (A) the total amount, if any, received or receivable by the Company as consideration for the granting, sale, or
exercise of all such options (which sum shall constitute the applicable consideration received for purposes of Section 1(a)), by
(B) the total maximum number of shares of Common Stock issuable upon the exercise of all such options or upon the conversion or
exchange of all convertible securities issuable upon the exercise of all such options. No further adjustment of the Exercise Price
of Warrant Shares shall be made upon the actual issuance of Common Stock or of convertible securities upon exercise of such options
or upon the actual issuance of Common Stock upon conversion or exchange of convertible securities issuable upon exercise of such
options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Issuance of Convertible Securities</I>. If the Company shall, at any time or from time to time after the Adjustment Date,
grant or sell any convertible securities, whether or not the right to convert or exchange any such convertible securities is immediately
exercisable, and the price per share (determined as provided in this paragraph and in Section 1(d)(iii)) for which Common Stock
is issuable upon the conversion or exchange of such convertible securities is less than the Exercise Price in effect immediately
prior to the time of the granting or sale of such convertible securities, then the total maximum number of shares of Common Stock
issuable upon conversion or exchange of the total maximum amount of such convertible securities shall be deemed to have been issued
as of the date of granting or sale of such convertible securities at a price per share equal to the quotient obtained by dividing
(A) the total amount, if any, received or receivable by the Company as consideration for the granting, sale, or exercise of such
convertible securities (which sum shall constitute the applicable consideration received for purposes of Section 1(a)), by (B)
the total maximum number of shares of Common Stock issuable upon the conversion or exchange of all such convertible securities.
No further adjustment of the Exercise Price shall be made upon the actual issuance of Common Stock upon conversion or exchange
of such convertible securities or by reason of the issue or sale of convertible securities upon exercise of any options to purchase
any such convertible securities for which adjustments of the Exercise Price have been made pursuant to the other provisions of
this Section 1(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Calculation of Consideration Received</I>. If the Company shall, at any time or from time to time after the Adjustment
Date, issue or sell, or is deemed to have issued or sold in accordance with Section 1(d), any shares of Common Stock, options or
convertible securities: (A) for cash, the consideration received therefor shall be deemed to be the net amount received or receivable
by the Company therefor; (B) for consideration other than cash, the amount of the consideration other than cash received or receivable
by the Company shall be the fair market value of such consideration, except where such consideration consists of marketable securities,
in which case the amount of consideration received or receivable by the Company shall be the market price (as reflected on any
securities exchange, quotation system or association or similar pricing system covering such security) for such securities as of
the end of business on the date of receipt of such securities; or (C) for no specifically allocated consideration in connection
with an issuance or sale of other securities of the Company, together comprising one integrated transaction, the amount of the
consideration therefor shall be deemed to be the fair market value of such portion of the aggregate consideration received or receivable
by the Company in such transaction as is attributable to such shares of Common Stock, options or convertible securities, as the
case may be, issued in such transaction. The net amount of any cash consideration and the fair market value of any consideration
other than cash or marketable securities shall be determined in good faith by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certificate as to Adjustment</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As promptly as reasonably practicable following any adjustment of the Exercise Price, but in any event not later than 15
Business Days thereafter, the Company shall furnish to the Holder a certificate of an executive officer setting forth in reasonable
detail such adjustment and the facts upon which it is based and certifying the calculation thereof. All calculations under this
Section 3 shall be made to the nearest cent or to the nearest one-hundredth of a share, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As promptly as reasonably practicable following the receipt by the Company of a written request by the Holder, but in any
event not later than 15 Business Days thereafter, the Company shall furnish to the Holder a certificate of an executive officer
certifying the Exercise Price then in effect and the number of Warrant Shares or the amount, if any, of other shares of stock,
securities or assets then issuable upon exercise of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Governing Law</U>. This Amendment shall be governed by and construed in accordance with the laws of the State
of New York, without regard to principles of conflict of laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>No Other Amendments</U>. Except as expressly amended herein, each of the Warrants remains in full force and effect
in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Counterparts</U>. This Amendment may be executed in any number of counterparts, each of which shall be an original,
but all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of this Amendment
by telefacsimile or other electronic means (including email with a &ldquo;pdf&rdquo;) shall have the same force and effect as the
delivery of an original executed counterpart of this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[<I>Signature Page to Follow</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">IN WITNESS WHEREOF, each of the undersigned
has duly executed this Amendment as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 3in">COMPANY:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt 3in">TherapeuticsMD, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in">By: <U>/s/ James D&rsquo;Arecca</U><BR>
Name: James D&rsquo;Arecca</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt 3in">Title: Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 3in">HOLDERS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt 3in">Tao Finance 1, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in">By: <U>/s/ Joshua Peck</U><BR>
Name: Joshua Peck</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt 3in">Title: Vice President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt 3in">Redwood IV Finance 1, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in">By: <U>/s/ Joshua Peck</U><BR>
Name: Joshua Peck</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt 3in">Title: Vice President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt 3in">Sixth Street Specialty Lending, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in">By: <U>/s/ Joshua Easterly</U><BR>
Name: Joshua Easterly</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt 3in">Title: Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>ex10-3.htm
<DESCRIPTION>INDEMNIFICATION AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="txmd-10q_093020.htm">TherapeuticsMD, Inc. 10-Q</A></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibit
10.3</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INDEMNIFICATION
AGREEMENT</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Indemnification Agreement (this &#8220;<B><I>Agreement</I></B>&#8221;), dated as of [&#9679;] [&#9679;], 20[__] (&#8220;<B><I>Effective
Date</I></B>&#8221;), is by and between TherapeuticsMD, Inc., a Nevada corporation (the &#8220;<B><I>Company</I></B>&#8221;),
and [NAME OF DIRECTOR/OFFICER] (the &#8220;<B><I>Indemnitee</I></B>&#8221;).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECITALS</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Indemnitee is a director or officer of the Company;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHEREAS,
both the Company and Indemnitee recognize the increased risk of litigation and other claims being asserted against directors and
officers of public companies;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the board of directors of the Company (the &#8220;<B><I>Board</I></B>&#8221;) has determined that enhancing the ability of the
Company to retain and attract as directors and officers the most capable persons is in the best interests of the Company and its
stockholders and that the Company therefore should seek to assure such persons that indemnification and insurance coverage is
available; and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Chapter 78 of the Nevada Revised Statutes (the &#8220;<B><I>NRS</I></B>&#8221;) authorizes a Nevada corporation to indemnify directors,
officers, employees, and agents of such a corporation and the Amended and Restated Articles of Incorporation of the Company, as
amended (the &#8220;<B><I>Articles</I></B>&#8221;), provides that the Company will indemnify any and all persons whom it has power
to indemnify under the NRS.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AGREEMENT</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NOW,
THEREFORE, in consideration of the foregoing and Indemnitee&#8217;s agreement to continue to provide services to the Company,
the parties agree as follows:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Definitions and Construction</U>. For purposes of this Agreement:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#8220;<B><I>Change in Control</I></B>&#8221; means the occurrence of any one of the following events:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
any &#8220;person&#8221; (as such term is defined in Section 3(a)(9) of the Exchange Act and as used in Sections 13(d)(3) and
14(d)(2) of the Exchange Act) is or becomes a &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under the Exchange Act),
directly or indirectly, of securities of the Company representing 30% or more of the combined voting power of the Company&#8217;s
then outstanding securities eligible to vote for the election of the Board (the &#8220;<B><I>Company Voting Securities</I></B>&#8221;)&#894;
<U>provided</U><I>, </I><U>however</U>, that the event described in this paragraph (i) will not be deemed to be a Change in Control
by virtue of any of the following acquisitions: (A) by the Company or any subsidiary&#894; (B) by any employee benefit plan (or
related trust) sponsored or maintained by the Company or any subsidiary&#894; (C) pursuant to a Non-Control Transaction (as defined
in paragraph (iii) below)&#894; or (D) a transaction (other than one described in paragraph (iii) below) in which Company Voting
Securities are acquired from the Company, if a majority of the Incumbent Board (as defined in paragraph (ii) below) approves a
resolution providing expressly that
the acquisition under this clause (D) does not constitute a Change in Control under this paragraph (i)&#894;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
individuals who, as of the Effective Date, constitute the Board (the &#8220;<B><I>Incumbent Board</I></B>&#8221;) cease for any
reason to constitute at least a majority thereof, provided that any person becoming a director subsequent to the Effective Date,
whose election or nomination for election was approved by a vote of at least two-thirds of the directors comprising the Incumbent
Board (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee
for director, without objection to such nomination) will be considered a member of the Incumbent Board (other than any individual
designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 1(a)(i),
(iii), (iv) or (v))&#894;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the consummation of a merger, consolidation, share exchange or similar form of corporate transaction involving the Company or
any of its subsidiaries that requires the approval of the Company&#8217;s stockholders (whether for such transaction or the issuance
of securities in the transaction or otherwise) (a &#8220;<B><I>Reorganization</I></B>&#8221;), unless immediately following such
Reorganization more than 50% of the total combined voting power of the entity that controls, directly or indirectly, the entity
resulting from such Reorganization (the &#8220;<B><I>Surviving Company</I></B>&#8221;) is represented by Company Voting Securities
that were outstanding immediately prior to such Reorganization (or, if applicable, is represented by shares into which such Company
Voting Securities were converted pursuant to such Reorganization), and with the power to elect at least a majority of the board
of directors or other governing body of such Surviving Company (a &#8220;<B><I>Non-Control Transaction</I></B>&#8221;)&#894; or</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the stockholders of the Company approve a plan of complete liquidation or dissolution&#894; or the consummation of a sale (or
series of sales) of all or substantially all of the assets of the Company and its subsidiaries to an entity that is not an affiliate
of the Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, a Change in Control will not be deemed to occur solely because any person acquires beneficial ownership of 30%
or more of the Company Voting Securities as a result of the acquisition of Company Voting Securities by the Company which reduces
the number of Company Voting Securities outstanding&#894; <U>provided that</U>, if, after such acquisition by the Company, such
person becomes the beneficial owner of additional Company Voting Securities that increases the percentage of outstanding Company
Voting Securities beneficially owned by such person, a Change in Control will then be deemed to have occurred.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#8220;<B><I>Corporate Status</I></B>&#8221; means the fact that a person is or was a director, officer, employee, or agent of
the Company or is or was serving at the request of the Company as a director, officer, employee, or agent of another corporation,
partnership, joint venture, trust, or other enterprise.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#8220;<B><I>Disinterested Director</I></B>&#8221; means a director of the Company who is not and was not a party to the Proceeding
in respect of which indemnification is sought by Indemnitee.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 &#8220;<B><I>Enterprise</I></B>&#8221; will mean the Company and any other corporation, partnership, joint venture, trust, or
other enterprise that Indemnitee is or was serving at the request of the Company as a director, officer, employee, or agent.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#8220;<B><I>Expenses</I></B>&#8221; will include all reasonable attorneys&#8217; fees, retainers, court costs, transcript costs,
fees of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone
charges, postage, delivery service fees, ERISA excise taxes and penalties, and all other disbursements or expenses of the types
customarily incurred or actually incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating,
participating, or being or preparing to be a witness in a Proceeding, or responding to, or objecting to, a request to provide
discovery in a Proceeding. Expenses also will include Expenses incurred in connection with any appeal resulting from any Proceeding,
including, without limitation, the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other
appeal bond or its equivalent. Should any payments by the Company to or for the account of Indemnitee under this Agreement be
determined to be subject to any federal, state, or local income or excise tax, Expenses will also include such amounts as are
necessary to place Indemnitee in the same after-tax position (after giving effect to all applicable taxes) Indemnitee would have
been in had no such tax been determined to apply to those payments. The parties agree that for the purposes of any advancement
of Expenses for which Indemnitee has made written demand to the Company in accordance with this Agreement, all Expenses included
in such demand that are certified by affidavit of Indemnitee&#8217;s counsel as being reasonable in the good faith judgment of
such counsel will be presumed conclusively to be reasonable. Expenses, however, will not include amounts paid in settlement by
Indemnitee or the amount of judgments or fines against Indemnitee.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#8220;<B><I>Independent Counsel</I></B>&#8221; means a law firm, or a member of a law firm, that is experienced in matters of
corporation law and neither presently is, nor in the past five (5) years has been, retained to represent: (i) the Company or Indemnitee
in any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or
of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim
for indemnification hereunder. Notwithstanding the foregoing, the term &#8220;Independent Counsel&#8221; will not include any
person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing
either the Company or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Agreement. The Company agrees
to pay the reasonable fees of the Independent Counsel referred to above and to fully indemnify such counsel against any and all
Expenses, claims, liabilities, and damages arising out of or relating to this Agreement or its engagement pursuant hereto.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#8220;<B><I>Proceeding</I></B>&#8221; includes any threatened, pending, or completed action, suit, claim, counterclaim, cross
claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing, or any
other actual, threatened, or completed proceeding, whether brought by or in the right of the Company or otherwise and whether
civil, criminal, administrative, legislative, or investigative (formal or informal), in each case whether or not Indemnitee&#8217;s
Corporate Status existed at the time any liability or expense is incurred for which indemnification can be provided under this
Agreement, including one pending on or before the <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Effective
Date, but excluding one initiated by an Indemnitee under Section 8 to enforce Indemnitee&#8217;s rights under this Agreement.</FONT></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Unless otherwise explicitly specified, this Agreement is to be interpreted such that (i) words denoting the singular will include
the plural and vice versa; (ii) the terms &#8220;include,&#8221; &#8220;including,&#8221; &#8220;comprise,&#8221; &#8220;comprises,&#8221;
and words of similar effect are used in the inclusive sense of &#8220;including, without limitation; (iii) &#8220;or&#8221; is
used in the inclusive sense of &#8220;and/or&#8221; unless used in connection with the word &#8220;either,&#8221; &#8220;unless,&#8221;
&#8220;alternatively,&#8221; and words of similar effect; (iv) &#8220;any&#8221; is used in the sense of &#8220;any and/or all&#8221;;
(v) &#8220;herein,&#8221; &#8220;hereof,&#8221; &#8220;hereunder,&#8221; and words of similar effect refer to the entirety of
this Agreement; and (vi) &#8220;days&#8221; refer to calendar days. The language of this Agreement will be construed according
to its fair meaning and not strictly against either Party. </FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 4.45pt 0 4.5pt; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 4.45pt 0 4.5pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Indemnity of Indemnitee</U>. The Company will hold harmless and indemnify Indemnitee to the fullest extent permitted by law,
as such may be amended from time to time. In furtherance of the foregoing indemnification, and without limiting the generality
thereof:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 4.45pt 0 4.5pt; text-align: justify; text-indent: 67.5pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 4.45pt 0 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Proceedings Other Than Proceedings by or in the Right of the Company</U>. Indemnitee will be entitled to the rights of indemnification
provided in this Section 2(a) if, by reason of Indemnitee&#8217;s Corporate Status, Indemnitee was or is a party, or is threatened
to be made a party, to any Proceeding other than a Proceeding by or in the right of the Company. Under this Section 2(a), the
Company will indemnify Indemnitee against all Expenses, judgments, fines, and amounts paid in settlement actually and reasonably
incurred by Indemnitee, or on Indemnitee&#8217;s behalf, in connection with such Proceeding or any claim, issue, or matter therein,
if Indemnitee either (i) is not liable under NRS 78.138, or (ii) acted in good faith and in a manner Indemnitee reasonably believed
to be in or not opposed to the best interests of the Company, and with respect to any criminal Proceeding, had no reasonable cause
to believe Indemnitee&#8217;s conduct was unlawful.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 4.45pt 0 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 4.45pt 0 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Proceedings by or in the Right of the Company. </U>Indemnitee will be entitled to the rights of indemnification provided in
this Section 2(b) if, by reason of Indemnitee&#8217;s Corporate Status, Indemnitee is, or is threatened to be made, a party to
or participant in any Proceeding brought by or in the right of the Company to procure a judgment in its favor. Under this Section
2(b), the Company will indemnify Indemnitee against all Expenses and amounts paid in settlement actually and reasonably incurred
by Indemnitee, or on Indemnitee&#8217;s behalf, in connection with such Proceeding or any claim, issue, or matters therein, if
Indemnitee either (i) is not liable under NRS 78.138, or (ii) acted in good faith and in a manner Indemnitee reasonably believed
to be in or not opposed to the best interests of the Company&#894; provided, however, if applicable law so provides, no indemnification
against such Expenses or other amounts will be made in respect of any claim, issue, or matter as to which Indemnitee will have
been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the Company or
for amounts paid in settlement to the Company, unless and only to the extent that the court in which the Proceeding was brought
or other court of competent jurisdiction will determine that in view of all the circumstances in the case, Indemnitee is fairly
and reasonably entitled to indemnity for such expenses as the court deems proper.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 4.45pt 0 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 4.45pt 0 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 4.45pt 0 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination of Proceeding</U>. The termination of any Proceeding by judgment, order, settlement, conviction, or upon a plea
of nolo contendere or its equivalent, will not, of itself, create a presumption that the Indemnitee is liable under NRS 78.138
or did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests
of the corporation, or that, with respect to any criminal action or proceeding, Indemnitee had reasonable cause to believe that
the conduct was unlawful.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 4.45pt 0 4.5pt; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Indemnification for Expenses of a Successful Party</U>. Notwithstanding any other provision of this Agreement, to the extent
that Indemnitee is, by reason of Indemnitee&#8217;s Corporate Status, a party to and is successful on the merits or otherwise
in any Proceeding, the Company will indemnify Indemnitee to the maximum extent permitted by law, as such may be amended from time
to time, against all Expenses actually and reasonably incurred by Indemnitee in connection with the defense of the Proceeding.
If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but
less than all claims, issues, or matters in such Proceeding, the Company will indemnify Indemnitee against all Expenses actually
and reasonably incurred Indemnitee, or on Indemnitee&#8217;s behalf, in connection with each successfully resolved claim, issue,
or matter. For purposes of this Section 2(d) and without limitation, the termination of any claim, issue, or matter in such a
Proceeding by dismissal, with or without prejudice, will be deemed to be a successful result as to such claim, issue, or matter.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Additional Indemnity</U>. In addition to, and without regard to any limitations on, the indemnification provided for in Section
1, the Company will and hereby does indemnify and hold harmless Indemnitee, to the fullest extent permitted by law, as may be
amended from time to time, against all Expenses, judgments, fines, and amounts paid in settlement actually and reasonably incurred
by Indemnitee, or on Indemnitee&#8217;s behalf, if, by reason of Indemnitee&#8217;s Corporate Status, Indemnitee was or is a party,
or is threatened to be made a party, to any Proceeding (including a Proceeding by or in the right of the Company). The only limitation
that will exist upon the Company&#8217;s obligations under this Agreement will be that the Company will not be obligated to make
any payment to Indemnitee that is finally determined (under the procedures, and subject to the presumptions, set forth in Section
7 and Section 8) to be unlawful.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Contribution</U>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Whether or not the indemnification provided herein is available, in respect of any Proceeding in which the Company is jointly
liable with Indemnitee (or would be if joined in such Proceeding), the Company will pay the entire amount of any judgment or settlement
of such Proceeding without requiring Indemnitee to contribute to such payment and the Company hereby waives and relinquishes any
right of contribution it may have against Indemnitee. The Company will not enter into any settlement of any Proceeding in which
the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding) unless such settlement provides for a
full and final release of all claims asserted against Indemnitee.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Without diminishing or impairing the obligations of the Company set forth in the preceding subparagraph, if, for any reason, Indemnitee
elects to or be required to pay all or any portion of any judgment or settlement in any Proceeding in which the Company is jointly
liable with Indemnitee (or would be if joined in such Proceeding), the Company will contribute to the amount of Expenses, judgments,
fines, and amounts paid in settlement actually and reasonably incurred and paid or payable by Indemnitee in proportion to the
relative benefits received by the Company and all officers, directors, or employees of the Company, other than Indemnitee, who
are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and Indemnitee, on the other hand,
from the transaction from which such Proceeding arose&#894; provided, however, that the proportion determined on the basis of
relative benefit may, to the extent necessary to conform to law, be further adjusted by reference to the relative fault of the
Company and all officers, directors, or employees of the Company other than Indemnitee who are jointly liable with Indemnitee
(or would be if joined in such Proceeding), on the one hand, and Indemnitee, on the other hand, in connection with the events
that resulted in such expenses, judgments, fines, or settlement amounts, as well as any other equitable considerations which applicable
law may require to be considered. The relative fault of the Company and all officers, directors, or employees of the Company,
other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and
Indemnitee, on the other hand, will be determined by reference to, among other things, the degree to which their actions were
motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary and the
degree to which their conduct is active or passive.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company hereby agrees to fully indemnify and hold Indemnitee harmless from any claims of contribution which may be brought
by officers, directors, or employees of the Company, other than Indemnitee, who may be jointly liable with Indemnitee.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to
Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, will contribute to the amount incurred
by Indemnitee, whether for judgments, fines, amounts paid or to be paid in settlement, or for Expenses, in connection with any
claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of
all of the circumstances of such Proceeding to reflect (i) the relative benefits received by the Company and Indemnitee as a result
of the event(s) or transaction(s) giving cause to such Proceeding&#894; or (ii) the relative fault of the Company (and its directors,
officers, employees and agents) and Indemnitee in connection with such event(s) or transaction(s).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company hereby acknowledges that Indemnitee may have rights to indemnification for payment of the judgment or settlement amount,
or the advancement of Expenses provided by another entity (&#8220;<B><I>Other Indemnitor(s)</I></B>&#8221;). The Company agrees
with Indemnitee that the Company is the indemnitor of first resort of Indemnitee with respect to matters for which indemnification
or advancement of Expenses is provided under this Agreement and that the Company will be obligated to make all payments due to
or for the benefit of Indemnitee under this agreement without regard to any rights that Indemnitee may have against the Other
Indemnitor(s). The Company hereby waives any equitable rights to contribution or indemnification from the Other Indemnitor in
respect of any amounts paid or advanced to Indemnitee hereunder. The Company further agrees that no payment of Expenses or losses
by the Other Indemnitor(s) to or for the benefit of Indemnitee will affect the obligations of the Company hereunder,
and that the Company will be obligated to repay the Other Indemnitor(s) for all amounts so paid or reimbursed to the extent that
the Company has an obligation to indemnify Indemnitee for such Expenses or losses hereunder.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Indemnification for Expenses of a Witness. </U>Notwithstanding any other provision of this Agreement, to the extent that Indemnitee,
by reason of Indemnitee&#8217;s Corporate Status, is a witness, or is made (or asked) to respond to discovery requests or otherwise
asked to participate in any Proceeding to which Indemnitee is not a party, the Company will indemnify Indemnitee against all Expenses
actually and reasonably incurred by Indemnitee, or on Indemnitee&#8217;s behalf, in connection therewith.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Advancement of Expenses</U>. Notwithstanding any other provision of this Agreement, the Company will advance all Expenses incurred
by or on behalf of Indemnitee in connection with defending any Proceeding within thirty (30) days after the receipt by the Company
of a statement or statements from Indemnitee requesting such advance or advances from time to time, whether prior to or after
final disposition of such Proceeding. Such statement or statements will reasonably evidence the Expenses incurred by Indemnitee
and, if required by law, at the time of such advance. Indemnitee will also submit an undertaking by or on behalf of Indemnitee
to repay any Expenses advanced if it is ultimately be determined by a court of competent jurisdiction that Indemnitee is not entitled
to be indemnified by the Company against such Expenses. Any advances and undertakings to repay under this Section 6 will be unsecured
and interest free. In furtherance of the foregoing, Indemnitee hereby undertakes to repay such amounts advanced only if, and to
the extent that, it will ultimately be determined by a court of competent jurisdiction that Indemnitee is not entitled to be indemnified
by the Company as authorized by this Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Procedures and Presumptions for Determination of Entitlement to Indemnification</U>. It is the intent of this Agreement to
secure for Indemnitee rights of indemnity that are as favorable as may be permitted under the NRS and public policy of the State
of Nevada. Accordingly, the parties agree that the following procedures and presumptions will apply if of any question as to whether
Indemnitee is entitled to indemnification under this Agreement:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
To obtain indemnification under this Agreement, Indemnitee will submit to the Company a written request, including therein or
therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine
whether and to what extent Indemnitee is entitled to indemnification. The General Counsel will, promptly upon receipt of such
a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification. Notwithstanding the
foregoing, any failure of Indemnitee to provide such a request to the Company, or to provide such a request in a timely fashion,
will not relieve the Company of any liability that it may have to Indemnitee unless, and to the extent that, the Company is actually
and materially prejudiced as a direct result of such failure.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Upon written request by Indemnitee for indemnification under the first sentence of Section 7(a), a determination with respect
to Indemnitee&#8217;s entitlement thereto will be made in the specific case by one of the following three methods, which will
be at the election of
the Board: (i) by a majority vote of a quorum consisting of Disinterested Directors (as hereinafter defined), (ii) if a majority
vote of a quorum consisting of Disinterested Directors so orders, or if a quorum of Disinterested Directors cannot be obtained,
by Independent Counsel (as hereinafter defined) in a written opinion to the Board, a copy of which will be delivered to Indemnitee,
or (iii) by the stockholders of the Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Notwithstanding anything to the contrary set forth in this Agreement, if a request for indemnification is made after a Change
in Control, at the election of Indemnitee made in writing to the Company, and if the Board by a majority vote of a quorum consisting
of Disinterested Directors orders the determination of Indemnitee&#8217;s entitlement to indemnification to be made by an Independent
Counsel, or if a quorum of Disinterested Directors cannot be obtained, any determination required to be made under Section 7(b)
as to whether Indemnitee is entitled to indemnification will be made by Independent Counsel selected as provided in this Section
7(c). The Independent Counsel will be selected by Indemnitee, unless Indemnitee requests that such selection be made by the Board.
The party making the selection will give written notice to the other party advising it of the identity of the Independent Counsel
so selected. The party receiving such notice may, within seven (7) days after such written notice of selection is received, deliver
to the other party a written objection to such selection. Such objection may be asserted only on the ground that the Independent
Counsel so selected does not meet the requirements of &#8220;Independent Counsel&#8221; as defined in Section 1, and the objection
sets forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected
will act as Independent Counsel. If a written objection is made, the Independent Counsel so selected may not serve as Independent
Counsel unless and until a court has determined that such objection is without merit. If, within twenty (20) days after submission
by Indemnitee of a written request for indemnification under Section 7(a), no Independent Counsel has been selected (or, if selected,
such selection has been objected to) in accordance with this paragraph, then either the Company or Indemnitee may petition the
courts of the State of Nevada or other court of competent jurisdiction for resolution of any objection which shall have been made
by the Company or Indemnitee to the other&#8217;s selection of Independent Counsel or for the appointment as Independent Counsel
of a person selected by the court or by such other person as the court designates, and the person with respect to whom an objection
is favorably resolved or the person so appointed will act as Independent Counsel under this Section. The Company will pay any
and all reasonable fees and expenses of Independent Counsel incurred by such Independent Counsel in connection with acting under
Section 7(b). The Company will pay any and all reasonable and necessary fees and expenses incident to the procedures of this Section
7(c), regardless of the manner in which such Independent Counsel was selected or appointed.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Except as set forth in Section 7(c), if the determination of entitlement to indemnification is to be made by Independent Counsel
under Section 7(b), the Independent Counsel will be selected by the Board. Indemnitee may, within ten (10) days after such written
notice of selection is given, deliver to the Company a written objection to such selection&#894; provided, however, that such
objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#8220;Independent
Counsel&#8221; as defined in Section 1, and the objection will set forth with particularity the factual basis of such assertion.
Absent a proper and timely objection, the person so selected will act as Independent Counsel. If a written objection is made and
substantiated, the Independent Counsel selected may not serve as Independent Counsel unless and until such objection is withdrawn
or a court has determined that such objection is without merit. If, within twenty (20) days after submission by Indemnitee of
a written request for indemnification under Section 7(a), no Independent Counsel has been selected (or, if selected, such selection
has been objected to) in accordance with this paragraph, then either the Company or Indemnitee may petition the appropriate courts
of the State of Nevada or other court of competent jurisdiction for resolution of any objection made by Indemnitee to the Company&#8217;s
selection of Independent Counsel or for the appointment as Independent Counsel of a person selected by the court or by such other
person as the court will designate, and the person with respect to whom an objection is favorably resolved or the person so appointed
will act as Independent Counsel under Section 7(b). The Company will pay any and all reasonable fees and expenses of Independent
Counsel incurred by such Independent Counsel in connection with acting under Section 7(b), and the Company will pay any and all
reasonable fees and expenses incident to the procedures of this Section 7(d), regardless of the manner in which such Independent
Counsel was selected or appointed.</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such
determination will presume that Indemnitee is entitled to indemnification under this Agreement. Anyone seeking to overcome this
presumption will have the burden of proof and the burden of persuasion by clear and convincing evidence. Neither the failure of
the Company (including by its directors or independent legal counsel) to have made a determination prior to the commencement of
any action under this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable
standard of conduct, nor an actual determination by the Company (including by its directors or independent legal counsel) that
Indemnitee has not met such applicable standard of conduct, will be a defense to the action or create a presumption that Indemnitee
has not met the applicable standard of conduct.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Indemnitee will be deemed to have acted in good faith if Indemnitee&#8217;s action is based on the records or books of account
of the Enterprise, including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise
in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports
made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable
care by the Enterprise. In addition, the knowledge or actions, or failure to act, of any director, officer, agent, or employee
of the Enterprise will not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.
Whether or not the foregoing provisions of this Section 7(f) are satisfied, Indemnitee will be presumed to have at all times acted
in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company. Anyone
seeking to overcome this presumption will have the burden of proof and the burden of persuasion by clear and convincing evidence.
The Company promptly will advise Indemnitee in writing with respect to any determination that Indemnitee is or is not entitled
to indemnification, including a description of any reason or basis for which indemnification has been denied.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 Notwithstanding anything to the contrary set forth in this Agreement, if the person, persons, or entity empowered or selected
under Section 7 to determine whether Indemnitee is entitled to indemnification will not have been appointed or will not have made
a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement
to indemnification will be deemed to have been made and Indemnitee will be entitled to such indemnification, unless the Company
establishes by written opinion of Independent Counsel that (i) a misstatement by Indemnitee of a material fact, or an omission
of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for
indemnification, or (ii) a prohibition of such indemnification under applicable law&#894; provided, however, that such sixty (60)-day
period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons, or entity
making such determination with respect to entitlement to indemnification in good faith requires such additional time to obtain
or evaluate documentation or information relating thereto&#894; and provided, further, that the foregoing provisions of this Section
7(g) will not apply if the determination of entitlement to indemnification is to be made by the stockholders under Section 7(b)
and if (A) within fifteen (15) days after receipt by the Company of the request for such determination, the Disinterested Directors
resolve as required by Section 7(b)(iii) to submit such determination to the stockholders for their consideration at an annual
meeting thereof to be held within ninety (90) days after such receipt and such determination is made thereat, or (B) a special
meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such
meeting is held for such purpose within ninety (90) days after having been so called and such determination is made thereat.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Indemnitee will cooperate with the person, persons, or entity making such determination with respect to Indemnitee&#8217;s entitlement
to indemnification, including providing to such person, persons, or entity upon reasonable advance request any documentation or
information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and
reasonably necessary to such determination. Any Independent Counsel or member of the Board or stockholder of the Company will
act reasonably and in good faith in making a determination regarding Indemnitee&#8217;s entitlement to indemnification under this
Agreement. Any costs or expenses (including attorneys&#8217; fees and disbursements) incurred by Indemnitee in so cooperating
with the person, persons, or entity making such determination will be borne by the Company (irrespective of the determination
as to Indemnitee&#8217;s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless
therefrom.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company acknowledges that a settlement or other disposition, including a conviction or a plea of nolo contendere short of
final judgment, may be successful if it permits a party to avoid expense, delay, distraction, disruption, or uncertainty. If any
Proceeding to which Indemnitee is a party is resolved in any manner other than by adverse judgment against Indemnitee (including,
without limitation, settlement of such Proceeding with or without payment of money or other consideration) it will be presumed
that Indemnitee has been successful on the merits or otherwise in such Proceeding and will not create a presumption that (i) Indemnitee
did not act in good faith or in a manner reasonably believed to be in or not opposed to the best interests of the Company or (ii)
that, with respect to any criminal Proceeding, Indemnitee did not have reasonable cause to believe that Indemnitee&#8217;s conduct
was <FONT STYLE="font: 10pt Times New Roman, Times, Serif">unlawful.
Anyone seeking to overcome this presumption will have the burden of proof and the burden of persuasion by clear and convincing
evidence.</FONT></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The termination of any Proceeding or of any claim, issue, or matter therein, by judgment, order, settlement, or conviction, or
upon a plea of nolo contendere or its equivalent, will not of itself adversely affect the right of Indemnitee to indemnification
or create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in
or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable
cause to believe that Indemnitee&#8217;s conduct was unlawful.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Remedies of Indemnitee.</U></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If (i) a determination is made under Section 7 that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement
of Expenses is not timely made under Section 6, (iii) no determination of entitlement to indemnification is made under Sections
7(b) or 7(c) within sixty (60) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification
is not made under this Agreement within ten (10) days after receipt by the Company of a written request therefor, or (v) payment
of indemnification is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification
or such determination is deemed to have been made under Section 6, Indemnitee will be entitled to an adjudication of Indemnitee&#8217;s
entitlement thereto, at Indemnitee&#8217;s sole option, in (1) an appropriate court of the State of Nevada, or any other court
of competent jurisdiction, or (2) an arbitration to be conducted by a single arbitrator, selected by mutual agreement of the Company
and Indemnitee, under the rules of the American Arbitration Association. The Company will not oppose Indemnitee&#8217;s right
to seek any such adjudication.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If a determination has been made under Sections 7(b) or 7(c) that Indemnitee is not entitled to indemnification, (i) any judicial
proceeding or arbitration commenced under this Section 8 will be conducted in all respects <I>de novo</I> on the merits, and Indemnitee
will not be prejudiced by reason of the adverse determination under Sections 7(b) or 7(c)&#894; and (ii) in any such judicial
proceeding or arbitration, the Company will have the burden of proving that Indemnitee is not entitled to indemnification under
this Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If a determination is made under Sections 7(b) or 7(c), or deemed to have been made pursuant to Section 7(g), that Indemnitee
is legally entitled to indemnification, the Company will be obligated to pay the amounts constituting such indemnification within
five (5) days after such determination has been made or has been deemed to have been made and will be conclusively bound by such
determination in any judicial proceeding commenced under this Section 8.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If Indemnitee, under this Section 8, seeks a judicial adjudication of or arbitration to enforce Indemnitee&#8217;s rights under,
or to recover damages for breach of, this Agreement, or to recover under any directors&#8217; and officers&#8217; liability insurance
policies maintained by the Company, the Company will pay to Indemnitee, or on Indemnitee&#8217;s behalf, in advance, and will
indemnify Indemnitee against any and all Expenses actually and reasonably incurred by Indemnitee in such judicial adjudication
or arbitration, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement
of expenses, or insurance recovery. The Company will indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee,
will (within ten (10) days after receipt by the Company of a written request therefore) advance, to the extent not prohibited
by law, such expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for
indemnification or advancement of Expenses from the Company under this Agreement or under any directors&#8217; and officers&#8217;
liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled
to such indemnification, advancement of Expenses, or insurance recovery, as the case may be.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company will be precluded from asserting in any judicial proceeding or arbitration commenced under Section 8 that the procedures
and presumptions of this Agreement are not valid, binding, or enforceable and will stipulate in any such court or before any such
arbitrator that the Company is bound by all the provisions of this Agreement. </FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Non-Exclusivity&#894; Survival of Rights&#894; Insurance&#894; Subrogation</U>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The rights of indemnification and advancement of Expenses as provided by this Agreement will not be deemed exclusive of and will
be in addition to any other rights to which Indemnitee may at any time be entitled under applicable law, the Articles, or the
Bylaws of the Company, as amended (the &#8220;<B><I>Bylaws</I></B>&#8221;), any agreement, a vote of stockholders, a resolution
of directors, or otherwise, and nothing in this Agreement will diminish or otherwise restrict Indemnitee&#8217;s rights to indemnification
or advancement of expenses under any of the foregoing. No amendment, alteration, or repeal of this Agreement or of any provision
hereof will limit or restrict any right of Indemnitee with respect to any action taken or omitted by such Indemnitee in Indemnitee&#8217;s
Corporate Status prior to such amendment, alteration, or repeal. To the extent that a change in the NRS, whether by statute or
judicial decision, permits greater indemnification than would be afforded currently under the Articles, the Bylaws, or this Agreement,
it is the intent of the parties hereto that Indemnitee will be entitled to the greater benefits so afforded by such change and
Indemnitee will be deemed to have such greater benefits hereunder. No right or remedy herein conferred is intended to be exclusive
of any other right or remedy, and every other right and remedy will be cumulative and in addition to every other right and remedy
hereunder or now or hereafter existing at law or in equity or otherwise. The assertion of any right or remedy hereunder, or otherwise,
will not prevent the concurrent assertion or employment of any other right or remedy. The Company will not adopt any amendments
to its Articles or Bylaws, the effect of which would be to deny, diminish, or encumber Indemnitee&#8217;s right to indemnification
or advancement of expenses under this Agreement, any other agreement or otherwise.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></p>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
To the extent that the Company maintains insurance providing liability insurance for directors, officers, employees, agents, or
fiduciaries of the Company, or of any other corporation, partnership, joint venture, or other enterprise that such person serves
at the request of the Company, Indemnitee will be covered by such policy or policies in accordance with its or their terms to
the maximum extent of the coverage available for any director, officer, employee, agent, or fiduciary under such policy or policies.
The Company will use commercially reasonable efforts (taking into account the scope and amount of coverage available relative
to the cost thereof) to maintain in effect for the duration of the Indemnitee&#8217;s service to the Company (and thereafter for
so long as Indemnitee will be subject to any pending Proceeding) such insurance policy or policies providing coverage that is
at least substantially comparable in scope and amount to that provided by the Company&#8217;s current such policies. If, at the
time of the receipt of a notice of a claim under the terms hereof, the Company has or had director and officer liability insurance
in effect, the Company will give prompt notice of the commencement of such Proceeding to the relevant insurers in accordance with
the procedures set forth in the respective policies. The Company will thereafter take all necessary or desirable action to cause
such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms
of such policies.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If the Company makes any payment under this Agreement, the Company will be subrogated to the extent of such payment to all of
the rights of recovery of Indemnitee, who will execute all papers required and take all action necessary to secure such rights,
including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights (with all of
Indemnitee&#8217;s Expenses related thereto reimbursed by or, at the option of Indemnitee, advanced by the Company).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company will not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to
the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement, or otherwise.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company&#8217;s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of
the Company as a director, officer, employee, or agent of any other corporation, partnership, joint venture, trust, or other enterprise
will be reduced by any amount Indemnitee has actually received as indemnification or advancement of expenses from such other corporation,
partnership, joint venture, trust, or other enterprise.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Exception to Right of Indemnification.</U> Notwithstanding any provision in this Agreement, the Company will not be obligated
under this Agreement to make any indemnity in connection with any claim made against Indemnitee:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision,
except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision&#894;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
on account of Indemnitee&#8217;s conduct that is established by a final, non-appealable judgment of a court of competent jurisdiction
as intentional misconduct, fraud, or a knowing violation of law, provided such misconduct, fraud, or violation was or is material
to the cause of action;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company
within the meaning of Section 16(b) of the Securities Exchange Act of 1934, as amended (the &#8220;<B><I>Exchange Act</I></B>&#8221;),
or similar provisions of state statutory law or common law&#894;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
if and to the extent indemnification is contrary to law, including specifically the provisions of the Securities Act of 1933,
as amended, or the Exchange Act, the NRS;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
for any reimbursement of the Company by Indemnitee of any bonus or other incentive-based or equity-based compensation or of any
profits realized by Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including
any such reimbursements that arise from an accounting restatement of the Company under Section 304 of the Sarbanes-Oxley Act of
2002 (the &#8220;<B><I>Sarbanes-Oxley Act</I></B>&#8221;), or the payment to the Company of profits arising from the purchase
and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act)&#894;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
for any reimbursement of the Company by Indemnitee of any compensation under any compensation recoupment or clawback policy adopted
by the Board or the compensation committee of the Board, including but not limited to any such policy adopted to comply with stock
exchange listing requirements implementing Section 10D of the Exchange Act&#894; or</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part
of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees, or other indemnitees, unless
(i) the Board authorized the Proceeding (or such part of the Proceeding) prior to its initiation, or (ii) the Company indemnifies
Indemnitee, in its sole discretion, independently of this Agreement under the powers vested in the Company under applicable law.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will have the burden of proof by clear and convincing evidence to set forth facts supporting an assertion that the Company
is not obligated under this Agreement to make any indemnity as a result of any of Sections 10(a) to 10(g).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Retroactive
Effect&#894; Duration of Agreement&#894; Successors and Binding Agreement.</U> All agreements and obligations of the Company
contained herein will be deemed to have become effective upon the date Indemnitee first had Corporate Status, will continue
during the period Indemnitee has Corporate Status, and will continue thereafter so long as Indemnitee may be subject to any
Proceeding (or any action commenced under Section 8) by reason of Indemnitee&#8217;s Corporate Status, whether or not
Indemnitee is acting or serving in any such capacity at the time any liability or expense is incurred for which
indemnification can be provided under this Agreement. This Agreement will be binding upon and inure to the benefit of and be
enforceable by the parties hereto and their respective successors (including any direct or indirect successor by purchase,
merger, consolidation, reorganization, or otherwise to all or substantially all of the business or assets of the Company),
assigns, spouses, heirs, executors, and personal and legal representatives. The Company will require any such successor to
all or substantially all of the business or assets of the Company, by agreement in form and substance satisfactory to
Indemnitee and Indemnitee&#8217;s counsel, to expressly assume and agree to perform this Agreement in the same manner and to
the same extent the Company would be required to perform if no <FONT STYLE="font: 10pt Times New Roman, Times, Serif">such
succession had taken place. Except as otherwise set forth in this Section 11, this Agreement will not be assignable or delegable
by the Company.</FONT></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Security</U>. To the extent requested by Indemnitee and approved by the Board, the Company may at any time and from time to
time provide security to Indemnitee for the Company&#8217;s obligations hereunder through an irrevocable bank line of credit,
funded trust, or other collateral. Any such security, once provided to Indemnitee, may not be revoked or released without the
prior written consent of Indemnitee.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Enforcement</U>. The Company expressly confirms and agrees that it has entered into this Agreement and assumes the obligations
imposed on it hereby to induce Indemnitee to serve, or continue to serve, as an officer or a director of the Company. The Company
acknowledges that Indemnitee is relying upon this Agreement in serving or continuing to serve as an officer or a director of the
Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Severability</U>. The invalidity or unenforceability of any provision hereof will in no way affect the validity or enforceability
of any other provision. Without limiting the generality of the foregoing, this Agreement intends to confer upon Indemnitee indemnification
rights to the fullest extent permitted by applicable laws. If any provision hereof conflicts with any applicable law, such provision
will be deemed modified, consistent with the aforementioned intent, to the extent necessary to resolve such conflict.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Modification and Waiver.</U> No supplement, modification, termination, or amendment of this Agreement will be binding unless
executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement will be deemed or will
constitute a waiver of any other provisions hereof (whether or not similar) nor will such waiver constitute a continuing waiver.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notice by Indemnitee; Defense of Claims.</U> Indemnitee agrees promptly to notify the Company in writing upon being served
with or otherwise receiving any summons, citation, subpoena, complaint, indictment, information, or other document relating to
any Proceeding or matter which may be subject to indemnification covered hereunder. The failure to so notify the Company will
not relieve the Company of any obligation which it may have to Indemnitee under this Agreement unless, and only to the extent
that, the Company is actually and materially prejudiced as a direct result of such delay or failure. The Company will be entitled
to participate in the defense of any Proceeding giving rise to a claim for indemnification hereunder at its own expense and, except
as otherwise provided below, to the extent the Company so wishes, it may assume the defense thereof with counsel reasonably satisfactory
to Indemnitee. After notice from the Company to Indemnitee of its election to assume the defense of any such Proceeding, the Company
will not be liable to Indemnitee under this Agreement or otherwise for any Expenses subsequently directly incurred by Indemnitee
in connection with Indemnitee&#8217;s defense of such Proceeding other than reasonable costs of investigation or as otherwise
provided below. Indemnitee will have the right to employ Indemnitee&#8217;s own legal counsel in such Proceeding, but all Expenses
related to such counsel incurred after notice from the Company of its assumption of the defense will be at Indemnitee&#8217;s
own expense; provided, however, that if (a) Indemnitee&#8217;s employment of its own legal counsel has been authorized by the
Company, (b) Indemnitee has <FONT STYLE="font: 10pt Times New Roman, Times, Serif">reasonably
determined that there may be a conflict of interest between Indemnitee and the Company in the defense of such Proceeding, (c)
after a Change in Control, Indemnitee&#8217;s employment of Indemnitee&#8217;s own counsel has been approved by the Independent
Counsel, or (d) the Company will not in fact have employed counsel to assume the defense of such Proceeding, then Indemnitee will
be entitled to retain Indemnitee&#8217;s own separate counsel and all Expenses related to such separate counsel will be borne
by the Company.</FONT></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notices</U>. All notices and other communications given or made under this Agreement will be in writing and will be deemed
effectively given: (a) upon personal delivery to the party to be notified, (b) when confirmed by a non-automated reply if sent
by electronic mail, or (c) when received or delivery is refused by the recipient when sent by registered or certified mail, return
receipt requested, postage prepaid, or via a nationally recognized overnight courier. All communications will be sent:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
To Indemnitee at the address set forth below Indemnitee&#8217;s signature hereto.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
To the Company at:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TherapeuticsMD,
Inc.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">951
Yamato Road, Suite 220</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boca
Raton, Florida 33431</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
General Counsel</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">or
to such other address as may have been provided to Indemnitee by the Company or to the Company by Indemnitee.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but
all of which together will constitute one and the same Agreement. Executed counterparts may be delivered by electronic transmission
and will be deemed an original, but all of such counterparts together will constitute the same instrument.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Headings</U>. The headings of the paragraphs of this Agreement are inserted for convenience only and will not be deemed to
constitute part of this Agreement or to affect the construction thereof.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Successors and Assigns.</U> The terms of this Agreement will be binding upon the Company and its successors and assigns and
will inure to the benefit of Indemnitee and Indemnitee&#8217;s spouse, assigns, heirs, devisees, executors, administrators, and
other legal representatives.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Governing Law and Consent to Jurisdiction. </U>This Agreement and the legal relations among the parties will be governed by,
and construed and enforced in accordance with, the laws of the State of Nevada, without regard to its conflict of laws rules.
The Company and Indemnitee hereby irrevocably and unconditionally (a) agree that any action or proceeding arising out of or in
connection with this Agreement (other than an arbitration under Section 8) will be brought in the appropriate court of the State
of Nevada (the &#8220;<B><I>Nevada Court</I></B>&#8221;), and not in any other state or federal court in the United States of
America or any court in any other country, (b) consent to submit to the exclusive jurisdiction of the Nevada Court for purposes
of such action or proceeding, (c) waive any objection to the laying of venue of any such action or proceeding in the Nevada Court,
(d) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Nevada Court has been
brought in an improper or inconvenient forum, and (e) appoint, to the extent such party is not otherwise subject to service of
process in the State of Nevada, Paracorp Incorporated, 318 N. Carson St., Ste. 208, Carson City, Nevada 87901, as its agent in
the State of Nevada for acceptance of legal process in connection with any such action or proceeding against such party with the
same legal force and validity as if served upon such party personally within the State of Nevada.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Entire Agreement</U>. This Agreement, and any exhibits or schedules attached hereto, constitutes the full and entire understanding
and agreement between the parties with regard to the subjects hereof and supersedes all prior agreements and understandings, oral,
written and implied, between the parties with regard to the subjects hereof. No party hereto will be liable or bound to any other
party in any manner with regard to the subjects hereof or thereof by any warranties, representations or covenants except as specifically
set forth herein.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<I>Signature
page to follow</I>)</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Effective Date.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 1.5pt; padding-bottom: 10pt; padding-left: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THERAPEUTICSMD,
                    INC.</B></FONT></P>
</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 1.5pt; padding-bottom: 10pt; padding-left: 1.5pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 6%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; padding-right: 1.5pt; padding-bottom: 10pt; padding-left: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; padding-right: 1.5pt; padding-bottom: 10pt; padding-left: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; padding-right: 1.5pt; padding-bottom: 10pt; padding-left: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 1.5pt; padding-bottom: 10pt; padding-left: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.5pt; padding-left: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEMNITEE</B></FONT><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt; text-align: justify"></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 1.5pt; padding-bottom: 10pt; padding-left: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 1.5pt; padding-left: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; padding-right: 1.5pt; padding-bottom: 10pt; padding-left: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 1.5pt; padding-left: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; padding-right: 1.5pt; padding-left: 1.5pt; vertical-align: bottom">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
 <!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->[Signature Page to Indemnification Agreement]<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>ex10-4.htm
<DESCRIPTION>AMENDMENT NO. 6 TO FINANCING AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR>
    <TD></TD></TR>
</TABLE>
 <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

 <!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="txmd-10q_093020.htm">TherapeuticsMD,
Inc. 10-Q</A></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibit
10.4</FONT></P>



<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>AMENDMENT NO. 6<BR>
TO FINANCING AGREEMENT</B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><B>AMENDMENT NO. 6
TO FINANCING AGREEMENT</B>, dated as of November 8, 2020 (this &#8220;<U>Amendment</U>&#8221;), to the Financing Agreement, dated
as of April 24, 2019 (as amended, restated, supplemented or otherwise modified from time to time, the &#8220;<U>Financing Agreement</U>&#8221;),
by and among THERAPEUTICSMD, INC., a Nevada corporation (&#8220;<U>Company</U>&#8221; or &#8220;<U>Borrower</U>&#8221;), certain
Subsidiaries of Borrower, as Guarantors, the Lenders from time to time party thereto, and SIXTH STREET SPECIALTY LENDING, INC.,
a Delaware corporation (&#8220;<U>Sixth Street</U>&#8221;), as administrative agent for the Lenders (in such capacity, together
with its successors and assigns in such capacity, the &#8220;<U>Administrative Agent</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><B>WHEREAS</B>, the
Loan Parties have requested that the Administrative Agent and the Lenders amend certain terms and conditions of the Financing Agreement;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>WHEREAS</B>, the Administrative
Agent and the Lenders are willing to amend such terms and conditions of the Financing Agreement on the terms and conditions set
forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><B>NOW THEREFORE</B>,
in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase">1.
</FONT><U>Definitions</U>. All terms used herein that are defined in the Financing Agreement and not otherwise defined herein shall
have the meanings assigned to them in the Financing Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in"><FONT STYLE="text-transform: uppercase">2.
</FONT><U>Amendments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(a) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>New Definitions</U>. <U>Section 1.01</U> of the Financing Agreement is hereby amended by adding the following definitions,
in appropriate alphabetical order:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;&#8220;<U>Amendment No. 6</U>&#8221; means Amendment No. 6 to Financing Agreement, dated as of November 8, 2020,
by and among the Loan Parties, the Administrative Agent and the Lenders.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;&#8220;<U>Amendment No. 6 Effective Date</U>&#8221; means the &#8220;Amendment Effective Date&#8221; as set forth
in Amendment No. 6.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="letter-spacing: -0.1pt">(b)
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Section
6.8(a) (Minimum Qualified Cash)</U>. <U>Section 6.8(a)</U> of the Financing Agreement is hereby amended and restated in its entirety
to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">&#8220;(b)&#9;<U>Minimum
Qualified Cash</U>. At all times, Borrower shall not permit Qualified Cash to be less than $60,000,000; <U>provided</U>, that,
Borrower shall not permit Qualified Cash to be less than $45,000,000 from and after the Amendment No. 6 Effective Date through
and including December 31, 2020.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase">3.
</FONT><U>Conditions to Effectiveness</U>. This Amendment shall become effective only upon satisfaction in full, in a manner satisfactory
to the Administrative Agent, of the following conditions precedent (the first date
upon which all such conditions shall have been satisfied being hereinafter referred to as the &#8220;<U>Amendment Effective Date</U>&#8221;):</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(a) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment of Fees, Etc</U>. The Borrowers shall have paid on or before the Amendment Effective Date all fees, costs, expenses
and taxes then payable, if any, pursuant to <A NAME="a_DV_C93"></A><A NAME="a_DV_M117"></A><U>Section 2.7</U> or <A NAME="a_DV_C95"></A><U>10.2</U>
of the Financing Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(b) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations and Warranties</U>. <FONT STYLE="letter-spacing: -0.1pt">The representations and </FONT>warranties <FONT STYLE="letter-spacing: -0.1pt">contained
in this Amendment and </FONT>in <U>Article&nbsp;IV</U> of the Financing Agreement and in each other Loan Document shall be true
and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations or
warranties that already are qualified or modified as to &#8220;materiality&#8221; or &#8220;Material Adverse Effect&#8221; in the
text thereof, which representations and warranties shall be true and correct in all respects subject to such qualification) on
and as the Amendment Effective Date to the same extent as though made on and as of that date, except to the extent such representations
and warranties specifically relate to an earlier date, in which case such representations and warranties shall have been true and
correct in all material respects (except that such materiality qualifier shall not be applicable to any representations or warranties
that already are qualified or modified as to &#8220;materiality&#8221; or &#8220;Material Adverse Effect&#8221; in the text thereof,
which representations and warranties shall be true and correct in all respects subject to such qualification) on and as of such
earlier date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(c) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Default; Event of Default</U>. No Default or Event of Default shall have occurred and be continuing on the Amendment
Effective Date or result from this Amendment becoming effective in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(d) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Documents</U>. The Administrative Agent shall have received on or before the Amendment Effective Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>this Amendment, duly executed by the Loan Parties, the Administrative Agent and the Lenders; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>an amendment to each Warrant to Purchase Common Stock dated August 5, 2020 issued by the Borrower to Sixth Street, Redwood
IV Finance 1, LLC and TAO Finance 1, LLC, in each case in form and substance satisfactory to the Administrative Agent and duly
executed by the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(e) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Material Adverse Effect</U>. The Administrative Agent shall have determined, in its reasonable judgment, that no event
or development shall have occurred since December 31, 2019, which could reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><A NAME="a_Ref24471569"></A>(f)
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Liens; Priority</U>. The Administrative Agent shall be satisfied that the Administrative Agent has been granted, and
holds, for the benefit of the Administrative Agent and the Lenders, a perfected, first priority Lien on and security interest in
all of the Collateral, subject only to Permitted Liens, to the extent such Liens and security interests are required pursuant to
the Loan Documents to be granted or perfected on or before the Amendment Effective Date.</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(g) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Approvals</U>. All consents, authorizations and approvals of, and filings and registrations with, and all other actions
in respect of, any Governmental Authority or other Person required in connection with any Loan Document or the transactions contemplated
thereby or the conduct of the Loan Parties&#8217; business shall have been obtained or made and shall be in full force and effect.
There shall exist no claim, action, suit, investigation, litigation or proceeding (including, without limitation, shareholder or
derivative litigation) pending or, to the knowledge of any Loan Party, threatened in any court or before any arbitrator or Governmental
Authority which (i)&nbsp;relates to the Loan Documents or the transactions contemplated thereby or (ii)&nbsp;could reasonably be
expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase">4.
</FONT><U>Continued Effectiveness of the Financing Agreement and Other Loan Documents</U>. Each Loan Party hereby (a) acknowledges
and consents to this Amendment, (b)&nbsp;confirms and agrees that the Financing Agreement and each other Loan Document to which
it is a party is, and shall continue to be, in full force and effect and is hereby ratified and confirmed in all respects, except
that on and after the Amendment Effective Date, all references in any such Loan Document to &#8220;the Financing Agreement&#8221;,
the &#8220;Agreement&#8221;, &#8220;thereto&#8221;, &#8220;thereof&#8221;, &#8220;thereunder&#8221; or words of like import referring
to the Financing Agreement shall mean the Financing Agreement as amended by this Amendment, and (c)&nbsp;confirms and agrees that,
to the extent that any such Loan Document purports to assign or pledge to the Administrative Agent, for the benefit of the Administrative
Agent and the Lenders, or to grant to the Administrative Agent, for the benefit of the Administrative Agent and the Lenders, a
security interest in or Lien on any Collateral as security for the Obligations of the Loan Parties from time to time existing in
respect of the Financing Agreement (as amended hereby) and the other Loan Documents, such pledge, assignment and/or grant of the
security interest or Lien is hereby ratified and confirmed in all respects. This Amendment does not and shall not affect any of
the obligations of the Loan Parties, other than as expressly provided herein, including, without limitation, the Loan Parties&#8217;
obligations to repay the Loans in accordance with the terms of Financing Agreement or the obligations of the Loan Parties under
any Loan Document to which they are a party, all of which obligations shall remain in full force and effect. Except as expressly
provided herein, the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power
or remedy of Administrative Agent or any Lender under the Financing Agreement or any other Loan Document nor constitute a waiver
of any provision of the Financing Agreement or any other Loan Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase">5.
</FONT><U>No Novation</U>. Nothing herein contained shall be construed as a substitution or novation of the Obligations outstanding
under the Financing Agreement or instruments securing the same, which shall remain in full force and effect, except as modified
hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase">6.
</FONT><U>No Representations by Administrative Agent or Lenders</U>. Each Loan Party hereby acknowledges that it has not relied
on any representation, written or oral, express or implied, by Administrative Agent or any Lender, other than those expressly contained
herein, in entering into this Amendment.</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase">7.
</FONT><U>Release</U>. Each Loan Party hereby acknowledges and agrees that: (a) neither it nor any of its Subsidiaries has any
claim or cause of action against Administrative Agent or any Lender (or any of the directors, officers, employees, agents, attorneys
or consultants of any of the foregoing) and (b) the Administrative Agent and the Lenders have heretofore properly performed and
satisfied in a timely manner all of their obligations to the Loan Parties, and all of their Subsidiaries and Affiliates. Notwithstanding
the foregoing, the Administrative Agent and the Lenders wish (and the Loan Parties agree) to eliminate any possibility that any
past conditions, acts, omissions, events or circumstances would impair or otherwise adversely affect any of their rights, interests,
security and/or remedies. Accordingly, for and in consideration of the agreements contained in this Amendment and other good and
valuable consideration, each Loan Party (for itself and its Subsidiaries and Affiliates and the successors, assigns, heirs and
representatives of each of the foregoing) (collectively, the &#8220;<U>Releasors</U>&#8221;) does hereby fully, finally, unconditionally
and irrevocably release, waive and forever discharge the Administrative Agent and the Lenders, together with their respective
Affiliates and Related Funds, and each of the directors, officers, employees, agents, attorneys and consultants of each of the
foregoing (collectively, the &#8220;<U>Released Parties</U>&#8221;), from any and all debts, claims, allegations, obligations,
damages, costs, attorneys&#8217; fees, suits, demands, liabilities, actions, proceedings and causes of action, in each case, whether
known or unknown, contingent or fixed, direct or indirect, and of whatever nature or description, and whether in law or in equity,
under contract, tort, statute or otherwise, which any Releasor has heretofore had or now or hereafter can, shall or may have against
any Released Party by reason of any act, omission or thing whatsoever done or omitted to be done, in each case, on or prior to
the Amendment Effective Date directly arising out of, connected with or related to this Amendment, the Financing Agreement or
any other Loan Document, or any act, event or transaction related or attendant thereto, or the agreements of Administrative Agent
or any Lender contained therein, or the possession, use, operation or control of any of the assets of any Loan Party, or the making
of any Loans or other advances, or the management of such Loans or other advances or the Collateral. Each Loan Party represents
and warrants that it has no knowledge of any claim by any Releasor against any Released Party or of any facts or acts or omissions
of any Released Party which on the date hereof would be the basis of a claim by any Releasor against any Released Party which
would not be released hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase">8.
</FONT><U>Further Assurances.</U> The Loan Parties shall execute any and all further documents, agreements and instruments, and
take all further actions, as may be required under applicable law or as Administrative Agent may reasonably request, in order to
effect the purposes of this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in"><FONT STYLE="text-transform: uppercase">9.
</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(a) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Amendment may be executed in any number of counterparts and by different parties hereto in separate counterparts, each
of which shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. Delivery
of an executed counterpart of this Amendment by facsimile or electronic mail shall be equally effective as delivery of an original
executed counterpart of this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(b) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section and paragraph headings herein are included for convenience of reference only and shall not constitute a part of
this Amendment for any other purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(c) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Amendment shall be governed by, and construed in accordance with, the laws of the State of New York.</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1.5in">(d) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> Each Loan Party hereby acknowledges and agrees that this Amendment constitutes a &#8220;Loan Document&#8221; under the
Financing Agreement. Accordingly, it shall be an immediate Event of Default under the Financing Agreement if (i) any representation
or warranty made by any Loan Party under or in connection with this Amendment shall have been incorrect in any respect when made
or deemed made, or (ii) any Loan Party shall fail to perform or observe any term, covenant or agreement contained in this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">(e) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any provision of this Amendment that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining portions hereof or affecting
the validity or enforceability of such provision in any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">[<I>Remainder of page intentionally left
blank.</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF,
the parties hereto have caused this Amendment to be executed and delivered as of the date set forth on the first page hereof.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BORROWER:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">THERAPEUTICSMD, INC.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">By:</TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; padding-right: 5.4pt;  text-align: justify">/s/ James D&#8217;Arecca</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Name:&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">James D&#8217;Arecca</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Title:&nbsp;&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt;  text-align: justify">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">GUARANTORS:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">VITAMEDMD, LLC</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt;  text-align: justify">/s/ James D&#8217;Arecca</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Name:</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">James D&rsquo;Arecca</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Title:</TD>
    <TD STYLE="padding-right: 5.4pt;  text-align: justify">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">BOCAGREENMD, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: justify">/s/ James D&#8217;Arecca</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Name:</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">James D&#8217;Arecca</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Title:</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">VITACARE PRESCRIPTION SERVICES, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: justify">/s/ John Milligan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Name:</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">John Milligan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Title:</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">President</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">



        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0">[Signature Page to Amendment No. 6]</P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 24pt 0 0 3in"></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        SIXTH STREET
SPECIALTY LENDING, INC., <BR>
as Administrative Agent and Lender</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">By:</TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; padding-right: 5.4pt;  text-align: justify">/s/ <FONT STYLE="letter-spacing: -0.1pt">Joshua
Easterly</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Name:&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify"><FONT STYLE="letter-spacing: -0.1pt">Joshua Easterly</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Title:&nbsp;&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt;  text-align: justify">Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">TOP IV TALENTS, LLC, as Lender</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt;  text-align: justify">/s/ <FONT STYLE="letter-spacing: -0.1pt">Joshua
Peck</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Name:</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify"><FONT STYLE="letter-spacing: -0.1pt">Joshua Peck</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Title:</TD>
    <TD STYLE="padding-right: 5.4pt;  text-align: justify"><FONT STYLE="letter-spacing: -0.1pt">Vice President</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">TAO TALENTS, LLC, as Lender</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: justify">/s/ Joshua
Peck</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Name:</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">Joshua Peck</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Title:</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">Vice President</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 24pt 0 0 3in">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center; width: 100%"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0">[Signature Page to Amendment No. 6]</P></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>5
<FILENAME>ex10-5.htm
<DESCRIPTION>AMENDMENT NO. 1 THE COMMERCIAL SUPPLY AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

 <!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="txmd-10q_093020.htm">TherapeuticsMD,
Inc. 10-Q</A></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.5</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>CERTAIN
IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>MATERIAL
AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>DISCLOSED.
[***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</B></FONT></P>

<P STYLE="font: 7.5pt Arial, Helvetica, Sans-Serif; margin: 16.2pt 0 0; text-align: right"><FONT STYLE="font-size: 10pt; letter-spacing: 0.4pt"><B>EXECUTION
VERSION</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0; text-align: right"><FONT STYLE="font-size: 10pt; letter-spacing: 0.4pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0in 0in; text-align: center;"><FONT STYLE="font-size: 10pt"><B><U>AMENDMENT
NO. 1 TO THE COMMERCIAL SUPPLY AGREEMENT BETWEEN</U></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0in 0in; text-align: center;"><FONT STYLE="font-size: 10pt"><B><U>THERAPEUTICSMD, INC. AND CATALENT PHARMA SOLUTIONS, LLC</U></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt; text-align: center;"><FONT STYLE="font-size: 10pt"><B><U>(Estradiol and Progesterone
softgel capsules)</U></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 26.1pt 0 0 0.7in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-size: 10pt; letter-spacing: 0.2pt">This
Amendment No. 1 (the &quot;First Amendment&quot;) by and between <B>THERAPEUTICSMD, INC. (&quot;TXMD&quot;) and CATALENT PHARMA
SOLUTIONS, LLC </B>(&quot;CATALENT&quot;), to the Agreement (as defined below), is made as of this 1<SUP>st</SUP> day of December,
2017 (the &quot;First Amendment Effective Date&quot;). TXMD and CATALENT are sometimes herein referred to individually as a &quot;Party&quot;
and collectively as the &quot;Parties&quot;.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12.6pt 0 0 0.7in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-size: 10pt">Unless
otherwise defined herein, capitalized terms used in this First Amendment shall have the meaning provided to such terms in the
Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 13.15pt 0 0 1.15in"><FONT STYLE="font-size: 10pt; letter-spacing: 0.1pt">The
following sets forth the background for this First Amendment:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12.85pt 0 0 0.7in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-size: 10pt"><B>WHEREAS,
</B>TXMD and CATALENT entered into that certain Commercial Supply Agreement, dated June 24, 2016 (the &quot;Agreement&quot;);
and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 13.05pt 0 0 1.15in; text-align: justify"><FONT STYLE="font-size: 10pt; letter-spacing: 0.1pt"><B>WHEREAS,
</B>TXMD and CATALENT wish to amend the Agreement as provided herein.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 13pt 0 0 0.7in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-size: 10pt"><B>NOW
THEREFORE, </B>in consideration of the foregoing premises and the mutual covenants and obligations set forth in this First Amendment,
the Parties hereby agree as follows:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12.7pt 0 0 1.15in; text-align: justify; text-indent: -0.2in"><FONT STYLE="font-size: 10pt">1.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>The foregoing recitals are hereby incorporated into this First Amendment and made a part hereof. Capitalized terms used
and not otherwise defined herein shall have the meanings ascribed to them in the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 13.15pt 0 0 1.15in; text-align: justify; text-indent: -0.2in"><FONT STYLE="font-size: 10pt">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="letter-spacing: 0.15pt">The following definitions shall be added to the Agreement.</FONT></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 13.1pt 0 0 1.15in; text-align: justify"><FONT STYLE="font-size: 10pt; letter-spacing: 0.15pt">&quot;Qualification
Conditions&quot; shall mean that (A) each Access Fee Payment has been made by the earlier of (i) June 30, 2018 or (ii) within
sixty (60) days of invoice date for such Access Fee Payment, (B) the Summary Report Payment is made within sixty (60) days of
invoice for such payment, and (C) the Qualification Quote has not been terminated prior to completion of, or payment for, all
Access Fee Payments and the Summary Report Payment listed in Section 3.1 of the Qualification Quote. For the avoidance of doubt,
the Access Fee Payments do not include the Summary Report Payment.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 13.1pt 0 0 1.15in; text-align: justify"><FONT STYLE="font-size: 10pt">&quot;Access
Fee Payment(s)&quot; shall mean all Manufacturing Process Development Access Fee payments listed in Section 3.1 of the Qualification
Quote and all costs, fees and expenses payable by Client pursuant to, or incurred by Client under, the Qualification Quote.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 13.3pt 0 0 1.15in; text-align: justify"><FONT STYLE="font-size: 10pt; letter-spacing: 0.65pt">&quot;Summary
Report Payment&quot; shall mean the payment listed in Section 3.1 of the </FONT><FONT STYLE="font-size: 10pt; letter-spacing: 0.1pt">Qualification
Quote that is due upon completion of the Summary Report.</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 16.05pt 0 0; text-align: right"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt"><B>EXECUTION
VERSION</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 22.15pt 0 0 1.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&quot;Qualification
Quote&quot; shall mean Quotation SPQ-TIZ-2310.00, between the Parties and dated as of October 19, 2017, and attached hereto as
Attachment C.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12.95pt 0 0 1.2in; text-indent: -0.25in"><FONT STYLE="font-size: 10pt; letter-spacing: 0.1pt">3.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 4.1 shall be amended by adding the following sentence at the end of the section:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12.8pt 0 0 1.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&quot;If
the Qualification Conditions have not been met, the Minimum Requirements set forth in Attachment B shall revert to the minimum
amounts in place prior to the First Amendment Effective Date.&quot;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 13.15pt 0 0 1.2in; text-indent: -0.25in"><FONT STYLE="font-size: 10pt; letter-spacing: 0.1pt">4.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt; letter-spacing: 0.05pt">The following language shall be added to the Agreement as
Section 4.8:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12.9pt 0 0 1.2in; text-align: justify"><FONT STYLE="font-size: 10pt; letter-spacing: 0.15pt">&quot;4.8
<U>Additional Equipment.</U> Subject to the terms of the Qualification Quote, Catalent shall procure, at its sole expense, any
additional equipment required to ensure that it is capable of providing to Client [***] ([***]) softgels of Product (in the aggregate
across all strengths) per Contract Year; provided, however, that such [***] ([***]) annual figure assumes that Purchase Orders
for Product shall be spread out across the Contract Year.&quot;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12.6pt 0 0 1.2in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt; letter-spacing: 0.1pt">5.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">Section 7.2 of the Agreement is amended by replacing the following PPI calculation
language:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12.8pt 0 0 1.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&quot;The
initial base period for comparison shall be the twelve (12) month period ending on the date most closely preceding July 1, 2017,
but which allows enough time for Catalent to provide to Client the notice required by this Section 7.2.&quot;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 13.15pt 0 0 1.2in"><FONT STYLE="font-size: 10pt; letter-spacing: 0.05pt">With
the following language:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12.85pt 0 0 1.2in; text-align: justify"><FONT STYLE="font-size: 10pt; letter-spacing: 0.15pt">&quot;The
initial base period for comparison shall be the twelve (12) month period ending on the date most closely preceding the effective
date of the first price increase, but which allows enough time for Catalent to provide to Client the notice required by this Section
7.2.&quot;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12.4pt 0 0 1.2in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt; letter-spacing: 0.1pt">6.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">Section 7.2 of the Agreement is amended by adding the following language at the end
of the section:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12.7pt 0 0 1.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&quot;If
the Qualification Conditions have been met, the first annual price adjustment shall be effective on July 1, 2018. If any Product
is sold by Catalent to Client at the Unit Pricing set forth in Attachment B, and the Qualification Conditions are not met, then
Catalent shall have the right to retroactively increase the Unit Pricing for Product, effective July 1, 2017, and invoice Client
for any additional amounts that Client would have had to pay for such Product if the retroactively increased pricing had been
in effect at the time of original invoice for such Product.&quot;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12.3pt 0 0 1.2in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt; letter-spacing: 0.1pt">7.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">The MINIMUM REQUIREMENT table in Attachment B of the Agreement is hereby deleted and
replaced with the following:</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 15.95pt 0.15in 20.55pt 0; text-align: right"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt"><B>EXECUTION
VERSION</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD COLSPAN="3" STYLE="border: black 1pt solid; padding-left: 149.55pt"><FONT STYLE="font-size: 10pt"><B>MINIMUM REQUIREMENT</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 34%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.55pt"><FONT STYLE="font-size: 10pt"><B>Contract
    Year</B></FONT></TD>
    <TD STYLE="width: 33%; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.05pt"><FONT STYLE="font-size: 10pt"><B>Product</B></FONT></TD>
    <TD STYLE="width: 33%; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.05pt"><FONT STYLE="font-size: 10pt"><B>Minimum
    Requirement*</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.55pt"><FONT STYLE="font-size: 10pt">Contract
    Year 1</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.05pt"><FONT STYLE="font-size: 10pt">Across
    all three strengths</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 0.35pt; padding-left: 5.05pt"><FONT STYLE="font-size: 10pt">[***]
    Softgels</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.55pt"><FONT STYLE="font-size: 10pt">Contract
    Year 2</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.05pt"><FONT STYLE="font-size: 10pt">Across
    all three strengths</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.05pt"><FONT STYLE="font-size: 10pt">[***]
    Softgels</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.55pt"><FONT STYLE="font-size: 10pt">Contract
    Year 3</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.05pt"><FONT STYLE="font-size: 10pt">Across
    all three strengths</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 0.05pt; padding-left: 5.05pt"><FONT STYLE="font-size: 10pt">[***]
    Softgels</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.55pt"><FONT STYLE="font-size: 10pt">Contract
    Year 4</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.05pt"><FONT STYLE="font-size: 10pt">Across
    all three strengths</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 0.35pt; padding-left: 5.05pt"><FONT STYLE="font-size: 10pt">[***]
    Softgels</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.55pt"><FONT STYLE="font-size: 10pt">Contract
    Year 5</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.05pt"><FONT STYLE="font-size: 10pt">Across
    all three strengths</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.05pt"><FONT STYLE="font-size: 10pt">[***]
    Softgels</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-bottom: 0.55pt; padding-left: 5.55pt"><FONT STYLE="font-size: 10pt">Each
    additional Contract Year</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 0.55pt; padding-left: 5.05pt"><FONT STYLE="font-size: 10pt">Across
    all three strengths</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 0.85pt; padding-left: 5.05pt"><FONT STYLE="font-size: 10pt">[***]
    Softgels</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.2in"><FONT STYLE="font-size: 10pt; letter-spacing: 0.1pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.2in"><FONT STYLE="font-size: 10pt; letter-spacing: 0.1pt">*Softgels
shipped per Contract Year qualify towards the Minimum Requirement</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12.75pt 0.15in 0 1.2in; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">8.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Exhibit 1 attached to this First Amendment shall be attached to the Agreement as Attachment C.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12.95pt 0.15in 0 1.2in; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">9.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This First Amendment shall be governed by the laws of the State of Delaware, as such laws are applied to contracts entered
into and to be performed within such state as though made and to be fully performed therein without regard to conflict of laws
principles.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 13pt 0.15in 0 1.2in; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">10.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The Parties hereby agree that, except as expressly modified herein, all terms and provisions of the Agreement shall remain
unmodified and in full force and effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 13pt 0.15in 0 1.2in; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">11.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>This First Amendment may be executed in facsimile counterparts, each of which shall be deemed an original but all of which
shall constitute the same First Amendment.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 13.2pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt; letter-spacing: 0.1pt"><B>[SIGNATURE
PAGE ON NEXT PAGE]</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 13.2pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt; letter-spacing: 0.1pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>IN WITNESS
WHEREOF</B>, the parties have caused this First Amendment to be executed by their duly authorized representatives as of the day
and year first indicated above.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><B>THERAPEUTICSMD, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 53%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 2%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; width: 23%"><FONT STYLE="font-size: 10pt">/s/ John Milligan</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 22%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">John Milligan</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">President</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><B>CATALENT PHARMA SOLUTIONS, LLC</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 53%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 2%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; width: 23%"><FONT STYLE="font-size: 10pt">/s/ Aris Gennadios,
    Ph.D</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 22%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Aris Gennadios, Ph.D</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">President, Softgel Technologies</FONT></TD></TR>
</TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 2.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 2.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 2.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>6
<FILENAME>ex10-6.htm
<DESCRIPTION>AMENDMENT NO. 2 TO THE COMMERCIAL SUPPLY AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

 <!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="txmd-10q_093020.htm">TherapeuticsMD,
Inc. 10-Q</A></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.6</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 8pt; text-align: center"><B>CERTAIN IDENTIFIED INFORMATION
HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS <BR>
NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF <BR>
PUBLICLY
DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXECUTION VERSION</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>AMENDMENT
NO. 2 TO THE COMMERCIAL SUPPLY AGREEMENT BETWEEN <BR>
THERAPEUTCSMD, INC. AND CATALENT PHARMA SOLUTIONS, LLC</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Estradiol
softgel capsules)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Amendment No. 2 to the Commercial Supply Agreement (<B>&ldquo;Second Amendment&rdquo;</B>) is made as of this 29<SUP>th</SUP>
day of September, 2020 (&ldquo;<B>Second Amendment Effective Date</B>&rdquo;) by and between TherapeuticsMD, Inc., a Nevada corporation,
with a place of business at 951 Yamato Road, Suite 220, Boca Raton, Florida 33431 (&ldquo;<B>Client</B>&rdquo;), and Catalent
Pharma Solutions, LLC, a Delaware limited liability company, having a place of business at 14 Schoolhouse Road, Somerset, New
Jersey 08873 (&ldquo;<B>Catalent</B>&rdquo;).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Client and Catalent entered into that certain Commercial Supply Agreement dated April 20, 2016, as amended (the &ldquo;<B>Agreement</B>&rdquo;).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Client and Catalent desire to amend the Agreement as more fully set forth herein.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants, terms and conditions set forth below, the parties agree as follows:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalized Terms</U>. All capitalized terms used in this <A NAME="a_Hlk40969209"></A>Second Amendment and not otherwise defined
herein shall have the meanings given to them in the Agreement. For clarity, the term &ldquo;Agreement&rdquo; as used in the Agreement
and herein shall mean the Agreement as amended hereby.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 1.53 of the Agreement, is hereby deleted and replaced with the following:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Territory</B>&rdquo;
means worldwide, except shall not include countries that are targeted by the comprehensive sanctions, restrictions or embargoes
administered by the United Nations, European Union, United Kingdom, or the United States. Catalent shall not be obliged to Process
Products for sale in any of such countries if it is prevented from doing so, or would be required to obtain or apply for special
permission to do so, due to any restrictions (such as embargoes) imposed on it by any governmental authorities, including without
limitation, those imposed by the U.S. Office of Foreign Asset Control.</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>&nbsp;</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXECUTION VERSION</B></P>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;<B>ROW</B>&rdquo;
means any country in the Territory excluding the United States, Canada, and Israel.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following definition shall be added to Section 1 of the Agreement:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Authorized
Generic(s)</B>&rdquo; means any drug sold, licensed, or marketed under the Product&rsquo;s New Drug Application that is marketed,
sold or distributed under a different labeler code, product code, trade name, trademark, or packaging (other than repackaging
the listed drug for use in institutions) than the Product.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Section 2.1 of the Agreement is hereby amended by adding the following to the end of the Section:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Client
and its Affiliates shall purchase exclusively from Catalent all of Client&rsquo;s and its Affiliates&rsquo; requirements of Product
for sale in the United States, Canada, and Israel. In the event Client or its Affiliate(s), alone or in partnership with a third
party, launches an Authorized Generic, then Client and its Affiliates shall purchase exclusively from Catalent all of Client&rsquo;s
and Client&rsquo;s Affiliate&rsquo;s requirements of the Authorized Generic in the Territory so long as Catalent&rsquo;s pricing
for the Authorized Generic is competitive with the pricing requirements for the Authorized Generic.&rdquo;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.1 of the Agreement, as amended, is hereby deleted in its entirety and replaced with the following: </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Minimum
Requirement</U>. During each Contract Year, Client shall purchase the minimum number of units of Product set forth on Attachment
B (&ldquo;<B>Minimum Requirement</B>&rdquo;). If Client does not purchase such Minimum Requirement during any Contract Year, then
within [***] ([***]) days after the end of such Contract Year, Client shall pay Catalent [***] percent ([***]%) of the difference
between (A) the total amount Client would have paid to Catalent if the Minimum Requirement had been fulfilled for the Product
and (B) the sum of all purchases of Product from Catalent during such Contract Year.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Article 2 of the Agreement is hereby amended by adding the following as a new Section 2.5:</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXECUTION VERSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Stability
Studies</U>. During the Term, Catalent shall have the right, but not the obligation, to perform all annual stability studies (including
testing and storage) for Product to be sold in the United States at the pricing set forth on Attachment D. If Catalent is unable
to perform the annual stability studies, Client may contract with a Third Party for the performance of the annual stability studies.
Price increases for such stability services shall not exceed [***] percent ([***]%) per year.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 7.1 of the Agreement is hereby amended by including the following as a new subsection D:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
January 1, 2021, Client shall pay Catalent the annual Hormone Suite Occupancy fees set forth on Attachment B. Catalent shall submit
an invoice to Client for such fees on January 1, 2021 and each January 1<SUP>st</SUP> thereafter during the Term.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 7.2 of the Agreement is hereby deleted in its entirety and replaced with the following:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Unit
Pricing Increase</U>. The Unit Pricing shall be adjusted on an annual basis, effective on each July 1<SUP>st</SUP> (with the first
Unit Pricing adjustment to be effective on July 1, 2017), upon sixty (60) days' prior written notice from Catalent to Client,
to reflect increases in labor, utilities and overhead and shall be in an amount equal to the change in the Producer Price Index
(&quot;PPI&quot;), &quot;Pharmaceutical Preparation Manufacturing&quot; (Series ID: PCU325412325412), not seasonally adjusted,
as published by the U.S. Department of Labor, Bureau of Labor Statistics; provided that beginning July 1, 2021 the annual increase
to the Unit Pricing for the PPI for Product to be sold in the United States, Canada, and Israel shall be capped at [***] percent
([***]%) per year. The initial base period for comparison shall be the twelve (12) month period ending on the date most closely
preceding the effective date of the first Unit Pricing increase, but which allows enough time for Catalent to provide to Client
the notice required by this Section 7.2. In addition, notwithstanding the foregoing, price increases for raw materials, and components
shall be passed through to Client annually.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 16.1 of the Agreement is hereby deleted in its entirety and replaced with the following:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Term</U>.
This Agreement shall commence on the Effective Date and shall continue until through July 22, 2028, unless earlier terminated in
accordance with Section 16.2 (as may be extended in accordance with this Section, the &ldquo;<B>Term</B>&rdquo;). The Term shall
automatically be extended for successive two (2)-year periods unless and until one party gives the other party at least twelve
(12) months&rsquo; prior written notice of its desire to terminate as of the end of the then-current Term.</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXECUTION VERSION</B></P>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 1in 8pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Attachment B of the Agreement, as amended, is hereby deleted in its entirety and replaced with the revised Attachment B, attached
hereto.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Agreement is hereby amended by adding Attachment D, attached hereto.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Governing Law</U>. This Second Amendment shall be governed by and construed under the laws of Delaware, USA, excluding its
conflicts of law provisions. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to
this Second Amendment.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Other Variations</U>. Except as specifically amended herein, all other terms and conditions of the Agreement remain in full
force and effect and shall apply to the construction of this Second Amendment.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Counterparts</U>. This Second Amendment may be executed in one or more counterparts, each of which will be deemed an original
but all of which together will constitute one and the same instrument. Any photocopy, facsimile or electronic reproduction of
the executed <A NAME="a_Hlk40969293"></A>Second Amendment shall constitute an original.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF</B>, the parties have caused their respective duly authorized Representatives to execute this Second Amendment
effective as of the Second Amendment Effective Date.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>CATALENT
PHARMA SOLUTIONS, LLC</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>THERAPEUTICSMD, INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 6%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 39%">/s/ Louis B. Weiner</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%"> /s/ James D&rsquo;Arecca</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Name:</TD>
    <TD> Louis B. Weiner</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>James D&rsquo;Arecca</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Title:</TD>
    <TD>VP Business Development, NA Softgel</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD> Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXECUTION VERSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ATTACHMENT
B</U></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIT
PRICING, FEES AND MINIMUM REQUIREMENT FOR US MARKET*</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD COLSPAN="3" STYLE="border-top: #575757 1pt solid; border-right: #4B4B4B 1pt solid; border-left: #4B4B4B 1pt solid; border-bottom: #4F4F4F 1pt solid"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.2pt; text-align: center; color: #1F1F1F"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIT**
                                         PRICING Effective through June 30, 2021</B></FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.2pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">Theoretical
        Batch Size of </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] <FONT STYLE="color: #1F1F1F">softgels
        per strength</FONT></FONT></P></TD></TR>
<TR>
    <TD STYLE="width: 34%; border-left: #4B4B4B 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; border-bottom: #646460 1pt solid; border-right: #878787 1pt solid; padding-top: 0.3pt; padding-left: 4.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F"><B>Product</B></FONT></TD>
    <TD STYLE="width: 33%; border-bottom: #4F4F4F 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; border-right: #4B4B4B 1pt solid; padding-top: 0.8pt; padding-left: 4.65pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F"><B>Unit
    Strength</B></FONT></TD>
    <TD STYLE="width: 33%; border-bottom: #5B5B5B 1pt solid; border-right: #4B4B4B 1pt solid"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0.7pt 0 0 4.45pt; text-align: center; color: #1F1F1F"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unit
                                         Pricing </B></FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0.7pt 0 0 4.45pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F"><B>per
        </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] <FONT STYLE="color: #1F1F1F"><B>softgels
        (USD)</B></FONT></FONT></P></TD></TR>
<TR>
    <TD STYLE="border-right: #444444 1pt solid; border-left: #4B4B4B 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; border-bottom: #6B6B6B 1pt solid; padding-left: 4.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">Estradiol
    Softgel Ovule</FONT></TD>
    <TD STYLE="border-right: #4B4B4B 1pt solid; border-bottom: #8C8C8C 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-left: 4.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">Estradiol
    10 mcg</FONT></TD>
    <TD STYLE="border-right: #4B4B4B 1pt solid; border-bottom: #5B5B5B 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-left: 4.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">$</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: #444444 1pt solid; border-left: #4B4B4B 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; border-bottom: #6B6B6B 1pt solid; padding-left: 4.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">Estradiol
    Softgel Ovule</FONT></TD>
    <TD STYLE="border-right: #4B4B4B 1pt solid; border-bottom: #6B6B6B 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-top: 0.3pt; padding-left: 4.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">Estradiol
    4 mcg</FONT></TD>
    <TD STYLE="border-right: #4B4B4B 1pt solid; border-bottom: #9C9C9C 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-top: 0.6pt; padding-left: 4.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">$</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: #444444 1pt solid; border-bottom: #6B6B6B 1pt solid; border-left: #4B4B4B 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-left: 4.35pt">&nbsp;</TD>
    <TD STYLE="border-right: #4B4B4B 1pt solid; border-bottom: #6B6B6B 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-top: 0.3pt; padding-left: 4.6pt">&nbsp;</TD>
    <TD STYLE="border-right: #4B4B4B 1pt solid; border-bottom: #9C9C9C 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; padding-top: 0.6pt; padding-left: 4.3pt">&nbsp;</TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #1F1F1F"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIT**
                                         PRICING Effective Through June 30, 2021</B></FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">Theoretical
        Batch Size of </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]<FONT STYLE="color: #1F1F1F">
        softgels per strength&nbsp;</FONT></FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="padding-bottom: 5.45pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 5.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tier
    1 Volume: </B>[***] <B>to </B>[***] <B>Total Softgels Shipped between July 1, 2020 and June 30, 2021</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 34%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.15pt; padding-left: 4.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F"><B>Product</B></FONT></TD>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 0.8pt; padding-left: 5.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F"><B>Unit
    Strength</B></FONT></TD>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 0.45pt; padding-left: 4.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F"><B>Unit
    Pricing per 1,000 softgels (USD)</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 4.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">Estradiol
    Softgel Ovule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">Estradiol
    10 mcg</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 4.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">$</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 4.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">Estradiol
    Softgel Ovule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">Estradiol
    4 mcg</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 4.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">$</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="padding-bottom: 5.45pt; text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5.45pt; padding-left: 48.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tier
    2 Volume: [***] and over Total Softgels Shipped between July 1, 2020 and June 30, 2021</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 0.25pt; padding-left: 4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F"><B>Product</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 0.75pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F"><B>Unit
    Strength</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 0.75pt; padding-right: 4.3pt; padding-left: 4.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F"><B>Unit
    Pricing per </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] <FONT STYLE="color: #1F1F1F"><B>softgels
    (USD) for all incremental volume over </B></FONT>[***] <FONT STYLE="color: #1F1F1F"><B>softgels</B></FONT></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 4.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">Estradiol
    Softgel Ovule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 4.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">Estradiol
    10 mcg</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 4.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">$</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 4.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">Estradiol
    Softgel Ovule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 4.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">Estradiol
    4 mcg</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 4.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1F1F">$</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*
For ROW markets, initial Unit Pricing and annual Unit Pricing increases will be negotiated in good faith between Catalent and
Client to be less than or equal to the Unit Pricing for the United States as required by the Client&rsquo;s licensee partner&rsquo;s
pricing requirements for the ROW markets. For the Canada and Israel markets, initial Unit Pricing and annual Unit Pricing increases
will be negotiated in good faith between Catalent and Client to be less than or equal to the Unit Pricing for the United States
as required by the Client&rsquo;s licensee partner&rsquo;s pricing requirements for the Canada and Israel markets.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
One unit is [***] softgel capsules. Unit Pricing includes full API release testing, cost of Processed softgels, Product full release
testing and bulk packaging. Unit Pricing does not include cost of API, tooling or other Product-specific capital items, artwork,
shipping, insurance or duty.</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXECUTION VERSION</B></P>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unit
Pricing also does not include any testing, retesting or testing supplies other than as expressly set forth in the Specifications.
Unit Pricing is based on certain assumptions as to manufacturing processes, storage conditions, etc. Accordingly, Unit Pricing
is subject to adjustment in the event any such assumptions are subject to revision in connection with the validation of the Product.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MINIMUM
    REQUIREMENT </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contract
    Year</B></FONT></TD>
    <TD STYLE="width: 43%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product</B></FONT></TD>
    <TD STYLE="width: 28%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Minimums
    Requirement</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across
    all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
    capsules</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across
    all strengths </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
    capsules </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across
    all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
    capsules</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across
    all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
    capsules</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across
    all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
    capsules</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across
    all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
    capsules</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across
    all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
    capsules</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_Hlk45637863"></A>[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across
    all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
    capsules</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across
    all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
    capsules</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across
    all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
    capsules</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 5.45pt 5.4pt; border: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADDITIONAL
    FEES</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E0E0E0">
    <TD STYLE="width: 33%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Type
    of Fee</B></FONT></TD>
    <TD STYLE="width: 34%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payable</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
    Maintenance Fee</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]
    for the first strength; $[***] for each additional strength</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hormone
    Suite Occupancy Fee</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXECUTION VERSION</B></P>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>ATTACHMENT
D</U></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STABILITY
STUDY PRICING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>
<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>7
<FILENAME>ex10-7.htm
<DESCRIPTION>AMENDMENT NO. 2 TO THE SOFTGEL COMMERCIAL SUPPLY AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

 <!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="txmd-10q_093020.htm">TherapeuticsMD,
Inc. 10-Q</A></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.7</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED
FROM THIS EXHIBIT BECAUSE IT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>PUBLICLY DISCLOSED. [***]
INDICATES THAT INFORMATION HAS BEEN REDACTED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>EXECUTION VERSION</B></P>
<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B><U></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B><U>AMENDMENT NO. 2 TO THE SOFTGEL COMMERCIAL
SUPPLY AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B><U>BETWEEN THERAPEUTCSMD, INC. AND CATALENT PHARMA SOLUTIONS, LLC</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>(Estradiol and Progesterone softgel
capsules)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">This Amendment No. 2 to the Softgel Commercial
Supply Agreement (<B>&ldquo;Second Amendment&rdquo;</B>) is made as of this 29<SUP>th</SUP> day of September, 2020 (&ldquo;<B>Second
Amendment Effective Date</B>&rdquo;) by and between TherapeuticsMD, Inc., a Nevada corporation, with a place of business at 951
Yamato Road, Suite 220, Boca Raton, Florida 33431 (&ldquo;<B>Client</B>&rdquo;), and Catalent Pharma Solutions, LLC, a Delaware
limited liability company, having a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873 (&ldquo;<B>Catalent</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.5in">WHEREAS, Client and
Catalent entered into that certain Softgel Commercial Supply Agreement dated June 24, 2016, as amended (the &ldquo;<B>Agreement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.5in">WHEREAS, Client and
Catalent desire to amend the Agreement as more fully set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in
consideration of the mutual covenants, terms and conditions set forth below, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalized
Terms</U>. All capitalized terms used in this <A NAME="a_Hlk40969209"></A>Second Amendment and not otherwise defined herein shall
have the meanings given to them in the Agreement. For clarity, the term &ldquo;Agreement&rdquo; as used in the Agreement and herein
shall mean the Agreement as amended hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 1.53 of the Agreement, is hereby deleted and replaced with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify">&ldquo;<B>Territory</B>&rdquo; means
worldwide, except shall not include countries that are targeted by the comprehensive sanctions, restrictions or embargoes administered
by the United Nations, European Union, United Kingdom, or the United States. Catalent shall not be obliged to Process Products
for sale in any of such countries if it is prevented from doing so, or would be required to obtain or apply for special permission
to do so, due to any restrictions (such as embargoes) imposed on it by any governmental authorities, including without limitation,
those imposed by the U.S. Office of Foreign Asset Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following definitions shall be added to Section 1 of the Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1in 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>EXECUTION VERSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>&nbsp;</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify">&ldquo;<B>Authorized Generic(s)</B>&rdquo;
means any drug sold, licensed, or marketed under the Product&rsquo;s New Drug Application that is marketed, sold or distributed
under a different labeler code, product code, trade name, trademark, or packaging (other than repackaging the listed drug for use
in institutions) than the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify">&ldquo;<B>ROW</B>&rdquo; means any
country in the Territory excluding the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 2.1 of the Agreement is hereby amended by adding the following to the end of the Section:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify">&ldquo;<A NAME="a_Hlk51156497"></A>Client
and its Affiliates shall purchase from Catalent: (1) at least [***] percent ([***]%) of Client&rsquo;s and its Affiliates&rsquo;
requirements of Product in the United States, and (2) at least [***] percent ([***]%) of Client&rsquo;s and its Affiliates&rsquo;
requirements of Product in the ROW as supplied by, through, or on behalf of Client. In the event Client or its Affiliate(s), alone
or in partnership with a third party, launches an Authorized Generic, then Client and its Affiliates shall purchase exclusively
from Catalent all of Client&rsquo;s and its Affiliates&rsquo; requirements of the Authorized Generic in the Territory so long as
Catalent&rsquo;s pricing for the Authorized Generic is competitive with the pricing requirements for the Authorized Generic.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Article 2 of the Agreement is hereby amended by adding the following as a new Section 2.5:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify"><U>Stability Studies</U>. During the
Term, Catalent shall have the right, but not the obligation, to perform all annual stability studies (including testing and storage)
for Product to be sold in the United States at the pricing set forth on Attachment D. If Catalent is unable to perform the annual
stability studies, Client may contract with a Third Party for the performance of the annual stability studies. Price increases
for such stability services shall not exceed [***] percent ([***]%) per year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 7.1 of the Agreement is hereby amended by including the following as a new subsection D:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify">Beginning January 1, 2021, Client shall
pay Catalent the annual Hormone Suite Occupancy fees as set forth on Attachment B. Catalent shall submit an invoice to Client for
such fees on January 1, 2021 and each January 1<SUP>st</SUP> thereafter during the Term.</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>EXECUTION VERSION</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 7.2 of the Agreement is hereby deleted in its entirety and replaced with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify"><U>Unit Pricing Increase</U>. The Unit
Pricing shall be adjusted on an annual basis, effective on each July 1<SUP>st</SUP> (with the first Unit Pricing adjustment to
be effective on July 1, 2017), upon sixty (60) days' prior written notice from Catalent to Client, to reflect increases in labor,
utilities and overhead and shall be in an amount equal to the change in the Producer Price Index (&quot;PPI&quot;), &quot;Pharmaceutical
Preparation Manufacturing&quot; (Series ID: PCU325412325412), not seasonally adjusted, as published by the U.S. Department of Labor,
Bureau of Labor Statistics; provided that beginning July 1, 2021 (a) the annual increase to the Unit Pricing for the PPI for Product
to be sold in United States, Canada, and Israel shall be capped at [***] percent ([***]%) per year, and (b) the annual increase
to the Unit Pricing for the PPI for Product to be sold in the ROW shall be capped at [***] percent ([***]%) per year. The initial
base period for comparison shall be the twelve (12) month period ending on the date most closely preceding the effective date of
the first Unit Pricing increase, but which allows enough time for Catalent to provide to Client the notice required by this Section
7.2. In addition, notwithstanding the foregoing, price increases for raw materials, and components shall be passed through to Client
annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 16.1 of the Agreement is hereby deleted in its entirety and replaced with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1in 8pt; text-align: justify"><U>Term</U>. This Agreement shall commence
on the Effective Date and shall continue through April 2, 2029, unless earlier terminated in accordance with Section 16.2 (as may
be extended in accordance with this Section, the &ldquo;<B>Term</B>&rdquo;). The Term shall automatically be extended for successive
two (2)-year periods unless and until one party gives the other party at least twelve (12) months&rsquo; prior written notice of
its desire to terminate as of the end of the then-current Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attachment B of the Agreement, as amended, is hereby deleted in its entirety and replaced with the revised Attachment B, attached
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Agreement is hereby amended by adding Attachment D, attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. This Second Amendment shall be governed by and construed under the laws of Delaware, USA, excluding its conflicts of
law provisions. The United Nations Convention on Contracts for the International
Sale of Goods shall not apply to this Second Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>EXECUTION VERSION</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Other Variations</U>. Except as specifically amended herein, all other terms and conditions of the Agreement remain in full force
and effect and shall apply to the construction of this Second Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>.
This Second Amendment may be executed in one or more counterparts, each of which will be deemed an original but all of which together
will constitute one and the same instrument. Any photocopy, facsimile or electronic reproduction of the executed <A NAME="a_Hlk40969293"></A>Second
Amendment shall constitute an original.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the parties have caused their respective duly authorized Representatives to execute this Second Amendment effective as of the Second
Amendment Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>CATALENT
PHARMA SOLUTIONS, LLC</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>THERAPEUTICSMD, INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 6%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 39%">/s/ Louis B. Weiner</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%"> /s/ James D&rsquo;Arecca</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Name:</TD>
    <TD> Louis B. Weiner</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>James D&rsquo;Arecca</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Title:</TD>
    <TD>VP Business Development, NA Softgel</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD> Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>EXECUTION VERSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>&nbsp;</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B><U><A NAME="a_Hlk51135569"></A> ATTACHMENT
B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>UNIT PRICING, FEES AND MINIMUM REQUIREMENT</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD COLSPAN="7" STYLE="padding-top: 5.4pt; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNIT PRICING FOR THE UNITED STATES</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Effective Through June 30, 2021</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P></TD></TR>
<TR>
    <TD ROWSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product Unit Strength</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product Size</B></FONT></TD>
    <TD ROWSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Batch Size</B></FONT></TD>
    <TD COLSPAN="4" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unit* Pricing for Total Softgels Shipped between July 1, 2020 and June 30, 2021</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>First [***] softgels</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Between [***] and [***] softgels</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Between [***] and [***] softgels</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***] and more softgels</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 22%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100mg Progesterone + 1mg Estradiol</FONT></TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] oval</FONT></TD>
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="width: 13%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="width: 13%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="width: 14%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100mg Progesterone + 0.5mg Estradiol</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] oval</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD COLSPAN="4" STYLE="padding-bottom: 5.4pt; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNIT PRICING FOR ROW</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Effective Through June 30, 2021</B></P></TD></TR>
<TR>
    <TD STYLE="width: 24%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product Unit Strength</B></FONT></TD>
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product Size</B></FONT></TD>
    <TD STYLE="width: 21%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Batch Size</B></FONT></TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unit* Pricing per [***] Softgels </B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100mg Progesterone + 1mg Estradiol</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] oval</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100mg Progesterone + 0.5mg Estradiol</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] oval</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">* One unit is [***] softgel capsules.
Unit Pricing includes full API release testing, cost of Processed softgels, Product full release testing and bulk packaging. Unit
Pricing does not include cost of API, tooling or other Product-specific capital items, artwork, shipping, insurance or duty. Unit
Pricing also does not include any testing, retesting or testing supplies other than as expressly set forth in the Specifications.
Unit Pricing is based on certain assumptions as to manufacturing processes, storage conditions, etc. Accordingly, Unit Pricing
is subject to adjustment in the event any such assumptions are subject to revision in connection with the validation of the Product.</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>&nbsp;</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>EXECUTION VERSION</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MINIMUM REQUIREMENT</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contract Year</B></FONT></TD>
    <TD STYLE="width: 43%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product</B></FONT></TD>
    <TD STYLE="width: 28%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Minimums Requirement</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] capsules</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] capsules </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] capsules</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] capsules</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] capsules</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] capsules</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] capsules</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A NAME="a_Hlk45637863"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] capsules</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] capsules</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Across all strengths</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] capsules</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 5.4pt 5.4pt 8pt; border: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADDITIONAL FEES</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #E0E0E0">
    <TD STYLE="width: 34%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Type of Fee</B></FONT></TD>
    <TD STYLE="width: 36%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payable</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product Maintenance Fee</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***] for the first Product strength; $[***] for each additional Product strength </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">[***]</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hormone Suite Occupancy Fee</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>EXECUTION VERSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B><U>ATTACHMENT D</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>STABILITY STUDIES PRICING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>[***]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>ex31-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">&nbsp;</P>



<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><A HREF="txmd-10q_093020.htm">TherapeuticsMD, Inc. 10-Q</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTIFICATION
OF CHIEF EXECUTIVE OFFICER</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Robert G. Finizio, certify that:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this quarterly report on Form 10-Q of TherapeuticsMD, Inc.;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
in this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
performing the equivalent functions):</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-align: justify; text-indent: -12pt; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    9, 2020</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 10%; text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Robert G. Finizio</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 40%; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    G. Finizio</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 12.25pt; text-align: justify; text-indent: -12.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 12.25pt; text-align: justify; text-indent: -12.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
Executive Officer)</FONT></P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">&nbsp;</P>



<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 47 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>ex31-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><A HREF="txmd-10q_093020.htm">TherapeuticsMD, Inc. 10-Q</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTIFICATION
OF CHIEF FINANCIAL OFFICER</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
James C. D&rsquo;Arecca, certify that:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this quarterly report on Form 10-Q of TherapeuticsMD, Inc.;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
in this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
performing the equivalent functions):</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-align: justify; text-indent: -12pt; width: 40%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">November
    9, 2020</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 10%; text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ James C. D&rsquo;Arecca</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 40%; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">James
    C. D&rsquo;Arecca</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 12.25pt; text-align: justify; text-indent: -12.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Financial Officer&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 12.25pt; text-align: justify; text-indent: -12.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
Financial Officer)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">&nbsp;</P>



<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 48 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>ex32-1.htm
<DESCRIPTION>SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><A HREF="txmd-10q_093020.htm">TherapeuticsMD, Inc. 10-Q</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the quarterly report of TherapeuticsMD, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the quarterly period ended
September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Robert
G. Finizio, Chief Executive Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. &sect; 1350,
as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities
                                         Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         information contained in the Report fairly presents, in all material respects, the financial
                                         condition and result of operations of the Company.</FONT></TD></TR></TABLE>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-align: justify; text-indent: -12pt; width: 70%"></TD>
    <TD STYLE="vertical-align: bottom; width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    9, 2020</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Robert G. Finizio</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    G. Finizio</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 12.25pt; text-align: justify; text-indent: -12.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                       Executive Officer&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 12.25pt; text-align: justify; text-indent: -12.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
        Executive Officer)</FONT></P></TD></TR>
</TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 49 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>ex32-2.htm
<DESCRIPTION>SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><A HREF="txmd-10q_093020.htm">TherapeuticsMD, Inc. 10-Q</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the quarterly report of TherapeuticsMD, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the quarterly period ended
September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, James
C. D&rsquo;Arecca, Chief Financial Officer of the Company, certify to my best knowledge and belief, pursuant to 18 U.S.C. &sect;
1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities
                                         Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         information contained in the Report fairly presents, in all material respects, the financial
                                         condition and result of operations of the Company.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-align: justify; text-indent: -12pt; width: 70%"></TD>
    <TD STYLE="vertical-align: bottom; width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    9, 2020</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    James C. D&rsquo;Arecca</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    C. D&rsquo;Arecca</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 12.25pt; text-align: justify; text-indent: -12.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                       Financial Officer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 12.25pt; text-align: justify; text-indent: -12.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
        Financial Officer)</FONT></P></TD></TR>
</TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 50 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>txmd-20200930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSaeJqbP9w5dzuelBtm9xHanqHyUuImljMCnJDN7mkcYB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:txmd="http://therapeuticsmd.com/20200930" elementFormDefault="qualified" targetNamespace="http://therapeuticsmd.com/20200930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" id="ConsolidatedStatementsOfStockholdersEquityDeficit">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note1Company" id="Note1Company">
	  <link:definition>00000007 - Disclosure - NOTE 1 &#8211; THE COMPANY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" id="Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements">
	  <link:definition>00000008 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" id="Note3SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note4InventoryNet" id="Note4InventoryNet">
	  <link:definition>00000010 - Disclosure - NOTE 4 &#8211; INVENTORY, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" id="Note5OtherCurrentAssets">
	  <link:definition>00000011 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNet" id="Note6FixedAssetsNet">
	  <link:definition>00000012 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNet" id="Note7IntangibleAssetsNet">
	  <link:definition>00000013 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" id="Note8OtherCurrentLiabilities">
	  <link:definition>00000014 - Disclosure - NOTE 8&#8211; OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note9Debt" id="Note9Debt">
	  <link:definition>00000015 - Disclosure - NOTE 9 &#8211; DEBT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShare" id="Note10NetLossPerShare">
	  <link:definition>00000016 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquity" id="Note11StockholdersEquity">
	  <link:definition>00000017 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note12IncomeTaxes" id="Note12IncomeTaxes">
	  <link:definition>00000018 - Disclosure - NOTE 12 &#8211; INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note13RelatedParties" id="Note13RelatedParties">
	  <link:definition>00000019 - Disclosure - NOTE 13 &#8211; RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note14-BusinessConcentrations" id="Note14-BusinessConcentrations">
	  <link:definition>00000020 - Disclosure - NOTE 14 - BUSINESS CONCENTRATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" id="Note15CommitmentsAndContingencies">
	  <link:definition>00000021 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note16SubsequentEvents" id="Note16SubsequentEvents">
	  <link:definition>00000022 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" id="Note3SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000023 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" id="Note3SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000024 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note4InventoryNetTables" id="Note4InventoryNetTables">
	  <link:definition>00000025 - Disclosure - NOTE 4 &#8211; INVENTORY, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" id="Note5OtherCurrentAssetsTables">
	  <link:definition>00000026 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" id="Note6FixedAssetsNetTables">
	  <link:definition>00000027 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables" id="Note7IntangibleAssetsNetTables">
	  <link:definition>00000028 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" id="Note8OtherCurrentLiabilitiesTables">
	  <link:definition>00000029 - Disclosure - NOTE 8&#8211; OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note9DebtTables" id="Note9DebtTables">
	  <link:definition>00000030 - Disclosure - NOTE 9 &#8211; DEBT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" id="Note10NetLossPerShareTables">
	  <link:definition>00000031 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" id="Note11StockholdersEquityTables">
	  <link:definition>00000032 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" id="Note15CommitmentsAndContingenciesTables">
	  <link:definition>00000033 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" id="Note1CompanyDetailsNarrative">
	  <link:definition>00000034 - Disclosure - NOTE 1 &#8211; THE COMPANY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" id="Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative">
	  <link:definition>00000035 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" id="FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails">
	  <link:definition>00000036 - Disclosure - The following table provides information about disaggregated revenue by product mix (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000037 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails" id="InventoryNetConsistsOfFollowingDetails">
	  <link:definition>00000038 - Disclosure - Inventory, net consists of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" id="OtherCurrentAssetsConsistOfFollowingDetails">
	  <link:definition>00000039 - Disclosure - Other current assets consist of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" id="FixedAssetsNetConsistOfFollowingDetails">
	  <link:definition>00000040 - Disclosure - Fixed assets, net consist of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" id="Note6FixedAssetsNetDetailsNarrative">
	  <link:definition>00000041 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details" id="FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details">
	  <link:definition>00000042 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2020 and December 31, 2019: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" id="EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails">
	  <link:definition>00000043 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative" id="Note7IntangibleAssetsNetDetailsNarrative">
	  <link:definition>00000044 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" id="OtherCurrentLiabilitiesConsistOfFollowingDetails">
	  <link:definition>00000045 - Disclosure - Other current liabilities consist of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" id="AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails">
	  <link:definition>00000046 - Disclosure - As of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" id="Note9DebtDetailsNarrative">
	  <link:definition>00000047 - Disclosure - NOTE 9 &#8211; DEBT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" id="ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails">
	  <link:definition>00000048 - Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details" id="RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details">
	  <link:definition>00000049 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020 and 2019 are set forth in the table below. (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails" id="SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails">
	  <link:definition>00000050 - Disclosure - A summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September 30, 2020 is as follows (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" id="ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails">
	  <link:definition>00000051 - Disclosure - Schedule of restricted stock units and performance stock units (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" id="Note11StockholdersEquityDetailsNarrative">
	  <link:definition>00000052 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" id="Note13RelatedPartiesDetailsNarrative">
	  <link:definition>00000053 - Disclosure - NOTE 13 &#8211; RELATED PARTIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative" id="Note14-BusinessConcentrationsDetailsNarrative">
	  <link:definition>00000054 - Disclosure - NOTE 14 - BUSINESS CONCENTRATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" id="SupplementalLeaseInformationDetails">
	  <link:definition>00000055 - Disclosure - Supplemental lease information (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" id="FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails">
	  <link:definition>00000056 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" id="Note15CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000057 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" id="Note16SubsequentEventsDetailsNarrative">
	  <link:definition>00000058 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="txmd_FinancingAgreementMember" name="FinancingAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment6Member" name="FinancingAgreementAmendment6Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment6Period1Member" name="FinancingAgreementAmendment6Period1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment6Period2Member" name="FinancingAgreementAmendment6Period2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_VitaminsAndImvexxyMember" name="VitaminsAndImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_BijuvaAndAnnoveraMember" name="BijuvaAndAnnoveraMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrescriptionVitaminsMember" name="PrescriptionVitaminsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ImvexxyMember" name="ImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_BijuvaMember" name="BijuvaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnoveraMember" name="AnnoveraMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementMember" name="CouncilLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementStep1Member" name="CouncilLicenseAgreementStep1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementStep2Member" name="CouncilLicenseAgreementStep2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementStep3Member" name="CouncilLicenseAgreementStep3Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_KnightLicenseAgreementMember" name="KnightLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" name="ApprovedHormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_HormoneTherapyDrugCandidatePatentsMember" name="HormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleTrademarksMember" name="MultipleTrademarksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSPatentsMember" name="DomesticUSPatentsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsMember" name="ForeignPatentsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticPatentsBijuvaMember" name="DomesticPatentsBijuvaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsBijuvaMember" name="ForeignPatentsBijuvaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticPatentsEstradiolAndProgesteroneCandidatesMember" name="DomesticPatentsEstradiolAndProgesteroneCandidatesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSPatentsImvexxyMember" name="DomesticUSPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSUtilityPatentsImvexxyMember" name="DomesticUSUtilityPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSDesignPatentsImvexxyMember" name="DomesticUSDesignPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsImvexxyMember" name="ForeignPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignUtilityPatentsImvexxyMember" name="ForeignUtilityPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignDesignPatentsImvexxyMember" name="ForeignDesignPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" name="DomesticUtilityPatentTopicalCreamCandidatesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentTransdermalPatchMember" name="DomesticUtilityPatentTransdermalPatchMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignUtilityPatentTransdermalPatchMember" name="ForeignUtilityPatentTransdermalPatchMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentTx009HRMember" name="DomesticUtilityPatentTx009HRMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticPatentsProgesteroneFormulationsMember" name="DomesticPatentsProgesteroneFormulationsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsProgesteroneFormulationsMember" name="ForeignPatentsProgesteroneFormulationsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentOperaMember" name="DomesticUtilityPatentOperaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TrancheTwoMember" name="TrancheTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ImvexxyBijuvaAndAnnoveraMember" name="ImvexxyBijuvaAndAnnoveraMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TrancheThreeMember" name="TrancheThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MidCapAgreementMember" name="MidCapAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LenderWarrantsMember" name="LenderWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TwoTranchesMember" name="TwoTranchesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PaycheckProtectionProgramLoanMember" name="PaycheckProtectionProgramLoanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockOptionsMember" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PerformanceStockUnitsMember" name="PerformanceStockUnitsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OutsideConsultant2Member" name="OutsideConsultant2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsCashlessExerciseMember" name="WarrantsCashlessExerciseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LongTermIncentiveCompensationPlan2009Member" name="LongTermIncentiveCompensationPlan2009Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonQualified2012StockIncentivePlanMember" name="NonQualified2012StockIncentivePlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Plan2019Member" name="Plan2019Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NewSharesMember" name="NewSharesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CatalentMember" name="CatalentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AmericanInternationalGroupMember" name="AmericanInternationalGroupMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SupplierOneConcentrationRiskMember" name="SupplierOneConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SupplierTwoConcentrationRiskMember" name="SupplierTwoConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SupplierThreeConcentrationRiskMember" name="SupplierThreeConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ThreeCustomersConcentrationRiskMember" name="ThreeCustomersConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FourCustomersConcentrationRiskMember" name="FourCustomersConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationPillPackRiskMember" name="CustomerConcentrationPillPackRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationCardinalHealthRiskMember" name="CustomerConcentrationCardinalHealthRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationMcKessonCorporationRiskMember" name="CustomerConcentrationMcKessonCorporationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationAmerisourceBergenRiskMember" name="CustomerConcentrationAmerisourceBergenRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationPIServicesMember" name="CustomerConcentrationPIServicesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LicenseRights" name="LicenseRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NoncashOperatingLeaseExpense" name="NoncashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AmortizationOfIntellectualPropertyLicenseFee" name="AmortizationOfIntellectualPropertyLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IncreaseDecreaseInSecurityDeposit" name="IncreaseDecreaseInSecurityDeposit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantGrantedInRelationToFinancingAgreement" name="WarrantGrantedInRelationToFinancingAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AmountAccruedForIntellectualPropertyLicense" name="AmountAccruedForIntellectualPropertyLicense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock" name="LicenseAgreementWithPopulationCouncilPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LicenseAgreementWithKnightPolicyTextBlock" name="LicenseAgreementWithKnightPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" name="ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfSubsidiaries" name="NumberOfSubsidiaries" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" name="MinimumCashBalanceRequirementUnderCreditAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" name="MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" name="ReturnPeriodOfUnsalablePrescriptionProducts" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShelfLifeOfPrescriptionProducts" name="ShelfLifeOfPrescriptionProducts" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MilestonePaymentUponFDAApproval" name="MilestonePaymentUponFDAApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" name="MilestonePaymentsAfterReleaseOfFirstCommercialBatch" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NetSalesAmountPerStepbasedRoyalty" name="NetSalesAmountPerStepbasedRoyalty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RoyaltyPercent" name="RoyaltyPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" name="AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" name="AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" name="MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" name="SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" name="SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" name="SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" name="MaximumCostsAndExpensesForPostApprovalStudyToBePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MilestonePaymentReceivedUponRegulatoryApproval" name="MilestonePaymentReceivedUponRegulatoryApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidSalesAndMarketingCostsCurrent" name="PrepaidSalesAndMarketingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidManufacturing" name="PrepaidManufacturing" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfIssuedPatents" name="NumberOfIssuedPatents" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SalesDiscountsReturnsAndAllowancesGoods1" name="SalesDiscountsReturnsAndAllowancesGoods1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AllowanceForWholesaleDistributorFeesCurrent" name="AllowanceForWholesaleDistributorFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedResearchAndDevelopment" name="AccruedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedRebates" name="AccruedRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DebtTrancheAxis" name="DebtTrancheAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="txmd_DebtTrancheDomain" name="DebtTrancheDomain" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" name="LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LiborFloorRate" name="LiborFloorRate" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrimeRateFloor" name="PrimeRateFloor" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfInstallmentPayments" name="NumberOfInstallmentPayments" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" name="PrepaymentFeeForFirstTwoYearsFundingPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeeThirdYearFundingPercent" name="PrepaymentFeeThirdYearFundingPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeeFourthYearFundingPercent" name="PrepaymentFeeFourthYearFundingPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeeFifthYearFundingPercent" name="PrepaymentFeeFifthYearFundingPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FacilityFeePaidPercent" name="FacilityFeePaidPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfTranchesUnderTermLoanFacility" name="NumberOfTranchesUnderTermLoanFacility" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeePercentage" name="PrepaymentFeePercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentFeePercentage" name="RepaymentFeePercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockOptionsExercisedInCashlessExercise" name="NumberOfStockOptionsExercisedInCashlessExercise" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" name="NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" name="WarrantsAndRightsWeightedAverageContractualRemainingLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" name="WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" name="NumberOfStockIssuedInCashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfCustomers" name="NumberOfCustomers" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CapitalLeaseObligationsTerm" name="CapitalLeaseObligationsTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NetRentableAreaLease" name="NetRentableAreaLease" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RentedAreaLease" name="RentedAreaLease" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdditionalAreaOfLeaseOccupied" name="AdditionalAreaOfLeaseOccupied" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" name="LesseeOperatingLeaseExistenceOfOptionToExtendNumber" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" name="LesseeOperatingLeaseLeaseNotYetCommencedArea" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SignificantSupplyCommitmentPercentagePayable" name="SignificantSupplyCommitmentPercentagePayable" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentOfDebtWithNewCreditFacility" name="RepaymentOfDebtWithNewCreditFacility" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" name="ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" name="CustomerConcentrationPharmacyInnovationsPaRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WriteOffOfPatentAndTrademarkCosts" name="WriteOffOfPatentAndTrademarkCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OperaPatentMember" name="OperaPatentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StatisticalMeasurementAxis" name="StatisticalMeasurementAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="txmd_SupplierFourConcentrationRiskMember" name="SupplierFourConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonextensionOfLineCreditTranche" name="NonextensionOfLineCreditTranche" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>txmd-20200930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Cover" xlink:href="txmd-20200930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20200930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20200930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20200930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="txmd-20200930.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20200930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1Company" xlink:href="txmd-20200930.xsd#Note1Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20200930.xsd#Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20200930.xsd#Note3SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4InventoryNet" xlink:href="txmd-20200930.xsd#Note4InventoryNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:href="txmd-20200930.xsd#Note5OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:href="txmd-20200930.xsd#Note6FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNet" xlink:href="txmd-20200930.xsd#Note7IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:href="txmd-20200930.xsd#Note8OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9Debt" xlink:href="txmd-20200930.xsd#Note9Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:href="txmd-20200930.xsd#Note10NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:href="txmd-20200930.xsd#Note11StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:href="txmd-20200930.xsd#Note12IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:href="txmd-20200930.xsd#Note13RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14-BusinessConcentrations" xlink:href="txmd-20200930.xsd#Note14-BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:href="txmd-20200930.xsd#Note15CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:href="txmd-20200930.xsd#Note16SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20200930.xsd#Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20200930.xsd#Note3SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4InventoryNetTables" xlink:href="txmd-20200930.xsd#Note4InventoryNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:href="txmd-20200930.xsd#Note5OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:href="txmd-20200930.xsd#Note6FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables" xlink:href="txmd-20200930.xsd#Note7IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:href="txmd-20200930.xsd#Note8OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtTables" xlink:href="txmd-20200930.xsd#Note9DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:href="txmd-20200930.xsd#Note10NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:href="txmd-20200930.xsd#Note11StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:href="txmd-20200930.xsd#Note15CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:href="txmd-20200930.xsd#Note1CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:href="txmd-20200930.xsd#Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:href="txmd-20200930.xsd#FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20200930.xsd#Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails" xlink:href="txmd-20200930.xsd#InventoryNetConsistsOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:href="txmd-20200930.xsd#OtherCurrentAssetsConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:href="txmd-20200930.xsd#FixedAssetsNetConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:href="txmd-20200930.xsd#Note6FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details" xlink:href="txmd-20200930.xsd#FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:href="txmd-20200930.xsd#EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative" xlink:href="txmd-20200930.xsd#Note7IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:href="txmd-20200930.xsd#OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:href="txmd-20200930.xsd#AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:href="txmd-20200930.xsd#Note9DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:href="txmd-20200930.xsd#ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details" xlink:href="txmd-20200930.xsd#RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails" xlink:href="txmd-20200930.xsd#SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:href="txmd-20200930.xsd#ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:href="txmd-20200930.xsd#Note11StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:href="txmd-20200930.xsd#Note13RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20200930.xsd#Note14-BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:href="txmd-20200930.xsd#SupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:href="txmd-20200930.xsd#FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20200930.xsd#Note15CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:href="txmd-20200930.xsd#Note16SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LicenseRights" xlink:label="loc_txmdLicenseRights" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_txmdLicenseRights" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="loc_us-gaapOtherAssetsMiscellaneousNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapOtherAssetsMiscellaneousNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (DEFICIT) (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="loc_txmdNoncashOperatingLeaseExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_txmdNoncashOperatingLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaapOperatingLeaseImpairmentLoss" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseImpairmentLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AmortizationOfIntellectualPropertyLicenseFee" xlink:label="loc_txmdAmortizationOfIntellectualPropertyLicenseFee" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_txmdAmortizationOfIntellectualPropertyLicenseFee" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_IncreaseDecreaseInSecurityDeposit" xlink:label="loc_txmdIncreaseDecreaseInSecurityDeposit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_txmdIncreaseDecreaseInSecurityDeposit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1Company" xlink:title="00000007 - Disclosure - NOTE 1 &#8211; THE COMPANY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000008 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4InventoryNet" xlink:title="00000010 - Disclosure - NOTE 4 &#8211; INVENTORY, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:title="00000011 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:title="00000012 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNet" xlink:title="00000013 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - NOTE 8&#8211; OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9Debt" xlink:title="00000015 - Disclosure - NOTE 9 &#8211; DEBT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:title="00000016 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:title="00000017 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:title="00000018 - Disclosure - NOTE 12 &#8211; INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:title="00000019 - Disclosure - NOTE 13 &#8211; RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14-BusinessConcentrations" xlink:title="00000020 - Disclosure - NOTE 14 - BUSINESS CONCENTRATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:title="00000022 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4InventoryNetTables" xlink:title="00000025 - Disclosure - NOTE 4 &#8211; INVENTORY, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:title="00000027 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables" xlink:title="00000028 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - NOTE 8&#8211; OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtTables" xlink:title="00000030 - Disclosure - NOTE 9 &#8211; DEBT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:title="00000031 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:title="00000032 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:title="00000034 - Disclosure - NOTE 1 &#8211; THE COMPANY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:title="00000035 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:title="00000036 - Disclosure - The following table provides information about disaggregated revenue by product mix (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000037 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails" xlink:title="00000038 - Disclosure - Inventory, net consists of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaapInventoryRawMaterialsAndSupplies" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterialsAndSupplies" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:title="00000039 - Disclosure - Other current assets consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="loc_txmdPrepaidSalesAndMarketingCostsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidSalesAndMarketingCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaidManufacturing" xlink:label="loc_txmdPrepaidManufacturing" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidManufacturing" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:title="00000040 - Disclosure - Fixed assets, net consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:title="00000041 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details" xlink:title="00000042 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2020 and December 31, 2019: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:title="00000043 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative" xlink:title="00000044 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:title="00000045 - Disclosure - Other current liabilities consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaapAccruedMarketingCostsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedMarketingCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="loc_txmdAccruedResearchAndDevelopment" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AccruedRebates" xlink:label="loc_txmdAccruedRebates" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedRebates" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:title="00000046 - Disclosure - As of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:title="00000047 - Disclosure - NOTE 9 &#8211; DEBT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:title="00000048 - Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details" xlink:title="00000049 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020 and 2019 are set forth in the table below. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails" xlink:title="00000050 - Disclosure - A summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September 30, 2020 is as follows (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:title="00000051 - Disclosure - Schedule of restricted stock units and performance stock units (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:title="00000052 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:title="00000053 - Disclosure - NOTE 13 &#8211; RELATED PARTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative" xlink:title="00000054 - Disclosure - NOTE 14 - BUSINESS CONCENTRATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:title="00000055 - Disclosure - Supplemental lease information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:title="00000056 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000057 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:title="00000058 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>txmd-20200930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Cover" xlink:href="txmd-20200930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20200930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20200930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20200930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="txmd-20200930.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20200930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1Company" xlink:href="txmd-20200930.xsd#Note1Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20200930.xsd#Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20200930.xsd#Note3SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4InventoryNet" xlink:href="txmd-20200930.xsd#Note4InventoryNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:href="txmd-20200930.xsd#Note5OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:href="txmd-20200930.xsd#Note6FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNet" xlink:href="txmd-20200930.xsd#Note7IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:href="txmd-20200930.xsd#Note8OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9Debt" xlink:href="txmd-20200930.xsd#Note9Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:href="txmd-20200930.xsd#Note10NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:href="txmd-20200930.xsd#Note11StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:href="txmd-20200930.xsd#Note12IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:href="txmd-20200930.xsd#Note13RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14-BusinessConcentrations" xlink:href="txmd-20200930.xsd#Note14-BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:href="txmd-20200930.xsd#Note15CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:href="txmd-20200930.xsd#Note16SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20200930.xsd#Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20200930.xsd#Note3SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4InventoryNetTables" xlink:href="txmd-20200930.xsd#Note4InventoryNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:href="txmd-20200930.xsd#Note5OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:href="txmd-20200930.xsd#Note6FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables" xlink:href="txmd-20200930.xsd#Note7IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:href="txmd-20200930.xsd#Note8OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtTables" xlink:href="txmd-20200930.xsd#Note9DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:href="txmd-20200930.xsd#Note10NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:href="txmd-20200930.xsd#Note11StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:href="txmd-20200930.xsd#Note15CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:href="txmd-20200930.xsd#Note1CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:href="txmd-20200930.xsd#Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:href="txmd-20200930.xsd#FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20200930.xsd#Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails" xlink:href="txmd-20200930.xsd#InventoryNetConsistsOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:href="txmd-20200930.xsd#OtherCurrentAssetsConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:href="txmd-20200930.xsd#FixedAssetsNetConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:href="txmd-20200930.xsd#Note6FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details" xlink:href="txmd-20200930.xsd#FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:href="txmd-20200930.xsd#EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative" xlink:href="txmd-20200930.xsd#Note7IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:href="txmd-20200930.xsd#OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:href="txmd-20200930.xsd#AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:href="txmd-20200930.xsd#Note9DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:href="txmd-20200930.xsd#ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details" xlink:href="txmd-20200930.xsd#RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails" xlink:href="txmd-20200930.xsd#SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:href="txmd-20200930.xsd#ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:href="txmd-20200930.xsd#Note11StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:href="txmd-20200930.xsd#Note13RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20200930.xsd#Note14-BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:href="txmd-20200930.xsd#SupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:href="txmd-20200930.xsd#FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20200930.xsd#Note15CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:href="txmd-20200930.xsd#Note16SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_130" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_130" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_130" xlink:to="loc_us-gaapDepreciationAndAmortization_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_130" xlink:to="loc_us-gaapOperatingExpenses_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_130" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_130" xlink:to="loc_us-gaapOtherNonoperatingIncome_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_130" xlink:to="loc_us-gaapInterestExpense_130" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_130" xlink:to="loc_us-gaapNonoperatingIncomeExpense_130" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_130" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_130" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_130" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract_130" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareAbstract_130" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted_130" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_130" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (DEFICIT) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1Company" xlink:title="00000007 - Disclosure - NOTE 1 &#8211; THE COMPANY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000008 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4InventoryNet" xlink:title="00000010 - Disclosure - NOTE 4 &#8211; INVENTORY, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:title="00000011 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:title="00000012 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNet" xlink:title="00000013 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - NOTE 8&#8211; OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9Debt" xlink:title="00000015 - Disclosure - NOTE 9 &#8211; DEBT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:title="00000016 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:title="00000017 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:title="00000018 - Disclosure - NOTE 12 &#8211; INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:title="00000019 - Disclosure - NOTE 13 &#8211; RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14-BusinessConcentrations" xlink:title="00000020 - Disclosure - NOTE 14 - BUSINESS CONCENTRATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:title="00000022 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4InventoryNetTables" xlink:title="00000025 - Disclosure - NOTE 4 &#8211; INVENTORY, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:title="00000027 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables" xlink:title="00000028 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - NOTE 8&#8211; OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtTables" xlink:title="00000030 - Disclosure - NOTE 9 &#8211; DEBT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:title="00000031 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:title="00000032 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:title="00000034 - Disclosure - NOTE 1 &#8211; THE COMPANY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:title="00000035 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Member" xlink:label="loc_txmdFinancingAgreementAmendment6Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Period1Member" xlink:label="loc_txmdFinancingAgreementAmendment6Period1Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Period1Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Period2Member" xlink:label="loc_txmdFinancingAgreementAmendment6Period2Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Period2Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:title="00000036 - Disclosure - The following table provides information about disaggregated revenue by product mix (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrescriptionVitaminsMember" xlink:label="loc_txmdPrescriptionVitaminsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdPrescriptionVitaminsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ImvexxyMember" xlink:label="loc_txmdImvexxyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_BijuvaMember" xlink:label="loc_txmdBijuvaMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_250" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000037 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaapTrademarksAndTradeNamesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksAndTradeNamesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_VitaminsAndImvexxyMember" xlink:label="loc_txmdVitaminsAndImvexxyMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdVitaminsAndImvexxyMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_BijuvaAndAnnoveraMember" xlink:label="loc_txmdBijuvaAndAnnoveraMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaAndAnnoveraMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CouncilLicenseAgreementMember" xlink:label="loc_txmdCouncilLicenseAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CouncilLicenseAgreementStep1Member" xlink:label="loc_txmdCouncilLicenseAgreementStep1Member_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep1Member_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CouncilLicenseAgreementStep2Member" xlink:label="loc_txmdCouncilLicenseAgreementStep2Member_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep2Member_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CouncilLicenseAgreementStep3Member" xlink:label="loc_txmdCouncilLicenseAgreementStep3Member_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep3Member_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_KnightLicenseAgreementMember" xlink:label="loc_txmdKnightLicenseAgreementMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdKnightLicenseAgreementMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability_270" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_270" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_270" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts_270" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmdShelfLifeOfPrescriptionProducts_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdShelfLifeOfPrescriptionProducts_270" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MilestonePaymentUponFDAApproval" xlink:label="loc_txmdMilestonePaymentUponFDAApproval_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdMilestonePaymentUponFDAApproval_270" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch_270" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_270" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AmortizationOfIntellectualPropertyLicenseFee" xlink:label="loc_txmdAmortizationOfIntellectualPropertyLicenseFee_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdAmortizationOfIntellectualPropertyLicenseFee_270" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="loc_txmdNetSalesAmountPerStepbasedRoyalty_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdNetSalesAmountPerStepbasedRoyalty_270" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_RoyaltyPercent" xlink:label="loc_txmdRoyaltyPercent_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdRoyaltyPercent_270" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_270" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_270" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" xlink:label="loc_txmdMilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdMilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_270" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" xlink:label="loc_txmdSpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdSpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_270" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" xlink:label="loc_txmdSpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdSpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_270" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" xlink:label="loc_txmdSpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdSpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_270" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid_270" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MilestonePaymentReceivedUponRegulatoryApproval" xlink:label="loc_txmdMilestonePaymentReceivedUponRegulatoryApproval_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdMilestonePaymentReceivedUponRegulatoryApproval_270" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInventoryValuationReserves_270" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails" xlink:title="00000038 - Disclosure - Inventory, net consists of the following: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:title="00000039 - Disclosure - Other current assets consist of the following: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:title="00000040 - Disclosure - Fixed assets, net consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:title="00000041 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details" xlink:title="00000042 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2020 and December 31, 2019: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MultipleTrademarksMember" xlink:label="loc_txmdMultipleTrademarksMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="loc_us-gaapIndefiniteLivedTrademarks_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedTrademarks_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_110" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:title="00000043 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative" xlink:title="00000044 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUSPatentsMember" xlink:label="loc_txmdDomesticUSPatentsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignPatentsMember" xlink:label="loc_txmdForeignPatentsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticPatentsBijuvaMember" xlink:label="loc_txmdDomesticPatentsBijuvaMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsBijuvaMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignPatentsBijuvaMember" xlink:label="loc_txmdForeignPatentsBijuvaMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsBijuvaMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticPatentsEstradiolAndProgesteroneCandidatesMember" xlink:label="loc_txmdDomesticPatentsEstradiolAndProgesteroneCandidatesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsEstradiolAndProgesteroneCandidatesMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUSPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSPatentsImvexxyMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsImvexxyMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSUtilityPatentsImvexxyMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSUtilityPatentsImvexxyMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUSDesignPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSDesignPatentsImvexxyMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSDesignPatentsImvexxyMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignPatentsImvexxyMember" xlink:label="loc_txmdForeignPatentsImvexxyMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsImvexxyMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignUtilityPatentsImvexxyMember" xlink:label="loc_txmdForeignUtilityPatentsImvexxyMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentsImvexxyMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignDesignPatentsImvexxyMember" xlink:label="loc_txmdForeignDesignPatentsImvexxyMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignDesignPatentsImvexxyMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" xlink:label="loc_txmdDomesticUtilityPatentTopicalCreamCandidatesMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTopicalCreamCandidatesMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdDomesticUtilityPatentTransdermalPatchMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTransdermalPatchMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdForeignUtilityPatentTransdermalPatchMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentTransdermalPatchMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUtilityPatentTx009HRMember" xlink:label="loc_txmdDomesticUtilityPatentTx009HRMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTx009HRMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:label="loc_txmdDomesticPatentsProgesteroneFormulationsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsProgesteroneFormulationsMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:label="loc_txmdForeignPatentsProgesteroneFormulationsMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsProgesteroneFormulationsMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUtilityPatentOperaMember" xlink:label="loc_txmdDomesticUtilityPatentOperaMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentOperaMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNumberOfIssuedPatents_220" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:title="00000045 - Disclosure - Other current liabilities consist of the following: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:title="00000046 - Disclosure - As of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtNoncurrent_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:title="00000047 - Disclosure - NOTE 9 &#8211; DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaapSecuredDebtMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapSecuredDebtMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdFinancingAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MidCapAgreementMember" xlink:label="loc_txmdMidCapAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdMidCapAgreementMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DebtTrancheAxis" xlink:label="loc_txmdDebtTrancheAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_txmdDebtTrancheAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmdDebtTrancheDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_txmdDebtTrancheAxis" xlink:to="loc_txmdDebtTrancheDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmdDebtTrancheDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_txmdDebtTrancheAxis" xlink:to="loc_txmdDebtTrancheDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_TrancheTwoMember" xlink:label="loc_txmdTrancheTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_TrancheThreeMember" xlink:label="loc_txmdTrancheThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheThreeMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_TwoTranchesMember" xlink:label="loc_txmdTwoTranchesMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTwoTranchesMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:label="loc_txmdImvexxyBijuvaAndAnnoveraMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyBijuvaAndAnnoveraMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Period1Member" xlink:label="loc_txmdFinancingAgreementAmendment6Period1Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Period1Member_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LenderWarrantsMember" xlink:label="loc_txmdLenderWarrantsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdLenderWarrantsMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PaycheckProtectionProgramLoanMember" xlink:label="loc_txmdPaycheckProtectionProgramLoanMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_txmdPaycheckProtectionProgramLoanMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_290" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_290" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" xlink:label="loc_txmdLineOfCreditFacilityUndrawnTrancheNoLongerAvailable_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdLineOfCreditFacilityUndrawnTrancheNoLongerAvailable_290" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_290" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_290" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LiborFloorRate" xlink:label="loc_txmdLiborFloorRate_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdLiborFloorRate_290" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrimeRateFloor" xlink:label="loc_txmdPrimeRateFloor_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrimeRateFloor_290" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfInstallmentPayments" xlink:label="loc_txmdNumberOfInstallmentPayments_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfInstallmentPayments_290" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:label="loc_txmdPrepaymentFeeForFirstTwoYearsFundingPercent_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeForFirstTwoYearsFundingPercent_290" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaymentFeeThirdYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeThirdYearFundingPercent_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeThirdYearFundingPercent_290" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaymentFeeFourthYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeFourthYearFundingPercent_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeFourthYearFundingPercent_290" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaymentFeeFifthYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeFifthYearFundingPercent_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeFifthYearFundingPercent_290" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FacilityFeePaidPercent" xlink:label="loc_txmdFacilityFeePaidPercent_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdFacilityFeePaidPercent_290" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement_290" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="loc_txmdNumberOfTranchesUnderTermLoanFacility_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfTranchesUnderTermLoanFacility_290" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit_290" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaymentFeePercentage" xlink:label="loc_txmdPrepaymentFeePercentage_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeePercentage_290" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_RepaymentFeePercentage" xlink:label="loc_txmdRepaymentFeePercentage_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentFeePercentage_290" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_290" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_290" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_290" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_290" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_290" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_290" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaapDeferredFinanceCostsGross_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsGross_290" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_290" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost_290" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaapInterestExpenseBorrowings_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseBorrowings_290" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_290" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_290" xlink:type="arc" order="29" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:title="00000048 - Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_StockOptionsMember" xlink:label="loc_txmdStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_txmdStockOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PerformanceStockUnitsMember" xlink:label="loc_txmdPerformanceStockUnitsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_txmdPerformanceStockUnitsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details" xlink:title="00000049 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020 and 2019 are set forth in the table below. (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails" xlink:title="00000050 - Disclosure - A summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September 30, 2020 is as follows (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_50" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:title="00000051 - Disclosure - Schedule of restricted stock units and performance stock units (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:title="00000052 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_WarrantsMember" xlink:label="loc_txmdWarrantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LenderWarrantsMember" xlink:label="loc_txmdLenderWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdLenderWarrantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmdOutsideConsultant2Member_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultant2Member_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_WarrantsCashlessExerciseMember" xlink:label="loc_txmdWarrantsCashlessExerciseMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsCashlessExerciseMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_Plan2019Member" xlink:label="loc_txmdPlan2019Member_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdPlan2019Member_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NewSharesMember" xlink:label="loc_txmdNewSharesMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNewSharesMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_EmployeeStockPurchasePlanMember" xlink:label="loc_txmdEmployeeStockPurchasePlanMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdEmployeeStockPurchasePlanMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_330" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_330" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_330" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_330" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_330" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_330" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_330" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_330" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_330" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise_330" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_330" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_330" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_330" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_330" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_330" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_330" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_330" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_330" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_330" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensation_330" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_330" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_330" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_330" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:label="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants_330" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_330" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_330" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_330" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_330" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_330" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_330" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_330" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapRestrictedStockExpense_330" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_330" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_330" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_330" xlink:type="arc" order="34" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:title="00000053 - Disclosure - NOTE 13 &#8211; RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CatalentMember" xlink:label="loc_txmdCatalentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdCatalentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AmericanInternationalGroupMember" xlink:label="loc_txmdAmericanInternationalGroupMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdAmericanInternationalGroupMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative" xlink:title="00000054 - Disclosure - NOTE 14 - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SupplierOneConcentrationRiskMember" xlink:label="loc_txmdSupplierOneConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierOneConcentrationRiskMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SupplierTwoConcentrationRiskMember" xlink:label="loc_txmdSupplierTwoConcentrationRiskMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierTwoConcentrationRiskMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SupplierThreeConcentrationRiskMember" xlink:label="loc_txmdSupplierThreeConcentrationRiskMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierThreeConcentrationRiskMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ThreeCustomersConcentrationRiskMember" xlink:label="loc_txmdThreeCustomersConcentrationRiskMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdThreeCustomersConcentrationRiskMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FourCustomersConcentrationRiskMember" xlink:label="loc_txmdFourCustomersConcentrationRiskMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdFourCustomersConcentrationRiskMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CustomerConcentrationPillPackRiskMember" xlink:label="loc_txmdCustomerConcentrationPillPackRiskMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPillPackRiskMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:label="loc_txmdCustomerConcentrationCardinalHealthRiskMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationCardinalHealthRiskMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:label="loc_txmdCustomerConcentrationMcKessonCorporationRiskMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationMcKessonCorporationRiskMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:label="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CustomerConcentrationPIServicesMember" xlink:label="loc_txmdCustomerConcentrationPIServicesMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPIServicesMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfCustomers" xlink:label="loc_txmdNumberOfCustomers_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_txmdNumberOfCustomers_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapRevenues_180" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:title="00000055 - Disclosure - Supplemental lease information (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:title="00000056 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000057 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CatalentMember" xlink:label="loc_txmdCatalentMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_txmdCatalentMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="loc_txmdCapitalLeaseObligationsTerm_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdCapitalLeaseObligationsTerm_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NetRentableAreaLease" xlink:label="loc_txmdNetRentableAreaLease_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdNetRentableAreaLease_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_RentedAreaLease" xlink:label="loc_txmdRentedAreaLease_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdRentedAreaLease_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AdditionalAreaOfLeaseOccupied" xlink:label="loc_txmdAdditionalAreaOfLeaseOccupied_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdAdditionalAreaOfLeaseOccupied_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:label="loc_txmdLesseeOperatingLeaseExistenceOfOptionToExtendNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdLesseeOperatingLeaseExistenceOfOptionToExtendNumber_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:label="loc_txmdLesseeOperatingLeaseLeaseNotYetCommencedArea_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdLesseeOperatingLeaseLeaseNotYetCommencedArea_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapVariableLeaseCost_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SignificantSupplyCommitmentPercentagePayable" xlink:label="loc_txmdSignificantSupplyCommitmentPercentagePayable_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdSignificantSupplyCommitmentPercentagePayable_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueWithinOneYear_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueWithinOneYear_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInSecondYear_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInSecondYear_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInThirdYear_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInThirdYear_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInFourthYear_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInFourthYear_110" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:title="00000058 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Member" xlink:label="loc_txmdFinancingAgreementAmendment6Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Period1Member" xlink:label="loc_txmdFinancingAgreementAmendment6Period1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Period1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Period2Member" xlink:label="loc_txmdFinancingAgreementAmendment6Period2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Period2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement_40" xlink:type="arc" order="1" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>txmd-20200930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US">License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementMember" xlink:label="txmd_FinancingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementMember" xlink:to="txmd_FinancingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementMember_lbl" xml:lang="en-US">Financing Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Member" xlink:label="txmd_FinancingAgreementAmendment6Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment6Member" xlink:to="txmd_FinancingAgreementAmendment6Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment6Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 6 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Period1Member" xlink:label="txmd_FinancingAgreementAmendment6Period1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment6Period1Member" xlink:to="txmd_FinancingAgreementAmendment6Period1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment6Period1Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 6 - Through December 31, 2020 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Period2Member" xlink:label="txmd_FinancingAgreementAmendment6Period2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment6Period2Member" xlink:to="txmd_FinancingAgreementAmendment6Period2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment6Period2Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 6 - After December 31, 2020 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="us-gaap_TrademarksAndTradeNamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksAndTradeNamesMember" xlink:to="us-gaap_TrademarksAndTradeNamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TrademarksAndTradeNamesMember_lbl" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_VitaminsAndImvexxyMember" xlink:label="txmd_VitaminsAndImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VitaminsAndImvexxyMember" xlink:to="txmd_VitaminsAndImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_VitaminsAndImvexxyMember_lbl" xml:lang="en-US">Vitamins and IMVEXXY [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_BijuvaAndAnnoveraMember" xlink:label="txmd_BijuvaAndAnnoveraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaAndAnnoveraMember" xlink:to="txmd_BijuvaAndAnnoveraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BijuvaAndAnnoveraMember_lbl" xml:lang="en-US">BIJUVA and ANNOVERA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrescriptionVitaminsMember" xlink:label="txmd_PrescriptionVitaminsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrescriptionVitaminsMember" xlink:to="txmd_PrescriptionVitaminsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrescriptionVitaminsMember_lbl" xml:lang="en-US">Prescription Vitamins [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ImvexxyMember" xlink:label="txmd_ImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyMember" xlink:to="txmd_ImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ImvexxyMember_lbl" xml:lang="en-US">Imvexxy [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_BijuvaMember" xlink:label="txmd_BijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaMember" xlink:to="txmd_BijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BijuvaMember_lbl" xml:lang="en-US">BIJUVA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AnnoveraMember" xlink:label="txmd_AnnoveraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnoveraMember" xlink:to="txmd_AnnoveraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnoveraMember_lbl" xml:lang="en-US">ANNOVERA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CouncilLicenseAgreementMember" xlink:label="txmd_CouncilLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementMember" xlink:to="txmd_CouncilLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementMember_lbl" xml:lang="en-US">Council License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CouncilLicenseAgreementStep1Member" xlink:label="txmd_CouncilLicenseAgreementStep1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep1Member" xlink:to="txmd_CouncilLicenseAgreementStep1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementStep1Member_lbl" xml:lang="en-US">Council License Agreement Step 1</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CouncilLicenseAgreementStep2Member" xlink:label="txmd_CouncilLicenseAgreementStep2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep2Member" xlink:to="txmd_CouncilLicenseAgreementStep2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementStep2Member_lbl" xml:lang="en-US">Council License Agreement Step 2</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CouncilLicenseAgreementStep3Member" xlink:label="txmd_CouncilLicenseAgreementStep3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep3Member" xlink:to="txmd_CouncilLicenseAgreementStep3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementStep3Member_lbl" xml:lang="en-US">Council License Agreement Step 3</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_KnightLicenseAgreementMember" xlink:label="txmd_KnightLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_KnightLicenseAgreementMember" xlink:to="txmd_KnightLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_KnightLicenseAgreementMember_lbl" xml:lang="en-US">Knight License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Approved Hormone Therapy Drug Candidate Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Hormone Therapy Drug Candidate Patents - (Pending) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MultipleTrademarksMember" xlink:label="txmd_MultipleTrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksMember" xlink:to="txmd_MultipleTrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleTrademarksMember_lbl" xml:lang="en-US">Multiple Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUSPatentsMember" xlink:label="txmd_DomesticUSPatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsMember" xlink:to="txmd_DomesticUSPatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSPatentsMember_lbl" xml:lang="en-US">Domestic US Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignPatentsMember" xlink:label="txmd_ForeignPatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsMember" xlink:to="txmd_ForeignPatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsMember_lbl" xml:lang="en-US">Foreign Patents Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticPatentsBijuvaMember" xlink:label="txmd_DomesticPatentsBijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsBijuvaMember" xlink:to="txmd_DomesticPatentsBijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticPatentsBijuvaMember_lbl" xml:lang="en-US">Domestic Patents BIJUVA</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignPatentsBijuvaMember" xlink:label="txmd_ForeignPatentsBijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsBijuvaMember" xlink:to="txmd_ForeignPatentsBijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsBijuvaMember_lbl" xml:lang="en-US">Foreign Patents BIJUVA</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticPatentsEstradiolAndProgesteroneCandidatesMember" xlink:label="txmd_DomesticPatentsEstradiolAndProgesteroneCandidatesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsEstradiolAndProgesteroneCandidatesMember" xlink:to="txmd_DomesticPatentsEstradiolAndProgesteroneCandidatesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticPatentsEstradiolAndProgesteroneCandidatesMember_lbl" xml:lang="en-US">Domestic Patents Estradiol and Progesterone Candidates</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUSPatentsImvexxyMember" xlink:label="txmd_DomesticUSPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsImvexxyMember" xlink:to="txmd_DomesticUSPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSPatentsImvexxyMember_lbl" xml:lang="en-US">Domestic US Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:label="txmd_DomesticUSUtilityPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:to="txmd_DomesticUSUtilityPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSUtilityPatentsImvexxyMember_lbl" xml:lang="en-US">Domestic US Utility Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUSDesignPatentsImvexxyMember" xlink:label="txmd_DomesticUSDesignPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSDesignPatentsImvexxyMember" xlink:to="txmd_DomesticUSDesignPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSDesignPatentsImvexxyMember_lbl" xml:lang="en-US">Domestic US Design Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignPatentsImvexxyMember" xlink:label="txmd_ForeignPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsImvexxyMember" xlink:to="txmd_ForeignPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsImvexxyMember_lbl" xml:lang="en-US">Foreign Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignUtilityPatentsImvexxyMember" xlink:label="txmd_ForeignUtilityPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentsImvexxyMember" xlink:to="txmd_ForeignUtilityPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignUtilityPatentsImvexxyMember_lbl" xml:lang="en-US">Foreign Utility Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignDesignPatentsImvexxyMember" xlink:label="txmd_ForeignDesignPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignDesignPatentsImvexxyMember" xlink:to="txmd_ForeignDesignPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignDesignPatentsImvexxyMember_lbl" xml:lang="en-US">Foreign Design Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" xlink:label="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" xlink:to="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember_lbl" xml:lang="en-US">Domestic Utility Patent Topical Cream Candidates [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:label="txmd_DomesticUtilityPatentTransdermalPatchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:to="txmd_DomesticUtilityPatentTransdermalPatchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentTransdermalPatchMember_lbl" xml:lang="en-US">Domestic Utility Patent Transdermal Patch</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:label="txmd_ForeignUtilityPatentTransdermalPatchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:to="txmd_ForeignUtilityPatentTransdermalPatchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignUtilityPatentTransdermalPatchMember_lbl" xml:lang="en-US">Foreign Utility Patent Transdermal Patch</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUtilityPatentTx009HRMember" xlink:label="txmd_DomesticUtilityPatentTx009HRMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTx009HRMember" xlink:to="txmd_DomesticUtilityPatentTx009HRMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentTx009HRMember_lbl" xml:lang="en-US">Domestic Utility Patent TX009HR</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:label="txmd_DomesticPatentsProgesteroneFormulationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:to="txmd_DomesticPatentsProgesteroneFormulationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticPatentsProgesteroneFormulationsMember_lbl" xml:lang="en-US">Domestic Patents Progesterone Formulations</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:label="txmd_ForeignPatentsProgesteroneFormulationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:to="txmd_ForeignPatentsProgesteroneFormulationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsProgesteroneFormulationsMember_lbl" xml:lang="en-US">Foreign Patents Progesterone Formulations</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUtilityPatentOperaMember" xlink:label="txmd_DomesticUtilityPatentOperaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentOperaMember" xlink:to="txmd_DomesticUtilityPatentOperaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentOperaMember_lbl" xml:lang="en-US">Domestic Utility Patent Opera</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US">Secured Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DebtTrancheAxis" xlink:label="txmd_DebtTrancheAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtTrancheAxis" xlink:to="txmd_DebtTrancheAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DebtTrancheAxis_lbl" xml:lang="en-US">Debt Tranche [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_TrancheTwoMember" xlink:label="txmd_TrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheTwoMember" xlink:to="txmd_TrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TrancheTwoMember_lbl" xml:lang="en-US">Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:label="txmd_ImvexxyBijuvaAndAnnoveraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:to="txmd_ImvexxyBijuvaAndAnnoveraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ImvexxyBijuvaAndAnnoveraMember_lbl" xml:lang="en-US">IMVEXXY, BIJUVA and ANNOVERA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_TrancheThreeMember" xlink:label="txmd_TrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheThreeMember" xlink:to="txmd_TrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TrancheThreeMember_lbl" xml:lang="en-US">Tranche Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US">Prime Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MidCapAgreementMember" xlink:label="txmd_MidCapAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MidCapAgreementMember" xlink:to="txmd_MidCapAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MidCapAgreementMember_lbl" xml:lang="en-US">Credit Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LenderWarrantsMember" xlink:label="txmd_LenderWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LenderWarrantsMember" xlink:to="txmd_LenderWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LenderWarrantsMember_lbl" xml:lang="en-US">Lender Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_TwoTranchesMember" xlink:label="txmd_TwoTranchesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TwoTranchesMember" xlink:to="txmd_TwoTranchesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TwoTranchesMember_lbl" xml:lang="en-US">Two Tranches [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PaycheckProtectionProgramLoanMember" xlink:label="txmd_PaycheckProtectionProgramLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaycheckProtectionProgramLoanMember" xlink:to="txmd_PaycheckProtectionProgramLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US">Paycheck Protection Program Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_StockOptionsMember" xlink:label="txmd_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockOptionsMember" xlink:to="txmd_StockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PerformanceStockUnitsMember" xlink:label="txmd_PerformanceStockUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PerformanceStockUnitsMember" xlink:to="txmd_PerformanceStockUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PerformanceStockUnitsMember_lbl" xml:lang="en-US">Performance Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_WarrantsMember" xlink:label="txmd_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsMember" xlink:to="txmd_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsMember_lbl" xml:lang="en-US">Warrants Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_OutsideConsultant2Member" xlink:label="txmd_OutsideConsultant2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultant2Member" xlink:to="txmd_OutsideConsultant2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OutsideConsultant2Member_lbl" xml:lang="en-US">Outside Consultants Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_WarrantsCashlessExerciseMember" xlink:label="txmd_WarrantsCashlessExerciseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsCashlessExerciseMember" xlink:to="txmd_WarrantsCashlessExerciseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsCashlessExerciseMember_lbl" xml:lang="en-US">Warrants - Cashless Exercise [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xml:lang="en-US">2009 Long Term Incentive Compensation Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="txmd_NonQualified2012StockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_lbl" xml:lang="en-US">2012 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_Plan2019Member" xlink:label="txmd_Plan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Plan2019Member" xlink:to="txmd_Plan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Plan2019Member_lbl" xml:lang="en-US">Plan 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NewSharesMember" xlink:label="txmd_NewSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NewSharesMember" xlink:to="txmd_NewSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NewSharesMember_lbl" xml:lang="en-US">New Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_EmployeeStockPurchasePlanMember" xlink:label="txmd_EmployeeStockPurchasePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EmployeeStockPurchasePlanMember" xlink:to="txmd_EmployeeStockPurchasePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CatalentMember" xlink:label="txmd_CatalentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CatalentMember" xlink:to="txmd_CatalentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CatalentMember_lbl" xml:lang="en-US">Catalent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AmericanInternationalGroupMember" xlink:label="txmd_AmericanInternationalGroupMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmericanInternationalGroupMember" xlink:to="txmd_AmericanInternationalGroupMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AmericanInternationalGroupMember_lbl" xml:lang="en-US">American International Group [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SupplierOneConcentrationRiskMember" xlink:label="txmd_SupplierOneConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierOneConcentrationRiskMember" xlink:to="txmd_SupplierOneConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SupplierOneConcentrationRiskMember_lbl" xml:lang="en-US">Supplier One Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SupplierTwoConcentrationRiskMember" xlink:label="txmd_SupplierTwoConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierTwoConcentrationRiskMember" xlink:to="txmd_SupplierTwoConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SupplierTwoConcentrationRiskMember_lbl" xml:lang="en-US">Supplier 2</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SupplierThreeConcentrationRiskMember" xlink:label="txmd_SupplierThreeConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierThreeConcentrationRiskMember" xlink:to="txmd_SupplierThreeConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SupplierThreeConcentrationRiskMember_lbl" xml:lang="en-US">Supplier 3</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ThreeCustomersConcentrationRiskMember" xlink:label="txmd_ThreeCustomersConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ThreeCustomersConcentrationRiskMember" xlink:to="txmd_ThreeCustomersConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ThreeCustomersConcentrationRiskMember_lbl" xml:lang="en-US">Three Customers Concentration Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FourCustomersConcentrationRiskMember" xlink:label="txmd_FourCustomersConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FourCustomersConcentrationRiskMember" xlink:to="txmd_FourCustomersConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FourCustomersConcentrationRiskMember_lbl" xml:lang="en-US">Four Customers Concentration Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CustomerConcentrationPillPackRiskMember" xlink:label="txmd_CustomerConcentrationPillPackRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPillPackRiskMember" xlink:to="txmd_CustomerConcentrationPillPackRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationPillPackRiskMember_lbl" xml:lang="en-US">PillPack - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:label="txmd_CustomerConcentrationCardinalHealthRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:to="txmd_CustomerConcentrationCardinalHealthRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationCardinalHealthRiskMember_lbl" xml:lang="en-US">Cardinal Health - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:label="txmd_CustomerConcentrationMcKessonCorporationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:to="txmd_CustomerConcentrationMcKessonCorporationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationMcKessonCorporationRiskMember_lbl" xml:lang="en-US">McKesson Corporation - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:label="txmd_CustomerConcentrationAmerisourceBergenRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:to="txmd_CustomerConcentrationAmerisourceBergenRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationAmerisourceBergenRiskMember_lbl" xml:lang="en-US">AmerisourceBergen - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CustomerConcentrationPIServicesMember" xlink:label="txmd_CustomerConcentrationPIServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPIServicesMember" xlink:to="txmd_CustomerConcentrationPIServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationPIServicesMember_lbl" xml:lang="en-US">PI Services - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US">Recorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $857,176 and $904,040, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">&#160;Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LicenseRights" xlink:label="txmd_LicenseRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseRights" xlink:to="txmd_LicenseRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicenseRights_lbl" xml:lang="en-US">License rights, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">&#160;LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xml:lang="en-US">Long-Term Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' (Deficit) Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - par value $0.001; 10,000,000 shares authorized; &#160;no shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - par value $0.001; 600,000,000 and 350,000,000&#160;&#160;shares authorized: 272,812,271 and 271,177,076 issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' (deficit) equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' (deficit) equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Total revenue, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales, general, and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (expense) income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Miscellaneous income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss per share, basic and diluted:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xml:lang="en-US">Shares issued for exercise of options and warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Shares issued for exercise of options and warrants, net (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of shares from release of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of shares from release of restricted stock (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrant granted in relation to Financing Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xml:lang="en-US">Write off of patent and trademark costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xml:lang="en-US">Write off of deferred financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="txmd_NoncashOperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NoncashOperatingLeaseExpense" xlink:to="txmd_NoncashOperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NoncashOperatingLeaseExpense_lbl" xml:lang="en-US">Non-cash operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">(Recovery of) provision for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xml:lang="en-US">Lease impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory obsolesence reserve</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AmortizationOfIntellectualPropertyLicenseFee" xlink:label="txmd_AmortizationOfIntellectualPropertyLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmortizationOfIntellectualPropertyLicenseFee" xlink:to="txmd_AmortizationOfIntellectualPropertyLicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AmortizationOfIntellectualPropertyLicenseFee_lbl" xml:lang="en-US">Amortization of intellectual property license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of deferred financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_IncreaseDecreaseInSecurityDeposit" xlink:label="txmd_IncreaseDecreaseInSecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IncreaseDecreaseInSecurityDeposit" xlink:to="txmd_IncreaseDecreaseInSecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IncreaseDecreaseInSecurityDeposit_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Repayment of the Credit Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from the Financing Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payment of deferred financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Decrease in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_WarrantGrantedInRelationToFinancingAgreement" xlink:label="txmd_WarrantGrantedInRelationToFinancingAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantGrantedInRelationToFinancingAgreement" xlink:to="txmd_WarrantGrantedInRelationToFinancingAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_WarrantGrantedInRelationToFinancingAgreement_lbl" xml:lang="en-US">Warrant granted in relation to Financing Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AmountAccruedForIntellectualPropertyLicense" xlink:label="txmd_AmountAccruedForIntellectualPropertyLicense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmountAccruedForIntellectualPropertyLicense" xlink:to="txmd_AmountAccruedForIntellectualPropertyLicense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AmountAccruedForIntellectualPropertyLicense_lbl" xml:lang="en-US">Amount accrued for intellectual property license</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">NOTE 1 &#8211; THE COMPANY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 4 &#8211; INVENTORY, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">NOTE 5 &#8211; OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 6 &#8211; FIXED ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 7 &#8211; INTANGIBLE ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">NOTE 8&#8211; OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">NOTE 9 &#8211; DEBT</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_2_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">NOTE 10 &#8211; NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 12 &#8211; INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 13 &#8211; RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 14 - BUSINESS CONCENTRATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">NOTE 16 &#8211; SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US">Trade Accounts Receivable and Allowance for Doubtful Accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock" xlink:label="txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock" xlink:to="txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock_lbl" xml:lang="en-US">License Agreement with the Population Council</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LicenseAgreementWithKnightPolicyTextBlock" xlink:label="txmd_LicenseAgreementWithKnightPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseAgreementWithKnightPolicyTextBlock" xlink:to="txmd_LicenseAgreementWithKnightPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicenseAgreementWithKnightPolicyTextBlock_lbl" xml:lang="en-US">License Agreement with Knight</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Sales</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory Obsolescence Reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">The following table provides information about disaggregated revenue by product mix</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Inventory, net consists of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Other current assets consist of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Fixed assets, net consist of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2020 and December 31, 2019:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Other current liabilities consist of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">As of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of calculation of diluted net loss per share allocable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020 and 2019 are set forth in the table below.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">A summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September 30, 2020 is as follows</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of restricted stock units and performance stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:label="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:to="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_lbl" xml:lang="en-US">Supplemental lease information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities recorded on the balance sheet:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfSubsidiaries" xlink:label="txmd_NumberOfSubsidiaries" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSubsidiaries" xlink:to="txmd_NumberOfSubsidiaries_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfSubsidiaries_lbl" xml:lang="en-US">Number of subsidiaries</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:to="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_lbl" xml:lang="en-US">Minimum cash balance required under credit agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" xlink:to="txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_lbl" xml:lang="en-US">Minimum cash balance requirement under credit agreement before adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Net revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Assets or liabilities valued at fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2_lbl" xml:lang="en-US">Impairment of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Common stock, shares, issued (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:to="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_lbl" xml:lang="en-US">Return period of unsalable prescription products</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="txmd_ShelfLifeOfPrescriptionProducts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShelfLifeOfPrescriptionProducts" xlink:to="txmd_ShelfLifeOfPrescriptionProducts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShelfLifeOfPrescriptionProducts_lbl" xml:lang="en-US">Shelf life of prescription products following product expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MilestonePaymentUponFDAApproval" xlink:label="txmd_MilestonePaymentUponFDAApproval" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentUponFDAApproval" xlink:to="txmd_MilestonePaymentUponFDAApproval_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentUponFDAApproval_lbl" xml:lang="en-US">Milestone payment upon FDA Approval</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:to="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_lbl" xml:lang="en-US">Milestone payments (payment after release of first commercial batch)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xml:lang="en-US">License rights acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="txmd_NetSalesAmountPerStepbasedRoyalty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetSalesAmountPerStepbasedRoyalty" xlink:to="txmd_NetSalesAmountPerStepbasedRoyalty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NetSalesAmountPerStepbasedRoyalty_lbl" xml:lang="en-US">Net sales amount per step-based royalty</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_RoyaltyPercent" xlink:label="txmd_RoyaltyPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyPercent" xlink:to="txmd_RoyaltyPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RoyaltyPercent_lbl" xml:lang="en-US">Royalty (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xml:lang="en-US">Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xml:lang="en-US">Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" xlink:label="txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" xlink:to="txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_lbl" xml:lang="en-US">Milestone payments upon specified levels of cumulative net sales</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" xlink:label="txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" xlink:to="txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_lbl" xml:lang="en-US">Specified level one of cumulative net sales for milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" xlink:label="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" xlink:to="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_lbl" xml:lang="en-US">Specified level two of cumulative net sales for milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" xlink:label="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" xlink:to="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_lbl" xml:lang="en-US">Specified level three of cumulative net sales for milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:to="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_lbl" xml:lang="en-US">Maximum costs and expenses for post approval</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MilestonePaymentReceivedUponRegulatoryApproval" xlink:label="txmd_MilestonePaymentReceivedUponRegulatoryApproval" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentReceivedUponRegulatoryApproval" xlink:to="txmd_MilestonePaymentReceivedUponRegulatoryApproval_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentReceivedUponRegulatoryApproval_lbl" xml:lang="en-US">Milestone payment received upon regulatory approval</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Inventory valuation reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished products</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">TOTAL INVENTORY, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:to="txmd_PrepaidSalesAndMarketingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent_lbl" xml:lang="en-US">Prepaid sales and marketing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US">Debt financing fees on undrawn tranches (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaidManufacturing" xlink:label="txmd_PrepaidManufacturing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturing" xlink:to="txmd_PrepaidManufacturing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidManufacturing_lbl" xml:lang="en-US">Prepaid manufacturing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">TOTAL FIXED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">TOTAL FIXED ASSETS, NET</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="us-gaap_IndefiniteLivedTrademarks" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedTrademarks" xlink:to="us-gaap_IndefiniteLivedTrademarks_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedTrademarks_lbl" xml:lang="en-US">Indefinite-Lived Trademarks</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US">2020 (3 months)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfIssuedPatents" xlink:label="txmd_NumberOfIssuedPatents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfIssuedPatents_lbl" xml:lang="en-US">Number of issued patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll, bonuses and commission costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xml:lang="en-US">Allowance for coupons and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="us-gaap_AccruedMarketingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedMarketingCostsCurrent" xlink:to="us-gaap_AccruedMarketingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedMarketingCostsCurrent_lbl" xml:lang="en-US">Accrued sales and marketing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued compensated absences</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xml:lang="en-US">Allowance for wholesale distributor fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued legal and accounting expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="txmd_AccruedResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedResearchAndDevelopment" xlink:to="txmd_AccruedResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedResearchAndDevelopment_lbl" xml:lang="en-US">Accrued research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AccruedRebates" xlink:label="txmd_AccruedRebates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedRebates" xlink:to="txmd_AccruedRebates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedRebates_lbl" xml:lang="en-US">Accrued rebates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Debt discount and financing fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_2_lbl" xml:lang="en-US">TOTAL LONG-TERM DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" xlink:label="txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" xlink:to="txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_lbl" xml:lang="en-US">Line Of Credit Facility Undrawn Tranche No Longer Available</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LiborFloorRate" xlink:label="txmd_LiborFloorRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LiborFloorRate" xlink:to="txmd_LiborFloorRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LiborFloorRate_lbl" xml:lang="en-US">LIBOR floor rate</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrimeRateFloor" xlink:label="txmd_PrimeRateFloor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrimeRateFloor" xlink:to="txmd_PrimeRateFloor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrimeRateFloor_lbl" xml:lang="en-US">Prime rate floor</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfInstallmentPayments" xlink:label="txmd_NumberOfInstallmentPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfInstallmentPayments" xlink:to="txmd_NumberOfInstallmentPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfInstallmentPayments_lbl" xml:lang="en-US">Number of quarterly principal installment payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:label="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:to="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_lbl" xml:lang="en-US">Prepayment fee for first two years funding (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaymentFeeThirdYearFundingPercent" xlink:label="txmd_PrepaymentFeeThirdYearFundingPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeThirdYearFundingPercent" xlink:to="txmd_PrepaymentFeeThirdYearFundingPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeeThirdYearFundingPercent_lbl" xml:lang="en-US">Prepayment fee third year funding (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaymentFeeFourthYearFundingPercent" xlink:label="txmd_PrepaymentFeeFourthYearFundingPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeFourthYearFundingPercent" xlink:to="txmd_PrepaymentFeeFourthYearFundingPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeeFourthYearFundingPercent_lbl" xml:lang="en-US">Prepayment fee fourth year funding (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaymentFeeFifthYearFundingPercent" xlink:label="txmd_PrepaymentFeeFifthYearFundingPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeFifthYearFundingPercent" xlink:to="txmd_PrepaymentFeeFifthYearFundingPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeeFifthYearFundingPercent_lbl" xml:lang="en-US">Prepayment fee fifth year funding (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FacilityFeePaidPercent" xlink:label="txmd_FacilityFeePaidPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FacilityFeePaidPercent" xlink:to="txmd_FacilityFeePaidPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FacilityFeePaidPercent_lbl" xml:lang="en-US">Facility fee paid (percent)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:to="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_2_lbl" xml:lang="en-US">Minimum cash balance requirement under credit agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="txmd_NumberOfTranchesUnderTermLoanFacility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfTranchesUnderTermLoanFacility" xlink:to="txmd_NumberOfTranchesUnderTermLoanFacility_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfTranchesUnderTermLoanFacility_lbl" xml:lang="en-US">Number of tranches under term loan facility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xml:lang="en-US">Repayments of Lines of Credit</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaymentFeePercentage" xlink:label="txmd_PrepaymentFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeePercentage" xlink:to="txmd_PrepaymentFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeePercentage_lbl" xml:lang="en-US">Prepayment fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_RepaymentFeePercentage" xlink:label="txmd_RepaymentFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentFeePercentage" xlink:to="txmd_RepaymentFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentFeePercentage_lbl" xml:lang="en-US">Repayment fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest Expense, Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseBorrowings" xlink:to="us-gaap_InterestExpenseBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xml:lang="en-US">Interest Expense, Borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares under options, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of shares under options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of shares under options, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of shares under options, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of shares under options, cancelled forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, cancelled forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares under options, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of shares under options, vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life, vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of shares under options, unvested ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual life in years, unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair values, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares, vested/released</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, vested/released</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of shares, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of shares, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average grant date fair value, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_2_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:to="txmd_NumberOfStockOptionsExercisedInCashlessExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise_lbl" xml:lang="en-US">Number of stock options exercised in cashless exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:to="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_lbl" xml:lang="en-US">Number of common stock issued during period for stock options exercised in cashless exercise</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xml:lang="en-US">Weighted-average contractual remaining life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price of warrants (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:label="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:to="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_lbl" xml:lang="en-US">Number of stock issued in cashless exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_lbl" xml:lang="en-US">Range - exercise price of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Restricted Stock or Unit Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US">Amount billed</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US">Amounts due to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfCustomers" xlink:label="txmd_NumberOfCustomers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCustomers" xlink:to="txmd_NumberOfCustomers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfCustomers_lbl" xml:lang="en-US">Number of customers - revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right-of-use asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Short-term operating lease liability (included in Other current liabilities)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Long-term operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities for operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2020 (3 months)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationTable_lbl" xml:lang="en-US">Recorded Unconditional Purchase Obligation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationLineItems_lbl" xml:lang="en-US">Recorded Unconditional Purchase Obligation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="txmd_CapitalLeaseObligationsTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CapitalLeaseObligationsTerm_lbl" xml:lang="en-US">Non-cancelable operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NetRentableAreaLease" xlink:label="txmd_NetRentableAreaLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetRentableAreaLease" xlink:to="txmd_NetRentableAreaLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NetRentableAreaLease_lbl" xml:lang="en-US">Net rentable area</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_RentedAreaLease" xlink:label="txmd_RentedAreaLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RentedAreaLease" xlink:to="txmd_RentedAreaLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RentedAreaLease_lbl" xml:lang="en-US">Rented area lease</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AdditionalAreaOfLeaseOccupied" xlink:label="txmd_AdditionalAreaOfLeaseOccupied" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalAreaOfLeaseOccupied" xlink:to="txmd_AdditionalAreaOfLeaseOccupied_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdditionalAreaOfLeaseOccupied_lbl" xml:lang="en-US">Additional area of lease occupied</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:label="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:to="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber_lbl" xml:lang="en-US">Lessee operating lease existence of option to extend number</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:label="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:to="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_lbl" xml:lang="en-US">Lease not yet commenced (area)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SignificantSupplyCommitmentPercentagePayable" xlink:label="txmd_SignificantSupplyCommitmentPercentagePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SignificantSupplyCommitmentPercentagePayable" xlink:to="txmd_SignificantSupplyCommitmentPercentagePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SignificantSupplyCommitmentPercentagePayable_lbl" xml:lang="en-US">Significant supply commitment percentage payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_lbl" xml:lang="en-US">Minimum purchase commitment, 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_lbl" xml:lang="en-US">Minimum purchase commitment, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear_lbl" xml:lang="en-US">Minimum purchase commitment, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear_lbl" xml:lang="en-US">Minimum purchase commitment, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear_lbl" xml:lang="en-US">Minimum purchase commitment, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyMember" xlink:to="txmd_ImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ImvexxyMember_doc" xml:lang="en-US">Information about ImvexxyTm.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsMember" xlink:to="txmd_DomesticUSPatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSPatentsMember_doc" xml:lang="en-US">Domestic US Patents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsMember" xlink:to="txmd_ForeignPatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsMember_doc" xml:lang="en-US">Foreign Patents Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsBijuvaMember" xlink:to="txmd_DomesticPatentsBijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticPatentsBijuvaMember_doc" xml:lang="en-US">Domestic Patents Bijuva</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsBijuvaMember" xlink:to="txmd_ForeignPatentsBijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsBijuvaMember_doc" xml:lang="en-US">Foreign Patents BIJUVA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsImvexxyMember" xlink:to="txmd_DomesticUSPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSPatentsImvexxyMember_doc" xml:lang="en-US">Domestic US Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:to="txmd_DomesticUSUtilityPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSUtilityPatentsImvexxyMember_doc" xml:lang="en-US">Domestic US Utility Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSDesignPatentsImvexxyMember" xlink:to="txmd_DomesticUSDesignPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSDesignPatentsImvexxyMember_doc" xml:lang="en-US">Domestic US Design Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsImvexxyMember" xlink:to="txmd_ForeignPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsImvexxyMember_doc" xml:lang="en-US">Foreign Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentsImvexxyMember" xlink:to="txmd_ForeignUtilityPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignUtilityPatentsImvexxyMember_doc" xml:lang="en-US">Foreign Utility Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignDesignPatentsImvexxyMember" xlink:to="txmd_ForeignDesignPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignDesignPatentsImvexxyMember_doc" xml:lang="en-US">Foreign Design Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:to="txmd_DomesticUtilityPatentTransdermalPatchMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentTransdermalPatchMember_doc" xml:lang="en-US">Domestic Utility Patent Transdermal Patch</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:to="txmd_ForeignUtilityPatentTransdermalPatchMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignUtilityPatentTransdermalPatchMember_doc" xml:lang="en-US">Foreign Utility Patent Transdermal Patch</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentOperaMember" xlink:to="txmd_DomesticUtilityPatentOperaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentOperaMember_doc" xml:lang="en-US">Domestic Utility Patent Opera</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTx009HRMember" xlink:to="txmd_DomesticUtilityPatentTx009HRMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentTx009HRMember_doc" xml:lang="en-US">Domestic Utility Patent TX009HR</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnoveraMember" xlink:to="txmd_AnnoveraMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnoveraMember_doc" xml:lang="en-US">The drug name.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep1Member" xlink:to="txmd_CouncilLicenseAgreementStep1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementStep1Member_doc" xml:lang="en-US">Council License Agreement Step 1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyPercent" xlink:to="txmd_RoyaltyPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RoyaltyPercent_doc" xml:lang="en-US">The percent of the net sales to be paid as royalty per license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep2Member" xlink:to="txmd_CouncilLicenseAgreementStep2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementStep2Member_doc" xml:lang="en-US">Council License Agreement Step 2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep3Member" xlink:to="txmd_CouncilLicenseAgreementStep3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementStep3Member_doc" xml:lang="en-US">Council License Agreement Step 3</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xml:lang="en-US">The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:to="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_doc" xml:lang="en-US">The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xml:lang="en-US">Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedResearchAndDevelopment" xlink:to="txmd_AccruedResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedResearchAndDevelopment_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedRebates" xlink:to="txmd_AccruedRebates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedRebates_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementMember" xlink:to="txmd_FinancingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementMember_doc" xml:lang="en-US">Represents member of financing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierTwoConcentrationRiskMember" xlink:to="txmd_SupplierTwoConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SupplierTwoConcentrationRiskMember_doc" xml:lang="en-US">Supplier Two Concentration Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierThreeConcentrationRiskMember" xlink:to="txmd_SupplierThreeConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SupplierThreeConcentrationRiskMember_doc" xml:lang="en-US">Supplier Three Concentration Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FourCustomersConcentrationRiskMember" xlink:to="txmd_FourCustomersConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FourCustomersConcentrationRiskMember_doc" xml:lang="en-US">Four Customers Concentration Risk</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPillPackRiskMember" xlink:to="txmd_CustomerConcentrationPillPackRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationPillPackRiskMember_doc" xml:lang="en-US">Major customers in concentration of sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:to="txmd_CustomerConcentrationAmerisourceBergenRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationAmerisourceBergenRiskMember_doc" xml:lang="en-US">Custome rConcentration AmerisourceBergen Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:to="txmd_CustomerConcentrationCardinalHealthRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationCardinalHealthRiskMember_doc" xml:lang="en-US">Customer Concentration Cardinal Health Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetRentableAreaLease" xlink:to="txmd_NetRentableAreaLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NetRentableAreaLease_doc" xml:lang="en-US">Net rentable area as defined in lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RentedAreaLease" xlink:to="txmd_RentedAreaLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RentedAreaLease_doc" xml:lang="en-US">Rented area as defined in lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:to="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_doc" xml:lang="en-US">Future rented area to be occupied for administrative office space as defined in lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:to="txmd_NumberOfStockOptionsExercisedInCashlessExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise_doc" xml:lang="en-US">Number of options exercised in the cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:to="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_doc" xml:lang="en-US">Number of shares of common stock issued attributable to stock options exercised in cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xml:lang="en-US">This item provides the weighted-average contractual remaining life of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsMember" xlink:to="txmd_WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsMember_doc" xml:lang="en-US">Warrants Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which warrant holders can acquire the shares reserved for issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultant2Member" xlink:to="txmd_OutsideConsultant2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OutsideConsultant2Member_doc" xml:lang="en-US">A person who provides consutling services to the Company.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:to="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_doc" xml:lang="en-US">Number of shares of common stock issued attributable to warrants exercised in cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xml:lang="en-US">Long Term Incentive Compensation Plan 2009 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_doc" xml:lang="en-US">Non Qualified 2012 Stock Incentive Plan Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Plan2019Member" xlink:to="txmd_Plan2019Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Plan2019Member_doc" xml:lang="en-US">New 2019 Plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalAreaOfLeaseOccupied" xlink:to="txmd_AdditionalAreaOfLeaseOccupied_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdditionalAreaOfLeaseOccupied_doc" xml:lang="en-US">Additional rented area occupied under the lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SignificantSupplyCommitmentPercentagePayable" xlink:to="txmd_SignificantSupplyCommitmentPercentagePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SignificantSupplyCommitmentPercentagePayable_doc" xml:lang="en-US">Percent of the difference between the total amount we would have paid to supplier if the minimum requirement had been fulfilled and the sum of all purchases of our products from supplier during the contract year, required to be paid to supplier.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtTrancheAxis" xlink:to="txmd_DebtTrancheAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DebtTrancheAxis_doc" xml:lang="en-US">Portions of the Credit and Security Agreement to draw funds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheTwoMember" xlink:to="txmd_TrancheTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TrancheTwoMember_doc" xml:lang="en-US">Tranche Two as defined in financing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LiborFloorRate" xlink:to="txmd_LiborFloorRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LiborFloorRate_doc" xml:lang="en-US">Represents libor floor rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:to="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_doc" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for first two years following the initial funding date of the applicable borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeThirdYearFundingPercent" xlink:to="txmd_PrepaymentFeeThirdYearFundingPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeeThirdYearFundingPercent_doc" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for third year following the initial funding date of the applicable borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeFourthYearFundingPercent" xlink:to="txmd_PrepaymentFeeFourthYearFundingPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeeFourthYearFundingPercent_doc" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for fourth year following the initial funding date of the applicable borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeFifthYearFundingPercent" xlink:to="txmd_PrepaymentFeeFifthYearFundingPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeeFifthYearFundingPercent_doc" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for fifth year following the initial funding date of the applicable borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FacilityFeePaidPercent" xlink:to="txmd_FacilityFeePaidPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FacilityFeePaidPercent_doc" xml:lang="en-US">The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:to="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_doc" xml:lang="en-US">The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfTranchesUnderTermLoanFacility" xlink:to="txmd_NumberOfTranchesUnderTermLoanFacility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfTranchesUnderTermLoanFacility_doc" xml:lang="en-US">The number of seperate tranches under terms of the Credit Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentFeePercentage" xlink:to="txmd_RepaymentFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentFeePercentage_doc" xml:lang="en-US">The repayment fee, expressed as a percentage of the tranche funding being repaid.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MidCapAgreementMember" xlink:to="txmd_MidCapAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MidCapAgreementMember_doc" xml:lang="en-US">Represents member of Mid Cap agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentUponFDAApproval" xlink:to="txmd_MilestonePaymentUponFDAApproval_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentUponFDAApproval_doc" xml:lang="en-US">The amount of milestone payments upon FDA approval.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaMember" xlink:to="txmd_BijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_BijuvaMember_doc" xml:lang="en-US">BIJUVA [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CapitalLeaseObligationsTerm_doc" xml:lang="en-US">The total term (in months) of the company's outstanding lease obligation.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DebtTrancheDomain" xlink:label="txmd_DebtTrancheDomain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtTrancheDomain" xlink:to="txmd_DebtTrancheDomain_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DebtTrancheDomain_doc" xml:lang="en-US">DebtTrancheDomain</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseRights" xlink:to="txmd_LicenseRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LicenseRights_doc" xml:lang="en-US">The amount of license rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:to="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_doc" xml:lang="en-US">The amount of milestone payments payable after release of first commercial batch.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetSalesAmountPerStepbasedRoyalty" xlink:to="txmd_NetSalesAmountPerStepbasedRoyalty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NetSalesAmountPerStepbasedRoyalty_doc" xml:lang="en-US">The net sales amount as defined in license agreement for step-based royalty payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NoncashOperatingLeaseExpense" xlink:to="txmd_NoncashOperatingLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NoncashOperatingLeaseExpense_doc" xml:lang="en-US">Amount of expense related to operating lease costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfInstallmentPayments" xlink:to="txmd_NumberOfInstallmentPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfInstallmentPayments_doc" xml:lang="en-US">Number of principal installment payments under credit and security agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:to="txmd_PrepaidSalesAndMarketingCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent_doc" xml:lang="en-US">It refers to the amount of prepaid sales and marketing costs incurred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrescriptionVitaminsMember" xlink:to="txmd_PrescriptionVitaminsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrescriptionVitaminsMember_doc" xml:lang="en-US">Information about Prescription Vitamins.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_RepaymentOfDebtWithNewCreditFacility" xlink:label="txmd_RepaymentOfDebtWithNewCreditFacility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentOfDebtWithNewCreditFacility" xlink:to="txmd_RepaymentOfDebtWithNewCreditFacility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentOfDebtWithNewCreditFacility_doc" xml:lang="en-US">Amount of the repayment of debt including all fees by borrowing funds from a new credit facility.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_doc" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire unvested shares reserved for issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCustomers" xlink:to="txmd_NumberOfCustomers_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfCustomers_doc" xml:lang="en-US">Number of customers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeePercentage" xlink:to="txmd_PrepaymentFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeePercentage_doc" xml:lang="en-US">The prepayment fee, expressed as a percentage of the tranche funding being repaid.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSubsidiaries" xlink:to="txmd_NumberOfSubsidiaries_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfSubsidiaries_doc" xml:lang="en-US">Number of subsidiaires for period reported.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfIssuedPatents_doc" xml:lang="en-US">Number of issued patents.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:to="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_doc" xml:lang="en-US">Disclosure of supplementary lease and cash flow information.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:to="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturing" xlink:to="txmd_PrepaidManufacturing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidManufacturing_doc" xml:lang="en-US">Prepaid manufacturing costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:to="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_doc" xml:lang="en-US">Period the company accepts returns of unsalable prescription products from customers following product expiration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShelfLifeOfPrescriptionProducts" xlink:to="txmd_ShelfLifeOfPrescriptionProducts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShelfLifeOfPrescriptionProducts_doc" xml:lang="en-US">Period shelf life of prescription products from date of manufacture.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VitaminsAndImvexxyMember" xlink:to="txmd_VitaminsAndImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_VitaminsAndImvexxyMember_doc" xml:lang="en-US">Vitamins and IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaAndAnnoveraMember" xlink:to="txmd_BijuvaAndAnnoveraMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_BijuvaAndAnnoveraMember_doc" xml:lang="en-US">BIJUVA and ANNOVERA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:to="txmd_DomesticPatentsProgesteroneFormulationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticPatentsProgesteroneFormulationsMember_doc" xml:lang="en-US">Domestic Patents Progesterone Formulations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:to="txmd_ForeignPatentsProgesteroneFormulationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsProgesteroneFormulationsMember_doc" xml:lang="en-US">Foreign Patents Progesterone Formulations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:to="txmd_CustomerConcentrationMcKessonCorporationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationMcKessonCorporationRiskMember_doc" xml:lang="en-US">McKesson Corporation - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" xlink:label="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" xlink:to="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember_doc" xml:lang="en-US">Pharmacy Innovations PA - Major Customer</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:to="txmd_ImvexxyBijuvaAndAnnoveraMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ImvexxyBijuvaAndAnnoveraMember_doc" xml:lang="en-US">IMVEXXY, BIJUVA and ANNOVERA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsCashlessExerciseMember" xlink:to="txmd_WarrantsCashlessExerciseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsCashlessExerciseMember_doc" xml:lang="en-US">Warrants - Cashless Exercise</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_doc" xml:lang="en-US">The exercise price as of the balance sheet date at which grantees can acquire the shares for options outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock" xlink:to="txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock_doc" xml:lang="en-US">License Agreement With Population Council</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrimeRateFloor" xlink:to="txmd_PrimeRateFloor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrimeRateFloor_doc" xml:lang="en-US">Prime rate floor.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:to="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber_doc" xml:lang="en-US">Number of options to extend lease.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_WriteOffOfPatentAndTrademarkCosts" xlink:label="txmd_WriteOffOfPatentAndTrademarkCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WriteOffOfPatentAndTrademarkCosts" xlink:to="txmd_WriteOffOfPatentAndTrademarkCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WriteOffOfPatentAndTrademarkCosts_doc" xml:lang="en-US">The amount represent write off of patent and trademark costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IncreaseDecreaseInSecurityDeposit" xlink:to="txmd_IncreaseDecreaseInSecurityDeposit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IncreaseDecreaseInSecurityDeposit_doc" xml:lang="en-US">The amount represent increase decrease in security deposit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementMember" xlink:to="txmd_CouncilLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementMember_doc" xml:lang="en-US">The member represent council license agreement.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_OperaPatentMember" xlink:label="txmd_OperaPatentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperaPatentMember" xlink:to="txmd_OperaPatentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OperaPatentMember_doc" xml:lang="en-US">The member represent opera patent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" xlink:to="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember_doc" xml:lang="en-US">The member represent domestic utility patent topical cream candidates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaycheckProtectionProgramLoanMember" xlink:to="txmd_PaycheckProtectionProgramLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PaycheckProtectionProgramLoanMember_doc" xml:lang="en-US">The member represent paycheck protection program loan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockOptionsMember" xlink:to="txmd_StockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockOptionsMember_doc" xml:lang="en-US">The member represent stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PerformanceStockUnitsMember" xlink:to="txmd_PerformanceStockUnitsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PerformanceStockUnitsMember_doc" xml:lang="en-US">The member represent performance stock units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NewSharesMember" xlink:to="txmd_NewSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NewSharesMember_doc" xml:lang="en-US">The member represent new shares.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_StatisticalMeasurementAxis" xlink:label="txmd_StatisticalMeasurementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StatisticalMeasurementAxis" xlink:to="txmd_StatisticalMeasurementAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StatisticalMeasurementAxis_doc" xml:lang="en-US">The axis represent statistical measurement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierOneConcentrationRiskMember" xlink:to="txmd_SupplierOneConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SupplierOneConcentrationRiskMember_doc" xml:lang="en-US">The member represent supplier one concentration risk.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SupplierFourConcentrationRiskMember" xlink:label="txmd_SupplierFourConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierFourConcentrationRiskMember" xlink:to="txmd_SupplierFourConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SupplierFourConcentrationRiskMember_doc" xml:lang="en-US">The member represent supplier four concentration risk.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmortizationOfIntellectualPropertyLicenseFee" xlink:to="txmd_AmortizationOfIntellectualPropertyLicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AmortizationOfIntellectualPropertyLicenseFee_doc" xml:lang="en-US">The amount represents amortization of intellectual property license fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmountAccruedForIntellectualPropertyLicense" xlink:to="txmd_AmountAccruedForIntellectualPropertyLicense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AmountAccruedForIntellectualPropertyLicense_doc" xml:lang="en-US">The amount represents amount accrued for intellectual property license.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" xlink:to="txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_doc" xml:lang="en-US">The amount represents specified level one of cumulative net sales for milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" xlink:to="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_doc" xml:lang="en-US">The amount represents specified level two of cumulative net sales for milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" xlink:to="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_doc" xml:lang="en-US">The amount represents specified level three of cumulative net sales for milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xml:lang="en-US">The percentage of annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NonextensionOfLineCreditTranche" xlink:label="txmd_NonextensionOfLineCreditTranche" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonextensionOfLineCreditTranche" xlink:to="txmd_NonextensionOfLineCreditTranche_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonextensionOfLineCreditTranche_doc" xml:lang="en-US">The amount represents nonextension of line credit tranche.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseAgreementWithKnightPolicyTextBlock" xlink:to="txmd_LicenseAgreementWithKnightPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LicenseAgreementWithKnightPolicyTextBlock_doc" xml:lang="en-US">Disclosure of accounting policy for license agreement with knight.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantGrantedInRelationToFinancingAgreement" xlink:to="txmd_WarrantGrantedInRelationToFinancingAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantGrantedInRelationToFinancingAgreement_doc" xml:lang="en-US">The amount of a warrant granted in relation to financing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" xlink:to="txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_doc" xml:lang="en-US">Milestone payments due upon specified levels of cumulative net sales for under agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentReceivedUponRegulatoryApproval" xlink:to="txmd_MilestonePaymentReceivedUponRegulatoryApproval_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentReceivedUponRegulatoryApproval_doc" xml:lang="en-US">The amount of milestone payment received upon regulatory approval.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_KnightLicenseAgreementMember" xlink:to="txmd_KnightLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_KnightLicenseAgreementMember_doc" xml:lang="en-US">Knight License Agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsEstradiolAndProgesteroneCandidatesMember" xlink:to="txmd_DomesticPatentsEstradiolAndProgesteroneCandidatesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticPatentsEstradiolAndProgesteroneCandidatesMember_doc" xml:lang="en-US">Domestic Patents Estradiol and Progesterone Candidates</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TwoTranchesMember" xlink:to="txmd_TwoTranchesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TwoTranchesMember_doc" xml:lang="en-US">Two Tranches</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LenderWarrantsMember" xlink:to="txmd_LenderWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LenderWarrantsMember_doc" xml:lang="en-US">Lender Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EmployeeStockPurchasePlanMember" xlink:to="txmd_EmployeeStockPurchasePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_EmployeeStockPurchasePlanMember_doc" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CatalentMember" xlink:to="txmd_CatalentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CatalentMember_doc" xml:lang="en-US">Catalent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmericanInternationalGroupMember" xlink:to="txmd_AmericanInternationalGroupMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AmericanInternationalGroupMember_doc" xml:lang="en-US">American International Group</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ThreeCustomersConcentrationRiskMember" xlink:to="txmd_ThreeCustomersConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ThreeCustomersConcentrationRiskMember_doc" xml:lang="en-US">Three Customers Concentration Risk</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksMember" xlink:to="txmd_MultipleTrademarksMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleTrademarksMember_doc" xml:lang="en-US">Multiple Trademarks</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPIServicesMember" xlink:to="txmd_CustomerConcentrationPIServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationPIServicesMember_doc" xml:lang="en-US">PI Services - Major Customer</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheThreeMember" xlink:to="txmd_TrancheThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TrancheThreeMember_doc" xml:lang="en-US">Tranche Three as defined in financing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" xlink:to="txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_doc" xml:lang="en-US">The amount of an undrawn tranche under a financing agreement that is no longer available.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment6Member" xlink:to="txmd_FinancingAgreementAmendment6Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment6Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 6</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment6Period1Member" xlink:to="txmd_FinancingAgreementAmendment6Period1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment6Period1Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 6 - Through December 31, 2020</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment6Period2Member" xlink:to="txmd_FinancingAgreementAmendment6Period2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment6Period2Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 6 - After December 31, 2020</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" xlink:to="txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_doc" xml:lang="en-US">The minimum cash balance the Borrower must maintain under the credit and secuirty agreement before adjustment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_2_lbl" xml:lang="en-US">Other Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantGrantedInRelationToFinancingAgreement" xlink:to="txmd_WarrantGrantedInRelationToFinancingAgreement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantGrantedInRelationToFinancingAgreement_3_lbl" xml:lang="en-US">Warrant Granted In Relation To Financing Agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>txmd-20200930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Cover" xlink:href="txmd-20200930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20200930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20200930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20200930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="txmd-20200930.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20200930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1Company" xlink:href="txmd-20200930.xsd#Note1Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20200930.xsd#Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20200930.xsd#Note3SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4InventoryNet" xlink:href="txmd-20200930.xsd#Note4InventoryNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:href="txmd-20200930.xsd#Note5OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:href="txmd-20200930.xsd#Note6FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNet" xlink:href="txmd-20200930.xsd#Note7IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:href="txmd-20200930.xsd#Note8OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9Debt" xlink:href="txmd-20200930.xsd#Note9Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:href="txmd-20200930.xsd#Note10NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:href="txmd-20200930.xsd#Note11StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:href="txmd-20200930.xsd#Note12IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:href="txmd-20200930.xsd#Note13RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14-BusinessConcentrations" xlink:href="txmd-20200930.xsd#Note14-BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:href="txmd-20200930.xsd#Note15CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:href="txmd-20200930.xsd#Note16SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20200930.xsd#Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20200930.xsd#Note3SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4InventoryNetTables" xlink:href="txmd-20200930.xsd#Note4InventoryNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:href="txmd-20200930.xsd#Note5OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:href="txmd-20200930.xsd#Note6FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables" xlink:href="txmd-20200930.xsd#Note7IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:href="txmd-20200930.xsd#Note8OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtTables" xlink:href="txmd-20200930.xsd#Note9DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:href="txmd-20200930.xsd#Note10NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:href="txmd-20200930.xsd#Note11StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:href="txmd-20200930.xsd#Note15CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:href="txmd-20200930.xsd#Note1CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:href="txmd-20200930.xsd#Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:href="txmd-20200930.xsd#FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20200930.xsd#Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails" xlink:href="txmd-20200930.xsd#InventoryNetConsistsOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:href="txmd-20200930.xsd#OtherCurrentAssetsConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:href="txmd-20200930.xsd#FixedAssetsNetConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:href="txmd-20200930.xsd#Note6FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details" xlink:href="txmd-20200930.xsd#FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:href="txmd-20200930.xsd#EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative" xlink:href="txmd-20200930.xsd#Note7IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:href="txmd-20200930.xsd#OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:href="txmd-20200930.xsd#AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:href="txmd-20200930.xsd#Note9DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:href="txmd-20200930.xsd#ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details" xlink:href="txmd-20200930.xsd#RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails" xlink:href="txmd-20200930.xsd#SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:href="txmd-20200930.xsd#ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:href="txmd-20200930.xsd#Note11StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:href="txmd-20200930.xsd#Note13RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20200930.xsd#Note14-BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:href="txmd-20200930.xsd#SupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:href="txmd-20200930.xsd#FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20200930.xsd#Note15CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:href="txmd-20200930.xsd#Note16SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LicenseRights" xlink:label="loc_txmdLicenseRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_txmdLicenseRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="loc_us-gaapOtherAssetsMiscellaneousNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsMiscellaneousNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaapLongTermDebtNoncurrentAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (DEFICIT) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="loc_txmdNoncashOperatingLeaseExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_txmdNoncashOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaapOperatingLeaseImpairmentLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AmortizationOfIntellectualPropertyLicenseFee" xlink:label="loc_txmdAmortizationOfIntellectualPropertyLicenseFee" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_txmdAmortizationOfIntellectualPropertyLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_IncreaseDecreaseInSecurityDeposit" xlink:label="loc_txmdIncreaseDecreaseInSecurityDeposit" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_txmdIncreaseDecreaseInSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_WarrantGrantedInRelationToFinancingAgreement" xlink:label="loc_txmdWarrantGrantedInRelationToFinancingAgreement" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_txmdWarrantGrantedInRelationToFinancingAgreement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AmountAccruedForIntellectualPropertyLicense" xlink:label="loc_txmdAmountAccruedForIntellectualPropertyLicense" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_txmdAmountAccruedForIntellectualPropertyLicense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1Company" xlink:title="00000007 - Disclosure - NOTE 1 &#8211; THE COMPANY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000008 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4InventoryNet" xlink:title="00000010 - Disclosure - NOTE 4 &#8211; INVENTORY, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:title="00000011 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:title="00000012 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNet" xlink:title="00000013 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - NOTE 8&#8211; OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9Debt" xlink:title="00000015 - Disclosure - NOTE 9 &#8211; DEBT">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:title="00000016 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:title="00000017 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:title="00000018 - Disclosure - NOTE 12 &#8211; INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:title="00000019 - Disclosure - NOTE 13 &#8211; RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14-BusinessConcentrations" xlink:title="00000020 - Disclosure - NOTE 14 - BUSINESS CONCENTRATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:title="00000022 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock" xlink:label="loc_txmdLicenseAgreementWithPopulationCouncilPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_txmdLicenseAgreementWithPopulationCouncilPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LicenseAgreementWithKnightPolicyTextBlock" xlink:label="loc_txmdLicenseAgreementWithKnightPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_txmdLicenseAgreementWithKnightPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaapCostOfSalesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCostOfSalesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4InventoryNetTables" xlink:title="00000025 - Disclosure - NOTE 4 &#8211; INVENTORY, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:title="00000027 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables" xlink:title="00000028 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - NOTE 8&#8211; OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtTables" xlink:title="00000030 - Disclosure - NOTE 9 &#8211; DEBT (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:title="00000031 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:title="00000032 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:label="loc_txmdScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:title="00000034 - Disclosure - NOTE 1 &#8211; THE COMPANY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfSubsidiaries" xlink:label="loc_txmdNumberOfSubsidiaries" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_txmdNumberOfSubsidiaries" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:title="00000035 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Member" xlink:label="loc_txmdFinancingAgreementAmendment6Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Period1Member" xlink:label="loc_txmdFinancingAgreementAmendment6Period1Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Period1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Period2Member" xlink:label="loc_txmdFinancingAgreementAmendment6Period2Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Period2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:title="00000036 - Disclosure - The following table provides information about disaggregated revenue by product mix (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrescriptionVitaminsMember" xlink:label="loc_txmdPrescriptionVitaminsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdPrescriptionVitaminsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ImvexxyMember" xlink:label="loc_txmdImvexxyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_BijuvaMember" xlink:label="loc_txmdBijuvaMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000037 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaapTrademarksAndTradeNamesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksAndTradeNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtProductOrServiceAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_VitaminsAndImvexxyMember" xlink:label="loc_txmdVitaminsAndImvexxyMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdVitaminsAndImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_BijuvaAndAnnoveraMember" xlink:label="loc_txmdBijuvaAndAnnoveraMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaAndAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CouncilLicenseAgreementMember" xlink:label="loc_txmdCouncilLicenseAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CouncilLicenseAgreementStep1Member" xlink:label="loc_txmdCouncilLicenseAgreementStep1Member" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CouncilLicenseAgreementStep2Member" xlink:label="loc_txmdCouncilLicenseAgreementStep2Member" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CouncilLicenseAgreementStep3Member" xlink:label="loc_txmdCouncilLicenseAgreementStep3Member" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_KnightLicenseAgreementMember" xlink:label="loc_txmdKnightLicenseAgreementMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdKnightLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmdShelfLifeOfPrescriptionProducts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdShelfLifeOfPrescriptionProducts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MilestonePaymentUponFDAApproval" xlink:label="loc_txmdMilestonePaymentUponFDAApproval" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdMilestonePaymentUponFDAApproval" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AmortizationOfIntellectualPropertyLicenseFee" xlink:label="loc_txmdAmortizationOfIntellectualPropertyLicenseFee" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdAmortizationOfIntellectualPropertyLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="loc_txmdNetSalesAmountPerStepbasedRoyalty" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdNetSalesAmountPerStepbasedRoyalty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_RoyaltyPercent" xlink:label="loc_txmdRoyaltyPercent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdRoyaltyPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" xlink:label="loc_txmdMilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdMilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" xlink:label="loc_txmdSpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdSpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" xlink:label="loc_txmdSpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdSpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" xlink:label="loc_txmdSpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdSpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MilestonePaymentReceivedUponRegulatoryApproval" xlink:label="loc_txmdMilestonePaymentReceivedUponRegulatoryApproval" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdMilestonePaymentReceivedUponRegulatoryApproval" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails" xlink:title="00000038 - Disclosure - Inventory, net consists of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaapInventoryRawMaterialsAndSupplies" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterialsAndSupplies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:title="00000039 - Disclosure - Other current assets consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="loc_txmdPrepaidSalesAndMarketingCostsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_txmdPrepaidSalesAndMarketingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaidManufacturing" xlink:label="loc_txmdPrepaidManufacturing" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_txmdPrepaidManufacturing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:title="00000040 - Disclosure - Fixed assets, net consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:title="00000041 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details" xlink:title="00000042 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2020 and December 31, 2019: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MultipleTrademarksMember" xlink:label="loc_txmdMultipleTrademarksMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="loc_us-gaapIndefiniteLivedTrademarks" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedTrademarks" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:title="00000043 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative" xlink:title="00000044 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUSPatentsMember" xlink:label="loc_txmdDomesticUSPatentsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignPatentsMember" xlink:label="loc_txmdForeignPatentsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticPatentsBijuvaMember" xlink:label="loc_txmdDomesticPatentsBijuvaMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignPatentsBijuvaMember" xlink:label="loc_txmdForeignPatentsBijuvaMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticPatentsEstradiolAndProgesteroneCandidatesMember" xlink:label="loc_txmdDomesticPatentsEstradiolAndProgesteroneCandidatesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsEstradiolAndProgesteroneCandidatesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUSPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSPatentsImvexxyMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSUtilityPatentsImvexxyMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSUtilityPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUSDesignPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSDesignPatentsImvexxyMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSDesignPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignPatentsImvexxyMember" xlink:label="loc_txmdForeignPatentsImvexxyMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignUtilityPatentsImvexxyMember" xlink:label="loc_txmdForeignUtilityPatentsImvexxyMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignDesignPatentsImvexxyMember" xlink:label="loc_txmdForeignDesignPatentsImvexxyMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignDesignPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" xlink:label="loc_txmdDomesticUtilityPatentTopicalCreamCandidatesMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTopicalCreamCandidatesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdDomesticUtilityPatentTransdermalPatchMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTransdermalPatchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdForeignUtilityPatentTransdermalPatchMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentTransdermalPatchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUtilityPatentTx009HRMember" xlink:label="loc_txmdDomesticUtilityPatentTx009HRMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTx009HRMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:label="loc_txmdDomesticPatentsProgesteroneFormulationsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsProgesteroneFormulationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:label="loc_txmdForeignPatentsProgesteroneFormulationsMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsProgesteroneFormulationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DomesticUtilityPatentOperaMember" xlink:label="loc_txmdDomesticUtilityPatentOperaMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentOperaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNumberOfIssuedPatents" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:title="00000045 - Disclosure - Other current liabilities consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaapAccruedMarketingCostsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedMarketingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="loc_txmdAccruedResearchAndDevelopment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdAccruedResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AccruedRebates" xlink:label="loc_txmdAccruedRebates" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdAccruedRebates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:title="00000046 - Disclosure - As of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:title="00000047 - Disclosure - NOTE 9 &#8211; DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaapSecuredDebtMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapSecuredDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdFinancingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MidCapAgreementMember" xlink:label="loc_txmdMidCapAgreementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdMidCapAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DebtTrancheAxis" xlink:label="loc_txmdDebtTrancheAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_txmdDebtTrancheAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmdDebtTrancheDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheAxis" xlink:to="loc_txmdDebtTrancheDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_TrancheTwoMember" xlink:label="loc_txmdTrancheTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_TrancheThreeMember" xlink:label="loc_txmdTrancheThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_TwoTranchesMember" xlink:label="loc_txmdTwoTranchesMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTwoTranchesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtProductOrServiceAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:label="loc_txmdImvexxyBijuvaAndAnnoveraMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyBijuvaAndAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Period1Member" xlink:label="loc_txmdFinancingAgreementAmendment6Period1Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Period1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LenderWarrantsMember" xlink:label="loc_txmdLenderWarrantsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdLenderWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PaycheckProtectionProgramLoanMember" xlink:label="loc_txmdPaycheckProtectionProgramLoanMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_txmdPaycheckProtectionProgramLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" xlink:label="loc_txmdLineOfCreditFacilityUndrawnTrancheNoLongerAvailable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdLineOfCreditFacilityUndrawnTrancheNoLongerAvailable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LiborFloorRate" xlink:label="loc_txmdLiborFloorRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdLiborFloorRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrimeRateFloor" xlink:label="loc_txmdPrimeRateFloor" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrimeRateFloor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfInstallmentPayments" xlink:label="loc_txmdNumberOfInstallmentPayments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfInstallmentPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:label="loc_txmdPrepaymentFeeForFirstTwoYearsFundingPercent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeForFirstTwoYearsFundingPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaymentFeeThirdYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeThirdYearFundingPercent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeThirdYearFundingPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaymentFeeFourthYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeFourthYearFundingPercent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeFourthYearFundingPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaymentFeeFifthYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeFifthYearFundingPercent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeFifthYearFundingPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FacilityFeePaidPercent" xlink:label="loc_txmdFacilityFeePaidPercent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdFacilityFeePaidPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="loc_txmdNumberOfTranchesUnderTermLoanFacility" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfTranchesUnderTermLoanFacility" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PrepaymentFeePercentage" xlink:label="loc_txmdPrepaymentFeePercentage" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_RepaymentFeePercentage" xlink:label="loc_txmdRepaymentFeePercentage" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaapDeferredFinanceCostsGross" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaapInterestExpenseBorrowings" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:title="00000048 - Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_StockOptionsMember" xlink:label="loc_txmdStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_txmdStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_PerformanceStockUnitsMember" xlink:label="loc_txmdPerformanceStockUnitsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_txmdPerformanceStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details" xlink:title="00000049 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020 and 2019 are set forth in the table below. (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails" xlink:title="00000050 - Disclosure - A summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September 30, 2020 is as follows (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:title="00000051 - Disclosure - Schedule of restricted stock units and performance stock units (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:title="00000052 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_WarrantsMember" xlink:label="loc_txmdWarrantsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LenderWarrantsMember" xlink:label="loc_txmdLenderWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdLenderWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmdOutsideConsultant2Member" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultant2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_WarrantsCashlessExerciseMember" xlink:label="loc_txmdWarrantsCashlessExerciseMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsCashlessExerciseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_Plan2019Member" xlink:label="loc_txmdPlan2019Member" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NewSharesMember" xlink:label="loc_txmdNewSharesMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNewSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_EmployeeStockPurchasePlanMember" xlink:label="loc_txmdEmployeeStockPurchasePlanMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdEmployeeStockPurchasePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:label="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:title="00000053 - Disclosure - NOTE 13 &#8211; RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CatalentMember" xlink:label="loc_txmdCatalentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdCatalentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AmericanInternationalGroupMember" xlink:label="loc_txmdAmericanInternationalGroupMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdAmericanInternationalGroupMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative" xlink:title="00000054 - Disclosure - NOTE 14 - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SupplierOneConcentrationRiskMember" xlink:label="loc_txmdSupplierOneConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierOneConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SupplierTwoConcentrationRiskMember" xlink:label="loc_txmdSupplierTwoConcentrationRiskMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierTwoConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SupplierThreeConcentrationRiskMember" xlink:label="loc_txmdSupplierThreeConcentrationRiskMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierThreeConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_ThreeCustomersConcentrationRiskMember" xlink:label="loc_txmdThreeCustomersConcentrationRiskMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdThreeCustomersConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FourCustomersConcentrationRiskMember" xlink:label="loc_txmdFourCustomersConcentrationRiskMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdFourCustomersConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CustomerConcentrationPillPackRiskMember" xlink:label="loc_txmdCustomerConcentrationPillPackRiskMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPillPackRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:label="loc_txmdCustomerConcentrationCardinalHealthRiskMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationCardinalHealthRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:label="loc_txmdCustomerConcentrationMcKessonCorporationRiskMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationMcKessonCorporationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:label="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CustomerConcentrationPIServicesMember" xlink:label="loc_txmdCustomerConcentrationPIServicesMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPIServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NumberOfCustomers" xlink:label="loc_txmdNumberOfCustomers" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_txmdNumberOfCustomers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:title="00000055 - Disclosure - Supplemental lease information (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:title="00000056 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000057 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CatalentMember" xlink:label="loc_txmdCatalentMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_txmdCatalentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="loc_txmdCapitalLeaseObligationsTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdCapitalLeaseObligationsTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_NetRentableAreaLease" xlink:label="loc_txmdNetRentableAreaLease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdNetRentableAreaLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_RentedAreaLease" xlink:label="loc_txmdRentedAreaLease" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdRentedAreaLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_AdditionalAreaOfLeaseOccupied" xlink:label="loc_txmdAdditionalAreaOfLeaseOccupied" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdAdditionalAreaOfLeaseOccupied" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:label="loc_txmdLesseeOperatingLeaseExistenceOfOptionToExtendNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdLesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:label="loc_txmdLesseeOperatingLeaseLeaseNotYetCommencedArea" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdLesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_SignificantSupplyCommitmentPercentagePayable" xlink:label="loc_txmdSignificantSupplyCommitmentPercentagePayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdSignificantSupplyCommitmentPercentagePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueWithinOneYear" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInSecondYear" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInThirdYear" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInThirdYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInFourthYear" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInFourthYear" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:title="00000058 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Member" xlink:label="loc_txmdFinancingAgreementAmendment6Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Period1Member" xlink:label="loc_txmdFinancingAgreementAmendment6Period1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Period1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_FinancingAgreementAmendment6Period2Member" xlink:label="loc_txmdFinancingAgreementAmendment6Period2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Period2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200930.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>txmd-10q_093020_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:txmd="http://therapeuticsmd.com/20200930"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="txmd-20200930.xsd" xlink:type="simple"/>
    <context id="From2020-01-01to2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-11-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="From2019-04-012019-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-11-09_custom_FinancingAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-09</instant>
        </period>
    </context>
    <context id="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-08</instant>
        </period>
    </context>
    <context id="AsOf2020-11-08_custom_FinancingAgreementAmendment6Period1Member_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment6Period1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-08</instant>
        </period>
    </context>
    <context id="AsOf2020-11-08_custom_FinancingAgreementAmendment6Period2Member_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment6Period2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-08</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_VitaminsAndImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:VitaminsAndImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_BijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaAndAnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_custom_PrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_PrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_PrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_PrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_custom_ImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_ImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_ImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_ImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_custom_BijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_BijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_BijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_BijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_srt_MaximumMember_custom_CouncilLicenseAgreementStep1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_CouncilLicenseAgreementStep1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_srt_MinimumMember_custom_CouncilLicenseAgreementStep2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_srt_MaximumMember_custom_CouncilLicenseAgreementStep2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_CouncilLicenseAgreementStep2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_srt_MinimumMember_custom_CouncilLicenseAgreementStep3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_CouncilLicenseAgreementStep3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_CouncilLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_custom_BijuvaAndAnnoveraMember_custom_KnightLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:KnightLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_HormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_MultipleTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_MultipleTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_DomesticUSPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_ForeignPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_DomesticPatentsBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsBijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_ForeignPatentsBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsBijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_DomesticPatentsEstradiolAndProgesteroneCandidatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsEstradiolAndProgesteroneCandidatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_DomesticUSPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_DomesticUSUtilityPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSUtilityPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_DomesticUSDesignPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSDesignPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_ForeignPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_ForeignUtilityPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_ForeignDesignPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignDesignPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_DomesticUtilityPatentTopicalCreamCandidatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTopicalCreamCandidatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_DomesticUtilityPatentTransdermalPatchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_ForeignUtilityPatentTransdermalPatchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_DomesticUtilityPatentTx009HRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTx009HRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_DomesticPatentsProgesteroneFormulationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsProgesteroneFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_ForeignPatentsProgesteroneFormulationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsProgesteroneFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_DomesticUtilityPatentOperaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentOperaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-04-24_us-gaap_RevolvingCreditFacilityMember_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="AsOf2019-04-24_us-gaap_SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_FinancingAgreementMember_custom_TrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_FinancingAgreementMember_custom_TrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="AsOf2018-05-01_us-gaap_SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-01</instant>
        </period>
    </context>
    <context id="From2018-04-302018-05-01_us-gaap_SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-05-01</endDate>
        </period>
    </context>
    <context id="From2018-04-302018-05-01_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-05-01</endDate>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_MidCapAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_MidCapAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-08-05_custom_LenderWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:LenderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-05</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_TwoTranchesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TwoTranchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_LenderWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:LenderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_custom_FinancingAgreementMember226851703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-04-27_custom_PaycheckProtectionProgramLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">txmd:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-27</instant>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_PerformanceStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_WarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_WarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_LenderWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:LenderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_WarrantMember226853968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_WarrantsCashlessExerciseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsCashlessExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_LongTermIncentiveCompensationPlan2009Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_NonQualified2012StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RestrictedStockMember_custom_NonQualified2012StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_Plan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_NewSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NewSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_Plan2019Member_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_Plan2019Member_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_srt_MinimumMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_srt_MaximumMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_srt_MinimumMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_srt_MaximumMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-18_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-18</instant>
        </period>
    </context>
    <context id="From2020-06-172020-06-18_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-17</startDate>
            <endDate>2020-06-18</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_custom_CatalentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_CatalentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_CatalentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_CatalentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_CatalentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_CatalentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_custom_AmericanInternationalGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:AmericanInternationalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_AmericanInternationalGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:AmericanInternationalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_SupplierOneConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierOneConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_SupplierTwoConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_SupplierThreeConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_SupplierOneConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierOneConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_SupplierTwoConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_SupplierThreeConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_ThreeCustomersConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:ThreeCustomersConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_FourCustomersConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:FourCustomersConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_CustomerConcentrationMcKessonCorporationRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_CustomerConcentrationAmerisourceBergenRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_CustomerConcentrationPIServicesMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPIServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2013-06-302013-07-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2013-06-30</startDate>
            <endDate>2013-07-01</endDate>
        </period>
    </context>
    <context id="AsOf2018-10-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-10-02</instant>
        </period>
    </context>
    <context id="AsOf2019-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="AsOf2019-06-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-06-01</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_CatalentMember226859265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">txmd:CatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Number">
        <measure>txmd:Number</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-09-30">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-09-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-09-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-09-30">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-09-30">Q3</dei:DocumentFiscalPeriodFocus>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl0125"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2020-09-30"
      id="xdx2ixbrl0136"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl0137"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-07-012020-09-30"
      id="xdx2ixbrl0236"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-07-012019-09-30"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-01-01to2020-09-30"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-07-012020-09-30"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2019-07-012019-09-30"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-01to2020-09-30"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2019-01-012019-09-30"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-07-012019-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-07-012019-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-07-012019-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-07-012019-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-07-012019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-03-31"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="From2019-01-012019-09-30"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="From2019-01-012019-09-30"
      id="xdx2ixbrl0512"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryWriteDown
      contextRef="From2019-01-012019-09-30"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-01-01to2020-09-30"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2020-01-01to2020-09-30"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <txmd:WarrantGrantedInRelationToFinancingAgreement
      contextRef="From2019-01-012019-09-30"
      id="xdx2ixbrl0596"
      unitRef="USD"
      xsi:nil="true"/>
    <txmd:AmountAccruedForIntellectualPropertyLicense
      contextRef="From2020-01-01to2020-09-30"
      id="xdx2ixbrl0598"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="AsOf2020-09-30"
      id="xdx2ixbrl0765"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      id="xdx2ixbrl0988"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <dei:DocumentType contextRef="From2020-01-01to2020-09-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2020-01-01to2020-09-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2020-01-01to2020-09-30">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2020-01-01to2020-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2020-01-01to2020-09-30">001-00100</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2020-01-01to2020-09-30">THERAPEUTICSMD, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-01-01to2020-09-30">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-01-01to2020-09-30">87-0233535</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-01-01to2020-09-30">951 Yamato Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2020-01-01to2020-09-30">Suite 220</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2020-01-01to2020-09-30">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-01-01to2020-09-30">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-01-01to2020-09-30">33431</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-01-01to2020-09-30">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-01-01to2020-09-30">961-1900</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2020-01-01to2020-09-30">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-01-01to2020-09-30">TXMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-01-01to2020-09-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2020-01-01to2020-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-01-01to2020-09-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2020-01-01to2020-09-30">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2020-01-01to2020-09-30">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-01-01to2020-09-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2020-01-01to2020-09-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2020-11-02" decimals="INF" unitRef="Shares">272812271</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">79633675</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">160829713</us-gaap:Cash>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">857176</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">904040</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">24059095</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">24395958</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">9932304</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11860716</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">8819239</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11329793</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">122444313</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">208416180</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">1969929</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2507775</us-gaap:PropertyPlantAndEquipmentNet>
    <txmd:LicenseRights contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">36959305</txmd:LicenseRights>
    <txmd:LicenseRights contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">39221308</txmd:LicenseRights>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">5537885</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5258211</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">9975725</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">10109154</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">403643</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">473009</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">52876558</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">55061682</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">177290800</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">265985637</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">16109638</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">19181212</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">31220484</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">33823613</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">47330122</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">53004825</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">237051202</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">194634643</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">8907995</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">9145049</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">35000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">245994197</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">203779692</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">293324319</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">256784517</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">272812271</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">272812271</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">271177076</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">271177076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">272812</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">271177</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">720551488</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">704351222</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">-836857819</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">-695421279</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">-116033519</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">9201120</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">177290800</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">265985637</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-07-012020-09-30_us-gaap_ProductMember"
      decimals="0"
      unitRef="USD">17342805</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30_us-gaap_ProductMember"
      decimals="0"
      unitRef="USD">8213341</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-09-30_us-gaap_ProductMember"
      decimals="0"
      unitRef="USD">40294495</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-09-30_us-gaap_ProductMember"
      decimals="0"
      unitRef="USD">18238857</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-07-012020-09-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">15506400</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-09-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-09-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">15506400</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">19342805</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">23719741</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">42294495</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">33745257</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">3278609</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">1444308</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">10394145</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">3455995</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">16064196</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">22275433</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">31900350</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">30289262</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">38751250</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">45126986</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">144018899</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">121378519</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">2027195</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">4077738</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">8038056</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">15359988</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">258787</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">141959</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">777338</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">363956</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">41037232</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">49346683</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">152834293</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">137102463</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-24973036</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">-27071250</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">-120933943</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">-106813201</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">41405</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">703662</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">465745</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">1878980</us-gaap:OtherNonoperatingIncome>
    <us-gaap:InterestExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">7679443</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">5599005</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">20968342</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">11717632</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-7638038</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">-4895343</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">-20502597</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">-19896284</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-32611074</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">-31966593</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">-141436540</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">-126709485</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-32611074</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">-31966593</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">-141436540</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">-126709485</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-07-012019-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-01-01to2020-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.52</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-01-012019-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.53</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="Shares">272564635</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="Shares">241261299</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="Shares">271968981</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="Shares">241163994</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">240462439</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">240463</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">616559938</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-519276280</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">97524121</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">759401</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">759</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">99348</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">100107</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2575369</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">2575369</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-39506375</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">-39506375</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">241221840</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">241222</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">619234655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-558782655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31" decimals="0" unitRef="USD">60693222</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">241221840</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">241222</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">619234655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-558782655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31" decimals="0" unitRef="USD">60693222</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2637264</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">2637264</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-55236517</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">-55236517</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2019-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">241221840</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">241222</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">621871919</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-614019172</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30" decimals="0" unitRef="USD">8093969</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2019-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">241221840</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">241222</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">621871919</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-614019172</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30" decimals="0" unitRef="USD">8093969</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2019-07-012019-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">55236</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-07-012019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">55</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-07-012019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">8494</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">8549</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-07-012019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2635146</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">2635146</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-07-012019-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-31966593</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">-31966593</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2019-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">241277076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">241277</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">624515559</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-645985765</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">-21228929</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">271177076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">271177</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">704351222</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-695421279</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">9201120</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">350666</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">351</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">71758</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2020-01-012020-03-31"
      decimals="0"
      unitRef="USD">72109</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">150</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-150</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2366453</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-03-31"
      decimals="0"
      unitRef="USD">2366453</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-56848802</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31"
      decimals="0"
      unitRef="USD">-56848802</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">271677742</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">271678</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">706789283</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-752270081</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">-45209120</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">271677742</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">271678</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">706789283</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-752270081</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">-45209120</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">313638</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">313</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">93762</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">94075</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">303000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">303</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-303</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3002826</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">3002826</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-51976664</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-51976664</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">272294380</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">272294</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">709885568</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-804246745</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">-94088883</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">272294380</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">272294</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">709885568</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-804246745</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">-94088883</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">517891</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">518</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">104976</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">105494</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3132765</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">3132765</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">7428179</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">7428179</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-32611074</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-32611074</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">272812271</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">272812</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">720551488</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-836857819</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">-116033519</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">-141436540</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">-126709485</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">576459</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">223750</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">200879</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">140206</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">584509</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">78864</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">275379</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <txmd:NoncashOperatingLeaseExpense
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">1050940</txmd:NoncashOperatingLeaseExpense>
    <txmd:NoncashOperatingLeaseExpense
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">711836</txmd:NoncashOperatingLeaseExpense>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">-46864</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">95097</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">81309</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:InventoryWriteDown
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">5744464</us-gaap:InventoryWriteDown>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">8502044</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">7859357</us-gaap:ShareBasedCompensation>
    <txmd:AmortizationOfIntellectualPropertyLicenseFee
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">2262002</txmd:AmortizationOfIntellectualPropertyLicenseFee>
    <txmd:AmortizationOfIntellectualPropertyLicenseFee
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">15998</txmd:AmortizationOfIntellectualPropertyLicenseFee>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">1370118</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">582829</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">-383727</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">4354890</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">3816053</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">7265174</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">-2003079</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">1128515</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">-3071574</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">1389665</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">-3812919</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">3402511</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">-129149041</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">-114900319</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">1065062</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">1068542</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">38613</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">2089413</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <txmd:IncreaseDecreaseInSecurityDeposit
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">35000</txmd:IncreaseDecreaseInSecurityDeposit>
    <txmd:IncreaseDecreaseInSecurityDeposit
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">-20420</txmd:IncreaseDecreaseInSecurityDeposit>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">-1068675</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">-3178375</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">271678</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">108656</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">81660719</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">50000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">200000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">1250000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">6652270</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">49021678</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">111795667</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">-81196038</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">-6283027</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">160829713</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">161613077</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">79633675</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">155330050</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <txmd:WarrantGrantedInRelationToFinancingAgreement
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">7428179</txmd:WarrantGrantedInRelationToFinancingAgreement>
    <txmd:AmountAccruedForIntellectualPropertyLicense
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">20000000</txmd:AmountAccruedForIntellectualPropertyLicense>
    <us-gaap:InterestPaidNet
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">19172847</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">12446792</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_809_eus-gaap--NatureOfOperations_zQC4O8yz5zy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_826_z8RpcEUJpw05"&gt;NOTE
1 &#x2013; THE COMPANY&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;TherapeuticsMD,
Inc., a Nevada corporation, or TherapeuticsMD or the Company, has&#160;&lt;span id="xdx_90E_ecustom--NumberOfSubsidiaries_iI_dc_uNumber_c20200930_zxqdmn83mIXb" title="Number of subsidiaries"&gt;three&lt;/span&gt;&#160;wholly owned subsidiaries, vitaMedMD, LLC, a
Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and vitaCare Prescription
Services, Inc., a Florida corporation, or vitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen,
and vitaCare collectively are sometimes referred to as &#x201c;our company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; or &#x201c;us.&#x201d;
TherapeuticsMD&lt;sup&gt;&#xae;&lt;/sup&gt;, vitaMedMD&lt;sup&gt;&#xae;&lt;/sup&gt;, BocaGreenMD&lt;sup&gt;&#xae;&lt;/sup&gt;, IMVEXXY&lt;sup&gt;&#xae;&lt;/sup&gt;, BIJUVA&lt;sup&gt;&#xae;&#160;&lt;/sup&gt;and
ANNOVERA&lt;sup&gt;&#xae;&lt;/sup&gt;&#160;are registered trademarks of our company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Nature
of Business&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
are a women&#x2019;s healthcare company with a mission of creating and commercializing innovative products to support the
lifespan of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical
expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women.
Our solutions range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical
products. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD and
BocaGreenMD brands. Our portfolio of products focused on women&#x2019;s health allows us to efficiently leverage our sales and
marketing plan to grow our recently approved products. During 2018, the U.S. Food and Drug Administration, or FDA, approval
of our pharmaceutical products has transitioned our company from predominately focused on conducting research and development
to one focused on commercializing our pharmaceutical products. In July 2018, we launched our FDA-approved product, IMVEXXY
(estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual
activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched our FDA-approved
product BIJUVA (estradiol and progesterone) capsules, our hormone therapy combination of bio-identical 17&#xdf;-estradiol and
bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or
VMS, due to menopause in women with a uterus. In October 2019, we began a test and learn market introduction for our
FDA-approved product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only annual
patient-controlled, procedure-free, reversible prescription contraceptive option for women. Although we expected to commence
the full commercial launch of ANNOVERA in the first quarter of 2020, as a result of the uncertainty surrounding the COVID-19
pandemic, we paused the commercial launch of ANNOVERA and deferred sales and marketing initiatives into subsequent quarters
as the pandemic began to negatively affect our revenue growth. We resumed the launch of ANNOVERA on July 1, 2020. On July 30,
2018, we entered into an exclusive license agreement, or the Population Council License Agreement, with the Population
Council, Inc., or the Population Council, to commercialize ANNOVERA in the U.S. In addition, on July 30, 2018, we entered
into a license and supply agreement, or the Knight License Agreement, with Knight Therapeutics Inc., or Knight, pursuant to
which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. On June 6, 2019, we
entered into an exclusive license and supply agreement, or the Theramex License Agreement, with Theramex HQ UK Limited, or
Theramex, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel, or the Theramex
Territory.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <txmd:NumberOfSubsidiaries contextRef="AsOf2020-09-30" decimals="INF" unitRef="Number">3</txmd:NumberOfSubsidiaries>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_801_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z5t4Jc3pzweg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_825_zNY5DSa5H6Hf"&gt;NOTE
2 &#x2013; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Interim
Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries,
should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report
on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission, or the SEC, from which
we derived the accompanying consolidated balance sheet as of December 31, 2019. The accompanying unaudited interim consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America,
or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly,
since they are interim statements, the accompanying unaudited interim consolidated financial statements do not include all of
the information and notes required by GAAP for complete financial statements. The accompanying unaudited interim consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management,
necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative
of results for a full year or any other interim period in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
continue to be subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the future impact of the
COVID-19 pandemic on our business continues to be highly uncertain and difficult to predict. We continue to provide an uninterrupted
supply of our portfolio of products for patients. We have sufficient inventory of finished product to meet anticipated demand
in the near future. Additionally, we currently do not foresee any interruption in our ability to continue to manufacture additional
product to be used beyond this period and have sufficient active pharmaceutical ingredients on hand for the continued manufacture
of our products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Since
the early phase of the COVID-19 pandemic, we have been using substantial virtual options to ensure business continuity. Our vitaCare
Prescription Services patient model assists patients in obtaining easy and convenient access to their prescriptions for products
at a retail pharmacy of their choice, including via home delivery retail pharmacy options. We have also partnered with independent
community pharmacies and multiple third-party online pharmacies and telemedicine providers that focus on contraception or menopause
to ensure patients have real-time access to both diagnosis and treatment. We continue to support prescribers&#x2019; needs with
samples and product materials through our sales force. If access is restricted, we have mailing options in place for these materials.
We also have business continuity plans and infrastructure in place that allows for virtual detailing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
part of our response to the COVID-19 pandemic, we implemented measures to reduce marketing expenses for 2020. We also implemented
cost saving measures, which included negotiating lower fees or suspending services from third party vendors; implementing a company-wide
hiring restriction; delaying or cancelling non-critical information technology projects; and eliminating non-essential travel,
entertainment, meeting, and event expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
full impact of the&#160;COVID-19 pandemic continues to evolve. However, we remain committed to the execution of our corporate
goals, despite the ongoing COVID-19 pandemic, as demonstrated in part by the increase of our third quarter 2020 product
revenues as compared to our second quarter 2020 product revenues. As of the date of issuance of these consolidated financial
statements, the future extent to which the COVID-19 pandemic may continue to materially impact our financial condition,
liquidity, or results of operations remains uncertain. We are continuing to assess the effect the COVID-19 pandemic on our
operations by monitoring the spread of COVID-19 and the various actions implemented to combat the virus throughout the world.
Even after the&#160;COVID-19 pandemic has subsided, we may continue to experience adverse impacts to our business as a result
of any economic recession or depression that has occurred or may occur in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;While
we currently believe that our COVID-19 contingency plan has the ability to mitigate the effect of the COVID-19 pandemic on our
business, the severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but
not limited to, the duration and severity of the pandemic, the duration of &#x201c;social distancing&#x201d; orders, the ability
of our sales force to access healthcare providers to promote our products, increases in unemployment, which could reduce access
to commercial health insurance for our patients, thus limiting payer coverage for our products, and the impact of the pandemic
on our global supply chain, all of which are uncertain. Our future results of operations and liquidity could be materially adversely
affected by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions, uncertain
demand, and the impact of any initiatives or programs that we may undertake to address financial and operations challenges that
we may face.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Liquidity
and Going Concern&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As of the filing date of this Quarterly Report on Form 10-Q, our cash balance was above the $&lt;span id="xdx_90F_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201109__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNRtFj0LMERf" title="Minimum cash balance required under credit agreement"&gt;60
million&lt;/span&gt; balance as required by the Financing Agreement (as defined in Note 9 - Debt). On November 8, 2020, we and our subsidiaries entered into
Amendment No. 6 to the Financing Agreement, or Amendment No. 6, with the Administrative Agent (as defined in Note 9 - Debt) and the lenders party thereto,
pursuant to which we temporarily lowered the minimum required cash balance from $&lt;span id="xdx_90E_ecustom--MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6yLSNY2GXQ7" title="Minimum cash balance requirement under credit agreement before adjustment"&gt;60
million&lt;/span&gt; to $&lt;span id="xdx_906_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Period1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zk6Xsvdsh0w3"&gt;45
million&lt;/span&gt; through December 31, 2020. After December 31, 2020, the minimum cash balance will revert to $&lt;span id="xdx_905_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Period2Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRnQcJzWfiDf"&gt;60
million&lt;/span&gt;. Based on our current projections, we will need to raise additional capital to remain in compliance with this
minimum cash balance covenant for the next twelve months from the issuance of these financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In order to address our projected capital needs, we are pursuing various equity financing and other alternatives including the sale of a controlling interest in vitaCare Prescription Services for which we commended a sale process and received initial indications of interest.   The equity financing alternatives may include the private placement of equity, equity-linked, or other similar instruments or obligations with one or more investors, lenders, or other institutional counterparties or an underwritten public equity or equity-linked securities offering. Our ability to sell equity securities may be limited by market conditions. To the extent that we raise additional capital through the sale of such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Along with considering additional financings, we have reviewed numerous potential scenarios in connection with the impact of COVID-19 on our business including the impact of the recent steps we have taken to reduce our operating expenses in response. Based on our analysis, we believe that our existing cash reserves along with potential proceeds from the sale of certain non-core assets of the Company and proceeds from potential future financings, if available to us, would be sufficient to meet our cash needs arising in the ordinary course of business for the next twelve months from the date of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;However,
if we are unsuccessful with future financings and if the successful commercialization of IMVEXXY, BIJUVA, or ANNOVERA is
delayed, or the continued impact of the COVID-19 pandemic on our business is worse than we anticipate, our existing cash
reserves would be insufficient to maintain compliance with the Financing Agreement covenants or satisfy our liquidity
requirements until we are able to successfully commercialize IMVEXXY, BIJUVA, and ANNOVERA. The presence of these projected
factors in conjunction with the uncertainty of the capital markets raises substantial doubt about the Company's ability to
continue as a going concern for the next twelve months from the issuance of these financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The accompanying unaudited consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
August 2018, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13 which
eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose
certain new information and modifies some disclosure requirements. The FASB developed the amendments to Accounting Standards Codification,
or ASC, 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the
notes to financial statements by focusing on requirements that clearly communicate the most important information to users of
the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and
for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions
that eliminate or modify requirements. We adopted this standard on January 1, 2020, and the adoption did not have a material effect
on our disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on
Financial Instruments. The amendments in this update require a financial asset (or a group of financial assets) measured at amortized
cost basis to be presented at the net amount expected to be collected based on historical experience, current conditions, and
reasonable supportable forecasts. The amendments in this update are effective for public business entities for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted no sooner than the
first quarter of 2019. A modified retrospective approach is required for all investments, except debt securities for which an
other-than-temporary impairment had been recognized prior to the effective date, which will require a prospective transition approach
and should be applied either prospectively or retrospectively depending on the nature of the disclosure. The adoption of ASU 2016-13
requires expanded quantitative and qualitative disclosures about the Company&#x2019;s expected credit losses. Effective January
1, 2020, we adopted ASU 2016-13 under a modified retrospective approach for all financial assets measured at amortized cost. There
was no adjustment recorded for the cumulative effect of adopting ASU 2016-13. The adoption expanded disclosures about our credit
losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified
Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial
position.&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="AsOf2020-11-09_custom_FinancingAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">60000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment
      contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">60000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Period1Member_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">45000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Period2Member_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">60000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zMxAWFQxgcpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_829_zWWUZJJcGga7"&gt;NOTE
3 &#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zk6qJabFcbz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zRx3vtNoY2zj"&gt;Trade
Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Trade
accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts
and credit card chargebacks and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,
historical collection information, reasonable supportable forecasts and existing economic conditions and we record an allowance
that presents the net amount expected to be collected. We evaluate trade accounts receivable for delinquency. We write off delinquent
receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts,
and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase
in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately reflect bad
debts, adjustments to these reserves may be required. Our exposure to credit losses may increase if our customers are adversely
affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or
global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. Although
we have historically not experienced significant credit losses, it is possible that there could be a material adverse impact from
potential adjustments of the carrying amount of trade receivables in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z3RRKW4uBKpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_ztJzml9JFsCf"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Our
financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The
carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the
short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount
for long-term debt as of September 30, 2020 (as disclosed in Note 9) approximates fair value based on market activity for other
debt instruments with similar characteristics and comparable risk (Level 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by ASC 820, Fair Value Measurements, or ASC 820. The fair value hierarchy gives the highest priority to quoted prices
in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets
and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;unadjusted
quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;quoted
prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly
or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;unobservable
inputs for the assets or liabilities.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
September 30, 2020 and 2019, we had&#160;&lt;span id="xdx_90A_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_do_c20200930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9mphHV13BCg" title="Assets or liabilities valued at fair value"&gt;&lt;span id="xdx_90B_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_do_c20190930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zD0l6Yjdgw3b" title="Assets or liabilities valued at fair value"&gt;no&lt;/span&gt;&lt;/span&gt;&#160;assets or liabilities that were valued at fair value on a recurring basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in
connection with any required impairment test. During the nine months ended September 30, 2020 and 2019, we wrote off $&lt;span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pp0p0_c20200101__20200930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zM1WG9lat7Nk" title="Impairment of intangible assets"&gt;&lt;span title="Impairment of intangible assets"&gt;584,509&lt;/span&gt;&lt;/span&gt;
and $&lt;span id="xdx_90D_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pp0p0_c20190101__20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zl3Y97le3Ikd" title="Impairment of intangible assets"&gt;78,864&lt;/span&gt;, respectively,&#160;in costs related to trademarks and patents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z2Q9w6a4qmGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zVqN6FWuK28k"&gt;Share-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs
in the financial statements over the period during which employees are required to provide services. Share-based compensation
arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and
employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award.
We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718,
Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected
life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield.
The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity
period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price
is expected to fluctuate each year during the term of the award. On January 1, 2017, we began using our own stock price in our
volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our
company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility
is based on historical stock prices over a period equal to the expected term of the awards. On January 1, 2020, we began calculating
the expected term of our stock-based awards, which represents the period that the stock-based awards are expected to be outstanding.
Prior to January 1, 2020, the average expected life of options was based on the contractual terms of the stock option using the
simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current
intention to pay cash dividends. The assumptions used in calculating the fair value of stock-based awards represent our best estimates,
but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change
and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize
the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with
ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service
period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which
simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments
to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted
to non-employees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and superseded the guidance
in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required
by ASC 505, Equity - Based Payments to Non-Employees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
grant performance-based stock units and restricted stock units for shares of common stock, par value $&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zOdMlYlKdZH9" title="Common stock, shares, issued (in dollars per share)"&gt;&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0bVDl65G6w1" title="Common stock, shares, issued (in dollars per share)"&gt;0.001&lt;/span&gt;&lt;/span&gt; per share, or Common
Stock, to employees. We value our restricted stock units and our performance-based stock units by reference to our stock price
on the date of grant. We recognize compensation expense for restricted stock units based on a straight-line basis over the requisite
service period of the entire award. We recognize performance-based restricted stock as compensation expense based on the most
likely probability of attaining the prescribed performance and over the requisite service period beginning at its grant date and
through the date the restricted stock vests. The number of target shares that vest are determined based on the level of attainment
of the targets. If a minimum level of performance is attained for the awards, restricted stock is issued based on the level of
attainment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zcotw2sU4114" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zQp4w9QBwzCi"&gt;Revenue
Recognition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
accordance with ASC 606,&#160;&lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, or ASC 606, revenue is recognized when a customer
obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect
to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which
we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to
which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1)
identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction
price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as,
we satisfy the performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Prescription
Products&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of September 30, 2020, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which
we began selling during the third quarter of 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA,
which we began selling in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused
the commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters.
We resumed the launch of ANNOVERA on July 1, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have
one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised
goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer
promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than
as a separate obligation. We recognize prescription product revenue only when we satisfy performance obligations by transferring
a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods
or service or obtains control. Control refers to the customer&#x2019;s ability to direct the use of, and obtain substantially all
of the remaining benefits from, an asset. Based on our contracts, we invoice customers once our performance obligations have been
satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement
of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent
to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring
promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined
based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns,
chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed
on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current
liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate
the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method,
depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable
consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount
of cumulative product revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently
resolved. In determining amounts of variable consideration to include in a contract&#x2019;s transaction price, we rely on our
historical experience and other evidence that supports our qualitative assessment of whether product revenue would be subject
to a significant reversal. We consider all the facts and circumstances associated with both the risk of a product revenue reversal
arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts
of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates,
we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become
known.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
accept returns of unsalable prescription products sold through wholesale distributors within a return period of &lt;span id="xdx_905_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dt_c20200101__20200930__srt--RangeAxis__srt--MinimumMember_zO3SbBGuQ4Lc" title="Return period of unsalable prescription products"&gt;six months&lt;/span&gt;
 prior to and up to &lt;span id="xdx_906_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20200930__srt--RangeAxis__srt--MaximumMember_zhsZ9iuNdub8" title="Return period of unsalable prescription products"&gt;12&lt;/span&gt;
months following product expiration. Our vitamins and IMVEXXY currently have a shelf life of &lt;span id="xdx_909_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200930__srt--ProductOrServiceAxis__custom--VitaminsAndImvexxyMember_z8av3zzitG1l" title="Shelf life of prescription products following product expiration"&gt;24&lt;/span&gt;
months from the date of manufacture and BIJUVA and ANNOVERA currently have a shelf life of &lt;span id="xdx_903_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200930__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zvsYL7Ka94gc"&gt;18&lt;/span&gt; months from the date of
manufacture. We do not allow product returns for prescription products that have been dispensed to a patient. We estimate the
amount of our product sales that may be returned by our customers and record this estimate as a reduction of product revenue
in the period the related product revenue is recognized. Where historical rates of return exist, we use history as a basis to
establish a returns reserve for products shipped to wholesalers. For our newly launched products, for which the right of
return exists but for which we currently do not have history of product returns, we estimate returns based on available
industry data, our own sales information and our visibility into the inventory remaining in the distribution channel. At the
end of each reporting period, we may decide to constrain product revenue for product returns based on information from
various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products
currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the
amount of expected returns as a refund liability, representing the obligation to return the customer&#x2019;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return
asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of
product revenue is deferred due to the anticipated return). Return estimates are recorded in other current liabilities on the
consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales
and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience
and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates
and coupons are deducted from gross product revenues at the time the product revenues are recognized. We record distributor fees
based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in other current liabilities
on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account
prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns
are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts
and chargebacks are deducted from gross product revenues at the time the product revenues are recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
part of commercial launches for our FDA-approved prescription products, we introduced a co-pay assistance program for eligible
enrolled patients whose out of pocket costs are reduced to a more affordable price. This allows patients to access the product
at a reasonable cost and is in line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party
vendors. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize
the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current
level of prescriptions covered by patients&#x2019; insurance. Payers may change coverage levels for our prescription products positively
or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction
price of our prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company.
As a result, we constrain variable consideration for our prescription products to an amount that will not result in a significant
product revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription products is
constrained by our estimates of the amount to be paid for the co-pay assistance program which is directly related to the level
of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other
patient assistance based on currently available third-party data and our internal analyses. We re-evaluate variable consideration
each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;License
Revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;License
arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending
technology, and various performance or sales milestones and future product royalty payments. Some of these arrangements may
include multiple performance obligations. Non-refundable up-front fees that are not contingent on any future performance by
us, and do not require continuing involvement on our part, are recognized as revenue when the right to use functional IP is
transferred to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Disaggregation
of revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_zwLSIYehkWu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&lt;span id="xdx_8BF_z1MXKnWRBXE9"&gt;The
following table provides information about disaggregated revenue by product mix&lt;/span&gt;&lt;/span&gt; for the three and nine months ended September
30, 2020 and 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;br/&gt; September 30,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Nine Months Ended&lt;br/&gt; September 30,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%; text-align: justify; padding-left: 5.4pt"&gt;Prescription vitamins&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zKejnfyswrQ" title="Net revenue"&gt;2,435,903&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z2NEamSswbvb" style="width: 10%; text-align: right"&gt;2,550,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z3bGmx2GXlVh" style="width: 10%; text-align: right"&gt;7,337,976&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z0sVZ7oZ6XXi" style="width: 10%; text-align: right"&gt;7,309,174&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;IMVEXXY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zDQQQ4gr8uv3" style="text-align: right"&gt;6,841,592&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zmw8LC9wVHT8" style="text-align: right"&gt;4,772,354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zUy2Zc3HzfH3" style="text-align: right"&gt;18,319,382&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_ztNgP73WaH98" style="text-align: right"&gt;9,904,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;BIJUVA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--BijuvaMember_zUGGP1HjNmp4" style="text-align: right"&gt;1,646,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zvySuT2nGia2" style="text-align: right"&gt;490,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--BijuvaMember_zTF6I1TkioOc" style="text-align: right"&gt;4,109,925&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_ztMez4EZEkhi" style="text-align: right"&gt;624,987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;ANNOVERA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zrOHwGmsEkP1" style="text-align: right"&gt;6,418,990&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zgXrEZCkkDdh" style="text-align: right"&gt;399,952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRYca6rAQPKb" style="text-align: right"&gt;10,527,212&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zgkMsGbGZwxb" style="text-align: right"&gt;399,952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;License revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z3tZZfCwZfq2" style="border-bottom: Black 1pt solid; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zRHR3xdmecB" style="border-bottom: Black 1pt solid; text-align: right"&gt;15,506,400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zWr0oyyGelj" style="border-bottom: Black 1pt solid; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z2tCEaEiV2j3" style="border-bottom: Black 1pt solid; text-align: right"&gt;15,506,400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 0.375in"&gt;Net revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930_zkEoA0IraXnd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;19,342,805&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930_zmbAw1ceQvGc" style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,719,741&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930_zK5AEdek3glc" style="border-bottom: Black 2.5pt double; text-align: right"&gt;42,294,495&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930_zI1PeJS4ECPk" style="border-bottom: Black 2.5pt double; text-align: right"&gt;33,745,257&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A5_zyVKyulKSYwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p id="xdx_848_ecustom--LicenseAgreementWithPopulationCouncilPolicyTextBlock_zESClL4UWTW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zxUXenFGCps4"&gt;License
Agreement with the Population Council&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
July 30, 2018, we entered into the Population Council License Agreement to commercialize ANNOVERA in the U.S. We began selling
ANNOVERA in a &#x201c;test and learn&#x201d; market introduction in the third quarter of 2019. As a result of the uncertainty surrounding
the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing
initiatives into subsequent quarters. &lt;span style="color: #212529"&gt;We resumed the launch of ANNOVERA on July 1, 2020.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $&lt;span id="xdx_90B_ecustom--MilestonePaymentUponFDAApproval_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zbb7Lr3z6SL7" title="Milestone payment upon FDA Approval"&gt;20,000,000&lt;/span&gt;&#160;within
30 days following the approval by the FDA of the new drug application, or NDA, for ANNOVERA and $&lt;span title="Milestone payments (payment after release of first commercial batch)"&gt;&lt;span id="xdx_90D_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_z5iWvTjpO881" title="Milestone payments (payment after release of first commercial batch)"&gt;20,000,000&lt;/span&gt;&lt;/span&gt;&#160;within 30 days
following the first commercial batch release of ANNOVERA. Both milestone payments of $&lt;span id="xdx_909_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zhM9QBi3N3zc" title="License rights acquired"&gt;20,000,000&lt;/span&gt;&#160;were recorded as license
rights in the consolidated balance sheets. We started amortizing license rights in the third quarter of 2019 once ANNOVERA became
commercially available for use. The cost is amortized over the remaining useful life over which the license rights will contribute
directly or indirectly to our cash flows, which is estimated to be the remaining patent life of the product, which expires in
December 2032. The cost is amortized using the straight-line method as the pattern of economic benefit cannot be reliably determined.
During the three and nine months ended September 30, 2020, we recorded $&lt;span id="xdx_901_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20200701__20200930_z7CLR3V5lPjj" title="Amortization of intellectual property license fee"&gt;762,389&lt;/span&gt;&#160;and $&lt;span id="xdx_90C_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20200101__20200930_zuKZh54Yu3g7" title="Amortization of intellectual property license fee"&gt;2,262,002&lt;/span&gt;, respectively, in amortization
expense related to the license fee. During both the three and nine months ended September 30, 2019, we recorded $&lt;span id="xdx_905_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20190701__20190930_zhO37Dwc4Pod" title="Amortization of intellectual property license fee"&gt;&lt;span id="xdx_902_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20190101__20190930_zpBN7tHPZXWd" title="Amortization of intellectual property license fee"&gt;15,998&lt;/span&gt;&lt;/span&gt; in amortization
expense related to the license fee which was recorded as a component of cost of sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Population Council is also eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible
for marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council,
on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates
and permitted licensees as follows: (i) if annual net sales are less than or equal to $&lt;span id="xdx_904_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_c20200101__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_z5EMzf4wPEh3" title="Net sales amount per step-based royalty"&gt;50,000,000&lt;/span&gt;, a royalty of&#160;&lt;span id="xdx_90A_ecustom--RoyaltyPercent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zrOEsMcETNhj" title="Royalty (percent)"&gt;5&lt;/span&gt;% of net
sales; (ii) for annual net sales greater than $&lt;span id="xdx_90F_ecustom--NetSalesAmountPerStepbasedRoyalty_c20200101__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zjIiAQCur1Fk" title="Net sales amount per step-based royalty"&gt;50,000,000&lt;/span&gt;&#160;and less than or equal to $&lt;span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_c20200101__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zP1BhwjvVltk"&gt;150,000,000&lt;/span&gt;, a royalty of&#160;&lt;span id="xdx_906_ecustom--RoyaltyPercent_pii_dp_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_ztvmIGBhNfpb" title="Royalty (percent)"&gt;10&lt;/span&gt;% of
such net sales; and (iii) for net sales greater than $&lt;span id="xdx_906_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_c20200101__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zhW87utZf6c9" title="Net sales amount per step-based royalty"&gt;150,000,000&lt;/span&gt;, a royalty of&#160;&lt;span id="xdx_907_ecustom--RoyaltyPercent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zIl6CGAPDBre" title="Royalty (percent)"&gt;15&lt;/span&gt;% of such net sales. The annual royalty
rate will be reduced to&#160;&lt;span id="xdx_901_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zkVZ25eQpoGk" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"&gt;50&lt;/span&gt;% of the initial rate during the six-month period beginning on the date of the first arms-length
commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the
U.S., and thereafter will be reduced to&#160;&lt;span id="xdx_907_ecustom--AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zrMItUXCRLZg" title="Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent"&gt;20&lt;/span&gt;% of the initial rate. We are required to pay the Population Council milestone
payments of $&lt;span id="xdx_90D_ecustom--MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_pp0p0_dm_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zohSQUs9Uz4d" title="Milestone payments upon specified levels of cumulative net sales"&gt;40 million&lt;/span&gt;&#160;upon cumulative net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees
of each of $&lt;span id="xdx_909_ecustom--SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_pn6n6_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zkw86Ij00lI6" title="Specified level one of cumulative net sales for milestone payments"&gt;200&lt;/span&gt;&#160;million, $&lt;span id="xdx_901_ecustom--SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_pn6n6_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zGDyxwW763r7" title="Specified level two of cumulative net sales for milestone payments"&gt;400&lt;/span&gt;&#160;million&#160;and $&lt;span id="xdx_90F_ecustom--SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_pn9n9_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_z4UimISN9gpk" title="Specified level three of cumulative net sales for milestone payments"&gt;1&lt;/span&gt;&#160;billion. The Population Council has agreed to perform and pay
the costs and expenses associated with four post-approval studies required by the FDA for ANNOVERA and we have agreed to perform
and pay the costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism,
provided that if the costs and expenses associated with such post-approval study exceed $&lt;span id="xdx_903_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_pii_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zNOQIfJLTYc6" title="Maximum costs and expenses for post approval"&gt;20,000,000&lt;/span&gt;, half of such excess will
be offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement.
We and the Population Council have agreed to form a joint product committee responsible for overseeing activities under the Population
Council License Agreement. We will be responsible for all aspects of promotion, product positioning, pricing, education programs,
publications, sales messages and any additional desired clinical studies for the one-year vaginal contraceptive system, subject
to oversight and decisions made by the joint product committee. The Population Council License Agreement includes exclusive rights
for us to negotiate co-development of two other investigational vaginal contraceptive systems in development by the Population
Council.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;





&lt;p id="xdx_848_ecustom--LicenseAgreementWithKnightPolicyTextBlock_zNPRMfR2xLZ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_z4pk4ByPb04g"&gt;License
Agreement with Knight&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
July 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we
granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the
Knight License Agreement, Knight paid us $&lt;span id="xdx_905_ecustom--MilestonePaymentReceivedUponRegulatoryApproval_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--KnightLicenseAgreementMember_zUkuasQPehic"&gt;2,000,000&lt;/span&gt;
in milestone fees upon the first regulatory approval in Canada for IMVEXXY and BIJUVA in the third quarter of 2020, and is
also required to pay us sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of
IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications,
submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada
within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents.
Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within
certain specified time periods or if the other party files for bankruptcy or other related matters. As part of the Knight
License Agreement, Knight is prohibited from exporting IMVEXXY and BIJUVA to the United States.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--CostOfSalesPolicyTextBlock_zSlKlmze6w85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zEpUISSlKSgk"&gt;Cost
of Sales&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cost
of sales includes the cost of inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping and
handling costs. The Population Council License Agreement requires payment of royalties based on the sale of future products. Such
royalties are recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related
to licensed products are classified as components of cost of sales to the extent such payments become due in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zo2CY4CWi0jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zV1WCTQZtMMl"&gt;Inventory
Obsolescence Reserve&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
evaluate inventory quarterly and record an allowance for obsolescence primarily associated with materials that are not
currently or likely to be used in production in the near future. As of September 30, 2020 and December 31, 2019, we recorded
an inventory obsolescence reserve of $&lt;span id="xdx_901_eus-gaap--InventoryValuationReserves_iI_pp0p0_c20200930_z3nH5S3tEYUi" title="Inventory valuation reserves"&gt;5,744,464&lt;/span&gt;&#160;and
$&lt;span id="xdx_909_eus-gaap--InventoryValuationReserves_iI_pp0p0_c20191231_zuB0z7VrASU6" title="Inventory valuation reserves"&gt;0&lt;/span&gt;,
respectively. The reserve recorded as of September 30, 2020 was primarily related to BIJUVA and resulted from the impact of
the COVID-19 pandemic on our business, which decreased demand for our products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zCPayzXjlSA2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zVGnNbixIvY8"&gt;Segment
Reporting&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single executive leadership team that is chaired by the Chief Executive Officer of our
Company, who oversees all operations. We do not operate separate lines of business with respect to any of our products and we
do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the
United States. Accordingly, we view our business as one reportable operating segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_z1glbuxYfOTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_z0EqH09uYUo6"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
and development, or R&amp;amp;D, expenses include internal R&amp;amp;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal
R&amp;amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO
activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;amp;D expenses include
assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes,
and scientific writing matters, including preparing protocols and FDA submissions. These consulting expenses were direct costs
associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal
R&amp;amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms,
which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services
that will be used in future R&amp;amp;D activities when the activity has been performed or when the goods have been received rather
than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed
and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO
costs are subject to revisions as such studies progress to completion. We charge revisions to expenses in the period in which
the facts that give rise to the revision become known.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85A_z0zaxpjxOijb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_84C_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zk6qJabFcbz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zRx3vtNoY2zj"&gt;Trade
Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Trade
accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts
and credit card chargebacks and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,
historical collection information, reasonable supportable forecasts and existing economic conditions and we record an allowance
that presents the net amount expected to be collected. We evaluate trade accounts receivable for delinquency. We write off delinquent
receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts,
and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase
in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately reflect bad
debts, adjustments to these reserves may be required. Our exposure to credit losses may increase if our customers are adversely
affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or
global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. Although
we have historically not experienced significant credit losses, it is possible that there could be a material adverse impact from
potential adjustments of the carrying amount of trade receivables in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z3RRKW4uBKpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_ztJzml9JFsCf"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Our
financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The
carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the
short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount
for long-term debt as of September 30, 2020 (as disclosed in Note 9) approximates fair value based on market activity for other
debt instruments with similar characteristics and comparable risk (Level 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by ASC 820, Fair Value Measurements, or ASC 820. The fair value hierarchy gives the highest priority to quoted prices
in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets
and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;unadjusted
quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;quoted
prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly
or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;unobservable
inputs for the assets or liabilities.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
September 30, 2020 and 2019, we had&#160;&lt;span id="xdx_90A_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_do_c20200930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9mphHV13BCg" title="Assets or liabilities valued at fair value"&gt;&lt;span id="xdx_90B_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_do_c20190930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zD0l6Yjdgw3b" title="Assets or liabilities valued at fair value"&gt;no&lt;/span&gt;&lt;/span&gt;&#160;assets or liabilities that were valued at fair value on a recurring basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in
connection with any required impairment test. During the nine months ended September 30, 2020 and 2019, we wrote off $&lt;span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pp0p0_c20200101__20200930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zM1WG9lat7Nk" title="Impairment of intangible assets"&gt;&lt;span title="Impairment of intangible assets"&gt;584,509&lt;/span&gt;&lt;/span&gt;
and $&lt;span id="xdx_90D_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pp0p0_c20190101__20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zl3Y97le3Ikd" title="Impairment of intangible assets"&gt;78,864&lt;/span&gt;, respectively,&#160;in costs related to trademarks and patents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2020-09-30_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      unitRef="USD">0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2019-09-30_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      unitRef="USD">0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="From2020-01-012020-09-30_us-gaap_TrademarksAndTradeNamesMember"
      decimals="0"
      unitRef="USD">584509</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="From2019-01-012019-09-30_us-gaap_TrademarksAndTradeNamesMember"
      decimals="0"
      unitRef="USD">78864</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z2Q9w6a4qmGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zVqN6FWuK28k"&gt;Share-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs
in the financial statements over the period during which employees are required to provide services. Share-based compensation
arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and
employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award.
We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718,
Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected
life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield.
The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity
period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price
is expected to fluctuate each year during the term of the award. On January 1, 2017, we began using our own stock price in our
volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our
company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility
is based on historical stock prices over a period equal to the expected term of the awards. On January 1, 2020, we began calculating
the expected term of our stock-based awards, which represents the period that the stock-based awards are expected to be outstanding.
Prior to January 1, 2020, the average expected life of options was based on the contractual terms of the stock option using the
simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current
intention to pay cash dividends. The assumptions used in calculating the fair value of stock-based awards represent our best estimates,
but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change
and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize
the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with
ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service
period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which
simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments
to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted
to non-employees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and superseded the guidance
in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required
by ASC 505, Equity - Based Payments to Non-Employees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
grant performance-based stock units and restricted stock units for shares of common stock, par value $&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zOdMlYlKdZH9" title="Common stock, shares, issued (in dollars per share)"&gt;&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0bVDl65G6w1" title="Common stock, shares, issued (in dollars per share)"&gt;0.001&lt;/span&gt;&lt;/span&gt; per share, or Common
Stock, to employees. We value our restricted stock units and our performance-based stock units by reference to our stock price
on the date of grant. We recognize compensation expense for restricted stock units based on a straight-line basis over the requisite
service period of the entire award. We recognize performance-based restricted stock as compensation expense based on the most
likely probability of attaining the prescribed performance and over the requisite service period beginning at its grant date and
through the date the restricted stock vests. The number of target shares that vest are determined based on the level of attainment
of the targets. If a minimum level of performance is attained for the awards, restricted stock is issued based on the level of
attainment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-09-30_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_844_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zcotw2sU4114" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zQp4w9QBwzCi"&gt;Revenue
Recognition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
accordance with ASC 606,&#160;&lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, or ASC 606, revenue is recognized when a customer
obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect
to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which
we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to
which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1)
identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction
price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as,
we satisfy the performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Prescription
Products&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of September 30, 2020, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which
we began selling during the third quarter of 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA,
which we began selling in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused
the commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters.
We resumed the launch of ANNOVERA on July 1, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have
one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised
goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer
promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than
as a separate obligation. We recognize prescription product revenue only when we satisfy performance obligations by transferring
a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods
or service or obtains control. Control refers to the customer&#x2019;s ability to direct the use of, and obtain substantially all
of the remaining benefits from, an asset. Based on our contracts, we invoice customers once our performance obligations have been
satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement
of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent
to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring
promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined
based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns,
chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed
on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current
liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate
the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method,
depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable
consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount
of cumulative product revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently
resolved. In determining amounts of variable consideration to include in a contract&#x2019;s transaction price, we rely on our
historical experience and other evidence that supports our qualitative assessment of whether product revenue would be subject
to a significant reversal. We consider all the facts and circumstances associated with both the risk of a product revenue reversal
arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts
of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates,
we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become
known.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
accept returns of unsalable prescription products sold through wholesale distributors within a return period of &lt;span id="xdx_905_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dt_c20200101__20200930__srt--RangeAxis__srt--MinimumMember_zO3SbBGuQ4Lc" title="Return period of unsalable prescription products"&gt;six months&lt;/span&gt;
 prior to and up to &lt;span id="xdx_906_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20200930__srt--RangeAxis__srt--MaximumMember_zhsZ9iuNdub8" title="Return period of unsalable prescription products"&gt;12&lt;/span&gt;
months following product expiration. Our vitamins and IMVEXXY currently have a shelf life of &lt;span id="xdx_909_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200930__srt--ProductOrServiceAxis__custom--VitaminsAndImvexxyMember_z8av3zzitG1l" title="Shelf life of prescription products following product expiration"&gt;24&lt;/span&gt;
months from the date of manufacture and BIJUVA and ANNOVERA currently have a shelf life of &lt;span id="xdx_903_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200930__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zvsYL7Ka94gc"&gt;18&lt;/span&gt; months from the date of
manufacture. We do not allow product returns for prescription products that have been dispensed to a patient. We estimate the
amount of our product sales that may be returned by our customers and record this estimate as a reduction of product revenue
in the period the related product revenue is recognized. Where historical rates of return exist, we use history as a basis to
establish a returns reserve for products shipped to wholesalers. For our newly launched products, for which the right of
return exists but for which we currently do not have history of product returns, we estimate returns based on available
industry data, our own sales information and our visibility into the inventory remaining in the distribution channel. At the
end of each reporting period, we may decide to constrain product revenue for product returns based on information from
various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products
currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the
amount of expected returns as a refund liability, representing the obligation to return the customer&#x2019;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return
asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of
product revenue is deferred due to the anticipated return). Return estimates are recorded in other current liabilities on the
consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales
and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience
and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates
and coupons are deducted from gross product revenues at the time the product revenues are recognized. We record distributor fees
based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in other current liabilities
on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account
prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns
are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts
and chargebacks are deducted from gross product revenues at the time the product revenues are recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
part of commercial launches for our FDA-approved prescription products, we introduced a co-pay assistance program for eligible
enrolled patients whose out of pocket costs are reduced to a more affordable price. This allows patients to access the product
at a reasonable cost and is in line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party
vendors. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize
the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current
level of prescriptions covered by patients&#x2019; insurance. Payers may change coverage levels for our prescription products positively
or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction
price of our prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company.
As a result, we constrain variable consideration for our prescription products to an amount that will not result in a significant
product revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription products is
constrained by our estimates of the amount to be paid for the co-pay assistance program which is directly related to the level
of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other
patient assistance based on currently available third-party data and our internal analyses. We re-evaluate variable consideration
each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;License
Revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;License
arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending
technology, and various performance or sales milestones and future product royalty payments. Some of these arrangements may
include multiple performance obligations. Non-refundable up-front fees that are not contingent on any future performance by
us, and do not require continuing involvement on our part, are recognized as revenue when the right to use functional IP is
transferred to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Disaggregation
of revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_zwLSIYehkWu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&lt;span id="xdx_8BF_z1MXKnWRBXE9"&gt;The
following table provides information about disaggregated revenue by product mix&lt;/span&gt;&lt;/span&gt; for the three and nine months ended September
30, 2020 and 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;br/&gt; September 30,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Nine Months Ended&lt;br/&gt; September 30,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%; text-align: justify; padding-left: 5.4pt"&gt;Prescription vitamins&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zKejnfyswrQ" title="Net revenue"&gt;2,435,903&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z2NEamSswbvb" style="width: 10%; text-align: right"&gt;2,550,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z3bGmx2GXlVh" style="width: 10%; text-align: right"&gt;7,337,976&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z0sVZ7oZ6XXi" style="width: 10%; text-align: right"&gt;7,309,174&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;IMVEXXY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zDQQQ4gr8uv3" style="text-align: right"&gt;6,841,592&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zmw8LC9wVHT8" style="text-align: right"&gt;4,772,354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zUy2Zc3HzfH3" style="text-align: right"&gt;18,319,382&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_ztNgP73WaH98" style="text-align: right"&gt;9,904,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;BIJUVA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--BijuvaMember_zUGGP1HjNmp4" style="text-align: right"&gt;1,646,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zvySuT2nGia2" style="text-align: right"&gt;490,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--BijuvaMember_zTF6I1TkioOc" style="text-align: right"&gt;4,109,925&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_ztMez4EZEkhi" style="text-align: right"&gt;624,987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;ANNOVERA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zrOHwGmsEkP1" style="text-align: right"&gt;6,418,990&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zgXrEZCkkDdh" style="text-align: right"&gt;399,952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRYca6rAQPKb" style="text-align: right"&gt;10,527,212&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zgkMsGbGZwxb" style="text-align: right"&gt;399,952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;License revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z3tZZfCwZfq2" style="border-bottom: Black 1pt solid; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zRHR3xdmecB" style="border-bottom: Black 1pt solid; text-align: right"&gt;15,506,400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zWr0oyyGelj" style="border-bottom: Black 1pt solid; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z2tCEaEiV2j3" style="border-bottom: Black 1pt solid; text-align: right"&gt;15,506,400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 0.375in"&gt;Net revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930_zkEoA0IraXnd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;19,342,805&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930_zmbAw1ceQvGc" style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,719,741&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930_zK5AEdek3glc" style="border-bottom: Black 2.5pt double; text-align: right"&gt;42,294,495&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930_zI1PeJS4ECPk" style="border-bottom: Black 2.5pt double; text-align: right"&gt;33,745,257&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A5_zyVKyulKSYwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <txmd:ReturnPeriodOfUnsalablePrescriptionProducts contextRef="From2020-01-012020-09-30_srt_MinimumMember">P6M</txmd:ReturnPeriodOfUnsalablePrescriptionProducts>
    <txmd:ReturnPeriodOfUnsalablePrescriptionProducts contextRef="From2020-01-012020-09-30_srt_MaximumMember">P12M</txmd:ReturnPeriodOfUnsalablePrescriptionProducts>
    <txmd:ShelfLifeOfPrescriptionProducts contextRef="From2020-01-012020-09-30_custom_VitaminsAndImvexxyMember">P24M</txmd:ShelfLifeOfPrescriptionProducts>
    <txmd:ShelfLifeOfPrescriptionProducts contextRef="From2020-01-012020-09-30_custom_BijuvaAndAnnoveraMember">P18M</txmd:ShelfLifeOfPrescriptionProducts>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_zwLSIYehkWu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&lt;span id="xdx_8BF_z1MXKnWRBXE9"&gt;The
following table provides information about disaggregated revenue by product mix&lt;/span&gt;&lt;/span&gt; for the three and nine months ended September
30, 2020 and 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;br/&gt; September 30,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Nine Months Ended&lt;br/&gt; September 30,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%; text-align: justify; padding-left: 5.4pt"&gt;Prescription vitamins&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zKejnfyswrQ" title="Net revenue"&gt;2,435,903&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z2NEamSswbvb" style="width: 10%; text-align: right"&gt;2,550,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z3bGmx2GXlVh" style="width: 10%; text-align: right"&gt;7,337,976&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z0sVZ7oZ6XXi" style="width: 10%; text-align: right"&gt;7,309,174&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;IMVEXXY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zDQQQ4gr8uv3" style="text-align: right"&gt;6,841,592&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zmw8LC9wVHT8" style="text-align: right"&gt;4,772,354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zUy2Zc3HzfH3" style="text-align: right"&gt;18,319,382&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_ztNgP73WaH98" style="text-align: right"&gt;9,904,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;BIJUVA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--BijuvaMember_zUGGP1HjNmp4" style="text-align: right"&gt;1,646,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zvySuT2nGia2" style="text-align: right"&gt;490,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--BijuvaMember_zTF6I1TkioOc" style="text-align: right"&gt;4,109,925&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_ztMez4EZEkhi" style="text-align: right"&gt;624,987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;ANNOVERA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zrOHwGmsEkP1" style="text-align: right"&gt;6,418,990&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zgXrEZCkkDdh" style="text-align: right"&gt;399,952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRYca6rAQPKb" style="text-align: right"&gt;10,527,212&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zgkMsGbGZwxb" style="text-align: right"&gt;399,952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;License revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z3tZZfCwZfq2" style="border-bottom: Black 1pt solid; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zRHR3xdmecB" style="border-bottom: Black 1pt solid; text-align: right"&gt;15,506,400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zWr0oyyGelj" style="border-bottom: Black 1pt solid; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z2tCEaEiV2j3" style="border-bottom: Black 1pt solid; text-align: right"&gt;15,506,400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 0.375in"&gt;Net revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930_zkEoA0IraXnd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;19,342,805&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930_zmbAw1ceQvGc" style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,719,741&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930_zK5AEdek3glc" style="border-bottom: Black 2.5pt double; text-align: right"&gt;42,294,495&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930_zI1PeJS4ECPk" style="border-bottom: Black 2.5pt double; text-align: right"&gt;33,745,257&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-07-012020-09-30_custom_PrescriptionVitaminsMember"
      decimals="0"
      unitRef="USD">2435903</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30_custom_PrescriptionVitaminsMember"
      decimals="0"
      unitRef="USD">2550330</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-09-30_custom_PrescriptionVitaminsMember"
      decimals="0"
      unitRef="USD">7337976</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-09-30_custom_PrescriptionVitaminsMember"
      decimals="0"
      unitRef="USD">7309174</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-07-012020-09-30_custom_ImvexxyMember"
      decimals="0"
      unitRef="USD">6841592</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30_custom_ImvexxyMember"
      decimals="0"
      unitRef="USD">4772354</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-09-30_custom_ImvexxyMember"
      decimals="0"
      unitRef="USD">18319382</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-09-30_custom_ImvexxyMember"
      decimals="0"
      unitRef="USD">9904744</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-07-012020-09-30_custom_BijuvaMember"
      decimals="0"
      unitRef="USD">1646320</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30_custom_BijuvaMember"
      decimals="0"
      unitRef="USD">490705</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-09-30_custom_BijuvaMember"
      decimals="0"
      unitRef="USD">4109925</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-09-30_custom_BijuvaMember"
      decimals="0"
      unitRef="USD">624987</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-07-012020-09-30_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">6418990</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">399952</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-09-30_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">10527212</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-09-30_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">399952</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-07-012020-09-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">15506400</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-09-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-09-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">15506400</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">19342805</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">23719741</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">42294495</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">33745257</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <txmd:LicenseAgreementWithPopulationCouncilPolicyTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_848_ecustom--LicenseAgreementWithPopulationCouncilPolicyTextBlock_zESClL4UWTW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zxUXenFGCps4"&gt;License
Agreement with the Population Council&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
July 30, 2018, we entered into the Population Council License Agreement to commercialize ANNOVERA in the U.S. We began selling
ANNOVERA in a &#x201c;test and learn&#x201d; market introduction in the third quarter of 2019. As a result of the uncertainty surrounding
the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing
initiatives into subsequent quarters. &lt;span style="color: #212529"&gt;We resumed the launch of ANNOVERA on July 1, 2020.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $&lt;span id="xdx_90B_ecustom--MilestonePaymentUponFDAApproval_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zbb7Lr3z6SL7" title="Milestone payment upon FDA Approval"&gt;20,000,000&lt;/span&gt;&#160;within
30 days following the approval by the FDA of the new drug application, or NDA, for ANNOVERA and $&lt;span title="Milestone payments (payment after release of first commercial batch)"&gt;&lt;span id="xdx_90D_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_z5iWvTjpO881" title="Milestone payments (payment after release of first commercial batch)"&gt;20,000,000&lt;/span&gt;&lt;/span&gt;&#160;within 30 days
following the first commercial batch release of ANNOVERA. Both milestone payments of $&lt;span id="xdx_909_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zhM9QBi3N3zc" title="License rights acquired"&gt;20,000,000&lt;/span&gt;&#160;were recorded as license
rights in the consolidated balance sheets. We started amortizing license rights in the third quarter of 2019 once ANNOVERA became
commercially available for use. The cost is amortized over the remaining useful life over which the license rights will contribute
directly or indirectly to our cash flows, which is estimated to be the remaining patent life of the product, which expires in
December 2032. The cost is amortized using the straight-line method as the pattern of economic benefit cannot be reliably determined.
During the three and nine months ended September 30, 2020, we recorded $&lt;span id="xdx_901_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20200701__20200930_z7CLR3V5lPjj" title="Amortization of intellectual property license fee"&gt;762,389&lt;/span&gt;&#160;and $&lt;span id="xdx_90C_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20200101__20200930_zuKZh54Yu3g7" title="Amortization of intellectual property license fee"&gt;2,262,002&lt;/span&gt;, respectively, in amortization
expense related to the license fee. During both the three and nine months ended September 30, 2019, we recorded $&lt;span id="xdx_905_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20190701__20190930_zhO37Dwc4Pod" title="Amortization of intellectual property license fee"&gt;&lt;span id="xdx_902_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20190101__20190930_zpBN7tHPZXWd" title="Amortization of intellectual property license fee"&gt;15,998&lt;/span&gt;&lt;/span&gt; in amortization
expense related to the license fee which was recorded as a component of cost of sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Population Council is also eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible
for marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council,
on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates
and permitted licensees as follows: (i) if annual net sales are less than or equal to $&lt;span id="xdx_904_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_c20200101__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_z5EMzf4wPEh3" title="Net sales amount per step-based royalty"&gt;50,000,000&lt;/span&gt;, a royalty of&#160;&lt;span id="xdx_90A_ecustom--RoyaltyPercent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zrOEsMcETNhj" title="Royalty (percent)"&gt;5&lt;/span&gt;% of net
sales; (ii) for annual net sales greater than $&lt;span id="xdx_90F_ecustom--NetSalesAmountPerStepbasedRoyalty_c20200101__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zjIiAQCur1Fk" title="Net sales amount per step-based royalty"&gt;50,000,000&lt;/span&gt;&#160;and less than or equal to $&lt;span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_c20200101__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zP1BhwjvVltk"&gt;150,000,000&lt;/span&gt;, a royalty of&#160;&lt;span id="xdx_906_ecustom--RoyaltyPercent_pii_dp_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_ztvmIGBhNfpb" title="Royalty (percent)"&gt;10&lt;/span&gt;% of
such net sales; and (iii) for net sales greater than $&lt;span id="xdx_906_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_c20200101__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zhW87utZf6c9" title="Net sales amount per step-based royalty"&gt;150,000,000&lt;/span&gt;, a royalty of&#160;&lt;span id="xdx_907_ecustom--RoyaltyPercent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zIl6CGAPDBre" title="Royalty (percent)"&gt;15&lt;/span&gt;% of such net sales. The annual royalty
rate will be reduced to&#160;&lt;span id="xdx_901_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zkVZ25eQpoGk" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"&gt;50&lt;/span&gt;% of the initial rate during the six-month period beginning on the date of the first arms-length
commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the
U.S., and thereafter will be reduced to&#160;&lt;span id="xdx_907_ecustom--AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zrMItUXCRLZg" title="Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent"&gt;20&lt;/span&gt;% of the initial rate. We are required to pay the Population Council milestone
payments of $&lt;span id="xdx_90D_ecustom--MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_pp0p0_dm_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zohSQUs9Uz4d" title="Milestone payments upon specified levels of cumulative net sales"&gt;40 million&lt;/span&gt;&#160;upon cumulative net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees
of each of $&lt;span id="xdx_909_ecustom--SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_pn6n6_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zkw86Ij00lI6" title="Specified level one of cumulative net sales for milestone payments"&gt;200&lt;/span&gt;&#160;million, $&lt;span id="xdx_901_ecustom--SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_pn6n6_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zGDyxwW763r7" title="Specified level two of cumulative net sales for milestone payments"&gt;400&lt;/span&gt;&#160;million&#160;and $&lt;span id="xdx_90F_ecustom--SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_pn9n9_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_z4UimISN9gpk" title="Specified level three of cumulative net sales for milestone payments"&gt;1&lt;/span&gt;&#160;billion. The Population Council has agreed to perform and pay
the costs and expenses associated with four post-approval studies required by the FDA for ANNOVERA and we have agreed to perform
and pay the costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism,
provided that if the costs and expenses associated with such post-approval study exceed $&lt;span id="xdx_903_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_pii_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zNOQIfJLTYc6" title="Maximum costs and expenses for post approval"&gt;20,000,000&lt;/span&gt;, half of such excess will
be offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement.
We and the Population Council have agreed to form a joint product committee responsible for overseeing activities under the Population
Council License Agreement. We will be responsible for all aspects of promotion, product positioning, pricing, education programs,
publications, sales messages and any additional desired clinical studies for the one-year vaginal contraceptive system, subject
to oversight and decisions made by the joint product committee. The Population Council License Agreement includes exclusive rights
for us to negotiate co-development of two other investigational vaginal contraceptive systems in development by the Population
Council.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;





</txmd:LicenseAgreementWithPopulationCouncilPolicyTextBlock>
    <txmd:MilestonePaymentUponFDAApproval
      contextRef="From2020-01-012020-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreementMember"
      decimals="0"
      unitRef="USD">20000000</txmd:MilestonePaymentUponFDAApproval>
    <txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch
      contextRef="From2020-01-012020-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreementMember"
      decimals="0"
      unitRef="USD">20000000</txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="From2020-01-012020-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreementMember"
      decimals="0"
      unitRef="USD">20000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <txmd:AmortizationOfIntellectualPropertyLicenseFee
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">762389</txmd:AmortizationOfIntellectualPropertyLicenseFee>
    <txmd:AmortizationOfIntellectualPropertyLicenseFee
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">2262002</txmd:AmortizationOfIntellectualPropertyLicenseFee>
    <txmd:AmortizationOfIntellectualPropertyLicenseFee
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">15998</txmd:AmortizationOfIntellectualPropertyLicenseFee>
    <txmd:AmortizationOfIntellectualPropertyLicenseFee
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">15998</txmd:AmortizationOfIntellectualPropertyLicenseFee>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2020-01-012020-09-30_srt_MaximumMember_custom_CouncilLicenseAgreementStep1Member"
      decimals="0"
      unitRef="USD">50000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="From2020-01-012020-09-30_custom_CouncilLicenseAgreementStep1Member"
      decimals="INF"
      unitRef="Pure">0.05</txmd:RoyaltyPercent>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2020-01-012020-09-30_srt_MinimumMember_custom_CouncilLicenseAgreementStep2Member"
      decimals="0"
      unitRef="USD">50000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2020-01-012020-09-30_srt_MaximumMember_custom_CouncilLicenseAgreementStep2Member"
      decimals="0"
      unitRef="USD">150000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="From2020-01-012020-09-30_custom_CouncilLicenseAgreementStep2Member"
      decimals="INF"
      unitRef="Pure">0.10</txmd:RoyaltyPercent>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2020-01-012020-09-30_srt_MinimumMember_custom_CouncilLicenseAgreementStep3Member"
      decimals="0"
      unitRef="USD">150000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="From2020-01-012020-09-30_custom_CouncilLicenseAgreementStep3Member"
      decimals="INF"
      unitRef="Pure">0.15</txmd:RoyaltyPercent>
    <txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
      contextRef="From2020-01-012020-09-30_custom_CouncilLicenseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.50</txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent>
    <txmd:AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent
      contextRef="From2020-01-012020-09-30_custom_CouncilLicenseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.20</txmd:AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent>
    <txmd:MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales
      contextRef="From2020-01-012020-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreementMember"
      decimals="0"
      unitRef="USD">40000000</txmd:MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales>
    <txmd:SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments
      contextRef="From2020-01-012020-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreementMember"
      decimals="-6"
      unitRef="USD">200000000</txmd:SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments>
    <txmd:SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments
      contextRef="From2020-01-012020-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreementMember"
      decimals="-6"
      unitRef="USD">400000000</txmd:SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments>
    <txmd:SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments
      contextRef="From2020-01-012020-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreementMember"
      decimals="-9"
      unitRef="USD">1000000000</txmd:SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments>
    <txmd:MaximumCostsAndExpensesForPostApprovalStudyToBePaid
      contextRef="From2020-01-012020-09-30_custom_CouncilLicenseAgreementMember"
      decimals="0"
      unitRef="USD">20000000</txmd:MaximumCostsAndExpensesForPostApprovalStudyToBePaid>
    <txmd:LicenseAgreementWithKnightPolicyTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_848_ecustom--LicenseAgreementWithKnightPolicyTextBlock_zNPRMfR2xLZ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_z4pk4ByPb04g"&gt;License
Agreement with Knight&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
July 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we
granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the
Knight License Agreement, Knight paid us $&lt;span id="xdx_905_ecustom--MilestonePaymentReceivedUponRegulatoryApproval_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--KnightLicenseAgreementMember_zUkuasQPehic"&gt;2,000,000&lt;/span&gt;
in milestone fees upon the first regulatory approval in Canada for IMVEXXY and BIJUVA in the third quarter of 2020, and is
also required to pay us sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of
IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications,
submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada
within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents.
Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within
certain specified time periods or if the other party files for bankruptcy or other related matters. As part of the Knight
License Agreement, Knight is prohibited from exporting IMVEXXY and BIJUVA to the United States.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</txmd:LicenseAgreementWithKnightPolicyTextBlock>
    <txmd:MilestonePaymentReceivedUponRegulatoryApproval
      contextRef="From2020-07-012020-09-30_custom_BijuvaAndAnnoveraMember_custom_KnightLicenseAgreementMember"
      decimals="0"
      unitRef="USD">2000000</txmd:MilestonePaymentReceivedUponRegulatoryApproval>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_846_eus-gaap--CostOfSalesPolicyTextBlock_zSlKlmze6w85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zEpUISSlKSgk"&gt;Cost
of Sales&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cost
of sales includes the cost of inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping and
handling costs. The Population Council License Agreement requires payment of royalties based on the sale of future products. Such
royalties are recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related
to licensed products are classified as components of cost of sales to the extent such payments become due in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zo2CY4CWi0jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zV1WCTQZtMMl"&gt;Inventory
Obsolescence Reserve&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
evaluate inventory quarterly and record an allowance for obsolescence primarily associated with materials that are not
currently or likely to be used in production in the near future. As of September 30, 2020 and December 31, 2019, we recorded
an inventory obsolescence reserve of $&lt;span id="xdx_901_eus-gaap--InventoryValuationReserves_iI_pp0p0_c20200930_z3nH5S3tEYUi" title="Inventory valuation reserves"&gt;5,744,464&lt;/span&gt;&#160;and
$&lt;span id="xdx_909_eus-gaap--InventoryValuationReserves_iI_pp0p0_c20191231_zuB0z7VrASU6" title="Inventory valuation reserves"&gt;0&lt;/span&gt;,
respectively. The reserve recorded as of September 30, 2020 was primarily related to BIJUVA and resulted from the impact of
the COVID-19 pandemic on our business, which decreased demand for our products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryValuationReserves contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">5744464</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">0</us-gaap:InventoryValuationReserves>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zCPayzXjlSA2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zVGnNbixIvY8"&gt;Segment
Reporting&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single executive leadership team that is chaired by the Chief Executive Officer of our
Company, who oversees all operations. We do not operate separate lines of business with respect to any of our products and we
do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the
United States. Accordingly, we view our business as one reportable operating segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_z1glbuxYfOTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_z0EqH09uYUo6"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
and development, or R&amp;amp;D, expenses include internal R&amp;amp;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal
R&amp;amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO
activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;amp;D expenses include
assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes,
and scientific writing matters, including preparing protocols and FDA submissions. These consulting expenses were direct costs
associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal
R&amp;amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms,
which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services
that will be used in future R&amp;amp;D activities when the activity has been performed or when the goods have been received rather
than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed
and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO
costs are subject to revisions as such studies progress to completion. We charge revisions to expenses in the period in which
the facts that give rise to the revision become known.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zbNjWte6NqIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_820_zP0RCQHVrPW9"&gt;NOTE
4 &#x2013; INVENTORY, NET&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z27FoMC11SCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;Inventory,
net consists of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20200930_z5U8PAj7D5U7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30,&lt;br/&gt; &#160;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20191231_zT02v8DIwNxj" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;
    2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--InventoryFinishedGoods_iI_uUSD_maINzGAn_zJhFtjBfcGtb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; text-align: justify; padding-left: 5.4pt"&gt;Finished products&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;4,794,132&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;4,976,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--InventoryWorkInProcess_iI_uUSD_maINzGAn_zDR0iYpgCtih" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Work in process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;440,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,182,059&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--InventoryRawMaterialsAndSupplies_iI_uUSD_maINzGAn_zZ2qVNfta8N9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Raw materials&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,698,023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,701,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--InventoryNet_iTI_uUSD_mtINzGAn_zSQLbTIK26f7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;TOTAL INVENTORY, NET&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,932,304&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,860,716&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AA_zRC4R1ao0pC5" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_897_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z27FoMC11SCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;Inventory,
net consists of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20200930_z5U8PAj7D5U7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30,&lt;br/&gt; &#160;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20191231_zT02v8DIwNxj" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;
    2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--InventoryFinishedGoods_iI_uUSD_maINzGAn_zJhFtjBfcGtb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; text-align: justify; padding-left: 5.4pt"&gt;Finished products&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;4,794,132&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;4,976,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--InventoryWorkInProcess_iI_uUSD_maINzGAn_zDR0iYpgCtih" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Work in process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;440,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,182,059&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--InventoryRawMaterialsAndSupplies_iI_uUSD_maINzGAn_zZ2qVNfta8N9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Raw materials&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,698,023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,701,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--InventoryNet_iTI_uUSD_mtINzGAn_zSQLbTIK26f7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;TOTAL INVENTORY, NET&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,932,304&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,860,716&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">4794132</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">4976910</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">440149</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1182059</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">4698023</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5701747</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryNet contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">9932304</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11860716</us-gaap:InventoryNet>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_808_eus-gaap--OtherCurrentAssetsTextBlock_z4ddYWwpBCl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_827_zvnOGWl3DmEj"&gt;NOTE
5 &#x2013; OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zOYOeTHRUikc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;Other
current assets consist of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20200930_zTNZhfb0cnbf" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30,&lt;br/&gt; &#160;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20191231_zrsIWwqy81jg" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;
    2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAzmtR_z3evkvY2zmXd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 54%; text-align: left; padding-left: 5.4pt"&gt;Prepaid sales and marketing costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;686,346&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,583,698&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAzmtR_z8nAdlxrBsHi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Debt financing fees on undrawn tranches (Note 9)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0765"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;550,757&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--PrepaidInsurance_iI_maPEAOAzmtR_z2F7mizyJHQg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,599,906&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,812,135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--PrepaidManufacturing_iI_maPEAOAzmtR_zD3xSwrjhuO9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Prepaid manufacturing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;543,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,595,721&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzmtR_zTWiqaYmfWd2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Other prepaid costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,989,937&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,787,482&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzmtR_zJ1DIvpddX25" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.75in; padding-right: 10pt"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,819,239&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,329,793&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_zDj0TaINv2Sj" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_899_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zOYOeTHRUikc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;Other
current assets consist of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20200930_zTNZhfb0cnbf" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30,&lt;br/&gt; &#160;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20191231_zrsIWwqy81jg" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;
    2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAzmtR_z3evkvY2zmXd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 54%; text-align: left; padding-left: 5.4pt"&gt;Prepaid sales and marketing costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;686,346&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,583,698&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAzmtR_z8nAdlxrBsHi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Debt financing fees on undrawn tranches (Note 9)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0765"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;550,757&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--PrepaidInsurance_iI_maPEAOAzmtR_z2F7mizyJHQg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,599,906&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,812,135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--PrepaidManufacturing_iI_maPEAOAzmtR_zD3xSwrjhuO9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Prepaid manufacturing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;543,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,595,721&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzmtR_zTWiqaYmfWd2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Other prepaid costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,989,937&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,787,482&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzmtR_zJ1DIvpddX25" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.75in; padding-right: 10pt"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,819,239&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,329,793&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <txmd:PrepaidSalesAndMarketingCostsCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">686346</txmd:PrepaidSalesAndMarketingCostsCurrent>
    <txmd:PrepaidSalesAndMarketingCostsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1583698</txmd:PrepaidSalesAndMarketingCostsCurrent>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">550757</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:PrepaidInsurance contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">3599906</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1812135</us-gaap:PrepaidInsurance>
    <txmd:PrepaidManufacturing contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">543050</txmd:PrepaidManufacturing>
    <txmd:PrepaidManufacturing contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2595721</txmd:PrepaidManufacturing>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">3989937</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">4787482</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">8819239</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11329793</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zNKkQipCW9Vd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82E_zkKdOm48YCQf"&gt;NOTE
6 &#x2013; FIXED ASSETS, NET&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zD5SrQtIcLT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;Fixed
assets, net consist of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20200930_zshcAQePpHz1" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30,&lt;br/&gt; &#160;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20191231_zaOonnrrItf4" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;
    2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left; padding-left: 5.4pt"&gt;Accounting system&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zW0GiXH9G3p4" style="width: 10%; text-align: right" title="TOTAL FIXED ASSETS"&gt;301,096&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z5fEDds8i5i6" style="width: 10%; text-align: right"&gt;301,096&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zWlsRjUPWYP1" style="text-align: right" title="TOTAL FIXED ASSETS"&gt;1,658,258&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zlmS80uBzi6j" style="text-align: right"&gt;1,619,646&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z5xX5IOq9fv4" style="text-align: right" title="TOTAL FIXED ASSETS"&gt;1,406,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zOsgU67cMY66" style="text-align: right"&gt;1,406,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Computer hardware&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zbLQ8uwDG3mk" style="text-align: right" title="TOTAL FIXED ASSETS"&gt;80,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zt274pS2tUT7" style="text-align: right"&gt;80,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zAjE9miBz6f2" style="border-bottom: Black 1pt solid; text-align: right" title="TOTAL FIXED ASSETS"&gt;68,788&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6FGsklpvoxc" style="border-bottom: Black 1pt solid; text-align: right"&gt;68,788&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzuyq_z2OECk4eH9cb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.625in; padding-right: 10pt"&gt;TOTAL FIXED ASSETS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,515,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,476,599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzuyq_zkoewWMaMsv1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,545,282&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(968,824&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzuyq_z6TXxXANuqJb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.375in; padding-right: 10pt"&gt;TOTAL FIXED ASSETS, NET&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,969,929&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,507,775&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A3_zUL09iHHnEMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation
expense for the three months ended September 30, 2020 and 2019 was $&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20200701__20200930_zOhS4HPggOpe" title="Depreciation expense"&gt;188,810&lt;/span&gt;&lt;span&gt;&#160;and
$&lt;/span&gt;&lt;span id="xdx_90D_eus-gaap--Depreciation_pp0p0_c20190701__20190930_zZZvwnwPnUTk" title="Depreciation expense"&gt;90,700&lt;/span&gt;&lt;span&gt;, respectively, and for the nine months ended September 30, 2020 and 2019
was $&lt;/span&gt;&lt;span id="xdx_907_eus-gaap--Depreciation_pp0p0_c20200101__20200930_zEQ8zkG3imee" title="Depreciation expense"&gt;576,459&lt;/span&gt;&lt;span&gt;&#160;and $&lt;/span&gt;&lt;span id="xdx_907_eus-gaap--Depreciation_pp0p0_c20190101__20190930_zbOAAwYcaOO6" title="Depreciation expense"&gt;223,750&lt;/span&gt;&lt;span&gt;, respectively.
&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zD5SrQtIcLT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;Fixed
assets, net consist of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20200930_zshcAQePpHz1" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30,&lt;br/&gt; &#160;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20191231_zaOonnrrItf4" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;
    2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left; padding-left: 5.4pt"&gt;Accounting system&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zW0GiXH9G3p4" style="width: 10%; text-align: right" title="TOTAL FIXED ASSETS"&gt;301,096&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z5fEDds8i5i6" style="width: 10%; text-align: right"&gt;301,096&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zWlsRjUPWYP1" style="text-align: right" title="TOTAL FIXED ASSETS"&gt;1,658,258&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zlmS80uBzi6j" style="text-align: right"&gt;1,619,646&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z5xX5IOq9fv4" style="text-align: right" title="TOTAL FIXED ASSETS"&gt;1,406,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zOsgU67cMY66" style="text-align: right"&gt;1,406,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Computer hardware&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zbLQ8uwDG3mk" style="text-align: right" title="TOTAL FIXED ASSETS"&gt;80,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zt274pS2tUT7" style="text-align: right"&gt;80,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zAjE9miBz6f2" style="border-bottom: Black 1pt solid; text-align: right" title="TOTAL FIXED ASSETS"&gt;68,788&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6FGsklpvoxc" style="border-bottom: Black 1pt solid; text-align: right"&gt;68,788&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzuyq_z2OECk4eH9cb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.625in; padding-right: 10pt"&gt;TOTAL FIXED ASSETS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,515,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,476,599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzuyq_zkoewWMaMsv1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,545,282&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(968,824&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzuyq_z6TXxXANuqJb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.375in; padding-right: 10pt"&gt;TOTAL FIXED ASSETS, NET&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,969,929&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,507,775&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-09-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      unitRef="USD">301096</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      unitRef="USD">301096</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-09-30_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">1658258</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">1619646</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-09-30_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">1406858</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">1406858</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-09-30_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">80211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">80211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-09-30_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">68788</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">68788</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">3515211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">3476599</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">1545282</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">968824</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">1969929</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2507775</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">188810</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">90700</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">576459</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">223750</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_802_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zowlklt9L3Md" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_826_znn2ph4EEmz"&gt;NOTE
7 &#x2013; INTANGIBLE ASSETS, NET&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zQ7rLu3fyk7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;The
following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets
as of September 30, 2020 and December 31, 2019:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Gross Carrying Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net&lt;br/&gt; Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted- Average&lt;br/&gt; Remaining Amortization
    Period (yrs.)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zcndpuWSOkxd" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Gross"&gt;4,108,745&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zT8YN1FkBoYg" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization"&gt;(679,959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zFVvC1C5NdF3" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Net"&gt;3,428,786&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zObdTbfHdJdb" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;12.25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zBNtQL8fa47g" style="text-align: right" title="Finite-Lived Intangible Assets, Gross"&gt;1,760,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zIMkqnkYoGCf" style="text-align: right" title="Finite-Lived Intangible Assets, Net"&gt;1,760,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Non-amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in"&gt;Multiple trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20200930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zIu7kB4Khspe" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks"&gt;348,176&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20200930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zsm7MR4r2CXi" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)"&gt;348,176&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.625in; text-indent: -0.125in; padding-right: 10pt"&gt;TOTAL&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20200930_zsoTsNWAQLw6" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)"&gt;6,217,844&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20200930_zMZWyL4XpNUb" style="border-bottom: Black 2.5pt double; text-align: right"&gt;(679,959&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20200930_zS4NdEtnGoZ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net"&gt;5,537,885&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Gross Carrying Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net&lt;br/&gt; Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted- Average&lt;br/&gt; Remaining Amortization
    Period (yrs.)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zy7FKrAtL3n8" style="width: 10%; text-align: right"&gt;3,463,082&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zfTrTI8UtTE1" style="width: 10%; text-align: right"&gt;(478,983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zcbMKJnrPMgf" style="width: 10%; text-align: right"&gt;2,984,099&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zmi7bd5E8OGk" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in"&gt;Hormone therapy drug candidate patents &#160;(pending)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z9yVdZwy4bVe" style="text-align: right"&gt;1,979,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zSaeK4vCLP7d" style="text-align: right"&gt;1,979,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"&gt;Multiple trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zGbPnFHgdsU3" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks"&gt;294,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zSi7S5C0JTwk" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)"&gt;294,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-right: 10pt; padding-left: 0.5in"&gt;TOTAL&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20191231_zoVg8icnFi7d" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)"&gt;5,737,194&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231_zDdsyjH116n7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;(478,983&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20191231_zjzSP5boAYLb" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net"&gt;5,258,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A4_ziJmNk4pJBsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent
is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated
useful life of approximately&#160;&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zX0WFC8sEiU7" title="Finite-Lived Intangible Asset, Useful Life"&gt;20&lt;/span&gt;&#160;years, which is the life of intellectual property patents. If the patent is not granted,
we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During
the nine months ended September 30, 2020 and 2019, we wrote off $&lt;span id="xdx_908_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pp0p0_c20200101__20200930_zEqH37p5BYR7" title="Write off of patent and trademark costs"&gt;584,509&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pp0p0_c20190101__20190930_z1HQK0NPv6bl" title="Write off of patent and trademark costs"&gt;78,864&lt;/span&gt;, respectively,&#160;in costs related to trademarks
and patents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of September 30, 2020, we had&#160;&lt;span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsMember_zvhgTOoolh2a" title="Number of issued patents"&gt;35&lt;/span&gt;&#160;issued domestic patents and&#160;&lt;span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsMember_z4TzhWTmboz2" title="Number of issued patents"&gt;35&lt;/span&gt;&#160;issued foreign patents, including:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsBijuvaMember_zxCrLKZenYMj" title="Number of issued patents"&gt;14&lt;/span&gt;
                                         domestic patents and &lt;span id="xdx_90F_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsBijuvaMember_zc5vZMnYaZM2" title="Number of issued patents"&gt;seven&lt;/span&gt; foreign patents that relate to BIJUVA as well as &lt;span id="xdx_90C_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsEstradiolAndProgesteroneCandidatesMember_zUrHwEOUUII3"&gt;three&lt;/span&gt; domestic
                                         patents that relate to estradiol and progesterone product candidates. These patents establish
                                         an important intellectual property foundation and are owned by us. The domestic patents
                                         will expire in 2032. The foreign patents will expire no earlier than 2032. In addition,
                                         we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia,
                                         Brazil, Canada, China, Europe, Hong Kong, Israel, Japan, Mexico, New Zealand, Russia,
                                         South Africa, and South Korea.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsImvexxyMember_z3KQgaGeHzlg" title="Number of issued patents"&gt;Ten&lt;/span&gt;&#160;domestic
                                         patents (&lt;span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSUtilityPatentsImvexxyMember_z6GfXZ1OVPB" title="Number of issued patents"&gt;eight&lt;/span&gt;&#160;utility and&#160;&lt;span id="xdx_907_ecustom--NumberOfIssuedPatents_iI_dc_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSDesignPatentsImvexxyMember_zVPCI27LvHV9" title="Number of issued patents"&gt;two&lt;/span&gt;&#160;design) and&#160;&lt;span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsImvexxyMember_zS4Mx0opSJnf" title="Number of issued patents"&gt;16&lt;/span&gt;&#160;foreign patents
                                         (&lt;span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentsImvexxyMember_zedi9vQ5MRpc" title="Number of issued patents"&gt;six&lt;/span&gt;&#160;utility and&#160;&lt;span id="xdx_90E_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignDesignPatentsImvexxyMember_zGVIa8cDElx6" title="Number of issued patents"&gt;ten&lt;/span&gt;&#160;design) that relate to IMVEXXY. These patents establish
                                         an important intellectual property foundation for IMVEXXY and are owned by us. The domestic
                                         patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier
                                         than 2033. The foreign design patents provide protection expiring no earlier than 2025.
                                         In certain countries, the foreign design patents provide protection through at least
                                         2037. In addition, we have pending patent applications related to IMVEXXY in the U.S.,
                                         Argentina, Australia, Brazil, Canada, Europe, Hong Kong, Israel, Japan, Mexico, New Zealand,
                                         Russia, South Africa, and South Korea.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;





&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTopicalCreamCandidatesMember_z1kW2DLjR936" title="Number of issued patents"&gt;One&lt;/span&gt;&#160;domestic
                                         utility patent that relates to our topical-cream candidates, which is owned by us. The
                                         domestic patent will expire in 2035.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTransdermalPatchMember_zznGE3DMxMXi" title="Number of issued patents"&gt;One&lt;/span&gt;&#160;domestic
                                         utility patent and&#160;&lt;span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_dc_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentTransdermalPatchMember_zd9Ko0fHz9yh"&gt;eight&lt;/span&gt;&#160;foreign patents that relate to our transdermal-patch
                                         candidates, which are owned by us. The domestic utility patent will expire in 2032. The
                                         foreign patents will expire no earlier than 2033. We have pending patent applications
                                         with respect to our transdermal-patch candidates in the U.S., Brazil, Canada, Mexico,
                                         and South Africa.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTx009HRMember_zU7wmSGHshla" title="Number of issued patents"&gt;Three&lt;/span&gt;&#160;domestic
                                         utility patents that relate to TX-009HR, a progesterone and estradiol product candidate,
                                         which are owned by us and will expire in 2037.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsProgesteroneFormulationsMember_zsSiHwpXiezd" title="Number of issued patents"&gt;Two&lt;/span&gt;&#160;domestic
                                         and&#160;&lt;span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsProgesteroneFormulationsMember_zNjMzCkPoRij" title="Number of issued patents"&gt;four&lt;/span&gt;&#160;foreign patents that relate to formulations containing progesterone,
                                         which are owned by us. The domestic patents will expire between 2032 and 2036. The foreign
                                         patents will expire no earlier than 2033.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentOperaMember_zb3xrCKblDdb" title="Number of issued patents"&gt;One&lt;/span&gt;&#160;domestic
                                         utility patent that relates to our OPERA information-technology platform, which is owned
                                         by us and will expire in 2031.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z4V1CUC0hoy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization
expense was $&lt;span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20200701__20200930_zUMstwvHguKh"&gt;69,977&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;and
$&lt;span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20190701__20190930_zef1mEBbIYZd"&gt;51,259&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;for
the three months ended September 30, 2020 and 2019, respectively, and $&lt;span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20200101__20200930_zdlMR4nQhdSe"&gt;200,879&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;and
$&lt;span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20190101__20190930_zKWSvIWlGIwj"&gt;140,206&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;for
the nine months ended September 30, 2020 and 2019, respectively. &lt;span id="xdx_8B3_zuQh9i88rL45"&gt;Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ending&lt;br/&gt; December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2px"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Estimated &lt;br/&gt;
    Amortization&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020 (3 months)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_uUSD_c20200930_zuJLzRelx1ob" style="width: 18%; text-align: right" title="2020 (3 months)"&gt;69,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_uUSD_c20200930_zfNvcy4TE9Ka" style="text-align: right" title="2021"&gt;279,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_uUSD_c20200930_zaomUZJ6Dvb6" style="text-align: right" title="2022"&gt;279,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_uUSD_c20200930_zUyu8cnU1idj" style="text-align: right" title="2023"&gt;279,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_uUSD_c20200930_zGx3RJsGkfP4" style="text-align: right" title="2024"&gt;279,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A3_zeYwC5mhU5Ag" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_896_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zQ7rLu3fyk7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;The
following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets
as of September 30, 2020 and December 31, 2019:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Gross Carrying Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net&lt;br/&gt; Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted- Average&lt;br/&gt; Remaining Amortization
    Period (yrs.)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zcndpuWSOkxd" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Gross"&gt;4,108,745&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zT8YN1FkBoYg" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization"&gt;(679,959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zFVvC1C5NdF3" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Net"&gt;3,428,786&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zObdTbfHdJdb" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;12.25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zBNtQL8fa47g" style="text-align: right" title="Finite-Lived Intangible Assets, Gross"&gt;1,760,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zIMkqnkYoGCf" style="text-align: right" title="Finite-Lived Intangible Assets, Net"&gt;1,760,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Non-amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in"&gt;Multiple trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20200930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zIu7kB4Khspe" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks"&gt;348,176&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20200930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zsm7MR4r2CXi" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)"&gt;348,176&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.625in; text-indent: -0.125in; padding-right: 10pt"&gt;TOTAL&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20200930_zsoTsNWAQLw6" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)"&gt;6,217,844&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20200930_zMZWyL4XpNUb" style="border-bottom: Black 2.5pt double; text-align: right"&gt;(679,959&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20200930_zS4NdEtnGoZ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net"&gt;5,537,885&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Gross Carrying Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net&lt;br/&gt; Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted- Average&lt;br/&gt; Remaining Amortization
    Period (yrs.)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zy7FKrAtL3n8" style="width: 10%; text-align: right"&gt;3,463,082&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zfTrTI8UtTE1" style="width: 10%; text-align: right"&gt;(478,983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zcbMKJnrPMgf" style="width: 10%; text-align: right"&gt;2,984,099&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zmi7bd5E8OGk" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in"&gt;Hormone therapy drug candidate patents &#160;(pending)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z9yVdZwy4bVe" style="text-align: right"&gt;1,979,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zSaeK4vCLP7d" style="text-align: right"&gt;1,979,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"&gt;Multiple trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zGbPnFHgdsU3" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks"&gt;294,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zSi7S5C0JTwk" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)"&gt;294,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-right: 10pt; padding-left: 0.5in"&gt;TOTAL&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20191231_zoVg8icnFi7d" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)"&gt;5,737,194&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231_zDdsyjH116n7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;(478,983&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20191231_zjzSP5boAYLb" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net"&gt;5,258,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">4108745</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">679959</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2020-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">3428786</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2020-01-012020-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P12Y3M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-09-30_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1760923</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2020-09-30_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1760923</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedTrademarks
      contextRef="AsOf2020-09-30_custom_MultipleTrademarksMember"
      decimals="0"
      unitRef="USD">348176</us-gaap:IndefiniteLivedTrademarks>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2020-09-30_custom_MultipleTrademarksMember"
      decimals="0"
      unitRef="USD">348176</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">6217844</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">679959</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">5537885</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">3463082</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">478983</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">2984099</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P13Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1979299</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1979299</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedTrademarks
      contextRef="AsOf2019-12-31_custom_MultipleTrademarksMember"
      decimals="0"
      unitRef="USD">294813</us-gaap:IndefiniteLivedTrademarks>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2019-12-31_custom_MultipleTrademarksMember"
      decimals="0"
      unitRef="USD">294813</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5737194</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">478983</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5258211</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-012020-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">584509</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">78864</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_DomesticUSPatentsMember"
      decimals="INF"
      unitRef="Number">35</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_ForeignPatentsMember"
      decimals="INF"
      unitRef="Number">35</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_DomesticPatentsBijuvaMember"
      decimals="0"
      unitRef="Number">14</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_ForeignPatentsBijuvaMember"
      decimals="0"
      unitRef="Number">7</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_DomesticPatentsEstradiolAndProgesteroneCandidatesMember"
      decimals="0"
      unitRef="Number">3</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_DomesticUSPatentsImvexxyMember"
      decimals="0"
      unitRef="Number">10</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_DomesticUSUtilityPatentsImvexxyMember"
      decimals="0"
      unitRef="Number">8</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_DomesticUSDesignPatentsImvexxyMember"
      decimals="0"
      unitRef="Number">2</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_ForeignPatentsImvexxyMember"
      decimals="0"
      unitRef="Number">16</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_ForeignUtilityPatentsImvexxyMember"
      decimals="0"
      unitRef="Number">6</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_ForeignDesignPatentsImvexxyMember"
      decimals="0"
      unitRef="Number">10</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_DomesticUtilityPatentTopicalCreamCandidatesMember"
      decimals="0"
      unitRef="Number">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_DomesticUtilityPatentTransdermalPatchMember"
      decimals="0"
      unitRef="Number">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_ForeignUtilityPatentTransdermalPatchMember"
      decimals="0"
      unitRef="Number">8</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_DomesticUtilityPatentTx009HRMember"
      decimals="0"
      unitRef="Number">3</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_DomesticPatentsProgesteroneFormulationsMember"
      decimals="0"
      unitRef="Number">2</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_ForeignPatentsProgesteroneFormulationsMember"
      decimals="0"
      unitRef="Number">4</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-09-30_custom_DomesticUtilityPatentOperaMember"
      decimals="0"
      unitRef="Number">1</txmd:NumberOfIssuedPatents>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z4V1CUC0hoy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization
expense was $&lt;span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20200701__20200930_zUMstwvHguKh"&gt;69,977&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;and
$&lt;span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20190701__20190930_zef1mEBbIYZd"&gt;51,259&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;for
the three months ended September 30, 2020 and 2019, respectively, and $&lt;span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20200101__20200930_zdlMR4nQhdSe"&gt;200,879&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;and
$&lt;span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20190101__20190930_zKWSvIWlGIwj"&gt;140,206&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;for
the nine months ended September 30, 2020 and 2019, respectively. &lt;span id="xdx_8B3_zuQh9i88rL45"&gt;Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ending&lt;br/&gt; December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2px"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Estimated &lt;br/&gt;
    Amortization&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020 (3 months)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_uUSD_c20200930_zuJLzRelx1ob" style="width: 18%; text-align: right" title="2020 (3 months)"&gt;69,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_uUSD_c20200930_zfNvcy4TE9Ka" style="text-align: right" title="2021"&gt;279,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_uUSD_c20200930_zaomUZJ6Dvb6" style="text-align: right" title="2022"&gt;279,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_uUSD_c20200930_zUyu8cnU1idj" style="text-align: right" title="2023"&gt;279,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_uUSD_c20200930_zGx3RJsGkfP4" style="text-align: right" title="2024"&gt;279,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">69977</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">279909</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">279909</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">279909</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">279909</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_809_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z9ztfjXAqfj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82A_ze3wETkBa5u9"&gt;NOTE
8&#x2013; OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_z47uqXV0qdcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
current liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20200930_z2UXOuVdXdV" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30,&lt;br/&gt; 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20191231_zhaxBHxeebj6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;
    2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--AccruedSalariesCurrent_iI_maOLCz3D1_zfWGmRvrEpl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 54%; text-align: justify; padding-left: 5.4pt"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;4,381,729&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;8,040,278&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCz3D1_zzK3HTf3QqH" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Allowance for coupons and returns&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,353,403&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,316,298&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCz3D1_z8U82KLNYREj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Accrued sales and marketing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,578,971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,285,662&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--AccruedVacationCurrent_iI_maOLCz3D1_zy2BO8mJBhZ3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Accrued compensated absences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,558,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,463,878&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCz3D1_z9ALBRofLxWf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Allowance for wholesale distributor fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,130,230&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,347,122&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCz3D1_zGf1Vg9E8o1k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Accrued legal and accounting expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,052,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;422,336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--AccruedResearchAndDevelopment_iI_maOLCz3D1_zWPlBP8Uhmxc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Accrued research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,059,077&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,049,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCz3D1_zsvnhSKLw4n9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,404,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,501,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--AccruedRebates_iI_maOLCz3D1_zZvhpyeHpvx" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Accrued rebates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,629,732&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,916,672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCz3D1_z7PSnGJp0Nhk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,072,066&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,480,225&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCz3D1_zq0QmxmnADJk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0.125in; padding-left: 0.25in"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,220,484&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;33,823,613&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A0_zLLbs11p2yfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_896_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_z47uqXV0qdcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
current liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20200930_z2UXOuVdXdV" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30,&lt;br/&gt; 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20191231_zhaxBHxeebj6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;
    2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--AccruedSalariesCurrent_iI_maOLCz3D1_zfWGmRvrEpl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 54%; text-align: justify; padding-left: 5.4pt"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;4,381,729&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;8,040,278&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCz3D1_zzK3HTf3QqH" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Allowance for coupons and returns&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,353,403&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,316,298&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCz3D1_z8U82KLNYREj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Accrued sales and marketing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,578,971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,285,662&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--AccruedVacationCurrent_iI_maOLCz3D1_zy2BO8mJBhZ3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Accrued compensated absences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,558,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,463,878&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCz3D1_z9ALBRofLxWf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Allowance for wholesale distributor fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,130,230&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,347,122&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCz3D1_zGf1Vg9E8o1k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Accrued legal and accounting expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,052,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;422,336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--AccruedResearchAndDevelopment_iI_maOLCz3D1_zWPlBP8Uhmxc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Accrued research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,059,077&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,049,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCz3D1_zsvnhSKLw4n9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,404,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,501,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--AccruedRebates_iI_maOLCz3D1_zZvhpyeHpvx" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Accrued rebates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,629,732&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,916,672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCz3D1_z7PSnGJp0Nhk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,072,066&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,480,225&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCz3D1_zq0QmxmnADJk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0.125in; padding-left: 0.25in"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,220,484&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;33,823,613&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">4381729</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">8040278</us-gaap:AccruedSalariesCurrent>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">8353403</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">10316298</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">1578971</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">3285662</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">2558055</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1463878</us-gaap:AccruedVacationCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">2130230</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2347122</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">1052935</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">422336</us-gaap:AccruedProfessionalFeesCurrent>
    <txmd:AccruedResearchAndDevelopment contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">1059077</txmd:AccruedResearchAndDevelopment>
    <txmd:AccruedResearchAndDevelopment contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1049603</txmd:AccruedResearchAndDevelopment>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">2404286</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1501539</us-gaap:OperatingLeaseLiabilityCurrent>
    <txmd:AccruedRebates contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">6629732</txmd:AccruedRebates>
    <txmd:AccruedRebates contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">3916672</txmd:AccruedRebates>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">1072066</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1480225</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">31220484</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">33823613</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_804_eus-gaap--LongTermDebtTextBlock_zmxRRFczUK8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_828_zdAjHrceEQB2"&gt;NOTE
9 &#x2013; DEBT&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
April 24, 2019, we entered into a Financing Agreement, as amended, or the Financing Agreement, with TPG Specialty Lending,
Inc., as administrative agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of
our subsidiaries party thereto from time to time as guarantors, which provides us with up to a $&lt;span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190424__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z9UqbFedBss2"&gt;300,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;first
lien secured term loan credit facility, or the Facility. The Facility provides for availability to us in three tranches: (i)
$&lt;span id="xdx_902_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190424__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zm5jCo6Y72R6"&gt;200,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;was
drawn upon entering into the Financing Agreement; (ii) $&lt;span id="xdx_902_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_zTLbIe2ZXyfa"&gt;50,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;was
drawn on February 18, 2020 following our achievement of more than $&lt;span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20191001__20191231__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember__srt--RangeAxis__srt--MinimumMember_z8ooUFyN7eij"&gt;11,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;in
net revenues from IMVEXXY, BIJUVA and ANNOVERA for the fourth quarter of 2019 and (iii) $&lt;span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20200630__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zI7QIojnIcV8"&gt;50,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;was
previously available to us in the Administrative Agent&#x2019;s sole and absolute discretion either contemporaneously with the
delivery of our financial statements for the quarter ended June 30, 2020 or at such earlier date as the Administrative Agent
may have consented to. Due to the pause in the successful full launch of ANNOVERA caused by the COVID-19 pandemic, the
undrawn $&lt;span id="xdx_90F_ecustom--LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_iI_pp0p0_c20200930__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zYP9BrtHDmAf"&gt;50,000,000&lt;/span&gt;
tranche under the Financing Agreement is no longer available. Borrowings under the Facility accrue interest at either
(i)&#160;&lt;span id="xdx_902_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zC1sjp4MooC5"&gt;3-month
LIBOR&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;plus&#160;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zPh3oVNyJcG7"&gt;7.75&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%,
subject to a LIBOR floor of&lt;span id="xdx_90A_ecustom--LiborFloorRate_iI_pii_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z3NlJALCpVid"&gt;&#160;2.70&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
or (ii) the&#160;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zvgF7rfaf3t8"&gt;prime
rate&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;plus&#160;&lt;span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zqXwFNjObkha"&gt;6.75&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%,
subject to a prime rate floor of&#160;&lt;span id="xdx_90B_ecustom--PrimeRateFloor_iI_pii_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zjuJRIaHBXda"&gt;5.2&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
as selected by us. Interest on amounts borrowed under the Facility is payable quarterly. The outstanding principal amount of
the Facility is payable in&#160;&lt;span id="xdx_906_ecustom--NumberOfInstallmentPayments_iI_dc_uNumber_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zSlmoJGd4Z8d"&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;equal
quarterly installments beginning on June 30, 2023, with the Facility maturing on March 31, 2024. We have the right to prepay
borrowings under the Facility in whole or in part at any time, subject to a prepayment fee on the principal amount being
prepaid of (i)&#160;&lt;span id="xdx_90E_ecustom--PrepaymentFeeForFirstTwoYearsFundingPercent_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zEzT0ORvbSuh"&gt;30.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
for the first two years following the initial funding date of the applicable borrowing, (ii)&#160;&lt;span id="xdx_90E_ecustom--PrepaymentFeeThirdYearFundingPercent_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zgTNRvhrkD79"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
for the third year following the initial funding date of the applicable borrowing, (iii)&#160;&lt;span id="xdx_901_ecustom--PrepaymentFeeFourthYearFundingPercent_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zfMK9yTLmEmd"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
for the fourth year following the initial funding date of the applicable borrowing and (iv)&#160;&lt;span id="xdx_90A_ecustom--PrepaymentFeeFifthYearFundingPercent_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zfOdkgedXmVg"&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
for the fifth year following the initial funding date of the applicable borrowing but prior to March 31, 2024. In connection
with the initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility fee equal to&#160;&lt;span id="xdx_901_ecustom--FacilityFeePaidPercent_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zQhHBHa4UwL6"&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of the initial amount borrowed and will be required to pay such a facility fee in connection with any subsequent borrowings
under the Facility. We are also required to pay the Administrative Agent and the lenders an annual administrative fee in
addition to other fees and expenses. The Financing Agreement contains customary mandatory prepayments, restrictions and
covenants applicable to us that are customary for financings of this type. Among other requirements, we are required to (i)
maintain a minimum unrestricted cash balance of $&lt;span id="xdx_909_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pp0p0_uUSD_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zfmlp8AMvu62" title="Minimum cash balance requirement under credit agreement"&gt;60,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our IMVEXXY, BIJUVA and
ANNOVERA products beginning with the fiscal quarter ending December 31, 2020. Pursuant to Amendment No. 6, the minimum
required cash balance was lowered to $&lt;span id="xdx_90C_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Period1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjQAClj3WUz7" title="Minimum cash balance requirement under credit agreement"&gt;45 million&lt;/span&gt; through December 31, 2020. As of September 30, 2020, we were in compliance
with all covenants under the Financing Agreement. The Financing Agreement also includes other representations, warranties,
indemnities and events of default that are customary for financings of this type, including an event of default relating to a
change of control of the Company. Upon or after an event of default, the Administrative Agent and the lenders may declare all
or a portion of our obligations under the Financing Agreement to be immediately due and payable and exercise other rights and
remedies provided for under the Financing Agreement. The obligations of our company and its subsidiaries under the Financing
Agreement are secured, subject to customary permitted liens and other agreed upon exceptions, by a first priority perfected
security interest in all existing and after acquired assets of our company and its subsidiaries. The obligations under the
Financing Agreement will be guaranteed by each of our future direct and indirect subsidiaries, subject to certain
exceptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
May 1, 2018, we entered into a Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap,
as agent, or Agent, and as lender, and the additional lenders party thereto from time to time (together with MidCap as a lender,
the Lenders), as amended. The Credit Agreement provided a secured term loan facility in an aggregate principal amount of up to
$&lt;span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zvPqJDd4qL6i" title="Line of Credit Facility, Maximum Borrowing Capacity"&gt;200,000,000&lt;/span&gt;, or the Term Loan. Under the terms of the Credit Agreement, the Term Loan was available to be made in&#160;&lt;span id="xdx_908_ecustom--NumberOfTranchesUnderTermLoanFacility_iI_pii_dc_uNumber_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zSFKQiBm1SYe" title="Number of tranches under term loan facility"&gt;three&lt;/span&gt;&#160;separate
tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. Amounts borrowed
under the Term Loan bore interest at a rate equal to the sum of (i)&#160;&lt;span id="xdx_900_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zgKUMdybmzt3" title="Debt Instrument, Description of Variable Rate Basis"&gt;one-month LIBOR&lt;/span&gt;&#160;(subject to a LIBOR floor of&#160;&lt;span id="xdx_90A_ecustom--LiborFloorRate_iI_pii_dp_uPure_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zd7EMhguzLnk" title="LIBOR floor rate"&gt;1.50&lt;/span&gt;%)
plus (ii)&#160;&lt;span id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPure_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zzrmO32ULdl6" title="Debt Instrument, Basis Spread on Variable Rate"&gt;7.75&lt;/span&gt;% per annum.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
April 24, 2019, we terminated the Credit Agreement. A portion of the initial tranche of borrowing under the Financing Agreement
in the amount of approximately $&lt;span id="xdx_90F_eus-gaap--RepaymentsOfLinesOfCredit_pp0p0_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z7ZkmRM0D9x7" title="Repayments of Lines of Credit"&gt;81,661,000&lt;/span&gt;&#160;was used to repay all amounts outstanding under the Credit Agreement, which included
a prepayment fee of&#160;&lt;span id="xdx_909_ecustom--PrepaymentFeePercentage_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z49XYv8pNpD1" title="Prepayment fee percentage"&gt;4&lt;/span&gt;%, a repayment fee of&#160;&lt;span id="xdx_907_ecustom--RepaymentFeePercentage_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z3xeFCoh1yXd" title="Repayment fee percentage"&gt;4&lt;/span&gt;%&#160;and other fees and expenses payable to the lenders under the Credit
Agreement. As a result of the termination of the Credit Agreement, we recorded $&lt;span id="xdx_903_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_dxL_c20190401__20190630_zeU3b5K41Le8" title="Loss on extinguishment of debt::XDX::-10057632"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0988"&gt;10,057,632&lt;/span&gt;&lt;/span&gt;&#160;in loss on extinguishment of debt
in the second quarter of 2019. Interest expense for the nine months ending September 30, 2019 related to the Credit Agreement
was $&lt;span id="xdx_903_eus-gaap--InterestExpenseDebt_pp0p0_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zWHH7uGRDABj" title="Interest Expense, Debt"&gt;1,816,747&lt;/span&gt;. During the nine months ended September 30, 2019, and prior to the repayment of the Credit Agreement, we amortized
$&lt;span id="xdx_903_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zYIBtGlnXce8" title="Amortization of deferred financing fees"&gt;120,146&lt;/span&gt;&#160;of deferred financing fees as interest expense in the accompanying unaudited consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
August 5, 2020, we entered into Amendment No. 5 to the Financing Agreement, or Amendment No. 5. Amendment No. 5 adjusts the covenant
in the Financing Agreement regarding our achievement of minimum consolidated net revenue attributable to commercial sales of our
IMVEXXY, BIJUVA, and ANNOVERA products to reflect the impact of COVID-19 on our business. The covenant is effective beginning
with the fiscal quarter ending December 31, 2020. In connection with Amendment No.5 and in lieu of a cash amendment fee, we issued
to the Administrative Agent and the lenders under the Financing Agreement warrants to purchase an aggregate of &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zMmQVXcAMJ05" title="Number of warrants issued"&gt;4,752,116&lt;/span&gt; shares
of Common Stock with an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zMXmWXl161Fj" title="Warrants exercise price"&gt;1.58&lt;/span&gt; per share and a &lt;span title="Warrants term"&gt;ten&lt;/span&gt;-year term, or the Lender Warrants. The Lender Warrants were
issued pursuant to an exemption from registration under the Securities Act of 1933, as amended, and no registration rights were
issued. The Company concluded that the modification accounting model is applicable to this transaction and recognized the fair value of
the warrants as a debt discount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of September 30, 2020, we &lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;had $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z5CHZGxeM2Rf" title="Long-term Debt, Gross"&gt;250,000,000&lt;/span&gt;&#160;in
borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying consolidated
financial statements. We incurred $&lt;span id="xdx_908_eus-gaap--DeferredFinanceCostsGross_iI_pp0p0_c20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zptmA0Ehhcsa" title="Debt Issuance Costs, Gross"&gt;7,902,270&lt;/span&gt;&#160;in
deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing Agreement
have been allocated pro rata between the funded and unfunded tranches. Allocated deferred financing fees related to the two
tranches of borrowings that we received of $&lt;span id="xdx_90B_eus-gaap--DeferredFinanceCostsGross_iI_pp0p0_c20200930__custom--DebtTrancheAxis__custom--TwoTranchesMember_zzOBP6hxXg82" title="Debt Issuance Costs, Gross"&gt;7,626,891&lt;/span&gt;&#160;have
been reflected as a debt discount upon each draw and are amortized to interest expense using the effective interest method.
In addition, during the three months ended September 30, 2020, we recorded the fair value of the Lender Warrants of $&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_c20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zctco8pzxO6c" title="Fair value of warrants"&gt;7,428,179&lt;/span&gt;
as a debt discount, which is being amortized to interest expense using the effective interest method over the term of the
Financing Agreement. During the three months ended September 30, 2020, we concluded that the undrawn $&lt;span id="xdx_90A_ecustom--LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_iI_pp0p0_c20200930__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zCvq8fWLeXUc"&gt;50,000,000&lt;/span&gt;&#160;tranche
under the Financing Agreement is no longer available to us. As such, we wrote off $&lt;span id="xdx_906_eus-gaap--WriteOffOfDeferredDebtIssuanceCost_pp0p0_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zIvf9LbwiAJe" title="Write off of deferred financing fees"&gt;275,379&lt;/span&gt;
of deferred financing fees associated with the unfunded tranche, which were previously deferred as assets until such tranche
had been drawn.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three and nine months ended September 30, 2020, we amortized $&lt;span id="xdx_900_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20200701__20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zVbN83Wcvq49" title="Amortization of deferred financing fees"&gt;677,676&lt;/span&gt;&#160;and $&lt;span id="xdx_902_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20200101__20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zSTkThpiBscl" title="Amortization of deferred financing fees"&gt;1,370,118&lt;/span&gt;, respectively, of deferred financing
fees related to the Financing Agreement&#160;&lt;span&gt;as interest expense in the accompanying consolidated
financial statements.&#160;&lt;/span&gt;During the three and nine months ended September 30, 2019, we amortized $&lt;span id="xdx_904_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20190701__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zovtXntihXMe" title="Amortization of deferred financing fees"&gt;265,949&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20190101__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_ztv8WYpA6kTd" title="Amortization of deferred financing fees"&gt;462,683&lt;/span&gt;,
respectively, of deferred financing fees related to the Financing Agreement&#160;&lt;span&gt;as interest
&lt;/span&gt;expense in the accompanying consolidated financial statements. Interest on amounts borrowed under the Financing Agreement
is due and payable quarterly in arrears. Interest expense for the three and nine months ended September 30, 2020 was $&lt;span id="xdx_902_eus-gaap--InterestExpenseBorrowings_pp0p0_c20200701__20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zTuX4uHZNUf3" title="Interest Expense, Borrowings"&gt;6,726,389&lt;/span&gt;&#160;and
$&lt;span id="xdx_906_eus-gaap--InterestExpenseBorrowings_pp0p0_c20200101__20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zfu6QG49xqre" title="Interest Expense, Borrowings"&gt;19,322,847&lt;/span&gt;, respectively. Interest expense for the three and nine months ended September 30, 2019 was $&lt;span id="xdx_90A_eus-gaap--InterestExpenseBorrowings_pp0p0_c20190701__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zBSSPYylhSK6" title="Interest Expense, Borrowings"&gt;5,333,056&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--InterestExpenseBorrowings_pp0p0_c20190101__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_ziWKBaLCxBA3" title="Interest Expense, Borrowings"&gt;9,318,056&lt;/span&gt;,
respectively. The overall effective interest rate under the Financing Agreement was approximately&#160;&lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pii_dp_c20200930_z2DZUgbk066l" title="Debt Instrument, Interest Rate, Effective Percentage"&gt;12.5&lt;/span&gt;%&#160;as of September
30, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfDebtTableTextBlock_zDrNLz8c39v4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;As
of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;September 30,&lt;br/&gt;
2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: justify; padding-left: 5.4pt"&gt;Financing Agreement&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zqHJ5q3dEWK1" title="Long-term Debt, Gross"&gt;250,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zPrnnkLRHK98" title="Long-term Debt, Gross"&gt;200,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Debt discount and financing fees&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20200930_zQxR7PVfX23e" style="border-bottom: Black 1pt solid; text-align: right" title="Debt discount and financing fees"&gt;&lt;span title="Debt discount and financing fees"&gt;(12,948,798&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20191231_zFkz36vv9bSd" style="border-bottom: Black 1pt solid; text-align: right" title="Debt discount and financing fees"&gt;&lt;span title="Debt discount and financing fees"&gt;(5,365,357&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.625in"&gt;TOTAL LONG-TERM DEBT&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_c20200930_zA5CKNEgBBS9" title="TOTAL LONG-TERM DEBT"&gt;237,051,202&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_c20191231_z1w0dYI3jfpl" title="TOTAL LONG-TERM DEBT"&gt;194,634,643&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A1_zhGu5VP4ia09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
April 27, 2020, we received a loan pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic
Security Act (the &#x201c;CARES Act&#x201d;), as administered by the U.S. Small Business Administration. The loan in the principal
amount of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20200427__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_z3fr3WEprPCg" title="Principal amount"&gt;6,477,094&lt;/span&gt;&#160;(the &#x201c;PPP Loan&#x201d;) was disbursed by Bank of America, NA, a national banking association, pursuant
to a promissory note issued by the Company. Although we believed, in good faith, we were qualified for the PPP Loan under the
available regulations, as a result of newly-issued guidance, particularly with respect to publicly traded companies receiving
funding under the CARES Act, we voluntarily returned the PPP Loan proceeds on May 14, 2020.&lt;/span&gt;&lt;/p&gt;

</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-04-24_us-gaap_RevolvingCreditFacilityMember_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-04-24_us-gaap_SecuredDebtMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2020-06-30_custom_FinancingAgreementMember_custom_TrancheThreeMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <txmd:LineOfCreditFacilityUndrawnTrancheNoLongerAvailable
      contextRef="AsOf2020-09-30_custom_FinancingAgreementMember_custom_TrancheThreeMember"
      decimals="0"
      unitRef="USD">50000000</txmd:LineOfCreditFacilityUndrawnTrancheNoLongerAvailable>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember">3-month
LIBOR</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.0775</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:LiborFloorRate
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.0270</txmd:LiborFloorRate>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">prime
rate</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember"
      decimals="INF"
      unitRef="Pure">0.0675</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:PrimeRateFloor
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember"
      decimals="INF"
      unitRef="Pure">0.052</txmd:PrimeRateFloor>
    <txmd:NumberOfInstallmentPayments
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Number">4</txmd:NumberOfInstallmentPayments>
    <txmd:PrepaymentFeeForFirstTwoYearsFundingPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.300</txmd:PrepaymentFeeForFirstTwoYearsFundingPercent>
    <txmd:PrepaymentFeeThirdYearFundingPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.050</txmd:PrepaymentFeeThirdYearFundingPercent>
    <txmd:PrepaymentFeeFourthYearFundingPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.030</txmd:PrepaymentFeeFourthYearFundingPercent>
    <txmd:PrepaymentFeeFifthYearFundingPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.010</txmd:PrepaymentFeeFifthYearFundingPercent>
    <txmd:FacilityFeePaidPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.025</txmd:FacilityFeePaidPercent>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">60000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Period1Member_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">45000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <txmd:NumberOfTranchesUnderTermLoanFacility
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="INF"
      unitRef="Number">3</txmd:NumberOfTranchesUnderTermLoanFacility>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2018-04-302018-05-01_us-gaap_SecuredDebtMember">one-month LIBOR</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <txmd:LiborFloorRate
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="INF"
      unitRef="Pure">0.0150</txmd:LiborFloorRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2018-04-302018-05-01_us-gaap_RevolvingCreditFacilityMember"
      decimals="INF"
      unitRef="Pure">0.0775</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">81661000</us-gaap:RepaymentsOfLinesOfCredit>
    <txmd:PrepaymentFeePercentage
      contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember"
      decimals="INF"
      unitRef="Pure">0.04</txmd:PrepaymentFeePercentage>
    <txmd:RepaymentFeePercentage
      contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember"
      decimals="INF"
      unitRef="Pure">0.04</txmd:RepaymentFeePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="From2020-01-012020-09-30_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">1816747</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2020-01-012020-09-30_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">120146</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-08-05_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="Shares">4752116</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-08-05_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.58</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2020-09-30_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="AsOf2020-09-30_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">7902270</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="AsOf2020-09-30_custom_TwoTranchesMember"
      decimals="0"
      unitRef="USD">7626891</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2020-09-30_custom_LenderWarrantsMember"
      decimals="0"
      unitRef="USD">7428179</us-gaap:WarrantsAndRightsOutstanding>
    <txmd:LineOfCreditFacilityUndrawnTrancheNoLongerAvailable
      contextRef="AsOf2020-09-30_custom_FinancingAgreementMember_custom_TrancheThreeMember"
      decimals="0"
      unitRef="USD">50000000</txmd:LineOfCreditFacilityUndrawnTrancheNoLongerAvailable>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="From2020-07-012020-09-30_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">275379</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2020-07-012020-09-30_custom_FinancingAgreementMember226851703"
      decimals="0"
      unitRef="USD">677676</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2020-01-012020-09-30_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">1370118</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2019-07-012019-09-30_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">265949</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2019-01-012019-09-30_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">462683</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseBorrowings
      contextRef="From2020-07-012020-09-30_custom_FinancingAgreementMember226851703"
      decimals="0"
      unitRef="USD">6726389</us-gaap:InterestExpenseBorrowings>
    <us-gaap:InterestExpenseBorrowings
      contextRef="From2020-01-012020-09-30_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">19322847</us-gaap:InterestExpenseBorrowings>
    <us-gaap:InterestExpenseBorrowings
      contextRef="From2019-07-012019-09-30_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">5333056</us-gaap:InterestExpenseBorrowings>
    <us-gaap:InterestExpenseBorrowings
      contextRef="From2019-01-012019-09-30_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">9318056</us-gaap:InterestExpenseBorrowings>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-09-30" decimals="INF" unitRef="Pure">0.125</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_896_eus-gaap--ScheduleOfDebtTableTextBlock_zDrNLz8c39v4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;As
of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;September 30,&lt;br/&gt;
2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: justify; padding-left: 5.4pt"&gt;Financing Agreement&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zqHJ5q3dEWK1" title="Long-term Debt, Gross"&gt;250,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zPrnnkLRHK98" title="Long-term Debt, Gross"&gt;200,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Debt discount and financing fees&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20200930_zQxR7PVfX23e" style="border-bottom: Black 1pt solid; text-align: right" title="Debt discount and financing fees"&gt;&lt;span title="Debt discount and financing fees"&gt;(12,948,798&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20191231_zFkz36vv9bSd" style="border-bottom: Black 1pt solid; text-align: right" title="Debt discount and financing fees"&gt;&lt;span title="Debt discount and financing fees"&gt;(5,365,357&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.625in"&gt;TOTAL LONG-TERM DEBT&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_c20200930_zA5CKNEgBBS9" title="TOTAL LONG-TERM DEBT"&gt;237,051,202&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_c20191231_z1w0dYI3jfpl" title="TOTAL LONG-TERM DEBT"&gt;194,634,643&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2020-09-30_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2019-12-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">12948798</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5365357</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">237051202</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">194634643</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-04-27_custom_PaycheckProtectionProgramLoanMember"
      decimals="0"
      unitRef="USD">6477094</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_807_eus-gaap--EarningsPerShareTextBlock_zPJ3QCRowgzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82C_zo8Jm2YAmdQ5"&gt;NOTE
10 &#x2013; NET LOSS PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
calculate earnings per share, or EPS, in accordance with ASC 260,&#160;&lt;i&gt;Earnings Per Share&lt;/i&gt;, which requires the computation
and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of Common
Stock outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock
outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive
shares of our Common Stock consist of options, warrants and restricted stock units and were excluded from the calculation of diluted
earnings per share because their effect would have been anti-dilutive due to the net loss reported by us. The table below presents
potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders
for the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zdmkJXXDt6df" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &lt;br/&gt;
    2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; text-align: justify; padding-left: 5.4pt"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBYeHEayNYId" style="width: 10%; text-align: right"&gt;23,893,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUPOt79jOXy1" style="width: 10%; text-align: right"&gt;24,849,984&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztJxaI3SeQ96" style="text-align: right"&gt;6,534,687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zulTC7er37df" style="text-align: right"&gt;1,832,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Performance stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zuLqCM3vNgIj" style="text-align: right"&gt;2,422,885&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgMTAgliBORVQgTE9TUyBQRVIgU0hBUkUgKERldGFpbHMpAA__" style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zop3yhrbWp67" style="border-bottom: Black 1pt solid; text-align: right"&gt;6,029,957&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zbzLxz63fPM8" style="border-bottom: Black 1pt solid; text-align: right"&gt;1,240,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930_z0ZrZaIS9hN" style="border-bottom: Black 2.5pt double; text-align: right"&gt;38,880,709&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930_zzeYKcOaaIXc" style="border-bottom: Black 2.5pt double; text-align: right"&gt;27,922,555&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2020-01-01to2020-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zdmkJXXDt6df" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &lt;br/&gt;
    2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; text-align: justify; padding-left: 5.4pt"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBYeHEayNYId" style="width: 10%; text-align: right"&gt;23,893,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUPOt79jOXy1" style="width: 10%; text-align: right"&gt;24,849,984&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztJxaI3SeQ96" style="text-align: right"&gt;6,534,687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zulTC7er37df" style="text-align: right"&gt;1,832,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Performance stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zuLqCM3vNgIj" style="text-align: right"&gt;2,422,885&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgMTAgliBORVQgTE9TUyBQRVIgU0hBUkUgKERldGFpbHMpAA__" style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zop3yhrbWp67" style="border-bottom: Black 1pt solid; text-align: right"&gt;6,029,957&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zbzLxz63fPM8" style="border-bottom: Black 1pt solid; text-align: right"&gt;1,240,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930_z0ZrZaIS9hN" style="border-bottom: Black 2.5pt double; text-align: right"&gt;38,880,709&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930_zzeYKcOaaIXc" style="border-bottom: Black 2.5pt double; text-align: right"&gt;27,922,555&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-09-30_custom_StockOptionsMember"
      decimals="INF"
      unitRef="Shares">23893180</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-09-30_custom_StockOptionsMember"
      decimals="INF"
      unitRef="Shares">24849984</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">6534687</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1832571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-09-30_custom_PerformanceStockUnitsMember"
      decimals="INF"
      unitRef="Shares">2422885</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">6029957</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">1240000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-01to2020-09-30"
      decimals="INF"
      unitRef="Shares">38880709</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-09-30"
      decimals="INF"
      unitRef="Shares">27922555</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zvSAt3k7HW5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82C_zN2NPPDvexjl"&gt;NOTE
11 &#x2013; STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Preferred
Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
September 30, 2020, we had&#160;&lt;span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_uShares_c20200930_zhEnoIfCTdz5" title="Preferred Stock, Shares Authorized"&gt;10,000,000&lt;/span&gt;&#160;shares of preferred stock, par value $&lt;span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20200930_zVGKOst75Pb2" title="Preferred Stock, Par or Stated Value Per Share"&gt;0.001&lt;/span&gt;&#160;per share, authorized for issuance,
of which&#160;&lt;span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_dco_uShares_c20200930_zZ8SBcS5OpJi" title="Preferred Stock, Shares Issued"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_dco_uShares_c20200930_znb2ZKAXONge" title="Preferred Stock, Shares Issued"&gt;no&lt;/span&gt;&lt;/span&gt;&#160;shares were issued or outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
September 30, 2020, we had&#160;&lt;span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_uShares_c20200930_zucQzDi7MeLc"&gt;600,000,000&lt;/span&gt;&#160;shares of Common Stock authorized for issuance, of which&#160;&lt;span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_uShares_c20200930_z2X68C4DTcma"&gt;&lt;span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_uShares_c20200930_zKFP9mrzzDl7"&gt;272,812,271&lt;/span&gt;&lt;/span&gt;&#160;shares
of Common Stock were issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Issuances
During the Three and Nine Months ended September 30, 2020&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three months ended September 30, 2020, stock options to purchase an aggregate of&#160;&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20200701__20200930_zsT6ui54UaWc" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"&gt;517,891&lt;/span&gt;&#160;shares of Common Stock
were exercised for $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_uUSD_c20200701__20200930_zf9Y5A4502f3" title="Stock Issued During Period, Value, Stock Options Exercised"&gt;105,494&lt;/span&gt;&#160;in cash. During the nine months ended September 30, 2020, stock options to purchase an aggregate
of&#160;&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20200101__20200930_zjwY7wiaTv8j"&gt;1,182,195&lt;/span&gt;&#160;shares of Common Stock were exercised for $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_uUSD_c20200101__20200930_z49LEfFQB0qd"&gt;271,678&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;in
cash.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Issuances
During the Three and Nine Months ended September 30, 2019&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three months ended September 30, 2019, certain individuals exercised stock options to purchase an aggregate of &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20190701__20190930_z9LPOMHhkSNb" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"&gt;55,236&lt;/span&gt; shares
of Common Stock for $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_uUSD_c20190701__20190930_z9QCVov1SE89"&gt;8,549&lt;/span&gt; in cash. During the nine months ended September 30, 2019, certain individuals exercised stock options
to purchase an aggregate of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20190101__20190930_zCxJ5gHw5N4j"&gt;331,619&lt;/span&gt; shares of Common Stock for $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_uUSD_c20190101__20190930_z5jDRIbR8pDh"&gt;108,656&lt;/span&gt; in cash. Also, during the same period, stock options to
purchase an aggregate of &lt;span id="xdx_902_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_uShares_c20190101__20190930_zjH6ZV7s9AS" title="Number of stock options exercised in cashless exercise"&gt;12,097&lt;/span&gt; shares of Common Stock were exercised pursuant to the options&#x2019; cashless exercise provisions,
wherein an aggregate of &lt;span id="xdx_90F_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_uShares_c20190101__20190930_z7dn0Fub2uDd" title="Number of common stock issued during period for stock options exercised in cashless exercise"&gt;11,834&lt;/span&gt; shares of Common Stock were issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Warrants
to Purchase Common Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of September 30, 2020, we had warrants outstanding to purchase an aggregate of&#160;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_uUSD_c20200930_z72xqmqA2Hp6" title="Warrants and Rights Outstanding"&gt;6,534,687&lt;/span&gt;&#160;shares of Common Stock with
a weighted-average contractual remaining life of approximately&#160;&lt;span id="xdx_900_ecustom--WarrantsAndRightsWeightedAverageContractualRemainingLife_dtY_c20200101__20200930_zC7h4cfCDxb9" title="Weighted-average contractual remaining life"&gt;7.5&lt;/span&gt;&#160;years, and exercise prices ranging from $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zLnLhGwfXvv" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;0.24&lt;/span&gt;&#160;to
$&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_z6mmRC3VLI0k" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;8.20&lt;/span&gt; per share, resulting in a weighted average exercise price of $&lt;span id="xdx_900_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iI_uUSDPShares_c20200930_ztOlIeUQARIg" title="Weighted average exercise price of warrants (in dollars per share)"&gt;1.83&lt;/span&gt;&#160;per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend yield and the
term of the warrant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
connection with Amendment No. 5 and in lieu of a cash amendment fee, we issued to the Administrative Agent and the lenders
under the Financing Agreement the Lender Warrants. The fair value for the Lender Warrants was determined by using the
Black-Scholes Model on the date of the grant using a term of ten years, volatility of&#160;&lt;span id="xdx_90C_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_uPure_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_z3ZfgKakfKJ4"&gt;68.8&lt;/span&gt;%,
risk-free interest rate of&#160;&lt;span id="xdx_90C_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_dp_uPure_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zUlV9L9MJ2h8"&gt;0.34&lt;/span&gt;%
and dividend yield of&#160;&lt;span id="xdx_909_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_dp_uPure_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zTmONOJzhoN4"&gt;0&lt;/span&gt;%.
The grant date fair value of the warrants was $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_z4m7hB62utpe"&gt;1.56&lt;/span&gt;&#160;per
share. The warrants vested upon issuance. We concluded that the modification accounting model is applicable to this warrant
issuance and recognized the fair value of the warrants as a debt discount. As a result, the fair value of the Lender Warrants
is being amortized to interest expense over the term of the Financing Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
recorded share-based compensation expense related to warrants previously issued of $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_uUSD_c20200701__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zjQO02FbWAdc" title="Share-based Payment Arrangement, Noncash Expense"&gt;0&lt;/span&gt;&#160;and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_uUSD_c20190701__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zNQqecM9XJBb" title="Share-based Payment Arrangement, Noncash Expense"&gt;56,418&lt;/span&gt;&#160;for the three months
ended September 30, 2020 and 2019, respectively, and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_uUSD_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zvZ2BDIWlZs8" title="Share-based Payment Arrangement, Noncash Expense"&gt;26,446&lt;/span&gt;&#160;and $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_uUSD_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zV3wIx0Q1ZP" title="Share-based Payment Arrangement, Noncash Expense"&gt;198,306&lt;/span&gt;&#160;for the nine months ended September 30, 2020
and 2019, respectively, in the accompanying consolidated financial statements. At September 30, 2020, there was no unrecognized
compensation expense remaining related to unvested warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the nine months ended September 30, 2019, we granted warrants to purchase an aggregate of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_uShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zgGhOGKZFna8" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted"&gt;75,000&lt;/span&gt; shares of Common Stock to outside
consultants at an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zfQfPKflXv79"&gt;5.63&lt;/span&gt;. The fair value for these warrants was determined by using the Black-Scholes Model on
the date of the grant using a term of five years, volatility of &lt;span id="xdx_906_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_uPure_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z52Q5tyzUyvg" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate"&gt;60.8&lt;/span&gt;%, risk-free interest rate of &lt;span id="xdx_90A_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_dp_uPure_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zYQDsy3LXbl8"&gt;2.52&lt;/span&gt;%, and dividend yield of
&lt;span id="xdx_900_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_dp_uPure_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_ztjjmrEpa2eb"&gt;0&lt;/span&gt;%. The grant date fair value of the warrants was $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zo4xKMthRmrc"&gt;3.00&lt;/span&gt; per share. The warrants are vesting ratably over a &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zwuSwJrx0Reg"&gt;12&lt;/span&gt;-month period and
have an expiration date of February 12, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the nine months ended &lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;September 30, 2020, no
warrants were exercised. During the nine months ended September 30, 2019, warrants to purchase an aggregate of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_uShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z8oPDnVUiLW9" title="Warrants exercised"&gt;1,250,000&lt;/span&gt; shares
of Common Stock were exercised pursuant to the warrants&#x2019; cashless exercise provisions, wherein an aggregate of &lt;span id="xdx_906_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_uShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsCashlessExerciseMember_z3FmxMSSfu1l" title="Number of stock issued in cashless exercise of warrants"&gt;471,184&lt;/span&gt; shares
of Common Stock were issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Options
to Purchase Common Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees,
directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder
value by providing them stock options and other stock and cash incentives, or the Awards. As of September 30, 2020, there were
non-qualified stock options to purchase an aggregate of&#160;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zqL8xWBgwgca" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"&gt;13,346,455&lt;/span&gt;&#160;shares of Common Stock outstanding under the 2009
Plan. Effective upon our adoption of the TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no
future awards may be made under the 2009 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012
Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain
consultants and advisors of our company. As of September 30, 2020, there were non-qualified stock options to purchase an aggregate
of&#160;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zgGVylhXaDN" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"&gt;6,305,974&lt;/span&gt;&#160;shares of Common Stock outstanding and an aggregate of&#160;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_uShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zeid45xOe6uk" title="Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"&gt;890,000&lt;/span&gt;&#160;restricted stock units under the
2012 Plan. Effective upon our adoption of the 2019 Plan, no future awards may be made under the 2012 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
June 20, 2019, we adopted the 2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers,
directors, and certain consultants and advisors of our company. The Awards available under the 2019 Plan consist of stock options,
stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or
cash awards as described in the 2019 Plan. Generally, the options vest annually over four years or as determined by our board
of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis
after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any.
The expiration date is generally ten years from the date the option is issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of September 30, 2020, there were&#160;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--Plan2019Member_z5WAgZoEAxic" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"&gt;3,465,514&lt;/span&gt;&#160;shares of Common Stock available for issuance under the 2019 Plan, consisting
of (i)&#160;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--NewSharesMember_znUURUMxncIk" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"&gt;470,522&lt;/span&gt;&#160;new shares, (ii)&#160;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zT1Ts67wqhz4"&gt;2,405,833&lt;/span&gt;&#160;unallocated shares previously available for issuance under the 2012
Plan that were not then subject to outstanding &#x201c;Awards&#x201d; (as defined in the 2012 Plan), and (iii)&#160;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zocLOgd2rCEd"&gt;589,159&lt;/span&gt;&#160;unallocated
shares previously available for issuance under the 2009 Plan that were not then subject to outstanding &#x201c;Awards&#x201d; (as
defined in the 2009 Plan). Any shares subject to outstanding options or other equity &#x201c;Awards&#x201d; under the 2019 Plan,
the 2012 Plan and the 2009 Plan that are forfeited, expire or otherwise terminate without issuance of the underlying shares, or
if any such Award is settled for cash or otherwise does not result in the issuance of all or a portion of the shares subject to
such Award (other than shares tendered or withheld in connection with the exercise of an Award or the satisfaction of withholding
tax liabilities), the shares to which those Awards were subject, shall, to the extent of such forfeiture, expiration, termination,
cash settlement or non-issuance, again be available for delivery with respect to Awards under the 2019 Plan. As of September 30,
2020, there were non-qualified stock options to purchase an aggregate of&#160;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--Plan2019Member_zTH1Bc3QKXsk" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"&gt;4,240,751&lt;/span&gt;&#160;shares of Common Stock outstanding
under the 2019 Plan and an aggregate of&#160;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zR7GgdpUsfge" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number"&gt;5,139,957&lt;/span&gt;&#160;restricted stock units and&#160;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z6XALpbgdNf5" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number"&gt;2,422,885&lt;/span&gt;&#160;performance stock units
outstanding under the 2019 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zdD7a759RKPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life
of the stock options. &lt;span id="xdx_8BA_zIVltiQHsPVg"&gt;The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020
and 2019 are set forth in the table below.&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &#160;&lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &#160;&lt;br/&gt;
    2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7nmiUGQaxu6" style="width: 15%; text-align: right" title="Weighted average grant date fair value"&gt;0.95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXJkhBZg91jc" style="width: 15%; text-align: right" title="Weighted average grant date fair value"&gt;1.84&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6X436sBviji" title="Risk-free interest rate, minimum"&gt;0.34&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5ZrKfDKyAY7" title="Risk-free interest rate, maximum"&gt;1.68&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPWL2pTK1bmc" title="Risk-free interest rate, minimum"&gt;1.83&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNVqFbgIC1te" title="Risk-free interest rate, maximum"&gt;2.54&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zswuhMgxdtgh" title="Volatility, minimum"&gt;63.53&lt;/span&gt;-&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPEior3MJAf7" title="Volatility, maximum"&gt;67.92&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z928l5oTFKuj" title="Volatility, minimum"&gt;61.25&lt;/span&gt;-&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4RPVGscCE95" title="Volatility, maximum"&gt;64.49&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhiXc8Uqg33k" title="Term"&gt;6&lt;/span&gt;-&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zP9PJqIzP45f" title="Term"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrkbCvLBWz71" title="Term"&gt;5.5&lt;/span&gt;-&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwEAjWx2Yqx" title="Term"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjImzCJUI6a6" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zP4UtUna5yp5" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AA_zuk8AaiD2Qv9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zvEVXoBYoxi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&lt;span id="xdx_8BF_z3HpGB15ZkHi"&gt;A
summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September
30, 2020 is as follows&lt;/span&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Number of Shares Under Options&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Remaining Contractual Life
    in Years&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%; padding-left: 5.4pt"&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMpi6OqO93mg" style="width: 10%; text-align: right" title="Number of shares under options, beginning"&gt;25,030,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsCMYOrb9io6" style="width: 10%; text-align: right" title="Weighted average exercise price, beginning"&gt;4.65&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZlMQ5IEoPQa" style="width: 10%; text-align: right" title="Weighted average remaining contractual life"&gt;5.84&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_uUSD_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSLzDKLI7LE1" style="width: 10%; text-align: right" title="Aggregate intrinsic value, beginning"&gt;3,668,171&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&#160;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5PqqEG2zYTg" title="Number of shares under options, granted"&gt;736,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znEtZXbedyLb" style="text-align: right" title="Weighted average exercise price, granted"&gt;1.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&#160;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFtA2f1Ronkf" style="text-align: right" title="Number of shares under options, exercised"&gt;(1,182,195&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv1ExzqMrWJg" title="Weighted average exercise price, exercised"&gt;0.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zk0L9xOZXdif" style="text-align: right" title="Aggregate intrinsic value, exercised"&gt;1,738,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&#160;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zc0S5Quq7m5g" style="text-align: right" title="Number of shares under options, expired"&gt;(361,109&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z33ShYQHAqF5" title="Weighted average exercise price, expired"&gt;3.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zO96vznw0Vx" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares under options, cancelled forfeited"&gt;(330,250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHvNR8QZyfs7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, cancelled forfeited"&gt;3.69&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Balance at September 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWs2yolFYyph" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares under options, ending"&gt;23,893,180&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsrdaKRFvgm1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending"&gt;4.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwGnABLUKPUb" style="border-bottom: Black 2.5pt double; text-align: right"&gt;5.46&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_uUSD_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z48nVCNdzIzd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, ending"&gt;379,535&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Vested and Exercisable at September 30, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_uShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHIfLHq3x253" style="text-align: right" title="Number of shares under options, vested and exercisable ending"&gt;19,827,306&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpVhxHr3u6j8" style="text-align: right" title="Weighted average exercise price, vested and exercisable ending"&gt;5.06&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z22ZbK8I6yUb" style="text-align: right" title="Weighted average remaining contractual life, vested and exercisable"&gt;4.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_uUSD_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z2ttQgGxMoHh" style="text-align: right" title="Aggregate intrinsic value, vested and exercisable ending"&gt;218,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;Unvested at September 30, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_uShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcCSBP4f1Rv2" style="text-align: right" title="Number of shares under options, unvested ending"&gt;4,065,874&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zx7WEQGpllm3" style="text-align: right" title="Weighted average exercise price, unvested"&gt;3.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7ig9lkWLbx5" style="text-align: right" title="Weighted average remaining contractual life in years, unvested"&gt;8.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iI_uUSD_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zI6nICZPvFg2" style="text-align: right" title="Aggregate intrinsic value, unvested"&gt;161,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AA_zMrOAAnKwmp8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
September 30, 2020, our outstanding options had exercise prices ranging from $&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_uUSDPShares_c20200930__srt--RangeAxis__srt--MinimumMember_zRvay1vvzg33" title="Range - exercise price of options"&gt;0.38&lt;/span&gt;&#160;to $&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_uUSDPShares_c20200930__srt--RangeAxis__srt--MaximumMember_zIAHwIeOReFk"&gt;8.92&lt;/span&gt;&#160;per share. Share-based compensation
expense related to options recognized in our results of operations for the three months ended September 30, 2020 and 2019 was
$&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_uUSD_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z2btrWeGGdk" title="Share-based Payment Arrangement, Noncash Expense"&gt;1,143,920&lt;/span&gt;&#160;and $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_uUSD_c20190701__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYQ3OG6mXXDa" title="Share-based Payment Arrangement, Noncash Expense"&gt;2,194,667&lt;/span&gt;, respectively, and for the nine months ended September 30, 2020 and 2019 was $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_uUSD_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMPHCE6RaaP5" title="Share-based Payment Arrangement, Noncash Expense"&gt;4,141,061&lt;/span&gt;&#160;and
$&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_uUSD_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDuob47NDCsc" title="Share-based Payment Arrangement, Noncash Expense"&gt;6,568,736&lt;/span&gt;, respectively, and it is based on awards vested. At September 30, 2020, total unrecognized estimated compensation expense
related to unvested options was approximately $&lt;span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_uUSD_c20200930_zNJftiPd1bQb" title="Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"&gt;6,500,000&lt;/span&gt;, which may be adjusted for future changes in forfeitures. This cost is
expected to be recognized over a weighted-average period of&#160;&lt;span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqXS1YAnaLN6" title="Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"&gt;2.0&lt;/span&gt;&#160;years. No tax benefit was realized due to a continued
pattern of operating losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Restricted
Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted
stock units granted under our 2009, 2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified
number of shares of our Common Stock. Share-based compensation expense is measured by the market value of our Common Stock on
the day of the grant. The shares vest ratably over the period specified in the grant. There is no partial vesting and any unvested
portion is forfeited.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Performance
stock units will vest if certain performance targets are achieved. If minimum performance thresholds are achieved, each award
will convert into Common Stock at a defined ratio depending on the degree of achievement of the performance target designated
by each individual award. If minimum performance thresholds are not achieved, then no shares will be issued. We recognize performance-based
restricted stock as compensation expense based on the most likely probability of attaining the prescribed performance and over
the requisite service period beginning at its grant date and through the date the restricted stock vests. The expected levels
of achievement are reassessed over the requisite service periods and, to the extent that the expected levels of achievement change,
stock-based compensation is adjusted and recorded on the consolidated statements of income and the remaining unrecognized stock-based
compensation is recognized over the remaining requisite service period.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three and nine months ended September 30, 2020 we recorded $&lt;span id="xdx_903_eus-gaap--RestrictedStockExpense_uUSD_c20200701__20200930_zFGtSFm0eEyb" title="Restricted Stock or Unit Expense"&gt;1,988,844&lt;/span&gt;&#160;and $&lt;span id="xdx_90B_eus-gaap--RestrictedStockExpense_uUSD_c20200101__20200930_zI5Z354jaZO7" title="Restricted Stock or Unit Expense"&gt;4,334,537&lt;/span&gt;, respectively, and during the three
and nine months ended September 30, 2019 we recorded $&lt;span id="xdx_902_eus-gaap--RestrictedStockExpense_uUSD_c20190701__20190930_zOrihx5Db0gb" title="Restricted Stock or Unit Expense"&gt;84,061&lt;/span&gt;&#160;and $&lt;span id="xdx_90C_eus-gaap--RestrictedStockExpense_uUSD_c20190101__20190930_zQoKGoC8pfEa"&gt;1,080,738&lt;/span&gt;, respectively, in share-based compensation expense
related to restricted stock units and performance stock units. As of September 30, 2020, we recognized performance-based compensation
expense using our assessment of the most likely probability of attaining EBITDA break-even which would result in vesting two times
the base number of performance stock units. At September 30, 2020, total unrecognized estimated compensation expense related to
unvested&#160;restricted stock units and performance stock units&#160;was approximately $&lt;span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_uUSD_c20200930_zOoYfyAYB9Dh" title="Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount"&gt;11,000,000&lt;/span&gt;, which may be adjusted if
certain performance targets are achieved or for future changes in forfeitures. &lt;span&gt;This cost is expected to be recognized over a weighted-average
period&lt;/span&gt; of&#160;&lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zN8WVIO8dfy"&gt;1.6&lt;/span&gt;&#160;years.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zRZh1FI0hsz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B5_zPcTQN99nnXa"&gt;Schedule of restricted stock units and performance stock units&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&lt;span&gt;
    &lt;span&gt;Restricted Stock Units&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;Performance Stock Units&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Grant
    Date Fair Value&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Grant
    Date Fair Value&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 37%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhydhkTMslOk" style="width: 10%; text-align: right" title="Number of shares, beginning"&gt;1,240,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhpXBRtSmzb5" style="width: 10%; text-align: right" title="Weighted average grant date fair values, beginning"&gt;3.56&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3ZfVf0avEcj" style="text-align: right" title="Number of shares, granted"&gt;5,102,817&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zGNnDtTLORRg" style="text-align: right" title="Weighted average grant date fair value, granted"&gt;1.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zJbU32lgehje" style="text-align: right" title="Number of shares, granted"&gt;2,585,745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z6vXzH8k03D7" style="text-align: right" title="Weighted average grant date fair value, granted"&gt;1.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Vested/Released&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z73pf6G8bBs7" style="text-align: right" title="Number of shares, vested/released"&gt;(301,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zb0bbIou4Swk" style="text-align: right" title="Weighted average grant date fair value, vested/released"&gt;1.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zSDPWOhKe4gh" style="text-align: right" title="Number of shares, vested/released"&gt;(151,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zkapLBpAhWa8" style="text-align: right" title="Weighted average grant date fair value, vested/released"&gt;1.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1x3WApsvY06" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited"&gt;(11,360&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0xEKqoWY9S2" style="text-align: right" title="Weighted average grant date fair value, forfeited"&gt;1.07&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zk7IQBLSKi84" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited"&gt;(11,360&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z3MDo8x2uR8e" style="text-align: right" title="Weighted average grant date fair value, forfeited"&gt;1.07&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBv8lGx9ef15" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, ending"&gt;6,029,957&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXc5a2LVVRmi" style="text-align: right" title="Weighted average grant date fair values, ending"&gt;1.83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKg_____z4K4eOLt9fu" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, ending"&gt;2,422,885&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ztqvxwfpYrTl" style="text-align: right" title="Weighted average grant date fair value, ending"&gt;1.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;sup id="xdx_F01_zF3D0gJ2TQ39"&gt;*&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F19_z8KYVpaGKtM7" style="font: 10pt Times New Roman, Times, Serif"&gt;The number
of performance stock units (PSUs) represents the base number of PSUs that may vest. The actual number of PSUs that will vest will
be between zero and two times the base number of PSUs depending on the Company's achievement of break-even quarterly EBITDA.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A6_zm1hgrfziUb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Employee
Stock Purchase Plan &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
June 18, 2020, our stockholders approved the TherapeuticsMD, Inc. 2020 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;),
which reserved &lt;span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200618__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_zEKsFf6lcNQ4"&gt;5,400,000&lt;/span&gt; shares of Common Stock for purchase. The ESPP permits eligible employee participants to purchase Common
Stock at a price per share which is equal to &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dp_c20200617__20200618__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_zUn94t2uT8e2"&gt;85&lt;/span&gt;% of the lesser of (a) the fair market value of the shares on the offering date
of the offering period or (b) the fair market value of the shares on the purchase date.&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">272812271</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">272812271</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="Shares">517891</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">105494</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-01to2020-09-30"
      decimals="INF"
      unitRef="Shares">1182195</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">271678</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-07-012019-09-30"
      decimals="INF"
      unitRef="Shares">55236</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">8549</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-01-012019-09-30"
      decimals="INF"
      unitRef="Shares">331619</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">108656</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <txmd:NumberOfStockOptionsExercisedInCashlessExercise
      contextRef="From2019-01-012019-09-30"
      decimals="INF"
      unitRef="Shares">12097</txmd:NumberOfStockOptionsExercisedInCashlessExercise>
    <txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares
      contextRef="From2019-01-012019-09-30"
      decimals="INF"
      unitRef="Shares">11834</txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">6534687</us-gaap:WarrantsAndRightsOutstanding>
    <txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife contextRef="From2020-01-01to2020-09-30">P7Y6M</txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-09-30_custom_WarrantsMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-09-30_custom_WarrantsMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">8.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30"
      decimals="INF"
      unitRef="USDPShares">1.83</txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
      contextRef="From2020-01-012020-09-30_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="Pure">0.688</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
      contextRef="From2020-01-012020-09-30_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="Pure">0.0034</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
      contextRef="From2020-01-012020-09-30_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-09-30_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-07-012020-09-30_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-07-012019-09-30_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">56418</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-09-30_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">26446</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-09-30_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">198306</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="USDPShares">5.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
      contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Pure">0.608</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
      contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Pure">0.0252</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
      contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="USDPShares">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2019-01-012019-09-30_us-gaap_WarrantMember226853968"
      decimals="INF"
      unitRef="Shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants
      contextRef="From2019-01-012019-09-30_custom_WarrantsCashlessExerciseMember"
      decimals="INF"
      unitRef="Shares">471184</txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-09-30_custom_LongTermIncentiveCompensationPlan2009Member"
      decimals="INF"
      unitRef="Shares">13346455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-09-30_custom_NonQualified2012StockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">6305974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-09-30_us-gaap_RestrictedStockMember_custom_NonQualified2012StockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">890000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-09-30_custom_Plan2019Member"
      decimals="INF"
      unitRef="Shares">3465514</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-09-30_custom_NewSharesMember"
      decimals="INF"
      unitRef="Shares">470522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-09-30_custom_NonQualified2012StockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">2405833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-09-30_custom_LongTermIncentiveCompensationPlan2009Member"
      decimals="INF"
      unitRef="Shares">589159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-09-30_custom_Plan2019Member"
      decimals="INF"
      unitRef="Shares">4240751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-09-30_custom_Plan2019Member_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">5139957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-09-30_custom_Plan2019Member_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">2422885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zdD7a759RKPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life
of the stock options. &lt;span id="xdx_8BA_zIVltiQHsPVg"&gt;The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020
and 2019 are set forth in the table below.&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &#160;&lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &#160;&lt;br/&gt;
    2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7nmiUGQaxu6" style="width: 15%; text-align: right" title="Weighted average grant date fair value"&gt;0.95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXJkhBZg91jc" style="width: 15%; text-align: right" title="Weighted average grant date fair value"&gt;1.84&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6X436sBviji" title="Risk-free interest rate, minimum"&gt;0.34&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5ZrKfDKyAY7" title="Risk-free interest rate, maximum"&gt;1.68&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPWL2pTK1bmc" title="Risk-free interest rate, minimum"&gt;1.83&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNVqFbgIC1te" title="Risk-free interest rate, maximum"&gt;2.54&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zswuhMgxdtgh" title="Volatility, minimum"&gt;63.53&lt;/span&gt;-&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPEior3MJAf7" title="Volatility, maximum"&gt;67.92&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z928l5oTFKuj" title="Volatility, minimum"&gt;61.25&lt;/span&gt;-&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4RPVGscCE95" title="Volatility, maximum"&gt;64.49&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhiXc8Uqg33k" title="Term"&gt;6&lt;/span&gt;-&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zP9PJqIzP45f" title="Term"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrkbCvLBWz71" title="Term"&gt;5.5&lt;/span&gt;-&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwEAjWx2Yqx" title="Term"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjImzCJUI6a6" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zP4UtUna5yp5" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6792</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-09-30_srt_MinimumMember_us-gaap_EmployeeStockOptionMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-09-30_srt_MaximumMember_us-gaap_EmployeeStockOptionMember">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-09-30_srt_MinimumMember_us-gaap_EmployeeStockOptionMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-09-30_srt_MaximumMember_us-gaap_EmployeeStockOptionMember">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zvEVXoBYoxi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&lt;span id="xdx_8BF_z3HpGB15ZkHi"&gt;A
summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September
30, 2020 is as follows&lt;/span&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Number of Shares Under Options&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Remaining Contractual Life
    in Years&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%; padding-left: 5.4pt"&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMpi6OqO93mg" style="width: 10%; text-align: right" title="Number of shares under options, beginning"&gt;25,030,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsCMYOrb9io6" style="width: 10%; text-align: right" title="Weighted average exercise price, beginning"&gt;4.65&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZlMQ5IEoPQa" style="width: 10%; text-align: right" title="Weighted average remaining contractual life"&gt;5.84&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_uUSD_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSLzDKLI7LE1" style="width: 10%; text-align: right" title="Aggregate intrinsic value, beginning"&gt;3,668,171&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&#160;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5PqqEG2zYTg" title="Number of shares under options, granted"&gt;736,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znEtZXbedyLb" style="text-align: right" title="Weighted average exercise price, granted"&gt;1.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&#160;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFtA2f1Ronkf" style="text-align: right" title="Number of shares under options, exercised"&gt;(1,182,195&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv1ExzqMrWJg" title="Weighted average exercise price, exercised"&gt;0.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zk0L9xOZXdif" style="text-align: right" title="Aggregate intrinsic value, exercised"&gt;1,738,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&#160;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zc0S5Quq7m5g" style="text-align: right" title="Number of shares under options, expired"&gt;(361,109&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z33ShYQHAqF5" title="Weighted average exercise price, expired"&gt;3.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zO96vznw0Vx" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares under options, cancelled forfeited"&gt;(330,250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHvNR8QZyfs7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, cancelled forfeited"&gt;3.69&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Balance at September 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWs2yolFYyph" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares under options, ending"&gt;23,893,180&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsrdaKRFvgm1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending"&gt;4.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwGnABLUKPUb" style="border-bottom: Black 2.5pt double; text-align: right"&gt;5.46&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_uUSD_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z48nVCNdzIzd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, ending"&gt;379,535&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Vested and Exercisable at September 30, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_uShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHIfLHq3x253" style="text-align: right" title="Number of shares under options, vested and exercisable ending"&gt;19,827,306&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpVhxHr3u6j8" style="text-align: right" title="Weighted average exercise price, vested and exercisable ending"&gt;5.06&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z22ZbK8I6yUb" style="text-align: right" title="Weighted average remaining contractual life, vested and exercisable"&gt;4.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_uUSD_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z2ttQgGxMoHh" style="text-align: right" title="Aggregate intrinsic value, vested and exercisable ending"&gt;218,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;Unvested at September 30, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_uShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcCSBP4f1Rv2" style="text-align: right" title="Number of shares under options, unvested ending"&gt;4,065,874&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zx7WEQGpllm3" style="text-align: right" title="Weighted average exercise price, unvested"&gt;3.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7ig9lkWLbx5" style="text-align: right" title="Weighted average remaining contractual life in years, unvested"&gt;8.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iI_uUSD_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zI6nICZPvFg2" style="text-align: right" title="Aggregate intrinsic value, unvested"&gt;161,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">25030234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">P5Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">3668171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">736500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">1182195</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">0.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">1738740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">361109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">330250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">23893180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember">P5Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">379535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">19827306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember">P4Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">218370</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">4065874</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.55</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember">P8Y6M10D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue
      contextRef="AsOf2020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">161165</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice
      contextRef="AsOf2020-09-30_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.38</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice
      contextRef="AsOf2020-09-30_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">8.92</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-07-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">1143920</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-07-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">2194667</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">4141061</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">6568736</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">6500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RestrictedStockExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">1988844</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">4334537</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">84061</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">1080738</us-gaap:RestrictedStockExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">11000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockUnitsRSUMember">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zRZh1FI0hsz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B5_zPcTQN99nnXa"&gt;Schedule of restricted stock units and performance stock units&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&lt;span&gt;
    &lt;span&gt;Restricted Stock Units&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;Performance Stock Units&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Grant
    Date Fair Value&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Grant
    Date Fair Value&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 37%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhydhkTMslOk" style="width: 10%; text-align: right" title="Number of shares, beginning"&gt;1,240,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhpXBRtSmzb5" style="width: 10%; text-align: right" title="Weighted average grant date fair values, beginning"&gt;3.56&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3ZfVf0avEcj" style="text-align: right" title="Number of shares, granted"&gt;5,102,817&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zGNnDtTLORRg" style="text-align: right" title="Weighted average grant date fair value, granted"&gt;1.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zJbU32lgehje" style="text-align: right" title="Number of shares, granted"&gt;2,585,745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z6vXzH8k03D7" style="text-align: right" title="Weighted average grant date fair value, granted"&gt;1.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Vested/Released&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z73pf6G8bBs7" style="text-align: right" title="Number of shares, vested/released"&gt;(301,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zb0bbIou4Swk" style="text-align: right" title="Weighted average grant date fair value, vested/released"&gt;1.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zSDPWOhKe4gh" style="text-align: right" title="Number of shares, vested/released"&gt;(151,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zkapLBpAhWa8" style="text-align: right" title="Weighted average grant date fair value, vested/released"&gt;1.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1x3WApsvY06" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited"&gt;(11,360&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0xEKqoWY9S2" style="text-align: right" title="Weighted average grant date fair value, forfeited"&gt;1.07&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zk7IQBLSKi84" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited"&gt;(11,360&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z3MDo8x2uR8e" style="text-align: right" title="Weighted average grant date fair value, forfeited"&gt;1.07&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBv8lGx9ef15" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, ending"&gt;6,029,957&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXc5a2LVVRmi" style="text-align: right" title="Weighted average grant date fair values, ending"&gt;1.83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKg_____z4K4eOLt9fu" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, ending"&gt;2,422,885&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ztqvxwfpYrTl" style="text-align: right" title="Weighted average grant date fair value, ending"&gt;1.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;sup id="xdx_F01_zF3D0gJ2TQ39"&gt;*&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F19_z8KYVpaGKtM7" style="font: 10pt Times New Roman, Times, Serif"&gt;The number
of performance stock units (PSUs) represents the base number of PSUs that may vest. The actual number of PSUs that will vest will
be between zero and two times the base number of PSUs depending on the Company's achievement of break-even quarterly EBITDA.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2019-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">1240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2019-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">3.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">5102817</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2020-01-012020-09-30_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">2585745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-09-30_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">301500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2020-01-012020-09-30_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">151500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-09-30_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">1.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">11360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2020-01-012020-09-30_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">11360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-09-30_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">6029957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2020-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-09-30_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001285"
      unitRef="Shares">2422885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2020-09-30_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2020-06-18_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      unitRef="Shares">5400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2020-06-172020-06-18_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      unitRef="Pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zl2bkZCExrW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_822_zuyb4w5wDyre"&gt;NOTE
12 &#x2013; INCOME TAXES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred
income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. We do not expect to pay any significant federal or state income tax for 2020 as a result of (i) the losses recorded
during the nine months ended September 30, 2020, (ii) additional losses expected for the remainder of 2020, and/or (iii) net operating
loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax
assets if it is &#x201c;more likely than not&#x201d; that some component or all of the benefits of deferred tax assets will not
be realized. As of September 30, 2020, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements,
no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the
reporting period.&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_80D_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zfIGDgj1Beb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82D_zx6Re9VbXMSf"&gt;NOTE
13 &#x2013; RELATED PARTIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to
time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements
with Catalent have been reviewed by independent directors of our Company, or a committee consisting of independent directors of
our company, since July 2015. During the three months ended September 30, 2020 and 2019, we were billed by Catalent approximately
$&lt;span id="xdx_904_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200701__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zXGnvS0h23Gc" title="Amount billed"&gt;520,000&lt;/span&gt;&#160;and $&lt;span id="xdx_906_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190701__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_z5dt4b7NDic" title="Amount billed"&gt;2,196,000&lt;/span&gt;, respectively, for manufacturing activities related to our clinical trials, scale-up, registration
batches, stability and validation testing. During the nine months ended September 30, 2020 and 2019, we were billed by Catalent
approximately $&lt;span id="xdx_90A_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200101__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zKEazzbXUBFl" title="Amount billed"&gt;2,563,000&lt;/span&gt;&#160;and $&lt;span id="xdx_908_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190101__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zPCO89AEoKYa" title="Amount billed"&gt;4,118,000&lt;/span&gt;, respectively, for manufacturing activities related to our clinical trials, scale-up,
registration batches, stability and validation testing. As of September 30, 2020 and December 31, 2019, there were amounts due
to Catalent of approximately $&lt;span id="xdx_901_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zDm37JWDPs12" title="Amounts due to related party"&gt;147,000&lt;/span&gt;&#160;and $&lt;span id="xdx_909_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zJlzvape1Zi9" title="Amounts due to related party"&gt;35,000&lt;/span&gt;, respectively. In addition, we have minimum purchase requirements in place
with Catalent as disclosed in Note 15, Commitments and Contingencies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
April 2020, Karen L. Ling, Executive Vice President and Chief Human Resources Officer of American International Group, Inc., or
AIG, was appointed to our board of directors. From time to time, we have entered into agreements with AIG in the normal course
of business. Agreements with AIG have been reviewed by independent directors of our Company, or a committee consisting of independent
directors of our Company, since April 2020. During the three and nine months ended September 30, 2020, we were billed by AIG approximately
$&lt;span id="xdx_90A_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200701__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AmericanInternationalGroupMember_zkAOYQNVfN6k"&gt;52,000&lt;/span&gt;&#160;and $&lt;span id="xdx_906_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200101__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AmericanInternationalGroupMember_zGrjldiNQJ03"&gt;195,000&lt;/span&gt;, respectively, for various insurance coverage for our Company.&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2020-07-012020-09-30_custom_CatalentMember"
      decimals="0"
      unitRef="USD">520000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2019-07-012019-09-30_custom_CatalentMember"
      decimals="0"
      unitRef="USD">2196000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2020-01-012020-09-30_custom_CatalentMember"
      decimals="0"
      unitRef="USD">2563000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2019-01-012019-09-30_custom_CatalentMember"
      decimals="0"
      unitRef="USD">4118000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2020-09-30_custom_CatalentMember"
      decimals="0"
      unitRef="USD">147000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2019-12-31_custom_CatalentMember"
      decimals="0"
      unitRef="USD">35000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2020-07-012020-09-30_custom_AmericanInternationalGroupMember"
      decimals="0"
      unitRef="USD">52000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2020-01-012020-09-30_custom_AmericanInternationalGroupMember"
      decimals="0"
      unitRef="USD">195000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_803_eus-gaap--ConcentrationRiskDisclosureTextBlock_zs4dc46xCZS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_825_zzV6I4qmYFii"&gt;NOTE
14 - BUSINESS CONCENTRATIONS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
purchase our prescription products from several suppliers with approximately&#160;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zwL4LakNGcXd" title="Concentration risk"&gt;42&lt;/span&gt;%,&#160;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zFxcoM0f0j6c" title="Concentration risk"&gt;25&lt;/span&gt;% and&#160;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zspJcPWjz2Jf" title="Concentration risk"&gt;24&lt;/span&gt;% of our purchases
supplied by three vendors each, respectively, during the nine months ended September 30, 2020, and&#160;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zoMLeAEOOue8" title="Concentration risk"&gt;36&lt;/span&gt;%,&#160;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zMWXVjNL8BVj" title="Concentration risk"&gt;28&lt;/span&gt;%,&#160;and
&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zP9uVKvZQzl7" title="Concentration risk"&gt;26&lt;/span&gt;% of our purchases supplied by three vendors each, respectively, during the nine months ended September 30, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
sell our prescription products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores
that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the nine months ended
September 30, 2020,&#160;&lt;span id="xdx_908_ecustom--NumberOfCustomers_dc_uNumber_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zqmZxC98tKt4" title="Number of customers - revenue"&gt;three&lt;/span&gt;&#160;customers each accounted for more than&#160;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zrFlZ5rQJlSe"&gt;10&lt;/span&gt;% of our total product revenues. Product revenue
from the three customers combined accounted for approximately&#160;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeCustomersConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zV1ZOrscOwnh"&gt;56&lt;/span&gt;% of our product revenue for the nine months ended September
30, 2020. During the nine months ended September 30, 2019,&#160;&lt;span id="xdx_90A_ecustom--NumberOfCustomers_dc_uNumber_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zoCRaEdNz5hh"&gt;four&lt;/span&gt;&#160;customers each generated more than&#160;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zvHJqShCp7oh"&gt;10&lt;/span&gt;% of our product
revenues. Revenue generated from the four customers combined accounted for approximately&#160;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z52f3dQl2IBi"&gt;68&lt;/span&gt;% of our product revenue for the
nine months ended September 30, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the nine months ended September 30, 2020, Pillpack, Inc. accounted for approximately $&lt;span id="xdx_90D_eus-gaap--Revenues_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zA69fHNTJ5v3" title="Revenues"&gt;9,319,000&lt;/span&gt;&#160;of our product revenue, Cardinal
Health accounted for approximately $&lt;span id="xdx_90E_eus-gaap--Revenues_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zl8aUhbFhMff" title="Revenues"&gt;7,415,000&lt;/span&gt;&#160;of our product revenue, and McKesson Corporation accounted for approximately
$&lt;span id="xdx_904_eus-gaap--Revenues_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zj31V7kJR2r6" title="Revenues"&gt;6,009,000&lt;/span&gt;&#160;of our product revenue. During the nine months ended September 30, 2019, Pillpack, Inc. accounted for approximately
$&lt;span id="xdx_903_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zBOik5QpNdPb"&gt;6,397,000&lt;/span&gt; of our product revenue, AmerisourceBergen accounted for approximately $&lt;span id="xdx_902_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zRnvTa6iyHhe"&gt;&lt;span id="xdx_905_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z8Fw1vzbTvy1" title="Revenues"&gt;2,226,000&lt;/span&gt;&lt;/span&gt; of our product revenue, PI Services
accounted for approximately $&lt;span id="xdx_907_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPIServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zatreSu1m1aj"&gt;1,935,000&lt;/span&gt; of our product revenue and Cardinal Health accounted for approximately $&lt;span id="xdx_90D_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_ze1RARlBUZa4" title="Revenues"&gt;1,863,000&lt;/span&gt; of our
product revenue.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-09-30_custom_SupplierOneConcentrationRiskMember"
      decimals="4"
      unitRef="Pure">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-09-30_custom_SupplierTwoConcentrationRiskMember"
      decimals="4"
      unitRef="Pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-09-30_custom_SupplierThreeConcentrationRiskMember"
      decimals="4"
      unitRef="Pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-09-30_custom_SupplierOneConcentrationRiskMember"
      decimals="4"
      unitRef="Pure">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-09-30_custom_SupplierTwoConcentrationRiskMember"
      decimals="4"
      unitRef="Pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-09-30_custom_SupplierThreeConcentrationRiskMember"
      decimals="4"
      unitRef="Pure">0.26</us-gaap:ConcentrationRiskPercentage1>
    <txmd:NumberOfCustomers
      contextRef="From2020-01-012020-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Number">3</txmd:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="4"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-09-30_custom_ThreeCustomersConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="4"
      unitRef="Pure">0.56</us-gaap:ConcentrationRiskPercentage1>
    <txmd:NumberOfCustomers
      contextRef="From2019-01-012019-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Number">4</txmd:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-09-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="4"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-09-30_custom_FourCustomersConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="4"
      unitRef="Pure">0.68</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-09-30_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">9319000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-09-30_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">7415000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-09-30_custom_CustomerConcentrationMcKessonCorporationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">6009000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-09-30_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">6397000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-09-30_custom_CustomerConcentrationAmerisourceBergenRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">2226000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-09-30_custom_CustomerConcentrationAmerisourceBergenRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">2226000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-09-30_custom_CustomerConcentrationPIServicesMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">1935000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-09-30_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">1863000</us-gaap:Revenues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zfcSSNYMY9g1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_822_z2diCo7MEkrk"&gt;NOTE
15 &#x2013; COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Operating
Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
adopted ASC 842, Leases, effective January 1, 2019. Substantially all our operating lease right-of-use assets and operating
lease liabilities represent leases for office space used to conduct our business. Upon adoption, we recognized a right-of-use
asset and a lease liability for all leases that have commenced as of January 1, 2019. The right-of-use assets represent the
right to use the leased asset for the lease term. The lease liabilities represent the present value of the lease payments
under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the
lease liability, plus any initial direct costs incurred, less any lease incentives received. All right-of-use assets are
reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted
using our secured incremental borrowing rate for the same term as the underlying lease because the rates are not implicit in
the leases. Some of our leases contain variable lease payments, including payments based on an index or rate. Variable lease
payments based on an index or rate are initially measured using the index or rate in effect at lease commencement. Additional
payments based on the change in an index or rate, or payments based on a change in our portion of the operating expenses are
recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease liability. Included in
lease expense are any variable lease payments incurred in the period that were not included in the initial lease
liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1,
2013 and originally provided for a&#160;&lt;span id="xdx_900_ecustom--CapitalLeaseObligationsTerm_dtM_c20130630__20130701_zHc41TLTz5af" title="Non-cancelable operating lease term"&gt;63&lt;/span&gt;-month term. On February 18, 2015, we entered into an agreement with the same lessors
to lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April
26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location.
This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021.
On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the
same location, pursuant to an addendum to such lease. This addendum became effective beginning November 1, 2016.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes&#160;&lt;span id="xdx_90D_ecustom--NetRentableAreaLease_iI_usqft_c20181002_zWCCrYB91eq7" title="Net rentable area"&gt;56,212&lt;/span&gt;&#160;rentable
square feet, or the full premises, of which the lease on&#160;&lt;span id="xdx_90E_ecustom--RentedAreaLease_iI_usqft_c20181002_zaAa5hIVEEgj" title="Rented area lease"&gt;7,561&lt;/span&gt;&#160;square
feet commenced in 2018 and the lease on the remaining&#160;&lt;span id="xdx_900_ecustom--AdditionalAreaOfLeaseOccupied_iI_usqft_c20190801_zI04oyrP58zl" title="Additional area of lease occupied"&gt;&lt;span id="xdx_904_ecustom--AdditionalAreaOfLeaseOccupied_iI_usqft_c20190801_zau1SkrRoYe4"&gt;48,651&lt;/span&gt;&lt;/span&gt;&#160;square
feet commenced in August 2019, or the full premises commencement date. The lease will expire&#160;&lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20190801_z6pzdY8AEFCj" title="Lessee, Operating Lease, Term of Contract"&gt;11
years&lt;/span&gt;&#160;after the full premises commencement date, unless terminated earlier in accordance with the terms of the
lease. We have the option to extend the term of the lease for&#160;&lt;span id="xdx_90E_ecustom--LesseeOperatingLeaseExistenceOfOptionToExtendNumber_iI_dc_uPure_c20200930_zyQCbBnKO0J1" title="Lessee operating lease existence of option to extend number"&gt;two&lt;/span&gt;&#160;additional
consecutive periods of&#160;&lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dt_c20200930_zsd62cQ0YDWh"&gt;five years&lt;/span&gt;. The extension option is not included in the determination
of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free
rent periods. We are also responsible for certain other operating costs under the lease, including electricity and utility
expenses. In June 2019, we entered into an &lt;span&gt;agreement with the same lessors&lt;/span&gt; to lease additional&#160;&lt;span id="xdx_90A_ecustom--LesseeOperatingLeaseLeaseNotYetCommencedArea_iI_usqft_c20190601_z7HsIlDliUjf" title="Lease not yet commenced (area)"&gt;6,536&lt;/span&gt;&#160;square
feet of administrative office space in the same location,&#160;&lt;span style="color: #212529"&gt;pursuant to an addendum to such
lease, which commenced in May 2020.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="color: #212529"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_z6BLGFmJmuaj" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - Supplemental lease information (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Supplemental lease information:&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20200930_zKMlsFVVsmd5" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20191231_z2lUPpRwwXri" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;
    2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zLqHZddMxG6g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 5.4pt"&gt;Right-of-use asset&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;9,975,725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;10,109,154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zPtQCwt4f2Y5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Short-term operating lease liability (included in Other current liabilities)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,404,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,501,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zUd5AYS1Trqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Long-term operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8,907,995&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,145,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;Weighted average remaining term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Weighted average remaining term::XDX::P8Y9M18D"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20200930_zgBZsKcJU8Xf" title="Weighted average remaining term"&gt;8.8&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Weighted average remaining term::XDX::P9Y"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_zInyTUJoHZUa" title="Weighted average remaining term"&gt;9&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_zCdfVlGrIQC4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.3%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.25%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20200101__20200930_zuf4wqSlwdgf" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20190101__20190930_zqgrKqMD0BI7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Supplemental cash flow information&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;for the nine months ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &#160;&lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &#160;&lt;br/&gt;
    2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--OperatingLeasePayments_zMuE9QMriFWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 5.4pt"&gt;Cash paid for amounts included in the measurement of lease liabilities for operating lease&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,006,970&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;849,440&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zkcI7REAWafk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Right-of-use assets obtained in exchange for lease obligation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;998,821&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11,171,471&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A1_zD4Xr3Z61old" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z9tqWaUXtFdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;The
following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities
recorded on the balance sheet:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20200930_z3Yh7MVxkvXi"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz1WK_zFQnea8plN43" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020 (3 months)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;610,675&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz1WK_zIu6XN3J8uWf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,334,582&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz1WK_zghllzAwiFZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,413,289&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz1WK_zNxrXusITLdl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,443,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz1WK_zizUHmGFOcH3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,476,534&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz1WK_zmejpP5unW48" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,947,869&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz1WK_zlrj5YfaeCM3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,226,092&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zqGQLbwDaeM6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,913,811&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_zKTLHCCZFCl1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Present value of lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,312,281&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AB_zwrJBIuQV3de" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three and nine months ended September 30, 2020, operating lease expense related to our real estate leases was
approximately $&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20200701__20200930_zKwi3X7g4mxl" title="Operating lease expense"&gt;590,000&lt;/span&gt;&lt;span&gt;&#160;and
$&lt;/span&gt;&lt;span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20200101__20200930_zaaXw6dUInt4" title="Operating lease expense"&gt;1,749,000&lt;/span&gt;&lt;span&gt;,
respectively, and variable lease expense was approximately $&lt;span id="xdx_90D_eus-gaap--VariableLeaseCost_c20200701__20200930_z1foDxKH1cC7" title="Variable lease expense"&gt;148,000&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--VariableLeaseCost_c20200101__20200930_zwNmiPOxUh0j"&gt;226,000&lt;/span&gt;, respectively, for the same periods. During
the three and nine months ended September 30, 2019, operating lease expense related to our real estate leases was
approximately $&lt;/span&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20190701__20190930_zCoEAZCum7B1" title="Operating lease expense"&gt;458,000&lt;/span&gt;&lt;span&gt;&#160;and
$&lt;/span&gt;&lt;span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20190101__20190930_z0LlTjbAU9Ae" title="Operating lease expense"&gt;1,062,000&lt;/span&gt;&lt;span&gt;,
respectively, and variable lease expense was insignificant for the same periods.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Intellectual
Property Licenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Population Council License Agreement provides for future milestone payments to be paid by us for access to certain technologies.
In addition, we pay royalties as a percent of product revenue as described in Note 7, Intangible Assets, to these consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Purchase
Commitments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
have manufacturing and supply agreements whereby we are required to purchase from Catalent a minimum number of softgels
during the first contract year and a higher number of softgels after the first contract year. If the minimum order quantities
of specific products are not met, we are required to pay Catalent&#160;&lt;span id="xdx_90E_ecustom--SignificantSupplyCommitmentPercentagePayable_iI_dp_uPure_c20200930_zxpW7tJ3qKae" title="Significant supply commitment percentage payable"&gt;50&lt;/span&gt;%
of the difference between the total amount we would have paid to Catalent if the minimum requirement had been fulfilled and
the sum of all purchases of our products from Catalent during the contract year. The updated minimum purchase commitments for
Catalent for the next five years are as follows: 2020 - $&lt;span id="xdx_90C_eus-gaap--RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_iI_c20200930__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zevIbu8GnDge" title="Minimum purchase commitment, 2020"&gt;3,719,000&lt;/span&gt;, 2021 - $&lt;span id="xdx_904_eus-gaap--RecordedUnconditionalPurchaseObligationDueWithinOneYear_iI_c20200930__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zg9l22o0tgmf" title="Minimum purchase commitment, 2021"&gt;2,150,000&lt;/span&gt;, 2022 - $&lt;span id="xdx_90E_eus-gaap--RecordedUnconditionalPurchaseObligationDueInSecondYear_iI_c20200930__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zp9BcAymo7p6" title="Minimum purchase commitment, 2022"&gt;2,991,000&lt;/span&gt;, 2023 - $&lt;span id="xdx_90E_eus-gaap--RecordedUnconditionalPurchaseObligationDueInThirdYear_iI_c20200930__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zZp5SkgPv99i" title="Minimum purchase commitment, 2023"&gt;3,347,000&lt;/span&gt;,
and 2024 - $&lt;span id="xdx_90B_eus-gaap--RecordedUnconditionalPurchaseObligationDueInFourthYear_iI_c20200930__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zAZ6gSQXiIg" title="Minimum purchase commitment, 2024"&gt;3,786,000&lt;/span&gt;. In addition, we have a manufacturing and supply agreement whereby we are required to purchase a minimum
number of units of ANNOVERA during a contract year. As of September 30, 2020, we have met our contract year purchase
commitments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Legal
Proceedings&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;From
time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved
in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations,
or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Off-Balance
Sheet Arrangements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of September 30, 2020 and 2019, we had no off-balance sheet arrangements that have had or are reasonably likely to have current
or future effects on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources that are material to investors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Employment
Agreements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits.
Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments,
if those circumstances occur during the term of the employment agreement.&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <txmd:CapitalLeaseObligationsTerm contextRef="From2013-06-302013-07-01">P63M</txmd:CapitalLeaseObligationsTerm>
    <txmd:NetRentableAreaLease contextRef="AsOf2018-10-02" decimals="INF" unitRef="sqft">56212</txmd:NetRentableAreaLease>
    <txmd:RentedAreaLease contextRef="AsOf2018-10-02" decimals="INF" unitRef="sqft">7561</txmd:RentedAreaLease>
    <txmd:AdditionalAreaOfLeaseOccupied contextRef="AsOf2019-08-01" decimals="INF" unitRef="sqft">48651</txmd:AdditionalAreaOfLeaseOccupied>
    <txmd:AdditionalAreaOfLeaseOccupied contextRef="AsOf2019-08-01" decimals="INF" unitRef="sqft">48651</txmd:AdditionalAreaOfLeaseOccupied>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2019-08-01">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <txmd:LesseeOperatingLeaseExistenceOfOptionToExtendNumber contextRef="AsOf2020-09-30" decimals="INF" unitRef="Pure">2</txmd:LesseeOperatingLeaseExistenceOfOptionToExtendNumber>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2020-09-30">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <txmd:LesseeOperatingLeaseLeaseNotYetCommencedArea contextRef="AsOf2019-06-01" decimals="INF" unitRef="sqft">6536</txmd:LesseeOperatingLeaseLeaseNotYetCommencedArea>
    <txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock contextRef="From2020-01-01to2020-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_z6BLGFmJmuaj" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - Supplemental lease information (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Supplemental lease information:&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20200930_zKMlsFVVsmd5" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20191231_z2lUPpRwwXri" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;
    2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zLqHZddMxG6g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 5.4pt"&gt;Right-of-use asset&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;9,975,725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;10,109,154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zPtQCwt4f2Y5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Short-term operating lease liability (included in Other current liabilities)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,404,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,501,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zUd5AYS1Trqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Long-term operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8,907,995&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,145,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;Weighted average remaining term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Weighted average remaining term::XDX::P8Y9M18D"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20200930_zgBZsKcJU8Xf" title="Weighted average remaining term"&gt;8.8&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Weighted average remaining term::XDX::P9Y"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_zInyTUJoHZUa" title="Weighted average remaining term"&gt;9&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_zCdfVlGrIQC4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.3%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.25%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20200101__20200930_zuf4wqSlwdgf" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20190101__20190930_zqgrKqMD0BI7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Supplemental cash flow information&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;for the nine months ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &#160;&lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &#160;&lt;br/&gt;
    2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--OperatingLeasePayments_zMuE9QMriFWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 5.4pt"&gt;Cash paid for amounts included in the measurement of lease liabilities for operating lease&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,006,970&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;849,440&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zkcI7REAWafk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Right-of-use assets obtained in exchange for lease obligation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;998,821&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11,171,471&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">9975725</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">10109154</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">2404286</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1501539</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">8907995</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">9145049</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2020-09-30">P8Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2019-12-31">P9Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2020-09-30" decimals="INF" unitRef="Pure">0.083</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2019-12-31" decimals="INF" unitRef="Pure">0.0825</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">1006970</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">849440</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">998821</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">11171471</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z9tqWaUXtFdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;The
following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities
recorded on the balance sheet:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20200930_z3Yh7MVxkvXi"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz1WK_zFQnea8plN43" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020 (3 months)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;610,675&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz1WK_zIu6XN3J8uWf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,334,582&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz1WK_zghllzAwiFZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,413,289&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz1WK_zNxrXusITLdl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,443,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz1WK_zizUHmGFOcH3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,476,534&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz1WK_zmejpP5unW48" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,947,869&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz1WK_zlrj5YfaeCM3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,226,092&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zqGQLbwDaeM6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,913,811&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_zKTLHCCZFCl1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Present value of lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,312,281&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">610675</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">2334582</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">1413289</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">1443143</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">1476534</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">8947869</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">16226092</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">4913811</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">11312281</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">590000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">1749000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeaseCost
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">148000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">226000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">458000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2019-01-012019-09-30"
      decimals="0"
      unitRef="USD">1062000</us-gaap:OperatingLeaseExpense>
    <txmd:SignificantSupplyCommitmentPercentagePayable contextRef="AsOf2020-09-30" decimals="INF" unitRef="Pure">0.50</txmd:SignificantSupplyCommitmentPercentagePayable>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear
      contextRef="AsOf2020-09-30_custom_CatalentMember226859265"
      decimals="0"
      unitRef="USD">3719000</us-gaap:RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear
      contextRef="AsOf2020-09-30_custom_CatalentMember226859265"
      decimals="0"
      unitRef="USD">2150000</us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear
      contextRef="AsOf2020-09-30_custom_CatalentMember226859265"
      decimals="0"
      unitRef="USD">2991000</us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueInThirdYear
      contextRef="AsOf2020-09-30_custom_CatalentMember226859265"
      decimals="0"
      unitRef="USD">3347000</us-gaap:RecordedUnconditionalPurchaseObligationDueInThirdYear>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueInFourthYear
      contextRef="AsOf2020-09-30_custom_CatalentMember226859265"
      decimals="0"
      unitRef="USD">3786000</us-gaap:RecordedUnconditionalPurchaseObligationDueInFourthYear>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2020-01-01to2020-09-30">&lt;p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_z5QRTRUrcB9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82A_zx0pPW90etH6"&gt;NOTE
16 &#x2013; SUBSEQUENT EVENTS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
November 8, 2020, we entered into Amendment No. 6 which temporarily lowered the minimum required cash balance under the Financing Agreement from $&lt;span id="xdx_90E_ecustom--MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVvdUE19b7mj"&gt;60
million&lt;/span&gt; to $&lt;span id="xdx_906_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Period1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIP3xT7anoVk"&gt;45
million&lt;/span&gt; through December 31, 2020. After December 31, 2020, the minimum required cash balance will revert to $&lt;span id="xdx_905_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Period2Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfFWG2YmwwC8"&gt;60
million&lt;/span&gt;.&#160;&#160;On November 8, 2020, in connection with entering into Amendment No. 6 to the Financing Agreement, we amended the Lender Warrants to provide for an adjustment to the exercise price if we conduct certain dilutive issuances prior to December 31, 2020, or if the volume-weighted average price of our Common Stock for the fifteen trading days ending December 31, 2020 is lower than the then-current exercise price.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment
      contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">60000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Period1Member_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">45000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Period2Member_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">60000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001285"
          xlink:label="Fact001285"
          xlink:type="locator"/>
        <link:footnote id="Footnote001288" xlink:label="Footnote001288" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The number
of performance stock units (PSUs) represents the base number of PSUs that may vest. The actual number of PSUs that will vest will
be between zero and two times the base number of PSUs depending on the Company's achievement of break-even quarterly EBITDA.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001285"
          xlink:to="Footnote001288"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129464006936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-00100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">THERAPEUTICSMD, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000025743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0233535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">951 Yamato Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca Raton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">961-1900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TXMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,812,271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129463802888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 79,633,675<span></span>
</td>
<td class="nump">$ 160,829,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $857,176 and $904,040, respectively</a></td>
<td class="nump">24,059,095<span></span>
</td>
<td class="nump">24,395,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">9,932,304<span></span>
</td>
<td class="nump">11,860,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">8,819,239<span></span>
</td>
<td class="nump">11,329,793<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">&#160;Total current assets</a></td>
<td class="nump">122,444,313<span></span>
</td>
<td class="nump">208,416,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">1,969,929<span></span>
</td>
<td class="nump">2,507,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LicenseRights', window );">License rights, net</a></td>
<td class="nump">36,959,305<span></span>
</td>
<td class="nump">39,221,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">5,537,885<span></span>
</td>
<td class="nump">5,258,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">9,975,725<span></span>
</td>
<td class="nump">10,109,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other assets</a></td>
<td class="nump">403,643<span></span>
</td>
<td class="nump">473,009<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">52,876,558<span></span>
</td>
<td class="nump">55,061,682<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">177,290,800<span></span>
</td>
<td class="nump">265,985,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">16,109,638<span></span>
</td>
<td class="nump">19,181,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">31,220,484<span></span>
</td>
<td class="nump">33,823,613<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">47,330,122<span></span>
</td>
<td class="nump">53,004,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">237,051,202<span></span>
</td>
<td class="nump">194,634,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">8,907,995<span></span>
</td>
<td class="nump">9,145,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">245,994,197<span></span>
</td>
<td class="nump">203,779,692<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">293,324,319<span></span>
</td>
<td class="nump">256,784,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' (Deficit) Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - par value $0.001; 10,000,000 shares authorized; &#160;no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - par value $0.001; 600,000,000 and 350,000,000&#160;&#160;shares authorized: 272,812,271 and 271,177,076 issued and outstanding, respectively</a></td>
<td class="nump">272,812<span></span>
</td>
<td class="nump">271,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">720,551,488<span></span>
</td>
<td class="nump">704,351,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(836,857,819)<span></span>
</td>
<td class="num">(695,421,279)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' (deficit) equity</a></td>
<td class="num">(116,033,519)<span></span>
</td>
<td class="nump">9,201,120<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' (deficit) equity</a></td>
<td class="nump">$ 177,290,800<span></span>
</td>
<td class="nump">$ 265,985,637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of license rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129391384744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 857,176<span></span>
</td>
<td class="nump">$ 904,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">272,812,271<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">272,812,271<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129390608152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="nump">$ 19,342,805<span></span>
</td>
<td class="nump">$ 23,719,741<span></span>
</td>
<td class="nump">$ 42,294,495<span></span>
</td>
<td class="nump">$ 33,745,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">3,278,609<span></span>
</td>
<td class="nump">1,444,308<span></span>
</td>
<td class="nump">10,394,145<span></span>
</td>
<td class="nump">3,455,995<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">16,064,196<span></span>
</td>
<td class="nump">22,275,433<span></span>
</td>
<td class="nump">31,900,350<span></span>
</td>
<td class="nump">30,289,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general, and administrative</a></td>
<td class="nump">38,751,250<span></span>
</td>
<td class="nump">45,126,986<span></span>
</td>
<td class="nump">144,018,899<span></span>
</td>
<td class="nump">121,378,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,027,195<span></span>
</td>
<td class="nump">4,077,738<span></span>
</td>
<td class="nump">8,038,056<span></span>
</td>
<td class="nump">15,359,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">258,787<span></span>
</td>
<td class="nump">141,959<span></span>
</td>
<td class="nump">777,338<span></span>
</td>
<td class="nump">363,956<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">41,037,232<span></span>
</td>
<td class="nump">49,346,683<span></span>
</td>
<td class="nump">152,834,293<span></span>
</td>
<td class="nump">137,102,463<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(24,973,036)<span></span>
</td>
<td class="num">(27,071,250)<span></span>
</td>
<td class="num">(120,933,943)<span></span>
</td>
<td class="num">(106,813,201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,057,632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Miscellaneous income</a></td>
<td class="nump">41,405<span></span>
</td>
<td class="nump">703,662<span></span>
</td>
<td class="nump">465,745<span></span>
</td>
<td class="nump">1,878,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(7,679,443)<span></span>
</td>
<td class="num">(5,599,005)<span></span>
</td>
<td class="num">(20,968,342)<span></span>
</td>
<td class="num">(11,717,632)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(7,638,038)<span></span>
</td>
<td class="num">(4,895,343)<span></span>
</td>
<td class="num">(20,502,597)<span></span>
</td>
<td class="num">(19,896,284)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(32,611,074)<span></span>
</td>
<td class="num">(31,966,593)<span></span>
</td>
<td class="num">(141,436,540)<span></span>
</td>
<td class="num">(126,709,485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,611,074)<span></span>
</td>
<td class="num">$ (31,966,593)<span></span>
</td>
<td class="num">$ (141,436,540)<span></span>
</td>
<td class="num">$ (126,709,485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding, basic and diluted</a></td>
<td class="nump">272,564,635<span></span>
</td>
<td class="nump">241,261,299<span></span>
</td>
<td class="nump">271,968,981<span></span>
</td>
<td class="nump">241,163,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="nump">$ 17,342,805<span></span>
</td>
<td class="nump">$ 8,213,341<span></span>
</td>
<td class="nump">$ 40,294,495<span></span>
</td>
<td class="nump">$ 18,238,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 15,506,400<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 15,506,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129464331816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2018</a></td>
<td class="nump">$ 240,463<span></span>
</td>
<td class="nump">$ 616,559,938<span></span>
</td>
<td class="num">$ (519,276,280)<span></span>
</td>
<td class="nump">$ 97,524,121<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="nump">240,462,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Shares issued for exercise of options and warrants, net</a></td>
<td class="nump">$ 759<span></span>
</td>
<td class="nump">99,348<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued for exercise of options and warrants, net (in shares)</a></td>
<td class="nump">759,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,575,369<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,575,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(39,506,375)<span></span>
</td>
<td class="num">(39,506,375)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2019</a></td>
<td class="nump">$ 241,222<span></span>
</td>
<td class="nump">619,234,655<span></span>
</td>
<td class="num">(558,782,655)<span></span>
</td>
<td class="nump">60,693,222<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Mar. 31, 2019</a></td>
<td class="nump">241,221,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2018</a></td>
<td class="nump">$ 240,463<span></span>
</td>
<td class="nump">616,559,938<span></span>
</td>
<td class="num">(519,276,280)<span></span>
</td>
<td class="nump">97,524,121<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="nump">240,462,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126,709,485)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2019</a></td>
<td class="nump">$ 241,277<span></span>
</td>
<td class="nump">624,515,559<span></span>
</td>
<td class="num">(645,985,765)<span></span>
</td>
<td class="num">(21,228,929)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2019</a></td>
<td class="nump">241,277,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2019</a></td>
<td class="nump">$ 241,222<span></span>
</td>
<td class="nump">619,234,655<span></span>
</td>
<td class="num">(558,782,655)<span></span>
</td>
<td class="nump">60,693,222<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2019</a></td>
<td class="nump">241,221,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,637,264<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,637,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(55,236,517)<span></span>
</td>
<td class="num">(55,236,517)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2019</a></td>
<td class="nump">$ 241,222<span></span>
</td>
<td class="nump">621,871,919<span></span>
</td>
<td class="num">(614,019,172)<span></span>
</td>
<td class="nump">8,093,969<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2019</a></td>
<td class="nump">241,221,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Shares issued for exercise of options and warrants, net</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">8,494<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued for exercise of options and warrants, net (in shares)</a></td>
<td class="nump">55,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,635,146<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,635,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(31,966,593)<span></span>
</td>
<td class="num">(31,966,593)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2019</a></td>
<td class="nump">$ 241,277<span></span>
</td>
<td class="nump">624,515,559<span></span>
</td>
<td class="num">(645,985,765)<span></span>
</td>
<td class="num">(21,228,929)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2019</a></td>
<td class="nump">241,277,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 271,177<span></span>
</td>
<td class="nump">704,351,222<span></span>
</td>
<td class="num">(695,421,279)<span></span>
</td>
<td class="nump">$ 9,201,120<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="nump">271,177,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Shares issued for exercise of options and warrants, net</a></td>
<td class="nump">$ 351<span></span>
</td>
<td class="nump">71,758<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 72,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued for exercise of options and warrants, net (in shares)</a></td>
<td class="nump">350,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,366,453<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,366,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(56,848,802)<span></span>
</td>
<td class="num">(56,848,802)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 271,678<span></span>
</td>
<td class="nump">706,789,283<span></span>
</td>
<td class="num">(752,270,081)<span></span>
</td>
<td class="num">(45,209,120)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Mar. 31, 2020</a></td>
<td class="nump">271,677,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of shares from release of restricted stock</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of shares from release of restricted stock (in shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 271,177<span></span>
</td>
<td class="nump">704,351,222<span></span>
</td>
<td class="num">(695,421,279)<span></span>
</td>
<td class="nump">$ 9,201,120<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="nump">271,177,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (141,436,540)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 272,812<span></span>
</td>
<td class="nump">720,551,488<span></span>
</td>
<td class="num">(836,857,819)<span></span>
</td>
<td class="num">$ (116,033,519)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2020</a></td>
<td class="nump">272,812,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,812,271<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 271,678<span></span>
</td>
<td class="nump">706,789,283<span></span>
</td>
<td class="num">(752,270,081)<span></span>
</td>
<td class="num">$ (45,209,120)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2020</a></td>
<td class="nump">271,677,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Shares issued for exercise of options and warrants, net</a></td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">93,762<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">94,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued for exercise of options and warrants, net (in shares)</a></td>
<td class="nump">313,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,002,826<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,002,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(51,976,664)<span></span>
</td>
<td class="num">(51,976,664)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2020</a></td>
<td class="nump">$ 272,294<span></span>
</td>
<td class="nump">709,885,568<span></span>
</td>
<td class="num">(804,246,745)<span></span>
</td>
<td class="num">(94,088,883)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2020</a></td>
<td class="nump">272,294,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of shares from release of restricted stock</a></td>
<td class="nump">$ 303<span></span>
</td>
<td class="num">(303)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of shares from release of restricted stock (in shares)</a></td>
<td class="nump">303,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Shares issued for exercise of options and warrants, net</a></td>
<td class="nump">$ 518<span></span>
</td>
<td class="nump">104,976<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">105,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued for exercise of options and warrants, net (in shares)</a></td>
<td class="nump">517,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,132,765<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,132,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(32,611,074)<span></span>
</td>
<td class="num">(32,611,074)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 272,812<span></span>
</td>
<td class="nump">720,551,488<span></span>
</td>
<td class="num">(836,857,819)<span></span>
</td>
<td class="num">$ (116,033,519)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2020</a></td>
<td class="nump">272,812,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,812,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant granted in relation to Financing Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,428,179<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,428,179<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121321822&amp;loc=d3e3913-113898<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121323062&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129464089288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (141,436,540)<span></span>
</td>
<td class="num">$ (126,709,485)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of fixed assets</a></td>
<td class="nump">576,459<span></span>
</td>
<td class="nump">223,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">200,879<span></span>
</td>
<td class="nump">140,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Write off of patent and trademark costs</a></td>
<td class="nump">584,509<span></span>
</td>
<td class="nump">78,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write off of deferred financing fees</a></td>
<td class="nump">275,379<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NoncashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">1,050,940<span></span>
</td>
<td class="nump">711,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">(Recovery of) provision for doubtful accounts</a></td>
<td class="num">(46,864)<span></span>
</td>
<td class="nump">95,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Lease impairment</a></td>
<td class="nump">81,309<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory obsolesence reserve</a></td>
<td class="nump">5,744,464<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,057,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">8,502,044<span></span>
</td>
<td class="nump">7,859,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AmortizationOfIntellectualPropertyLicenseFee', window );">Amortization of intellectual property license fee</a></td>
<td class="nump">2,262,002<span></span>
</td>
<td class="nump">15,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing fees</a></td>
<td class="nump">1,370,118<span></span>
</td>
<td class="nump">582,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">383,727<span></span>
</td>
<td class="num">(4,354,890)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(3,816,053)<span></span>
</td>
<td class="num">(7,265,174)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">2,003,079<span></span>
</td>
<td class="num">(1,128,515)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,071,574)<span></span>
</td>
<td class="nump">1,389,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current liabilities</a></td>
<td class="num">(3,812,919)<span></span>
</td>
<td class="nump">3,402,511<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(129,149,041)<span></span>
</td>
<td class="num">(114,900,319)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent costs</a></td>
<td class="num">(1,065,062)<span></span>
</td>
<td class="num">(1,068,542)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(38,613)<span></span>
</td>
<td class="num">(2,089,413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IncreaseDecreaseInSecurityDeposit', window );">Security deposit</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="num">(20,420)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,068,675)<span></span>
</td>
<td class="num">(3,178,375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options and warrants</a></td>
<td class="nump">271,678<span></span>
</td>
<td class="nump">108,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of the Credit Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(81,660,719)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from the Financing Agreement</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of deferred financing fees</a></td>
<td class="num">(1,250,000)<span></span>
</td>
<td class="num">(6,652,270)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">49,021,678<span></span>
</td>
<td class="nump">111,795,667<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Decrease in cash</a></td>
<td class="num">(81,196,038)<span></span>
</td>
<td class="num">(6,283,027)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of period</a></td>
<td class="nump">160,829,713<span></span>
</td>
<td class="nump">161,613,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of period</a></td>
<td class="nump">79,633,675<span></span>
</td>
<td class="nump">155,330,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantGrantedInRelationToFinancingAgreement', window );">Warrant granted in relation to Financing Agreement</a></td>
<td class="nump">7,428,179<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AmountAccruedForIntellectualPropertyLicense', window );">Amount accrued for intellectual property license</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 19,172,847<span></span>
</td>
<td class="nump">$ 12,446,792<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AmortizationOfIntellectualPropertyLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents amortization of intellectual property license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AmortizationOfIntellectualPropertyLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AmountAccruedForIntellectualPropertyLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents amount accrued for intellectual property license.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AmountAccruedForIntellectualPropertyLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_IncreaseDecreaseInSecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represent increase decrease in security deposit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_IncreaseDecreaseInSecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to operating lease costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantGrantedInRelationToFinancingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a warrant granted in relation to financing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantGrantedInRelationToFinancingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121593497&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129385546184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 1 &#8211; THE COMPANY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NOTE 1 &#8211; THE COMPANY</a></td>
<td class="text"><p id="xdx_809_eus-gaap--NatureOfOperations_zQC4O8yz5zy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_826_z8RpcEUJpw05">NOTE
1 &#8211; THE COMPANY</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD,
Inc., a Nevada corporation, or TherapeuticsMD or the Company, has&#160;<span id="xdx_90E_ecustom--NumberOfSubsidiaries_iI_dc_uNumber_c20200930_zxqdmn83mIXb" title="Number of subsidiaries">three</span>&#160;wholly owned subsidiaries, vitaMedMD, LLC, a
Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and vitaCare Prescription
Services, Inc., a Florida corporation, or vitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen,
and vitaCare collectively are sometimes referred to as &#8220;our company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us.&#8221;
TherapeuticsMD<sup>&#174;</sup>, vitaMedMD<sup>&#174;</sup>, BocaGreenMD<sup>&#174;</sup>, IMVEXXY<sup>&#174;</sup>, BIJUVA<sup>&#174;&#160;</sup>and
ANNOVERA<sup>&#174;</sup>&#160;are registered trademarks of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Nature
of Business</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">We
are a women&#8217;s healthcare company with a mission of creating and commercializing innovative products to support the
lifespan of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical
expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women.
Our solutions range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical
products. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD and
BocaGreenMD brands. Our portfolio of products focused on women&#8217;s health allows us to efficiently leverage our sales and
marketing plan to grow our recently approved products. During 2018, the U.S. Food and Drug Administration, or FDA, approval
of our pharmaceutical products has transitioned our company from predominately focused on conducting research and development
to one focused on commercializing our pharmaceutical products. In July 2018, we launched our FDA-approved product, IMVEXXY
(estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual
activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched our FDA-approved
product BIJUVA (estradiol and progesterone) capsules, our hormone therapy combination of bio-identical 17&#223;-estradiol and
bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or
VMS, due to menopause in women with a uterus. In October 2019, we began a test and learn market introduction for our
FDA-approved product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only annual
patient-controlled, procedure-free, reversible prescription contraceptive option for women. Although we expected to commence
the full commercial launch of ANNOVERA in the first quarter of 2020, as a result of the uncertainty surrounding the COVID-19
pandemic, we paused the commercial launch of ANNOVERA and deferred sales and marketing initiatives into subsequent quarters
as the pandemic began to negatively affect our revenue growth. We resumed the launch of ANNOVERA on July 1, 2020. On July 30,
2018, we entered into an exclusive license agreement, or the Population Council License Agreement, with the Population
Council, Inc., or the Population Council, to commercialize ANNOVERA in the U.S. In addition, on July 30, 2018, we entered
into a license and supply agreement, or the Knight License Agreement, with Knight Therapeutics Inc., or Knight, pursuant to
which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. On June 6, 2019, we
entered into an exclusive license and supply agreement, or the Theramex License Agreement, with Theramex HQ UK Limited, or
Theramex, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel, or the Theramex
Territory.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129385558696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text"><p id="xdx_801_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z5t4Jc3pzweg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_825_zNY5DSa5H6Hf">NOTE
2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Interim
Financial Statements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries,
should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report
on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission, or the SEC, from which
we derived the accompanying consolidated balance sheet as of December 31, 2019. The accompanying unaudited interim consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America,
or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly,
since they are interim statements, the accompanying unaudited interim consolidated financial statements do not include all of
the information and notes required by GAAP for complete financial statements. The accompanying unaudited interim consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management,
necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative
of results for a full year or any other interim period in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Risks
and Uncertainties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">We
continue to be subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the future impact of the
COVID-19 pandemic on our business continues to be highly uncertain and difficult to predict. We continue to provide an uninterrupted
supply of our portfolio of products for patients. We have sufficient inventory of finished product to meet anticipated demand
in the near future. Additionally, we currently do not foresee any interruption in our ability to continue to manufacture additional
product to be used beyond this period and have sufficient active pharmaceutical ingredients on hand for the continued manufacture
of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">Since
the early phase of the COVID-19 pandemic, we have been using substantial virtual options to ensure business continuity. Our vitaCare
Prescription Services patient model assists patients in obtaining easy and convenient access to their prescriptions for products
at a retail pharmacy of their choice, including via home delivery retail pharmacy options. We have also partnered with independent
community pharmacies and multiple third-party online pharmacies and telemedicine providers that focus on contraception or menopause
to ensure patients have real-time access to both diagnosis and treatment. We continue to support prescribers&#8217; needs with
samples and product materials through our sales force. If access is restricted, we have mailing options in place for these materials.
We also have business continuity plans and infrastructure in place that allows for virtual detailing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">As
part of our response to the COVID-19 pandemic, we implemented measures to reduce marketing expenses for 2020. We also implemented
cost saving measures, which included negotiating lower fees or suspending services from third party vendors; implementing a company-wide
hiring restriction; delaying or cancelling non-critical information technology projects; and eliminating non-essential travel,
entertainment, meeting, and event expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">The
full impact of the&#160;COVID-19 pandemic continues to evolve. However, we remain committed to the execution of our corporate
goals, despite the ongoing COVID-19 pandemic, as demonstrated in part by the increase of our third quarter 2020 product
revenues as compared to our second quarter 2020 product revenues. As of the date of issuance of these consolidated financial
statements, the future extent to which the COVID-19 pandemic may continue to materially impact our financial condition,
liquidity, or results of operations remains uncertain. We are continuing to assess the effect the COVID-19 pandemic on our
operations by monitoring the spread of COVID-19 and the various actions implemented to combat the virus throughout the world.
Even after the&#160;COVID-19 pandemic has subsided, we may continue to experience adverse impacts to our business as a result
of any economic recession or depression that has occurred or may occur in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">While
we currently believe that our COVID-19 contingency plan has the ability to mitigate the effect of the COVID-19 pandemic on our
business, the severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but
not limited to, the duration and severity of the pandemic, the duration of &#8220;social distancing&#8221; orders, the ability
of our sales force to access healthcare providers to promote our products, increases in unemployment, which could reduce access
to commercial health insurance for our patients, thus limiting payer coverage for our products, and the impact of the pandemic
on our global supply chain, all of which are uncertain. Our future results of operations and liquidity could be materially adversely
affected by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions, uncertain
demand, and the impact of any initiatives or programs that we may undertake to address financial and operations challenges that
we may face.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Liquidity
and Going Concern</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">As of the filing date of this Quarterly Report on Form 10-Q, our cash balance was above the $<span id="xdx_90F_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201109__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNRtFj0LMERf" title="Minimum cash balance required under credit agreement">60
million</span> balance as required by the Financing Agreement (as defined in Note 9 - Debt). On November 8, 2020, we and our subsidiaries entered into
Amendment No. 6 to the Financing Agreement, or Amendment No. 6, with the Administrative Agent (as defined in Note 9 - Debt) and the lenders party thereto,
pursuant to which we temporarily lowered the minimum required cash balance from $<span id="xdx_90E_ecustom--MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6yLSNY2GXQ7" title="Minimum cash balance requirement under credit agreement before adjustment">60
million</span> to $<span id="xdx_906_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Period1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zk6Xsvdsh0w3">45
million</span> through December 31, 2020. After December 31, 2020, the minimum cash balance will revert to $<span id="xdx_905_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Period2Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRnQcJzWfiDf">60
million</span>. Based on our current projections, we will need to raise additional capital to remain in compliance with this
minimum cash balance covenant for the next twelve months from the issuance of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">In order to address our projected capital needs, we are pursuing various equity financing and other alternatives including the sale of a controlling interest in vitaCare Prescription Services for which we commended a sale process and received initial indications of interest.   The equity financing alternatives may include the private placement of equity, equity-linked, or other similar instruments or obligations with one or more investors, lenders, or other institutional counterparties or an underwritten public equity or equity-linked securities offering. Our ability to sell equity securities may be limited by market conditions. To the extent that we raise additional capital through the sale of such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">Along with considering additional financings, we have reviewed numerous potential scenarios in connection with the impact of COVID-19 on our business including the impact of the recent steps we have taken to reduce our operating expenses in response. Based on our analysis, we believe that our existing cash reserves along with potential proceeds from the sale of certain non-core assets of the Company and proceeds from potential future financings, if available to us, would be sufficient to meet our cash needs arising in the ordinary course of business for the next twelve months from the date of this Quarterly Report on Form 10-Q.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">However,
if we are unsuccessful with future financings and if the successful commercialization of IMVEXXY, BIJUVA, or ANNOVERA is
delayed, or the continued impact of the COVID-19 pandemic on our business is worse than we anticipate, our existing cash
reserves would be insufficient to maintain compliance with the Financing Agreement covenants or satisfy our liquidity
requirements until we are able to successfully commercialize IMVEXXY, BIJUVA, and ANNOVERA. The presence of these projected
factors in conjunction with the uncertainty of the capital markets raises substantial doubt about the Company's ability to
continue as a going concern for the next twelve months from the issuance of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Recently
Issued Accounting Pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2018, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13 which
eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose
certain new information and modifies some disclosure requirements. The FASB developed the amendments to Accounting Standards Codification,
or ASC, 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the
notes to financial statements by focusing on requirements that clearly communicate the most important information to users of
the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and
for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions
that eliminate or modify requirements. We adopted this standard on January 1, 2020, and the adoption did not have a material effect
on our disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"/></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on
Financial Instruments. The amendments in this update require a financial asset (or a group of financial assets) measured at amortized
cost basis to be presented at the net amount expected to be collected based on historical experience, current conditions, and
reasonable supportable forecasts. The amendments in this update are effective for public business entities for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted no sooner than the
first quarter of 2019. A modified retrospective approach is required for all investments, except debt securities for which an
other-than-temporary impairment had been recognized prior to the effective date, which will require a prospective transition approach
and should be applied either prospectively or retrospectively depending on the nature of the disclosure. The adoption of ASU 2016-13
requires expanded quantitative and qualitative disclosures about the Company&#8217;s expected credit losses. Effective January
1, 2020, we adopted ASU 2016-13 under a modified retrospective approach for all financial assets measured at amortized cost. There
was no adjustment recorded for the cumulative effect of adopting ASU 2016-13. The adoption expanded disclosures about our credit
losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">Other
recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified
Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial
position.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129386079368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zMxAWFQxgcpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_829_zWWUZJJcGga7">NOTE
3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84C_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zk6qJabFcbz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_864_zRx3vtNoY2zj">Trade
Accounts Receivable and Allowance for Doubtful Accounts</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">Trade
accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts
and credit card chargebacks and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,
historical collection information, reasonable supportable forecasts and existing economic conditions and we record an allowance
that presents the net amount expected to be collected. We evaluate trade accounts receivable for delinquency. We write off delinquent
receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts,
and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase
in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately reflect bad
debts, adjustments to these reserves may be required. Our exposure to credit losses may increase if our customers are adversely
affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or
global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. Although
we have historically not experienced significant credit losses, it is possible that there could be a material adverse impact from
potential adjustments of the carrying amount of trade receivables in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z3RRKW4uBKpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86F_ztJzml9JFsCf">Fair
Value of Financial Instruments</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">Our
financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The
carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the
short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount
for long-term debt as of September 30, 2020 (as disclosed in Note 9) approximates fair value based on market activity for other
debt instruments with similar characteristics and comparable risk (Level 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by ASC 820, Fair Value Measurements, or ASC 820. The fair value hierarchy gives the highest priority to quoted prices
in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets
and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level 1</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">unadjusted
quoted prices in active markets for identical assets or liabilities;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level 2</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">quoted
prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly
or indirectly through market corroboration, for substantially the full term of the financial instrument; and</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level 3</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">unobservable
inputs for the assets or liabilities.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2020 and 2019, we had&#160;<span id="xdx_90A_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_do_c20200930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9mphHV13BCg" title="Assets or liabilities valued at fair value"><span id="xdx_90B_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_do_c20190930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zD0l6Yjdgw3b" title="Assets or liabilities valued at fair value">no</span></span>&#160;assets or liabilities that were valued at fair value on a recurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in
connection with any required impairment test. During the nine months ended September 30, 2020 and 2019, we wrote off $<span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pp0p0_c20200101__20200930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zM1WG9lat7Nk" title="Impairment of intangible assets"><span title="Impairment of intangible assets">584,509</span></span>
and $<span id="xdx_90D_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pp0p0_c20190101__20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zl3Y97le3Ikd" title="Impairment of intangible assets">78,864</span>, respectively,&#160;in costs related to trademarks and patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z2Q9w6a4qmGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_zVqN6FWuK28k">Share-Based
Compensation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs
in the financial statements over the period during which employees are required to provide services. Share-based compensation
arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and
employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award.
We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718,
Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected
life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield.
The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity
period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price
is expected to fluctuate each year during the term of the award. On January 1, 2017, we began using our own stock price in our
volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our
company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility
is based on historical stock prices over a period equal to the expected term of the awards. On January 1, 2020, we began calculating
the expected term of our stock-based awards, which represents the period that the stock-based awards are expected to be outstanding.
Prior to January 1, 2020, the average expected life of options was based on the contractual terms of the stock option using the
simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current
intention to pay cash dividends. The assumptions used in calculating the fair value of stock-based awards represent our best estimates,
but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change
and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize
the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with
ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#8217;s requisite service
period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which
simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments
to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted
to non-employees in exchange for goods or services used or consumed in an entity&#8217;s own operations and superseded the guidance
in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required
by ASC 505, Equity - Based Payments to Non-Employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
grant performance-based stock units and restricted stock units for shares of common stock, par value $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zOdMlYlKdZH9" title="Common stock, shares, issued (in dollars per share)"><span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0bVDl65G6w1" title="Common stock, shares, issued (in dollars per share)">0.001</span></span> per share, or Common
Stock, to employees. We value our restricted stock units and our performance-based stock units by reference to our stock price
on the date of grant. We recognize compensation expense for restricted stock units based on a straight-line basis over the requisite
service period of the entire award. We recognize performance-based restricted stock as compensation expense based on the most
likely probability of attaining the prescribed performance and over the requisite service period beginning at its grant date and
through the date the restricted stock vests. The number of target shares that vest are determined based on the level of attainment
of the targets. If a minimum level of performance is attained for the awards, restricted stock is issued based on the level of
attainment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_844_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zcotw2sU4114" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86E_zQp4w9QBwzCi">Revenue
Recognition</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
accordance with ASC 606,&#160;<i>Revenue from Contracts with Customers</i>, or ASC 606, revenue is recognized when a customer
obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect
to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which
we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to
which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1)
identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction
price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as,
we satisfy the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Prescription
Products</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which
we began selling during the third quarter of 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA,
which we began selling in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused
the commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters.
We resumed the launch of ANNOVERA on July 1, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have
one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised
goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer
promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than
as a separate obligation. We recognize prescription product revenue only when we satisfy performance obligations by transferring
a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods
or service or obtains control. Control refers to the customer&#8217;s ability to direct the use of, and obtain substantially all
of the remaining benefits from, an asset. Based on our contracts, we invoice customers once our performance obligations have been
satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement
of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent
to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring
promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined
based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns,
chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed
on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current
liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate
the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method,
depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable
consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount
of cumulative product revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently
resolved. In determining amounts of variable consideration to include in a contract&#8217;s transaction price, we rely on our
historical experience and other evidence that supports our qualitative assessment of whether product revenue would be subject
to a significant reversal. We consider all the facts and circumstances associated with both the risk of a product revenue reversal
arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts
of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates,
we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become
known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
accept returns of unsalable prescription products sold through wholesale distributors within a return period of <span id="xdx_905_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dt_c20200101__20200930__srt--RangeAxis__srt--MinimumMember_zO3SbBGuQ4Lc" title="Return period of unsalable prescription products">six months</span>
 prior to and up to <span id="xdx_906_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20200930__srt--RangeAxis__srt--MaximumMember_zhsZ9iuNdub8" title="Return period of unsalable prescription products">12</span>
months following product expiration. Our vitamins and IMVEXXY currently have a shelf life of <span id="xdx_909_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200930__srt--ProductOrServiceAxis__custom--VitaminsAndImvexxyMember_z8av3zzitG1l" title="Shelf life of prescription products following product expiration">24</span>
months from the date of manufacture and BIJUVA and ANNOVERA currently have a shelf life of <span id="xdx_903_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200930__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zvsYL7Ka94gc">18</span> months from the date of
manufacture. We do not allow product returns for prescription products that have been dispensed to a patient. We estimate the
amount of our product sales that may be returned by our customers and record this estimate as a reduction of product revenue
in the period the related product revenue is recognized. Where historical rates of return exist, we use history as a basis to
establish a returns reserve for products shipped to wholesalers. For our newly launched products, for which the right of
return exists but for which we currently do not have history of product returns, we estimate returns based on available
industry data, our own sales information and our visibility into the inventory remaining in the distribution channel. At the
end of each reporting period, we may decide to constrain product revenue for product returns based on information from
various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products
currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the
amount of expected returns as a refund liability, representing the obligation to return the customer&#8217;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return
asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of
product revenue is deferred due to the anticipated return). Return estimates are recorded in other current liabilities on the
consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales
and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience
and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates
and coupons are deducted from gross product revenues at the time the product revenues are recognized. We record distributor fees
based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in other current liabilities
on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account
prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns
are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts
and chargebacks are deducted from gross product revenues at the time the product revenues are recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
part of commercial launches for our FDA-approved prescription products, we introduced a co-pay assistance program for eligible
enrolled patients whose out of pocket costs are reduced to a more affordable price. This allows patients to access the product
at a reasonable cost and is in line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party
vendors. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize
the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current
level of prescriptions covered by patients&#8217; insurance. Payers may change coverage levels for our prescription products positively
or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction
price of our prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company.
As a result, we constrain variable consideration for our prescription products to an amount that will not result in a significant
product revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription products is
constrained by our estimates of the amount to be paid for the co-pay assistance program which is directly related to the level
of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other
patient assistance based on currently available third-party data and our internal analyses. We re-evaluate variable consideration
each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">License
Revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">License
arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending
technology, and various performance or sales milestones and future product royalty payments. Some of these arrangements may
include multiple performance obligations. Non-refundable up-front fees that are not contingent on any future performance by
us, and do not require continuing involvement on our part, are recognized as revenue when the right to use functional IP is
transferred to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Disaggregation
of revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_zwLSIYehkWu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span><span id="xdx_8BF_z1MXKnWRBXE9">The
following table provides information about disaggregated revenue by product mix</span></span> for the three and nine months ended September
30, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Three Months Ended<br/> September 30,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Nine Months Ended<br/> September 30,</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: justify; padding-left: 5.4pt">Prescription vitamins</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zKejnfyswrQ" title="Net revenue">2,435,903</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z2NEamSswbvb" style="width: 10%; text-align: right">2,550,330</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z3bGmx2GXlVh" style="width: 10%; text-align: right">7,337,976</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z0sVZ7oZ6XXi" style="width: 10%; text-align: right">7,309,174</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">IMVEXXY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zDQQQ4gr8uv3" style="text-align: right">6,841,592</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zmw8LC9wVHT8" style="text-align: right">4,772,354</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zUy2Zc3HzfH3" style="text-align: right">18,319,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_ztNgP73WaH98" style="text-align: right">9,904,744</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">BIJUVA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--BijuvaMember_zUGGP1HjNmp4" style="text-align: right">1,646,320</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zvySuT2nGia2" style="text-align: right">490,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--BijuvaMember_zTF6I1TkioOc" style="text-align: right">4,109,925</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_ztMez4EZEkhi" style="text-align: right">624,987</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zrOHwGmsEkP1" style="text-align: right">6,418,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zgXrEZCkkDdh" style="text-align: right">399,952</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRYca6rAQPKb" style="text-align: right">10,527,212</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zgkMsGbGZwxb" style="text-align: right">399,952</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">License revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z3tZZfCwZfq2" style="border-bottom: Black 1pt solid; text-align: right">2,000,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zRHR3xdmecB" style="border-bottom: Black 1pt solid; text-align: right">15,506,400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zWr0oyyGelj" style="border-bottom: Black 1pt solid; text-align: right">2,000,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z2tCEaEiV2j3" style="border-bottom: Black 1pt solid; text-align: right">15,506,400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 0.375in">Net revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930_zkEoA0IraXnd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">19,342,805</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930_zmbAw1ceQvGc" style="border-bottom: Black 2.5pt double; text-align: right">23,719,741</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930_zK5AEdek3glc" style="border-bottom: Black 2.5pt double; text-align: right">42,294,495</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930_zI1PeJS4ECPk" style="border-bottom: Black 2.5pt double; text-align: right">33,745,257</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A5_zyVKyulKSYwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p id="xdx_848_ecustom--LicenseAgreementWithPopulationCouncilPolicyTextBlock_zESClL4UWTW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_865_zxUXenFGCps4">License
Agreement with the Population Council</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
July 30, 2018, we entered into the Population Council License Agreement to commercialize ANNOVERA in the U.S. We began selling
ANNOVERA in a &#8220;test and learn&#8221; market introduction in the third quarter of 2019. As a result of the uncertainty surrounding
the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing
initiatives into subsequent quarters. <span style="color: #212529">We resumed the launch of ANNOVERA on July 1, 2020.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $<span id="xdx_90B_ecustom--MilestonePaymentUponFDAApproval_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zbb7Lr3z6SL7" title="Milestone payment upon FDA Approval">20,000,000</span>&#160;within
30 days following the approval by the FDA of the new drug application, or NDA, for ANNOVERA and $<span title="Milestone payments (payment after release of first commercial batch)"><span id="xdx_90D_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_z5iWvTjpO881" title="Milestone payments (payment after release of first commercial batch)">20,000,000</span></span>&#160;within 30 days
following the first commercial batch release of ANNOVERA. Both milestone payments of $<span id="xdx_909_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zhM9QBi3N3zc" title="License rights acquired">20,000,000</span>&#160;were recorded as license
rights in the consolidated balance sheets. We started amortizing license rights in the third quarter of 2019 once ANNOVERA became
commercially available for use. The cost is amortized over the remaining useful life over which the license rights will contribute
directly or indirectly to our cash flows, which is estimated to be the remaining patent life of the product, which expires in
December 2032. The cost is amortized using the straight-line method as the pattern of economic benefit cannot be reliably determined.
During the three and nine months ended September 30, 2020, we recorded $<span id="xdx_901_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20200701__20200930_z7CLR3V5lPjj" title="Amortization of intellectual property license fee">762,389</span>&#160;and $<span id="xdx_90C_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20200101__20200930_zuKZh54Yu3g7" title="Amortization of intellectual property license fee">2,262,002</span>, respectively, in amortization
expense related to the license fee. During both the three and nine months ended September 30, 2019, we recorded $<span id="xdx_905_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20190701__20190930_zhO37Dwc4Pod" title="Amortization of intellectual property license fee"><span id="xdx_902_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20190101__20190930_zpBN7tHPZXWd" title="Amortization of intellectual property license fee">15,998</span></span> in amortization
expense related to the license fee which was recorded as a component of cost of sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Population Council is also eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible
for marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council,
on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates
and permitted licensees as follows: (i) if annual net sales are less than or equal to $<span id="xdx_904_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_c20200101__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_z5EMzf4wPEh3" title="Net sales amount per step-based royalty">50,000,000</span>, a royalty of&#160;<span id="xdx_90A_ecustom--RoyaltyPercent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zrOEsMcETNhj" title="Royalty (percent)">5</span>% of net
sales; (ii) for annual net sales greater than $<span id="xdx_90F_ecustom--NetSalesAmountPerStepbasedRoyalty_c20200101__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zjIiAQCur1Fk" title="Net sales amount per step-based royalty">50,000,000</span>&#160;and less than or equal to $<span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_c20200101__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zP1BhwjvVltk">150,000,000</span>, a royalty of&#160;<span id="xdx_906_ecustom--RoyaltyPercent_pii_dp_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_ztvmIGBhNfpb" title="Royalty (percent)">10</span>% of
such net sales; and (iii) for net sales greater than $<span id="xdx_906_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_c20200101__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zhW87utZf6c9" title="Net sales amount per step-based royalty">150,000,000</span>, a royalty of&#160;<span id="xdx_907_ecustom--RoyaltyPercent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zIl6CGAPDBre" title="Royalty (percent)">15</span>% of such net sales. The annual royalty
rate will be reduced to&#160;<span id="xdx_901_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zkVZ25eQpoGk" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent">50</span>% of the initial rate during the six-month period beginning on the date of the first arms-length
commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the
U.S., and thereafter will be reduced to&#160;<span id="xdx_907_ecustom--AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zrMItUXCRLZg" title="Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent">20</span>% of the initial rate. We are required to pay the Population Council milestone
payments of $<span id="xdx_90D_ecustom--MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_pp0p0_dm_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zohSQUs9Uz4d" title="Milestone payments upon specified levels of cumulative net sales">40 million</span>&#160;upon cumulative net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees
of each of $<span id="xdx_909_ecustom--SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_pn6n6_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zkw86Ij00lI6" title="Specified level one of cumulative net sales for milestone payments">200</span>&#160;million, $<span id="xdx_901_ecustom--SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_pn6n6_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zGDyxwW763r7" title="Specified level two of cumulative net sales for milestone payments">400</span>&#160;million&#160;and $<span id="xdx_90F_ecustom--SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_pn9n9_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_z4UimISN9gpk" title="Specified level three of cumulative net sales for milestone payments">1</span>&#160;billion. The Population Council has agreed to perform and pay
the costs and expenses associated with four post-approval studies required by the FDA for ANNOVERA and we have agreed to perform
and pay the costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism,
provided that if the costs and expenses associated with such post-approval study exceed $<span id="xdx_903_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_pii_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zNOQIfJLTYc6" title="Maximum costs and expenses for post approval">20,000,000</span>, half of such excess will
be offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement.
We and the Population Council have agreed to form a joint product committee responsible for overseeing activities under the Population
Council License Agreement. We will be responsible for all aspects of promotion, product positioning, pricing, education programs,
publications, sales messages and any additional desired clinical studies for the one-year vaginal contraceptive system, subject
to oversight and decisions made by the joint product committee. The Population Council License Agreement includes exclusive rights
for us to negotiate co-development of two other investigational vaginal contraceptive systems in development by the Population
Council.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>





<p id="xdx_848_ecustom--LicenseAgreementWithKnightPolicyTextBlock_zNPRMfR2xLZ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86A_z4pk4ByPb04g">License
Agreement with Knight</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we
granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the
Knight License Agreement, Knight paid us $<span id="xdx_905_ecustom--MilestonePaymentReceivedUponRegulatoryApproval_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--KnightLicenseAgreementMember_zUkuasQPehic">2,000,000</span>
in milestone fees upon the first regulatory approval in Canada for IMVEXXY and BIJUVA in the third quarter of 2020, and is
also required to pay us sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of
IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications,
submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada
within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents.
Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within
certain specified time periods or if the other party files for bankruptcy or other related matters. As part of the Knight
License Agreement, Knight is prohibited from exporting IMVEXXY and BIJUVA to the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_846_eus-gaap--CostOfSalesPolicyTextBlock_zSlKlmze6w85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86E_zEpUISSlKSgk">Cost
of Sales</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of sales includes the cost of inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping and
handling costs. The Population Council License Agreement requires payment of royalties based on the sale of future products. Such
royalties are recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related
to licensed products are classified as components of cost of sales to the extent such payments become due in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zo2CY4CWi0jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_864_zV1WCTQZtMMl">Inventory
Obsolescence Reserve</span> </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
evaluate inventory quarterly and record an allowance for obsolescence primarily associated with materials that are not
currently or likely to be used in production in the near future. As of September 30, 2020 and December 31, 2019, we recorded
an inventory obsolescence reserve of $<span id="xdx_901_eus-gaap--InventoryValuationReserves_iI_pp0p0_c20200930_z3nH5S3tEYUi" title="Inventory valuation reserves">5,744,464</span>&#160;and
$<span id="xdx_909_eus-gaap--InventoryValuationReserves_iI_pp0p0_c20191231_zuB0z7VrASU6" title="Inventory valuation reserves">0</span>,
respectively. The reserve recorded as of September 30, 2020 was primarily related to BIJUVA and resulted from the impact of
the COVID-19 pandemic on our business, which decreased demand for our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zCPayzXjlSA2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_865_zVGnNbixIvY8">Segment
Reporting</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single executive leadership team that is chaired by the Chief Executive Officer of our
Company, who oversees all operations. We do not operate separate lines of business with respect to any of our products and we
do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the
United States. Accordingly, we view our business as one reportable operating segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_z1glbuxYfOTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_z0EqH09uYUo6">Research
and Development Expenses</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development, or R&amp;D, expenses include internal R&amp;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal
R&amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO
activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;D expenses include
assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes,
and scientific writing matters, including preparing protocols and FDA submissions. These consulting expenses were direct costs
associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal
R&amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms,
which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services
that will be used in future R&amp;D activities when the activity has been performed or when the goods have been received rather
than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed
and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO
costs are subject to revisions as such studies progress to completion. We charge revisions to expenses in the period in which
the facts that give rise to the revision become known.</span></p>

<p id="xdx_85A_z0zaxpjxOijb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129383972488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 4 &#8211; INVENTORY, NET<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">NOTE 4 &#8211; INVENTORY, NET</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zbNjWte6NqIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_820_zP0RCQHVrPW9">NOTE
4 &#8211; INVENTORY, NET</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z27FoMC11SCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>Inventory,
net consists of the following:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20200930_z5U8PAj7D5U7" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,<br/> &#160;2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_498_20191231_zT02v8DIwNxj" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--InventoryFinishedGoods_iI_uUSD_maINzGAn_zJhFtjBfcGtb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: justify; padding-left: 5.4pt">Finished products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,794,132</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,976,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--InventoryWorkInProcess_iI_uUSD_maINzGAn_zDR0iYpgCtih" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440,149</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,182,059</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--InventoryRawMaterialsAndSupplies_iI_uUSD_maINzGAn_zZ2qVNfta8N9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Raw materials</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,698,023</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,701,747</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--InventoryNet_iTI_uUSD_mtINzGAn_zSQLbTIK26f7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">TOTAL INVENTORY, NET</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,932,304</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,860,716</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AA_zRC4R1ao0pC5" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129384051096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 5 &#8211; OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">NOTE 5 &#8211; OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_808_eus-gaap--OtherCurrentAssetsTextBlock_z4ddYWwpBCl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_827_zvnOGWl3DmEj">NOTE
5 &#8211; OTHER CURRENT ASSETS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zOYOeTHRUikc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>Other
current assets consist of the following:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20200930_zTNZhfb0cnbf" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,<br/> &#160;2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_498_20191231_zrsIWwqy81jg" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_406_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAzmtR_z3evkvY2zmXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: left; padding-left: 5.4pt">Prepaid sales and marketing costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">686,346</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,583,698</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAzmtR_z8nAdlxrBsHi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Debt financing fees on undrawn tranches (Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0765">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">550,757</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--PrepaidInsurance_iI_maPEAOAzmtR_z2F7mizyJHQg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,599,906</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,812,135</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--PrepaidManufacturing_iI_maPEAOAzmtR_zD3xSwrjhuO9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Prepaid manufacturing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">543,050</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,595,721</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzmtR_zTWiqaYmfWd2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Other prepaid costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,989,937</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,787,482</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzmtR_zJ1DIvpddX25" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.75in; padding-right: 10pt">TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,819,239</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,329,793</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_zDj0TaINv2Sj" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129384267048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 6 &#8211; FIXED ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">NOTE 6 &#8211; FIXED ASSETS, NET</a></td>
<td class="text"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zNKkQipCW9Vd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_82E_zkKdOm48YCQf">NOTE
6 &#8211; FIXED ASSETS, NET</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zD5SrQtIcLT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>Fixed
assets, net consist of the following:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20200930_zshcAQePpHz1" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,<br/> &#160;2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_49F_20191231_zaOonnrrItf4" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left; padding-left: 5.4pt">Accounting system</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zW0GiXH9G3p4" style="width: 10%; text-align: right" title="TOTAL FIXED ASSETS">301,096</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z5fEDds8i5i6" style="width: 10%; text-align: right">301,096</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zWlsRjUPWYP1" style="text-align: right" title="TOTAL FIXED ASSETS">1,658,258</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zlmS80uBzi6j" style="text-align: right">1,619,646</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z5xX5IOq9fv4" style="text-align: right" title="TOTAL FIXED ASSETS">1,406,858</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zOsgU67cMY66" style="text-align: right">1,406,858</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Computer hardware</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zbLQ8uwDG3mk" style="text-align: right" title="TOTAL FIXED ASSETS">80,211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zt274pS2tUT7" style="text-align: right">80,211</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zAjE9miBz6f2" style="border-bottom: Black 1pt solid; text-align: right" title="TOTAL FIXED ASSETS">68,788</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6FGsklpvoxc" style="border-bottom: Black 1pt solid; text-align: right">68,788</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzuyq_z2OECk4eH9cb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.625in; padding-right: 10pt">TOTAL FIXED ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,515,211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,476,599</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzuyq_zkoewWMaMsv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,545,282</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(968,824</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzuyq_z6TXxXANuqJb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.375in; padding-right: 10pt">TOTAL FIXED ASSETS, NET</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,969,929</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,507,775</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8A3_zUL09iHHnEMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation
expense for the three months ended September 30, 2020 and 2019 was $</span><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--Depreciation_pp0p0_c20200701__20200930_zOhS4HPggOpe" title="Depreciation expense">188,810</span><span>&#160;and
$</span><span id="xdx_90D_eus-gaap--Depreciation_pp0p0_c20190701__20190930_zZZvwnwPnUTk" title="Depreciation expense">90,700</span><span>, respectively, and for the nine months ended September 30, 2020 and 2019
was $</span><span id="xdx_907_eus-gaap--Depreciation_pp0p0_c20200101__20200930_zEQ8zkG3imee" title="Depreciation expense">576,459</span><span>&#160;and $</span><span id="xdx_907_eus-gaap--Depreciation_pp0p0_c20190101__20190930_zbOAAwYcaOO6" title="Depreciation expense">223,750</span><span>, respectively.
</span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129384202792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 7 &#8211; INTANGIBLE ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">NOTE 7 &#8211; INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p id="xdx_802_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zowlklt9L3Md" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_826_znn2ph4EEmz">NOTE
7 &#8211; INTANGIBLE ASSETS, NET</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_896_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zQ7rLu3fyk7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span>The
following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets
as of September 30, 2020 and December 31, 2019:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, 2020</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Net<br/> Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted- Average<br/> Remaining Amortization
    Period (yrs.)</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-left: 0.25in; text-indent: -0.125in">Approved hormone therapy drug candidate patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zcndpuWSOkxd" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Gross">4,108,745</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zT8YN1FkBoYg" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(679,959</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zFVvC1C5NdF3" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Net">3,428,786</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zObdTbfHdJdb" title="Finite-Lived Intangible Assets, Remaining Amortization Period">12.25</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Hormone therapy drug candidate patents (pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zBNtQL8fa47g" style="text-align: right" title="Finite-Lived Intangible Assets, Gross">1,760,923</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zIMkqnkYoGCf" style="text-align: right" title="Finite-Lived Intangible Assets, Net">1,760,923</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in">Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20200930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zIu7kB4Khspe" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks">348,176</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20200930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zsm7MR4r2CXi" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)">348,176</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.625in; text-indent: -0.125in; padding-right: 10pt">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20200930_zsoTsNWAQLw6" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)">6,217,844</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20200930_zMZWyL4XpNUb" style="border-bottom: Black 2.5pt double; text-align: right">(679,959</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20200930_zS4NdEtnGoZ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">5,537,885</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Net<br/> Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted- Average<br/> Remaining Amortization
    Period (yrs.)</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-left: 0.25in; text-indent: -0.125in">Approved hormone therapy drug candidate patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zy7FKrAtL3n8" style="width: 10%; text-align: right">3,463,082</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zfTrTI8UtTE1" style="width: 10%; text-align: right">(478,983</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zcbMKJnrPMgf" style="width: 10%; text-align: right">2,984,099</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zmi7bd5E8OGk" title="Finite-Lived Intangible Assets, Remaining Amortization Period">13</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Hormone therapy drug candidate patents &#160;(pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z9yVdZwy4bVe" style="text-align: right">1,979,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zSaeK4vCLP7d" style="text-align: right">1,979,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zGbPnFHgdsU3" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks">294,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zSi7S5C0JTwk" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)">294,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-right: 10pt; padding-left: 0.5in">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20191231_zoVg8icnFi7d" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)">5,737,194</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231_zDdsyjH116n7" style="border-bottom: Black 2.5pt double; text-align: right">(478,983</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20191231_zjzSP5boAYLb" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">5,258,211</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8A4_ziJmNk4pJBsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent
is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated
useful life of approximately&#160;<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zX0WFC8sEiU7" title="Finite-Lived Intangible Asset, Useful Life">20</span>&#160;years, which is the life of intellectual property patents. If the patent is not granted,
we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During
the nine months ended September 30, 2020 and 2019, we wrote off $<span id="xdx_908_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pp0p0_c20200101__20200930_zEqH37p5BYR7" title="Write off of patent and trademark costs">584,509</span> and $<span id="xdx_900_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pp0p0_c20190101__20190930_z1HQK0NPv6bl" title="Write off of patent and trademark costs">78,864</span>, respectively,&#160;in costs related to trademarks
and patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, we had&#160;<span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsMember_zvhgTOoolh2a" title="Number of issued patents">35</span>&#160;issued domestic patents and&#160;<span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsMember_z4TzhWTmboz2" title="Number of issued patents">35</span>&#160;issued foreign patents, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsBijuvaMember_zxCrLKZenYMj" title="Number of issued patents">14</span>
                                         domestic patents and <span id="xdx_90F_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsBijuvaMember_zc5vZMnYaZM2" title="Number of issued patents">seven</span> foreign patents that relate to BIJUVA as well as <span id="xdx_90C_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsEstradiolAndProgesteroneCandidatesMember_zUrHwEOUUII3">three</span> domestic
                                         patents that relate to estradiol and progesterone product candidates. These patents establish
                                         an important intellectual property foundation and are owned by us. The domestic patents
                                         will expire in 2032. The foreign patents will expire no earlier than 2032. In addition,
                                         we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia,
                                         Brazil, Canada, China, Europe, Hong Kong, Israel, Japan, Mexico, New Zealand, Russia,
                                         South Africa, and South Korea.</span></td></tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsImvexxyMember_z3KQgaGeHzlg" title="Number of issued patents">Ten</span>&#160;domestic
                                         patents (<span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSUtilityPatentsImvexxyMember_z6GfXZ1OVPB" title="Number of issued patents">eight</span>&#160;utility and&#160;<span id="xdx_907_ecustom--NumberOfIssuedPatents_iI_dc_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSDesignPatentsImvexxyMember_zVPCI27LvHV9" title="Number of issued patents">two</span>&#160;design) and&#160;<span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsImvexxyMember_zS4Mx0opSJnf" title="Number of issued patents">16</span>&#160;foreign patents
                                         (<span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentsImvexxyMember_zedi9vQ5MRpc" title="Number of issued patents">six</span>&#160;utility and&#160;<span id="xdx_90E_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignDesignPatentsImvexxyMember_zGVIa8cDElx6" title="Number of issued patents">ten</span>&#160;design) that relate to IMVEXXY. These patents establish
                                         an important intellectual property foundation for IMVEXXY and are owned by us. The domestic
                                         patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier
                                         than 2033. The foreign design patents provide protection expiring no earlier than 2025.
                                         In certain countries, the foreign design patents provide protection through at least
                                         2037. In addition, we have pending patent applications related to IMVEXXY in the U.S.,
                                         Argentina, Australia, Brazil, Canada, Europe, Hong Kong, Israel, Japan, Mexico, New Zealand,
                                         Russia, South Africa, and South Korea.</span></td></tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"/></p>





<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTopicalCreamCandidatesMember_z1kW2DLjR936" title="Number of issued patents">One</span>&#160;domestic
                                         utility patent that relates to our topical-cream candidates, which is owned by us. The
                                         domestic patent will expire in 2035.</span></td></tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTransdermalPatchMember_zznGE3DMxMXi" title="Number of issued patents">One</span>&#160;domestic
                                         utility patent and&#160;<span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_dc_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentTransdermalPatchMember_zd9Ko0fHz9yh">eight</span>&#160;foreign patents that relate to our transdermal-patch
                                         candidates, which are owned by us. The domestic utility patent will expire in 2032. The
                                         foreign patents will expire no earlier than 2033. We have pending patent applications
                                         with respect to our transdermal-patch candidates in the U.S., Brazil, Canada, Mexico,
                                         and South Africa.</span></td></tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTx009HRMember_zU7wmSGHshla" title="Number of issued patents">Three</span>&#160;domestic
                                         utility patents that relate to TX-009HR, a progesterone and estradiol product candidate,
                                         which are owned by us and will expire in 2037.</span></td></tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsProgesteroneFormulationsMember_zsSiHwpXiezd" title="Number of issued patents">Two</span>&#160;domestic
                                         and&#160;<span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsProgesteroneFormulationsMember_zNjMzCkPoRij" title="Number of issued patents">four</span>&#160;foreign patents that relate to formulations containing progesterone,
                                         which are owned by us. The domestic patents will expire between 2032 and 2036. The foreign
                                         patents will expire no earlier than 2033.</span></td></tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_dc_uNumber_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentOperaMember_zb3xrCKblDdb" title="Number of issued patents">One</span>&#160;domestic
                                         utility patent that relates to our OPERA information-technology platform, which is owned
                                         by us and will expire in 2031.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z4V1CUC0hoy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Amortization
expense was $<span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20200701__20200930_zUMstwvHguKh">69,977</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;and
$<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20190701__20190930_zef1mEBbIYZd">51,259</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;for
the three months ended September 30, 2020 and 2019, respectively, and $<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20200101__20200930_zdlMR4nQhdSe">200,879</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;and
$<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20190101__20190930_zKWSvIWlGIwj">140,206</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;for
the nine months ended September 30, 2020 and 2019, respectively. <span id="xdx_8B3_zuQh9i88rL45">Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Year Ending<br/> December 31,</b></td>
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 2px"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Estimated <br/>
    Amortization</b></td>
    <td style="text-align: center"><b>&#160;</b></td></tr>
<tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2020 (3 months)</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_uUSD_c20200930_zuJLzRelx1ob" style="width: 18%; text-align: right" title="2020 (3 months)">69,977</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_uUSD_c20200930_zfNvcy4TE9Ka" style="text-align: right" title="2021">279,909</td><td style="text-align: left">&#160;</td></tr>
<tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_uUSD_c20200930_zaomUZJ6Dvb6" style="text-align: right" title="2022">279,909</td><td style="text-align: left">&#160;</td></tr>
<tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_uUSD_c20200930_zUyu8cnU1idj" style="text-align: right" title="2023">279,909</td><td style="text-align: left">&#160;</td></tr>
<tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_uUSD_c20200930_zGx3RJsGkfP4" style="text-align: right" title="2024">279,909</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A3_zeYwC5mhU5Ag" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129390550776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 8&#8211; OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">NOTE 8&#8211; OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_809_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z9ztfjXAqfj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_82A_ze3wETkBa5u9">NOTE
8&#8211; OTHER CURRENT LIABILITIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_896_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_z47uqXV0qdcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Other
current liabilities consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20200930_z2UXOuVdXdV" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,<br/> 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_496_20191231_zhaxBHxeebj6" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--AccruedSalariesCurrent_iI_maOLCz3D1_zfWGmRvrEpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: justify; padding-left: 5.4pt">Accrued payroll, bonuses and commission costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,381,729</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">8,040,278</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCz3D1_zzK3HTf3QqH" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Allowance for coupons and returns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,353,403</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,316,298</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCz3D1_z8U82KLNYREj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">Accrued sales and marketing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,578,971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,285,662</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedVacationCurrent_iI_maOLCz3D1_zy2BO8mJBhZ3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Accrued compensated absences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,558,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,463,878</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCz3D1_z9ALBRofLxWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">Allowance for wholesale distributor fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,130,230</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,347,122</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCz3D1_zGf1Vg9E8o1k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Accrued legal and accounting expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,052,935</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">422,336</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--AccruedResearchAndDevelopment_iI_maOLCz3D1_zWPlBP8Uhmxc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">Accrued research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,059,077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,049,603</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCz3D1_zsvnhSKLw4n9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,404,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,501,539</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--AccruedRebates_iI_maOLCz3D1_zZvhpyeHpvx" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">Accrued rebates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,629,732</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,916,672</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCz3D1_z7PSnGJp0Nhk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Other accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,072,066</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,480,225</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCz3D1_zq0QmxmnADJk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0.125in; padding-left: 0.25in">TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,220,484</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33,823,613</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8A0_zLLbs11p2yfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129389958696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 9 &#8211; DEBT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">NOTE 9 &#8211; DEBT</a></td>
<td class="text"><p id="xdx_804_eus-gaap--LongTermDebtTextBlock_zmxRRFczUK8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_828_zdAjHrceEQB2">NOTE
9 &#8211; DEBT</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
April 24, 2019, we entered into a Financing Agreement, as amended, or the Financing Agreement, with TPG Specialty Lending,
Inc., as administrative agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of
our subsidiaries party thereto from time to time as guarantors, which provides us with up to a $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190424__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z9UqbFedBss2">300,000,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;first
lien secured term loan credit facility, or the Facility. The Facility provides for availability to us in three tranches: (i)
$<span id="xdx_902_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190424__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zm5jCo6Y72R6">200,000,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;was
drawn upon entering into the Financing Agreement; (ii) $<span id="xdx_902_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_zTLbIe2ZXyfa">50,000,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;was
drawn on February 18, 2020 following our achievement of more than $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20191001__20191231__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember__srt--RangeAxis__srt--MinimumMember_z8ooUFyN7eij">11,000,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;in
net revenues from IMVEXXY, BIJUVA and ANNOVERA for the fourth quarter of 2019 and (iii) $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20200630__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zI7QIojnIcV8">50,000,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;was
previously available to us in the Administrative Agent&#8217;s sole and absolute discretion either contemporaneously with the
delivery of our financial statements for the quarter ended June 30, 2020 or at such earlier date as the Administrative Agent
may have consented to. Due to the pause in the successful full launch of ANNOVERA caused by the COVID-19 pandemic, the
undrawn $<span id="xdx_90F_ecustom--LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_iI_pp0p0_c20200930__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zYP9BrtHDmAf">50,000,000</span>
tranche under the Financing Agreement is no longer available. Borrowings under the Facility accrue interest at either
(i)&#160;<span id="xdx_902_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zC1sjp4MooC5">3-month
LIBOR</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;plus&#160;<span id="xdx_90D_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zPh3oVNyJcG7">7.75</span></span><span style="font: 10pt Times New Roman, Times, Serif">%,
subject to a LIBOR floor of<span id="xdx_90A_ecustom--LiborFloorRate_iI_pii_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z3NlJALCpVid">&#160;2.70</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
or (ii) the&#160;<span id="xdx_90D_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zvgF7rfaf3t8">prime
rate</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;plus&#160;<span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zqXwFNjObkha">6.75</span></span><span style="font: 10pt Times New Roman, Times, Serif">%,
subject to a prime rate floor of&#160;<span id="xdx_90B_ecustom--PrimeRateFloor_iI_pii_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zjuJRIaHBXda">5.2</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
as selected by us. Interest on amounts borrowed under the Facility is payable quarterly. The outstanding principal amount of
the Facility is payable in&#160;<span id="xdx_906_ecustom--NumberOfInstallmentPayments_iI_dc_uNumber_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zSlmoJGd4Z8d">four</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;equal
quarterly installments beginning on June 30, 2023, with the Facility maturing on March 31, 2024. We have the right to prepay
borrowings under the Facility in whole or in part at any time, subject to a prepayment fee on the principal amount being
prepaid of (i)&#160;<span id="xdx_90E_ecustom--PrepaymentFeeForFirstTwoYearsFundingPercent_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zEzT0ORvbSuh">30.0</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
for the first two years following the initial funding date of the applicable borrowing, (ii)&#160;<span id="xdx_90E_ecustom--PrepaymentFeeThirdYearFundingPercent_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zgTNRvhrkD79">5.0</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
for the third year following the initial funding date of the applicable borrowing, (iii)&#160;<span id="xdx_901_ecustom--PrepaymentFeeFourthYearFundingPercent_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zfMK9yTLmEmd">3.0</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
for the fourth year following the initial funding date of the applicable borrowing and (iv)&#160;<span id="xdx_90A_ecustom--PrepaymentFeeFifthYearFundingPercent_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zfOdkgedXmVg">1.0</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
for the fifth year following the initial funding date of the applicable borrowing but prior to March 31, 2024. In connection
with the initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility fee equal to&#160;<span id="xdx_901_ecustom--FacilityFeePaidPercent_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zQhHBHa4UwL6">2.5</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the initial amount borrowed and will be required to pay such a facility fee in connection with any subsequent borrowings
under the Facility. We are also required to pay the Administrative Agent and the lenders an annual administrative fee in
addition to other fees and expenses. The Financing Agreement contains customary mandatory prepayments, restrictions and
covenants applicable to us that are customary for financings of this type. Among other requirements, we are required to (i)
maintain a minimum unrestricted cash balance of $<span id="xdx_909_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pp0p0_uUSD_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zfmlp8AMvu62" title="Minimum cash balance requirement under credit agreement">60,000,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our IMVEXXY, BIJUVA and
ANNOVERA products beginning with the fiscal quarter ending December 31, 2020. Pursuant to Amendment No. 6, the minimum
required cash balance was lowered to $<span id="xdx_90C_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Period1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjQAClj3WUz7" title="Minimum cash balance requirement under credit agreement">45 million</span> through December 31, 2020. As of September 30, 2020, we were in compliance
with all covenants under the Financing Agreement. The Financing Agreement also includes other representations, warranties,
indemnities and events of default that are customary for financings of this type, including an event of default relating to a
change of control of the Company. Upon or after an event of default, the Administrative Agent and the lenders may declare all
or a portion of our obligations under the Financing Agreement to be immediately due and payable and exercise other rights and
remedies provided for under the Financing Agreement. The obligations of our company and its subsidiaries under the Financing
Agreement are secured, subject to customary permitted liens and other agreed upon exceptions, by a first priority perfected
security interest in all existing and after acquired assets of our company and its subsidiaries. The obligations under the
Financing Agreement will be guaranteed by each of our future direct and indirect subsidiaries, subject to certain
exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
May 1, 2018, we entered into a Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap,
as agent, or Agent, and as lender, and the additional lenders party thereto from time to time (together with MidCap as a lender,
the Lenders), as amended. The Credit Agreement provided a secured term loan facility in an aggregate principal amount of up to
$<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zvPqJDd4qL6i" title="Line of Credit Facility, Maximum Borrowing Capacity">200,000,000</span>, or the Term Loan. Under the terms of the Credit Agreement, the Term Loan was available to be made in&#160;<span id="xdx_908_ecustom--NumberOfTranchesUnderTermLoanFacility_iI_pii_dc_uNumber_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zSFKQiBm1SYe" title="Number of tranches under term loan facility">three</span>&#160;separate
tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. Amounts borrowed
under the Term Loan bore interest at a rate equal to the sum of (i)&#160;<span id="xdx_900_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zgKUMdybmzt3" title="Debt Instrument, Description of Variable Rate Basis">one-month LIBOR</span>&#160;(subject to a LIBOR floor of&#160;<span id="xdx_90A_ecustom--LiborFloorRate_iI_pii_dp_uPure_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zd7EMhguzLnk" title="LIBOR floor rate">1.50</span>%)
plus (ii)&#160;<span id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPure_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zzrmO32ULdl6" title="Debt Instrument, Basis Spread on Variable Rate">7.75</span>% per annum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
April 24, 2019, we terminated the Credit Agreement. A portion of the initial tranche of borrowing under the Financing Agreement
in the amount of approximately $<span id="xdx_90F_eus-gaap--RepaymentsOfLinesOfCredit_pp0p0_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z7ZkmRM0D9x7" title="Repayments of Lines of Credit">81,661,000</span>&#160;was used to repay all amounts outstanding under the Credit Agreement, which included
a prepayment fee of&#160;<span id="xdx_909_ecustom--PrepaymentFeePercentage_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z49XYv8pNpD1" title="Prepayment fee percentage">4</span>%, a repayment fee of&#160;<span id="xdx_907_ecustom--RepaymentFeePercentage_pii_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z3xeFCoh1yXd" title="Repayment fee percentage">4</span>%&#160;and other fees and expenses payable to the lenders under the Credit
Agreement. As a result of the termination of the Credit Agreement, we recorded $<span id="xdx_903_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_dxL_c20190401__20190630_zeU3b5K41Le8" title="Loss on extinguishment of debt::XDX::-10057632"><span style="-sec-ix-hidden: xdx2ixbrl0988">10,057,632</span></span>&#160;in loss on extinguishment of debt
in the second quarter of 2019. Interest expense for the nine months ending September 30, 2019 related to the Credit Agreement
was $<span id="xdx_903_eus-gaap--InterestExpenseDebt_pp0p0_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zWHH7uGRDABj" title="Interest Expense, Debt">1,816,747</span>. During the nine months ended September 30, 2019, and prior to the repayment of the Credit Agreement, we amortized
$<span id="xdx_903_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zYIBtGlnXce8" title="Amortization of deferred financing fees">120,146</span>&#160;of deferred financing fees as interest expense in the accompanying unaudited consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
August 5, 2020, we entered into Amendment No. 5 to the Financing Agreement, or Amendment No. 5. Amendment No. 5 adjusts the covenant
in the Financing Agreement regarding our achievement of minimum consolidated net revenue attributable to commercial sales of our
IMVEXXY, BIJUVA, and ANNOVERA products to reflect the impact of COVID-19 on our business. The covenant is effective beginning
with the fiscal quarter ending December 31, 2020. In connection with Amendment No.5 and in lieu of a cash amendment fee, we issued
to the Administrative Agent and the lenders under the Financing Agreement warrants to purchase an aggregate of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zMmQVXcAMJ05" title="Number of warrants issued">4,752,116</span> shares
of Common Stock with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zMXmWXl161Fj" title="Warrants exercise price">1.58</span> per share and a <span title="Warrants term">ten</span>-year term, or the Lender Warrants. The Lender Warrants were
issued pursuant to an exemption from registration under the Securities Act of 1933, as amended, and no registration rights were
issued. The Company concluded that the modification accounting model is applicable to this transaction and recognized the fair value of
the warrants as a debt discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, we </span><span style="font: 10pt Times New Roman, Times, Serif">had $<span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z5CHZGxeM2Rf" title="Long-term Debt, Gross">250,000,000</span>&#160;in
borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying consolidated
financial statements. We incurred $<span id="xdx_908_eus-gaap--DeferredFinanceCostsGross_iI_pp0p0_c20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zptmA0Ehhcsa" title="Debt Issuance Costs, Gross">7,902,270</span>&#160;in
deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing Agreement
have been allocated pro rata between the funded and unfunded tranches. Allocated deferred financing fees related to the two
tranches of borrowings that we received of $<span id="xdx_90B_eus-gaap--DeferredFinanceCostsGross_iI_pp0p0_c20200930__custom--DebtTrancheAxis__custom--TwoTranchesMember_zzOBP6hxXg82" title="Debt Issuance Costs, Gross">7,626,891</span>&#160;have
been reflected as a debt discount upon each draw and are amortized to interest expense using the effective interest method.
In addition, during the three months ended September 30, 2020, we recorded the fair value of the Lender Warrants of $<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_c20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zctco8pzxO6c" title="Fair value of warrants">7,428,179</span>
as a debt discount, which is being amortized to interest expense using the effective interest method over the term of the
Financing Agreement. During the three months ended September 30, 2020, we concluded that the undrawn $<span id="xdx_90A_ecustom--LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_iI_pp0p0_c20200930__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zCvq8fWLeXUc">50,000,000</span>&#160;tranche
under the Financing Agreement is no longer available to us. As such, we wrote off $<span id="xdx_906_eus-gaap--WriteOffOfDeferredDebtIssuanceCost_pp0p0_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zIvf9LbwiAJe" title="Write off of deferred financing fees">275,379</span>
of deferred financing fees associated with the unfunded tranche, which were previously deferred as assets until such tranche
had been drawn.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three and nine months ended September 30, 2020, we amortized $<span id="xdx_900_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20200701__20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zVbN83Wcvq49" title="Amortization of deferred financing fees">677,676</span>&#160;and $<span id="xdx_902_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20200101__20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zSTkThpiBscl" title="Amortization of deferred financing fees">1,370,118</span>, respectively, of deferred financing
fees related to the Financing Agreement&#160;<span>as interest expense in the accompanying consolidated
financial statements.&#160;</span>During the three and nine months ended September 30, 2019, we amortized $<span id="xdx_904_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20190701__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zovtXntihXMe" title="Amortization of deferred financing fees">265,949</span> and $<span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20190101__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_ztv8WYpA6kTd" title="Amortization of deferred financing fees">462,683</span>,
respectively, of deferred financing fees related to the Financing Agreement&#160;<span>as interest
</span>expense in the accompanying consolidated financial statements. Interest on amounts borrowed under the Financing Agreement
is due and payable quarterly in arrears. Interest expense for the three and nine months ended September 30, 2020 was $<span id="xdx_902_eus-gaap--InterestExpenseBorrowings_pp0p0_c20200701__20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zTuX4uHZNUf3" title="Interest Expense, Borrowings">6,726,389</span>&#160;and
$<span id="xdx_906_eus-gaap--InterestExpenseBorrowings_pp0p0_c20200101__20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zfu6QG49xqre" title="Interest Expense, Borrowings">19,322,847</span>, respectively. Interest expense for the three and nine months ended September 30, 2019 was $<span id="xdx_90A_eus-gaap--InterestExpenseBorrowings_pp0p0_c20190701__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zBSSPYylhSK6" title="Interest Expense, Borrowings">5,333,056</span> and $<span id="xdx_908_eus-gaap--InterestExpenseBorrowings_pp0p0_c20190101__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_ziWKBaLCxBA3" title="Interest Expense, Borrowings">9,318,056</span>,
respectively. The overall effective interest rate under the Financing Agreement was approximately&#160;<span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pii_dp_c20200930_z2DZUgbk066l" title="Debt Instrument, Interest Rate, Effective Percentage">12.5</span>%&#160;as of September
30, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfDebtTableTextBlock_zDrNLz8c39v4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><span>As
of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><b>September 30,<br/>
2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><b>December 31,<br/>
2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: justify; padding-left: 5.4pt">Financing Agreement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zqHJ5q3dEWK1" title="Long-term Debt, Gross">250,000,000</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zPrnnkLRHK98" title="Long-term Debt, Gross">200,000,000</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Debt discount and financing fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20200930_zQxR7PVfX23e" style="border-bottom: Black 1pt solid; text-align: right" title="Debt discount and financing fees"><span title="Debt discount and financing fees">(12,948,798</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20191231_zFkz36vv9bSd" style="border-bottom: Black 1pt solid; text-align: right" title="Debt discount and financing fees"><span title="Debt discount and financing fees">(5,365,357</span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.625in">TOTAL LONG-TERM DEBT</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_c20200930_zA5CKNEgBBS9" title="TOTAL LONG-TERM DEBT">237,051,202</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_c20191231_z1w0dYI3jfpl" title="TOTAL LONG-TERM DEBT">194,634,643</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8A1_zhGu5VP4ia09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
April 27, 2020, we received a loan pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic
Security Act (the &#8220;CARES Act&#8221;), as administered by the U.S. Small Business Administration. The loan in the principal
amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20200427__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_z3fr3WEprPCg" title="Principal amount">6,477,094</span>&#160;(the &#8220;PPP Loan&#8221;) was disbursed by Bank of America, NA, a national banking association, pursuant
to a promissory note issued by the Company. Although we believed, in good faith, we were qualified for the PPP Loan under the
available regulations, as a result of newly-issued guidance, particularly with respect to publicly traded companies receiving
funding under the CARES Act, we voluntarily returned the PPP Loan proceeds on May 14, 2020.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129384141720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 10 &#8211; NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NOTE 10 &#8211; NET LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_807_eus-gaap--EarningsPerShareTextBlock_zPJ3QCRowgzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_82C_zo8Jm2YAmdQ5">NOTE
10 &#8211; NET LOSS PER SHARE</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
calculate earnings per share, or EPS, in accordance with ASC 260,&#160;<i>Earnings Per Share</i>, which requires the computation
and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of Common
Stock outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock
outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive
shares of our Common Stock consist of options, warrants and restricted stock units and were excluded from the calculation of diluted
earnings per share because their effect would have been anti-dilutive due to the net loss reported by us. The table below presents
potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders
for the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zdmkJXXDt6df" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br/>
    2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br/>
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: justify; padding-left: 5.4pt">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBYeHEayNYId" style="width: 10%; text-align: right">23,893,180</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUPOt79jOXy1" style="width: 10%; text-align: right">24,849,984</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztJxaI3SeQ96" style="text-align: right">6,534,687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zulTC7er37df" style="text-align: right">1,832,571</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">Performance stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zuLqCM3vNgIj" style="text-align: right">2,422,885</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgMTAgliBORVQgTE9TUyBQRVIgU0hBUkUgKERldGFpbHMpAA__" style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zop3yhrbWp67" style="border-bottom: Black 1pt solid; text-align: right">6,029,957</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zbzLxz63fPM8" style="border-bottom: Black 1pt solid; text-align: right">1,240,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930_z0ZrZaIS9hN" style="border-bottom: Black 2.5pt double; text-align: right">38,880,709</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930_zzeYKcOaaIXc" style="border-bottom: Black 2.5pt double; text-align: right">27,922,555</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129384051928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zvSAt3k7HW5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_82C_zN2NPPDvexjl">NOTE
11 &#8211; STOCKHOLDERS&#8217; EQUITY</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Preferred
Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2020, we had&#160;<span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_uShares_c20200930_zhEnoIfCTdz5" title="Preferred Stock, Shares Authorized">10,000,000</span>&#160;shares of preferred stock, par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20200930_zVGKOst75Pb2" title="Preferred Stock, Par or Stated Value Per Share">0.001</span>&#160;per share, authorized for issuance,
of which&#160;<span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_dco_uShares_c20200930_zZ8SBcS5OpJi" title="Preferred Stock, Shares Issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_dco_uShares_c20200930_znb2ZKAXONge" title="Preferred Stock, Shares Issued">no</span></span>&#160;shares were issued or outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Common
Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2020, we had&#160;<span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_uShares_c20200930_zucQzDi7MeLc">600,000,000</span>&#160;shares of Common Stock authorized for issuance, of which&#160;<span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_uShares_c20200930_z2X68C4DTcma"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_uShares_c20200930_zKFP9mrzzDl7">272,812,271</span></span>&#160;shares
of Common Stock were issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Issuances
During the Three and Nine Months ended September 30, 2020</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended September 30, 2020, stock options to purchase an aggregate of&#160;<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20200701__20200930_zsT6ui54UaWc" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period">517,891</span>&#160;shares of Common Stock
were exercised for $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_uUSD_c20200701__20200930_zf9Y5A4502f3" title="Stock Issued During Period, Value, Stock Options Exercised">105,494</span>&#160;in cash. During the nine months ended September 30, 2020, stock options to purchase an aggregate
of&#160;<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20200101__20200930_zjwY7wiaTv8j">1,182,195</span>&#160;shares of Common Stock were exercised for $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_uUSD_c20200101__20200930_z49LEfFQB0qd">271,678</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;in
cash.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Issuances
During the Three and Nine Months ended September 30, 2019</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended September 30, 2019, certain individuals exercised stock options to purchase an aggregate of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20190701__20190930_z9LPOMHhkSNb" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period">55,236</span> shares
of Common Stock for $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_uUSD_c20190701__20190930_z9QCVov1SE89">8,549</span> in cash. During the nine months ended September 30, 2019, certain individuals exercised stock options
to purchase an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_uShares_c20190101__20190930_zCxJ5gHw5N4j">331,619</span> shares of Common Stock for $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_uUSD_c20190101__20190930_z5jDRIbR8pDh">108,656</span> in cash. Also, during the same period, stock options to
purchase an aggregate of <span id="xdx_902_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_uShares_c20190101__20190930_zjH6ZV7s9AS" title="Number of stock options exercised in cashless exercise">12,097</span> shares of Common Stock were exercised pursuant to the options&#8217; cashless exercise provisions,
wherein an aggregate of <span id="xdx_90F_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_uShares_c20190101__20190930_z7dn0Fub2uDd" title="Number of common stock issued during period for stock options exercised in cashless exercise">11,834</span> shares of Common Stock were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Warrants
to Purchase Common Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, we had warrants outstanding to purchase an aggregate of&#160;<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_uUSD_c20200930_z72xqmqA2Hp6" title="Warrants and Rights Outstanding">6,534,687</span>&#160;shares of Common Stock with
a weighted-average contractual remaining life of approximately&#160;<span id="xdx_900_ecustom--WarrantsAndRightsWeightedAverageContractualRemainingLife_dtY_c20200101__20200930_zC7h4cfCDxb9" title="Weighted-average contractual remaining life">7.5</span>&#160;years, and exercise prices ranging from $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zLnLhGwfXvv" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">0.24</span>&#160;to
$<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_z6mmRC3VLI0k" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">8.20</span> per share, resulting in a weighted average exercise price of $<span id="xdx_900_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iI_uUSDPShares_c20200930_ztOlIeUQARIg" title="Weighted average exercise price of warrants (in dollars per share)">1.83</span>&#160;per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend yield and the
term of the warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with Amendment No. 5 and in lieu of a cash amendment fee, we issued to the Administrative Agent and the lenders
under the Financing Agreement the Lender Warrants. The fair value for the Lender Warrants was determined by using the
Black-Scholes Model on the date of the grant using a term of ten years, volatility of&#160;<span id="xdx_90C_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_uPure_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_z3ZfgKakfKJ4">68.8</span>%,
risk-free interest rate of&#160;<span id="xdx_90C_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_dp_uPure_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zUlV9L9MJ2h8">0.34</span>%
and dividend yield of&#160;<span id="xdx_909_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_dp_uPure_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zTmONOJzhoN4">0</span>%.
The grant date fair value of the warrants was $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_z4m7hB62utpe">1.56</span>&#160;per
share. The warrants vested upon issuance. We concluded that the modification accounting model is applicable to this warrant
issuance and recognized the fair value of the warrants as a debt discount. As a result, the fair value of the Lender Warrants
is being amortized to interest expense over the term of the Financing Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
recorded share-based compensation expense related to warrants previously issued of $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_uUSD_c20200701__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zjQO02FbWAdc" title="Share-based Payment Arrangement, Noncash Expense">0</span>&#160;and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_uUSD_c20190701__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zNQqecM9XJBb" title="Share-based Payment Arrangement, Noncash Expense">56,418</span>&#160;for the three months
ended September 30, 2020 and 2019, respectively, and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_uUSD_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zvZ2BDIWlZs8" title="Share-based Payment Arrangement, Noncash Expense">26,446</span>&#160;and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_uUSD_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zV3wIx0Q1ZP" title="Share-based Payment Arrangement, Noncash Expense">198,306</span>&#160;for the nine months ended September 30, 2020
and 2019, respectively, in the accompanying consolidated financial statements. At September 30, 2020, there was no unrecognized
compensation expense remaining related to unvested warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2019, we granted warrants to purchase an aggregate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_uShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zgGhOGKZFna8" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted">75,000</span> shares of Common Stock to outside
consultants at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zfQfPKflXv79">5.63</span>. The fair value for these warrants was determined by using the Black-Scholes Model on
the date of the grant using a term of five years, volatility of <span id="xdx_906_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_uPure_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z52Q5tyzUyvg" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate">60.8</span>%, risk-free interest rate of <span id="xdx_90A_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_dp_uPure_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zYQDsy3LXbl8">2.52</span>%, and dividend yield of
<span id="xdx_900_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_dp_uPure_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_ztjjmrEpa2eb">0</span>%. The grant date fair value of the warrants was $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zo4xKMthRmrc">3.00</span> per share. The warrants are vesting ratably over a <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zwuSwJrx0Reg">12</span>-month period and
have an expiration date of February 12, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended </span><span style="font: 10pt Times New Roman, Times, Serif">September 30, 2020, no
warrants were exercised. During the nine months ended September 30, 2019, warrants to purchase an aggregate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_uShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z8oPDnVUiLW9" title="Warrants exercised">1,250,000</span> shares
of Common Stock were exercised pursuant to the warrants&#8217; cashless exercise provisions, wherein an aggregate of <span id="xdx_906_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_uShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsCashlessExerciseMember_z3FmxMSSfu1l" title="Number of stock issued in cashless exercise of warrants">471,184</span> shares
of Common Stock were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Options
to Purchase Common Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees,
directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder
value by providing them stock options and other stock and cash incentives, or the Awards. As of September 30, 2020, there were
non-qualified stock options to purchase an aggregate of&#160;<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zqL8xWBgwgca" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number">13,346,455</span>&#160;shares of Common Stock outstanding under the 2009
Plan. Effective upon our adoption of the TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no
future awards may be made under the 2009 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012
Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain
consultants and advisors of our company. As of September 30, 2020, there were non-qualified stock options to purchase an aggregate
of&#160;<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zgGVylhXaDN" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number">6,305,974</span>&#160;shares of Common Stock outstanding and an aggregate of&#160;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_uShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zeid45xOe6uk" title="Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number">890,000</span>&#160;restricted stock units under the
2012 Plan. Effective upon our adoption of the 2019 Plan, no future awards may be made under the 2012 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 20, 2019, we adopted the 2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers,
directors, and certain consultants and advisors of our company. The Awards available under the 2019 Plan consist of stock options,
stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or
cash awards as described in the 2019 Plan. Generally, the options vest annually over four years or as determined by our board
of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis
after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any.
The expiration date is generally ten years from the date the option is issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, there were&#160;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--Plan2019Member_z5WAgZoEAxic" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized">3,465,514</span>&#160;shares of Common Stock available for issuance under the 2019 Plan, consisting
of (i)&#160;<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--NewSharesMember_znUURUMxncIk" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized">470,522</span>&#160;new shares, (ii)&#160;<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zT1Ts67wqhz4">2,405,833</span>&#160;unallocated shares previously available for issuance under the 2012
Plan that were not then subject to outstanding &#8220;Awards&#8221; (as defined in the 2012 Plan), and (iii)&#160;<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zocLOgd2rCEd">589,159</span>&#160;unallocated
shares previously available for issuance under the 2009 Plan that were not then subject to outstanding &#8220;Awards&#8221; (as
defined in the 2009 Plan). Any shares subject to outstanding options or other equity &#8220;Awards&#8221; under the 2019 Plan,
the 2012 Plan and the 2009 Plan that are forfeited, expire or otherwise terminate without issuance of the underlying shares, or
if any such Award is settled for cash or otherwise does not result in the issuance of all or a portion of the shares subject to
such Award (other than shares tendered or withheld in connection with the exercise of an Award or the satisfaction of withholding
tax liabilities), the shares to which those Awards were subject, shall, to the extent of such forfeiture, expiration, termination,
cash settlement or non-issuance, again be available for delivery with respect to Awards under the 2019 Plan. As of September 30,
2020, there were non-qualified stock options to purchase an aggregate of&#160;<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--Plan2019Member_zTH1Bc3QKXsk" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number">4,240,751</span>&#160;shares of Common Stock outstanding
under the 2019 Plan and an aggregate of&#160;<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zR7GgdpUsfge" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number">5,139,957</span>&#160;restricted stock units and&#160;<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_uShares_c20200930__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z6XALpbgdNf5" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number">2,422,885</span>&#160;performance stock units
outstanding under the 2019 Plan.</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zdD7a759RKPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life
of the stock options. <span id="xdx_8BA_zIVltiQHsPVg">The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020
and 2019 are set forth in the table below.</span></span><span style="font: 10pt Times New Roman, Times, Serif"/>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, &#160;<br/>
    2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, &#160;<br/>
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Weighted average grant date fair value</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7nmiUGQaxu6" style="width: 15%; text-align: right" title="Weighted average grant date fair value">0.95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXJkhBZg91jc" style="width: 15%; text-align: right" title="Weighted average grant date fair value">1.84</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6X436sBviji" title="Risk-free interest rate, minimum">0.34</span>-<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5ZrKfDKyAY7" title="Risk-free interest rate, maximum">1.68</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPWL2pTK1bmc" title="Risk-free interest rate, minimum">1.83</span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNVqFbgIC1te" title="Risk-free interest rate, maximum">2.54</span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zswuhMgxdtgh" title="Volatility, minimum">63.53</span>-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPEior3MJAf7" title="Volatility, maximum">67.92</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z928l5oTFKuj" title="Volatility, minimum">61.25</span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4RPVGscCE95" title="Volatility, maximum">64.49</span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhiXc8Uqg33k" title="Term">6</span>-<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zP9PJqIzP45f" title="Term">6.8</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrkbCvLBWz71" title="Term">5.5</span>-<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwEAjWx2Yqx" title="Term">6.5</span></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjImzCJUI6a6" title="Dividend yield">0.00</span>%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zP4UtUna5yp5" title="Dividend yield">0.00</span>%</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AA_zuk8AaiD2Qv9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zvEVXoBYoxi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span><span id="xdx_8BF_z3HpGB15ZkHi">A
summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September
30, 2020 is as follows</span>:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Number of Shares Under Options</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Exercise Price</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Remaining Contractual Life
    in Years</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Aggregate Intrinsic Value</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; padding-left: 5.4pt">Balance at December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMpi6OqO93mg" style="width: 10%; text-align: right" title="Number of shares under options, beginning">25,030,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsCMYOrb9io6" style="width: 10%; text-align: right" title="Weighted average exercise price, beginning">4.65</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZlMQ5IEoPQa" style="width: 10%; text-align: right" title="Weighted average remaining contractual life">5.84</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_uUSD_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSLzDKLI7LE1" style="width: 10%; text-align: right" title="Aggregate intrinsic value, beginning">3,668,171</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;&#160;Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5PqqEG2zYTg" title="Number of shares under options, granted">736,500</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znEtZXbedyLb" style="text-align: right" title="Weighted average exercise price, granted">1.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 5.4pt">&#160;&#160;Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFtA2f1Ronkf" style="text-align: right" title="Number of shares under options, exercised">(1,182,195</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv1ExzqMrWJg" title="Weighted average exercise price, exercised">0.23</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zk0L9xOZXdif" style="text-align: right" title="Aggregate intrinsic value, exercised">1,738,740</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;&#160;Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zc0S5Quq7m5g" style="text-align: right" title="Number of shares under options, expired">(361,109</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z33ShYQHAqF5" title="Weighted average exercise price, expired">3.66</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;Cancelled/Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zO96vznw0Vx" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares under options, cancelled forfeited">(330,250</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHvNR8QZyfs7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, cancelled forfeited">3.69</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Balance at September 30, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWs2yolFYyph" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares under options, ending">23,893,180</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsrdaKRFvgm1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending">4.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwGnABLUKPUb" style="border-bottom: Black 2.5pt double; text-align: right">5.46</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_uUSD_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z48nVCNdzIzd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, ending">379,535</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Vested and Exercisable at September 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_uShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHIfLHq3x253" style="text-align: right" title="Number of shares under options, vested and exercisable ending">19,827,306</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpVhxHr3u6j8" style="text-align: right" title="Weighted average exercise price, vested and exercisable ending">5.06</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z22ZbK8I6yUb" style="text-align: right" title="Weighted average remaining contractual life, vested and exercisable">4.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_uUSD_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z2ttQgGxMoHh" style="text-align: right" title="Aggregate intrinsic value, vested and exercisable ending">218,370</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">Unvested at September 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_uShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcCSBP4f1Rv2" style="text-align: right" title="Number of shares under options, unvested ending">4,065,874</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zx7WEQGpllm3" style="text-align: right" title="Weighted average exercise price, unvested">3.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7ig9lkWLbx5" style="text-align: right" title="Weighted average remaining contractual life in years, unvested">8.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iI_uUSD_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zI6nICZPvFg2" style="text-align: right" title="Aggregate intrinsic value, unvested">161,165</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AA_zMrOAAnKwmp8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2020, our outstanding options had exercise prices ranging from $<span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_uUSDPShares_c20200930__srt--RangeAxis__srt--MinimumMember_zRvay1vvzg33" title="Range - exercise price of options">0.38</span>&#160;to $<span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_uUSDPShares_c20200930__srt--RangeAxis__srt--MaximumMember_zIAHwIeOReFk">8.92</span>&#160;per share. Share-based compensation
expense related to options recognized in our results of operations for the three months ended September 30, 2020 and 2019 was
$<span id="xdx_90F_eus-gaap--ShareBasedCompensation_uUSD_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z2btrWeGGdk" title="Share-based Payment Arrangement, Noncash Expense">1,143,920</span>&#160;and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_uUSD_c20190701__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYQ3OG6mXXDa" title="Share-based Payment Arrangement, Noncash Expense">2,194,667</span>, respectively, and for the nine months ended September 30, 2020 and 2019 was $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_uUSD_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMPHCE6RaaP5" title="Share-based Payment Arrangement, Noncash Expense">4,141,061</span>&#160;and
$<span id="xdx_901_eus-gaap--ShareBasedCompensation_uUSD_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDuob47NDCsc" title="Share-based Payment Arrangement, Noncash Expense">6,568,736</span>, respectively, and it is based on awards vested. At September 30, 2020, total unrecognized estimated compensation expense
related to unvested options was approximately $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_uUSD_c20200930_zNJftiPd1bQb" title="Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount">6,500,000</span>, which may be adjusted for future changes in forfeitures. This cost is
expected to be recognized over a weighted-average period of&#160;<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqXS1YAnaLN6" title="Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition">2.0</span>&#160;years. No tax benefit was realized due to a continued
pattern of operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Restricted
Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Restricted
stock units granted under our 2009, 2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified
number of shares of our Common Stock. Share-based compensation expense is measured by the market value of our Common Stock on
the day of the grant. The shares vest ratably over the period specified in the grant. There is no partial vesting and any unvested
portion is forfeited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Performance
stock units will vest if certain performance targets are achieved. If minimum performance thresholds are achieved, each award
will convert into Common Stock at a defined ratio depending on the degree of achievement of the performance target designated
by each individual award. If minimum performance thresholds are not achieved, then no shares will be issued. We recognize performance-based
restricted stock as compensation expense based on the most likely probability of attaining the prescribed performance and over
the requisite service period beginning at its grant date and through the date the restricted stock vests. The expected levels
of achievement are reassessed over the requisite service periods and, to the extent that the expected levels of achievement change,
stock-based compensation is adjusted and recorded on the consolidated statements of income and the remaining unrecognized stock-based
compensation is recognized over the remaining requisite service period.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three and nine months ended September 30, 2020 we recorded $<span id="xdx_903_eus-gaap--RestrictedStockExpense_uUSD_c20200701__20200930_zFGtSFm0eEyb" title="Restricted Stock or Unit Expense">1,988,844</span>&#160;and $<span id="xdx_90B_eus-gaap--RestrictedStockExpense_uUSD_c20200101__20200930_zI5Z354jaZO7" title="Restricted Stock or Unit Expense">4,334,537</span>, respectively, and during the three
and nine months ended September 30, 2019 we recorded $<span id="xdx_902_eus-gaap--RestrictedStockExpense_uUSD_c20190701__20190930_zOrihx5Db0gb" title="Restricted Stock or Unit Expense">84,061</span>&#160;and $<span id="xdx_90C_eus-gaap--RestrictedStockExpense_uUSD_c20190101__20190930_zQoKGoC8pfEa">1,080,738</span>, respectively, in share-based compensation expense
related to restricted stock units and performance stock units. As of September 30, 2020, we recognized performance-based compensation
expense using our assessment of the most likely probability of attaining EBITDA break-even which would result in vesting two times
the base number of performance stock units. At September 30, 2020, total unrecognized estimated compensation expense related to
unvested&#160;restricted stock units and performance stock units&#160;was approximately $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_uUSD_c20200930_zOoYfyAYB9Dh" title="Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount">11,000,000</span>, which may be adjusted if
certain performance targets are achieved or for future changes in forfeitures. <span>This cost is expected to be recognized over a weighted-average
period</span> of&#160;<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zN8WVIO8dfy">1.6</span>&#160;years.</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zRZh1FI0hsz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B5_zPcTQN99nnXa">Schedule of restricted stock units and performance stock units</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b><span>
    <span>Restricted Stock Units</span></span></b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>Performance Stock Units</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>Number of Shares</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>Weighted Average Grant
    Date Fair Value</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>Number of Shares</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>Weighted Average Grant
    Date Fair Value</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2019</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhydhkTMslOk" style="width: 10%; text-align: right" title="Number of shares, beginning">1,240,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhpXBRtSmzb5" style="width: 10%; text-align: right" title="Weighted average grant date fair values, beginning">3.56</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3ZfVf0avEcj" style="text-align: right" title="Number of shares, granted">5,102,817</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zGNnDtTLORRg" style="text-align: right" title="Weighted average grant date fair value, granted">1.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zJbU32lgehje" style="text-align: right" title="Number of shares, granted">2,585,745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z6vXzH8k03D7" style="text-align: right" title="Weighted average grant date fair value, granted">1.08</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Vested/Released</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z73pf6G8bBs7" style="text-align: right" title="Number of shares, vested/released">(301,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zb0bbIou4Swk" style="text-align: right" title="Weighted average grant date fair value, vested/released">1.78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zSDPWOhKe4gh" style="text-align: right" title="Number of shares, vested/released">(151,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zkapLBpAhWa8" style="text-align: right" title="Weighted average grant date fair value, vested/released">1.14</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1x3WApsvY06" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited">(11,360</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0xEKqoWY9S2" style="text-align: right" title="Weighted average grant date fair value, forfeited">1.07</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zk7IQBLSKi84" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited">(11,360</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z3MDo8x2uR8e" style="text-align: right" title="Weighted average grant date fair value, forfeited">1.07</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBv8lGx9ef15" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, ending">6,029,957</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXc5a2LVVRmi" style="text-align: right" title="Weighted average grant date fair values, ending">1.83</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKg_____z4K4eOLt9fu" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, ending">2,422,885</td><td style="padding-bottom: 2.5pt; text-align: left"><sup>*</sup></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ztqvxwfpYrTl" style="text-align: right" title="Weighted average grant date fair value, ending">1.08</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><sup id="xdx_F01_zF3D0gJ2TQ39">*</sup></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F19_z8KYVpaGKtM7" style="font: 10pt Times New Roman, Times, Serif">The number
of performance stock units (PSUs) represents the base number of PSUs that may vest. The actual number of PSUs that will vest will
be between zero and two times the base number of PSUs depending on the Company's achievement of break-even quarterly EBITDA.</span></td>
</tr></table>

<p id="xdx_8A6_zm1hgrfziUb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Employee
Stock Purchase Plan </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 18, 2020, our stockholders approved the TherapeuticsMD, Inc. 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;),
which reserved <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200618__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_zEKsFf6lcNQ4">5,400,000</span> shares of Common Stock for purchase. The ESPP permits eligible employee participants to purchase Common
Stock at a price per share which is equal to <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dp_c20200617__20200618__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_zUn94t2uT8e2">85</span>% of the lesser of (a) the fair market value of the shares on the offering date
of the offering period or (b) the fair market value of the shares on the purchase date.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129384273288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 12 &#8211; INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">NOTE 12 &#8211; INCOME TAXES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zl2bkZCExrW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_822_zuyb4w5wDyre">NOTE
12 &#8211; INCOME TAXES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. We do not expect to pay any significant federal or state income tax for 2020 as a result of (i) the losses recorded
during the nine months ended September 30, 2020, (ii) additional losses expected for the remainder of 2020, and/or (iii) net operating
loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax
assets if it is &#8220;more likely than not&#8221; that some component or all of the benefits of deferred tax assets will not
be realized. As of September 30, 2020, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements,
no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the
reporting period.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129384131112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 13 &#8211; RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">NOTE 13 &#8211; RELATED PARTIES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zfIGDgj1Beb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_82D_zx6Re9VbXMSf">NOTE
13 &#8211; RELATED PARTIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to
time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements
with Catalent have been reviewed by independent directors of our Company, or a committee consisting of independent directors of
our company, since July 2015. During the three months ended September 30, 2020 and 2019, we were billed by Catalent approximately
$<span id="xdx_904_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200701__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zXGnvS0h23Gc" title="Amount billed">520,000</span>&#160;and $<span id="xdx_906_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190701__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_z5dt4b7NDic" title="Amount billed">2,196,000</span>, respectively, for manufacturing activities related to our clinical trials, scale-up, registration
batches, stability and validation testing. During the nine months ended September 30, 2020 and 2019, we were billed by Catalent
approximately $<span id="xdx_90A_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200101__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zKEazzbXUBFl" title="Amount billed">2,563,000</span>&#160;and $<span id="xdx_908_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190101__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zPCO89AEoKYa" title="Amount billed">4,118,000</span>, respectively, for manufacturing activities related to our clinical trials, scale-up,
registration batches, stability and validation testing. As of September 30, 2020 and December 31, 2019, there were amounts due
to Catalent of approximately $<span id="xdx_901_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zDm37JWDPs12" title="Amounts due to related party">147,000</span>&#160;and $<span id="xdx_909_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zJlzvape1Zi9" title="Amounts due to related party">35,000</span>, respectively. In addition, we have minimum purchase requirements in place
with Catalent as disclosed in Note 15, Commitments and Contingencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2020, Karen L. Ling, Executive Vice President and Chief Human Resources Officer of American International Group, Inc., or
AIG, was appointed to our board of directors. From time to time, we have entered into agreements with AIG in the normal course
of business. Agreements with AIG have been reviewed by independent directors of our Company, or a committee consisting of independent
directors of our Company, since April 2020. During the three and nine months ended September 30, 2020, we were billed by AIG approximately
$<span id="xdx_90A_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200701__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AmericanInternationalGroupMember_zkAOYQNVfN6k">52,000</span>&#160;and $<span id="xdx_906_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200101__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AmericanInternationalGroupMember_zGrjldiNQJ03">195,000</span>, respectively, for various insurance coverage for our Company.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129390174120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 14 - BUSINESS CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">NOTE 14 - BUSINESS CONCENTRATIONS</a></td>
<td class="text"><p id="xdx_803_eus-gaap--ConcentrationRiskDisclosureTextBlock_zs4dc46xCZS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_825_zzV6I4qmYFii">NOTE
14 - BUSINESS CONCENTRATIONS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
purchase our prescription products from several suppliers with approximately&#160;<span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zwL4LakNGcXd" title="Concentration risk">42</span>%,&#160;<span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zFxcoM0f0j6c" title="Concentration risk">25</span>% and&#160;<span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zspJcPWjz2Jf" title="Concentration risk">24</span>% of our purchases
supplied by three vendors each, respectively, during the nine months ended September 30, 2020, and&#160;<span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zoMLeAEOOue8" title="Concentration risk">36</span>%,&#160;<span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zMWXVjNL8BVj" title="Concentration risk">28</span>%,&#160;and
<span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zP9uVKvZQzl7" title="Concentration risk">26</span>% of our purchases supplied by three vendors each, respectively, during the nine months ended September 30, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
sell our prescription products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores
that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the nine months ended
September 30, 2020,&#160;<span id="xdx_908_ecustom--NumberOfCustomers_dc_uNumber_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zqmZxC98tKt4" title="Number of customers - revenue">three</span>&#160;customers each accounted for more than&#160;<span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zrFlZ5rQJlSe">10</span>% of our total product revenues. Product revenue
from the three customers combined accounted for approximately&#160;<span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeCustomersConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zV1ZOrscOwnh">56</span>% of our product revenue for the nine months ended September
30, 2020. During the nine months ended September 30, 2019,&#160;<span id="xdx_90A_ecustom--NumberOfCustomers_dc_uNumber_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zoCRaEdNz5hh">four</span>&#160;customers each generated more than&#160;<span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zvHJqShCp7oh">10</span>% of our product
revenues. Revenue generated from the four customers combined accounted for approximately&#160;<span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z52f3dQl2IBi">68</span>% of our product revenue for the
nine months ended September 30, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2020, Pillpack, Inc. accounted for approximately $<span id="xdx_90D_eus-gaap--Revenues_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zA69fHNTJ5v3" title="Revenues">9,319,000</span>&#160;of our product revenue, Cardinal
Health accounted for approximately $<span id="xdx_90E_eus-gaap--Revenues_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zl8aUhbFhMff" title="Revenues">7,415,000</span>&#160;of our product revenue, and McKesson Corporation accounted for approximately
$<span id="xdx_904_eus-gaap--Revenues_c20200101__20200930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zj31V7kJR2r6" title="Revenues">6,009,000</span>&#160;of our product revenue. During the nine months ended September 30, 2019, Pillpack, Inc. accounted for approximately
$<span id="xdx_903_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zBOik5QpNdPb">6,397,000</span> of our product revenue, AmerisourceBergen accounted for approximately $<span id="xdx_902_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zRnvTa6iyHhe"><span id="xdx_905_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z8Fw1vzbTvy1" title="Revenues">2,226,000</span></span> of our product revenue, PI Services
accounted for approximately $<span id="xdx_907_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPIServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zatreSu1m1aj">1,935,000</span> of our product revenue and Cardinal Health accounted for approximately $<span id="xdx_90D_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_ze1RARlBUZa4" title="Revenues">1,863,000</span> of our
product revenue.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129390170616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zfcSSNYMY9g1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_822_z2diCo7MEkrk">NOTE
15 &#8211; COMMITMENTS AND CONTINGENCIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Operating
Leases</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
adopted ASC 842, Leases, effective January 1, 2019. Substantially all our operating lease right-of-use assets and operating
lease liabilities represent leases for office space used to conduct our business. Upon adoption, we recognized a right-of-use
asset and a lease liability for all leases that have commenced as of January 1, 2019. The right-of-use assets represent the
right to use the leased asset for the lease term. The lease liabilities represent the present value of the lease payments
under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the
lease liability, plus any initial direct costs incurred, less any lease incentives received. All right-of-use assets are
reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted
using our secured incremental borrowing rate for the same term as the underlying lease because the rates are not implicit in
the leases. Some of our leases contain variable lease payments, including payments based on an index or rate. Variable lease
payments based on an index or rate are initially measured using the index or rate in effect at lease commencement. Additional
payments based on the change in an index or rate, or payments based on a change in our portion of the operating expenses are
recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease liability. Included in
lease expense are any variable lease payments incurred in the period that were not included in the initial lease
liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1,
2013 and originally provided for a&#160;<span id="xdx_900_ecustom--CapitalLeaseObligationsTerm_dtM_c20130630__20130701_zHc41TLTz5af" title="Non-cancelable operating lease term">63</span>-month term. On February 18, 2015, we entered into an agreement with the same lessors
to lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April
26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location.
This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021.
On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the
same location, pursuant to an addendum to such lease. This addendum became effective beginning November 1, 2016.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes&#160;<span id="xdx_90D_ecustom--NetRentableAreaLease_iI_usqft_c20181002_zWCCrYB91eq7" title="Net rentable area">56,212</span>&#160;rentable
square feet, or the full premises, of which the lease on&#160;<span id="xdx_90E_ecustom--RentedAreaLease_iI_usqft_c20181002_zaAa5hIVEEgj" title="Rented area lease">7,561</span>&#160;square
feet commenced in 2018 and the lease on the remaining&#160;<span id="xdx_900_ecustom--AdditionalAreaOfLeaseOccupied_iI_usqft_c20190801_zI04oyrP58zl" title="Additional area of lease occupied"><span id="xdx_904_ecustom--AdditionalAreaOfLeaseOccupied_iI_usqft_c20190801_zau1SkrRoYe4">48,651</span></span>&#160;square
feet commenced in August 2019, or the full premises commencement date. The lease will expire&#160;<span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20190801_z6pzdY8AEFCj" title="Lessee, Operating Lease, Term of Contract">11
years</span>&#160;after the full premises commencement date, unless terminated earlier in accordance with the terms of the
lease. We have the option to extend the term of the lease for&#160;<span id="xdx_90E_ecustom--LesseeOperatingLeaseExistenceOfOptionToExtendNumber_iI_dc_uPure_c20200930_zyQCbBnKO0J1" title="Lessee operating lease existence of option to extend number">two</span>&#160;additional
consecutive periods of&#160;<span id="xdx_903_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dt_c20200930_zsd62cQ0YDWh">five years</span>. The extension option is not included in the determination
of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free
rent periods. We are also responsible for certain other operating costs under the lease, including electricity and utility
expenses. In June 2019, we entered into an <span>agreement with the same lessors</span> to lease additional&#160;<span id="xdx_90A_ecustom--LesseeOperatingLeaseLeaseNotYetCommencedArea_iI_usqft_c20190601_z7HsIlDliUjf" title="Lease not yet commenced (area)">6,536</span>&#160;square
feet of administrative office space in the same location,&#160;<span style="color: #212529">pursuant to an addendum to such
lease, which commenced in May 2020.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="color: #212529">&#160;</span></span></p>


<table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_z6BLGFmJmuaj" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - Supplemental lease information (Details)">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Supplemental lease information:</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20200930_zKMlsFVVsmd5" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br/>
    2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_49F_20191231_z2lUPpRwwXri" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zLqHZddMxG6g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 5.4pt">Right-of-use asset</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">9,975,725</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">10,109,154</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zPtQCwt4f2Y5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Short-term operating lease liability (included in Other current liabilities)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,404,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,501,539</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zUd5AYS1Trqg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Long-term operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,907,995</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,145,049</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">Weighted average remaining term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Weighted average remaining term::XDX::P8Y9M18D"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20200930_zgBZsKcJU8Xf" title="Weighted average remaining term">8.8</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Weighted average remaining term::XDX::P9Y"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_zInyTUJoHZUa" title="Weighted average remaining term">9</span> years</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_zCdfVlGrIQC4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 5.4pt">Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.3%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.25%</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20200101__20200930_zuf4wqSlwdgf" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20190101__20190930_zqgrKqMD0BI7" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Supplemental cash flow information</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>for the nine months ended</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, &#160;<br/>
    2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, &#160;<br/>
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--OperatingLeasePayments_zMuE9QMriFWl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 5.4pt">Cash paid for amounts included in the measurement of lease liabilities for operating lease</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,006,970</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">849,440</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zkcI7REAWafk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Right-of-use assets obtained in exchange for lease obligation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">998,821</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,171,471</td><td style="text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8A1_zD4Xr3Z61old" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&#160;</p>

<p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z9tqWaUXtFdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><span>The
following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities
recorded on the balance sheet:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Years Ended December 31,</b></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20200930_z3Yh7MVxkvXi">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz1WK_zFQnea8plN43" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2020 (3 months)</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">610,675</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz1WK_zIu6XN3J8uWf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,334,582</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz1WK_zghllzAwiFZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,413,289</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz1WK_zNxrXusITLdl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,443,143</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz1WK_zizUHmGFOcH3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,476,534</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz1WK_zmejpP5unW48" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,947,869</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz1WK_zlrj5YfaeCM3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Total undiscounted lease payments</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,226,092</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zqGQLbwDaeM6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Less: imputed interest</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,913,811</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_zKTLHCCZFCl1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Present value of lease payments</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,312,281</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8AB_zwrJBIuQV3de" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">During
the three and nine months ended September 30, 2020, operating lease expense related to our real estate leases was
approximately $</span><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20200701__20200930_zKwi3X7g4mxl" title="Operating lease expense">590,000</span><span>&#160;and
$</span><span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20200101__20200930_zaaXw6dUInt4" title="Operating lease expense">1,749,000</span><span>,
respectively, and variable lease expense was approximately $<span id="xdx_90D_eus-gaap--VariableLeaseCost_c20200701__20200930_z1foDxKH1cC7" title="Variable lease expense">148,000</span> and $<span id="xdx_908_eus-gaap--VariableLeaseCost_c20200101__20200930_zwNmiPOxUh0j">226,000</span>, respectively, for the same periods. During
the three and nine months ended September 30, 2019, operating lease expense related to our real estate leases was
approximately $</span><span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20190701__20190930_zCoEAZCum7B1" title="Operating lease expense">458,000</span><span>&#160;and
$</span><span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20190101__20190930_z0LlTjbAU9Ae" title="Operating lease expense">1,062,000</span><span>,
respectively, and variable lease expense was insignificant for the same periods.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Intellectual
Property Licenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Population Council License Agreement provides for future milestone payments to be paid by us for access to certain technologies.
In addition, we pay royalties as a percent of product revenue as described in Note 7, Intangible Assets, to these consolidated
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Purchase
Commitments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">We
have manufacturing and supply agreements whereby we are required to purchase from Catalent a minimum number of softgels
during the first contract year and a higher number of softgels after the first contract year. If the minimum order quantities
of specific products are not met, we are required to pay Catalent&#160;<span id="xdx_90E_ecustom--SignificantSupplyCommitmentPercentagePayable_iI_dp_uPure_c20200930_zxpW7tJ3qKae" title="Significant supply commitment percentage payable">50</span>%
of the difference between the total amount we would have paid to Catalent if the minimum requirement had been fulfilled and
the sum of all purchases of our products from Catalent during the contract year. The updated minimum purchase commitments for
Catalent for the next five years are as follows: 2020 - $<span id="xdx_90C_eus-gaap--RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_iI_c20200930__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zevIbu8GnDge" title="Minimum purchase commitment, 2020">3,719,000</span>, 2021 - $<span id="xdx_904_eus-gaap--RecordedUnconditionalPurchaseObligationDueWithinOneYear_iI_c20200930__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zg9l22o0tgmf" title="Minimum purchase commitment, 2021">2,150,000</span>, 2022 - $<span id="xdx_90E_eus-gaap--RecordedUnconditionalPurchaseObligationDueInSecondYear_iI_c20200930__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zp9BcAymo7p6" title="Minimum purchase commitment, 2022">2,991,000</span>, 2023 - $<span id="xdx_90E_eus-gaap--RecordedUnconditionalPurchaseObligationDueInThirdYear_iI_c20200930__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zZp5SkgPv99i" title="Minimum purchase commitment, 2023">3,347,000</span>,
and 2024 - $<span id="xdx_90B_eus-gaap--RecordedUnconditionalPurchaseObligationDueInFourthYear_iI_c20200930__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zAZ6gSQXiIg" title="Minimum purchase commitment, 2024">3,786,000</span>. In addition, we have a manufacturing and supply agreement whereby we are required to purchase a minimum
number of units of ANNOVERA during a contract year. As of September 30, 2020, we have met our contract year purchase
commitments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Legal
Proceedings</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">From
time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved
in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations,
or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Off-Balance
Sheet Arrangements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020 and 2019, we had no off-balance sheet arrangements that have had or are reasonably likely to have current
or future effects on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources that are material to investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Employment
Agreements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits.
Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments,
if those circumstances occur during the term of the employment agreement.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129385510856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 16 &#8211; SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">NOTE 16 &#8211; SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_z5QRTRUrcB9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_82A_zx0pPW90etH6">NOTE
16 &#8211; SUBSEQUENT EVENTS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
November 8, 2020, we entered into Amendment No. 6 which temporarily lowered the minimum required cash balance under the Financing Agreement from $<span id="xdx_90E_ecustom--MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVvdUE19b7mj">60
million</span> to $<span id="xdx_906_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Period1Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIP3xT7anoVk">45
million</span> through December 31, 2020. After December 31, 2020, the minimum required cash balance will revert to $<span id="xdx_905_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_dm_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Period2Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfFWG2YmwwC8">60
million</span>.&#160;&#160;On November 8, 2020, in connection with entering into Amendment No. 6 to the Financing Agreement, we amended the Lender Warrants to provide for an adjustment to the exercise price if we conduct certain dilutive issuances prior to December 31, 2020, or if the volume-weighted average price of our Common Stock for the fifteen trading days ending December 31, 2020 is lower than the then-current exercise price.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129473983224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zk6qJabFcbz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_864_zRx3vtNoY2zj">Trade
Accounts Receivable and Allowance for Doubtful Accounts</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">Trade
accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts
and credit card chargebacks and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,
historical collection information, reasonable supportable forecasts and existing economic conditions and we record an allowance
that presents the net amount expected to be collected. We evaluate trade accounts receivable for delinquency. We write off delinquent
receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts,
and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase
in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately reflect bad
debts, adjustments to these reserves may be required. Our exposure to credit losses may increase if our customers are adversely
affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or
global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. Although
we have historically not experienced significant credit losses, it is possible that there could be a material adverse impact from
potential adjustments of the carrying amount of trade receivables in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z3RRKW4uBKpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86F_ztJzml9JFsCf">Fair
Value of Financial Instruments</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">Our
financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The
carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the
short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount
for long-term debt as of September 30, 2020 (as disclosed in Note 9) approximates fair value based on market activity for other
debt instruments with similar characteristics and comparable risk (Level 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by ASC 820, Fair Value Measurements, or ASC 820. The fair value hierarchy gives the highest priority to quoted prices
in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets
and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level 1</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">unadjusted
quoted prices in active markets for identical assets or liabilities;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level 2</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">quoted
prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly
or indirectly through market corroboration, for substantially the full term of the financial instrument; and</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.75in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level 3</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">unobservable
inputs for the assets or liabilities.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2020 and 2019, we had&#160;<span id="xdx_90A_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_do_c20200930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9mphHV13BCg" title="Assets or liabilities valued at fair value"><span id="xdx_90B_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_do_c20190930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zD0l6Yjdgw3b" title="Assets or liabilities valued at fair value">no</span></span>&#160;assets or liabilities that were valued at fair value on a recurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in
connection with any required impairment test. During the nine months ended September 30, 2020 and 2019, we wrote off $<span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pp0p0_c20200101__20200930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zM1WG9lat7Nk" title="Impairment of intangible assets"><span title="Impairment of intangible assets">584,509</span></span>
and $<span id="xdx_90D_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_pp0p0_c20190101__20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zl3Y97le3Ikd" title="Impairment of intangible assets">78,864</span>, respectively,&#160;in costs related to trademarks and patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z2Q9w6a4qmGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_zVqN6FWuK28k">Share-Based
Compensation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs
in the financial statements over the period during which employees are required to provide services. Share-based compensation
arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and
employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award.
We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718,
Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected
life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield.
The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity
period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price
is expected to fluctuate each year during the term of the award. On January 1, 2017, we began using our own stock price in our
volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our
company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility
is based on historical stock prices over a period equal to the expected term of the awards. On January 1, 2020, we began calculating
the expected term of our stock-based awards, which represents the period that the stock-based awards are expected to be outstanding.
Prior to January 1, 2020, the average expected life of options was based on the contractual terms of the stock option using the
simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current
intention to pay cash dividends. The assumptions used in calculating the fair value of stock-based awards represent our best estimates,
but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change
and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize
the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with
ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#8217;s requisite service
period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which
simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments
to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted
to non-employees in exchange for goods or services used or consumed in an entity&#8217;s own operations and superseded the guidance
in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required
by ASC 505, Equity - Based Payments to Non-Employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
grant performance-based stock units and restricted stock units for shares of common stock, par value $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zOdMlYlKdZH9" title="Common stock, shares, issued (in dollars per share)"><span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0bVDl65G6w1" title="Common stock, shares, issued (in dollars per share)">0.001</span></span> per share, or Common
Stock, to employees. We value our restricted stock units and our performance-based stock units by reference to our stock price
on the date of grant. We recognize compensation expense for restricted stock units based on a straight-line basis over the requisite
service period of the entire award. We recognize performance-based restricted stock as compensation expense based on the most
likely probability of attaining the prescribed performance and over the requisite service period beginning at its grant date and
through the date the restricted stock vests. The number of target shares that vest are determined based on the level of attainment
of the targets. If a minimum level of performance is attained for the awards, restricted stock is issued based on the level of
attainment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_844_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zcotw2sU4114" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86E_zQp4w9QBwzCi">Revenue
Recognition</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
accordance with ASC 606,&#160;<i>Revenue from Contracts with Customers</i>, or ASC 606, revenue is recognized when a customer
obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect
to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which
we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to
which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1)
identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction
price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as,
we satisfy the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Prescription
Products</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which
we began selling during the third quarter of 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA,
which we began selling in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused
the commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters.
We resumed the launch of ANNOVERA on July 1, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have
one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised
goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer
promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than
as a separate obligation. We recognize prescription product revenue only when we satisfy performance obligations by transferring
a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods
or service or obtains control. Control refers to the customer&#8217;s ability to direct the use of, and obtain substantially all
of the remaining benefits from, an asset. Based on our contracts, we invoice customers once our performance obligations have been
satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement
of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent
to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring
promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined
based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns,
chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed
on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current
liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate
the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method,
depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable
consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount
of cumulative product revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently
resolved. In determining amounts of variable consideration to include in a contract&#8217;s transaction price, we rely on our
historical experience and other evidence that supports our qualitative assessment of whether product revenue would be subject
to a significant reversal. We consider all the facts and circumstances associated with both the risk of a product revenue reversal
arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts
of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates,
we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become
known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
accept returns of unsalable prescription products sold through wholesale distributors within a return period of <span id="xdx_905_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dt_c20200101__20200930__srt--RangeAxis__srt--MinimumMember_zO3SbBGuQ4Lc" title="Return period of unsalable prescription products">six months</span>
 prior to and up to <span id="xdx_906_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20200930__srt--RangeAxis__srt--MaximumMember_zhsZ9iuNdub8" title="Return period of unsalable prescription products">12</span>
months following product expiration. Our vitamins and IMVEXXY currently have a shelf life of <span id="xdx_909_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200930__srt--ProductOrServiceAxis__custom--VitaminsAndImvexxyMember_z8av3zzitG1l" title="Shelf life of prescription products following product expiration">24</span>
months from the date of manufacture and BIJUVA and ANNOVERA currently have a shelf life of <span id="xdx_903_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200930__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zvsYL7Ka94gc">18</span> months from the date of
manufacture. We do not allow product returns for prescription products that have been dispensed to a patient. We estimate the
amount of our product sales that may be returned by our customers and record this estimate as a reduction of product revenue
in the period the related product revenue is recognized. Where historical rates of return exist, we use history as a basis to
establish a returns reserve for products shipped to wholesalers. For our newly launched products, for which the right of
return exists but for which we currently do not have history of product returns, we estimate returns based on available
industry data, our own sales information and our visibility into the inventory remaining in the distribution channel. At the
end of each reporting period, we may decide to constrain product revenue for product returns based on information from
various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products
currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the
amount of expected returns as a refund liability, representing the obligation to return the customer&#8217;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return
asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of
product revenue is deferred due to the anticipated return). Return estimates are recorded in other current liabilities on the
consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales
and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience
and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates
and coupons are deducted from gross product revenues at the time the product revenues are recognized. We record distributor fees
based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in other current liabilities
on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account
prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns
are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts
and chargebacks are deducted from gross product revenues at the time the product revenues are recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
part of commercial launches for our FDA-approved prescription products, we introduced a co-pay assistance program for eligible
enrolled patients whose out of pocket costs are reduced to a more affordable price. This allows patients to access the product
at a reasonable cost and is in line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party
vendors. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize
the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current
level of prescriptions covered by patients&#8217; insurance. Payers may change coverage levels for our prescription products positively
or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction
price of our prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company.
As a result, we constrain variable consideration for our prescription products to an amount that will not result in a significant
product revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription products is
constrained by our estimates of the amount to be paid for the co-pay assistance program which is directly related to the level
of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other
patient assistance based on currently available third-party data and our internal analyses. We re-evaluate variable consideration
each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">License
Revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">License
arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending
technology, and various performance or sales milestones and future product royalty payments. Some of these arrangements may
include multiple performance obligations. Non-refundable up-front fees that are not contingent on any future performance by
us, and do not require continuing involvement on our part, are recognized as revenue when the right to use functional IP is
transferred to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Disaggregation
of revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_zwLSIYehkWu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span><span id="xdx_8BF_z1MXKnWRBXE9">The
following table provides information about disaggregated revenue by product mix</span></span> for the three and nine months ended September
30, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Three Months Ended<br/> September 30,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Nine Months Ended<br/> September 30,</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: justify; padding-left: 5.4pt">Prescription vitamins</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zKejnfyswrQ" title="Net revenue">2,435,903</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z2NEamSswbvb" style="width: 10%; text-align: right">2,550,330</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z3bGmx2GXlVh" style="width: 10%; text-align: right">7,337,976</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z0sVZ7oZ6XXi" style="width: 10%; text-align: right">7,309,174</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">IMVEXXY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zDQQQ4gr8uv3" style="text-align: right">6,841,592</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zmw8LC9wVHT8" style="text-align: right">4,772,354</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zUy2Zc3HzfH3" style="text-align: right">18,319,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_ztNgP73WaH98" style="text-align: right">9,904,744</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">BIJUVA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--BijuvaMember_zUGGP1HjNmp4" style="text-align: right">1,646,320</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zvySuT2nGia2" style="text-align: right">490,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--BijuvaMember_zTF6I1TkioOc" style="text-align: right">4,109,925</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_ztMez4EZEkhi" style="text-align: right">624,987</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zrOHwGmsEkP1" style="text-align: right">6,418,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zgXrEZCkkDdh" style="text-align: right">399,952</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRYca6rAQPKb" style="text-align: right">10,527,212</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zgkMsGbGZwxb" style="text-align: right">399,952</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">License revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z3tZZfCwZfq2" style="border-bottom: Black 1pt solid; text-align: right">2,000,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zRHR3xdmecB" style="border-bottom: Black 1pt solid; text-align: right">15,506,400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zWr0oyyGelj" style="border-bottom: Black 1pt solid; text-align: right">2,000,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z2tCEaEiV2j3" style="border-bottom: Black 1pt solid; text-align: right">15,506,400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 0.375in">Net revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930_zkEoA0IraXnd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">19,342,805</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930_zmbAw1ceQvGc" style="border-bottom: Black 2.5pt double; text-align: right">23,719,741</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930_zK5AEdek3glc" style="border-bottom: Black 2.5pt double; text-align: right">42,294,495</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930_zI1PeJS4ECPk" style="border-bottom: Black 2.5pt double; text-align: right">33,745,257</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A5_zyVKyulKSYwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock', window );">License Agreement with the Population Council</a></td>
<td class="text"><p id="xdx_848_ecustom--LicenseAgreementWithPopulationCouncilPolicyTextBlock_zESClL4UWTW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_865_zxUXenFGCps4">License
Agreement with the Population Council</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
July 30, 2018, we entered into the Population Council License Agreement to commercialize ANNOVERA in the U.S. We began selling
ANNOVERA in a &#8220;test and learn&#8221; market introduction in the third quarter of 2019. As a result of the uncertainty surrounding
the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing
initiatives into subsequent quarters. <span style="color: #212529">We resumed the launch of ANNOVERA on July 1, 2020.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $<span id="xdx_90B_ecustom--MilestonePaymentUponFDAApproval_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zbb7Lr3z6SL7" title="Milestone payment upon FDA Approval">20,000,000</span>&#160;within
30 days following the approval by the FDA of the new drug application, or NDA, for ANNOVERA and $<span title="Milestone payments (payment after release of first commercial batch)"><span id="xdx_90D_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_z5iWvTjpO881" title="Milestone payments (payment after release of first commercial batch)">20,000,000</span></span>&#160;within 30 days
following the first commercial batch release of ANNOVERA. Both milestone payments of $<span id="xdx_909_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zhM9QBi3N3zc" title="License rights acquired">20,000,000</span>&#160;were recorded as license
rights in the consolidated balance sheets. We started amortizing license rights in the third quarter of 2019 once ANNOVERA became
commercially available for use. The cost is amortized over the remaining useful life over which the license rights will contribute
directly or indirectly to our cash flows, which is estimated to be the remaining patent life of the product, which expires in
December 2032. The cost is amortized using the straight-line method as the pattern of economic benefit cannot be reliably determined.
During the three and nine months ended September 30, 2020, we recorded $<span id="xdx_901_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20200701__20200930_z7CLR3V5lPjj" title="Amortization of intellectual property license fee">762,389</span>&#160;and $<span id="xdx_90C_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20200101__20200930_zuKZh54Yu3g7" title="Amortization of intellectual property license fee">2,262,002</span>, respectively, in amortization
expense related to the license fee. During both the three and nine months ended September 30, 2019, we recorded $<span id="xdx_905_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20190701__20190930_zhO37Dwc4Pod" title="Amortization of intellectual property license fee"><span id="xdx_902_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20190101__20190930_zpBN7tHPZXWd" title="Amortization of intellectual property license fee">15,998</span></span> in amortization
expense related to the license fee which was recorded as a component of cost of sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Population Council is also eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible
for marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council,
on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates
and permitted licensees as follows: (i) if annual net sales are less than or equal to $<span id="xdx_904_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_c20200101__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_z5EMzf4wPEh3" title="Net sales amount per step-based royalty">50,000,000</span>, a royalty of&#160;<span id="xdx_90A_ecustom--RoyaltyPercent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zrOEsMcETNhj" title="Royalty (percent)">5</span>% of net
sales; (ii) for annual net sales greater than $<span id="xdx_90F_ecustom--NetSalesAmountPerStepbasedRoyalty_c20200101__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zjIiAQCur1Fk" title="Net sales amount per step-based royalty">50,000,000</span>&#160;and less than or equal to $<span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_c20200101__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zP1BhwjvVltk">150,000,000</span>, a royalty of&#160;<span id="xdx_906_ecustom--RoyaltyPercent_pii_dp_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_ztvmIGBhNfpb" title="Royalty (percent)">10</span>% of
such net sales; and (iii) for net sales greater than $<span id="xdx_906_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_c20200101__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zhW87utZf6c9" title="Net sales amount per step-based royalty">150,000,000</span>, a royalty of&#160;<span id="xdx_907_ecustom--RoyaltyPercent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zIl6CGAPDBre" title="Royalty (percent)">15</span>% of such net sales. The annual royalty
rate will be reduced to&#160;<span id="xdx_901_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zkVZ25eQpoGk" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent">50</span>% of the initial rate during the six-month period beginning on the date of the first arms-length
commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the
U.S., and thereafter will be reduced to&#160;<span id="xdx_907_ecustom--AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_pii_dp_uPure_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zrMItUXCRLZg" title="Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent">20</span>% of the initial rate. We are required to pay the Population Council milestone
payments of $<span id="xdx_90D_ecustom--MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_pp0p0_dm_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zohSQUs9Uz4d" title="Milestone payments upon specified levels of cumulative net sales">40 million</span>&#160;upon cumulative net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees
of each of $<span id="xdx_909_ecustom--SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_pn6n6_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zkw86Ij00lI6" title="Specified level one of cumulative net sales for milestone payments">200</span>&#160;million, $<span id="xdx_901_ecustom--SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_pn6n6_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zGDyxwW763r7" title="Specified level two of cumulative net sales for milestone payments">400</span>&#160;million&#160;and $<span id="xdx_90F_ecustom--SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_pn9n9_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_z4UimISN9gpk" title="Specified level three of cumulative net sales for milestone payments">1</span>&#160;billion. The Population Council has agreed to perform and pay
the costs and expenses associated with four post-approval studies required by the FDA for ANNOVERA and we have agreed to perform
and pay the costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism,
provided that if the costs and expenses associated with such post-approval study exceed $<span id="xdx_903_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_pii_uUSD_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zNOQIfJLTYc6" title="Maximum costs and expenses for post approval">20,000,000</span>, half of such excess will
be offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement.
We and the Population Council have agreed to form a joint product committee responsible for overseeing activities under the Population
Council License Agreement. We will be responsible for all aspects of promotion, product positioning, pricing, education programs,
publications, sales messages and any additional desired clinical studies for the one-year vaginal contraceptive system, subject
to oversight and decisions made by the joint product committee. The Population Council License Agreement includes exclusive rights
for us to negotiate co-development of two other investigational vaginal contraceptive systems in development by the Population
Council.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>





<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LicenseAgreementWithKnightPolicyTextBlock', window );">License Agreement with Knight</a></td>
<td class="text"><p id="xdx_848_ecustom--LicenseAgreementWithKnightPolicyTextBlock_zNPRMfR2xLZ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86A_z4pk4ByPb04g">License
Agreement with Knight</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we
granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the
Knight License Agreement, Knight paid us $<span id="xdx_905_ecustom--MilestonePaymentReceivedUponRegulatoryApproval_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--KnightLicenseAgreementMember_zUkuasQPehic">2,000,000</span>
in milestone fees upon the first regulatory approval in Canada for IMVEXXY and BIJUVA in the third quarter of 2020, and is
also required to pay us sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of
IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications,
submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada
within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents.
Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within
certain specified time periods or if the other party files for bankruptcy or other related matters. As part of the Knight
License Agreement, Knight is prohibited from exporting IMVEXXY and BIJUVA to the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text"><p id="xdx_846_eus-gaap--CostOfSalesPolicyTextBlock_zSlKlmze6w85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86E_zEpUISSlKSgk">Cost
of Sales</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of sales includes the cost of inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping and
handling costs. The Population Council License Agreement requires payment of royalties based on the sale of future products. Such
royalties are recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related
to licensed products are classified as components of cost of sales to the extent such payments become due in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory Obsolescence Reserve</a></td>
<td class="text"><p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zo2CY4CWi0jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_864_zV1WCTQZtMMl">Inventory
Obsolescence Reserve</span> </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
evaluate inventory quarterly and record an allowance for obsolescence primarily associated with materials that are not
currently or likely to be used in production in the near future. As of September 30, 2020 and December 31, 2019, we recorded
an inventory obsolescence reserve of $<span id="xdx_901_eus-gaap--InventoryValuationReserves_iI_pp0p0_c20200930_z3nH5S3tEYUi" title="Inventory valuation reserves">5,744,464</span>&#160;and
$<span id="xdx_909_eus-gaap--InventoryValuationReserves_iI_pp0p0_c20191231_zuB0z7VrASU6" title="Inventory valuation reserves">0</span>,
respectively. The reserve recorded as of September 30, 2020 was primarily related to BIJUVA and resulted from the impact of
the COVID-19 pandemic on our business, which decreased demand for our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zCPayzXjlSA2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_865_zVGnNbixIvY8">Segment
Reporting</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single executive leadership team that is chaired by the Chief Executive Officer of our
Company, who oversees all operations. We do not operate separate lines of business with respect to any of our products and we
do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the
United States. Accordingly, we view our business as one reportable operating segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_z1glbuxYfOTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_z0EqH09uYUo6">Research
and Development Expenses</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development, or R&amp;D, expenses include internal R&amp;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal
R&amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO
activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;D expenses include
assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes,
and scientific writing matters, including preparing protocols and FDA submissions. These consulting expenses were direct costs
associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal
R&amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms,
which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services
that will be used in future R&amp;D activities when the activity has been performed or when the goods have been received rather
than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed
and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO
costs are subject to revisions as such studies progress to completion. We charge revisions to expenses in the period in which
the facts that give rise to the revision become known.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LicenseAgreementWithKnightPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for license agreement with knight.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LicenseAgreementWithKnightPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement With Population Council</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129390535784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">The following table provides information about disaggregated revenue by product mix</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--DisaggregationOfRevenueTableTextBlock_zwLSIYehkWu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span><span id="xdx_8BF_z1MXKnWRBXE9">The
following table provides information about disaggregated revenue by product mix</span></span> for the three and nine months ended September
30, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Three Months Ended<br/> September 30,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Nine Months Ended<br/> September 30,</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: justify; padding-left: 5.4pt">Prescription vitamins</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zKejnfyswrQ" title="Net revenue">2,435,903</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z2NEamSswbvb" style="width: 10%; text-align: right">2,550,330</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z3bGmx2GXlVh" style="width: 10%; text-align: right">7,337,976</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_z0sVZ7oZ6XXi" style="width: 10%; text-align: right">7,309,174</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">IMVEXXY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zDQQQ4gr8uv3" style="text-align: right">6,841,592</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zmw8LC9wVHT8" style="text-align: right">4,772,354</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zUy2Zc3HzfH3" style="text-align: right">18,319,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_ztNgP73WaH98" style="text-align: right">9,904,744</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">BIJUVA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--BijuvaMember_zUGGP1HjNmp4" style="text-align: right">1,646,320</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zvySuT2nGia2" style="text-align: right">490,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--BijuvaMember_zTF6I1TkioOc" style="text-align: right">4,109,925</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_ztMez4EZEkhi" style="text-align: right">624,987</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zrOHwGmsEkP1" style="text-align: right">6,418,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zgXrEZCkkDdh" style="text-align: right">399,952</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRYca6rAQPKb" style="text-align: right">10,527,212</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zgkMsGbGZwxb" style="text-align: right">399,952</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">License revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z3tZZfCwZfq2" style="border-bottom: Black 1pt solid; text-align: right">2,000,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zRHR3xdmecB" style="border-bottom: Black 1pt solid; text-align: right">15,506,400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zWr0oyyGelj" style="border-bottom: Black 1pt solid; text-align: right">2,000,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z2tCEaEiV2j3" style="border-bottom: Black 1pt solid; text-align: right">15,506,400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 0.375in">Net revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200701__20200930_zkEoA0IraXnd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">19,342,805</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190701__20190930_zmbAw1ceQvGc" style="border-bottom: Black 2.5pt double; text-align: right">23,719,741</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200101__20200930_zK5AEdek3glc" style="border-bottom: Black 2.5pt double; text-align: right">42,294,495</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20190101__20190930_zI1PeJS4ECPk" style="border-bottom: Black 2.5pt double; text-align: right">33,745,257</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129385543944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 4 &#8211; INVENTORY, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory, net consists of the following:</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z27FoMC11SCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>Inventory,
net consists of the following:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20200930_z5U8PAj7D5U7" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,<br/> &#160;2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_498_20191231_zT02v8DIwNxj" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--InventoryFinishedGoods_iI_uUSD_maINzGAn_zJhFtjBfcGtb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: justify; padding-left: 5.4pt">Finished products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,794,132</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,976,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--InventoryWorkInProcess_iI_uUSD_maINzGAn_zDR0iYpgCtih" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440,149</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,182,059</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--InventoryRawMaterialsAndSupplies_iI_uUSD_maINzGAn_zZ2qVNfta8N9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Raw materials</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,698,023</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,701,747</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--InventoryNet_iTI_uUSD_mtINzGAn_zSQLbTIK26f7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">TOTAL INVENTORY, NET</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,932,304</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,860,716</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129384050536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 5 &#8211; OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Other current assets consist of the following:</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zOYOeTHRUikc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>Other
current assets consist of the following:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20200930_zTNZhfb0cnbf" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,<br/> &#160;2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_498_20191231_zrsIWwqy81jg" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_406_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAzmtR_z3evkvY2zmXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: left; padding-left: 5.4pt">Prepaid sales and marketing costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">686,346</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,583,698</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAzmtR_z8nAdlxrBsHi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Debt financing fees on undrawn tranches (Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0765">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">550,757</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--PrepaidInsurance_iI_maPEAOAzmtR_z2F7mizyJHQg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,599,906</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,812,135</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--PrepaidManufacturing_iI_maPEAOAzmtR_zD3xSwrjhuO9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Prepaid manufacturing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">543,050</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,595,721</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzmtR_zTWiqaYmfWd2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Other prepaid costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,989,937</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,787,482</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzmtR_zJ1DIvpddX25" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.75in; padding-right: 10pt">TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,819,239</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,329,793</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129390533256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 6 &#8211; FIXED ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Fixed assets, net consist of the following:</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zD5SrQtIcLT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>Fixed
assets, net consist of the following:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20200930_zshcAQePpHz1" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,<br/> &#160;2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_49F_20191231_zaOonnrrItf4" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left; padding-left: 5.4pt">Accounting system</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zW0GiXH9G3p4" style="width: 10%; text-align: right" title="TOTAL FIXED ASSETS">301,096</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z5fEDds8i5i6" style="width: 10%; text-align: right">301,096</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zWlsRjUPWYP1" style="text-align: right" title="TOTAL FIXED ASSETS">1,658,258</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zlmS80uBzi6j" style="text-align: right">1,619,646</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z5xX5IOq9fv4" style="text-align: right" title="TOTAL FIXED ASSETS">1,406,858</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zOsgU67cMY66" style="text-align: right">1,406,858</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Computer hardware</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zbLQ8uwDG3mk" style="text-align: right" title="TOTAL FIXED ASSETS">80,211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zt274pS2tUT7" style="text-align: right">80,211</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zAjE9miBz6f2" style="border-bottom: Black 1pt solid; text-align: right" title="TOTAL FIXED ASSETS">68,788</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6FGsklpvoxc" style="border-bottom: Black 1pt solid; text-align: right">68,788</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzuyq_z2OECk4eH9cb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.625in; padding-right: 10pt">TOTAL FIXED ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,515,211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,476,599</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzuyq_zkoewWMaMsv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,545,282</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(968,824</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzuyq_z6TXxXANuqJb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.375in; padding-right: 10pt">TOTAL FIXED ASSETS, NET</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,969,929</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,507,775</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129383987384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2020 and December 31, 2019:</a></td>
<td class="text"><p id="xdx_896_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zQ7rLu3fyk7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span>The
following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets
as of September 30, 2020 and December 31, 2019:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, 2020</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Net<br/> Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted- Average<br/> Remaining Amortization
    Period (yrs.)</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-left: 0.25in; text-indent: -0.125in">Approved hormone therapy drug candidate patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zcndpuWSOkxd" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Gross">4,108,745</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zT8YN1FkBoYg" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(679,959</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zFVvC1C5NdF3" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Net">3,428,786</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zObdTbfHdJdb" title="Finite-Lived Intangible Assets, Remaining Amortization Period">12.25</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Hormone therapy drug candidate patents (pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zBNtQL8fa47g" style="text-align: right" title="Finite-Lived Intangible Assets, Gross">1,760,923</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zIMkqnkYoGCf" style="text-align: right" title="Finite-Lived Intangible Assets, Net">1,760,923</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in">Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20200930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zIu7kB4Khspe" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks">348,176</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20200930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zsm7MR4r2CXi" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)">348,176</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.625in; text-indent: -0.125in; padding-right: 10pt">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20200930_zsoTsNWAQLw6" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)">6,217,844</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20200930_zMZWyL4XpNUb" style="border-bottom: Black 2.5pt double; text-align: right">(679,959</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20200930_zS4NdEtnGoZ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">5,537,885</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Net<br/> Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted- Average<br/> Remaining Amortization
    Period (yrs.)</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-left: 0.25in; text-indent: -0.125in">Approved hormone therapy drug candidate patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zy7FKrAtL3n8" style="width: 10%; text-align: right">3,463,082</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zfTrTI8UtTE1" style="width: 10%; text-align: right">(478,983</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zcbMKJnrPMgf" style="width: 10%; text-align: right">2,984,099</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zmi7bd5E8OGk" title="Finite-Lived Intangible Assets, Remaining Amortization Period">13</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Hormone therapy drug candidate patents &#160;(pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z9yVdZwy4bVe" style="text-align: right">1,979,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zSaeK4vCLP7d" style="text-align: right">1,979,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zGbPnFHgdsU3" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks">294,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zSi7S5C0JTwk" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)">294,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-right: 10pt; padding-left: 0.5in">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20191231_zoVg8icnFi7d" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)">5,737,194</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231_zDdsyjH116n7" style="border-bottom: Black 2.5pt double; text-align: right">(478,983</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20191231_zjzSP5boAYLb" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">5,258,211</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z4V1CUC0hoy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Amortization
expense was $<span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20200701__20200930_zUMstwvHguKh">69,977</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;and
$<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20190701__20190930_zef1mEBbIYZd">51,259</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;for
the three months ended September 30, 2020 and 2019, respectively, and $<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20200101__20200930_zdlMR4nQhdSe">200,879</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;and
$<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20190101__20190930_zKWSvIWlGIwj">140,206</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;for
the nine months ended September 30, 2020 and 2019, respectively. <span id="xdx_8B3_zuQh9i88rL45">Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Year Ending<br/> December 31,</b></td>
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 2px"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Estimated <br/>
    Amortization</b></td>
    <td style="text-align: center"><b>&#160;</b></td></tr>
<tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2020 (3 months)</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_uUSD_c20200930_zuJLzRelx1ob" style="width: 18%; text-align: right" title="2020 (3 months)">69,977</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_uUSD_c20200930_zfNvcy4TE9Ka" style="text-align: right" title="2021">279,909</td><td style="text-align: left">&#160;</td></tr>
<tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_uUSD_c20200930_zaomUZJ6Dvb6" style="text-align: right" title="2022">279,909</td><td style="text-align: left">&#160;</td></tr>
<tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_uUSD_c20200930_zUyu8cnU1idj" style="text-align: right" title="2023">279,909</td><td style="text-align: left">&#160;</td></tr>
<tr class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgNyCWIElOVEFOR0lCTEUgQVNTRVRTLCBORVQgKERldGFpbHMgMSkA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_uUSD_c20200930_zGx3RJsGkfP4" style="text-align: right" title="2024">279,909</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129391114760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 8&#8211; OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other current liabilities consist of the following:</a></td>
<td class="text"><p id="xdx_896_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_z47uqXV0qdcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Other
current liabilities consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20200930_z2UXOuVdXdV" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,<br/> 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_496_20191231_zhaxBHxeebj6" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--AccruedSalariesCurrent_iI_maOLCz3D1_zfWGmRvrEpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: justify; padding-left: 5.4pt">Accrued payroll, bonuses and commission costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,381,729</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">8,040,278</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCz3D1_zzK3HTf3QqH" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Allowance for coupons and returns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,353,403</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,316,298</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCz3D1_z8U82KLNYREj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">Accrued sales and marketing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,578,971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,285,662</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedVacationCurrent_iI_maOLCz3D1_zy2BO8mJBhZ3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Accrued compensated absences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,558,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,463,878</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCz3D1_z9ALBRofLxWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">Allowance for wholesale distributor fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,130,230</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,347,122</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCz3D1_zGf1Vg9E8o1k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Accrued legal and accounting expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,052,935</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">422,336</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--AccruedResearchAndDevelopment_iI_maOLCz3D1_zWPlBP8Uhmxc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">Accrued research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,059,077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,049,603</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCz3D1_zsvnhSKLw4n9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,404,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,501,539</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--AccruedRebates_iI_maOLCz3D1_zZvhpyeHpvx" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">Accrued rebates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,629,732</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,916,672</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCz3D1_z7PSnGJp0Nhk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Other accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,072,066</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,480,225</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCz3D1_zq0QmxmnADJk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0.125in; padding-left: 0.25in">TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,220,484</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33,823,613</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129384121800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 9 &#8211; DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">As of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following:</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfDebtTableTextBlock_zDrNLz8c39v4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><span>As
of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><b>September 30,<br/>
2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><b>December 31,<br/>
2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: justify; padding-left: 5.4pt">Financing Agreement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20200930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zqHJ5q3dEWK1" title="Long-term Debt, Gross">250,000,000</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zPrnnkLRHK98" title="Long-term Debt, Gross">200,000,000</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Debt discount and financing fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20200930_zQxR7PVfX23e" style="border-bottom: Black 1pt solid; text-align: right" title="Debt discount and financing fees"><span title="Debt discount and financing fees">(12,948,798</span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20191231_zFkz36vv9bSd" style="border-bottom: Black 1pt solid; text-align: right" title="Debt discount and financing fees"><span title="Debt discount and financing fees">(5,365,357</span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.625in">TOTAL LONG-TERM DEBT</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_c20200930_zA5CKNEgBBS9" title="TOTAL LONG-TERM DEBT">237,051,202</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_c20191231_z1w0dYI3jfpl" title="TOTAL LONG-TERM DEBT">194,634,643</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129389975560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 10 &#8211; NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of calculation of diluted net loss per share allocable to common stockholders</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zdmkJXXDt6df" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br/>
    2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br/>
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: justify; padding-left: 5.4pt">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zBYeHEayNYId" style="width: 10%; text-align: right">23,893,180</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zUPOt79jOXy1" style="width: 10%; text-align: right">24,849,984</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztJxaI3SeQ96" style="text-align: right">6,534,687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zulTC7er37df" style="text-align: right">1,832,571</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt">Performance stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zuLqCM3vNgIj" style="text-align: right">2,422,885</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIE5PVEUgMTAgliBORVQgTE9TUyBQRVIgU0hBUkUgKERldGFpbHMpAA__" style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zop3yhrbWp67" style="border-bottom: Black 1pt solid; text-align: right">6,029,957</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zbzLxz63fPM8" style="border-bottom: Black 1pt solid; text-align: right">1,240,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200930_z0ZrZaIS9hN" style="border-bottom: Black 2.5pt double; text-align: right">38,880,709</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20190930_zzeYKcOaaIXc" style="border-bottom: Black 2.5pt double; text-align: right">27,922,555</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129384090824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020 and 2019 are set forth in the table below.</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zdD7a759RKPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life
of the stock options. <span id="xdx_8BA_zIVltiQHsPVg">The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020
and 2019 are set forth in the table below.</span></span><span style="font: 10pt Times New Roman, Times, Serif"/>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, &#160;<br/>
    2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, &#160;<br/>
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Weighted average grant date fair value</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7nmiUGQaxu6" style="width: 15%; text-align: right" title="Weighted average grant date fair value">0.95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXJkhBZg91jc" style="width: 15%; text-align: right" title="Weighted average grant date fair value">1.84</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6X436sBviji" title="Risk-free interest rate, minimum">0.34</span>-<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5ZrKfDKyAY7" title="Risk-free interest rate, maximum">1.68</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPWL2pTK1bmc" title="Risk-free interest rate, minimum">1.83</span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNVqFbgIC1te" title="Risk-free interest rate, maximum">2.54</span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zswuhMgxdtgh" title="Volatility, minimum">63.53</span>-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPEior3MJAf7" title="Volatility, maximum">67.92</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z928l5oTFKuj" title="Volatility, minimum">61.25</span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4RPVGscCE95" title="Volatility, maximum">64.49</span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhiXc8Uqg33k" title="Term">6</span>-<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zP9PJqIzP45f" title="Term">6.8</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrkbCvLBWz71" title="Term">5.5</span>-<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwEAjWx2Yqx" title="Term">6.5</span></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjImzCJUI6a6" title="Dividend yield">0.00</span>%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zP4UtUna5yp5" title="Dividend yield">0.00</span>%</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">A summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September 30, 2020 is as follows</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zvEVXoBYoxi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span><span id="xdx_8BF_z3HpGB15ZkHi">A
summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September
30, 2020 is as follows</span>:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Number of Shares Under Options</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Exercise Price</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Remaining Contractual Life
    in Years</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Aggregate Intrinsic Value</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; padding-left: 5.4pt">Balance at December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMpi6OqO93mg" style="width: 10%; text-align: right" title="Number of shares under options, beginning">25,030,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsCMYOrb9io6" style="width: 10%; text-align: right" title="Weighted average exercise price, beginning">4.65</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZlMQ5IEoPQa" style="width: 10%; text-align: right" title="Weighted average remaining contractual life">5.84</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_uUSD_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSLzDKLI7LE1" style="width: 10%; text-align: right" title="Aggregate intrinsic value, beginning">3,668,171</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;&#160;Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5PqqEG2zYTg" title="Number of shares under options, granted">736,500</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znEtZXbedyLb" style="text-align: right" title="Weighted average exercise price, granted">1.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 5.4pt">&#160;&#160;Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFtA2f1Ronkf" style="text-align: right" title="Number of shares under options, exercised">(1,182,195</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv1ExzqMrWJg" title="Weighted average exercise price, exercised">0.23</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zk0L9xOZXdif" style="text-align: right" title="Aggregate intrinsic value, exercised">1,738,740</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;&#160;Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zc0S5Quq7m5g" style="text-align: right" title="Number of shares under options, expired">(361,109</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z33ShYQHAqF5" title="Weighted average exercise price, expired">3.66</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 5.4pt">&#160;&#160;Cancelled/Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zO96vznw0Vx" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares under options, cancelled forfeited">(330,250</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHvNR8QZyfs7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, cancelled forfeited">3.69</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Balance at September 30, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_uShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWs2yolFYyph" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares under options, ending">23,893,180</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_uUSDPShares_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsrdaKRFvgm1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending">4.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwGnABLUKPUb" style="border-bottom: Black 2.5pt double; text-align: right">5.46</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_uUSD_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z48nVCNdzIzd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, ending">379,535</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Vested and Exercisable at September 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_uShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHIfLHq3x253" style="text-align: right" title="Number of shares under options, vested and exercisable ending">19,827,306</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpVhxHr3u6j8" style="text-align: right" title="Weighted average exercise price, vested and exercisable ending">5.06</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z22ZbK8I6yUb" style="text-align: right" title="Weighted average remaining contractual life, vested and exercisable">4.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_uUSD_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z2ttQgGxMoHh" style="text-align: right" title="Aggregate intrinsic value, vested and exercisable ending">218,370</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">Unvested at September 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_uShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcCSBP4f1Rv2" style="text-align: right" title="Number of shares under options, unvested ending">4,065,874</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zx7WEQGpllm3" style="text-align: right" title="Weighted average exercise price, unvested">3.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7ig9lkWLbx5" style="text-align: right" title="Weighted average remaining contractual life in years, unvested">8.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iI_uUSD_c20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zI6nICZPvFg2" style="text-align: right" title="Aggregate intrinsic value, unvested">161,165</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of restricted stock units and performance stock units</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zRZh1FI0hsz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B5_zPcTQN99nnXa">Schedule of restricted stock units and performance stock units</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b><span>
    <span>Restricted Stock Units</span></span></b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>Performance Stock Units</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>Number of Shares</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>Weighted Average Grant
    Date Fair Value</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>Number of Shares</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><b>Weighted Average Grant
    Date Fair Value</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2019</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhydhkTMslOk" style="width: 10%; text-align: right" title="Number of shares, beginning">1,240,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhpXBRtSmzb5" style="width: 10%; text-align: right" title="Weighted average grant date fair values, beginning">3.56</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3ZfVf0avEcj" style="text-align: right" title="Number of shares, granted">5,102,817</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zGNnDtTLORRg" style="text-align: right" title="Weighted average grant date fair value, granted">1.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zJbU32lgehje" style="text-align: right" title="Number of shares, granted">2,585,745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z6vXzH8k03D7" style="text-align: right" title="Weighted average grant date fair value, granted">1.08</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Vested/Released</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z73pf6G8bBs7" style="text-align: right" title="Number of shares, vested/released">(301,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zb0bbIou4Swk" style="text-align: right" title="Weighted average grant date fair value, vested/released">1.78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zSDPWOhKe4gh" style="text-align: right" title="Number of shares, vested/released">(151,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zkapLBpAhWa8" style="text-align: right" title="Weighted average grant date fair value, vested/released">1.14</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1x3WApsvY06" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited">(11,360</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0xEKqoWY9S2" style="text-align: right" title="Weighted average grant date fair value, forfeited">1.07</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zk7IQBLSKi84" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited">(11,360</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z3MDo8x2uR8e" style="text-align: right" title="Weighted average grant date fair value, forfeited">1.07</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBv8lGx9ef15" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, ending">6,029,957</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXc5a2LVVRmi" style="text-align: right" title="Weighted average grant date fair values, ending">1.83</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKg_____z4K4eOLt9fu" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, ending">2,422,885</td><td style="padding-bottom: 2.5pt; text-align: left"><sup>*</sup></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_ztqvxwfpYrTl" style="text-align: right" title="Weighted average grant date fair value, ending">1.08</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><sup id="xdx_F01_zF3D0gJ2TQ39">*</sup></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F19_z8KYVpaGKtM7" style="font: 10pt Times New Roman, Times, Serif">The number
of performance stock units (PSUs) represents the base number of PSUs that may vest. The actual number of PSUs that will vest will
be between zero and two times the base number of PSUs depending on the Company's achievement of break-even quarterly EBITDA.</span></td>
</tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129385564088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock', window );">Supplemental lease information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_z6BLGFmJmuaj" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - Supplemental lease information (Details)">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Supplemental lease information:</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20200930_zKMlsFVVsmd5" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br/>
    2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_49F_20191231_z2lUPpRwwXri" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zLqHZddMxG6g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 5.4pt">Right-of-use asset</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">9,975,725</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">10,109,154</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zPtQCwt4f2Y5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Short-term operating lease liability (included in Other current liabilities)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,404,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,501,539</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zUd5AYS1Trqg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Long-term operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,907,995</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,145,049</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">Weighted average remaining term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Weighted average remaining term::XDX::P8Y9M18D"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20200930_zgBZsKcJU8Xf" title="Weighted average remaining term">8.8</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Weighted average remaining term::XDX::P9Y"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_zInyTUJoHZUa" title="Weighted average remaining term">9</span> years</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_zCdfVlGrIQC4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 5.4pt">Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.3%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.25%</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20200101__20200930_zuf4wqSlwdgf" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20190101__20190930_zqgrKqMD0BI7" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Supplemental cash flow information</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>for the nine months ended</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, &#160;<br/>
    2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, &#160;<br/>
    2019</b></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--OperatingLeasePayments_zMuE9QMriFWl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 5.4pt">Cash paid for amounts included in the measurement of lease liabilities for operating lease</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,006,970</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">849,440</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zkcI7REAWafk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 5.4pt">Right-of-use assets obtained in exchange for lease obligation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">998,821</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,171,471</td><td style="text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities recorded on the balance sheet:</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z9tqWaUXtFdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><span>The
following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities
recorded on the balance sheet:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Years Ended December 31,</b></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20200930_z3Yh7MVxkvXi">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz1WK_zFQnea8plN43" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2020 (3 months)</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">610,675</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz1WK_zIu6XN3J8uWf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,334,582</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz1WK_zghllzAwiFZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,413,289</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz1WK_zNxrXusITLdl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,443,143</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz1WK_zizUHmGFOcH3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,476,534</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz1WK_zmejpP5unW48" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,947,869</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz1WK_zlrj5YfaeCM3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Total undiscounted lease payments</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,226,092</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zqGQLbwDaeM6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Less: imputed interest</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,913,811</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_zKTLHCCZFCl1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Present value of lease payments</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,312,281</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplementary lease and cash flow information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129386012168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NOTE 1 &#8211; THE COMPANY (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>Number</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfSubsidiaries', window );">Number of subsidiaries</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of subsidiaires for period reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129390741336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Nov. 09, 2020</div></th>
<th class="th"><div>Nov. 08, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance required under credit agreement</a></td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member', window );">Financing Agreement Amendment No. 6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment', window );">Minimum cash balance requirement under credit agreement before adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Period1Member', window );">Financing Agreement Amendment No. 6 - Through December 31, 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance required under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Period2Member', window );">Financing Agreement Amendment No. 6 - After December 31, 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance required under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MinimumCashBalanceRequirementUnderCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum cash balance the Borrower must maintain under the credit and secuirty agreement before adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Period1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Period1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Period2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Period2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129464037144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table provides information about disaggregated revenue by product mix (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 19,342,805<span></span>
</td>
<td class="nump">$ 23,719,741<span></span>
</td>
<td class="nump">$ 42,294,495<span></span>
</td>
<td class="nump">$ 33,745,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember', window );">Prescription Vitamins [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">2,435,903<span></span>
</td>
<td class="nump">2,550,330<span></span>
</td>
<td class="nump">7,337,976<span></span>
</td>
<td class="nump">7,309,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyMember', window );">Imvexxy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">6,841,592<span></span>
</td>
<td class="nump">4,772,354<span></span>
</td>
<td class="nump">18,319,382<span></span>
</td>
<td class="nump">9,904,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_BijuvaMember', window );">BIJUVA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">1,646,320<span></span>
</td>
<td class="nump">490,705<span></span>
</td>
<td class="nump">4,109,925<span></span>
</td>
<td class="nump">624,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember', window );">ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">6,418,990<span></span>
</td>
<td class="nump">399,952<span></span>
</td>
<td class="nump">10,527,212<span></span>
</td>
<td class="nump">399,952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 15,506,400<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 15,506,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_ImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_ImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_BijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_BijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_AnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129386643544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 584,509<span></span>
</td>
<td class="nump">$ 78,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AmortizationOfIntellectualPropertyLicenseFee', window );">Amortization of intellectual property license fee</a></td>
<td class="nump">$ 762,389<span></span>
</td>
<td class="nump">$ 15,998<span></span>
</td>
<td class="nump">2,262,002<span></span>
</td>
<td class="nump">15,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory valuation reserves</a></td>
<td class="nump">5,744,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,744,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementMember', window );">Council License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent', window );">Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent', window );">Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid', window );">Maximum costs and expenses for post approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member', window );">Council License Agreement Step 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member', window );">Council License Agreement Step 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member', window );">Council License Agreement Step 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_VitaminsAndImvexxyMember', window );">Vitamins and IMVEXXY [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShelfLifeOfPrescriptionProducts', window );">Shelf life of prescription products following product expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember', window );">BIJUVA and ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShelfLifeOfPrescriptionProducts', window );">Shelf life of prescription products following product expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember', window );">BIJUVA and ANNOVERA [Member] | Knight License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MilestonePaymentReceivedUponRegulatoryApproval', window );">Milestone payment received upon regulatory approval</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember', window );">ANNOVERA [Member] | Council License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MilestonePaymentUponFDAApproval', window );">Milestone payment upon FDA Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch', window );">Milestone payments (payment after release of first commercial batch)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">License rights acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales', window );">Milestone payments upon specified levels of cumulative net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments', window );">Specified level one of cumulative net sales for milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments', window );">Specified level two of cumulative net sales for milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments', window );">Specified level three of cumulative net sales for milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts', window );">Return period of unsalable prescription products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Council License Agreement Step 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Council License Agreement Step 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts', window );">Return period of unsalable prescription products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Council License Agreement Step 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Council License Agreement Step 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock, shares, issued (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock, shares, issued (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 584,509<span></span>
</td>
<td class="nump">78,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Assets or liabilities valued at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AmortizationOfIntellectualPropertyLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents amortization of intellectual property license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AmortizationOfIntellectualPropertyLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentReceivedUponRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment received upon regulatory approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentReceivedUponRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentUponFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments upon FDA approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentUponFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments payable after release of first commercial batch.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments due upon specified levels of cumulative net sales for under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NetSalesAmountPerStepbasedRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net sales amount as defined in license agreement for step-based royalty payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NetSalesAmountPerStepbasedRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the company accepts returns of unsalable prescription products from customers following product expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ReturnPeriodOfUnsalablePrescriptionProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of the net sales to be paid as royalty per license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShelfLifeOfPrescriptionProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period shelf life of prescription products from date of manufacture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShelfLifeOfPrescriptionProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents specified level one of cumulative net sales for milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents specified level three of cumulative net sales for milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents specified level two of cumulative net sales for milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_VitaminsAndImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_VitaminsAndImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_KnightLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_KnightLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_AnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129386117944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory, net consists of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished products</a></td>
<td class="nump">$ 4,794,132<span></span>
</td>
<td class="nump">$ 4,976,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">440,149<span></span>
</td>
<td class="nump">1,182,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Raw materials</a></td>
<td class="nump">4,698,023<span></span>
</td>
<td class="nump">5,701,747<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">TOTAL INVENTORY, NET</a></td>
<td class="nump">$ 9,932,304<span></span>
</td>
<td class="nump">$ 11,860,716<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129390966552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current assets consist of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidSalesAndMarketingCostsCurrent', window );">Prepaid sales and marketing costs</a></td>
<td class="nump">$ 686,346<span></span>
</td>
<td class="nump">$ 1,583,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing fees on undrawn tranches (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">550,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">3,599,906<span></span>
</td>
<td class="nump">1,812,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidManufacturing', window );">Prepaid manufacturing</a></td>
<td class="nump">543,050<span></span>
</td>
<td class="nump">2,595,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid costs</a></td>
<td class="nump">3,989,937<span></span>
</td>
<td class="nump">4,787,482<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">TOTAL OTHER CURRENT ASSETS</a></td>
<td class="nump">$ 8,819,239<span></span>
</td>
<td class="nump">$ 11,329,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid manufacturing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidSalesAndMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to the amount of prepaid sales and marketing costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidSalesAndMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129482985544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed assets, net consist of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">$ 3,515,211<span></span>
</td>
<td class="nump">$ 3,476,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(1,545,282)<span></span>
</td>
<td class="num">(968,824)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">TOTAL FIXED ASSETS, NET</a></td>
<td class="nump">1,969,929<span></span>
</td>
<td class="nump">2,507,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software and Software Development Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">301,096<span></span>
</td>
<td class="nump">301,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">1,658,258<span></span>
</td>
<td class="nump">1,619,646<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">1,406,858<span></span>
</td>
<td class="nump">1,406,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">80,211<span></span>
</td>
<td class="nump">80,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">$ 68,788<span></span>
</td>
<td class="nump">$ 68,788<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129385615704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 6 &#8211; FIXED ASSETS, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 188,810<span></span>
</td>
<td class="nump">$ 90,700<span></span>
</td>
<td class="nump">$ 576,459<span></span>
</td>
<td class="nump">$ 223,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129464328824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2020 and December 31, 2019: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="num">$ (679,959)<span></span>
</td>
<td class="num">$ (478,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross (Excluding Goodwill)</a></td>
<td class="nump">6,217,844<span></span>
</td>
<td class="nump">5,737,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">5,537,885<span></span>
</td>
<td class="nump">5,258,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksMember', window );">Multiple Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedTrademarks', window );">Indefinite-Lived Trademarks</a></td>
<td class="nump">348,176<span></span>
</td>
<td class="nump">294,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">348,176<span></span>
</td>
<td class="nump">294,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">4,108,745<span></span>
</td>
<td class="nump">3,463,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="num">(679,959)<span></span>
</td>
<td class="num">(478,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 3,428,786<span></span>
</td>
<td class="nump">$ 2,984,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">12 years 3 months<span></span>
</td>
<td class="text">13 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember', window );">Hormone Therapy Drug Candidate Patents - (Pending) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">$ 1,760,923<span></span>
</td>
<td class="nump">$ 1,979,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 1,760,923<span></span>
</td>
<td class="nump">$ 1,979,299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedTrademarks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedTrademarks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129390978136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2020 (3 months)</a></td>
<td class="nump">$ 69,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">279,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">279,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">279,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">$ 279,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129386451896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Write off of patent and trademark costs | $</a></td>
<td class="nump">$ 584,509<span></span>
</td>
<td class="nump">$ 78,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember', window );">Domestic US Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember', window );">Foreign Patents Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember', window );">Domestic Patents BIJUVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember', window );">Foreign Patents BIJUVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsEstradiolAndProgesteroneCandidatesMember', window );">Domestic Patents Estradiol and Progesterone Candidates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember', window );">Domestic US Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember', window );">Domestic US Utility Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember', window );">Domestic US Design Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember', window );">Foreign Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember', window );">Foreign Utility Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember', window );">Foreign Design Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTopicalCreamCandidatesMember', window );">Domestic Utility Patent Topical Cream Candidates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember', window );">Domestic Utility Patent Transdermal Patch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember', window );">Foreign Utility Patent Transdermal Patch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember', window );">Domestic Utility Patent TX009HR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsProgesteroneFormulationsMember', window );">Domestic Patents Progesterone Formulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsProgesteroneFormulationsMember', window );">Foreign Patents Progesterone Formulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember', window );">Domestic Utility Patent Opera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfIssuedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issued patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfIssuedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsEstradiolAndProgesteroneCandidatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsEstradiolAndProgesteroneCandidatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTopicalCreamCandidatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTopicalCreamCandidatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsProgesteroneFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsProgesteroneFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsProgesteroneFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsProgesteroneFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129391096552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current liabilities consist of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll, bonuses and commission costs</a></td>
<td class="nump">$ 4,381,729<span></span>
</td>
<td class="nump">$ 8,040,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1', window );">Allowance for coupons and returns</a></td>
<td class="nump">8,353,403<span></span>
</td>
<td class="nump">10,316,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued sales and marketing costs</a></td>
<td class="nump">1,578,971<span></span>
</td>
<td class="nump">3,285,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued compensated absences</a></td>
<td class="nump">2,558,055<span></span>
</td>
<td class="nump">1,463,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AllowanceForWholesaleDistributorFeesCurrent', window );">Allowance for wholesale distributor fees</a></td>
<td class="nump">2,130,230<span></span>
</td>
<td class="nump">2,347,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting expense</a></td>
<td class="nump">1,052,935<span></span>
</td>
<td class="nump">422,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedResearchAndDevelopment', window );">Accrued research and development</a></td>
<td class="nump">1,059,077<span></span>
</td>
<td class="nump">1,049,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,404,286<span></span>
</td>
<td class="nump">1,501,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedRebates', window );">Accrued rebates</a></td>
<td class="nump">6,629,732<span></span>
</td>
<td class="nump">3,916,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">1,072,066<span></span>
</td>
<td class="nump">1,480,225<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">TOTAL OTHER CURRENT LIABILITIES</a></td>
<td class="nump">$ 31,220,484<span></span>
</td>
<td class="nump">$ 33,823,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AllowanceForWholesaleDistributorFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AllowanceForWholesaleDistributorFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SalesDiscountsReturnsAndAllowancesGoods1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129390866840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>As of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and financing fees</a></td>
<td class="num">$ (12,948,798)<span></span>
</td>
<td class="num">$ (5,365,357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">TOTAL LONG-TERM DEBT</a></td>
<td class="nump">237,051,202<span></span>
</td>
<td class="nump">194,634,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129375465192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 9 &#8211; DEBT (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 24, 2019 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>May 01, 2018 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 09, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 08, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 05, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 27, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,342,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,719,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,294,495<span></span>
</td>
<td class="nump">$ 33,745,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of Lines of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">81,660,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (10,057,632)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,057,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,370,118<span></span>
</td>
<td class="nump">582,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,534,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,534,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write off of deferred financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,379<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=txmd_PaycheckProtectionProgramLoanMember', window );">Paycheck Protection Program Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,477,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_LenderWarrantsMember', window );">Lender Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,752,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,428,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,428,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Period1Member', window );">Financing Agreement Amendment No. 6 - Through December 31, 2020 [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">677,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,370,118<span></span>
</td>
<td class="nump">462,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,902,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,902,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest Expense, Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,726,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,333,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,322,847<span></span>
</td>
<td class="nump">$ 9,318,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DebtTrancheAxis=txmd_TwoTranchesMember', window );">Two Tranches [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,626,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,626,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">3-month
LIBOR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LiborFloorRate', window );">LIBOR floor rate</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfInstallmentPayments', window );">Number of quarterly principal installment payments | Number</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeeForFirstTwoYearsFundingPercent', window );">Prepayment fee for first two years funding (percent)</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeeThirdYearFundingPercent', window );">Prepayment fee third year funding (percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeeFourthYearFundingPercent', window );">Prepayment fee fourth year funding (percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeeFifthYearFundingPercent', window );">Prepayment fee fifth year funding (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_FacilityFeePaidPercent', window );">Facility fee paid (percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write off of deferred financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">prime
rate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrimeRateFloor', window );">Prime rate floor</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable', window );">Line Of Credit Facility Undrawn Tranche No Longer Available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MidCapAgreementMember', window );">Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of Lines of Credit</a></td>
<td class="nump">$ 81,661,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RepaymentFeePercentage', window );">Repayment fee percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,816,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-month LIBOR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LiborFloorRate', window );">LIBOR floor rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfTranchesUnderTermLoanFacility', window );">Number of tranches under term loan facility | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_FacilityFeePaidPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_FacilityFeePaidPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LiborFloorRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents libor floor rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LiborFloorRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an undrawn tranche under a financing agreement that is no longer available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MinimumCashBalanceRequirementUnderCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of principal installment payments under credit and security agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfTranchesUnderTermLoanFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of seperate tranches under terms of the Credit Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfTranchesUnderTermLoanFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeeFifthYearFundingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee expressed as a percentage of the funding being repaid for fifth year following the initial funding date of the applicable borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeeFifthYearFundingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeeForFirstTwoYearsFundingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee expressed as a percentage of the funding being repaid for first two years following the initial funding date of the applicable borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeeForFirstTwoYearsFundingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeeFourthYearFundingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee expressed as a percentage of the funding being repaid for fourth year following the initial funding date of the applicable borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeeFourthYearFundingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee, expressed as a percentage of the tranche funding being repaid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeeThirdYearFundingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee expressed as a percentage of the funding being repaid for third year following the initial funding date of the applicable borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeeThirdYearFundingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrimeRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prime rate floor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrimeRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The repayment fee, expressed as a percentage of the tranche funding being repaid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7,8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=txmd_PaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=txmd_PaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_LenderWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_LenderWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Period1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Period1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_TwoTranchesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_TwoTranchesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_MidCapAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_MidCapAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129383916600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of calculation of diluted net loss per share allocable to common stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">38,880,709<span></span>
</td>
<td class="nump">27,922,555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=txmd_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">23,893,180<span></span>
</td>
<td class="nump">24,849,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">6,534,687<span></span>
</td>
<td class="nump">1,832,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=txmd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">2,422,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">6,029,957<span></span>
</td>
<td class="nump">1,240,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=txmd_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=txmd_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=txmd_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=txmd_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129469921576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020 and 2019 are set forth in the table below. (Details) - Share-based Payment Arrangement, Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.34%<span></span>
</td>
<td class="nump">1.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">2.54%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">63.53%<span></span>
</td>
<td class="nump">61.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">67.92%<span></span>
</td>
<td class="nump">64.49%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129463701640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>A summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September 30, 2020 is as follows (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares under options, exercised</a></td>
<td class="num">(517,891)<span></span>
</td>
<td class="num">(55,236)<span></span>
</td>
<td class="num">(1,182,195)<span></span>
</td>
<td class="num">(331,619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares under options, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,030,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 5 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,668,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares under options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">736,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares under options, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,182,195)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,738,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares under options, expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(361,109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares under options, cancelled forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(330,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, cancelled forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares under options, ending</a></td>
<td class="nump">23,893,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,893,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,030,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending</a></td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, ending</a></td>
<td class="nump">$ 379,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 379,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,668,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares under options, vested and exercisable ending</a></td>
<td class="nump">19,827,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,827,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and exercisable ending</a></td>
<td class="nump">$ 5.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, vested and exercisable ending</a></td>
<td class="nump">$ 218,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares under options, unvested ending</a></td>
<td class="nump">4,065,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,065,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, unvested</a></td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual life in years, unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, unvested</a></td>
<td class="nump">$ 161,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire unvested shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129385906872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of restricted stock units and performance stock units (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, beginning | shares</a></td>
<td class="nump">1,240,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair values, beginning | $ / shares</a></td>
<td class="nump">$ 3.56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted | shares</a></td>
<td class="nump">5,102,817<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted | $ / shares</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, vested/released | shares</a></td>
<td class="num">(301,500)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, vested/released | $ / shares</a></td>
<td class="nump">$ 1.78<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, forfeited | shares</a></td>
<td class="num">(11,360)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited | $ / shares</a></td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, ending | shares</a></td>
<td class="nump">6,029,957<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, ending | $ / shares</a></td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted | shares</a></td>
<td class="nump">2,585,745<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted | $ / shares</a></td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, vested/released | shares</a></td>
<td class="num">(151,500)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, vested/released | $ / shares</a></td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, forfeited | shares</a></td>
<td class="num">(11,360)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited | $ / shares</a></td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, ending | shares</a></td>
<td class="nump">2,422,885<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, ending | $ / shares</a></td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The number
of performance stock units (PSUs) represents the base number of PSUs that may vest. The actual number of PSUs that will vest will
be between zero and two times the base number of PSUs depending on the Company's achievement of break-even quarterly EBITDA.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129378226968">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 18, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Aug. 05, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,812,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,812,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,812,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,812,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,891<span></span>
</td>
<td class="nump">55,236<span></span>
</td>
<td class="nump">1,182,195<span></span>
</td>
<td class="nump">331,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,494<span></span>
</td>
<td class="nump">$ 8,549<span></span>
</td>
<td class="nump">$ 271,678<span></span>
</td>
<td class="nump">$ 108,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise', window );">Number of stock options exercised in cashless exercise</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares', window );">Number of common stock issued during period for stock options exercised in cashless exercise</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,534,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,534,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife', window );">Weighted-average contractual remaining life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price of warrants (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Payment Arrangement, Noncash Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,502,044<span></span>
</td>
<td class="nump">$ 7,859,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted Stock or Unit Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,988,844<span></span>
</td>
<td class="nump">84,061<span></span>
</td>
<td class="nump">4,334,537<span></span>
</td>
<td class="nump">1,080,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,029,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,029,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,422,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,422,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,182,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Payment Arrangement, Noncash Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,143,920<span></span>
</td>
<td class="nump">2,194,667<span></span>
</td>
<td class="nump">$ 4,141,061<span></span>
</td>
<td class="nump">6,568,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,893,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,893,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,030,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member', window );">2009 Long Term Incentive Compensation Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,346,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,346,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,305,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,305,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,405,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,405,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member] | Restricted Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">890,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">890,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_Plan2019Member', window );">Plan 2019 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,240,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,240,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,465,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,465,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_Plan2019Member', window );">Plan 2019 [Member] | Restricted Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,139,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,139,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_Plan2019Member', window );">Plan 2019 [Member] | Performance Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,422,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,422,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NewSharesMember', window );">New Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice', window );">Range - exercise price of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice', window );">Range - exercise price of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember', window );">Warrants Member</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Payment Arrangement, Noncash Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 56,418<span></span>
</td>
<td class="nump">$ 26,446<span></span>
</td>
<td class="nump">$ 198,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember', window );">Warrants Member | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember', window );">Warrants Member | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_LenderWarrantsMember', window );">Lender Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,428,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,428,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member', window );">Outside Consultants Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsCashlessExerciseMember', window );">Warrants - Cashless Exercise [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants', window );">Number of stock issued in cashless exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The number
of performance stock units (PSUs) represents the base number of PSUs that may vest. The actual number of PSUs that will vest will
be between zero and two times the base number of PSUs depending on the Company's achievement of break-even quarterly EBITDA.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued attributable to stock options exercised in cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued attributable to warrants exercised in cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options exercised in the cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfStockOptionsExercisedInCashlessExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price as of the balance sheet date at which grantees can acquire the shares for options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item provides the weighted-average contractual remaining life of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which warrant holders can acquire the shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_Plan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_Plan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_NewSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_NewSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_LenderWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_LenderWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsCashlessExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsCashlessExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129390988840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 13 &#8211; RELATED PARTIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_CatalentMember', window );">Catalent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Amount billed</a></td>
<td class="nump">$ 520,000<span></span>
</td>
<td class="nump">$ 2,196,000<span></span>
</td>
<td class="nump">$ 2,563,000<span></span>
</td>
<td class="nump">$ 4,118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Amounts due to related party</a></td>
<td class="nump">147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_AmericanInternationalGroupMember', window );">American International Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Amount billed</a></td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_CatalentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_CatalentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_AmericanInternationalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_AmericanInternationalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129490943896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 14 - BUSINESS CONCENTRATIONS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierOneConcentrationRiskMember', window );">Supplier One Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierTwoConcentrationRiskMember', window );">Supplier 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierThreeConcentrationRiskMember', window );">Supplier 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfCustomers', window );">Number of customers - revenue | Number</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_ThreeCustomersConcentrationRiskMember', window );">Three Customers Concentration Risk | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">56.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_FourCustomersConcentrationRiskMember', window );">Four Customers Concentration Risk | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPillPackRiskMember', window );">PillPack - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 9,319,000<span></span>
</td>
<td class="nump">$ 6,397,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationCardinalHealthRiskMember', window );">Cardinal Health - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">7,415,000<span></span>
</td>
<td class="nump">1,863,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationMcKessonCorporationRiskMember', window );">McKesson Corporation - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 6,009,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationAmerisourceBergenRiskMember', window );">AmerisourceBergen - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,226,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPIServicesMember', window );">PI Services - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,935,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierOneConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierOneConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierTwoConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierTwoConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierThreeConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierThreeConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_ThreeCustomersConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_ThreeCustomersConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_FourCustomersConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_FourCustomersConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPillPackRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPillPackRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationCardinalHealthRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationCardinalHealthRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationMcKessonCorporationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationMcKessonCorporationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationAmerisourceBergenRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationAmerisourceBergenRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPIServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPIServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129469965416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental lease information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 9,975,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,109,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term operating lease liability (included in Other current liabilities)</a></td>
<td class="nump">2,404,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,501,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">$ 8,907,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,145,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities for operating lease</a></td>
<td class="nump">$ 1,006,970<span></span>
</td>
<td class="nump">$ 849,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligation</a></td>
<td class="nump">$ 998,821<span></span>
</td>
<td class="nump">$ 11,171,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129384158584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (3 months)</a></td>
<td class="nump">$ 610,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">2,334,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,413,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">1,443,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">1,476,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">8,947,869<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">16,226,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(4,913,811)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease payments</a></td>
<td class="nump">$ 11,312,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129463735928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2013</div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 01, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 02, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CapitalLeaseObligationsTerm', window );">Non-cancelable operating lease term</a></td>
<td class="text">63 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetRentableAreaLease', window );">Net rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RentedAreaLease', window );">Rented area lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalAreaOfLeaseOccupied', window );">Additional area of lease occupied | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber', window );">Lessee operating lease existence of option to extend number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea', window );">Lease not yet commenced (area) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 590,000<span></span>
</td>
<td class="nump">$ 458,000<span></span>
</td>
<td class="nump">$ 1,749,000<span></span>
</td>
<td class="nump">$ 1,062,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SignificantSupplyCommitmentPercentagePayable', window );">Significant supply commitment percentage payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_CatalentMember', window );">Catalent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear', window );">Minimum purchase commitment, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,719,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,719,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear', window );">Minimum purchase commitment, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear', window );">Minimum purchase commitment, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,991,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,991,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear', window );">Minimum purchase commitment, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear', window );">Minimum purchase commitment, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,786,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,786,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdditionalAreaOfLeaseOccupied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional rented area occupied under the lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AdditionalAreaOfLeaseOccupied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CapitalLeaseObligationsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total term (in months) of the company's outstanding lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CapitalLeaseObligationsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options to extend lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future rented area to be occupied for administrative office space as defined in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NetRentableAreaLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area as defined in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NetRentableAreaLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RentedAreaLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rented area as defined in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RentedAreaLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SignificantSupplyCommitmentPercentagePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of the difference between the total amount we would have paid to supplier if the minimum requirement had been fulfilled and the sum of all purchases of our products from supplier during the contract year, required to be paid to supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SignificantSupplyCommitmentPercentagePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recorded unconditional purchase obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25383-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recorded unconditional purchase obligation to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25383-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recorded unconditional purchase obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25383-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25383-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_CatalentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_CatalentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140129390616648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NOTE 16 &#8211; SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member]<br></strong></div></th>
<th class="th">
<div>Nov. 08, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member', window );">Financing Agreement Amendment No. 6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment', window );">Minimum cash balance requirement under credit agreement before adjustment</a></td>
<td class="nump">$ 60,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Period1Member', window );">Financing Agreement Amendment No. 6 - Through December 31, 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="nump">45,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Period2Member', window );">Financing Agreement Amendment No. 6 - After December 31, 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="nump">$ 60,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MinimumCashBalanceRequirementUnderCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum cash balance the Borrower must maintain under the credit and secuirty agreement before adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Period1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Period1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Period2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Period2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MW6C#^^5^MW%_HD1B-NP60BD1F<,U9SZ7^@&XOQ1"'4_T"_(]W]Y_4$L#!!0
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M$8ZIX(1UDCO(@@Y9X$5V,9_K*C<E%-Q<I4_R(5-CE$-ST LD,RAAF<\5@F:
M$ET]F$6505UM5$#D* [YF/ (R3Q!1P('8QS >RQ4N59-^64O+K];3.&6.S3
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M>+[0VKS>U$?*W;\0IO\!4$L#!!0    ( --*:5&41M:F' ,  #(*   8
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULG99M;]HP$,>_BA7M12MUY %(H (D
M"JU6J6M1TW8OIKTPR4&L)C&SG=+MT\]VTBQ "!20P';N?_>[XXP]6%/VRB,
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M0F(H9V90A+S*0SI[0OJP:J&V=8$<R[%JY)-F^10"*;>5W.YORDV9?%D!IZR
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M/7V438+BD%/C,8DWZC%9WPR*(P@<=RI6O(;]O':F&H]-EL,4,.889ZQ #@\
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MZC$GK"S]$> Z2D(4%I'_RQDK8A*0U) =G4OHQJN(@YSNF)7?U8AU"S&9! .
M0J3OYIZJQV1 CUT!%0:1YQ^V\C<=(]BICEL1"R3)"L49TY^F)H-,NZ(I2B+/
M/')U]/3*D?,L9ZXX0OI#GSDQ\8B#* RI7*OJD\SRZ#($!!'&B;Z;:[.5>2.4
M/XXM Z*HBSSWY%6_*I:C5SM5<.BH450Q&?4SV8D6>M0D) ST*D MR&58Q?Z
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M)Y_^YGN%?#U?*O.R_HN>&MDP&*%T5U9RLQ\,"#:B:#Z3Y[TA#@; //8!9#^
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M:0'X?25E]?I%+]!>_9__'U!+ P04    " #32FE1B !@57('   P$0  &
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MN1QSZ6UE ZP[:CD#E]Q=WCYFC^.VDMX=&U 4U[0]=9T&.X-.K&F=$6X$L E
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M>*^X0LZ*R0EP%EQH07QX*ZR2V2$),JQG],5/6_!;#YC7J36: @83E6:IY6A
M4C]@JN_ERQL?ZNJHN(#3E%Z1-^^7$DPAM?,)9F];F=(%?3YY5U>(]YAI:<Q1
M,P#KA.T21R&Z10'EZ9S G#V5*93*D#XQOI(0OF3>5G$9@PS\^38Y_V6#IKW8
MXWA+8 )"4S8B<08=10OTLJ4 /1_#+>#(]Y"N=JU3_B5W/@@#R:-97PGA2"!
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M-5O'S3"ZNR&06_JM(,9?U+<G18,,IG2:_/GXF_N^O7223U-]4^C])MXL-<@
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MT5^_.9!Y3/[0^99?S5[ZKO,-_[DQQ.#H ?R^\B!;Z0,=,+RK__Q?4$L#!!0
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M^".\^VDT3EI1B1-L;T%!!SC#)1PLC9[X.&<K[KZ&,$&N"%$X'J'OR5KB/(:
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ME#; G*^$T ?')FA&[.@74$L#!!0    ( --*:5$,I*!M"0,  #D&   9
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M$T<.J'Y0]1LCFVXX'*6A4=,MSS3;45D#NB\DI7C86 ?CO\7R'U!+ P04
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MT+0:K5C2OPBE,:#W>R'T@V((SG^WQ=]02P,$%     @ TTII49A:3-<&!0
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M K-"6"JI-91,J3M+PQK9"1-00Y5=T]7,8&5QRO OK.\T"JF@>?*  ^0"9*>
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MR@;TLC2L\>>!733 ?F5MV$UB@/'OR/)O4$L#!!0    ( --*:5%%,E8<M@,
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MQOTWHP!T^[2V"ZMJ_YQERM+CZ*<E_1M![0QH?ZV4/2Q<@.[_S>1O4$L#!!0
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MD!IM/$>9Q=X2^'1?%/G21WO,UP$3Z6:77'K.DV.13P;R3V?UB? 0[9PL(?S
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MB!) ?F3]/I2"'@4RGH(ZR"*"+.]*,9827$XN$^DQP2H]) /L/5W5\39T5!X
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M33<[6&'HW&FNB\8=K#'5CI:JVMJVBJVX;TX+/S_K[E'E?C2[;_5]Z(!(N:@
MQ.T6XO2,P_<[6RM=0'(=+3DT3N(PUAYA-$HM1S;?P/3II'O!S>0HVV\-1_>/
M*+^CKZHY^OPXGQ&H\$"E_\8JXJ)MZXP)KQZ*'0D.;+?8+*(ZY^ K#1*OM<IB
M&8!\/7='UQ+_0A,*++LAH#(3H(\93<31C5PB^B8_[XR7C>U]9VE[?73J7.
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M#<Y['0]D+>K:T:)R0EH);63IS-R\@RAM@#E?"Z$/CDW0O*SCWU!+ P04
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MJ/$(-;!'*+M(8X^HH3</ R-[UP\+:;"[NO"(GS-0-@'?[Z4T+P-+,'T@E_\
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M[$6A ^A[S+G:&WJ#=IK/_@!02P,$%     @ TTII41ZJ38"T @  @04  !D
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M?:_0ZG4HZZ*$2A>R8@HV$_<B&%TFM-]N^+. G7ZQ9E3)2LJO9-RL)ZY/"8&
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M,>'#+=Y[\3$N06WME4,SFUW[7>Z>=K>:B_9C_GU[>R6ZY6I;5!I3V*"K?S[
MAE+M-:,UC*SMIWTE#5X4[#+'FQDHVH#O-U*:9X,"='>]Z;]02P,$%     @
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MW5F:8:E[/PB3H-<+SM5[8-I+]V^2_@502P,$%     @ TTII47:HCFDG P
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M6CA>G<VKB61Y>;Q]9%(=ELOA1OW/ -<&ZOV*,?D\T2?FY@]I^C]02P,$%
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M/O!-032--Q.AROZCI_Q>:FZ>K946T::QZ4$4Q/DG^[X1HM0 =VH:X$T#O-O
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MS[ZL.4K43D74.DV!.YZ=.UM-CW_G 2U>$QZ* &/(Z3P4J7JHNCF* '2('3K
MTA<#%=V+))BQ$(TD9U%I977(;P,$D$.:L%D$,$1.9[-(U6:Y-6J7?D(ZT&7M
MJBU9K.9<1D9Q<VFVLE4+#")-^"X"/"*G\UUDC^^J41?X1 ZS7?]'7( 1:<*(
M$2 3.9T1(U4C5K/HHD J>J 1VU7WB^/T/MQ9:J0 (]J$XZ* 'WHZQT4/=EP4
M<$0/=%S;J>R%G4UW4M8A2S=D;(:6 GUH$P:,EGYU/IT!HU4#5K.@I< C:N?1
M[H+V/ZD+]*%-N# * **G<V&TZL+JMA0 2/10%_82"!\3+IEMYP"0XS=AP'S
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M":L#D4VA1QU8'GA9'>@@Y#F.MX%X51UHV]3!"--B8,E"3F$AI\%",_:J3)^
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M<BJIF0LU0'X_B>-T]4;]9*3X'=G)_P%02P,$%     @ TTII41UC(A)O P
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MC((!J595\5YUC-RX^G<A#573KIG3A0>5'4#O5U*:8\=.T%RAIO\ 4$L#!!0
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M7&UOD<4R_XOVI:S30XNM5%E2*@.")$J+_^RE#,21 M@Q*Y!2@9PK#%L4:*E
MSQ1(VPK#4F%XZ0INJ>!>NH)7*GAY[(M@Y9&>,L4F8Y'MD=#28$U?Y.G*M2'
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MN:YV;:!(HW1QW_5;(-4<A.E_UO.GI6UKES[%55,1MG-19ZCLP(:-8#E]0EM
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M$?- == C>KC()WS>T2"WYS*WYR:S)V#9[X_K(8EN(+;L#CU$; /5P4T1'*:
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MS0S[EV[GH'9A5>,G@XVR.&?XQQ)G1]#. +]OE;*O"^>@GT87_P-02P,$%
M  @ TTII42-G-H(+ P  .@@  !D   !X;"]W;W)K<VAE971S+W-H965T-38N
M>&ULC9;=;MLX$(5?A1#V(@6ZD4C)LAS8!IH$BRW0 D'3[EXL>D%+(XLH):KD
M*$[?OD/:4=U$=O;&(D7.?.>,^./ESMAOK@% ]MCJSJVB!K&_BF-7-M!*=VEZ
MZ&BD-K:52%V[C5UO058AJ-6Q2)(\;J7JHO4RO+NSZZ494*L.[BQS0]M*^^,:
MM-FM(AX]O?BDM@WZ%_%ZV<LMW -^Z>\L]>(Q2Z5:Z)PR';-0KZ)W_.J:AX P
MXQ\%.W?49M[*QIAOOO.^6D6)5P0:2O0I)#T>X :T]IE(Q_=#TFAD^L#C]E/V
MOX)Y,K.1#FZ,_E=5V*RB(F(5U'+0^,GL_H:#H9G/5QKMPB_;'>8F$2L'AZ8]
M!)."5G7[IWP\%.(H0/ 3 >(0((+N/2BHO)4HUTMK=LSZV93--X+5$$WB5.>_
MRCU:&E44A^O/#;#::/HXJMLRE!L-5.S2=*72X!C2\-!5RI5FZ! J5DK7L)JF
M.PJS3&K-:(58B3Y< ]7',8GL'GJ$=@.6I<E;)A*1,#0AV[/93"NY45JAHD /
MMA51Z'/YN1NI95<""_:NV,4MH%3:O5G&2-:]@;@\V+S>VQ0G;)*>RU'*E_M;
M=O''LRPQ%6ZLGABK)T+:]$3:&].V"FF1(KGN*G9C.F\-J'IDYY;*IHT;++#_
MWFT<6EJ"7\]0TY&:!FIV@AK*>9&REFC-=#7V"?*0P&_,AW7.DWP^6\8/$^!L
M!&>O@?D4;1\U.Z*)-,UFA9C&S4;<[#6<F,+-7N!XQE-1+*9Q^8C+7\.E4[A\
M I>E/$NG<?,1-W\-ETWAYA.X>3Y+LVE<,>**LSC:Z'1JUPAV"EJ\@!:+;%[D
M)TJZ&*&+\U"#4O]^@.QW?2]_A%TSI67QL@"Y$'FR.+&<>/+KK$O.ROD SETQ
MU?:#5Z)(CP6'DZ=)\D+$G]F"IP7G)T0<';C\K(@[8I)U]B#U0,=A_3\J<LAX
MO)TY3[D0Q7,U\=%-X&_5C])N5>>(45-H<CDG1W9_4>T[:/IP.6P,TE43F@U=
M[F#]!!JOC<&GCK]OQK\+ZY]02P,$%     @ TTII47XZ3GNX!   S!(  !D
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M:XPBS&2 >+^DE+_=R*-Z_0&K_R]02P,$%     @ TTII482V=&V> @  MP<
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M^7])=3G=FR^//R^_3Z*$BS/."?Y*N?\"4$L#!!0    ( --*:5%B(^<8V $
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MKYZZ5(A\K,<_\2,QE3[Z^Z@_[9+*7V:G[7VV?CV<1V##[?@]_GS&'_4/[$.
M]"%!^E @?6B0/N8@?9R"]'$&TL<Y2!]\AM((BJ@<A52.8BI'096CJ,I16.4H
MKG(46#F*K )%5H$BJT"15:#(*E!D%2BR"A19!8JL D56@2*K1)%5HL@J4625
M*+)*%%DEBJP215:)(JM$D56BR*I09%4HLBH4616*K I%5H4BJT*15:'(JE!D
M52BR:A19-8JL&D56C2*K1I%5H\BJ4635*++J_Y3UR=KU7__;T-_SUM3=>SX;
M?B"Y>@502P$"% ,4    " #32FE1!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( --*:5$Z=(L2[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( --*:5&97)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ TTII45QN=%E !0  _Q4  !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( --*:5&+K,[W8 8  $X8   8              " @8,-  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #32FE1E$;6IAP#   R
M"@  &               @($9%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ TTII4:F(U1:<!@  'AL  !@              ("!:Q<
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( --*:5';#MZU
M<PD  ",[   8              " @3T>  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " #32FE1_!<!8O$'   &(   &
M@('F)P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ TTII
M48@ 8%5R!P  ,!$  !@              ("!#3   'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( --*:5$MN'G[/1(  +<O   8
M      " @;4W  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" #32FE1&)]M0KX=  !K4P  &               @($H2@  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ TTII45[D[N&< @  ;@4  !D
M             ("!'&@  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " #32FE1#*2@;0D#   Y!@  &0              @('O:@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( --*:5'7P0<5/P,
M .D&   9              " @2]N  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ TTII49A:3-<&!0  1@P  !D              ("!
MI7$  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #32FE1
MR+4@TH$#   _!P  &0              @('B=@  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( --*:5$MH/@J$0H  !$9   9
M      " @9IZ  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ TTII45:G9#.X @  OP4  !D              ("!XH0  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #32FE14O ,[/D,  "0(@
M&0              @('1AP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( --*:5%F65-Z^P,  )H(   9              " @0&5  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ TTII444R5ARV
M P  ZP@  !D              ("!,YD  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " #32FE1!J:M!14#  "V!@  &0
M@($@G0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( --*
M:5$W^+\!8@H   (9   9              " @6R@  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ TTII468#(SQE @  -P4  !D
M         ("!!:L  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " #32FE1HKGM#8L>   &60  &0              @(&AK0  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( --*:5'*L)FW1@,  * &
M   9              " @6/,  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ TTII43<ZLUJD @  904  !D              ("!X,\
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #32FE1)SD1
M=A$#   I!@  &0              @(&[T@  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( --*:5'^Q.(>_P(  !4&   9
M  " @0/6  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
MTTII42U+Q1!8!   WPL  !D              ("!.=D  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " #32FE1:2(J X@#   L!P  &0
M            @('(W0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( --*:5'@$P8ZJ@(  -D%   9              " @8?A  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ TTII41ZJ38"T @
M@04  !D              ("!:.0  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " #32FE1!_^GQ?T%   *#P  &0              @(%3
MYP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( --*:5'_
MSS7@100  /<)   9              " @8?M  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ TTII483F1K0+ @  _@,  !D
M     ("! _(  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( --*:5%VJ(YI)P,  #((   9              "
M@8@& 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ TTII
M4?!6._2" P  +0T  !D              ("!Y@D! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " #32FE1=.N=^HP"  "D!@  &0
M        @(&?#0$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( --*:5$?Y..K0@0  $(0   9              " @6(0 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ TTII4<VERW5G @  Z04
M !D              ("!VQ0! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " #32FE1<+!%_W<%  #M'@  &0              @(%Y%P$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( --*:5$]MC]Q
MTP,  (\+   9              " @2<= 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ TTII47X ,"NU @  U08  !D
M ("!,2$! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #3
M2FE1I6ZJL1L*  !3-@  &0              @($=) $ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( --*:5$=8R(2;P,  -0,   9
M          " @6\N 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#
M%     @ TTII4: I]9[" P  3@T  !D              ("!%3(! 'AL+W=O
M<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #32FE154W-_),%  #^
M&0  &0              @($.-@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM
M;%!+ 0(4 Q0    ( --*:5'/;0= CP0  .D2   9              " @=@[
M 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ TTII45PP
MR.VN#   >TX  !D              ("!GD ! 'AL+W=O<FMS:&5E=',O<VAE
M970U,BYX;6Q02P$"% ,4    " #32FE1:J+0#@ #  "C"0  &0
M    @(&#30$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M --*:5%YMS#90 0   X5   9              " @;I0 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ TTII4:GAQW^@ P  F0H  !D
M             ("!,54! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    " #32FE1(V<V@@L#   Z"   &0              @($(60$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( --*:5%^.DY[N 0
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( --*:5&G)?=G=P4  /4F   /
M      "  55G 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #32FE1$R?L
MNN\!  "E(@  &@              @ 'Y; $ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " #32FE18B/G&-@!  !((@  $P
M    @ $@;P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     0@!"  42   I
%<0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>242</ContextCount>
  <ElementCount>396</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>93</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - NOTE 1 ??? THE COMPANY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note1Company</Role>
      <ShortName>NOTE 1 ??? THE COMPANY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - NOTE 2 ??? BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements</Role>
      <ShortName>NOTE 2 ??? BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - NOTE 4 ??? INVENTORY, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note4InventoryNet</Role>
      <ShortName>NOTE 4 ??? INVENTORY, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - NOTE 5 ??? OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note5OtherCurrentAssets</Role>
      <ShortName>NOTE 5 ??? OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - NOTE 6 ??? FIXED ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note6FixedAssetsNet</Role>
      <ShortName>NOTE 6 ??? FIXED ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - NOTE 7 ??? INTANGIBLE ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note7IntangibleAssetsNet</Role>
      <ShortName>NOTE 7 ??? INTANGIBLE ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - NOTE 8??? OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities</Role>
      <ShortName>NOTE 8??? OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - NOTE 9 ??? DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note9Debt</Role>
      <ShortName>NOTE 9 ??? DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - NOTE 10 ??? NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note10NetLossPerShare</Role>
      <ShortName>NOTE 10 ??? NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - NOTE 11 ??? STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note11StockholdersEquity</Role>
      <ShortName>NOTE 11 ??? STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - NOTE 12 ??? INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note12IncomeTaxes</Role>
      <ShortName>NOTE 12 ??? INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - NOTE 13 ??? RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note13RelatedParties</Role>
      <ShortName>NOTE 13 ??? RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - NOTE 14 - BUSINESS CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note14-BusinessConcentrations</Role>
      <ShortName>NOTE 14 - BUSINESS CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - NOTE 15 ??? COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies</Role>
      <ShortName>NOTE 15 ??? COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - NOTE 16 ??? SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note16SubsequentEvents</Role>
      <ShortName>NOTE 16 ??? SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - NOTE 4 ??? INVENTORY, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note4InventoryNetTables</Role>
      <ShortName>NOTE 4 ??? INVENTORY, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note4InventoryNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - NOTE 5 ??? OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables</Role>
      <ShortName>NOTE 5 ??? OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note5OtherCurrentAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - NOTE 6 ??? FIXED ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note6FixedAssetsNetTables</Role>
      <ShortName>NOTE 6 ??? FIXED ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note6FixedAssetsNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - NOTE 7 ??? INTANGIBLE ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables</Role>
      <ShortName>NOTE 7 ??? INTANGIBLE ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note7IntangibleAssetsNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - NOTE 8??? OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables</Role>
      <ShortName>NOTE 8??? OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - NOTE 9 ??? DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note9DebtTables</Role>
      <ShortName>NOTE 9 ??? DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note9Debt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - NOTE 10 ??? NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note10NetLossPerShareTables</Role>
      <ShortName>NOTE 10 ??? NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note10NetLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - NOTE 11 ??? STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note11StockholdersEquityTables</Role>
      <ShortName>NOTE 11 ??? STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note11StockholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - NOTE 15 ??? COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables</Role>
      <ShortName>NOTE 15 ??? COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - NOTE 1 ??? THE COMPANY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative</Role>
      <ShortName>NOTE 1 ??? THE COMPANY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note1Company</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - NOTE 2 ??? BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative</Role>
      <ShortName>NOTE 2 ??? BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - The following table provides information about disaggregated revenue by product mix (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails</Role>
      <ShortName>The following table provides information about disaggregated revenue by product mix (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Inventory, net consists of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails</Role>
      <ShortName>Inventory, net consists of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Other current assets consist of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails</Role>
      <ShortName>Other current assets consist of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Fixed assets, net consist of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails</Role>
      <ShortName>Fixed assets, net consist of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - NOTE 6 ??? FIXED ASSETS, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative</Role>
      <ShortName>NOTE 6 ??? FIXED ASSETS, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note6FixedAssetsNetTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2020 and December 31, 2019: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details</Role>
      <ShortName>The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2020 and December 31, 2019: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails</Role>
      <ShortName>Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - NOTE 7 ??? INTANGIBLE ASSETS, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative</Role>
      <ShortName>NOTE 7 ??? INTANGIBLE ASSETS, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Other current liabilities consist of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails</Role>
      <ShortName>Other current liabilities consist of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - As of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails</Role>
      <ShortName>As of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - NOTE 9 ??? DEBT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note9DebtDetailsNarrative</Role>
      <ShortName>NOTE 9 ??? DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note9DebtTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails</Role>
      <ShortName>Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020 and 2019 are set forth in the table below. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details</Role>
      <ShortName>The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020 and 2019 are set forth in the table below. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - A summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September 30, 2020 is as follows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails</Role>
      <ShortName>A summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September 30, 2020 is as follows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Schedule of restricted stock units and performance stock units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails</Role>
      <ShortName>Schedule of restricted stock units and performance stock units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - NOTE 11 ??? STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative</Role>
      <ShortName>NOTE 11 ??? STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note11StockholdersEquityTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - NOTE 13 ??? RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative</Role>
      <ShortName>NOTE 13 ??? RELATED PARTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note13RelatedParties</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - NOTE 14 - BUSINESS CONCENTRATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative</Role>
      <ShortName>NOTE 14 - BUSINESS CONCENTRATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note14-BusinessConcentrations</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Supplemental lease information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails</Role>
      <ShortName>Supplemental lease information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails</Role>
      <ShortName>The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - NOTE 15 ??? COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>NOTE 15 ??? COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="txmd-10q_093020.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - NOTE 16 ??? SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative</Role>
      <ShortName>NOTE 16 ??? SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note16SubsequentEvents</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="txmd-10q_093020.htm">txmd-10q_093020.htm</File>
    <File>ex10-3.htm</File>
    <File>ex10-4.htm</File>
    <File>ex10-5.htm</File>
    <File>ex10-6.htm</File>
    <File>ex10-7.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>ex4-2.htm</File>
    <File>txmd-20200930.xsd</File>
    <File>txmd-20200930_cal.xml</File>
    <File>txmd-20200930_def.xml</File>
    <File>txmd-20200930_lab.xml</File>
    <File>txmd-20200930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "txmd-10q_093020.htm": {
   "axisCustom": 1,
   "axisStandard": 20,
   "contextCount": 242,
   "dts": {
    "calculationLink": {
     "local": [
      "txmd-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "txmd-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "txmd-10q_093020.htm"
     ]
    },
    "labelLink": {
     "local": [
      "txmd-20200930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "txmd-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "txmd-20200930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 549,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 52,
    "http://therapeuticsmd.com/20200930": 2,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 59
   },
   "keyCustom": 62,
   "keyStandard": 334,
   "memberCustom": 65,
   "memberStandard": 25,
   "nsprefix": "txmd",
   "nsuri": "http://therapeuticsmd.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://therapeuticsmd.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - NOTE 4 \u2013 INVENTORY, NET",
     "role": "http://therapeuticsmd.com/role/Note4InventoryNet",
     "shortName": "NOTE 4 \u2013 INVENTORY, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - NOTE 5 \u2013 OTHER CURRENT ASSETS",
     "role": "http://therapeuticsmd.com/role/Note5OtherCurrentAssets",
     "shortName": "NOTE 5 \u2013 OTHER CURRENT ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - NOTE 6 \u2013 FIXED ASSETS, NET",
     "role": "http://therapeuticsmd.com/role/Note6FixedAssetsNet",
     "shortName": "NOTE 6 \u2013 FIXED ASSETS, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - NOTE 7 \u2013 INTANGIBLE ASSETS, NET",
     "role": "http://therapeuticsmd.com/role/Note7IntangibleAssetsNet",
     "shortName": "NOTE 7 \u2013 INTANGIBLE ASSETS, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - NOTE 8\u2013 OTHER CURRENT LIABILITIES",
     "role": "http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities",
     "shortName": "NOTE 8\u2013 OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - NOTE 9 \u2013 DEBT",
     "role": "http://therapeuticsmd.com/role/Note9Debt",
     "shortName": "NOTE 9 \u2013 DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - NOTE 10 \u2013 NET LOSS PER SHARE",
     "role": "http://therapeuticsmd.com/role/Note10NetLossPerShare",
     "shortName": "NOTE 10 \u2013 NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY",
     "role": "http://therapeuticsmd.com/role/Note11StockholdersEquity",
     "shortName": "NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - NOTE 12 \u2013 INCOME TAXES",
     "role": "http://therapeuticsmd.com/role/Note12IncomeTaxes",
     "shortName": "NOTE 12 \u2013 INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - NOTE 13 \u2013 RELATED PARTIES",
     "role": "http://therapeuticsmd.com/role/Note13RelatedParties",
     "shortName": "NOTE 13 \u2013 RELATED PARTIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - NOTE 14 - BUSINESS CONCENTRATIONS",
     "role": "http://therapeuticsmd.com/role/Note14-BusinessConcentrations",
     "shortName": "NOTE 14 - BUSINESS CONCENTRATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES",
     "role": "http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies",
     "shortName": "NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - NOTE 16 \u2013 SUBSEQUENT EVENTS",
     "role": "http://therapeuticsmd.com/role/Note16SubsequentEvents",
     "shortName": "NOTE 16 \u2013 SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - NOTE 4 \u2013 INVENTORY, NET (Tables)",
     "role": "http://therapeuticsmd.com/role/Note4InventoryNetTables",
     "shortName": "NOTE 4 \u2013 INVENTORY, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - NOTE 5 \u2013 OTHER CURRENT ASSETS (Tables)",
     "role": "http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables",
     "shortName": "NOTE 5 \u2013 OTHER CURRENT ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - NOTE 6 \u2013 FIXED ASSETS, NET (Tables)",
     "role": "http://therapeuticsmd.com/role/Note6FixedAssetsNetTables",
     "shortName": "NOTE 6 \u2013 FIXED ASSETS, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - NOTE 7 \u2013 INTANGIBLE ASSETS, NET (Tables)",
     "role": "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables",
     "shortName": "NOTE 7 \u2013 INTANGIBLE ASSETS, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - NOTE 8\u2013 OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables",
     "shortName": "NOTE 8\u2013 OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - NOTE 9 \u2013 DEBT (Tables)",
     "role": "http://therapeuticsmd.com/role/Note9DebtTables",
     "shortName": "NOTE 9 \u2013 DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - NOTE 10 \u2013 NET LOSS PER SHARE (Tables)",
     "role": "http://therapeuticsmd.com/role/Note10NetLossPerShareTables",
     "shortName": "NOTE 10 \u2013 NET LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY (Tables)",
     "role": "http://therapeuticsmd.com/role/Note11StockholdersEquityTables",
     "shortName": "NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES (Tables)",
     "role": "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables",
     "shortName": "NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - NOTE 1 \u2013 THE COMPANY (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative",
     "shortName": "NOTE 1 \u2013 THE COMPANY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-11-09_custom_FinancingAgreementMember_us-gaap_SubsequentEventMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:MinimumCashBalanceRequirementUnderCreditAgreement",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - NOTE 2 \u2013 BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
     "shortName": "NOTE 2 \u2013 BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-07-012020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - The following table provides information about disaggregated revenue by product mix (Details)",
     "role": "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails",
     "shortName": "The following table provides information about disaggregated revenue by product mix (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-07-012020-09-30_custom_PrescriptionVitaminsMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Inventory, net consists of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails",
     "shortName": "Inventory, net consists of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:PrepaidSalesAndMarketingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Other current assets consist of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails",
     "shortName": "Other current assets consist of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:PrepaidSalesAndMarketingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-07-012020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-07-012020-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Fixed assets, net consist of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails",
     "shortName": "Fixed assets, net consist of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-07-012020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - NOTE 6 \u2013 FIXED ASSETS, NET (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative",
     "shortName": "NOTE 6 \u2013 FIXED ASSETS, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2020 and December 31, 2019: (Details)",
     "role": "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details",
     "shortName": "The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2020 and December 31, 2019: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)",
     "role": "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails",
     "shortName": "Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - NOTE 7 \u2013 INTANGIBLE ASSETS, NET (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative",
     "shortName": "NOTE 7 \u2013 INTANGIBLE ASSETS, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-012020-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Other current liabilities consist of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails",
     "shortName": "Other current liabilities consist of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - As of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails",
     "shortName": "As of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-07-012020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - NOTE 9 \u2013 DEBT (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative",
     "shortName": "NOTE 9 \u2013 DEBT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-04-27_custom_PaycheckProtectionProgramLoanMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)",
     "role": "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails",
     "shortName": "Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020 and 2019 are set forth in the table below. (Details)",
     "role": "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details",
     "shortName": "The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020 and 2019 are set forth in the table below. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2018-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2019-01-012019-03-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-07-012020-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - A summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September 30, 2020 is as follows (Details)",
     "role": "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails",
     "shortName": "A summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September 30, 2020 is as follows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_RestrictedStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - Schedule of restricted stock units and performance stock units (Details)",
     "role": "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails",
     "shortName": "Schedule of restricted stock units and performance stock units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_RestrictedStockMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
     "shortName": "NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-07-012020-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-07-012020-09-30_custom_CatalentMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - NOTE 13 \u2013 RELATED PARTIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative",
     "shortName": "NOTE 13 \u2013 RELATED PARTIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-07-012020-09-30_custom_CatalentMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-012020-09-30_custom_SupplierOneConcentrationRiskMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - NOTE 14 - BUSINESS CONCENTRATIONS (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative",
     "shortName": "NOTE 14 - BUSINESS CONCENTRATIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-012020-09-30_custom_SupplierOneConcentrationRiskMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - Supplemental lease information (Details)",
     "role": "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails",
     "shortName": "Supplemental lease information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)",
     "role": "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails",
     "shortName": "The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2013-06-302013-07-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:CapitalLeaseObligationsTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2013-06-302013-07-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:CapitalLeaseObligationsTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "AsOf2020-11-08_custom_FinancingAgreementAmendment6Member_us-gaap_SubsequentEventMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - NOTE 16 \u2013 SUBSEQUENT EVENTS (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative",
     "shortName": "NOTE 16 \u2013 SUBSEQUENT EVENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - NOTE 1 \u2013 THE COMPANY",
     "role": "http://therapeuticsmd.com/role/Note1Company",
     "shortName": "NOTE 1 \u2013 THE COMPANY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - NOTE 2 \u2013 BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS",
     "role": "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements",
     "shortName": "NOTE 2 \u2013 BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies",
     "shortName": "NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093020.htm",
      "contextRef": "From2020-01-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 93,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r409",
      "r411",
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r227",
      "r228",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r385",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r227",
      "r228",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r385",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r146",
      "r220",
      "r221",
      "r350",
      "r384",
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r146",
      "r220",
      "r221",
      "r350",
      "r384",
      "r386"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r225",
      "r227",
      "r228",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r385",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r225",
      "r227",
      "r228",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r385",
      "r387"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_AccruedRebates": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebates",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AccruedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopment",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AdditionalAreaOfLeaseOccupied": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional rented area occupied under the lease.",
        "label": "Additional area of lease occupied"
       }
      }
     },
     "localname": "AdditionalAreaOfLeaseOccupied",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_AllowanceForWholesaleDistributorFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Allowance for wholesale distributor fees"
       }
      }
     },
     "localname": "AllowanceForWholesaleDistributorFeesCurrent",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AmericanInternationalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "American International Group",
        "label": "American International Group [Member]"
       }
      }
     },
     "localname": "AmericanInternationalGroupMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_AmortizationOfIntellectualPropertyLicenseFee": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount represents amortization of intellectual property license fee.",
        "label": "Amortization of intellectual property license fee"
       }
      }
     },
     "localname": "AmortizationOfIntellectualPropertyLicenseFee",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AmountAccruedForIntellectualPropertyLicense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount represents amount accrued for intellectual property license.",
        "label": "Amount accrued for intellectual property license"
       }
      }
     },
     "localname": "AmountAccruedForIntellectualPropertyLicense",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AnnoveraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The drug name.",
        "label": "ANNOVERA [Member]"
       }
      }
     },
     "localname": "AnnoveraMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent.",
        "label": "Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent"
       }
      }
     },
     "localname": "AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.",
        "label": "Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"
       }
      }
     },
     "localname": "AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hormone Therapy Drug Candidate Patents Member.",
        "label": "Approved Hormone Therapy Drug Candidate Patents [Member]"
       }
      }
     },
     "localname": "ApprovedHormoneTherapyDrugCandidatePatentsMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_BijuvaAndAnnoveraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIJUVA and ANNOVERA",
        "label": "BIJUVA and ANNOVERA [Member]"
       }
      }
     },
     "localname": "BijuvaAndAnnoveraMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_BijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIJUVA [Member]",
        "label": "BIJUVA [Member]"
       }
      }
     },
     "localname": "BijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CapitalLeaseObligationsTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total term (in months) of the company's outstanding lease obligation.",
        "label": "Non-cancelable operating lease term"
       }
      }
     },
     "localname": "CapitalLeaseObligationsTerm",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_CatalentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Catalent",
        "label": "Catalent [Member]"
       }
      }
     },
     "localname": "CatalentMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative",
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The member represent council license agreement.",
        "label": "Council License Agreement [Member]"
       }
      }
     },
     "localname": "CouncilLicenseAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementStep1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Council License Agreement Step 1",
        "label": "Council License Agreement Step 1"
       }
      }
     },
     "localname": "CouncilLicenseAgreementStep1Member",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementStep2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Council License Agreement Step 2",
        "label": "Council License Agreement Step 2"
       }
      }
     },
     "localname": "CouncilLicenseAgreementStep2Member",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementStep3Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Council License Agreement Step 3",
        "label": "Council License Agreement Step 3"
       }
      }
     },
     "localname": "CouncilLicenseAgreementStep3Member",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationAmerisourceBergenRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Custome rConcentration AmerisourceBergen Risk Member",
        "label": "AmerisourceBergen - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationAmerisourceBergenRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationCardinalHealthRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer Concentration Cardinal Health Risk Member",
        "label": "Cardinal Health - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationCardinalHealthRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationMcKessonCorporationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "McKesson Corporation - Major Customer",
        "label": "McKesson Corporation - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationMcKessonCorporationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationPIServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "PI Services - Major Customer",
        "label": "PI Services - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationPIServicesMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationPillPackRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Major customers in concentration of sales.",
        "label": "PillPack - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationPillPackRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DebtTrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portions of the Credit and Security Agreement to draw funds.",
        "label": "Debt Tranche [Axis]"
       }
      }
     },
     "localname": "DebtTrancheAxis",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "txmd_DebtTrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "DebtTrancheDomain"
       }
      }
     },
     "localname": "DebtTrancheDomain",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticPatentsBijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Patents Bijuva",
        "label": "Domestic Patents BIJUVA"
       }
      }
     },
     "localname": "DomesticPatentsBijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticPatentsEstradiolAndProgesteroneCandidatesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Patents Estradiol and Progesterone Candidates",
        "label": "Domestic Patents Estradiol and Progesterone Candidates"
       }
      }
     },
     "localname": "DomesticPatentsEstradiolAndProgesteroneCandidatesMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticPatentsProgesteroneFormulationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Patents Progesterone Formulations",
        "label": "Domestic Patents Progesterone Formulations"
       }
      }
     },
     "localname": "DomesticPatentsProgesteroneFormulationsMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSDesignPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Design Patents IMVEXXY",
        "label": "Domestic US Design Patents IMVEXXY"
       }
      }
     },
     "localname": "DomesticUSDesignPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Patents IMVEXXY",
        "label": "Domestic US Patents IMVEXXY"
       }
      }
     },
     "localname": "DomesticUSPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Patents",
        "label": "Domestic US Patents"
       }
      }
     },
     "localname": "DomesticUSPatentsMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSUtilityPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Utility Patents IMVEXXY",
        "label": "Domestic US Utility Patents IMVEXXY"
       }
      }
     },
     "localname": "DomesticUSUtilityPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentOperaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Utility Patent Opera",
        "label": "Domestic Utility Patent Opera"
       }
      }
     },
     "localname": "DomesticUtilityPatentOperaMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentTopicalCreamCandidatesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The member represent domestic utility patent topical cream candidates.",
        "label": "Domestic Utility Patent Topical Cream Candidates [Member]"
       }
      }
     },
     "localname": "DomesticUtilityPatentTopicalCreamCandidatesMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentTransdermalPatchMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Utility Patent Transdermal Patch",
        "label": "Domestic Utility Patent Transdermal Patch"
       }
      }
     },
     "localname": "DomesticUtilityPatentTransdermalPatchMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentTx009HRMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Utility Patent TX009HR",
        "label": "Domestic Utility Patent TX009HR"
       }
      }
     },
     "localname": "DomesticUtilityPatentTx009HRMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FacilityFeePaidPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.",
        "label": "Facility fee paid (percent)"
       }
      }
     },
     "localname": "FacilityFeePaidPercent",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_FinancingAgreementAmendment6Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 6",
        "label": "Financing Agreement Amendment No. 6 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment6Member",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment6Period1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 6 - Through December 31, 2020",
        "label": "Financing Agreement Amendment No. 6 - Through December 31, 2020 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment6Period1Member",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment6Period2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 6 - After December 31, 2020",
        "label": "Financing Agreement Amendment No. 6 - After December 31, 2020 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment6Period2Member",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents member of financing agreement.",
        "label": "Financing Agreement [Member]"
       }
      }
     },
     "localname": "FinancingAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignDesignPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Design Patents IMVEXXY",
        "label": "Foreign Design Patents IMVEXXY"
       }
      }
     },
     "localname": "ForeignDesignPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsBijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Patents BIJUVA",
        "label": "Foreign Patents BIJUVA"
       }
      }
     },
     "localname": "ForeignPatentsBijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Patents IMVEXXY",
        "label": "Foreign Patents IMVEXXY"
       }
      }
     },
     "localname": "ForeignPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Patents Member",
        "label": "Foreign Patents Member"
       }
      }
     },
     "localname": "ForeignPatentsMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsProgesteroneFormulationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Patents Progesterone Formulations",
        "label": "Foreign Patents Progesterone Formulations"
       }
      }
     },
     "localname": "ForeignPatentsProgesteroneFormulationsMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignUtilityPatentTransdermalPatchMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Utility Patent Transdermal Patch",
        "label": "Foreign Utility Patent Transdermal Patch"
       }
      }
     },
     "localname": "ForeignUtilityPatentTransdermalPatchMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignUtilityPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Utility Patents IMVEXXY",
        "label": "Foreign Utility Patents IMVEXXY"
       }
      }
     },
     "localname": "ForeignUtilityPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FourCustomersConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Four Customers Concentration Risk",
        "label": "Four Customers Concentration Risk"
       }
      }
     },
     "localname": "FourCustomersConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_HormoneTherapyDrugCandidatePatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hormone Therapy Drug Candidate Patents Member.",
        "label": "Hormone Therapy Drug Candidate Patents - (Pending) [Member]"
       }
      }
     },
     "localname": "HormoneTherapyDrugCandidatePatentsMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ImvexxyBijuvaAndAnnoveraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IMVEXXY, BIJUVA and ANNOVERA",
        "label": "IMVEXXY, BIJUVA and ANNOVERA [Member]"
       }
      }
     },
     "localname": "ImvexxyBijuvaAndAnnoveraMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about ImvexxyTm.",
        "label": "Imvexxy [Member]"
       }
      }
     },
     "localname": "ImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_IncreaseDecreaseInSecurityDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount represent increase decrease in security deposit.",
        "label": "Security deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInSecurityDeposit",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_KnightLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Knight License Agreement",
        "label": "Knight License Agreement [Member]"
       }
      }
     },
     "localname": "KnightLicenseAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_LenderWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lender Warrants",
        "label": "Lender Warrants [Member]"
       }
      }
     },
     "localname": "LenderWarrantsMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options to extend lease.",
        "label": "Lessee operating lease existence of option to extend number"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtendNumber",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future rented area to be occupied for administrative office space as defined in lease.",
        "label": "Lease not yet commenced (area)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedArea",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_LiborFloorRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents libor floor rate.",
        "label": "LIBOR floor rate"
       }
      }
     },
     "localname": "LiborFloorRate",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_LicenseAgreementWithKnightPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for license agreement with knight.",
        "label": "License Agreement with Knight"
       }
      }
     },
     "localname": "LicenseAgreementWithKnightPolicyTextBlock",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement With Population Council",
        "label": "License Agreement with the Population Council"
       }
      }
     },
     "localname": "LicenseAgreementWithPopulationCouncilPolicyTextBlock",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_LicenseRights": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of license rights.",
        "label": "License rights, net"
       }
      }
     },
     "localname": "LicenseRights",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of an undrawn tranche under a financing agreement that is no longer available.",
        "label": "Line Of Credit Facility Undrawn Tranche No Longer Available"
       }
      }
     },
     "localname": "LineOfCreditFacilityUndrawnTrancheNoLongerAvailable",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_LongTermIncentiveCompensationPlan2009Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long Term Incentive Compensation Plan 2009 Member.",
        "label": "2009 Long Term Incentive Compensation Plan [Member]"
       }
      }
     },
     "localname": "LongTermIncentiveCompensationPlan2009Member",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.",
        "label": "Maximum costs and expenses for post approval"
       }
      }
     },
     "localname": "MaximumCostsAndExpensesForPostApprovalStudyToBePaid",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MidCapAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents member of Mid Cap agreement.",
        "label": "Credit Agreement [Member]"
       }
      }
     },
     "localname": "MidCapAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_MilestonePaymentReceivedUponRegulatoryApproval": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of milestone payment received upon regulatory approval.",
        "label": "Milestone payment received upon regulatory approval"
       }
      }
     },
     "localname": "MilestonePaymentReceivedUponRegulatoryApproval",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MilestonePaymentUponFDAApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of milestone payments upon FDA approval.",
        "label": "Milestone payment upon FDA Approval"
       }
      }
     },
     "localname": "MilestonePaymentUponFDAApproval",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of milestone payments payable after release of first commercial batch.",
        "label": "Milestone payments (payment after release of first commercial batch)"
       }
      }
     },
     "localname": "MilestonePaymentsAfterReleaseOfFirstCommercialBatch",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone payments due upon specified levels of cumulative net sales for under agreement.",
        "label": "Milestone payments upon specified levels of cumulative net sales"
       }
      }
     },
     "localname": "MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MinimumCashBalanceRequirementUnderCreditAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.",
        "label": "Minimum cash balance required under credit agreement",
        "verboseLabel": "Minimum cash balance requirement under credit agreement"
       }
      }
     },
     "localname": "MinimumCashBalanceRequirementUnderCreditAgreement",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum cash balance the Borrower must maintain under the credit and secuirty agreement before adjustment.",
        "label": "Minimum cash balance requirement under credit agreement before adjustment"
       }
      }
     },
     "localname": "MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MultipleTrademarksMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Multiple Trademarks",
        "label": "Multiple Trademarks [Member]"
       }
      }
     },
     "localname": "MultipleTrademarksMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_NetRentableAreaLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net rentable area as defined in lease.",
        "label": "Net rentable area"
       }
      }
     },
     "localname": "NetRentableAreaLease",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_NetSalesAmountPerStepbasedRoyalty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net sales amount as defined in license agreement for step-based royalty payments.",
        "label": "Net sales amount per step-based royalty"
       }
      }
     },
     "localname": "NetSalesAmountPerStepbasedRoyalty",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_NewSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The member represent new shares.",
        "label": "New Shares [Member]"
       }
      }
     },
     "localname": "NewSharesMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_NonQualified2012StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non Qualified 2012 Stock Incentive Plan Member.",
        "label": "2012 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "NonQualified2012StockIncentivePlanMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_NoncashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to operating lease costs.",
        "label": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "NoncashOperatingLeaseExpense",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock issued attributable to stock options exercised in cashless transaction.",
        "label": "Number of common stock issued during period for stock options exercised in cashless exercise"
       }
      }
     },
     "localname": "NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfCustomers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of customers.",
        "label": "Number of customers - revenue"
       }
      }
     },
     "localname": "NumberOfCustomers",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfInstallmentPayments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of principal installment payments under credit and security agreement.",
        "label": "Number of quarterly principal installment payments"
       }
      }
     },
     "localname": "NumberOfInstallmentPayments",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfIssuedPatents": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of issued patents.",
        "label": "Number of issued patents"
       }
      }
     },
     "localname": "NumberOfIssuedPatents",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock issued attributable to warrants exercised in cashless transaction.",
        "label": "Number of stock issued in cashless exercise of warrants"
       }
      }
     },
     "localname": "NumberOfStockIssuedInCashlessExerciseOfWarrants",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfStockOptionsExercisedInCashlessExercise": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options exercised in the cashless transaction.",
        "label": "Number of stock options exercised in cashless exercise"
       }
      }
     },
     "localname": "NumberOfStockOptionsExercisedInCashlessExercise",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of subsidiaires for period reported.",
        "label": "Number of subsidiaries"
       }
      }
     },
     "localname": "NumberOfSubsidiaries",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfTranchesUnderTermLoanFacility": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of seperate tranches under terms of the Credit Agreement.",
        "label": "Number of tranches under term loan facility"
       }
      }
     },
     "localname": "NumberOfTranchesUnderTermLoanFacility",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_OutsideConsultant2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A person who provides consutling services to the Company.",
        "label": "Outside Consultants Warrants [Member]"
       }
      }
     },
     "localname": "OutsideConsultant2Member",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PaycheckProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The member represent paycheck protection program loan.",
        "label": "Paycheck Protection Program Loan [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PerformanceStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The member represent performance stock units.",
        "label": "Performance Stock Units [Member]"
       }
      }
     },
     "localname": "PerformanceStockUnitsMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Plan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New 2019 Plan.",
        "label": "Plan 2019 [Member]"
       }
      }
     },
     "localname": "Plan2019Member",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PrepaidManufacturing": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid manufacturing costs.",
        "label": "Prepaid manufacturing"
       }
      }
     },
     "localname": "PrepaidManufacturing",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_PrepaidSalesAndMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "It refers to the amount of prepaid sales and marketing costs incurred.",
        "label": "Prepaid sales and marketing costs"
       }
      }
     },
     "localname": "PrepaidSalesAndMarketingCostsCurrent",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_PrepaymentFeeFifthYearFundingPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee expressed as a percentage of the funding being repaid for fifth year following the initial funding date of the applicable borrowing.",
        "label": "Prepayment fee fifth year funding (percent)"
       }
      }
     },
     "localname": "PrepaymentFeeFifthYearFundingPercent",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentFeeForFirstTwoYearsFundingPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee expressed as a percentage of the funding being repaid for first two years following the initial funding date of the applicable borrowing.",
        "label": "Prepayment fee for first two years funding (percent)"
       }
      }
     },
     "localname": "PrepaymentFeeForFirstTwoYearsFundingPercent",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentFeeFourthYearFundingPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee expressed as a percentage of the funding being repaid for fourth year following the initial funding date of the applicable borrowing.",
        "label": "Prepayment fee fourth year funding (percent)"
       }
      }
     },
     "localname": "PrepaymentFeeFourthYearFundingPercent",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee, expressed as a percentage of the tranche funding being repaid.",
        "label": "Prepayment fee percentage"
       }
      }
     },
     "localname": "PrepaymentFeePercentage",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentFeeThirdYearFundingPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee expressed as a percentage of the funding being repaid for third year following the initial funding date of the applicable borrowing.",
        "label": "Prepayment fee third year funding (percent)"
       }
      }
     },
     "localname": "PrepaymentFeeThirdYearFundingPercent",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrescriptionVitaminsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about Prescription Vitamins.",
        "label": "Prescription Vitamins [Member]"
       }
      }
     },
     "localname": "PrescriptionVitaminsMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PrimeRateFloor": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prime rate floor.",
        "label": "Prime rate floor"
       }
      }
     },
     "localname": "PrimeRateFloor",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_RentedAreaLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rented area as defined in lease.",
        "label": "Rented area lease"
       }
      }
     },
     "localname": "RentedAreaLease",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_RepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The repayment fee, expressed as a percentage of the tranche funding being repaid.",
        "label": "Repayment fee percentage"
       }
      }
     },
     "localname": "RepaymentFeePercentage",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_ReturnPeriodOfUnsalablePrescriptionProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period the company accepts returns of unsalable prescription products from customers following product expiration.",
        "label": "Return period of unsalable prescription products"
       }
      }
     },
     "localname": "ReturnPeriodOfUnsalablePrescriptionProducts",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_RoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percent of the net sales to be paid as royalty per license agreement.",
        "label": "Royalty (percent)"
       }
      }
     },
     "localname": "RoyaltyPercent",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_SalesDiscountsReturnsAndAllowancesGoods1": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.",
        "label": "Allowance for coupons and returns"
       }
      }
     },
     "localname": "SalesDiscountsReturnsAndAllowancesGoods1",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of supplementary lease and cash flow information.",
        "label": "Supplemental lease information"
       }
      }
     },
     "localname": "ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,",
        "label": "Weighted average remaining contractual life in years, unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exercise price as of the balance sheet date at which grantees can acquire the shares for options outstanding.",
        "label": "Range - exercise price of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire unvested shares reserved for issuance.",
        "label": "Weighted average exercise price, unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.",
        "label": "Aggregate intrinsic value, unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ShelfLifeOfPrescriptionProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period shelf life of prescription products from date of manufacture.",
        "label": "Shelf life of prescription products following product expiration"
       }
      }
     },
     "localname": "ShelfLifeOfPrescriptionProducts",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_SignificantSupplyCommitmentPercentagePayable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percent of the difference between the total amount we would have paid to supplier if the minimum requirement had been fulfilled and the sum of all purchases of our products from supplier during the contract year, required to be paid to supplier.",
        "label": "Significant supply commitment percentage payable"
       }
      }
     },
     "localname": "SignificantSupplyCommitmentPercentagePayable",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount represents specified level one of cumulative net sales for milestone payments.",
        "label": "Specified level one of cumulative net sales for milestone payments"
       }
      }
     },
     "localname": "SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount represents specified level three of cumulative net sales for milestone payments.",
        "label": "Specified level three of cumulative net sales for milestone payments"
       }
      }
     },
     "localname": "SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount represents specified level two of cumulative net sales for milestone payments.",
        "label": "Specified level two of cumulative net sales for milestone payments"
       }
      }
     },
     "localname": "SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_StockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The member represent stock options.",
        "label": "Stock Options [Member]"
       }
      }
     },
     "localname": "StockOptionsMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SupplierOneConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The member represent supplier one concentration risk.",
        "label": "Supplier One Concentration Risk [Member]"
       }
      }
     },
     "localname": "SupplierOneConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SupplierThreeConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplier Three Concentration Risk Member",
        "label": "Supplier 3"
       }
      }
     },
     "localname": "SupplierThreeConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SupplierTwoConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplier Two Concentration Risk Member",
        "label": "Supplier 2"
       }
      }
     },
     "localname": "SupplierTwoConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ThreeCustomersConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Three Customers Concentration Risk",
        "label": "Three Customers Concentration Risk"
       }
      }
     },
     "localname": "ThreeCustomersConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tranche Three as defined in financing agreement.",
        "label": "Tranche Three [Member]"
       }
      }
     },
     "localname": "TrancheThreeMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tranche Two as defined in financing agreement.",
        "label": "Tranche Two [Member]"
       }
      }
     },
     "localname": "TrancheTwoMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TwoTranchesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two Tranches",
        "label": "Two Tranches [Member]"
       }
      }
     },
     "localname": "TwoTranchesMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_VitaminsAndImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vitamins and IMVEXXY",
        "label": "Vitamins and IMVEXXY [Member]"
       }
      }
     },
     "localname": "VitaminsAndImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_WarrantGrantedInRelationToFinancingAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of a warrant granted in relation to financing agreement.",
        "label": "Warrant Granted In Relation To Financing Agreement",
        "verboseLabel": "Warrant granted in relation to Financing Agreement"
       }
      }
     },
     "localname": "WarrantGrantedInRelationToFinancingAgreement",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item provides the weighted-average contractual remaining life of warrants.",
        "label": "Weighted-average contractual remaining life"
       }
      }
     },
     "localname": "WarrantsAndRightsWeightedAverageContractualRemainingLife",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_WarrantsCashlessExerciseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants - Cashless Exercise",
        "label": "Warrants - Cashless Exercise [Member]"
       }
      }
     },
     "localname": "WarrantsCashlessExerciseMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants Member",
        "label": "Warrants Member"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which warrant holders can acquire the shares reserved for issuance.",
        "label": "Weighted average exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20200930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "NOTE 8\u2013 OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r41",
      "r95",
      "r336",
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Amounts due to related party"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r25",
      "r149",
      "r150"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net of allowance for doubtful accounts of $857,176 and $904,040, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued sales and marketing costs"
       }
      }
     },
     "localname": "AccruedMarketingCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r44"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued legal and accounting expense"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r44"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued payroll, bonuses and commission costs"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedVacationCurrent": {
     "auth_ref": [
      "r10",
      "r44",
      "r224"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensated absences"
       }
      }
     },
     "localname": "AccruedVacationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r39",
      "r184"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r265",
      "r266",
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r230",
      "r232",
      "r270",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r195",
      "r203",
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Warrant granted in relation to Financing Agreement"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r151",
      "r156",
      "r157",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r66",
      "r82",
      "r317"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of deferred financing fees"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r82",
      "r168",
      "r176"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r90",
      "r129",
      "r138",
      "r144",
      "r154",
      "r289",
      "r291",
      "r305",
      "r366",
      "r377"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r57",
      "r90",
      "r154",
      "r289",
      "r291",
      "r305"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r233",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails",
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails",
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r37",
      "r394",
      "r395"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r78",
      "r84",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, end of period",
        "periodStartLabel": "Cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r78",
      "r306"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Decrease in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental disclosure of noncash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r209",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Warrants exercise price",
        "verboseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Number of warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r209",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r187",
      "r189",
      "r192",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r98",
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r24",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock - par value $0.001; 600,000,000 and 350,000,000\u00a0\u00a0shares authorized: 272,812,271 and 271,177,076 issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r121",
      "r122",
      "r148",
      "r302",
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r121",
      "r122",
      "r148",
      "r302",
      "r303",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r121",
      "r122",
      "r148",
      "r302",
      "r303",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "NOTE 14 - BUSINESS CONCENTRATIONS"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r121",
      "r122",
      "r148",
      "r302",
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r119",
      "r121",
      "r122",
      "r123",
      "r302",
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r121",
      "r122",
      "r148",
      "r302",
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r68",
      "r350"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r120",
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r367",
      "r368",
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r21",
      "r196",
      "r368",
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.",
        "label": "Debt Instrument, Description of Variable Rate Basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r316",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r46",
      "r198",
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r47",
      "r93",
      "r204",
      "r205",
      "r206",
      "r207",
      "r315",
      "r316",
      "r318",
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r197",
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Debt discount and financing fees"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "auth_ref": [
      "r56",
      "r317"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt financing fees on undrawn tranches (Note 9)"
       }
      }
     },
     "localname": "DeferredFinanceCostsCurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r82",
      "r182"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation of fixed assets",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r82",
      "r182"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "The following table provides information about disaggregated revenue by product mix"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Loss per share, basic and diluted:",
        "verboseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "NOTE 10 \u2013 NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note10NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r102",
      "r107",
      "r109",
      "r117",
      "r155",
      "r203",
      "r208",
      "r265",
      "r266",
      "r267",
      "r278",
      "r279",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r298",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Assets or liabilities valued at fair value"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r87",
      "r300",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Finite-Lived Intangible Assets, Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "2020 (3 months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2020 and December 31, 2019:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r169",
      "r172",
      "r175",
      "r179",
      "r351",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r175",
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r169",
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r175",
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "License rights acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r82",
      "r200",
      "r201"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Loss on extinguishment of debt",
        "negatedLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "NOTE 7 \u2013 INTANGIBLE ASSETS, NET"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r67",
      "r90",
      "r129",
      "r137",
      "r140",
      "r143",
      "r145",
      "r154",
      "r305"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r82",
      "r180"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Write off of patent and trademark costs",
        "verboseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r62",
      "r129",
      "r137",
      "r140",
      "r143",
      "r145",
      "r365",
      "r370",
      "r374",
      "r382"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r280",
      "r282",
      "r284",
      "r285",
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "NOTE 12 \u2013 INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note12IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r108",
      "r109",
      "r128",
      "r274",
      "r281",
      "r283",
      "r383"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r171",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r171",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IndefiniteLivedTrademarks": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Trademarks"
       }
      }
     },
     "localname": "IndefiniteLivedTrademarks",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r167",
      "r173"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r60",
      "r127",
      "r314",
      "r317",
      "r373"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseBorrowings": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate amount of interest expense on all borrowings.",
        "label": "Interest Expense, Borrowings"
       }
      }
     },
     "localname": "InterestExpenseBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r71",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r77",
      "r79",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "NOTE 4 \u2013 INVENTORY, NET"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note4InventoryNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r54"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, net",
        "totalLabel": "TOTAL INVENTORY, NET"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r55",
      "r87",
      "r116",
      "r160",
      "r162",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory Obsolescence Reserve"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSupplies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r54",
      "r96",
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory valuation reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryNetConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory obsolesence reserve"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2020 to the operating lease liabilities recorded on the balance sheet:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "verboseLabel": "2020 (3 months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43",
      "r90",
      "r139",
      "r154",
      "r290",
      "r291",
      "r292",
      "r305"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r30",
      "r90",
      "r154",
      "r305",
      "r369",
      "r379"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' (deficit) equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r45",
      "r90",
      "r154",
      "r290",
      "r291",
      "r292",
      "r305"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r21",
      "r22",
      "r90",
      "r154",
      "r290",
      "r291",
      "r292",
      "r305"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term debt",
        "verboseLabel": "TOTAL LONG-TERM DEBT"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-Term Liabilities:"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "NOTE 9 \u2013 DEBT"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r47",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r118",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "NOTE 1 \u2013 THE COMPANY"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note1Company"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r58",
      "r59",
      "r63",
      "r83",
      "r90",
      "r101",
      "r103",
      "r104",
      "r105",
      "r106",
      "r108",
      "r109",
      "r110",
      "r129",
      "r137",
      "r140",
      "r143",
      "r145",
      "r154",
      "r305",
      "r371",
      "r381"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other (expense) income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r129",
      "r137",
      "r140",
      "r143",
      "r145"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Lease impairment"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Present value of lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Short-term operating lease liability (included in Other current liabilities)",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails",
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liability",
        "verboseLabel": "Long-term operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r323",
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Cash paid for amounts included in the measurement of lease liabilities for operating lease"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use assets",
        "verboseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r329",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r328",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "NOTE 2 \u2013 BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r44"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Assets:"
       }
      }
     },
     "localname": "OtherAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Total other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "NOTE 5 \u2013 OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note5OtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other current liabilities consist of the following:"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r44"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other current liabilities",
        "totalLabel": "TOTAL OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Miscellaneous income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r7",
      "r166"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other prepaid costs"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payment of deferred financing fees"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Patent costs"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r233",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock - par value $0.001; 10,000,000 shares authorized; \u00a0no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r35",
      "r36"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Other current assets",
        "totalLabel": "TOTAL OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r5",
      "r7",
      "r165",
      "r166"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r74",
      "r94"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from the Financing Agreement"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r73",
      "r264"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of options and warrants"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r39",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r186",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "NOTE 6 \u2013 FIXED ASSETS, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note6FixedAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r38",
      "r183"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "TOTAL FIXED ASSETS"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r185",
      "r380"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Fixed assets, net",
        "totalLabel": "TOTAL FIXED ASSETS, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Fixed assets, net consist of the following:"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note6FixedAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r64",
      "r158"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "(Recovery of) provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r31",
      "r87",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Trade Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pertinent information about recorded unconditional purchase arrangements to acquire goods or services, by category of goods or services.",
        "label": "Recorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of recorded unconditional purchase obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Minimum purchase commitment, 2024"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of recorded unconditional purchase obligation to be paid in remainder of current fiscal year.",
        "label": "Minimum purchase commitment, 2020"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of recorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Minimum purchase commitment, 2022"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of recorded unconditional purchase obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Minimum purchase commitment, 2023"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of recorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Minimum purchase commitment, 2021"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationDueWithinOneYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Recorded Unconditional Purchase Obligation [Line Items]"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationTable": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes each recorded unconditional purchase obligation arrangement to purchase goods and services that extend over multiple periods, any assets pledged to secure payment, and the fixed or determinable amount of payments due in each of the next five years and thereafter.",
        "label": "Recorded Unconditional Purchase Obligation [Table]"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r226",
      "r334",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Amount billed"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r226",
      "r334",
      "r337",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r332",
      "r333",
      "r335",
      "r338",
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "NOTE 13 \u2013 RELATED PARTIES"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r75",
      "r94"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedLabel": "Repayment of the Credit Agreement"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r273",
      "r399"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r87",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockExpense": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.",
        "label": "Restricted Stock or Unit Expense"
       }
      }
     },
     "localname": "RestrictedStockExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails",
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r27",
      "r208",
      "r268",
      "r378",
      "r391",
      "r392"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r102",
      "r107",
      "r109",
      "r155",
      "r265",
      "r266",
      "r267",
      "r278",
      "r279",
      "r388",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r125",
      "r126",
      "r136",
      "r141",
      "r142",
      "r146",
      "r147",
      "r148",
      "r219",
      "r220",
      "r350"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Total revenue, net",
        "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Net revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r61",
      "r90",
      "r125",
      "r126",
      "r136",
      "r141",
      "r142",
      "r146",
      "r147",
      "r148",
      "r154",
      "r305",
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r327",
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-use assets obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r121",
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14-BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of calculation of diluted net loss per share allocable to common stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note10NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "As of September 30, 2020 and December 31, 2019, the carrying value of our debt consisted of the following:"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r169",
      "r174",
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302020AndDecember312019Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r13",
      "r32",
      "r33",
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, net consists of the following:"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note4InventoryNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Other current assets consist of the following:"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r39",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r92",
      "r336",
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r246",
      "r251",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Schedule of restricted stock units and performance stock units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r233",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails",
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails",
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r238",
      "r251",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "A summary of option activity under the 2009, 2012 and 2019 Plans and related information during the nine months ended September 30, 2020 is as follows"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "The ranges of assumptions used in the Black-Scholes Model during the nine months ended September 30, 2020 and 2019 are set forth in the table below."
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Sales, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of shares, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Weighted average grant date fair value, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Number of shares, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Weighted average grant date fair value, granted",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of shares, ending",
        "periodStartLabel": "Number of shares, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average grant date fair value, ending",
        "periodStartLabel": "Weighted average grant date fair values, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of shares, vested/released"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Weighted average grant date fair value, vested/released"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails",
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails",
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Warrants exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r239",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Aggregate intrinsic value, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of shares under options, expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of shares under options, cancelled forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of shares under options, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, ending",
        "periodStartLabel": "Aggregate intrinsic value, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r240",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares under options, ending",
        "periodStartLabel": "Number of shares under options, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, ending",
        "periodStartLabel": "Weighted average exercise price, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Number of shares under options, vested and exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted average exercise price, vested and exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r231",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails",
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails",
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted average exercise price, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Weighted average exercise price, expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted average exercise price, cancelled forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r87",
      "r233",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r257",
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringNineMonthsEndedSeptember302020And2019AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate intrinsic value, vested and exercisable ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life, vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Number of shares under options, unvested ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Common stock, shares, issued (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r50",
      "r98",
      "r99",
      "r100",
      "r102",
      "r107",
      "r109",
      "r117",
      "r155",
      "r203",
      "r208",
      "r265",
      "r266",
      "r267",
      "r278",
      "r279",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r117",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "auth_ref": [
      "r229",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares issued for exercise of options and warrants, net"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r23",
      "r24",
      "r203",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Issuance of shares from release of restricted stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r23",
      "r24",
      "r203",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares issued for exercise of options and warrants, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r24",
      "r203",
      "r208",
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of shares under options, exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOptionActivityUnder20092012And2019PlansAndRelatedInformationDuringNineMonthsEndedSeptember302020IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r203",
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Issuance of shares from release of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r50",
      "r203",
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r28",
      "r29",
      "r90",
      "r153",
      "r154",
      "r305"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders' (deficit) equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' (Deficit) Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r208",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r313",
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r313",
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r313",
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r313",
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r340",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "NOTE 16 \u2013 SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r190",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the unconditional purchase arrangement."
       }
      }
     },
     "localname": "UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r325",
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Fair value of warrants",
        "verboseLabel": "Warrants and Rights Outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted average number of common shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.",
        "label": "Write off of deferred financing fees"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5144-111524"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25383-109308"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121321822&loc=d3e3913-113898"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121323062&loc=d3e15009-113911"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121593497&loc=SL77918431-209957"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.7,8)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r401": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r402": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r403": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r404": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r405": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r406": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r407": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r408": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r409": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r411": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r412": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r413": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r414": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r415": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r416": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r417": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r418": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4),(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0001387131-20-009695-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001387131-20-009695-xbrl.zip
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M&.V]VN?(PM)8@A$35!/-\Z2(]DJPE"J5DXT'<K@&0JSG\!HXX)1..LD*=(W
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MYVJ,,1AY!7]*[T9%GH>&WSZ# H4.=O*N!8JW452<& ]:"44RXR24A%>JU'"
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M<:UD'& B4<RN,+16J2B\1",#-H-SNL@O!S^T:(.Y'EH!S<G;"L0EBF!RJ"_
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M;)MS>,\RVGMX&!#NB&HG\!Q\*[:<=#UT:TQ;WX@MRM[]T+WG[:[LE0R8KS\
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M@@O266]1L[30ZVC\HK3IWGD>W,-(,;9"D-HT$_74!;NBL L&*QBA!E&.4+?
MG93DGF U@>_E&GM&9:_!%%F-%KW+@2GIG::V4A+3[40#@YC^2*L[1;F9]^Z;
M_0WJ>_'.*K]U!CS9"@.V;-C/Q_1ZG'"E?D\SU:PW_)8870L,+PLR"%<"-&FZ
M$J.R_,1%@V.\"Q8QY03#:\ L:N5F>F)9## SN#FVT$67L[F)G76+1-NIS9?K
MJM%0HLZ[* *JM4S3,"BKHK3%3&K]JH:1*<1Z]ZZR48;MH#WS(_V<-X',??X
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MT2L#D2E*5IW,E&[EX6:9TN<FU=39-%W=:SQ#SBLR[&ERU=Y:C'\CV\_@H:G
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M$C$TY\JGY;R]N;6-%V_2F-KD"XTAFL"/04"Z&-[A58=_!45/K#OD>)S$ /4
MS@D9CH>RK\"_D:$@%^^[K],=8HY^<G^\^6I>6JC3@, !K*.S4H*>N)Z-J#V
M:WHV+I^!^^OHF$QR";\TF?!FL+)I!W=/+%]>GL_-8=$=#'#5 H4/@673#"\A
MXN+5ZDON!4E81Q#4H85:Z^N^N&7U9X57H4K!'FX8!/[1Y:[8V-K<1C:L]Y_
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M)D!/ QZRFPJ*Q(A.1 WI3F/M/&KIWJ@0'N]V!ACYQ(@4 0:$PX5=K\QX_C(
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MK(@80)JP?#[0(0,N3,-@09XH5F2GT.I&%)H8,\4Q'821B\P"EQ(\#VU*27T
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M?2,^1@:H$ %J7MW=#7P+5IZ,=#!=$UAR]V/R8M0)#_(J<*L!($W3AU0G"-J
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MUV@L4(1# P"?=(HFY!9,!\=&'@4[@OK>$%P5- L*>E(19&1.X8.HE[Z&\HP
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ME0?>6\0ZIN.C#6*9!6*!EK9!>4M[!.#_+NTT'_"J;"5M\OSJN-B& JV.KU?
M..&&"D1(0T^&=-7[!8S:@V4#39H<#9*^'[5*X=I@ &8<6%P6[8,C "ZH0)-R
MK/K2WW !@!$;7$;]-[8NP1R#)J:W2)\[TB/&_FUT(X+K^1R";J&U:*K!HA&%
M 4Z8%F[#+'@JDOI6O1H;Z,N7!@<92H. Q<O%62:/>7.!6X]_FJ'DC<2(7CC
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MC@LP)'I2'<BY44H_T:AJ3V;B'K\M$'^,ZUS\!TS3SE%).=/_@U8 IFHXW//
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M,::Q345-8!9F#";)!G(U59&XM.:X4'$-F:[O<#>^T"HC*O?, EK= 9P3T"E
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M%$SC5ROSYPK+]]5V_9M4[A>]RQ;\\?]02P,$%     @ TTII43\N:O8/%P
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M0;_8; "JQ]9<1,20.F!%0$4QM6R,NJ"L!+D%%>YJPS-2DV>8LT@NO(!8#@U
MTZE%0U!C*4R>T^*':Y@B,<'D;@Q*/B=AD1#,2D(LZ_AL?[P<YG\&(\0.YGIG
MK:R$_;IHGT%0R\7CPUA:$UH7T"]01 96<1AJ7ERC@$GC92M+C*\HF01>6;M4
M+G$Q2!DX\F%G+#4J(*/ ZEXPSA@5R:HBG[OW L>^!PU8(.R'Q3"5)SD9!8^[
MEA.!EV5YD1L&J-2D^:.H]@$(25\@-1(4_86 #1DH4Q!&05U+^QH!.*4!5[\1
M$#OPQ>!5#Q6D/>(N%]*XYG-ZG!M7.B(MJE\WH\#S4:C@!KI!^O[?8>EL;U3
M$3.O=4.PMJ*8^CXI+GWP7?I (=1+'GK+%KHP\*\=62'0 ?0X@.TPE')P?)"W
M1&0-,[CS >$A<A@@>H=.@4T&@3<BMH<.DO D,/=>Y*"7"'C_$?% S>;UI;L
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M<V6F"=2V&'(_SC&'0Q[8\@9,Z]#(M888:8&K/J/K9>+#S>3VGEA:J40PNG-
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M"TZKC"(=KH3,I=JBQ'']RB@4XU &'W*(.@"0?I<!HR#:L>0VIR''57"3?N@
M"J((8::/)*8%V@Q+G43H"$-(!J@4A#38,Z"X59%+,32"!6HDJ_0">IAL)9UE
MP:<QPX80O$!_9M?)FN<I:QYELNF=TN>M^3+^)OBRM_?;HLW^?C.+/0;")H6P
M*=!NQFTD!97"IQ@F4 F$PFP:F4)#.U%8X!&G8^YRM< 0/&MN)++6;:VVAG[I
MIK$H5BFY#DD>XZ4%41@ =Z1.'"P+'(E&H9/S"?,A'7"!0O"$!4A0;!+YRM $
MB,P#B GJ1YY\E2?6^^-)9T;=B*J$**@_S'$@3^0SV'29D>\M ^ ]G(FYC%/
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M:_-DFV8/NB$P\,R?.02(9P7_#U!+ P04    " #32FE1WG_ I)<%  !)'
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M1=:CTR1M9+Y-I6BMVF+^(3?<\(L%*_!]:@D6^!C%Q1+$DL)M3#CZEKL"3L.
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MVH?SRP%$11VB!B4:5L.^'K0%R9YF:28#N':C0EQ.SRP$&0 /^!IO7EQ7CVZ
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M\#<7]MLX0=U*Q/;FUB_FII,0R]^(X2X"^;B)]*+*GP!%,T6F9FHP&M##X X
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MU^#7U UZ3D?H)M.E,!U$)M 7CQ%)[NVT!D -=&$YBX'T+,P)9S&Q$5&IDP%
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MSP4F7BR::,(.1PY?KW*^/A&4:+=*6&))]%] %BLA"=*^1DTIEZ2?"R*(>H2
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M3*Y[-E;5A4LJL-,NIT7H,C([HU5JX4\],J J@,M5.^@>QMJ:W25FYQ/"QX+
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M-OY[B2 OUXQ<)S;P'X#B?Q$*_^&H_P-02P,$%     @ TTII46GA$W=\\ $
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MKS+Y5"$X6Y5$4YZKDJ;5]TW[[*[M<'^L8/3957<[&Z)!X_Y;YT<+P97E3#9
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MVV:)5L?XL42,+?II2]WO#.U3M>W',-.3\@.JPT*'8?@"1^<I]M@Q= 3QP=%
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MHUW2:_LRHR=JRKO]]]^[,/K@(ZN>W9\USXCIJ8?&&F+ULT#T!TCL9[&!1Q_
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M^[RYR0YLW+O%8;5]W\7(5#1@;HC,__1^-9YK<DGH1M(AO'%IHP=! 58U1B,
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M*H,N.H[];Z+R,D(-2=@EI-8E<%BU,&''3AC&;1(N(;?5)91$LT]<JOK;/"/
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MFJ;%YYHMNF?Z-2T>SKG9%*,^EI$)5FJ;R4!G*T-CG]3,<V2>.5:MVYEU$4Y
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MTM\^0RYX,&0(GY+M&$!\SCH+^;X0HOHF3LSE,:PP8D'@F4TO6:0)T>H()&T
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MM[\3./30-)[SFQ!JPN*!IBB2IOR/!]D]2ED\\+$H/XU,RVZ5;.D;<.T]^GL
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M)5J3(1Q3T1 [BO25J$%3X8R]IJ-A<HLW?7;O0M^X[!M"WD$N>#!D")^2[1A
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MCV 3&^M9[8)KNKROWQ+U!HP>6]7:%5$LM:J/U98=*Z9O;BE=U'B)7]C8WJ5
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MT('M\M'61FD>&(X5L,^CE+>(=GW'(-Q7Q_<&])1OM=B[1A^+"<!78R+M ?/
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M [;;L7"U*!.]=MBQ'#$/?>$=N3= W?1">)H3%Y?@;VY\/ZE/$A _S,0[OT-
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MG;X/&Z<9[9 !8:=Q.:(^612+JP_CU"9\LDV&F&$BD$SXJP+!/E)?4-Q@Y+A
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M+@\?/4;0B)85SM2X2:SRQ:X-5YS?Z@Z9[W-LR0RXD"0.[UU2Q]8@+'TRP]S
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M(@[4@3_ ]B.,4 TZL@*A+'V/?S ( XE<3*TA@5@]5NZ $B.Q(1&J8PP8P5H
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M6842FH!-OE\6RYUCDN(*A(UBW9?_U^CU/^_I,?:5NPFI/J*/<#C^B(*#U+6
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M;6[,LR7UYK'%#?@X4,#?1#3DDEU78EW&+ZH]&Z%[**E<1^S^HNZ0["07=J?
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M@X*%:^&AP%[?W+TTJ^_)^\BB250-@(5I;V@=P"M%=XM "^P[\%*3)3V&SL*
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MW!N"=UJKD^#B#5GO+W=U)D']Q:,Y+(8+J"KKN>)'8+OUT6-]\(L$A#5)O6-
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M$-!@/"@X5O'0;TY4O</!;4042<MX' R&5LL*LF2I6X47)-+&.^ #N]D\B:A
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ML$_5V@2R1G6QRTG6R4@X^(<5*]5Y^XCH1_2K$Y[%Y[/#QXP[X(J^:C\/&P.
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M2K?WV5I5:=QSX3BOVNI.UZ7N0*N&-9$^HA]_$S1,Q&N_.;0@O.-4$CK^_(-
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MS'B<&S_/+PL?J71ER4#1;QZ='/I[N70J**]N1SV88QBKLJT%0>83_-T4) %
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M=:NG]O$1[O./[':0Y$_HBPJ>PD0^QZ(:67\PY0^F/(D]9-PCVZLG("Q&QU-
M;01/E^L603<@T]K1FZS^^L"@1<)(R0!2>^#%\9%K<$:4$3 T6@DM!0X/("FT
M"W-%NTVX-5.>3/3AB7P@CZ+[^AN8N@A+R(B5VX-1CX]@&:K+J>H,5B!3KGN(
MOX%"@IXQA["6NEUH$ \[1D>7>?PU/#%(%>S)12(O$(+'@,;R@OS*29(RP?8X
M;)(WL1#N#2$"03^Q9T[<-E7GH8(6-H<<("C#1"S=5*4)U#6X>1@EH,C8+E;A
M+99T,H?%8HQSO\Y"=HPR:$5LK%O39%=,<8!;Q2W?.:IG@,4?<CS81L [3RGL
MHS0EIB98MX>=D\@X@$F3R/@0-7Q_JCWO%I9T\ P!',E9]"%"< N7K'&5$P'/
M$G.&JGCF+[AFZ&H+\SW1CS  PZ)9<^S3.E*\^C9_[(O9B3&^%FK]@W<6)"#:
MFV1^10-I_+,VTDLUHKIIJR5]Q3.K)?(J;_->[:+2?V?.A$Y23<[WH Y4WN;3
M7%,H/G:>;UL]6QU(V^I LWI3:E<K5*/4;-=VH1'\^UPE->PJ08R733%9FKHZ
MI6[!D)6I,A(3BB3!!& >L:ZNKJC68-XN\5;2E#EV11%E<W8%YL<*$AB8&9N/
M$>.:TY$1!*-+L&\%2 \[2?$0&/@!\]T!-P9.A301/*87QGW#J$8R&&\BZH/%
M=4 [P$RNUT/:!2@,-#!4YUOFK%\9C#68&VD@+0 [5D'G0*85$@3V&V"XI.L5
M9#<F^QV+PH2,*P9Y"^Y;^(;GB.;,8G(U(!S@HH:BK@NFR"33=_!\O^ ED)7F
MOEZT0R1G;.B<4I6% 5PK9\E9DZ#QY6*9@90PB9S#/J9G<,[QD6]R3F8UT[+L
M8PW@ZOY.X""ZMY4\\&SF_L3K;+#V;2?#7,CC5FK IB^Z=LB2C+@Q#[MZL-5Z
M9XHVW,[R(WBWN^D FRR[U(NU9#Q8;DOH^2:NQ0N]+*]G.OF[BKA'X/F'N,4+
M/)9FBKGEPX>\4\Q #T2\VNA!) J3/$>&GXC8K+"GEV%N@60KQ",I747F&&)_
MV-MT8HQ@T3[B.400(^V7T[L#X(](J3>GB '"(-469I#"S>ID/IB'ST0:61F%
MS2#M?_F KM+V;"8L#2(.1+VN<O-YY_GA[%S:+YMA$F0S+)W-I3=D-(7M&0V3
M(*-IE.N%8JFJ7+]P^^4T3(*<)D,S3&'WG 8L2H?54&MPFC K'#_@ZR^/!V9;
MUB^'@:=1O"%@%X^MSX!#8CFK85RH:GH[M 8W@V"Y"X+H"LH&LNQEW0FXQ8^7
ME6$Z?_54:6@,NX"7^&AD2"6!PPBCU0HTC7*>I5E.L2(DD\EOR$Z*F\&(*3)L
MFHD91E?2?,R-!.95+.X51G9O[UAAE,Y&YQBGR.RR'9..R68/OK=B0VZ'%]A@
M(XGK"HOV%;(>>>+LP-8>#*L4*+!"R]AN(@\#<I05[(X4Y"ZZ'Y^SZK ,ZJ]@
M] =,!Q3P_%#A]W_^Z^2$.A<%B?])-;B^\ L]\VF 5_TG!?Y8G"6)?J1.3JQ4
M6EX<VW3+IO-O\]2M_/E\T2@-,]'K7/TI>![7&9LNOLV?;@:EPN50*,RX;7/^
MP@;3+&PCA;?ANA+K,GY1D%7[DRJI2,)U?U$0$R<7=J? U;",^ZF_K<?@(V>:
MX'_^1E<7?(N5M_G=E!<_6@^C2<<)E8[0"TY(3EA'0-2.WLE)$VZF>8]GW9[Y
ME N3?H2]WKU;. ;L%+,$"S%\B.(&#O,V9Z\>SNMW@YQ2$@_+0^DC2/^Q#HLZ
MP257&JFB9,8CKCDD#ZB;4^H&\4"8]"MT#>#&U"-DD300>Q:Q)PESRH$H]*A+
M RU+-04-J6T0#JOW>NBKV']7PFYP]&D-$%[FS #3A:J Q0@^-?!=H0W4+@+\
M>Z &^OU[7G<>M88W#[TET$.'TQ6"7'3.8[MPSAT?A:]!G',.G *\<P"0:/$^
MO]D,1USEF(O!8H[3,6>AE@>S,&+931)*]9?[N\?>7>YCOTZY55O=W$VW)R]=
MS,Z/U:"\4-\E7KR[OTJE]^OX2 J43'$-M9@8TF-.%14#]%W-4'&,N*N8)3/P
ML8M]K!5P1;I 6KSIO'S6>MK-^X$+UT0"KDC_!P6-N!>:HO:Q.M*:]B38KG[\
M;:YE^&XF-RV_MC*'=<?;A%BS;_/Y8ZZ6^1R^G(NB'6+-4"?4V4.K=E=MM:AR
M_:Y<O6LW2^U:_>X[R)K 'I^00F.;QL &H"JEJXJX.@U207BCJYNI.!ID*B%%
M2#-&(TF$3'6L\GAT ?/,2W*$?2AOYL B7L2\C4:9$?MF0 KJ"MGA6^9LYE03
M6L*B9>ZT+@N^[UOB8G*3N>$^[BZZS[SM0?%\F5+1MU>GGX>?:CVIL7K/$>5&
M9EEZ;X8-3>^E@V'(K ?#&*'7GBBAT#N?=I7;5"_UGNL>%/3"]QP']-@ER=E(
MB0L&8'[/1-@&RR,4D-KHJMMX>D?&>N^P +EDU[& ,JC]K)-GCUFRI8X>'YFL
M%]MAQ)(;(],-C$"!ZPX6-;^UDSM#<:?R_]E[T^:VC:9=^+NJ]!]0/LEY[2I(
M(2EJB^^3*EF28R66Y5A>DGQQ@<201 P"#!;1]*]_>YD-(+B*U.+PJ>=V;(D$
M9NGIZ>7JJY>4G2F9LY4I\/CRM3@YO[K*Q=$=2L[D?-G=*/"]JAZ74Q5XXY[W
M<)H:O_STY\=_WKP^>O'QGP>UAVM6XU4U]84]A ,))N,4U-.];.141?[V./_X
M^\W??WP+#Q_65JY;D4\^D&.*W%FC'J\?;])0*W&+4H%(_HDN418[PUX<BA0$
M I.%61*T<HS'N@[N7>"%V<@9]#R0*\P-VC\M?AJC;B 60>3X28Z%#7&"5SV5
M%W1%A"Y7.')H-/;+$Y%Y05AX0R].J?)5/C1&2 *&?. 4YC*:SH="8&1\&I1J
M>ZO"/*B^5HX^"Z4@F.#GJG.J7O+9;W_.)872+2Q)\RGYX$G*9^KS7HBHW<,B
MPM)#KV$#TW=(9)"+-T)GUO_M__WU]/@H^SVKHLW5Z^CL4 4/?'>22LN^]OV?
MQY9F0?+-63-7GZN<3$&][:2BC2IN&"=^*J+)A<J2KND7TD_3 \=F-5!].1Z#
M"&0U$-708/%,M?P<WYE?>2]BE+P,_]Y/_O@MO)XH("MT7E8O+DO>AO6)X6E]
M&V8QJ"JETM0A KWTMOB3[2T*/IG<E1&V=MQO45E@4>#F"$C=G= IW<CFAQKZ
M74C>Q_K?5TG:OAI&O;MSF^>;YMK%;W\.8ZPH9KIP<8J%M;VE[L(%@<CUXPF7
MY\G\E^>RUON]:+WX])UW[K_YMM^;*'OS7XL5MOT#N!8[($0+W8ILRZ&2FG$C
M'BVLG!Z5;-R\^NW?Z][IX#!>N5ZZ$TE9WXTH51)BEM5E*$=B"8^^#3N$?%[!
M93@U(;E2>5.Z[B4,_4[OPOU&9\__(VQ<O CN+O(PURS7+G<'DX-,,Z["[:U-
MM.%N"#'(ED"7?]Y _=L :2?;7U2MZ>0C/P[H*59ZLZ)9A85;J6%QH&]AH&LZ
MUR<'QYU7;][_MG^SIYUT-:?9X!_YN<6JF>:<Y2K.]1CRY]C= U-R)HZK^EB[
M6#CM!Y$7;F^]$EZ8E1WU&7)S?I=RHX;* UV3](1'WH=>ZV7OLM.Y3^F9.->U
MR-"AVZQ/Q8]-ER$,+%ZV?Q=I"DMR&B<#B?69)DLS*[?7+$QJO-9PUR11_^S5
M/QY^^>U=(SFX3XF:/N&UB!56$2^MFA9WIQ>X 2ND;V^"]-W6KKV/*_#%5?!E
M_X_!&_]MZS82-J7^\SYOO -W[WAJG=X$&];E<@(N,W@A$O"?%KOM&G<I(F-C
M79.LO(MNWGL'P>A5;PR0>5S;_QYG?/1R6+_YUGI_,ZJO5"$O>%RF37<MY^;[
MG5G#;30F4594JXA9FN+M!3IB-T$;TZX+*8G#.[U'+M0HUW!.O"P1UWF]7_?^
MN<M;I#REM4A,W3V>7D@\*0Y"96O2.'>6<9DFN=IKD8\[<9E$_=W)N_#%A[^]
MYGWJT[MUF>KNT73N$2E VUMENW:18IJ#S]].:D>MDS?AL!WZ#ZO0XZZ*:71Q
M_4GD%TKK9Y?5G)=XZ^=_T.=OG?;U]9N_+O\Z[M8?UKK?DM*XX0>G\>'E^9?D
MBRZPV=<<AJ=7EY<7[R_/W[R_=D[>G&&US?N+-[^>OSG=,!K>;S..*T.,^UH@
M8'#3?V.%P#[/CP=X@9]<GSI'S8;K\!J[DK<9Z]=_\Z+<2T:.9/?9=:[S%C(.
M9P&!\3R)#-0$QDXHB%L$.R;MQ)V='/YA,5K;1,?T09MS6G<"XH>D7)%)=?$.
M3!+^S%.N<0<=2[<+U;KK$O0/R(9-<PHD\8G%M^L5QB1YCIGFVBD.9:1I@^4P
M"(!(M>Q8CXX<$3[RHL!5-[8ZV(2B:NYF:DSNBQ_!B>!'N(, D1'SH!0 @X>%
ME-_\X&DK1JS_\N^%Q@#\I0$W80"SG@Z7^<VD(2/U<P!W/V^S9@&'A6C':>;*
M=AB#!"R%)(!/("$FN#^RH9+\IN1_TIS&I75VG4&8IT3KK;[ M?ST#GQ_&WEV
M?)<:+-#G^ D!&4 @GD3@+> O2!8-&U8I=@FQ*4O^ :)O[@^\(,'UJ%K7T>2I
MS[G(+E'FL'$,"T[$Z=3;1K1SIEEH,^T.3+@5)TD\Q$\DU*M/;GWJ]7GG4=#P
M!ZP31^:$M43;4](C6=B);CK#Z85!&]F[(\ZDL1C#T472:FGA2]%&8P4!MU@6
M36W<RC.!L88YM<%2/Y/4\WC4(B)B^(I<#3B$7>=CX3%@!<[\#HVZ8K4-W7SQ
MXX94WI-J0A]*WM 3S<A>]7JB1N]AFQ)\4GDPQ#I1,6;K*^0=(3$WLZI3NPZM
M^Y#[/4J%ECG)^TT4]+*7A_P(4^(K =]EQ>OT8Y^X[?'IJ2*M#Y ]0ZZ+:CF6
MC4LMLCX178I/^\Z_56_#1<;C,V&;]4 4T8<<+-/Y"R57YOF%0R[WVHSD85]\
MC^5RYBWR?.3M8MJ^&U&\#6$?7L1MSWGG97C?O0SC)/ ]+*[ QDYTOWBP<]%.
M&XD.0MKX\D5-6VRN-9!JXC*NN]M;<*/M\:4-:A5]3/@Y4>+[RN>O1M'4#)1/
M-J BZ;YJP=JP:+\'Q?;9SRXI K!7.T"_G_Z&5"??7K6;]?>OWW_;]TPR\LV,
M6< #M=,]V1&K[V'_H+T:_PUI1\:1;WZ>4,KEB8W.FS*/)[\<[(UYLRQ<._0@
M>8%?1<Y+T4K87*"69\BB-BR3[T2&?X>+RO5M@'=@G*3$HZAD0S>?F"$FYB$Q
M:Q>W*"7$%R? INKC/],<KG9I'12HY$ ZB$P'9.. 9G"PS R<54Q@=WOK?0\N
M:NM=H&:-W=H2(+(12LBEI^RS Y)F$ E.II'NEJ*-FC*0^=N"?J4[& 9\U<YB
M0W/9J,/[84?53YMWOAK;6\OM)R^:^B4:$?"4JF5[$]]PIE&NW4:KWQNE7V,.
M2K^SS]_\PU[VZI_WS9='X>HH_?8^?VN>W_S]\NCJ/2CJ!T_IU[@UI=^[C[7&
M;[5_/Z4WC8="Z3>5UN_%YV]7UZ-&Y_*O]T._];""=H^2UD_I=%!Z1Q4*72IK
MM'\B>$Q; DN4DDXG6&6VIRD-Z70BPX"NA!!@O434(/@$I(_,#^30S=-_.QD9
M3T?U6JWQ^=NGT]/DKQ?'=?&O*36&+SN)_#8Z -[T^H.*5U72VQ[MU&L[M<92
M'3]QV%B2XC;J$UE7>%'4P.&:PY[*L-Y"9.2>$> [IQ)0T0\H6@47-H<CS+4=
M3Z@H.#>+B],5_O1U]4Z\_=[%Q_/S[C]6DH>27KBB_+*IZUIZRYJ6]-#=/ZA/
M7U%>Q^TM7$C+X =IQ1%P8SAK^:S696 -S#3TC=>-4[WJL*7<;N>#0/C%I3VN
M':&5?U%KQJ/D[?[1-XNKW[* <'EA8^5XY)/&L1K-VXS!R^O77Y)W\5]B8E==
MVL2I3YY  ET[*KL7BVWI QM.\\@]V*\2L:E(@UFB=Y)W8?,DD*WJ<!>".]S-
MU%*DU#:.+'<QNX#H-39I%3JA0(N&#ARVH<5L:IOHR?V"@!P,OOE_'9V<OSPU
MYY^?XSKZ21R\@:L$707J4<R/F^J03MD8Y8;J JQB;G#V/)[\4J]O;U&GP F>
MJ>34Z&1BKC5W01HH!,OM)ZGZ!IZ.9!(41FMCH(O(%+6+@Y],BX%?:NQ(872.
MFI%8PY7*#IG^5M'_@G69J<FK5N3\*[A/.(FKSA6]Z7U\3N^1=82XU>T"M1.B
M#[Z-_CAMO8A^OZK]5B]M^%C,0:@W4$BU/)M(%L=-.<9+#'M:4X#EBOBX-"8;
MQC,(4:VH*@PA5?3&'"C$C9Y=454U7[@>Q= +*2"D3Y_:C-0_:+3_J/UU]JDW
MQUF:O Z+G25K2$]^Z> DIYTD5D>TZ=PID@4!G.RJD*EJX$H^N^[W;$4:O%2V
MW<1O@W)/8<E;F%X1"<7I0<!:^#J1M.&H<JO)BE.C+$P"&80LM6A2T37?201%
MI^&?<OOH9%*,.$QCHEQ!MF6T&]',5>]F%@US##A)4\HGV1D#$8IVEF J@IN+
M@,A@?'A[2\7)*;ST6QX)TYFH'#TA@?IE1@Q%@4\J0BDSJXVK1(#^>!-G?XGL
M5%U7>-66C8@#O",.7Z47X5D8?/BG8ZD,' 7NX:APY3U%L^;9PEIATG@FW?4'
MM[OK#]S]R:1:%5<Z-G-9-/YH[XMTT]HQN$H_._\'G(/]QO&37V9$M.2MHE*1
M!;L"8WY4G?XHX )35Z'D0Q?FL5+L$4G?=;LG_#R$ZX?8HF26DN3O(F*!0JAK
MY)]Z:0]<VZ'UT_?HL-F@)'8]VP+K$WS4"(0HPW^C8*A_:YS.T9XYE:L;!QAQ
M+U[_^K+_6S_WD)@Y[\-.CNB5/SL& ^7L./:;M![53W6>GA'/4/IL^2!8*#KP
M!2_/XN>.C,S!=H?>(!4_.^IOST''^5GO9^>X]J/^)B6V^:M/$'*6)6H0-Z"=
ML>.3$D:.H3U1 :;,GS<4B+/9&0I^42L._:I0W9-?IJ_2S__[*?-_L=XJ=UZ_
MMFX'P^"C9I@P?Q3N__>D862B>;QO"J"^_7X9IB\_?DS[_O[< <ZJ*?RO]4NQ
MD.9_K<3Y20X%7\<@KSDF D]2<UGZ&[-6X.5GW3'I6R/\\';P;CC\,PENNP*%
MQEW%!:@?SST=:R?ACT2*IAY\ 8M8,K-0T*XZ'U)Q@C@-O%J_O?[WU=^^?_GU
MUP/3L[I:ON'\P#2[20SFQXY4F4FW];11:[J-O2.WL;__K.(,R)-UT/RQN"YX
M,)\[:H9\3/=WFSC#=V.0DO+"R(?6?YP@V.6/C;_ZR2\_3'IHK?1Q4@2S\,53
M5WIN'V*A<MSCPWWWL)*-=\)B5:V"+4W?U?JJIF!+XZYK;KUV[-;WJSAREUS@
MJN-Z-O&XOE;H#JN5V[>WV1^GPZS9:?RUO\1Y_=0+,E%Q2.<\F->].,EVV/<I
MN>8&RO74]L"NR(%I\P1L'-TSM8A3!6P.J;JE))47>1U'M>$V44<>51GXDR=3
M=3X?P6+=^MRY^S7XW][Q+1>KZJP=S#YK;^*H;1VW#_[^R5_7]??)OVNZ'N<\
M>:]C^,GT@_?09,2LY#K.U)%[7#MTCX]G7W^/Y4Q-7Z_;'BNXR9K[;JVYNF.U
MLLNG4N _D5>$23_9*D@GQBCVMN3FE:P=&3J:\:Z??_[S[,^??WY[]-?Q9?WH
M[,FTC;]--**Z94E16M103WBD[]1 =4JBSC'=O^R@;O?%W^GO[=\^'/UIPF4S
MYGS;X"_&;\N1WT5G H=\]VA"#%@%B&5L9JTG_E9"<_S7'<C+_FKD1;F\%]'H
M_8??XE=_?_!6*"^5&FRU\G*\>FFI,B/VYEWN,UF3\,[+A&1RP^4>!,%G?_#Y
MVZG?^1C^FES\<=I<CW$QGV95E1.$QU_-&5G-U3A[-5=@65 T?C*#W='NWMB-
M^>/=*IS[7,P%S8Z9BUD1KEAP-?E +A>/K8K+52_V;6.HS<\5=%+?\DYS^.]U
M./2[G<I;X79C6N'P3S]7\ 1\^[>;_/[OY5GMQ<7A.H8_IVFY1)R],AZ[VH24
M?NS2M=:%*'_;2WM.)XR'=J2_5 CM/+@I3*2Q+HU\->*ZRG2$?-G#2TJL>Y(K
M3#P<3S2+WLJBM\_?+O/SXS\ND^#EI_#!I!LPGPF_"62%%=7/IF,XDE(YX'AA
M,%5.%X,SCRVLKO9I&@M@,:N];(RO5CMPCP^K.$V^^]S%M$4>9Z)9.C[6/':;
MS14N<-6)+_#4%5,R5RT$, G_(CK_RJ6\+^-D0N3K\[<O[8O#=^<GG[S.E[O/
M:HRG&U,GEL.GXF<Y 3KA$ARM"Q+O+8IXB_5>]_$^/CYRCQI5R.4''IE=\9JN
M[C37ZV[]L.XV#V^[J/(4_T0XH5_*X1()<+*8C4[JG[^=-?],]OX^J,=K(H9Z
M[DP"8)FBO163/54B_M167GI9GL!_Q\!5UKH<G\Q V<YXVN=OQ]F_G[P/?V8O
M_>".5O4VP<9?WB.FO!.'(3-G,,X,Z1:B=A *39BA23B,!Y-J;I>2=90BG\0X
MP3R"#8L<#V.VED7T(,MF6EY(8/BT)T3V\UU"$%>\SC.PA_/A^^X&++=_MV"Y
M"2[.7QC:=<ZIO-P&6"WEUJPN@K)GA7WV_NH=7G[\^N7FSV %P1%C?C7GU4'*
MY.2@N8]-CUX&&*;#Q<.(=-][??7Z]=MO]4^_?_[V\H](>$>#\$US;ZT^VMY!
MI=&YY/$AU?%T3X8=GDT(]G\7_L3R>[V.3/Q!O>8>'*X0AE8EZG-?MVKZ9TB]
M^35[/Q3AC;@DF1@3](O\X,\W>[\=Y9\Z:_0Z2#3KCR-EL.S2K@<UM;?7=/>/
MJLJ6;YO!FU6D6#5G/#_OA_&8%'5[8?CM9!B\_'M-6;Q*@6I\7P(E%W<=<@1N
M4WW/;1RM U"VM!QAI\HQ27KS-?DS3R_>O_:7"8XNI(_VOD/QP35=DP U]]QZ
M<SP1?'L!>KFD &%[MS'Y";Y]>-7_]>55^]6:#+=*46I^?Z*$J[LF23K$2K_9
MD/+%)>EX"4DZP6ITFG!P,ZZ.^N*?P=O]//K4/%JK.EK2X'_?$XF@>OH)MGZ%
M3S6_U3^__[>$^SKMQ8L\9Z6"7Q"&-4%VFX?NT<'LBWB)G5N5<OT<O(=CD%G'
M($S^V?^KXXG3RSO3JLN>"&IJ7HC"%4E'[P4ON6Z%O19%?<"-7H[7X7SLSRN6
M'ZR=//_:AH^>4'+Z<_#FXK,??/[V[Z]_O&X-SSQQ>? 0-31.[F?D1LXSIA<
MA9UF_W5M_?068C])(M9Q!IKN,?A-1_79*:<YM^[9?)',24EB+,?Y_?WK5Z>G
M?[\\#>L/7!>_+7.6SZ6)RRO9V-V_S3&@KR]Q$.A[CA_GK5#,%<Y<\"FW*9-9
MB[JONWOUAMLX6ES6Y]JA8M95IG*FM.,Y>?'YVS#Y[<5%_L?'/5\\[/S@'=+
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MBX./$PR0PH(.%_P(5X$S7!)JQ^>*CB2XKO;Y3=!WAK=@^@U#$;#3WP05.F/
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MC-8O!GMI!^B-@I!%*HK"T4,U"'),2,F@Y0(>A#=RM8^B\Q,8A,-DB,HU@1.
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M7*@6Q[^M:U2G:QH/\Q9P0PR3[]-)U-3#*$FZ2.V2^FH!"V(:#W&_&>-VFIX
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MRH()M'!RX%D'?LXZCW<CV=C7:PMEJY;FFV#V.H/9&F="=C.%RNCV0@QN!*Y
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MJT0:00ADGAO19=[U=DYT$7 7:[X(K[@T3M7*[+G[BR^,@9E9_!2RQ>CVUKC
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M9;GJ1;-N4!IQZM#M"7,XJ#&YQMSO-]71]JQW'4K7%F'->'"P,QRE3R?<Y 7
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MA^+5FL4# N5B#[4^7'?VR@SCF8N-RE?F"HF=0EFA]K+//RBZ:G!45V_/WYW
M>3IL/L=>[? 2"1#0,T4.L@Q_X6H&YV$2D]'=49C"@K047SLVD?=_[M1JQZ_>
MN=+BL,6&0%I:JOPD[QH)VG7.#-R2NE=);((@IH?Q0T5/TRZN'K/SP_Y1T]VO
M'7.(_X?#(_?HH.G2]<6<+W")LH9!0X3 8W;9(=+#X]4MZZ>DP?3XE-$CN:/^
M%_SR3J3"2]!4QA4_L]+HYQ+0Q_&CS;6UIFL+K&.[^3DF QC(A >X!PY)G!"
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MOLQ>XH?X:1@=F(=Y0B]M8[V;UQ7DG6#6I2V[-E09A%02!J8@EH$J9R>,41?
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MSZ!WTQNJ' (7X@7N>]J#1=*K,]-ANP5# =B.9@N D3 ,BS$?#HE4F;>*5^B
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MZ@-US:-6&A$=W$0<!;/2J#G5FPDC+FG?2J/-S_LFJ4L'V]0E35TZ>/2I2X^
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M@$#L'5))PNI%='F8B(R?$A\YBLP70]238C ;K-#/@>_G#*(".+VH7NE$-9[
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MB8:"27D74%VY&$NZ:I1B)0E99WXN2O-3H]E*0^5E:7XNZ\//KPZ;+Z1^T.R
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M]$B$V@6/FPC\"2%8,HF\X9U@U>\D>'_F/PT+/_\/4$L#!!0    ( --*:5'
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M"ES03H(I5$<0 Y?)K*#Y7@3D0S/\Y*\;:B$;)\@=)L $&^VT:=KC29F8*(L
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MO>-NETAM3A?J*:9'-!SF3YB*^-7V09U2&9,E A%%(TM$NGID3O@[LCX.PLO
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M?GJ5T@P8$_]YA<-DF9T8LD1UFYV3:LQH\06%Y'=SRC<QBF"\ZOYLRS2@&7&
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M&UQ1\XUL%S=$,231JJ\8H#/#)J*-?1XZ'A0:M4&B/(HAB58-,995["&4ND%
M227'$I:& A"OH$<;9"TE'Q)\U6@\4)718_;=:T3+Z5W[49Q,O^'?D1O%UVE(
M[<5;%,T1-T=QIC7*([0!F-+L0$!5#9=0 6JZ]"./4E0>(:!KZZ 1\J'[1E!M
M\J11LJP&"M2W=:B(&='N,E?"Q5]4AH7?M7VHB/@ 0=$=_+@^T!)Z;EW?$\/
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M9E[;.TIM8WP%RR/8I26(2>@'@3+KFRGRN.&!AM[T%PL:@_\D=J9Q1249IB6
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M4S:44S:44S:4.J5[RH:B_6NG;"CMRH:BI="YI>>INNN<6_N:/W_:88Y;&:Q
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MD@-,^U7)YL/4*;M(3=E%.I\LC;BM.[\(8QPT=#^]EAPCWW&2$6&6D<HI7O4
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MM2L)$KV3#[G/+M8=^.W;!;^(!Q FLW[Q^M;5[4A9I_WCL(G=3T)2NY3-L)A
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M'_@/+C="EK>6EAW)Z-:@1*PDM++<*-8$7%;%_& K*B_#=@1G*G)V^=)S$_2
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MH924D@F!R[*@>WVK $161[93&8]"?U.Y*?7@<LB*=L]?98#.CP3HW&R>2IT
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M6L%ODE.K@(:*-BB[Q-OH\$.#_%_Y=0=L^UF39R\-#.O-'1FG.^TR>*V=]:8
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MBV1%X>K9YWNC-U**.F.% 6Q-"H4<#D[HP74I44F3S_>5VSA45K8DI>$R-M)
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MFJZFK*)C>+0<WEBA<<:O0@ &4- L@0]1=[<R/KQ0FP5S>]W1Z;0EX"[50("
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M>/FV6I EA>K\[HH&4E@5 5H_HFAZ&:*>(VBU^*B#P.6+_\B@4<75"+F8Z\%
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M^=1H4<>>*TL9F.SI.V@ZV0$+UW]6MOX4A#-I]3&^T\0/KK&_PC_[,/H4F8B
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M<133:35NY71Z79H@#Z\-XF*;4D-AX3^P&/KD192?^:S2[<(/DSAH_Z$A*5(
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ME+4%KF%RI%@W^*:V12IC2(Z@2:>D]MRV4W;+Z"$%:O/81A,1>P? [7-6OJ"
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M>_^1!D7$)C[WCUX*EW9H<%[E&PV3> +QP9+OC&9GKQN9\N3LA 40P5QR0_$
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M3'D()DDM:^3^D7&_O[Q[D*_@I,XABJ@F6,;%Q*$,^"[)P#P)^9>)EXMM+S[
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M=?\#;[;JU)ZJ./&,8R?.[MY3&HWDJ#(CS4H:9W._I#@D-.*:(A60G)?]]1<
M*8FB\-*@2 &2M;7KM6< L/MY&F^-1N/O__.R")TGA),@CO[QS<5W;[]Q4.3%
M?A ]_N.;^\F;SJ0[&'SC)*D;^6X81^@?WT3Q-__S?__W_W+(?_[^?]Z\<?H!
M"OV?G>O8>S.(9O'?G*&[0#\[GU"$L)O&^&_.9S?,Z$_B?A B['3CQ3)$*2*_
MR#_\L_/^N_</SILW@&8_H\B/\?UXL&YVGJ;+G[___OGY^;LH?G*?8_PE^<Z+
M8<U-4C?-DG5;;U_>%O_)J_\]#*(O/],_'MP$.02L*/GY)0G^\4WIJ\_OOHOQ
MX_>7;]]>?/^OVYN)-T<+]TT04= \],VJ%FV%5^_BX\>/W[/?KHKNE'QYP.'J
M&^^^7XFS;IG\-I"4+TF2!#\G3+R;V'-3QKGR,XZP!/W7FU6Q-_1';RXNW[R[
M^.XE\;]9@<\0Q'&(QFCFT/\GW*V_FLZ)C2Q1E@9>LO ):XOO:9'ONS&Q22(O
MJSS':/:/;]*7A4^^0;[R\=U;^H6_;!5*7Y?$-I. FM8WSO=[?CU*XC#PW13Y
M5VY(L9O,$4H3M42*B@>1\L[%*"*U2 4WK"TRMY6VY*?=$"W(]Y+1;+2DXP:Q
M32VXY2T<0NY)&GM?YG'HDT&M]V<6I*_7:!9X05I7#66#A]"JZR;S?A@_UR9C
MIX$FI1[&*;J@\XD;O:H$Y)5M6I;+*S<)B-)W&"5$?6:$G<@?(X_\*WP=)$F&
M_([GQ5F4DBGV#L<1^:N78P51H)$/-*WUNTFV6+CXE9AL\!@%Q$;=*"T)0<S"
M"Q!(/\VFFM;DAT'T1)"*\>L0*?NML$+34KT?T=]V,TQ'Y$Z2 &8B1;6F)?S0
M#UZ(W;%O )$35&E:LA\'I)=$C\%#B+3$D]5K6L:?RD3=!.Y#$ 8IL,.HZC8M
MZ\=K]  "<*M@XV/^6T+'39PD=PA/YF2E AK\194:E^YB=^H&"2BIU[B,EP.R
MSUN@J?L",S1NA<:E>C=&(5U!D-4GM >(ZC0NVP]OKK(DB%"2D+4.G6^!RU10
MY<:E?4^6.HL@91,_62&0K]()E&SNH;!"&FA<Z@^3["%!?V;DH[TGZ*)(7,O0
M2J>%%4_;*Q^@&%.73(A-ZK7=8*OK.;CLDFH'6-O!Y516;GF=!Y=46O$0:SZX
MJ.K:AUK_P66&M=#*6A N)*=XZ^M"N'2*JH=8(VH(JZQ]T/6$AN#P9MKR$UVC
MU W"9.ABN@1[@FT=%'6M\B/54;"5#S:)2C\.P_B9?)H9"?G^4^"CA![EX$4N
M[4.<I==!XCX^8O1(]P-C1";Q#%V]DM)^YJ6WP4LAJ0J15CYF:,56QQKV;+I)
M3<LK,>IB#A+J5%X3!"14KY4FY=]=H17?UU>B1E.-]L"M%5QM+32;:7D%6Z=W
M )MH;_2;D _W8YS./V&R7NF2#[^27W46M'N27IHM,N8/(3_ :?"?U5A.T=XJ
M.IJ-,EQ=[';HP1-:IFCQ@/"[MU1Y4O>:S /L!Q>7;R\^UAI%+1.Z279Z21HL
MJL+W7I8H2A"95Y$_BHIN>T=*1<3HD_0*Y2K1\L@GP S12]HGYO,[<G$R("KE
M\"5 L \IPR'V:W4ZIDX[;8WQI<U7(P.]3GM-Z@3I4JN>R8)G6,>D.[Q"3&)Q
MVHJW^M%6=K]US%1:L4DI:222GX6('L*''AU?R9@PFET'84:0JFQW.P0UCP[4
MTYANT>*HO,,$\M?:!YM$94R&"$0,C0P1V6+)G/#W9'P<1%>AZWUYDWA$!)3<
MQCX*KS-,[&@81.B6[%/G22_RD;]KH-0L.YC.<&R"&T1LPKM"Q R_ R)G5*A&
M;6ZU<Q@Q+3H>,>X@?;TG0F*J+Q'KLI#N+G2CA&TRV<Q?VEY!5-2?(BT0K9W>
M/49)B@./!=Z0+G0?!<RW0CH:$YN&=*U_KMV3]VC\$#ZS6MX<C7;:/N&L)3^P
MC8.=@-920K>Q9D>I)6F%.J_<\ :1Y7&YAT-'$W 3[>T$Q\@CV 5D:B"C6) P
M!PWRUR%W9.0GLVP1#AD],C&33EH9KJ;Q=HG2DI.VCWVZ>2C'AM;:_UDAZD&]
MXK5Z19T&VS^%KZ4*N!69_,N20_J&_&"K"MFN(CK_KAJB&NC%EJ=!2JL40?\7
MSAMZ0R"CZ)._YB4+<58"D47KE@QT$9O&E6!U*D)"9&#Q\@GROGN,G[[W4? ]
M18G^A<'UYNU%$2W_%_*C/]CG.@]DNG6]=>14Z#Z@D'WE#U*F4N3[@\FV0F5*
MVN6+MEVB*EF9Q@[V'-I5,<%]U9:+O2WR=B\;%"6^7[*X]#?>/ C7O,]PO!!A
M5. 1"P0MPT4^<4A,.T0*GTK2#]U'/JB5(D!4+TS RM7&+*[7*/%PP!;["GBW
M2@)1OC2*,D<W(V"O>M,8/09)L81;A__+1PI!%2#\[TR.'5)MC?+0B:+,#<=H
M23;]<OBW2P)1_\$DZCS=C(+]SXQLP! .7R%X[Q0&0O[>).0"#8VB/L5NE 04
M)0CLNZ6!N'\PNC@1Z&@4>+*C"L,B$@8"/:\\$/P?38(OUM,:^-F&ZII,/' &
M2E6 )/QD"PD[VAKEX0[A(*9W'#& @9W"0.P_FL1>H*$%J/<B'XKYNBAXUV0>
M\HIZ1@'O!XGGAKE<??*S1 XZIS@4>"/[5:6:%H!/XS# T)<*0X$WLH55J&@$
M]B+88B.2=)P1EX8";V3SJE+2"/*]* W25YH89IA1/S\?\=U24*2-;%A%2AE$
M>.6QB%*:^$:&<K4D%&DC^U29<@;1[K+CS' 0^>CE5_0J@WNG*!1O(_M3J7H&
M ;_# 8WMF 2>>AC9+0N%W,BN5*Z@0<RG[LO )[JQ^P$4*C7TPBI0!HQL24'J
M&B2"7LS'R[CDCN[2TW7\VHU]Z5"OJ @EQ<A>54-U@]1T?)^ EA3_=Q-$Z$)&
M"+<X^#S*' T2-:T"_U(/_$LX^$;VL$HUK0+_G1[X[^#@&]G'*M4T#WZ7_'6$
MI_&SX/Q;6!@*O)%]K$)%\["S>6B$V;W1/.^F"ON=&E "#&YOY<J:9Z%8"$ L
M?U42BKK!K2Y?.?-HW\5)ZH;_+UBJUIS\\E#D#6YZ98J:<5KF-D"='Z( ITH1
M*,I&]KE<=<P 2]G&R!6;\G8)**Q&-J\\98R@>A/3<Y9Y'$D]O;NEH.@:V86*
ME#(S(--PZ$0X&)1^#8ZQ,S+<5M4P N9O.$B)'#0</XL*CX_@'$Y0% JRD:VC
M5#TC@$]85A%ZV^&6K"AQL,DZOHTVKQP4:B,;1;%B1G"^PXBRCHKL/5-Z@P*/
M9C/1B"PK#\7=R#Y1K:@-^+/42EB7!4XM*!=&MHQ0I<V,/,C+R'#X>G'Y,*7W
M@03CSDXI*.)&MHLBI8P@/(RGV*6/RDQ>%P]Q*+[PPBT(Q=G(YE"BFA&HMZ3A
M@UPI H77R*Z0JX[14:+WXLUIM@9Q' 6_)!1F([M$F7*&Q^1'T)C\J#DF&]DM
MBI0RBG >X4[ZV.@A#!Y=\6TY:07P_2&3N$M4-7-3D5UH*B4.Z)._\,$7%(7"
M;N9*J$P],X!G?D!SI#'!^D'D1A[9CFV>*Q)@KZP%I<',G5&@T@8/$7Y#8?AK
M%#]'$^0F<83\?(,@.T<05H%R8?#L4J&N02(^QV%&L,(L>!4+^H.@*!1X@V>6
M O5,1HKF0=GKF2E_D%*&NZ@&%'Z#AY=R98U&T*6(2AX\H6LW=0LY92R(:D!9
M,'B0*5?6\"T W"73TF,L/[>O%(1B;C!\EZN:0:@G"S<,5_FW9%!7"D*A-ABG
MRU7-(-2]!<*/9+#[A./G=%YY@)('N: "%'J#T;A254U2\+*Y3Y_?])/BSRD-
MSM5@$'RADF83DJR?#9BP1\2Q 'M9>2CZ1B^2BA4U@C]+(EU>:3&1!F3/)PN_
M4->"<F%DJPM5VN3,6\IK()UXM\I!43>XJ>4I9O)&6/80!EX_C%WI.GZK&!1E
M@SM8CEH&0;YRHR\X6Z8>??;&0X@>U23K_@?81@$;@!)C<&^K!85)A\,FUSI+
MPYZ,LC2A R614NIVD-:#$F3RTBI <:,KI61SF0WY5Z]C-$.8!DQ,T4MZ13[W
M1;YP E2'LF0T^Q(8!@Y9?_]^1Z\;\H/6,\I&21P&/A.XE'QXL_O<RC)[Z;QQ
MUMYWFF9V-)R,;@;7G6GOVKGJW'2&W9XS^:77FTZ<O]Y';NZ^_^_:B6A7]CAS
MDP?&6Y:\>73=96Z4*$R3U4^JUEG\^(^UM*/9^OS@+LZW&I*$M45U6.W:_6U_
M]8I'A)2*5,N92G*KA>MV/Q-HTMSHUQ0;JW?.@*3L%#>6*E>.,(\&@:IVL$$3
MM(O!SW]K+&$N",:8([%-"!=^ YK '@5/-%4^??1,N'1>Z2RM92R';@U&(/K;
MP53Y%4DQ,]NEC.75K<$$3S\[D+_#:.D&?O&>72?RF:-G2S<Q(:#*QI+QUN!)
M PT[Z ,258^2YK>4=08Q!?A$=K*-P<B_R;462LC$2V/ZJ PM:;C7Q4N$TU?Z
M&E9*S(R^E+2D"T[I^">O92S_K\ZZ#**X'3VKU//52V5N86.Y@'4(D:BY+P^[
MC]?0G_QQ$WAT<!T'CW-N6" M5"EC++,O *18*+5-ULQYO[7WXH49==%]BF/_
M.0AY5QK6RQ=(;7/9@.$T:2ED$X';KW,Q$QO-[I-<?LG )*]F+H^P-F4@ "SA
M:J/4;9!X*"23'8JS9!A'GFJE!JEK+@FQ/FM@**RC3I.M.@2UYB6H19"4DZ-<
M9N=ZJ;9%)E,>Z_LT3X6;T@.39!^P^VRL>M$-;\%<HN7]#Q1T<;)C'"U)#3YO
MD-4QE[JY+@U"%JT^E%BYC._<5^HO!CO+J^7-Y7V& \YWEO,UMX,=-EGO:J98
MG_ JF,L*79<?A>YV$*3#S3ZTM.;IT*8%Q,AQ+E#BZ'&*\.(:/:2;I3%@&E/4
M,Y=TNJ&I#(2+)?V1*ZLN=R9S5>N!#F'*+H;XK\Z_@C;?ZJKFTESOPQL8$TLH
MK,S,8,>)H(ZY%-E[D:9$P0ZV-(G:DZ/6/";U!L2CH@=$BLG4VHUOC4]EZ5C'
MF]6 _ZJ%'-[-4'PL7JN[E;$Q@3^[8<;+CK6)%=HM;"X/.!SJG9 GD<YVD%*Z
M7:)@9+>DN?SA=>D0:6L'%QW?9SYK-[QS W\0==UE0$;<DM 25R&@KKF,Y'7Y
M@B-B!X-CE+I!A/R>BR-ZCZ[C>=DB"^D%FVLTH]F4Q0Q"ZIK+?UZ703@B=C"X
MJZ#.HL)D\O2Z#(DU/O:%HFI=5?_PTV3F]L;W!5)L&K4!RZXYWC&<YXA4*.6V
MW[KS^*[>G4?GKUMMG^] MK=F"L/XF5+:C_%UG#VDLRS<O9DC63<!ZQ_QG4DM
MA.R8A;>W3:0OC3!#P&>K]CN$V4UXZ.Y17-_T;<L]:-6#R$9:\VP&G2R=QSCX
MSV905]&Y6\_T1<[&:!1!8B]]+ .L)G6K.J9O>S9,VS84]E(F3YPB4;!.YI36
MCB@:)J^EI"J-.NCTYT%09=-72/=@4@,<Z]B$3W_22J9OFS;#GMT3WXZ@JEE/
M6,'T-=(FV;)QOM/,$B92K<Y,U^(I1W.<P:8Y\WZ:S2L/HUD1L%-^YW'+1_.#
MS$<SF9+_N^T-IQ-GU'=&=[UQ9SH@!2S)4$5SABW06GJU0T98P:C/O)!F*O>U
M5,NI.M:.?;;2O104['C+MW4H7[NU@0+2%1'-&RN);^&5M8,*OB&)&"B)7X[J
M;8Z%!*<E!LB_JNB3']%D$W[FI63MB?!3X*'.2\##GA3EESP&Y(7"E_QC9F!G
MAQ>Y1,EUO' #WAM@&_%YQ0T3(,161 %/AXWWV6S:%2K?+1*DZ5[OOK>*&7/!
MRA$5. XX&MJQ\"VR8ZC KQ0SMO6O 3Y70SO 'Z,G%&6H3]0CBUBV?/@M2.?=
M+$G)T@*ODU_0.\;DO_[4?9'%@=1HS);CJ9WEQTXX2&VD[*"Z&R=D'T:SF)0-
M=Q*'4F^ N(XU)U JYM2*VT'0)QPG"1E;9K)8JZU"UIP>J2C@J';L(3KKRSA%
M4D!(-C!Q%6L.E%1,*M6VHR]-4!C2G$TH(N*&I-MW_$40!514^@I;(;QDIPFL
M;_HL24U'7$LOF[@<$TB)#',B[369A,.8)0944JBH9OKL2)<Y$ IV$':-")A>
MD$-)3&Q!7^3XC^B=ZZ*6M)+IHR)=L@ (V$'5CF(:LY?Y,R%=6H3:GLQB)'<)
MW\3<)R:K*)0+6W-4!%Z [*IZ["P.XRC>UFZ5<%JYM 14-9TL%<PP& 8[AM!/
M;A EU Q1,HIZ+U3J+$CF^;$GO88LV<RIJQI/G@IG(];5S286V37]75TEHZBH
M@O'<J7494T!@!T_L*6V4J)?_.P6-9T>MRXM 9?W9[F,^VT7HD08J6#S?U9CG
M+$BN6I=?)0S'OJ[9K-16WO,@RHBRF_"8*S2+,<K+3=T7E) ) [N$L2!R\2M;
M+-#$'-3O'C,'QJI/J,)-6OJH\<2PX,74 ; _#?,DJA?=[@I%2.J#%U:P)Y\L
MS"R$.MLQUP]1"MG/5HH93PD+W^CP]#OVWK2Z+K^*8E?O7<4UC&>+!5.ITMJ.
M#E65\LI- H\ZE(,P2V51X<J*QO/&*@F0\R5 P@[:?D/T50OD=Y[(G/V(AAF-
M(QG-F."EL&@PFW7;,YZ%%MP=]T/,^KCRW:0'U8PD6V'F[^%AYI/IJ/OK+Z.;
MZ]YX\E_N,D[^YO3^>3^8_N[\];K7'W0'T_^V)/Z\=+>@7EHU4'4; J./,C9=
MBYYSI+HM\=(2\=N)5*_/0FY*W7BQC",Z+ K"UZL:\:L=(S=\35H);-=?:6[+
M)@QP7RW'^,4M8T5F<=7U)5^A4CB0'5<-55'7G*+6Q'UJT"'4V(X%OB!9H(H<
M135KHD,UB (A80=IU?R *K9$Y:T)_=2@2:Z['?P<*!^B^?CV%E+@+1$.8KKE
MQ*EYCZ+!F_'F(^<U[\$?,<U,QT_8C6B"U0P3_>Z8>"PG"M/]P4V03\<G%"6*
M:-):C5DS$H-Z?#VH+!J;\RP<9?ES"U\Y9+6XUFW,=."^'M?UH+*#ZX[_[RQ)
MF>=R&@O6=WR;'2,RFR5!BHH[6[GF8^3%CQ%K19'WO?TOF[Y$ +:B0Y%@A\FU
M>G!L_[FQZ8&]]J+[CTOS=PKV6'93\1M9D?4B"Z+SFE]V:]!K_IZ!2I'3(5JP
MPF#C^A@E*0Z\M,@XV7EVL4^&G]&L'^,9"M(,RZX,[=_RT5Q:: I$BX9QT:*S
M%9O0:=KXG8AF%N_'9Q:05>1O+J8;4U6>R1I-&;]8T>AJFXN3]9$G73>9]\/X
M69#0\ ,\TJ3;F?SB]&]&O]F2T+ 4L;#64BN.A%/+[!Z("G2'XZ> L'_U>D\V
M=H-H?7VRXZ7!4_Z*BOIV88VV;,GK(V%S=UM5$S$[1N=VPZ5;NS53'_6CV15O
MS0?4=1)Y08BV!)[&C?76=KYF^L2D,3MIDPP[S*V<?4)L)MNE3)]]M,J*.#F'
M7<25\X2,9@,"?_08/(2(YI1+)4.ZJI[IPXX#D@N#T ZZ!XNE&^!\D5*5=$"6
M[+,@(HOB,'A"_CJ]($UC]QR$H=@8]FO5](G& 4VE"?CM,*3?,!%T-)O1Q JY
M#Y(F6*!;2_IZ&LU_*#872%W3)R,'- HXE/M2G[XL?$;HVX_OWC(ZZ4_HI7B/
M:+*6_ :YB>1>/*TCKV+Z0.40Y*E1L*F[,D43 C_G74-Q1Y77,GVN<L N"H'/
M#J*W;7$SWP#S<W%KF3X1.2#1$/CL('H0/1&Y8OS*IH_K^%FR[^*5-7ZB<<AE
MEQ K.[BT(Y]7:_ZV S)=)P78D:8RTHY9W"\LL;TD50<T#W#PHEYDQ1/"#W&"
M]K$)P=)\Q[> PA!Y:>:&! RB?OI:O/301Z*ENEX3QE-:'6KM7@=9.V:+;<F+
M5^ZB1[I1!#OLJK6,9Y<RYJ_CXV<'TT1W3->AURC__Y*VQ9$^Z T\<!O&DTD=
M=$VHBZVM-K':B!*\4/ DS]P JVT\GU4-<E3LBE$Z_J7@KK:K'4\@BXM35#.>
M"JL%*^#@<HKTL[RZFS%1<98'K6\\XU8+!B%#ZA0M8S4,WKFO=6>*=57CR;E:
MG"8J^)C<&AYFD+@)W(<@9"NG^B/%5B/@\)TC,@\E9L=O*/"HIR:B-^%F<A3A
M@)K('7OF58'&=)65-!3Q*VT+:COM)U78.^87@)D=&U R,ZZN&7A_9@'-XPT-
M&@-4A3+:7DK]^O3$NLJ>RC)S1]65"_4N=*.T$_GTLBI[/$[#-B1M0(VD-6]E
M>T:B1,ZDM0@.*7:721/D99CEB%W&"3>O/:T(J =ENC6/Y/Y, S6U:8B'*]W$
M= YGN35_8V/]61^Y$UT"KH]5&E@"2MN"VD[[V1OV7@(",+-C?""">PCY['T7
M=I%XM&3ONO1>$/:"1'8)%U 5RFAK;L8]Z-D)&X3A9 >M8[0LEB.CV4T0(7KY
MEHQ&LG=I)%6@-+;F'6R,1B4N)[""+UDJD'I)%?#-+NNI5^)B1\^]6]LG-!Q$
M7 -*WJ']<37(4Z!R_-T6#E43BRZX;1SZ2JZ^;>@C=^P+=:HN_1_U*#RY(6*Q
M$*MT,/07G<C?_D&I9)Y$IKJ-7=]1(W^9N]$C&I-NT9O-D&R1?V@YH#;;?HY5
M^ ;!#%=?M86W9+!P^VL_[^N![&]O<[(J1[2-1J61U?!=^XE@#V16IY4!<059
M<85TXR",?,X:Y#I(O#!.,LC;EONW##6M]M/2ZIE6$WBV=,6Z2+U6)% ?1&,4
M,CBG\4:Z1XR0X(R,MJ'7!)3#UMRBC1$2UX7 ?$".^%)/%J4=S\,9\OLQEEP^
M$=B"5@M04VC-G]J&*=3 T Y7S21;+D-FH6ZX F80S6*\R E1I_^#-@#EO?U,
MMO!A7!,=.RA=O4Y/DVT.D?0N3J4@.$M2:Q1IXEV-C^0J;DU*T6&<H@MZT].-
M-@\4;64/_=%YXVP&'/*/X6C:<RZ<__K+3Y<7%W]SIK_TG.[H]JXS_-U@GM 1
M?G2CXL;:)DTJY2?R[TJHK1V=;KC)H*H>41IJWJ0?U*6IBT>S(M22Z"#Q=W+*
M&LX<VBB_54>G$!JKNNDE?1@[&<W*ZK+=()G"T_ USUE<!.?3I-8XCLA?O1P"
M?M_^B=NW+]=]^ZHS&;"\P'?CWJ0WG':F@]'0Z0ROG7&O2_Y]\[LSF$SN>]=.
MI]L=W0^G@^$G4G8T)'_OYEF%SV."O6/"7AIL[&9*3/J*B/FE):RX7SKA\:@M
M6JP:S=Y-LL7"Q:^CV21XC()9X+ELL[(:O8C27OEH:6O<^L@=M]ZMQZW)_>UM
M9_P[';DF@T_#07_0[0RG6X/4Z&;0'?1,#D^[R@*R"$OJF-RQR2@$# _0^H8[
MO9JQZEY-"Q>K^N</ZXQ0Y6U+N1=>O.7VPA_6O7 P_$Q6 */Q[]\ZP][48$];
MJZ+C))96LB&KF=8$+*]EN%\!^!&E*SN6Z>X]NQ;9S3"%HW*Y9:M377 [U?MU
MIQJ1_?;8Z=Z/QSTZHTTF/:-K[%4^5A8U5%P9#?Z#Z#IEZ08^6;$PQ7.-=;K?
MW@V;7%?O< U9(LLJ&>Z@#;%<7>>J8;*J#W_H!R]DA\TD%4Z*E]S^^V'=?_N#
M?]'M,NNWIN=%X4TJ=?<$5#4;J\N73FO.U&O%<!<%<[D;OJL-E56]\L?JI5%A
MUWS'[9H_EM:KT\[PT^#JIF=)_USEM2>T5)74F4HUFS&9Y14B*:#GZK9CN._6
MXKF:UK46=%;UY)_*"P)>XI"MWOP#MS?_Q%\GWPPZ5X.;P=2LQZ?(F),0CMBQ
MO!L"7#[22B9S;&ZG 2KB#$JTK5:%I1]M^"I8!O3EIK]C>IY6VT U&6<K0%O5
M\S]NY9W>ZN;ON=W\XWK2ONY=F9RBJ>!ZVUI^>8,=^2:.'J<(+ZAH@/XH*&Y\
MARKCH=*CI!I;U3$NWI+5+,WI>H<PR\S-[R0?^#$:;]>]A*QCG9O19.+<D4EQ
M\DMGW#/89WHNCH+H<:V3NM>(:QCL-U6A 'U'4L5P_U%Q4NE!2MWMZD47[&KY
M/ X)A@G=X:;\8*<+0;#3)MII,AUU?_UE='/=&T_8SW[\F]/[Y_U@:C+X*=<(
MT(TJY4R_9;]%""5*:Y.GT83ISL7EA_<JO0XB=G6QRSS_^-1]$6W8^,%&%Y<E
M_TMW=-MSIIU_&=VEK171.RV45#*;T[0J%^BT4%;+^&FADI_=)*5*$.SJ3>_8
MO0WDW[E8[ 'A1\%<;,)@QKV;SK1W[=QUQH8]'R5U7J?8C1)"%@VT5'<L=4VC
MZ6#XPFEU-JU&#/<]*(\[Z6&T<;*K/_[PYBI+:'*3I!M'--ZV&BA<[IB7_, 8
MYK&\NI\,ACVR$>N.AC2"=LQ":HUVS2#Y0EU(]T0OG+I!!$M$IJAF\MYHF2$J
MIE9OA-4VW0TAG%6O?VK 8E?G>]^-%XL@?_.&*$T4H6%T*!+&AU[R@V@N-E$T
M9*%Y.YBR '46SDYZ(PT+[0T-QX1*--6ZX*S7C-'."I 4U&WUVC'<@6OQO-.A
MZT!G5]?^,,D>$O1G1IKN/0GOJ5SR@VHN/I0"OJ\FO7_>TZ.^WF?#UTZJ*D'N
MJXIJ&+V%NRT4Q",CKF*XOZDXV;ECJ]#=JEX$O$HAO5)QR0^.J7.EPOGKZDO_
M?;Y=T<PN<_4>6T(V3SY:AUONO-?6"</XV27K/,XC[$RE5\F"OM&O'-M-C38P
MMN/J?=\-\&<WS%#INM@@(F!D;.F@,@M@=?!;Z;80K@6+'4SRGV;.$R:SL"^Z
MOPN>$ WE5/):JS'P>U6VL+P'9'9P/D9D 9(AFER7KO"IJK\%Z;R;)6F\0#@7
M&>1DU&L'G)_8%J;K =52+JLBK<XZTQ*5Y"Y>9F%QIS>CC_:JN:-MU6L*G#7%
M.'WU=3PX@[]&P>,\K4^;H#Z0J_9>E-Z;*RDP=HRC].82V1^Y8;$/@HR9LCI
MTEK+_Z<]/JH!L(.H]<U.,$WB&D"26DOPITV22GD[*)J@1]KSQV@9X[5R<+Z
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M@QR%L:D):FB9U0I#PB&/KXXM2S*EG<E9.<B$<QM$P2);T&.B*S>DZ5S'1(0
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M@LA/_C]02P$"% ,4    " #32FE11_+2XF5*  #MR $ "@
M@ $     97@Q,"TS+FAT;5!+ 0(4 Q0    ( --*:5%1_D[>1QD  !ZV   *
M              "  8U*  !E>#$P+30N:'1M4$L! A0#%     @ TTII4<!^
M%APX$   FF@   H              ( !_&,  &5X,3 M-2YH=&U02P$"% ,4
M    " #32FE1AZIE,O49  "'TP  "@              @ %<=   97@Q,"TV
M+FAT;5!+ 0(4 Q0    ( --*:5$_+FKV#Q<  -.Y   *              "
M 7F.  !E>#$P+3<N:'1M4$L! A0#%     @ TTII44M3^<S4"   \#H   H
M             ( !L*4  &5X,S$M,2YH=&U02P$"% ,4    " #32FE1/8C5
M$<,(   R.   "@              @ &LK@  97@S,2TR+FAT;5!+ 0(4 Q0
M   ( --*:5'>?\"DEP4  $D<   *              "  9>W  !E>#,R+3$N
M:'1M4$L! A0#%     @ TTII4=>7]Z6F!0  G1P   H              ( !
M5KT  &5X,S(M,BYH=&U02P$"% ,4    " #32FE1Q:<$B (5   _:@  "0
M            @ $DPP  97@T+3(N:'1M4$L! A0#%     @ TTII46GA$W=\
M\ $ ]R41 !,              ( !3=@  '1X;60M,3!Q7S Y,S R,"YH=&U0
M2P$"% ,4    " #32FE1.V[@(=47  ";Z@  $0              @ 'ZR (
M='AM9"TR,#(P,#DS,"YX<V102P$"% ,4    " #32FE1P/61@\$8  #T$ $
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E,#(P,#DS,%]P<F4N>&UL4$L%!@     0 !  NP,  'X*!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
